Abstract Id: DrugDDI.d390
Sentence Id: DrugDDI.d390.s0
No drug , nutritional supplement, food or herb interactions have yet been reported.

DrugDDI.d390.s0.e0 2 5
drug
drug



Abstract Id: DrugDDI.d385
Sentence Id: DrugDDI.d385.s0
Formal drug interaction studies have not been conducted with ORENCIA .

DrugDDI.d385.s0.e0 52 58
drug
ORENCIA



Abstract Id: DrugDDI.d385
Sentence Id: DrugDDI.d385.s1
Population pharmacokinetic analyses revealed that MTX , NSAIDs , corticosteroids , and TNF blocking agents did not influence abatacept clearance.

DrugDDI.d385.s1.e0 45 47
drug
MTX
DrugDDI.d385.s1.e1 49 54
drug
NSAIDs
DrugDDI.d385.s1.e2 56 70
drug
corticosteroids
DrugDDI.d385.s1.e3 107 115
drug
abatacept



Abstract Id: DrugDDI.d385
Sentence Id: DrugDDI.d385.s2
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents, azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .

DrugDDI.d385.s2.e0 82 92
drug
medications
DrugDDI.d385.s2.e1 97 103
drug
ORENCIA
DrugDDI.d385.s2.e2 105 107
drug
MTX
DrugDDI.d385.s2.e3 109 114
drug
NSAIDs
DrugDDI.d385.s2.e4 116 130
drug
corticosteroids
DrugDDI.d385.s2.e5 150 161
drug
azathioprine
DrugDDI.d385.s2.e6 163 173
drug
chloroquine
DrugDDI.d385.s2.e7 175 178
drug
gold
DrugDDI.d385.s2.e8 180 197
drug
hydroxychloroquine
DrugDDI.d385.s2.e9 199 209
drug
leflunomide
DrugDDI.d385.s2.e10 211 223
drug
sulfasalazine
DrugDDI.d385.s2.e11 228 235
drug
anakinra



Abstract Id: DrugDDI.d385
Sentence Id: DrugDDI.d385.s3
Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.

DrugDDI.d385.s3.e0 27 29
drug
TNF
DrugDDI.d385.s3.e1 44 50
drug
ORENCIA

interaction DrugDDI.d385.s3.e0 DrugDDI.d385.s3.e1

Abstract Id: DrugDDI.d385
Sentence Id: DrugDDI.d385.s4
Concurrent therapy with ORENCIA and TNF antagonists is not recommended.

DrugDDI.d385.s4.e0 21 27
drug
ORENCIA
DrugDDI.d385.s4.e1 31 33
drug
TNF

interaction DrugDDI.d385.s4.e0 DrugDDI.d385.s4.e1

Abstract Id: DrugDDI.d385
Sentence Id: DrugDDI.d385.s5
There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra , and therefore such use is not recommended.

DrugDDI.d385.s5.e0 59 65
drug
ORENCIA
DrugDDI.d385.s5.e1 94 101
drug
anakinra



Abstract Id: DrugDDI.d110
Sentence Id: DrugDDI.d110.s0
Formal drug interaction studies with Abciximab have not been conducted.

DrugDDI.d110.s0.e0 32 40
drug
Abciximab



Abstract Id: DrugDDI.d110
Sentence Id: DrugDDI.d110.s1
Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina myocardial infarction and hypertension.

DrugDDI.d110.s1.e0 0 8
drug
Abciximab
DrugDDI.d110.s1.e1 99 109
drug
medications



Abstract Id: DrugDDI.d110
Sentence Id: DrugDDI.d110.s2
These medications have included heparin warfarin, beta-adrenergic receptor blockers , calcium channel antagonists, angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin .

DrugDDI.d110.s2.e0 5 15
drug
medications
DrugDDI.d110.s2.e1 28 34
drug
heparin
DrugDDI.d110.s2.e2 44 74
drug
beta-adrenergic receptor blockers
DrugDDI.d110.s2.e3 76 89
drug
calcium channel
DrugDDI.d110.s2.e4 102 138
drug
angiotensin converting enzyme inhibitors
DrugDDI.d110.s2.e5 158 165
drug
nitrates
DrugDDI.d110.s2.e6 167 177
drug
ticlopidine
DrugDDI.d110.s2.e7 182 188
drug
aspirin



Abstract Id: DrugDDI.d110
Sentence Id: DrugDDI.d110.s3
Heparin , other anticoagulants , thrombolytic s, and anti platelet agents are associated with an increase in bleeding.

DrugDDI.d110.s3.e0 0 6
drug
Heparin
DrugDDI.d110.s3.e1 13 26
drug
anticoagulants
DrugDDI.d110.s3.e2 28 39
drug
thrombolytic
DrugDDI.d110.s3.e3 45 62
drug
anti platelet agents



Abstract Id: DrugDDI.d110
Sentence Id: DrugDDI.d110.s4
Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies .

DrugDDI.d110.s4.e0 107 126
drug
monoclonal antibodies



Abstract Id: DrugDDI.d426
Sentence Id: DrugDDI.d426.s0
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate .

DrugDDI.d426.s0.e0 22 28
drug
alcohol
DrugDDI.d426.s0.e1 32 42
drug
Acamprosate
DrugDDI.d426.s0.e2 83 89
drug
alcohol
DrugDDI.d426.s0.e3 92 102
drug
acamprosate



Abstract Id: DrugDDI.d426
Sentence Id: DrugDDI.d426.s1
Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate .

DrugDDI.d426.s1.e0 50 59
drug
disulfiram
DrugDDI.d426.s1.e1 62 69
drug
diazepam
DrugDDI.d426.s1.e2 104 114
drug
acamprosate



Abstract Id: DrugDDI.d426
Sentence Id: DrugDDI.d426.s2
Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate .

DrugDDI.d426.s2.e0 19 28
drug
naltrexone
DrugDDI.d426.s2.e1 33 43
drug
Acamprosate
DrugDDI.d426.s2.e2 95 105
drug
acamprosate

interaction DrugDDI.d426.s2.e0 DrugDDI.d426.s2.e1

Abstract Id: DrugDDI.d426
Sentence Id: DrugDDI.d426.s4
The pharmacokinetics of naltrexone and its major metabolite 6- beta-naltrexol were unaffected following co-administration with Acamprosate .

DrugDDI.d426.s4.e0 21 30
drug
naltrexone
DrugDDI.d426.s4.e1 54 67
drug
beta-naltrexol
DrugDDI.d426.s4.e2 112 122
drug
Acamprosate



Abstract Id: DrugDDI.d426
Sentence Id: DrugDDI.d426.s5
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives (including benzodiazepines ), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .

DrugDDI.d426.s5.e0 80 90
drug
Acamprosate
DrugDDI.d426.s5.e1 108 118
drug
anxiolytics
DrugDDI.d426.s5.e2 120 128
drug
hypnotics
DrugDDI.d426.s5.e3 132 140
drug
sedatives
DrugDDI.d426.s5.e4 151 165
drug
benzodiazepines
DrugDDI.d426.s5.e5 170 189
drug
non-opioid analgesics
DrugDDI.d426.s5.e6 249 259
drug
medications



Abstract Id: DrugDDI.d426
Sentence Id: DrugDDI.d426.s6
Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.

DrugDDI.d426.s6.e0 14 24
drug
Acamprosate
DrugDDI.d426.s6.e1 42 56
drug
antidepressants
DrugDDI.d426.s6.e2 137 146
drug
medication

interaction DrugDDI.d426.s6.e0 DrugDDI.d426.s6.e1

Abstract Id: DrugDDI.d574
Sentence Id: DrugDDI.d574.s0
Concomitant use with iron supplement s may result in the reduced absorption of iron .

DrugDDI.d574.s0.e0 18 31
drug
iron supplement
DrugDDI.d574.s0.e1 66 69
drug
iron



Abstract Id: DrugDDI.d89
Sentence Id: DrugDDI.d89.s0
Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.

DrugDDI.d89.s0.e0 19 28
drug
probenecid
DrugDDI.d89.s0.e1 33 41
drug
acyclovir

interaction DrugDDI.d89.s0.e0 DrugDDI.d89.s0.e1

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s0
Ethanol :Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol .

DrugDDI.d6.s0.e0 0 6
drug
Ethanol
DrugDDI.d6.s0.e1 36 45
drug
etretinate
DrugDDI.d6.s0.e2 82 90
drug
acitretin
DrugDDI.d6.s0.e3 94 100
drug
ethanol

interaction DrugDDI.d6.s0.e2 DrugDDI.d6.s0.e3

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s1
Glibenclamide : In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide ) in 3 of the 7 subjects.

DrugDDI.d6.s1.e0 0 12
drug
Glibenclamide
DrugDDI.d6.s1.e1 47 55
drug
acitretin
DrugDDI.d6.s1.e2 107 119
drug
glibenclamide
DrugDDI.d6.s1.e3 122 133
drug
sulfonylurea
DrugDDI.d6.s1.e4 143 156
drug
chlorpropamide

interaction DrugDDI.d6.s1.e1 DrugDDI.d6.s1.e2

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s2
Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.

DrugDDI.d6.s2.e0 57 69
drug
glibenclamide
DrugDDI.d6.s2.e1 92 100
drug
acitretin



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s3
Careful supervision of diabetic patients under treatment with Soriatane is recommended.

DrugDDI.d6.s3.e0 54 62
drug
Soriatane



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s4
Hormonal Contraceptives : It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives .

DrugDDI.d6.s4.e0 8 21
drug
Contraceptives
DrugDDI.d6.s4.e1 89 97
drug
acitretin
DrugDDI.d6.s4.e2 101 126
drug
combined oral contraceptives



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s5
However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations .

DrugDDI.d6.s5.e0 32 40
drug
acitretin
DrugDDI.d6.s5.e1 58 70
drug
contraceptive
DrugDDI.d6.s5.e2 79 117
drug
microdosed progestin minipill preparations

interaction DrugDDI.d6.s5.e0 DrugDDI.d6.s5.e2

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s6
Microdosed minipill progestin preparations are not recommended for use with Soriatane .

DrugDDI.d6.s6.e0 18 38
drug
progestin preparations
DrugDDI.d6.s6.e1 66 74
drug
Soriatane

interaction DrugDDI.d6.s6.e0 DrugDDI.d6.s6.e1

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s7
It is not known whether other progestational contraceptives , such as implants and injectables, are adequate methods of contraception during acitretin therapy.

DrugDDI.d6.s7.e0 38 51
drug
contraceptives
DrugDDI.d6.s7.e1 121 129
drug
acitretin



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s8
Methotrexate : An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate .

DrugDDI.d6.s8.e0 0 11
drug
Methotrexate
DrugDDI.d6.s8.e1 79 90
drug
methotrexate
DrugDDI.d6.s8.e2 94 103
drug
etretinate

interaction DrugDDI.d6.s8.e1 DrugDDI.d6.s8.e2

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s9
Consequently, the combination of methotrexate with acitretin is also contraindicated.

DrugDDI.d6.s9.e0 29 40
drug
methotrexate
DrugDDI.d6.s9.e1 45 53
drug
acitretin

interaction DrugDDI.d6.s9.e0 DrugDDI.d6.s9.e1

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s10
Phenytoin : If acitretin is given concurrently with phenytoin , the protein binding of phenytoin may be reduced.

DrugDDI.d6.s10.e0 0 8
drug
Phenytoin
DrugDDI.d6.s10.e1 12 20
drug
acitretin
DrugDDI.d6.s10.e2 44 52
drug
phenytoin
DrugDDI.d6.s10.e3 73 81
drug
phenytoin

interaction DrugDDI.d6.s10.e1 DrugDDI.d6.s10.e2

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s11
Tetracyclines : Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.

DrugDDI.d6.s11.e0 0 12
drug
Tetracyclines
DrugDDI.d6.s11.e1 23 31
drug
acitretin
DrugDDI.d6.s11.e2 35 47
drug
tetracyclines

interaction DrugDDI.d6.s11.e1 DrugDDI.d6.s11.e2

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s12
Vitamin A and oral retinoids : Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.

DrugDDI.d6.s12.e0 0 7
drug
Vitamin A
DrugDDI.d6.s12.e1 15 23
drug
retinoids
DrugDDI.d6.s12.e2 52 59
drug
vitamin A
DrugDDI.d6.s12.e3 75 83
drug
retinoids
DrugDDI.d6.s12.e4 88 96
drug
acitretin

interaction DrugDDI.d6.s12.e2 DrugDDI.d6.s12.e4

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s13
Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine , digoxin , or glyburide .

DrugDDI.d6.s13.e0 57 65
drug
acitretin
DrugDDI.d6.s13.e1 69 78
drug
cimetidine
DrugDDI.d6.s13.e2 80 86
drug
digoxin
DrugDDI.d6.s13.e3 90 98
drug
glyburide



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s14
Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type ( warfarin ) revealed no interaction.

DrugDDI.d6.s14.e0 29 37
drug
acitretin
DrugDDI.d6.s14.e1 59 72
drug
anticoagulants
DrugDDI.d6.s14.e2 78 85
drug
coumarin
DrugDDI.d6.s14.e3 91 98
drug
warfarin



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s16
Blood Sugar: Some patients receiving retinoids have experienced problems with blood sugar control.

DrugDDI.d6.s16.e0 32 40
drug
retinoids



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s17
In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.

DrugDDI.d6.s17.e0 52 59
drug
retinoid



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s21
It is recommended that these tests be performed weekly or every other week until the lipid response to Soriatane has stabilized.

DrugDDI.d6.s21.e0 85 93
drug
Soriatane



Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s22
Liver Function Tests: Elevations of AST (SGOT), ALT (SGPT) or LDH were experienced by approximately 1 in 3 patients treated with Soriatane .

DrugDDI.d6.s22.e0 31 33
drug
AST
DrugDDI.d6.s22.e1 52 54
drug
LDH
DrugDDI.d6.s22.e2 108 116
drug
Soriatane

interaction DrugDDI.d6.s22.e0 DrugDDI.d6.s22.e2

Abstract Id: DrugDDI.d6
Sentence Id: DrugDDI.d6.s23
It is recommended that these tests be performed prior to initiation of Soriatane therapy, at 1- to 2-week intervals until stable and thereafter at intervals as clinically indicated.

DrugDDI.d6.s23.e0 59 67
drug
Soriatane



Abstract Id: DrugDDI.d49
Sentence Id: DrugDDI.d49.s0
Methotrexate HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX .

DrugDDI.d49.s0.e0 0 11
drug
Methotrexate
DrugDDI.d49.s0.e1 78 80
drug
MTX



Abstract Id: DrugDDI.d49
Sentence Id: DrugDDI.d49.s1
The data do not suggest the need for dose adjustment of either HUMIRA or MTX .

DrugDDI.d49.s1.e0 51 56
drug
HUMIRA
DrugDDI.d49.s1.e1 59 61
drug
MTX



Abstract Id: DrugDDI.d49
Sentence Id: DrugDDI.d49.s2
Anakinra Concurrent administration of anakinra (an interleukin-1 antagonist ) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal product s alone.

DrugDDI.d49.s2.e0 0 7
drug
Anakinra
DrugDDI.d49.s2.e1 34 41
drug
anakinra
DrugDDI.d49.s2.e2 45 67
drug
interleukin-1 antagonist
DrugDDI.d49.s2.e3 217 232
drug
medicinal product



Abstract Id: DrugDDI.d49
Sentence Id: DrugDDI.d49.s3
The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.

DrugDDI.d49.s3.e0 22 29
drug
anakinra
DrugDDI.d49.s3.e1 51 56
drug
HUMIRA



Abstract Id: DrugDDI.d49
Sentence Id: DrugDDI.d49.s4
Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA , may also result i n similar toxicities.

DrugDDI.d49.s4.e0 26 33
drug
anakinra
DrugDDI.d49.s4.e1 71 76
drug
HUMIRA

interaction DrugDDI.d49.s4.e0 DrugDDI.d49.s4.e1

Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s0
Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta-adrenergic blocking agents , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile.

DrugDDI.d420.s0.e0 11 19
drug
Adenocard
DrugDDI.d420.s0.e1 21 29
drug
adenosine
DrugDDI.d420.s0.e2 81 97
drug
cardioactive drugs
DrugDDI.d420.s0.e3 105 113
drug
quinidine
DrugDDI.d420.s0.e4 115 143
drug
beta-adrenergic blocking agents
DrugDDI.d420.s0.e5 145 172
drug
calcium channel blocking agents
DrugDDI.d420.s0.e6 177 213
drug
angiotensin converting enzyme inhibitors



Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s1
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard .

DrugDDI.d420.s1.e0 0 6
drug
Digoxin
DrugDDI.d420.s1.e1 10 18
drug
verapamil
DrugDDI.d420.s1.e2 86 94
drug
Adenocard

interaction DrugDDI.d420.s1.e0 DrugDDI.d420.s1.e2

Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s2
Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents.

DrugDDI.d420.s2.e0 88 96
drug
Adenocard



Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s3
The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.

DrugDDI.d420.s3.e0 8 16
drug
Adenocard
DrugDDI.d420.s3.e1 36 44
drug
digitalis

interaction DrugDDI.d420.s3.e0 DrugDDI.d420.s3.e1

Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s4
The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .

DrugDDI.d420.s4.e0 12 20
drug
adenosine
DrugDDI.d420.s4.e1 37 51
drug
methylxanthines
DrugDDI.d420.s4.e2 58 65
drug
caffeine
DrugDDI.d420.s4.e3 69 80
drug
theophylline

interaction DrugDDI.d420.s4.e0 DrugDDI.d420.s4.e1
interaction DrugDDI.d420.s4.e0 DrugDDI.d420.s4.e2
interaction DrugDDI.d420.s4.e0 DrugDDI.d420.s4.e3

Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s5
In the presence of these methylxanthines , larger doses of adenosine may be required or adenosine may not be effective.

DrugDDI.d420.s5.e0 20 34
drug
methylxanthines
DrugDDI.d420.s5.e1 49 57
drug
adenosine
DrugDDI.d420.s5.e2 73 81
drug
adenosine

interaction DrugDDI.d420.s5.e0 DrugDDI.d420.s5.e2

Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s6
Adenosine effects are potentiated by dipyridamole .

DrugDDI.d420.s6.e0 0 8
drug
Adenosine
DrugDDI.d420.s6.e1 32 43
drug
dipyridamole

interaction DrugDDI.d420.s6.e0 DrugDDI.d420.s6.e1

Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s7
Thus, smaller doses of adenosine may be effective in the presence of dipyridamole .

DrugDDI.d420.s7.e0 19 27
drug
adenosine
DrugDDI.d420.s7.e1 57 68
drug
dipyridamole

interaction DrugDDI.d420.s7.e0 DrugDDI.d420.s7.e1

Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s8
Carbamazepine has been reported to increase the degree of heart block produced by other agents.

DrugDDI.d420.s8.e0 0 12
drug
Carbamazepine



Abstract Id: DrugDDI.d420
Sentence Id: DrugDDI.d420.s9
As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine .

DrugDDI.d420.s9.e0 20 28
drug
adenosine
DrugDDI.d420.s9.e1 122 134
drug
carbamazepine



Abstract Id: DrugDDI.d389
Sentence Id: DrugDDI.d389.s0
Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended.

DrugDDI.d389.s0.e0 21 36
drug
antifungal agents
DrugDDI.d389.s0.e1 43 54
drug
ketoconazole
DrugDDI.d389.s0.e2 57 68
drug
itraconazole



Abstract Id: DrugDDI.d389
Sentence Id: DrugDDI.d389.s1
Nafazodone, fluvoxamine , cimetidine (consider Xanax dose reduction).

DrugDDI.d389.s1.e0 11 21
drug
fluvoxamine
DrugDDI.d389.s1.e1 23 32
drug
cimetidine
DrugDDI.d389.s1.e2 42 46
drug
Xanax



Abstract Id: DrugDDI.d389
Sentence Id: DrugDDI.d389.s2
Fluoxetine , OCs, sertraline , diltiazem , macrolide antibiotics (exercise caution).

DrugDDI.d389.s2.e0 0 9
drug
Fluoxetine
DrugDDI.d389.s2.e1 15 24
drug
sertraline
DrugDDI.d389.s2.e2 26 34
drug
diltiazem
DrugDDI.d389.s2.e3 36 55
drug
macrolide antibiotics



Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s0
Dexamethasone : Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.

DrugDDI.d552.s0.e0 0 12
drug
Dexamethasone
DrugDDI.d552.s0.e1 48 67
drug
albendazole sulfoxide
DrugDDI.d552.s0.e2 93 105
drug
dexamethasone
DrugDDI.d552.s0.e3 137 147
drug
albendazole

interaction DrugDDI.d552.s0.e2 DrugDDI.d552.s0.e3

Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s1
Praziquantel : In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.

DrugDDI.d552.s1.e0 0 11
drug
Praziquantel
DrugDDI.d552.s1.e1 27 38
drug
praziquantel
DrugDDI.d552.s1.e2 109 128
drug
albendazole sulfoxide
DrugDDI.d552.s1.e3 208 218
drug
albendazole

interaction DrugDDI.d552.s1.e1 DrugDDI.d552.s1.e2

Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s2
Mean T max and mean plasma elimination half-life of albendazole sulfoxide were unchanged.

DrugDDI.d552.s2.e0 5 7
drug
max
DrugDDI.d552.s2.e1 43 62
drug
albendazole sulfoxide



Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s3
The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).

DrugDDI.d552.s3.e0 21 32
drug
praziquantel
DrugDDI.d552.s3.e1 75 85
drug
albendazole



Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s4
Cimetidine : Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) ( n=7 ) compared with albendazole (20 mg/kg/day) alone (n=12).

DrugDDI.d552.s4.e0 0 9
drug
Cimetidine
DrugDDI.d552.s4.e1 11 30
drug
Albendazole sulfoxide
DrugDDI.d552.s4.e2 123 132
drug
cimetidine
DrugDDI.d552.s4.e3 147 149
drug
n=7
DrugDDI.d552.s4.e4 163 173
drug
albendazole

interaction DrugDDI.d552.s4.e1 DrugDDI.d552.s4.e2

Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s5
Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.

DrugDDI.d552.s5.e0 0 19
drug
Albendazole sulfoxide



Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s6
Theophylline : The pharmacokinetics of theophylline ( aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.

DrugDDI.d552.s6.e0 0 11
drug
Theophylline
DrugDDI.d552.s6.e1 34 45
drug
theophylline
DrugDDI.d552.s6.e2 47 59
drug
aminophylline
DrugDDI.d552.s6.e3 128 138
drug
albendazole



Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s0
PROLEUKIN may affect central nervous function.

DrugDDI.d567.s0.e0 0 8
drug
PROLEUKIN



Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s1
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics , analgesics , antiemetics , sedatives , tranquilizers ).

DrugDDI.d567.s1.e0 68 84
drug
psychotropic drugs
DrugDDI.d567.s1.e1 91 99
drug
narcotics
DrugDDI.d567.s1.e2 101 110
drug
analgesics
DrugDDI.d567.s1.e3 112 122
drug
antiemetics
DrugDDI.d567.s1.e4 124 132
drug
sedatives
DrugDDI.d567.s1.e5 134 146
drug
tranquilizers



Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s2
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides , indomethacin ), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin ) or hepatotoxic (e.g., methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems.

DrugDDI.d567.s2.e0 26 30
drug
drugs
DrugDDI.d567.s2.e1 58 72
drug
aminoglycosides
DrugDDI.d567.s2.e2 74 85
drug
indomethacin
DrugDDI.d567.s2.e3 144 154
drug
doxorubicin
DrugDDI.d567.s2.e4 175 186
drug
methotrexate
DrugDDI.d567.s2.e5 188 199
drug
asparaginase
DrugDDI.d567.s2.e6 212 220
drug
PROLEUKIN

interaction DrugDDI.d567.s2.e0 DrugDDI.d567.s2.e6
interaction DrugDDI.d567.s2.e2 DrugDDI.d567.s2.e6
interaction DrugDDI.d567.s2.e4 DrugDDI.d567.s2.e6

Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s3
The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.

DrugDDI.d567.s3.e0 22 30
drug
PROLEUKIN
DrugDDI.d567.s3.e1 51 70
drug
antineoplastic agents



Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s4
In addition, reduced kidney and liver function secondary to PROLEUKIN treatment may delay elimination of concomitant medications and increase the risk of adverse events from those drugs .

DrugDDI.d567.s4.e0 27 31
drug
liver
DrugDDI.d567.s4.e1 51 59
drug
PROLEUKIN
DrugDDI.d567.s4.e2 101 111
drug
medications
DrugDDI.d567.s4.e3 154 158
drug
drugs

interaction DrugDDI.d567.s4.e1 DrugDDI.d567.s4.e2

Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s5
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa .

DrugDDI.d567.s5.e0 107 115
drug
PROLEUKIN
DrugDDI.d567.s5.e1 119 138
drug
antineoplastic agents
DrugDDI.d567.s5.e2 153 163
drug
dacarbazine
DrugDDI.d567.s5.e3 165 176
drug
cis-platinum
DrugDDI.d567.s5.e4 178 186
drug
tamoxifen
DrugDDI.d567.s5.e5 190 204
drug
interferon-alfa

interaction DrugDDI.d567.s5.e0 DrugDDI.d567.s5.e1
interaction DrugDDI.d567.s5.e0 DrugDDI.d567.s5.e3
interaction DrugDDI.d567.s5.e0 DrugDDI.d567.s5.e5

Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s8
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.

DrugDDI.d567.s8.e0 143 151
drug
PROLEUKIN
DrugDDI.d567.s8.e1 155 169
drug
interferon-alfa

interaction DrugDDI.d567.s8.e0 DrugDDI.d567.s8.e1

Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s9
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN , including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.

DrugDDI.d567.s9.e0 120 134
drug
interferon-alfa
DrugDDI.d567.s9.e1 138 146
drug
PROLEUKIN

interaction DrugDDI.d567.s9.e0 DrugDDI.d567.s9.e1

Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s10
Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .

DrugDDI.d567.s10.e0 8 22
drug
glucocorticoids
DrugDDI.d567.s10.e1 44 52
drug
PROLEUKIN
DrugDDI.d567.s10.e2 188 196
drug
PROLEUKIN
DrugDDI.d567.s10.e3 233 241
drug
PROLEUKIN
DrugDDI.d567.s10.e4 265 279
drug
12 Beta-blockers
DrugDDI.d567.s10.e5 283 304
drug
other antihypertensives
DrugDDI.d567.s10.e6 340 348
drug
PROLEUKIN

interaction DrugDDI.d567.s10.e0 DrugDDI.d567.s10.e1
interaction DrugDDI.d567.s10.e4 DrugDDI.d567.s10.e6
interaction DrugDDI.d567.s10.e5 DrugDDI.d567.s10.e6

Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s11
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.

DrugDDI.d567.s11.e0 131 143
drug
interleukin-2



Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s14
Some clinicians have noted that these reactions resemble the immediate side effects caused by interleukin-2 administration, however the cause of contrast reactions after interleukin-2 therapy is unknown.

DrugDDI.d567.s14.e0 80 92
drug
interleukin-2



Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s15
Most events were reported to occur when contrast media was given within 4 weeks after the last dose of interleukin-2 .

DrugDDI.d567.s15.e0 84 96
drug
interleukin-2



Abstract Id: DrugDDI.d567
Sentence Id: DrugDDI.d567.s16
These events were also reported to occur when contrast media was given several months after interleukin-2 treatment.

DrugDDI.d567.s16.e0 77 89
drug
interleukin-2



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s3
In a chronic toxicity study, cynomolgus monkeys were dosed weekly for 52 weeks with intravenous alefacept at 1 mg/kg/dose or 20 mg/kg/dose.

DrugDDI.d275.s3.e0 81 89
drug
alefacept



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s8
In a separate study, baboons given 3 doses of alefacept at 1 mg/kg every 8 weeks were found to have centroblast proliferation in B-cell dependent areas in the germinal centers of the spleen following a 116-day washout period.

DrugDDI.d275.s8.e0 37 45
drug
alefacept



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s16
Since the effect of AMEVIVE@ on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE@ who become pregnant into the Biogen Pregnancy Registry by calling 1-866- AMEVIVE (1-866-263-8483).

DrugDDI.d275.s16.e0 232 238
drug
AMEVIVE



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s18
No abortifacient or teratogenic effects were observed in cynomolgus monkeys following intravenous bolus injections of AMEVIVE@ administered weekly during the period of organogenesis to gestation.

DrugDDI.d275.s18.e0 2 14
drug
abortifacient



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s24
If pregnancy occurs while taking AMEVIVE@, continued use of the drug should be assessed.

DrugDDI.d275.s24.e0 54 57
drug
drug



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s27
Because many drugs are excreted in human milk, and because there exists the potential for serious adverse reactions in nursing infants from AMEVIVE@, a decision should be made whether to discontinue nursing while taking the drug or to discontinue the use of the drug , taking into account the importance of the drug to the mother.

DrugDDI.d275.s27.e0 11 15
drug
drugs
DrugDDI.d275.s27.e1 189 192
drug
drug
DrugDDI.d275.s27.e2 219 222
drug
drug
DrugDDI.d275.s27.e3 259 262
drug
drug



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s34
Pediatric Use .

DrugDDI.d275.s34.e0 0 8
drug
Pediatric



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s35
The safety and efficacy of AMEVIVE@ in pediatric patients have not been studied.

DrugDDI.d275.s35.e0 32 40
drug
pediatric



Abstract Id: DrugDDI.d275
Sentence Id: DrugDDI.d275.s36
AMEVIVE@ is not indicated for pediatric patients.

DrugDDI.d275.s36.e0 25 33
drug
pediatric



Abstract Id: DrugDDI.d318
Sentence Id: DrugDDI.d318.s0
Intravenous ranitidine was shown to double the bioavailability of oral alendronate .

DrugDDI.d318.s0.e0 11 20
drug
ranitidine
DrugDDI.d318.s0.e1 61 71
drug
alendronate

interaction DrugDDI.d318.s0.e0 DrugDDI.d318.s0.e1

Abstract Id: DrugDDI.d318
Sentence Id: DrugDDI.d318.s3
Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate .

DrugDDI.d318.s3.e0 18 24
drug
calcium
DrugDDI.d318.s3.e1 44 50
drug
cations
DrugDDI.d318.s3.e2 86 96
drug
alendronate

interaction DrugDDI.d318.s3.e0 DrugDDI.d318.s3.e2
interaction DrugDDI.d318.s3.e1 DrugDDI.d318.s3.e2

Abstract Id: DrugDDI.d566
Sentence Id: DrugDDI.d566.s0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics .

DrugDDI.d566.s0.e0 90 96
drug
ALFENTA
DrugDDI.d566.s0.e1 133 146
drug
CNS depressants
DrugDDI.d566.s0.e2 153 164
drug
barbiturates
DrugDDI.d566.s0.e3 166 178
drug
tranquilizers
DrugDDI.d566.s0.e4 180 186
drug
opioids
DrugDDI.d566.s0.e5 200 217
drug
general anesthetics

interaction DrugDDI.d566.s0.e0 DrugDDI.d566.s0.e1
interaction DrugDDI.d566.s0.e0 DrugDDI.d566.s0.e2
interaction DrugDDI.d566.s0.e0 DrugDDI.d566.s0.e3
interaction DrugDDI.d566.s0.e0 DrugDDI.d566.s0.e4
interaction DrugDDI.d566.s0.e0 DrugDDI.d566.s0.e5

Abstract Id: DrugDDI.d566
Sentence Id: DrugDDI.d566.s3
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.

DrugDDI.d566.s3.e0 71 81
drug
anesthetics
DrugDDI.d566.s3.e1 137 143
drug
ALFENTA
DrugDDI.d566.s3.e2 172 183
drug
erythromycin
DrugDDI.d566.s3.e3 188 194
drug
ALFENTA
DrugDDI.d566.s3.e4 218 224
drug
ALFENTA

interaction DrugDDI.d566.s3.e0 DrugDDI.d566.s3.e1

Abstract Id: DrugDDI.d566
Sentence Id: DrugDDI.d566.s4
Cimetidine reduces the clearance of ALFENTA .

DrugDDI.d566.s4.e0 0 9
drug
Cimetidine
DrugDDI.d566.s4.e1 31 37
drug
ALFENTA

interaction DrugDDI.d566.s4.e0 DrugDDI.d566.s4.e1

Abstract Id: DrugDDI.d566
Sentence Id: DrugDDI.d566.s5
Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.

DrugDDI.d566.s5.e0 16 22
drug
ALFENTA
DrugDDI.d566.s5.e1 93 99
drug
ALFENTA



Abstract Id: DrugDDI.d566
Sentence Id: DrugDDI.d566.s6
Perioperative administration of drugs affecting hepatic blood flow or enzyme function may reduce plasma clearance and prolong recovery.

DrugDDI.d566.s6.e0 29 33
drug
drugs



Abstract Id: DrugDDI.d291
Sentence Id: DrugDDI.d291.s0
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.

DrugDDI.d291.s0.e0 77 85
drug
UROXATRAL
DrugDDI.d291.s0.e1 94 107
drug
alpha-blockers



Abstract Id: DrugDDI.d291
Sentence Id: DrugDDI.d291.s1
However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers .

DrugDDI.d291.s1.e0 37 45
drug
UROXATRAL
DrugDDI.d291.s1.e1 83 96
drug
alpha-blockers

interaction DrugDDI.d291.s1.e0 DrugDDI.d291.s1.e1

Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s0
Effects of Other Drugs on Aliskiren Based on in-vitro studies, aliskiren is metabolized by CYP 3A4.

DrugDDI.d456.s0.e0 14 18
drug
Drugs
DrugDDI.d456.s0.e1 21 29
drug
Aliskiren
DrugDDI.d456.s0.e2 53 61
drug
aliskiren
DrugDDI.d456.s0.e3 77 79
drug
CYP

interaction DrugDDI.d456.s0.e2 DrugDDI.d456.s0.e3

Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s1
Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramapril, valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.

DrugDDI.d456.s1.e0 19 28
drug
lovastatin
DrugDDI.d456.s1.e1 30 37
drug
atenolol
DrugDDI.d456.s1.e2 39 46
drug
warfarin
DrugDDI.d456.s1.e3 48 57
drug
furosemide
DrugDDI.d456.s1.e4 59 65
drug
digoxin
DrugDDI.d456.s1.e5 67 75
drug
celecoxib
DrugDDI.d456.s1.e6 77 95
drug
hydrochlorothiazide
DrugDDI.d456.s1.e7 106 114
drug
valsartan
DrugDDI.d456.s1.e8 116 124
drug
metformin
DrugDDI.d456.s1.e9 128 137
drug
amlodipine
DrugDDI.d456.s1.e10 184 192
drug
aliskiren



Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s2
Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.

DrugDDI.d456.s2.e0 19 28
drug
irbesartan
DrugDDI.d456.s2.e1 36 44
drug
aliskiren

interaction DrugDDI.d456.s2.e0 DrugDDI.d456.s2.e1

Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s3
Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.

DrugDDI.d456.s3.e0 19 30
drug
atorvastatin
DrugDDI.d456.s3.e1 60 68
drug
aliskiren

interaction DrugDDI.d456.s3.e0 DrugDDI.d456.s3.e1

Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s4
Ketoconazole Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren .

DrugDDI.d456.s4.e0 0 11
drug
Ketoconazole
DrugDDI.d456.s4.e1 47 58
drug
ketoconazole
DrugDDI.d456.s4.e2 63 71
drug
aliskiren
DrugDDI.d456.s4.e3 122 130
drug
aliskiren

interaction DrugDDI.d456.s4.e1 DrugDDI.d456.s4.e2

Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s5
A 400 mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.

DrugDDI.d456.s5.e0 61 69
drug
aliskiren



Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s6
Effects of Aliskiren on Other Drugs Aliskiren does not inhibit the CYP450 isoenzymes ( CYP1A2 , 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.

DrugDDI.d456.s6.e0 9 17
drug
Aliskiren
DrugDDI.d456.s6.e1 25 29
drug
Drugs
DrugDDI.d456.s6.e2 62 71
drug
isoenzymes
DrugDDI.d456.s6.e3 73 78
drug
CYP1A2
DrugDDI.d456.s6.e4 104 106
drug
CYP
DrugDDI.d456.s6.e5 118 120
drug
CYP



Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s7
Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide .

DrugDDI.d456.s7.e0 19 27
drug
aliskiren
DrugDDI.d456.s7.e1 74 83
drug
lovastatin
DrugDDI.d456.s7.e2 85 91
drug
digoxin
DrugDDI.d456.s7.e3 93 101
drug
valsartan
DrugDDI.d456.s7.e4 103 112
drug
amlodipine
DrugDDI.d456.s7.e5 114 122
drug
metformin
DrugDDI.d456.s7.e6 124 132
drug
celecoxib
DrugDDI.d456.s7.e7 134 141
drug
atenolol
DrugDDI.d456.s7.e8 143 154
drug
atorvastatin
DrugDDI.d456.s7.e9 156 163
drug
ramipril
DrugDDI.d456.s7.e10 166 184
drug
hydrochlorothiazide



Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s8
Warfarin The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.

DrugDDI.d456.s8.e0 0 7
drug
Warfarin
DrugDDI.d456.s8.e1 20 28
drug
aliskiren
DrugDDI.d456.s8.e2 31 38
drug
warfarin



Abstract Id: DrugDDI.d456
Sentence Id: DrugDDI.d456.s9
Furosemide When aliskiren was co-administered with furosemide , the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.

DrugDDI.d456.s9.e0 0 9
drug
Furosemide
DrugDDI.d456.s9.e1 14 22
drug
aliskiren
DrugDDI.d456.s9.e2 45 54
drug
furosemide
DrugDDI.d456.s9.e3 71 80
drug
furosemide

interaction DrugDDI.d456.s9.e1 DrugDDI.d456.s9.e2

Abstract Id: DrugDDI.d14
Sentence Id: DrugDDI.d14.s0
Patients who are applying Panretin@ gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide ), a common component of insect repellent products.

DrugDDI.d14.s0.e0 77 80
drug
DEET
DrugDDI.d14.s0.e1 84 104
drug
N-diethyl-m-toluamide



Abstract Id: DrugDDI.d14
Sentence Id: DrugDDI.d14.s1
Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation.

DrugDDI.d14.s1.e0 38 41
drug
DEET
DrugDDI.d14.s1.e1 54 57
drug
DEET



Abstract Id: DrugDDI.d14
Sentence Id: DrugDDI.d14.s2
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents , including protease inhibitors , macrolide antibiotics , and azole antifungals , the effect of Panretin@ gel on the steady-state concentrations of these drugs is not known.

DrugDDI.d14.s2.e0 94 113
drug
antiretroviral agents
DrugDDI.d14.s2.e1 124 141
drug
protease inhibitors
DrugDDI.d14.s2.e2 143 162
drug
macrolide antibiotics
DrugDDI.d14.s2.e3 167 182
drug
azole antifungals
DrugDDI.d14.s2.e4 245 249
drug
drugs



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s0
The following drug interactions were observed in some patients undergoing treatment with oral allopurinol .

DrugDDI.d61.s0.e0 81 91
drug
allopurinol



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s1
Although the pattern of use for oral allopurinol includes longer term therapy, particularly for gout and renal calculi, the experience gained may be relevant.

DrugDDI.d61.s1.e0 30 40
drug
allopurinol



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s2
Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.

DrugDDI.d61.s2.e0 0 13
drug
Mercaptopurine
DrugDDI.d61.s2.e1 15 26
drug
Azathioprine
DrugDDI.d61.s2.e2 28 38
drug
Allopurinol
DrugDDI.d61.s2.e3 70 83
drug
mercaptopurine
DrugDDI.d61.s2.e4 87 98
drug
azathioprine

interaction DrugDDI.d61.s2.e2 DrugDDI.d61.s2.e3
interaction DrugDDI.d61.s2.e2 DrugDDI.d61.s2.e4

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s3
This oxidation, which is catalyzed by xanthine oxidase , inactivates mercaptopurine .

DrugDDI.d61.s3.e0 32 46
drug
xanthine oxidase
DrugDDI.d61.s3.e1 59 72
drug
mercaptopurine



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s4
In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine .

DrugDDI.d61.s4.e0 19 32
drug
mercaptopurine
DrugDDI.d61.s4.e1 34 43
drug
Purinethol
DrugDDI.d61.s4.e2 47 58
drug
azathioprine
DrugDDI.d61.s4.e3 60 65
drug
Imuran
DrugDDI.d61.s4.e4 109 119
drug
allopurinol
DrugDDI.d61.s4.e5 205 218
drug
mercaptopurine
DrugDDI.d61.s4.e6 221 232
drug
azathioprine

interaction DrugDDI.d61.s4.e4 DrugDDI.d61.s4.e5

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s5
Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.

DrugDDI.d61.s5.e0 29 42
drug
mercaptopurine
DrugDDI.d61.s5.e1 45 56
drug
azathioprine



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s6
Dicumarol : It has been reported that allopurinol prolongs the half-life of the anticoagulant , dicumarol .

DrugDDI.d61.s6.e0 0 8
drug
Dicumarol
DrugDDI.d61.s6.e1 31 41
drug
allopurinol
DrugDDI.d61.s6.e2 67 79
drug
anticoagulant
DrugDDI.d61.s6.e3 81 89
drug
dicumarol

interaction DrugDDI.d61.s6.e1 DrugDDI.d61.s6.e2

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s7
The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.

DrugDDI.d61.s7.e0 78 88
drug
allopurinol
DrugDDI.d61.s7.e1 115 123
drug
dicumarol

interaction DrugDDI.d61.s7.e0 DrugDDI.d61.s7.e1

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s8
Consequently, prothrombin time should be reassessed periodically in patients receiving both drugs .

DrugDDI.d61.s8.e0 81 85
drug
drugs



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s9
Uricosuric Agents : Since the excretion of oxipurinol is similar to that of urate , uricosuric agents , which increase the excretion of urate , are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase .

DrugDDI.d61.s9.e0 0 15
drug
Uricosuric Agents
DrugDDI.d61.s9.e1 36 45
drug
oxipurinol
DrugDDI.d61.s9.e2 63 67
drug
urate
DrugDDI.d61.s9.e3 69 84
drug
uricosuric agents
DrugDDI.d61.s9.e4 113 117
drug
urate
DrugDDI.d61.s9.e5 156 165
drug
oxipurinol
DrugDDI.d61.s9.e6 201 215
drug
xanthine oxidase

interaction DrugDDI.d61.s9.e3 DrugDDI.d61.s9.e4
interaction DrugDDI.d61.s9.e3 DrugDDI.d61.s9.e5
interaction DrugDDI.d61.s9.e3 DrugDDI.d61.s9.e6

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s10
The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines ( hypoxanthine and xanthine ) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.

DrugDDI.d61.s10.e0 30 45
drug
uricosuric agents
DrugDDI.d61.s10.e1 49 59
drug
allopurinol
DrugDDI.d61.s10.e2 117 128
drug
hypoxanthine
DrugDDI.d61.s10.e3 132 139
drug
xanthine
DrugDDI.d61.s10.e4 208 218
drug
allopurinol

interaction DrugDDI.d61.s10.e0 DrugDDI.d61.s10.e1

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s11
Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents , the possibility should be kept in mind.

DrugDDI.d61.s11.e0 96 106
drug
allopurinol
DrugDDI.d61.s11.e1 131 146
drug
uricosuric agents



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s12
Thiazide Diuretics : The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.

DrugDDI.d61.s12.e0 0 16
drug
Thiazide Diuretics
DrugDDI.d61.s12.e1 51 61
drug
allopurinol
DrugDDI.d61.s12.e2 65 81
drug
thiazide diuretics
DrugDDI.d61.s12.e3 113 123
drug
allopurinol

interaction DrugDDI.d61.s12.e1 DrugDDI.d61.s12.e2

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s13
Review of these case reports indicates that the patients were mainly receiving thiazide diuretics for hypertension and that tests to rule out decreased renal function secondary to hypertensive nephropathy were not often performed.

DrugDDI.d61.s13.e0 67 83
drug
thiazide diuretics



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s14
In those patients in whom renal insufficiency was documented, however, the recommendation to lower the dose of allopurinol was not followed.

DrugDDI.d61.s14.e0 94 104
drug
allopurinol



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s15
Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..

DrugDDI.d61.s15.e0 148 164
drug
thiazide diuretics
DrugDDI.d61.s15.e1 168 178
drug
allopurinol

interaction DrugDDI.d61.s15.e0 DrugDDI.d61.s15.e1

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s16
Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs .

DrugDDI.d61.s16.e0 0 9
drug
Ampicillin
DrugDDI.d61.s16.e1 11 21
drug
Amoxicillin
DrugDDI.d61.s16.e2 94 103
drug
ampicillin
DrugDDI.d61.s16.e3 106 116
drug
amoxicillin
DrugDDI.d61.s16.e4 133 143
drug
allopurinol
DrugDDI.d61.s16.e5 184 188
drug
drugs

interaction DrugDDI.d61.s16.e2 DrugDDI.d61.s16.e4

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s18
Cytotoxic Agent s: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agent s has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol .

DrugDDI.d61.s18.e0 0 13
drug
Cytotoxic Agent
DrugDDI.d61.s18.e1 47 62
drug
cyclophosphamide
DrugDDI.d61.s18.e2 71 84
drug
cytotoxic agent
DrugDDI.d61.s18.e3 166 176
drug
allopurinol

interaction DrugDDI.d61.s18.e1 DrugDDI.d61.s18.e3

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s19
However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine .

DrugDDI.d61.s19.e0 74 84
drug
allopurinol
DrugDDI.d61.s19.e1 137 152
drug
cyclophosphamide
DrugDDI.d61.s19.e2 154 164
drug
doxorubicin
DrugDDI.d61.s19.e3 166 174
drug
bleomycin
DrugDDI.d61.s19.e4 176 187
drug
procarbazine
DrugDDI.d61.s19.e5 194 208
drug
mechlorethamine



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s20
Chlorpropamide : Chlorpropamide s plasma half-life may be prolonged by allopurinol , since allopurinol and chlorpropamide may compete for excretion in the renal tubule.

DrugDDI.d61.s20.e0 0 13
drug
Chlorpropamide
DrugDDI.d61.s20.e1 15 28
drug
Chlorpropamide
DrugDDI.d61.s20.e2 61 71
drug
allopurinol
DrugDDI.d61.s20.e3 78 88
drug
allopurinol
DrugDDI.d61.s20.e4 92 105
drug
chlorpropamide
DrugDDI.d61.s20.e5 109 115
drug
compete

interaction DrugDDI.d61.s20.e1 DrugDDI.d61.s20.e2

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s21
The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.

DrugDDI.d61.s21.e0 61 71
drug
allopurinol
DrugDDI.d61.s21.e1 75 88
drug
chlorpropamide

interaction DrugDDI.d61.s21.e0 DrugDDI.d61.s21.e1

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s22
Cyclosporin : Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.

DrugDDI.d61.s22.e0 0 10
drug
Cyclosporin
DrugDDI.d61.s22.e1 31 42
drug
cyclosporine
DrugDDI.d61.s22.e2 93 109
drug
allopurinol sodium

interaction DrugDDI.d61.s22.e1 DrugDDI.d61.s22.e2

Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s23
Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.

DrugDDI.d61.s23.e0 12 23
drug
cyclosporine
DrugDDI.d61.s23.e1 53 64
drug
cyclosporine
DrugDDI.d61.s23.e2 98 102
drug
drugs



Abstract Id: DrugDDI.d61
Sentence Id: DrugDDI.d61.s24
Tolbutamide s conversion to inactive metabolites has been shown to be catalyzed by xanthine oxidase from rat liver .

DrugDDI.d61.s24.e0 0 10
drug
Tolbutamide
DrugDDI.d61.s24.e1 32 42
drug
metabolites
DrugDDI.d61.s24.e2 70 84
drug
xanthine oxidase
DrugDDI.d61.s24.e3 92 96
drug
liver

interaction DrugDDI.d61.s24.e0 DrugDDI.d61.s24.e2

Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s0
Ergot-Containing Drugs These drugs have been reported to cause prolonged vasospastic reactions.

DrugDDI.d91.s0.e0 0 20
drug
Ergot-Containing Drugs



Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s1
Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type medications (like dihydroergotamine or methysergide ) and AXERT@ within 24 hours of each other should be avoided.

DrugDDI.d91.s1.e0 66 75
drug
ergotamine
DrugDDI.d91.s1.e1 99 109
drug
medications
DrugDDI.d91.s1.e2 115 131
drug
dihydroergotamine
DrugDDI.d91.s1.e3 134 145
drug
methysergide
DrugDDI.d91.s1.e4 150 155
drug
AXERT@

interaction DrugDDI.d91.s1.e0 DrugDDI.d91.s1.e4
interaction DrugDDI.d91.s1.e1 DrugDDI.d91.s1.e4
interaction DrugDDI.d91.s1.e2 DrugDDI.d91.s1.e4
interaction DrugDDI.d91.s1.e3 DrugDDI.d91.s1.e4

Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s2
Monoamine Oxidase Inhibitors Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.

DrugDDI.d91.s2.e0 0 25
drug
Monoamine Oxidase Inhibitors
DrugDDI.d91.s2.e1 44 54
drug
moclobemide
DrugDDI.d91.s2.e2 79 89
drug
almotriptan

interaction DrugDDI.d91.s2.e1 DrugDDI.d91.s2.e2

Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s4
Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT@ is contraindicated.

DrugDDI.d91.s4.e0 52 59
drug
agonists
DrugDDI.d91.s4.e1 88 93
drug
AXERT@



Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s5
Propanolol The pharmacokinetics of almotriptan were not affected by coadministration of propranolol .

DrugDDI.d91.s5.e0 0 9
drug
Propanolol
DrugDDI.d91.s5.e1 31 41
drug
almotriptan
DrugDDI.d91.s5.e2 77 87
drug
propranolol



Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s6
Selective Serotonin Reuptake Inhibitors (SSRIs) SSRIs (e.g., fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists .

DrugDDI.d91.s6.e0 9 35
drug
Serotonin Reuptake Inhibitors
DrugDDI.d91.s6.e1 54 63
drug
fluoxetine
DrugDDI.d91.s6.e2 65 75
drug
fluvoxamine
DrugDDI.d91.s6.e3 77 86
drug
paroxetine
DrugDDI.d91.s6.e4 88 97
drug
sertraline
DrugDDI.d91.s6.e5 195 202
drug
agonists

interaction DrugDDI.d91.s6.e0 DrugDDI.d91.s6.e5
interaction DrugDDI.d91.s6.e2 DrugDDI.d91.s6.e5
interaction DrugDDI.d91.s6.e4 DrugDDI.d91.s6.e5

Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s7
If concomitant treatment with AXERT@ and an SSRI is clinically warranted, appropriate observation of the patient is advised.

DrugDDI.d91.s7.e0 26 31
drug
AXERT@



Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s8
Verapamil Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan .

DrugDDI.d91.s8.e0 0 8
drug
Verapamil
DrugDDI.d91.s8.e1 27 37
drug
almotriptan
DrugDDI.d91.s8.e2 41 49
drug
verapamil
DrugDDI.d91.s8.e3 96 106
drug
almotriptan

interaction DrugDDI.d91.s8.e1 DrugDDI.d91.s8.e2

Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s10
Ketoconazole and Other Potent CYP3A4 Inhibitors Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan .

DrugDDI.d91.s10.e0 0 11
drug
Ketoconazole
DrugDDI.d91.s10.e1 60 70
drug
almotriptan
DrugDDI.d91.s10.e2 98 109
drug
ketoconazole
DrugDDI.d91.s10.e3 243 253
drug
almotriptan

interaction DrugDDI.d91.s10.e1 DrugDDI.d91.s10.e2

Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s11
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications .

DrugDDI.d91.s11.e0 29 39
drug
almotriptan
DrugDDI.d91.s11.e1 54 59
drug
CYP3A4
DrugDDI.d91.s11.e2 76 87
drug
itraconazole
DrugDDI.d91.s11.e3 89 97
drug
ritonavir
DrugDDI.d91.s11.e4 102 113
drug
erythromycin
DrugDDI.d91.s11.e5 153 163
drug
almotriptan
DrugDDI.d91.s11.e6 181 191
drug
almotriptan
DrugDDI.d91.s11.e7 220 230
drug
medications

interaction DrugDDI.d91.s11.e6 DrugDDI.d91.s11.e7

Abstract Id: DrugDDI.d91
Sentence Id: DrugDDI.d91.s12
Drug /Laboratory Test Interactions AXERT@ is not known to interfere with commonly employed clinical laboratory tests.

DrugDDI.d91.s12.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s0
The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression.

DrugDDI.d23.s0.e0 3 17
drug
benzodiazepines
DrugDDI.d23.s0.e1 28 37
drug
alprazolam
DrugDDI.d23.s0.e2 54 66
drug
CNS depressant
DrugDDI.d23.s0.e3 102 124
drug
psychotropic medications
DrugDDI.d23.s0.e4 126 140
drug
anticonvulsants
DrugDDI.d23.s0.e5 142 156
drug
antihistaminics
DrugDDI.d23.s0.e6 158 164
drug
ethanol
DrugDDI.d23.s0.e7 174 178
drug
drugs

interaction DrugDDI.d23.s0.e0 DrugDDI.d23.s0.e3
interaction DrugDDI.d23.s0.e0 DrugDDI.d23.s0.e6
interaction DrugDDI.d23.s0.e0 DrugDDI.d23.s0.e7
interaction DrugDDI.d23.s0.e1 DrugDDI.d23.s0.e4
interaction DrugDDI.d23.s0.e1 DrugDDI.d23.s0.e6

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s1
The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.

DrugDDI.d23.s1.e0 36 45
drug
imipramine
DrugDDI.d23.s1.e1 49 59
drug
desipramine
DrugDDI.d23.s1.e2 155 164
drug
alprazolam

interaction DrugDDI.d23.s1.e0 DrugDDI.d23.s1.e2

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s3
Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A : The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A ( CYP 3A).

DrugDDI.d23.s3.e0 0 4
drug
Drugs
DrugDDI.d23.s3.e1 16 25
drug
Alprazolam
DrugDDI.d23.s3.e2 39 54
drug
Cytochrome P450 3A
DrugDDI.d23.s3.e3 72 81
drug
alprazolam
DrugDDI.d23.s3.e4 118 133
drug
cytochrome P450 3A
DrugDDI.d23.s3.e5 135 137
drug
CYP

interaction DrugDDI.d23.s3.e0 DrugDDI.d23.s3.e1
interaction DrugDDI.d23.s3.e3 DrugDDI.d23.s3.e4

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s4
Drugs which inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam .

DrugDDI.d23.s4.e0 0 4
drug
Drugs
DrugDDI.d23.s4.e1 75 84
drug
alprazolam

interaction DrugDDI.d23.s4.e0 DrugDDI.d23.s4.e1

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s5
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam ): Fluoxetine : Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.

DrugDDI.d23.s5.e0 0 4
drug
Drugs
DrugDDI.d23.s5.e1 21 23
drug
CYP
DrugDDI.d23.s5.e2 102 111
drug
Alprazolam
DrugDDI.d23.s5.e3 159 168
drug
alprazolam
DrugDDI.d23.s5.e4 171 180
drug
Fluoxetine
DrugDDI.d23.s5.e5 200 209
drug
fluoxetine
DrugDDI.d23.s5.e6 214 223
drug
alprazolam
DrugDDI.d23.s5.e7 264 273
drug
alprazolam

interaction DrugDDI.d23.s5.e5 DrugDDI.d23.s5.e6

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s6
Propoxyphene : Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.

DrugDDI.d23.s6.e0 0 11
drug
Propoxyphene
DrugDDI.d23.s6.e1 31 42
drug
propoxyphene
DrugDDI.d23.s6.e2 83 92
drug
alprazolam

interaction DrugDDI.d23.s6.e1 DrugDDI.d23.s6.e2

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s7
Oral Contraceptives : Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.

DrugDDI.d23.s7.e0 0 17
drug
Oral Contraceptives
DrugDDI.d23.s7.e1 37 54
drug
oral contraceptives
DrugDDI.d23.s7.e2 95 104
drug
alprazolam

interaction DrugDDI.d23.s7.e1 DrugDDI.d23.s7.e2

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s8
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice.

DrugDDI.d23.s8.e0 0 4
drug
Drugs
DrugDDI.d23.s8.e1 39 41
drug
CYP
DrugDDI.d23.s8.e2 90 104
drug
benzodiazepines
DrugDDI.d23.s8.e3 127 136
drug
alprazolam
DrugDDI.d23.s8.e4 169 178
drug
alprazolam
DrugDDI.d23.s8.e5 186 200
drug
benzodiazepines
DrugDDI.d23.s8.e6 248 257
drug
alprazolam
DrugDDI.d23.s8.e7 294 308
drug
benzodiazepines
DrugDDI.d23.s8.e8 318 327
drug
alprazolam
DrugDDI.d23.s8.e9 363 372
drug
alprazolam
DrugDDI.d23.s8.e10 389 397
drug
diltiazem
DrugDDI.d23.s8.e11 399 407
drug
isoniazid
DrugDDI.d23.s8.e12 409 428
drug
macrolide antibiotics
DrugDDI.d23.s8.e13 435 446
drug
erythromycin
DrugDDI.d23.s8.e14 450 463
drug
clarithromycin

interaction DrugDDI.d23.s8.e7 DrugDDI.d23.s8.e8

Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s9
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine .

DrugDDI.d23.s9.e0 24 33
drug
alprazolam
DrugDDI.d23.s9.e1 69 78
drug
alprazolam
DrugDDI.d23.s9.e2 95 104
drug
sertraline
DrugDDI.d23.s9.e3 108 117
drug
paroxetine



Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s10
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine .

DrugDDI.d23.s10.e0 24 38
drug
benzodiazepines
DrugDDI.d23.s10.e1 48 57
drug
alprazolam
DrugDDI.d23.s10.e2 105 114
drug
ergotamine
DrugDDI.d23.s10.e3 116 127
drug
cyclosporine
DrugDDI.d23.s10.e4 129 138
drug
amiodarone
DrugDDI.d23.s10.e5 140 150
drug
nicardipine
DrugDDI.d23.s10.e6 155 164
drug
nifedipine



Abstract Id: DrugDDI.d23
Sentence Id: DrugDDI.d23.s11
Caution is recommended during the coadministration of any of these with alprazolam .

DrugDDI.d23.s11.e0 61 70
drug
alprazolam



Abstract Id: DrugDDI.d568
Sentence Id: DrugDDI.d568.s0
Prostin VR Pediatric Sterile Solution No drug interactions have been reported between Prostin VR Pediatric and the therapy standard in neonates with restricted pulmonary or systemic blood flow.

DrugDDI.d568.s0.e0 0 8
drug
Prostin VR
DrugDDI.d568.s0.e1 74 82
drug
Prostin VR



Abstract Id: DrugDDI.d568
Sentence Id: DrugDDI.d568.s1
Standard therapy includes antibiotics , such as penicillin and gentamicin ; .

DrugDDI.d568.s1.e0 23 33
drug
antibiotics
DrugDDI.d568.s1.e1 41 50
drug
penicillin
DrugDDI.d568.s1.e2 54 63
drug
gentamicin



Abstract Id: DrugDDI.d568
Sentence Id: DrugDDI.d568.s2
vasopressor s, such as dopamine and isoproterenol ; .

DrugDDI.d568.s2.e0 0 10
drug
vasopressor
DrugDDI.d568.s2.e1 19 26
drug
dopamine
DrugDDI.d568.s2.e2 30 42
drug
isoproterenol



Abstract Id: DrugDDI.d568
Sentence Id: DrugDDI.d568.s3
cardiac glycosides ; .

DrugDDI.d568.s3.e0 0 16
drug
cardiac glycosides



Abstract Id: DrugDDI.d568
Sentence Id: DrugDDI.d568.s4
and diuretics , such as furosemide .

DrugDDI.d568.s4.e0 3 11
drug
diuretics
DrugDDI.d568.s4.e1 19 28
drug
furosemide



Abstract Id: DrugDDI.d568
Sentence Id: DrugDDI.d568.s5
Caverject The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents has not been formally studied.

DrugDDI.d568.s5.e0 0 8
drug
Caverject
DrugDDI.d568.s5.e1 67 77
drug
alprostadil



Abstract Id: DrugDDI.d280
Sentence Id: DrugDDI.d280.s0
Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension. Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model.

DrugDDI.d280.s0.e0 26 32
drug
HEXALEN
DrugDDI.d280.s0.e1 36 50
drug
antidepressants
DrugDDI.d280.s0.e2 56 67
drug
MAO inhibitor
DrugDDI.d280.s0.e3 110 119
drug
Cimetidine
DrugDDI.d280.s0.e4 168 178
drug
altretamine

interaction DrugDDI.d280.s0.e0 DrugDDI.d280.s0.e1
interaction DrugDDI.d280.s0.e0 DrugDDI.d280.s0.e2

Abstract Id: DrugDDI.d280
Sentence Id: DrugDDI.d280.s1
Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity; .

DrugDDI.d280.s1.e0 26 32
drug
HEXALEN
DrugDDI.d280.s1.e1 36 44
drug
cisplatin
DrugDDI.d280.s1.e2 56 65
drug
pyridoxine
DrugDDI.d280.s1.e3 94 103
drug
pyridoxine



Abstract Id: DrugDDI.d280
Sentence Id: DrugDDI.d280.s2
however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin .1 .

DrugDDI.d280.s2.e0 57 66
drug
pyridoxine
DrugDDI.d280.s2.e1 94 100
drug
HEXALEN
DrugDDI.d280.s2.e2 107 115
drug
cisplatin

interaction DrugDDI.d280.s2.e0 DrugDDI.d280.s2.e1

Abstract Id: DrugDDI.d509
Sentence Id: DrugDDI.d509.s0
Careful observation is required when amantadine is administered concurrently with central nervous system stimulants .

DrugDDI.d509.s0.e0 32 41
drug
amantadine
DrugDDI.d509.s0.e1 72 101
drug
central nervous system stimulants

interaction DrugDDI.d509.s0.e0 DrugDDI.d509.s0.e1

Abstract Id: DrugDDI.d509
Sentence Id: DrugDDI.d509.s1
Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinsons disease; .

DrugDDI.d509.s1.e0 18 29
drug
thioridazine



Abstract Id: DrugDDI.d509
Sentence Id: DrugDDI.d509.s2
however, it is not known if other phenothiazines produce a similar response.

DrugDDI.d509.s2.e0 27 40
drug
phenothiazines



Abstract Id: DrugDDI.d509
Sentence Id: DrugDDI.d509.s3
Coadministration of triamterene and hydrochlorothiazide capsules resulted in a higher plasma amantadine concentration in a 61 year old man receiving amantadine ( amantadine hydrochloride ) 100 mg TID for Parkinsons disease.1 It is not known which of the components of triamterene and hydrochlorothiazide capsules contributed to the observation or if related drugs produce a similar response.

DrugDDI.d509.s3.e0 18 28
drug
triamterene
DrugDDI.d509.s3.e1 32 50
drug
hydrochlorothiazide
DrugDDI.d509.s3.e2 82 91
drug
amantadine
DrugDDI.d509.s3.e3 129 138
drug
amantadine
DrugDDI.d509.s3.e4 140 162
drug
amantadine hydrochloride
DrugDDI.d509.s3.e5 228 238
drug
triamterene
DrugDDI.d509.s3.e6 242 260
drug
hydrochlorothiazide
DrugDDI.d509.s3.e7 307 311
drug
drugs

interaction DrugDDI.d509.s3.e0 DrugDDI.d509.s3.e1

Abstract Id: DrugDDI.d442
Sentence Id: DrugDDI.d442.s0
Interactions can occur with the following medications : demecarium ( Humorsol ), echothiophate ( Phospholine Iodide ), isoflurophate ( Floropryl ), malathion (using these medicines with antimyasthenics may result in serious side effects), guanadrel ( Hylorel ), guanethidine ( Ismelin ), mecamylamine ( Inversine ), procainamide ( Pronestyl ), and trimethaphan (the effects of these medicines may interfere with the actions of the antimyasthenics).

DrugDDI.d442.s0.e0 36 46
drug
medications
DrugDDI.d442.s0.e1 48 57
drug
demecarium
DrugDDI.d442.s0.e2 59 66
drug
Humorsol
DrugDDI.d442.s0.e3 69 81
drug
echothiophate
DrugDDI.d442.s0.e4 83 99
drug
Phospholine Iodide
DrugDDI.d442.s0.e5 102 114
drug
isoflurophate
DrugDDI.d442.s0.e6 116 124
drug
Floropryl
DrugDDI.d442.s0.e7 127 135
drug
malathion
DrugDDI.d442.s0.e8 147 155
drug
medicines
DrugDDI.d442.s0.e9 206 214
drug
guanadrel
DrugDDI.d442.s0.e10 216 222
drug
Hylorel
DrugDDI.d442.s0.e11 225 236
drug
guanethidine
DrugDDI.d442.s0.e12 238 244
drug
Ismelin
DrugDDI.d442.s0.e13 247 258
drug
mecamylamine
DrugDDI.d442.s0.e14 260 268
drug
Inversine
DrugDDI.d442.s0.e15 271 282
drug
procainamide
DrugDDI.d442.s0.e16 284 292
drug
Pronestyl
DrugDDI.d442.s0.e17 298 309
drug
trimethaphan
DrugDDI.d442.s0.e18 328 336
drug
medicines



Abstract Id: DrugDDI.d453
Sentence Id: DrugDDI.d453.s0
When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor , the risk of hyperkalemia may be increased.

DrugDDI.d453.s0.e0 4 15
drug
amiloride HCl
DrugDDI.d453.s0.e1 49 85
drug
angiotensin-converting enzyme inhibitor

interaction DrugDDI.d453.s0.e0 DrugDDI.d453.s0.e1

Abstract Id: DrugDDI.d453
Sentence Id: DrugDDI.d453.s2
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.

DrugDDI.d453.s2.e0 0 6
drug
Lithium
DrugDDI.d453.s2.e1 36 44
drug
diuretics

interaction DrugDDI.d453.s2.e0 DrugDDI.d453.s2.e1

Abstract Id: DrugDDI.d453
Sentence Id: DrugDDI.d453.s3
Read circulars for lithium preparation s before use of such concomitant therapy.

DrugDDI.d453.s3.e0 16 33
drug
lithium preparation



Abstract Id: DrugDDI.d453
Sentence Id: DrugDDI.d453.s4
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium -sparing and thiazide diuretics .

DrugDDI.d453.s4.e0 35 69
drug
non-steroidal anti-inflammatory agent
DrugDDI.d453.s4.e1 82 89
drug
diuretic
DrugDDI.d453.s4.e2 106 121
drug
antihypertensive
DrugDDI.d453.s4.e3 136 144
drug
potassium
DrugDDI.d453.s4.e4 156 172
drug
thiazide diuretics

interaction DrugDDI.d453.s4.e0 DrugDDI.d453.s4.e3

Abstract Id: DrugDDI.d453
Sentence Id: DrugDDI.d453.s5
Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

DrugDDI.d453.s5.e0 14 20
drug
MIDAMOR
DrugDDI.d453.s5.e1 24 59
drug
non-steroidal anti-inflammatory agents
DrugDDI.d453.s5.e2 148 155
drug
diuretic



Abstract Id: DrugDDI.d453
Sentence Id: DrugDDI.d453.s6
Since indomethacin and potassium-sparing diuretics , including MIDAMOR , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.

DrugDDI.d453.s6.e0 5 16
drug
indomethacin
DrugDDI.d453.s6.e1 20 45
drug
potassium-sparing diuretics
DrugDDI.d453.s6.e2 56 62
drug
MIDAMOR
DrugDDI.d453.s6.e3 138 146
drug
potassium

interaction DrugDDI.d453.s6.e0 DrugDDI.d453.s6.e1

Abstract Id: DrugDDI.d375
Sentence Id: DrugDDI.d375.s0
Drug Laboratory Test Interactions@ Prolongation of the template bleeding time has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day.

DrugDDI.d375.s0.e0 0 3
drug
Drug
DrugDDI.d375.s0.e1 120 125
drug
AMICAR



Abstract Id: DrugDDI.d375
Sentence Id: DrugDDI.d375.s2
However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) EACA inhibits ADP and collagen -induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner.

DrugDDI.d375.s2.e0 105 112
drug
collagen
DrugDDI.d375.s2.e1 184 193
drug
fibrinogen



Abstract Id: DrugDDI.d375
Sentence Id: DrugDDI.d375.s3
Following a 10 g bolus of AMICAR , transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained.

DrugDDI.d375.s3.e0 20 25
drug
AMICAR



Abstract Id: DrugDDI.d375
Sentence Id: DrugDDI.d375.s4
The concentration of AMICAR necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL.

DrugDDI.d375.s4.e0 18 23
drug
AMICAR



Abstract Id: DrugDDI.d375
Sentence Id: DrugDDI.d375.s7
However, higher plasma concentrations of AMICAR may occur in patients with severe renal failure.?

DrugDDI.d375.s7.e0 36 41
drug
AMICAR



Abstract Id: DrugDDI.d302
Sentence Id: DrugDDI.d302.s0
Cytadren accelerates the metabolism of dexamethasone ; .

DrugDDI.d302.s0.e0 0 7
drug
Cytadren
DrugDDI.d302.s0.e1 34 46
drug
dexamethasone

interaction DrugDDI.d302.s0.e0 DrugDDI.d302.s0.e1

Abstract Id: DrugDDI.d302
Sentence Id: DrugDDI.d302.s1
therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.

DrugDDI.d302.s1.e0 46 59
drug
hydrocortisone



Abstract Id: DrugDDI.d302
Sentence Id: DrugDDI.d302.s2
Aminoglutethimide diminishes the effect of coumarin and warfarin .

DrugDDI.d302.s2.e0 0 16
drug
Aminoglutethimide
DrugDDI.d302.s2.e1 38 45
drug
coumarin
DrugDDI.d302.s2.e2 49 56
drug
warfarin

interaction DrugDDI.d302.s2.e0 DrugDDI.d302.s2.e1

Abstract Id: DrugDDI.d295
Sentence Id: DrugDDI.d295.s0
There have been no formal studies of the interaction of LEVULAN KERASTICK for Topical Solution with any other drugs , and no drug-specific interactions were noted during any of the controlled clinical trials.

DrugDDI.d295.s0.e0 46 61
drug
LEVULAN KERASTICK
DrugDDI.d295.s0.e1 92 96
drug
drugs



Abstract Id: DrugDDI.d295
Sentence Id: DrugDDI.d295.s1
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.

DrugDDI.d295.s1.e0 51 72
drug
photosensitizing agents
DrugDDI.d295.s1.e1 79 90
drug
griseofulvin
DrugDDI.d295.s1.e2 92 108
drug
thiazide diuretics
DrugDDI.d295.s1.e3 110 122
drug
sulfonylureas
DrugDDI.d295.s1.e4 124 137
drug
phenothiazines
DrugDDI.d295.s1.e5 139 150
drug
sulfonamides
DrugDDI.d295.s1.e6 154 166
drug
tetracyclines
DrugDDI.d295.s1.e7 239 254
drug
LEVULAN KERASTICK

interaction DrugDDI.d295.s1.e0 DrugDDI.d295.s1.e7
interaction DrugDDI.d295.s1.e2 DrugDDI.d295.s1.e7
interaction DrugDDI.d295.s1.e4 DrugDDI.d295.s1.e7
interaction DrugDDI.d295.s1.e6 DrugDDI.d295.s1.e7

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s0
Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 ( debrisoquin hydroxylase ) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called poor metabolizers); .

DrugDDI.d351.s0.e0 0 4
drug
Drugs
DrugDDI.d351.s0.e1 18 24
drug
P450 2D6
DrugDDI.d351.s0.e2 53 56
drug
drug
DrugDDI.d351.s0.e3 94 115
drug
debrisoquin hydroxylase



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s1
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.

DrugDDI.d351.s1.e0 41 54
drug
P450 2D6 isozyme



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s2
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

DrugDDI.d351.s2.e0 60 83
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s3
Depending on the fraction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).

DrugDDI.d351.s3.e0 24 27
drug
drug
DrugDDI.d351.s3.e1 41 47
drug
P450 2D6



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s4
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.

DrugDDI.d351.s4.e0 18 22
drug
drugs
DrugDDI.d351.s4.e1 47 53
drug
isozyme

interaction DrugDDI.d351.s4.e0 DrugDDI.d351.s4.e1

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s5
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

DrugDDI.d351.s5.e0 91 95
drug
drugs



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s6
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme ( quinidine ; .

DrugDDI.d351.s6.e0 3 7
drug
drugs
DrugDDI.d351.s6.e1 19 35
drug
cytochrome P450 2D6
DrugDDI.d351.s6.e2 80 88
drug
quinidine



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s7
cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and flecainide ).

DrugDDI.d351.s7.e0 0 9
drug
cimetidine
DrugDDI.d351.s7.e1 38 44
drug
P450 2D6
DrugDDI.d351.s7.e2 55 69
drug
antidepressants
DrugDDI.d351.s7.e3 71 84
drug
phenothiazines
DrugDDI.d351.s7.e4 113 123
drug
propafenone
DrugDDI.d351.s7.e5 127 136
drug
flecainide



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s8
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition.

DrugDDI.d351.s8.e0 20 46
drug
serotonin reuptake inhibitors
DrugDDI.d351.s8.e1 60 69
drug
fluoxetine
DrugDDI.d351.s8.e2 71 80
drug
sertraline
DrugDDI.d351.s8.e3 85 94
drug
paroxetine
DrugDDI.d351.s8.e4 103 109
drug
P450 2D6

interaction DrugDDI.d351.s8.e0 DrugDDI.d351.s8.e4
interaction DrugDDI.d351.s8.e2 DrugDDI.d351.s8.e4

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s11
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

DrugDDI.d351.s11.e0 103 112
drug
fluoxetine
DrugDDI.d351.s11.e1 149 164
drug
active metabolite



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s12
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

DrugDDI.d351.s12.e0 16 39
drug
tricyclic antidepressants
DrugDDI.d351.s12.e1 44 48
drug
drugs
DrugDDI.d351.s12.e2 63 79
drug
cytochrome P450 2D6
DrugDDI.d351.s12.e3 133 155
drug
tricyclic antidepressant
DrugDDI.d351.s12.e4 166 169
drug
drug



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s13
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.

DrugDDI.d351.s13.e0 35 39
drug
drugs
DrugDDI.d351.s13.e1 83 105
drug
tricyclic antidepressant



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s14
It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6 .

DrugDDI.d351.s14.e0 85 88
drug
drug
DrugDDI.d351.s14.e1 111 117
drug
P450 2D6



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s15
Monoamine Oxidase Inhibitors : Guanethidine or similarly acting compounds; .

DrugDDI.d351.s15.e0 0 25
drug
Monoamine Oxidase Inhibitors
DrugDDI.d351.s15.e1 27 38
drug
Guanethidine



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s16
thyroid medication ; .

DrugDDI.d351.s16.e0 0 16
drug
thyroid medication



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s17
alcohol , barbiturates and other CNS depressants ; .

DrugDDI.d351.s17.e0 0 6
drug
alcohol
DrugDDI.d351.s17.e1 8 19
drug
barbiturates
DrugDDI.d351.s17.e2 28 41
drug
CNS depressants



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s18
and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs , including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required.

DrugDDI.d351.s18.e0 3 12
drug
disulfiram
DrugDDI.d351.s18.e1 17 32
drug
amitriptyline HCl
DrugDDI.d351.s18.e2 44 64
drug
anticholinergic agents
DrugDDI.d351.s18.e3 67 86
drug
sympathomimetic drugs
DrugDDI.d351.s18.e4 97 107
drug
epinephrine
DrugDDI.d351.s18.e5 120 135
drug
local anesthetics



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s19
Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs , particularly during hot weather.

DrugDDI.d351.s19.e0 31 46
drug
amitriptyline HCl
DrugDDI.d351.s19.e1 65 85
drug
anticholinergic agents
DrugDDI.d351.s19.e2 92 107
drug
neuroleptic drugs

interaction DrugDDI.d351.s19.e0 DrugDDI.d351.s19.e1

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s20
Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs .

DrugDDI.d351.s20.e0 38 61
drug
tricyclic antidepressants
DrugDDI.d351.s20.e1 79 103
drug
anticholinergic-type drugs

interaction DrugDDI.d351.s20.e0 DrugDDI.d351.s20.e1

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s21
Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants , thereby delaying elimination and increasing steady-state concentrations of these drugs .

DrugDDI.d351.s21.e0 0 9
drug
Cimetidine
DrugDDI.d351.s21.e1 54 77
drug
tricyclic antidepressants
DrugDDI.d351.s21.e2 151 155
drug
drugs

interaction DrugDDI.d351.s21.e0 DrugDDI.d351.s21.e1

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s22
Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine .

DrugDDI.d351.s22.e0 51 74
drug
tricyclic antidepressants
DrugDDI.d351.s22.e1 100 109
drug
cimetidine

interaction DrugDDI.d351.s22.e0 DrugDDI.d351.s22.e1

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s23
Increases in plasma levels of tricyclic antidepressants , and in the frequency and severity of side effects, particularly anticholinergic , have been reported when cimetidine was added to the drug regimen.

DrugDDI.d351.s23.e0 25 48
drug
tricyclic antidepressants
DrugDDI.d351.s23.e1 104 118
drug
anticholinergic
DrugDDI.d351.s23.e2 140 149
drug
cimetidine
DrugDDI.d351.s23.e3 163 166
drug
drug

interaction DrugDDI.d351.s23.e0 DrugDDI.d351.s23.e2

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s24
Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants .

DrugDDI.d351.s24.e0 17 26
drug
cimetidine
DrugDDI.d351.s24.e1 61 84
drug
tricyclic antidepressants
DrugDDI.d351.s24.e2 88 97
drug
cimetidine
DrugDDI.d351.s24.e3 140 154
drug
antidepressants

interaction DrugDDI.d351.s24.e1 DrugDDI.d351.s24.e2

Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s25
Caution is advised if patients receive large doses of ethchlorvynol concurrently.

DrugDDI.d351.s25.e0 45 57
drug
ethchlorvynol



Abstract Id: DrugDDI.d351
Sentence Id: DrugDDI.d351.s26
Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl .

DrugDDI.d351.s26.e0 69 81
drug
ethchlorvynol
DrugDDI.d351.s26.e1 95 110
drug
amitriptyline HCl

interaction DrugDDI.d351.s26.e0 DrugDDI.d351.s26.e1

Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s0
Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic drugs .

DrugDDI.d327.s0.e0 38 61
drug
tricyclic antidepressants
DrugDDI.d327.s0.e1 79 98
drug
anticholinergic drugs

interaction DrugDDI.d327.s0.e0 DrugDDI.d327.s0.e1

Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s1
Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants .

DrugDDI.d327.s1.e0 0 8
drug
Amoxapine
DrugDDI.d327.s1.e1 32 38
drug
alcohol
DrugDDI.d327.s1.e2 54 65
drug
barbiturates
DrugDDI.d327.s1.e3 74 87
drug
CNS depressants

interaction DrugDDI.d327.s1.e0 DrugDDI.d327.s1.e1
interaction DrugDDI.d327.s1.e0 DrugDDI.d327.s1.e3

Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s2
Serum levels of several tricyclic antidepressants have been reported to be significantly increased when cimetidine is administered concurrently Although such an interaction has not been reported to date with amoxapine , specific interaction studies have not been done, and the possibility should be considered.

DrugDDI.d327.s2.e0 20 43
drug
tricyclic antidepressants
DrugDDI.d327.s2.e1 90 99
drug
cimetidine
DrugDDI.d327.s2.e2 179 187
drug
amoxapine

interaction DrugDDI.d327.s2.e0 DrugDDI.d327.s2.e1

Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s3
Drugs Metabolized by P450 2D6 .

DrugDDI.d327.s3.e0 0 4
drug
Drugs
DrugDDI.d327.s3.e1 18 24
drug
P450 2D6



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s4
The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (dehrisoquin hydroxylase ) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called of reduced P450 2D6 isozyme activity among p.o. metabolizers); .

DrugDDI.d327.s4.e0 27 30
drug
drug
DrugDDI.d327.s4.e1 79 89
drug
hydroxylase
DrugDDI.d327.s4.e2 177 190
drug
P450 2D6 isozyme



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s6
Poor metabolizers have higher than expected plasma concentrations tricyclic antidepressants (TCAs) when given usual doses.

DrugDDI.d327.s6.e0 58 81
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s7
Depending on the fraction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).

DrugDDI.d327.s7.e0 24 27
drug
drug
DrugDDI.d327.s7.e1 41 47
drug
P450 2D6



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s8
In addition certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o. metabolizers.

DrugDDI.d327.s8.e0 17 21
drug
drugs
DrugDDI.d327.s8.e1 46 52
drug
isozyme

interaction DrugDDI.d327.s8.e0 DrugDDI.d327.s8.e1

Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s9
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

DrugDDI.d327.s9.e0 91 95
drug
drugs



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s10
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzymes quinidine , cimetidine , and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and flecainide ).

DrugDDI.d327.s10.e0 3 7
drug
drugs
DrugDDI.d327.s10.e1 19 35
drug
cytochrome P450 2D6
DrugDDI.d327.s10.e2 80 88
drug
quinidine
DrugDDI.d327.s10.e3 90 99
drug
cimetidine
DrugDDI.d327.s10.e4 128 134
drug
P450 2D6
DrugDDI.d327.s10.e5 145 159
drug
antidepressants
DrugDDI.d327.s10.e6 161 174
drug
phenothiazines
DrugDDI.d327.s10.e7 203 213
drug
propafenone
DrugDDI.d327.s10.e8 217 226
drug
flecainide



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s11
While all the selective serotonin reuptake inhibitors (SSRls), e.g. fluoxetine , sertraline , and paroxetine inhibit P450 2D6 , they may vary in the extent of inhibition.

DrugDDI.d327.s11.e0 20 46
drug
serotonin reuptake inhibitors
DrugDDI.d327.s11.e1 59 68
drug
fluoxetine
DrugDDI.d327.s11.e2 70 79
drug
sertraline
DrugDDI.d327.s11.e3 84 93
drug
paroxetine
DrugDDI.d327.s11.e4 101 107
drug
P450 2D6

interaction DrugDDI.d327.s11.e0 DrugDDI.d327.s11.e4
interaction DrugDDI.d327.s11.e2 DrugDDI.d327.s11.e4

Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s14
Sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine given.

DrugDDI.d327.s14.e0 80 89
drug
fluoxetine



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s15
The long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

DrugDDI.d327.s15.e0 30 45
drug
active metabolite



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s16
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

DrugDDI.d327.s16.e0 16 39
drug
tricyclic antidepressants
DrugDDI.d327.s16.e1 44 48
drug
drugs
DrugDDI.d327.s16.e2 63 79
drug
cytochrome P450 2D6
DrugDDI.d327.s16.e3 133 155
drug
tricyclic antidepressant
DrugDDI.d327.s16.e4 166 169
drug
drug

interaction DrugDDI.d327.s16.e0 DrugDDI.d327.s16.e1

Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s17
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.

DrugDDI.d327.s17.e0 35 39
drug
drugs
DrugDDI.d327.s17.e1 83 105
drug
tricyclic antidepressant



Abstract Id: DrugDDI.d327
Sentence Id: DrugDDI.d327.s18
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6 .

DrugDDI.d327.s18.e0 86 89
drug
drug
DrugDDI.d327.s18.e1 112 118
drug
P450 2D6



Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s0
Acidifying agents - Gastrointestinal acidifying agents ( guanethidine , reserpine , glutamic acid HCl , ascorbic acid , fruit juices, etc.) lower absorption of amphetamines .

DrugDDI.d418.s0.e0 0 15
drug
Acidifying agents
DrugDDI.d418.s0.e1 50 61
drug
guanethidine
DrugDDI.d418.s0.e2 63 71
drug
reserpine
DrugDDI.d418.s0.e3 73 87
drug
glutamic acid HCl
DrugDDI.d418.s0.e4 89 100
drug
ascorbic acid
DrugDDI.d418.s0.e5 136 147
drug
amphetamines

interaction DrugDDI.d418.s0.e0 DrugDDI.d418.s0.e5
interaction DrugDDI.d418.s0.e2 DrugDDI.d418.s0.e5
interaction DrugDDI.d418.s0.e4 DrugDDI.d418.s0.e5

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s1
Urinary acidifying agents -( ammonium chloride , sodium acid phosphate , etc.) .

DrugDDI.d418.s1.e0 7 22
drug
acidifying agents
DrugDDI.d418.s1.e1 25 40
drug
ammonium chloride
DrugDDI.d418.s1.e2 42 60
drug
sodium acid phosphate



Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s2
Increase the concentration of the ionized species of the amphetamine .

DrugDDI.d418.s2.e0 48 58
drug
amphetamine



Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s3
Primary excretion - Both Groups of agents lower blood levels and efficacy of amphetamines .

DrugDDI.d418.s3.e0 64 75
drug
amphetamines



Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s4
Adrenergic blockers - Adrenergic blockers are inhibited by amphetamines .

DrugDDI.d418.s4.e0 0 17
drug
Adrenergic blockers
DrugDDI.d418.s4.e1 51 62
drug
amphetamines

interaction DrugDDI.d418.s4.e0 DrugDDI.d418.s4.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s5
Alkalinizing agents -Gastrointestinal alkalinizing agents ( sodium bicarbonate , etc.)increase absorption of amphetamines .

DrugDDI.d418.s5.e0 0 17
drug
Alkalinizing agents
DrugDDI.d418.s5.e1 54 70
drug
sodium bicarbonate
DrugDDI.d418.s5.e2 97 108
drug
amphetamines

interaction DrugDDI.d418.s5.e0 DrugDDI.d418.s5.e2

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s6
Urinary alkalinizing agents ( acetazolamide , some thiazides ) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.

DrugDDI.d418.s6.e0 7 24
drug
alkalinizing agents
DrugDDI.d418.s6.e1 26 38
drug
acetazolamide
DrugDDI.d418.s6.e2 44 52
drug
thiazides
DrugDDI.d418.s6.e3 106 116
drug
amphetamine

interaction DrugDDI.d418.s6.e0 DrugDDI.d418.s6.e3
interaction DrugDDI.d418.s6.e2 DrugDDI.d418.s6.e3

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s7
Both groups of agents increase blood levels and therefore potentate the actions of amphetamines .

DrugDDI.d418.s7.e0 70 81
drug
amphetamines



Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s8
Antidepressants , tricyclic - Amphetamines may enhance the activity of tricyclic or sympathomimetic agents ; .

DrugDDI.d418.s8.e0 0 14
drug
Antidepressants
DrugDDI.d418.s8.e1 16 37
drug
tricyclic - Amphetamines
DrugDDI.d418.s8.e2 72 92
drug
sympathomimetic agents

interaction DrugDDI.d418.s8.e1 DrugDDI.d418.s8.e2

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s9
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; .

DrugDDI.d418.s9.e0 0 12
drug
d-amphetamine
DrugDDI.d418.s9.e1 17 27
drug
desipramine
DrugDDI.d418.s9.e2 30 42
drug
protriptyline
DrugDDI.d418.s9.e3 59 68
drug
tricyclics
DrugDDI.d418.s9.e4 123 135
drug
d-amphetamine

interaction DrugDDI.d418.s9.e0 DrugDDI.d418.s9.e1
interaction DrugDDI.d418.s9.e0 DrugDDI.d418.s9.e3

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s11
MAO inhibitors - MAO antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism.

DrugDDI.d418.s11.e0 17 31
drug
antidepressants
DrugDDI.d418.s11.e1 42 51
drug
metabolite
DrugDDI.d418.s11.e2 54 65
drug
furazolidone
DrugDDI.d418.s11.e3 71 81
drug
amphetamine

interaction DrugDDI.d418.s11.e0 DrugDDI.d418.s11.e3

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s12
This slowing potentiates amphetamines , increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings, this can cause headaches and other signs of hypertensive crisis.

DrugDDI.d418.s12.e0 22 33
drug
amphetamines
DrugDDI.d418.s12.e1 70 83
drug
norepinephrine

interaction DrugDDI.d418.s12.e0 DrugDDI.d418.s12.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s14
Antihistamines - Amphetamines may counteract the sedative effect of antihistamines .

DrugDDI.d418.s14.e0 0 13
drug
Antihistamines
DrugDDI.d418.s14.e1 59 72
drug
antihistamines

interaction DrugDDI.d418.s14.e0 DrugDDI.d418.s14.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s15
Antihypertensives - Amphetamines may antagonize the hypotensive effects of antihypertensives .

DrugDDI.d418.s15.e0 0 16
drug
Antihypertensives
DrugDDI.d418.s15.e1 66 82
drug
antihypertensives

interaction DrugDDI.d418.s15.e0 DrugDDI.d418.s15.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s16
Chlorpromazine - Chlorpromazine blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of amphetamines , and can be used to treat amphetamine poisoning.

DrugDDI.d418.s16.e0 0 13
drug
Chlorpromazine
DrugDDI.d418.s16.e1 35 42
drug
dopamine
DrugDDI.d418.s16.e2 46 68
drug
norepinephrine receptors
DrugDDI.d418.s16.e3 87 102
drug
central stimulant
DrugDDI.d418.s16.e4 112 123
drug
amphetamines

interaction DrugDDI.d418.s16.e0 DrugDDI.d418.s16.e1
interaction DrugDDI.d418.s16.e0 DrugDDI.d418.s16.e4

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s17
Ethosuximide - Amphetamines may delay intestinal absorption of ethosuximide .

DrugDDI.d418.s17.e0 0 11
drug
Ethosuximide
DrugDDI.d418.s17.e1 55 66
drug
ethosuximide

interaction DrugDDI.d418.s17.e0 DrugDDI.d418.s17.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s18
Haloperidol - Haloperidol blocks dopamine receptors , thus inhibiting the central stimulant effects of amphetamines .

DrugDDI.d418.s18.e0 0 10
drug
Haloperidol
DrugDDI.d418.s18.e1 29 45
drug
dopamine receptors
DrugDDI.d418.s18.e2 64 79
drug
central stimulant
DrugDDI.d418.s18.e3 89 100
drug
amphetamines

interaction DrugDDI.d418.s18.e0 DrugDDI.d418.s18.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s19
Lithium carbonate - The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate .

DrugDDI.d418.s19.e0 0 15
drug
Lithium carbonate
DrugDDI.d418.s19.e1 52 63
drug
amphetamines
DrugDDI.d418.s19.e2 80 95
drug
lithium carbonate

interaction DrugDDI.d418.s19.e1 DrugDDI.d418.s19.e2

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s20
Meperidine - Amphetamines pone the analgesic effect of meperidine .

DrugDDI.d418.s20.e0 0 9
drug
Meperidine
DrugDDI.d418.s20.e1 47 56
drug
meperidine

interaction DrugDDI.d418.s20.e0 DrugDDI.d418.s20.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s21
Methenamine therapy - Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.

DrugDDI.d418.s21.e0 0 10
drug
Methenamine
DrugDDI.d418.s21.e1 37 48
drug
amphetamines
DrugDDI.d418.s21.e2 84 99
drug
acidifying agents
DrugDDI.d418.s21.e3 106 116
drug
methenamine

interaction DrugDDI.d418.s21.e1 DrugDDI.d418.s21.e2

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s22
Norepinephrine - Amphetamines enhance the adrenergic effect of norepinephrine .

DrugDDI.d418.s22.e0 0 13
drug
Norepinephrine
DrugDDI.d418.s22.e1 55 68
drug
norepinephrine

interaction DrugDDI.d418.s22.e0 DrugDDI.d418.s22.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s23
Phenobarbital - Amphetamines may delay intestinal absorption of phenobarbital ; .

DrugDDI.d418.s23.e0 0 12
drug
Phenobarbital
DrugDDI.d418.s23.e1 56 68
drug
phenobarbital

interaction DrugDDI.d418.s23.e0 DrugDDI.d418.s23.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s24
co-administration of phenobarbital may produce a synergistic anticonvulsant action.

DrugDDI.d418.s24.e0 19 31
drug
phenobarbital
DrugDDI.d418.s24.e1 54 67
drug
anticonvulsant

interaction DrugDDI.d418.s24.e0 DrugDDI.d418.s24.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s25
Phenytoin - Amphetamines may delay intestinal absorption of phenytoin ; .

DrugDDI.d418.s25.e0 0 21
drug
Phenytoin - Amphetamines
DrugDDI.d418.s25.e1 52 60
drug
phenytoin

interaction DrugDDI.d418.s25.e0 DrugDDI.d418.s25.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s26
co-administration of phenytoin may produce a synergistic anticonvulsant action.

DrugDDI.d418.s26.e0 19 27
drug
phenytoin
DrugDDI.d418.s26.e1 50 63
drug
anticonvulsant



Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s27
Propoxyphene - In cases of propoxyphene overdose, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.

DrugDDI.d418.s27.e0 0 11
drug
Propoxyphene
DrugDDI.d418.s27.e1 22 33
drug
propoxyphene
DrugDDI.d418.s27.e2 43 56
drug
amphetamine CNS

interaction DrugDDI.d418.s27.e1 DrugDDI.d418.s27.e2

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s28
Veratrum alkaloids - Amphetamines inhibit the hypotensive effect of veratrum alkaloids .

DrugDDI.d418.s28.e0 0 16
drug
Veratrum alkaloids
DrugDDI.d418.s28.e1 59 75
drug
veratrum alkaloids

interaction DrugDDI.d418.s28.e0 DrugDDI.d418.s28.e1

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s29
Drug /Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels.

DrugDDI.d418.s29.e0 0 3
drug
Drug
DrugDDI.d418.s29.e1 31 42
drug
Amphetamines
DrugDDI.d418.s29.e2 80 93
drug
corticosteroid

interaction DrugDDI.d418.s29.e1 DrugDDI.d418.s29.e2

Abstract Id: DrugDDI.d418
Sentence Id: DrugDDI.d418.s31
Amphetamines may interfere with urinary steroid determinations.

DrugDDI.d418.s31.e0 0 11
drug
Amphetamines



Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s0
When administered concurrently, the following drugs may interact with amphotericin B : Antineoplastic agents : may enhance the potential for renal toxicity, bronchospasm and hypotension.

DrugDDI.d350.s0.e0 41 45
drug
drugs
DrugDDI.d350.s0.e1 61 73
drug
amphotericin B
DrugDDI.d350.s0.e2 75 94
drug
Antineoplastic agents

interaction DrugDDI.d350.s0.e0 DrugDDI.d350.s0.e1

Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s1
Antineoplastic agents (e. g., nitrogen mustard , etc.) should be given concomitantly only with great caution.

DrugDDI.d350.s1.e0 0 19
drug
Antineoplastic agents
DrugDDI.d350.s1.e1 26 40
drug
nitrogen mustard



Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s2
Corticosteroids and Corticotropin ( ACTH ): may potentiate amphotericin B - induced hypokalemia which may predispose the patient to cardiac dysfunction.

DrugDDI.d350.s2.e0 0 14
drug
Corticosteroids
DrugDDI.d350.s2.e1 18 30
drug
Corticotropin
DrugDDI.d350.s2.e2 32 35
drug
ACTH
DrugDDI.d350.s2.e3 51 63
drug
amphotericin B



Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s3
Avoid concomitant use unless necessary to control side effects of amphotericin B .

DrugDDI.d350.s3.e0 56 68
drug
amphotericin B



Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s5
Digitalis glycosides : amphotericin B -induced hypokalemia may potentiate digitalis toxicity.

DrugDDI.d350.s5.e0 0 18
drug
Digitalis glycosides
DrugDDI.d350.s5.e1 20 32
drug
amphotericin B



Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s7
Flucytosine : while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.

DrugDDI.d350.s7.e0 0 10
drug
Flucytosine
DrugDDI.d350.s7.e1 45 57
drug
amphotericin B
DrugDDI.d350.s7.e2 112 122
drug
flucytosine



Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s8
Imidazoles (e. g., ketoconazole , miconazole , clotrimazole , fluconazole , etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B .

DrugDDI.d350.s8.e0 0 9
drug
Imidazoles
DrugDDI.d350.s8.e1 16 27
drug
ketoconazole
DrugDDI.d350.s8.e2 29 38
drug
miconazole
DrugDDI.d350.s8.e3 40 51
drug
clotrimazole
DrugDDI.d350.s8.e4 53 63
drug
fluconazole
DrugDDI.d350.s8.e5 114 126
drug
amphotericin B
DrugDDI.d350.s8.e6 130 139
drug
imidazoles
DrugDDI.d350.s8.e7 151 160
drug
imidazoles
DrugDDI.d350.s8.e8 188 200
drug
amphotericin B

interaction DrugDDI.d350.s8.e7 DrugDDI.d350.s8.e8

Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s10
Other nephrotoxic medications : agents such as aminoglycosides , cyclosporine , and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.

DrugDDI.d350.s10.e0 5 26
drug
nephrotoxic medications
DrugDDI.d350.s10.e1 40 54
drug
aminoglycosides
DrugDDI.d350.s10.e2 56 67
drug
cyclosporine
DrugDDI.d350.s10.e3 72 82
drug
pentamidine

interaction DrugDDI.d350.s10.e1 DrugDDI.d350.s10.e2
interaction DrugDDI.d350.s10.e2 DrugDDI.d350.s10.e3

Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s11
Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications .

DrugDDI.d350.s11.e0 93 103
drug
medications



Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s12
Skeletal muscle relaxants : amphotericin B -induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine ).

DrugDDI.d350.s12.e0 0 22
drug
Skeletal muscle relaxants
DrugDDI.d350.s12.e1 24 36
drug
amphotericin B
DrugDDI.d350.s12.e2 69 84
drug
curariform effect
DrugDDI.d350.s12.e3 87 109
drug
skeletal muscle relaxants
DrugDDI.d350.s12.e4 116 127
drug
tubocurarine

interaction DrugDDI.d350.s12.e1 DrugDDI.d350.s12.e3

Abstract Id: DrugDDI.d350
Sentence Id: DrugDDI.d350.s14
Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.

DrugDDI.d350.s14.e0 89 101
drug
amphotericin B



Abstract Id: DrugDDI.d526
Sentence Id: DrugDDI.d526.s0
When administered concurrently, the following drugs may interact with ampicillin .

DrugDDI.d526.s0.e0 41 45
drug
drugs
DrugDDI.d526.s0.e1 61 70
drug
ampicillin

interaction DrugDDI.d526.s0.e0 DrugDDI.d526.s0.e1

Abstract Id: DrugDDI.d526
Sentence Id: DrugDDI.d526.s1
Allopurinol : Increased possibility of skin rash, particularly in hyperuricemic patients may occur.

DrugDDI.d526.s1.e0 0 10
drug
Allopurinol



Abstract Id: DrugDDI.d526
Sentence Id: DrugDDI.d526.s2
Bacteriostat ic Antibiotics: Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins .

DrugDDI.d526.s2.e0 0 11
drug
Bacteriostat
DrugDDI.d526.s2.e1 26 40
drug
Chloramphenicol
DrugDDI.d526.s2.e2 42 54
drug
erythromycins
DrugDDI.d526.s2.e3 56 67
drug
sulfonamides
DrugDDI.d526.s2.e4 71 83
drug
tetracyclines
DrugDDI.d526.s2.e5 123 133
drug
penicillins

interaction DrugDDI.d526.s2.e1 DrugDDI.d526.s2.e5
interaction DrugDDI.d526.s2.e2 DrugDDI.d526.s2.e5
interaction DrugDDI.d526.s2.e3 DrugDDI.d526.s2.e5
interaction DrugDDI.d526.s2.e4 DrugDDI.d526.s2.e5

Abstract Id: DrugDDI.d526
Sentence Id: DrugDDI.d526.s4
Oral Contraceptives : May be less effective and increased breakthrough bleeding may occur.

DrugDDI.d526.s4.e0 0 17
drug
Oral Contraceptives



Abstract Id: DrugDDI.d526
Sentence Id: DrugDDI.d526.s5
Probenecid : May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.

DrugDDI.d526.s5.e0 0 9
drug
Probenecid
DrugDDI.d526.s5.e1 45 54
drug
ampicillin
DrugDDI.d526.s5.e2 92 101
drug
ampicillin

interaction DrugDDI.d526.s5.e0 DrugDDI.d526.s5.e1

Abstract Id: DrugDDI.d526
Sentence Id: DrugDDI.d526.s6
Drug /Laboratory Test Interaction After treatment with ampicillin , a false-positive reaction for glucose in the urine may occur with copper sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.

DrugDDI.d526.s6.e0 0 3
drug
Drug
DrugDDI.d526.s6.e1 48 57
drug
ampicillin
DrugDDI.d526.s6.e2 85 91
drug
glucose
DrugDDI.d526.s6.e3 114 126
drug
copper sulfate
DrugDDI.d526.s6.e4 231 237
drug
Glucose

interaction DrugDDI.d526.s6.e1 DrugDDI.d526.s6.e3

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s0
Amprenavir is metabolized in the liver by the cytochrome P450 enzyme system.

DrugDDI.d140.s0.e0 0 9
drug
Amprenavir
DrugDDI.d140.s0.e1 28 32
drug
liver
DrugDDI.d140.s0.e2 38 51
drug
cytochrome P450

interaction DrugDDI.d140.s0.e0 DrugDDI.d140.s0.e2

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s1
Amprenavir inhibits CYP3A4 .

DrugDDI.d140.s1.e0 0 9
drug
Amprenavir
DrugDDI.d140.s1.e1 18 23
drug
CYP3A4

interaction DrugDDI.d140.s1.e0 DrugDDI.d140.s1.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s2
Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4 , or potentially toxic medications that are metabolized by CYP3A4 .

DrugDDI.d140.s2.e0 38 48
drug
medications
DrugDDI.d140.s2.e1 90 95
drug
CYP3A4
DrugDDI.d140.s2.e2 115 125
drug
medications
DrugDDI.d140.s2.e3 146 151
drug
CYP3A4

interaction DrugDDI.d140.s2.e0 DrugDDI.d140.s2.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s3
Amprenavir does not inhibit CYP2D6 , CYP1A2 , CYP2C9 , CYP2C19 , CYP2E1 , or uridine glucuronosyltransferase ( UDPGT ).

DrugDDI.d140.s3.e0 0 9
drug
Amprenavir
DrugDDI.d140.s3.e1 24 29
drug
CYP2D6
DrugDDI.d140.s3.e2 31 36
drug
CYP1A2
DrugDDI.d140.s3.e3 38 43
drug
CYP2C9
DrugDDI.d140.s3.e4 45 51
drug
CYP2C19
DrugDDI.d140.s3.e5 53 58
drug
CYP2E1
DrugDDI.d140.s3.e6 62 68
drug
uridine
DrugDDI.d140.s3.e7 93 97
drug
UDPGT



Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s4
HIV Protease Inhibitors : The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.

DrugDDI.d140.s4.e0 0 20
drug
HIV Protease Inhibitors
DrugDDI.d140.s4.e1 33 42
drug
amprenavir
DrugDDI.d140.s4.e2 75 95
drug
HIV protease inhibitors



Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s5
Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir .

DrugDDI.d140.s5.e0 0 8
drug
Indinavir
DrugDDI.d140.s5.e1 93 102
drug
amprenavir

interaction DrugDDI.d140.s5.e0 DrugDDI.d140.s5.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s7
Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir .

DrugDDI.d140.s7.e0 0 9
drug
Saquinavir
DrugDDI.d140.s7.e1 110 119
drug
amprenavir

interaction DrugDDI.d140.s7.e0 DrugDDI.d140.s7.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s8
Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir .

DrugDDI.d140.s8.e0 0 9
drug
Nelfinavir
DrugDDI.d140.s8.e1 94 103
drug
amprenavir

interaction DrugDDI.d140.s8.e0 DrugDDI.d140.s8.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s9
Methadone : Coadministration of amprenavir and methadone can decrease plasma levels ofmethadone.

DrugDDI.d140.s9.e0 0 8
drug
Methadone
DrugDDI.d140.s9.e1 28 37
drug
amprenavir
DrugDDI.d140.s9.e2 41 49
drug
methadone

interaction DrugDDI.d140.s9.e1 DrugDDI.d140.s9.e2

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s10
Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.

DrugDDI.d140.s10.e0 18 27
drug
amprenavir
DrugDDI.d140.s10.e1 31 39
drug
methadone
DrugDDI.d140.s10.e2 126 135
drug
amprenavir

interaction DrugDDI.d140.s10.e0 DrugDDI.d140.s10.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s11
Amprenavir is an inhibitor of cytochrome P450 C.P.A. metabolism and therefore should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 .

DrugDDI.d140.s11.e0 0 9
drug
Amprenavir
DrugDDI.d140.s11.e1 25 38
drug
cytochrome P450
DrugDDI.d140.s11.e2 106 116
drug
medications
DrugDDI.d140.s11.e3 164 169
drug
CYP3A4

interaction DrugDDI.d140.s11.e0 DrugDDI.d140.s11.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s13
Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides , SGOT ( AST ), and SGPT (ALT) in some patients.

DrugDDI.d140.s13.e0 32 41
drug
Amprenavir
DrugDDI.d140.s13.e1 53 61
drug
ritonavir
DrugDDI.d140.s13.e2 95 105
drug
cholesterol
DrugDDI.d140.s13.e3 109 121
drug
triglycerides
DrugDDI.d140.s13.e4 128 130
drug
AST

interaction DrugDDI.d140.s13.e0 DrugDDI.d140.s13.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s14
Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.

DrugDDI.d140.s14.e0 85 94
drug
Amprenavir
DrugDDI.d140.s14.e1 98 106
drug
ritonavir

interaction DrugDDI.d140.s14.e0 DrugDDI.d140.s14.e1

Abstract Id: DrugDDI.d140
Sentence Id: DrugDDI.d140.s15
For comprehensive information concerning laboratory test alterations associated with ritonavir , physicians should refer to the complete prescribing information for NORVIR ( ritonavir ).

DrugDDI.d140.s15.e0 76 84
drug
ritonavir
DrugDDI.d140.s15.e1 145 150
drug
NORVIR
DrugDDI.d140.s15.e2 152 160
drug
ritonavir



Abstract Id: DrugDDI.d88
Sentence Id: DrugDDI.d88.s0
Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.

DrugDDI.d88.s0.e0 6 16
drug
amyl nitrite
DrugDDI.d88.s0.e1 22 36
drug
drinking alcohol

interaction DrugDDI.d88.s0.e0 DrugDDI.d88.s0.e1

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s0
Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal product s have been conducted.

DrugDDI.d65.s0.e0 7 8
drug
PK
DrugDDI.d65.s0.e1 64 73
drug
anagrelide
DrugDDI.d65.s0.e2 82 97
drug
medicinal product



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s1
In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin .

DrugDDI.d65.s1.e0 52 58
drug
digoxin
DrugDDI.d65.s1.e1 62 69
drug
warfarin
DrugDDI.d65.s1.e2 84 85
drug
PK
DrugDDI.d65.s1.e3 98 107
drug
anagrelide
DrugDDI.d65.s1.e4 116 125
drug
anagrelide
DrugDDI.d65.s1.e5 135 136
drug
PK
DrugDDI.d65.s1.e6 149 155
drug
digoxin
DrugDDI.d65.s1.e7 158 165
drug
warfarin



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s2
Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol .

DrugDDI.d65.s2.e0 74 84
drug
medications
DrugDDI.d65.s2.e1 106 115
drug
anagrelide
DrugDDI.d65.s2.e2 136 142
drug
aspirin
DrugDDI.d65.s2.e3 144 156
drug
acetaminophen
DrugDDI.d65.s2.e4 158 167
drug
furosemide
DrugDDI.d65.s2.e5 169 172
drug
iron
DrugDDI.d65.s2.e6 174 183
drug
ranitidine
DrugDDI.d65.s2.e7 185 195
drug
hydroxyurea
DrugDDI.d65.s2.e8 200 210
drug
allopurinol



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s3
There is no clinical evidence to suggest that anagrelide interacts with any of these compounds.

DrugDDI.d65.s3.e0 38 47
drug
anagrelide



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s4
An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated.

DrugDDI.d65.s4.e0 64 73
drug
anagrelide
DrugDDI.d65.s4.e1 121 127
drug
aspirin



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s6
No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed.

DrugDDI.d65.s6.e0 54 63
drug
anagrelide
DrugDDI.d65.s6.e1 67 85
drug
acetylsalicylic acid



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s7
In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo.

DrugDDI.d65.s7.e0 16 22
drug
aspirin



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s8
Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin .

DrugDDI.d65.s8.e0 0 9
drug
Anagrelide
DrugDDI.d65.s8.e1 105 111
drug
aspirin

interaction DrugDDI.d65.s8.e0 DrugDDI.d65.s8.e1

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s9
Anagrelide is metabolized at least in part by CYP1A2 .

DrugDDI.d65.s9.e0 0 9
drug
Anagrelide
DrugDDI.d65.s9.e1 38 43
drug
CYP1A2

interaction DrugDDI.d65.s9.e0 DrugDDI.d65.s9.e1

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s10
It is known that CYP1A2 is inhibited by several medicinal product s, including fluvoxamine , and such medicinal product s could theoretically adversely influence the clearance of anagrelide .

DrugDDI.d65.s10.e0 13 18
drug
CYP1A2
DrugDDI.d65.s10.e1 39 54
drug
medicinal product
DrugDDI.d65.s10.e2 66 76
drug
fluvoxamine
DrugDDI.d65.s10.e3 85 100
drug
medicinal product
DrugDDI.d65.s10.e4 152 161
drug
anagrelide

interaction DrugDDI.d65.s10.e0 DrugDDI.d65.s10.e1
interaction DrugDDI.d65.s10.e0 DrugDDI.d65.s10.e3

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s11
Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal product s sharing that clearance mechanism e.g.

DrugDDI.d65.s11.e0 0 9
drug
Anagrelide
DrugDDI.d65.s11.e1 58 63
drug
CYP1A2
DrugDDI.d65.s11.e2 137 152
drug
medicinal product

interaction DrugDDI.d65.s11.e0 DrugDDI.d65.s11.e2

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s12
theophylline .

DrugDDI.d65.s12.e0 0 11
drug
theophylline



Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s13
Anagrelide is an inhibitor of cyclic AMP PDE III.

DrugDDI.d65.s13.e0 0 9
drug
Anagrelide
DrugDDI.d65.s13.e1 25 33
drug
cyclic AMP

interaction DrugDDI.d65.s13.e0 DrugDDI.d65.s13.e1

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s14
The effects of medicinal product s with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and cilostazol may be exacerbated by anagrelide .

DrugDDI.d65.s14.e0 12 27
drug
medicinal product
DrugDDI.d65.s14.e1 65 73
drug
milrinone
DrugDDI.d65.s14.e2 75 83
drug
enoximone
DrugDDI.d65.s14.e3 85 92
drug
amrinone
DrugDDI.d65.s14.e4 94 102
drug
olprinone
DrugDDI.d65.s14.e5 106 115
drug
cilostazol
DrugDDI.d65.s14.e6 134 143
drug
anagrelide

interaction DrugDDI.d65.s14.e0 DrugDDI.d65.s14.e6
interaction DrugDDI.d65.s14.e2 DrugDDI.d65.s14.e6

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s15
There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.

DrugDDI.d65.s15.e0 42 51
drug
sucralfate
DrugDDI.d65.s15.e1 68 77
drug
anagrelide

interaction DrugDDI.d65.s15.e0 DrugDDI.d65.s15.e1

Abstract Id: DrugDDI.d65
Sentence Id: DrugDDI.d65.s16
Food has no clinically significant effect on the bioavailability of anagrelide .

DrugDDI.d65.s16.e0 58 67
drug
anagrelide



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s0
Anastrozole inhibited in vitro metabolic reactions catalyzed by cytochromes P450 1A2 , 2C8/9, and 3A4 but only at relatively high concentrations.

DrugDDI.d69.s0.e0 0 10
drug
Anastrozole
DrugDDI.d69.s0.e1 56 73
drug
cytochromes P450 1A2



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s1
Anastrozole did not inhibit P450 2A6 or the polymorphic P450 2D6 in human liver microsomes.

DrugDDI.d69.s1.e0 0 10
drug
Anastrozole
DrugDDI.d69.s1.e1 24 27
drug
P450
DrugDDI.d69.s1.e2 36 53
drug
polymorphic P450 2D6



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s2
Anastrozole did not alter the pharmacokinetics of antipyrine .

DrugDDI.d69.s2.e0 0 10
drug
Anastrozole
DrugDDI.d69.s2.e1 43 52
drug
antipyrine



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s3
Although there have been no formal interaction studies other than with antipyrine , based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450 -mediated metabolism of the other drugs .

DrugDDI.d69.s3.e0 60 69
drug
antipyrine
DrugDDI.d69.s3.e1 152 159
drug
ARIMIDEX
DrugDDI.d69.s3.e2 169 173
drug
drugs
DrugDDI.d69.s3.e3 207 210
drug
drug
DrugDDI.d69.s3.e4 223 236
drug
cytochrome P450
DrugDDI.d69.s3.e5 266 270
drug
drugs



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s4
An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.

DrugDDI.d69.s4.e0 22 29
drug
warfarin
DrugDDI.d69.s4.e1 67 77
drug
anastrozole
DrugDDI.d69.s4.e2 80 87
drug
warfarin



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s5
At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor -positive subpopulation.

DrugDDI.d69.s5.e0 45 52
drug
ARIMIDEX
DrugDDI.d69.s5.e1 56 64
drug
tamoxifen
DrugDDI.d69.s5.e2 116 124
drug
tamoxifen
DrugDDI.d69.s5.e3 151 165
drug
hormone receptor



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s7
Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY @ Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).

DrugDDI.d69.s7.e0 57 65
drug
tamoxifen
DrugDDI.d69.s7.e1 93 103
drug
anastrozole

interaction DrugDDI.d69.s7.e0 DrugDDI.d69.s7.e1

Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s8
Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.

DrugDDI.d69.s8.e0 19 29
drug
anastrozole
DrugDDI.d69.s8.e1 33 41
drug
tamoxifen
DrugDDI.d69.s8.e2 64 74
drug
anastrozole
DrugDDI.d69.s8.e3 121 131
drug
anastrozole

interaction DrugDDI.d69.s8.e0 DrugDDI.d69.s8.e1

Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s9
Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.

DrugDDI.d69.s9.e0 47 54
drug
ARIMIDEX



Abstract Id: DrugDDI.d69
Sentence Id: DrugDDI.d69.s10
Drug /Laboratory Test Interactions No clinically significant changes in the results of clinical laboratory tests have been observed .

DrugDDI.d69.s10.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s0
Addition or deletion of any drug from the therapeutic regimen of patients receiving oral anticoagulants may affect patient response to the anticoagulant .

DrugDDI.d282.s0.e0 23 26
drug
drug
DrugDDI.d282.s0.e1 71 88
drug
oral anticoagulants
DrugDDI.d282.s0.e2 118 130
drug
anticoagulant

interaction DrugDDI.d282.s0.e0 DrugDDI.d282.s0.e1

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s1
Frequent determination of prothrombin time and close monitoring of the patient is essential to ascertain when adjustment of dosage of anticoagulant may be needed.

DrugDDI.d282.s1.e0 114 126
drug
anticoagulant



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s2
Because of the variability of individual patient response, multiple interacting mechanisms with some drugs , the dependency of the extent of the interaction on the dosage and duration of therapy, and the possible administration of several interacting drugs simultaneously, it is difficult to predict the direction and degree of the ultimate effect of concomitant medications on anticoagulant response.

DrugDDI.d282.s2.e0 88 92
drug
drugs
DrugDDI.d282.s2.e1 214 218
drug
drugs
DrugDDI.d282.s2.e2 309 319
drug
medications
DrugDDI.d282.s2.e3 322 334
drug
anticoagulant



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s3
For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K , the net effects are unpredictable.

DrugDDI.d282.s3.e0 16 29
drug
cholestyramine
DrugDDI.d282.s3.e1 77 94
drug
oral anticoagulants
DrugDDI.d282.s3.e2 98 105
drug
vitamin K
DrugDDI.d282.s3.e3 110 112
drug
net

interaction DrugDDI.d282.s3.e0 DrugDDI.d282.s3.e1

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s4
Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.

DrugDDI.d282.s4.e0 0 13
drug
Chloral hydrate
DrugDDI.d282.s4.e1 33 43
drug
prothrombin
DrugDDI.d282.s4.e2 67 79
drug
anticoagulant
DrugDDI.d282.s4.e3 84 90
drug
protein
DrugDDI.d282.s4.e4 116 126
drug
prothrombin
DrugDDI.d282.s4.e5 173 176
drug
drug
DrugDDI.d282.s4.e6 247 257
drug
prothrombin

interaction DrugDDI.d282.s4.e0 DrugDDI.d282.s4.e2

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s5
An interacting drug which leads to a decrease in prothrombin time necessitating an increased dose of oral anticoagulant to maintain an adequate degree of anticoagulation may, if abruptly discontinued, increase the risk of subsequent bleeding.

DrugDDI.d282.s5.e0 13 16
drug
drug
DrugDDI.d282.s5.e1 85 101
drug
oral anticoagulant



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s6
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; .

DrugDDI.d282.s6.e0 0 4
drug
Drugs
DrugDDI.d282.s6.e1 35 51
drug
oral anticoagulant

interaction DrugDDI.d282.s6.e0 DrugDDI.d282.s6.e1

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s7
alcohol *; .

DrugDDI.d282.s7.e0 0 6
drug
alcohol



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s8
antacids ; .

DrugDDI.d282.s8.e0 0 7
drug
antacids



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s9
antihistamines ; .

DrugDDI.d282.s9.e0 0 13
drug
antihistamines



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s10
barbiturates ; .

DrugDDI.d282.s10.e0 0 11
drug
barbiturates



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s11
carbamazepine ; .

DrugDDI.d282.s11.e0 0 12
drug
carbamazepine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s12
chloral hydrate *; .

DrugDDI.d282.s12.e0 0 13
drug
chloral hydrate



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s13
chlordiazepoxide ; .

DrugDDI.d282.s13.e0 0 15
drug
chlordiazepoxide



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s14
cholestyramine ; .

DrugDDI.d282.s14.e0 0 13
drug
cholestyramine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s15
diet high in vitamin K ; .

DrugDDI.d282.s15.e0 10 17
drug
vitamin K



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s16
diuretics *; .

DrugDDI.d282.s16.e0 0 8
drug
diuretics



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s17
ethchlorvynol ; .

DrugDDI.d282.s17.e0 0 12
drug
ethchlorvynol



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s18
glu -tethimide; .

DrugDDI.d282.s18.e0 0 2
drug
glu



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s19
griseofulvin ; .

DrugDDI.d282.s19.e0 0 11
drug
griseofulvin



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s20
haloperidol ; .

DrugDDI.d282.s20.e0 0 10
drug
haloperidol



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s21
meprobamate ; .

DrugDDI.d282.s21.e0 0 10
drug
meprobamate



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s22
oral contraceptives ; .

DrugDDI.d282.s22.e0 0 17
drug
oral contraceptives



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s23
paraldehyde ; .

DrugDDI.d282.s23.e0 0 10
drug
paraldehyde



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s24
primidone ; .

DrugDDI.d282.s24.e0 0 8
drug
primidone



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s25
ranitidine *; .

DrugDDI.d282.s25.e0 0 9
drug
ranitidine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s26
rifampin ; .

DrugDDI.d282.s26.e0 0 7
drug
rifampin



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s28
vitamin C ; .

DrugDDI.d282.s28.e0 0 7
drug
vitamin C



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s29
warfarin sodium under-dosage.

DrugDDI.d282.s29.e0 0 13
drug
warfarin sodium



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s30
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: alcohol *; .

DrugDDI.d282.s30.e0 0 4
drug
Drugs
DrugDDI.d282.s30.e1 30 46
drug
oral anticoagulant
DrugDDI.d282.s30.e2 68 78
drug
prothrombin
DrugDDI.d282.s30.e3 101 107
drug
alcohol

interaction DrugDDI.d282.s30.e0 DrugDDI.d282.s30.e1

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s31
allopurinol ; .

DrugDDI.d282.s31.e0 0 10
drug
allopurinol



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s32
aminosalicylic acid ; .

DrugDDI.d282.s32.e0 0 17
drug
aminosalicylic acid



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s33
amiodarone ; .

DrugDDI.d282.s33.e0 0 9
drug
amiodarone



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s34
anabolic steroids ; .

DrugDDI.d282.s34.e0 0 15
drug
anabolic steroids



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s35
antibiotics ; .

DrugDDI.d282.s35.e0 0 10
drug
antibiotics



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s36
bromelains ; .

DrugDDI.d282.s36.e0 0 9
drug
bromelains



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s37
chloral hydrate *; .

DrugDDI.d282.s37.e0 0 13
drug
chloral hydrate



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s38
chlorpro -pamide; .

DrugDDI.d282.s38.e0 0 7
drug
chlorpro



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s39
chymotrypsin ; .

DrugDDI.d282.s39.e0 0 11
drug
chymotrypsin



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s40
cimetidine ; .

DrugDDI.d282.s40.e0 0 9
drug
cimetidine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s41
cinchophen ; .

DrugDDI.d282.s41.e0 0 9
drug
cinchophen



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s42
clofibrate ; .

DrugDDI.d282.s42.e0 0 9
drug
clofibrate



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s43
dextran ; .

DrugDDI.d282.s43.e0 0 6
drug
dextran



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s44
dextrothyroxine ; .

DrugDDI.d282.s44.e0 0 14
drug
dextrothyroxine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s45
diazoxide ; .

DrugDDI.d282.s45.e0 0 8
drug
diazoxide



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s47
diflunisal ; .

DrugDDI.d282.s47.e0 0 9
drug
diflunisal



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s48
diuretics *; .

DrugDDI.d282.s48.e0 0 8
drug
diuretics



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s49
disulfiram ; .

DrugDDI.d282.s49.e0 0 9
drug
disulfiram



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s50
drugs affecting blood elements; .

DrugDDI.d282.s50.e0 0 4
drug
drugs



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s51
ethacrynic acid ; .

DrugDDI.d282.s51.e0 0 13
drug
ethacrynic acid



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s52
fenoprofen ; .

DrugDDI.d282.s52.e0 0 9
drug
fenoprofen



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s53
glucagon ; .

DrugDDI.d282.s53.e0 0 7
drug
glucagon



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s54
hepatotoxic drugs ; .

DrugDDI.d282.s54.e0 11 15
drug
drugs



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s55
ibuprofen ; .

DrugDDI.d282.s55.e0 0 8
drug
ibuprofen



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s56
indomethacin ; .

DrugDDI.d282.s56.e0 0 11
drug
indomethacin



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s57
influenza virus vaccine ; .

DrugDDI.d282.s57.e0 0 20
drug
influenza virus vaccine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s58
inhalation anesthetics ; .

DrugDDI.d282.s58.e0 10 20
drug
anesthetics



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s59
mefenamic acid ; .

DrugDDI.d282.s59.e0 0 12
drug
mefenamic acid



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s60
methyldopa ; .

DrugDDI.d282.s60.e0 0 9
drug
methyldopa



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s61
methylphenidate ; .

DrugDDI.d282.s61.e0 0 14
drug
methylphenidate



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s62
metronidazole ; .

DrugDDI.d282.s62.e0 0 12
drug
metronidazole



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s63
miconazole ; .

DrugDDI.d282.s63.e0 0 9
drug
miconazole



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s64
monoamine oxidase inhibitors ; .

DrugDDI.d282.s64.e0 0 25
drug
monoamine oxidase inhibitors



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s65
nalidixic acid ; .

DrugDDI.d282.s65.e0 0 12
drug
nalidixic acid



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s66
naproxen ; .

DrugDDI.d282.s66.e0 0 7
drug
naproxen



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s67
oxolinic acid ; .

DrugDDI.d282.s67.e0 0 11
drug
oxolinic acid



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s68
oxyphenbutazone ; .

DrugDDI.d282.s68.e0 0 14
drug
oxyphenbutazone



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s70
phenylbutazone ; .

DrugDDI.d282.s70.e0 0 13
drug
phenylbutazone



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s71
phenyramidol ; .

DrugDDI.d282.s71.e0 0 11
drug
phenyramidol



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s74
prolonged narcotics ; .

DrugDDI.d282.s74.e0 9 17
drug
narcotics



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s76
quinidine ; .

DrugDDI.d282.s76.e0 0 8
drug
quinidine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s77
quinine ; .

DrugDDI.d282.s77.e0 0 6
drug
quinine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s78
ranitidine *; .

DrugDDI.d282.s78.e0 0 9
drug
ranitidine



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s79
sali- cylate s; sulfinpyrazone ; .

DrugDDI.d282.s79.e0 5 10
drug
cylate
DrugDDI.d282.s79.e1 13 26
drug
sulfinpyrazone



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s80
sulfonamides , long acting; .

DrugDDI.d282.s80.e0 0 11
drug
sulfonamides



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s81
sulindac ; .

DrugDDI.d282.s81.e0 0 7
drug
sulindac



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s82
thyroid drug s; .

DrugDDI.d282.s82.e0 0 10
drug
thyroid drug



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s83
tolbutamide ; .

DrugDDI.d282.s83.e0 0 10
drug
tolbutamide



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s84
triclofos sodium ; .

DrugDDI.d282.s84.e0 0 14
drug
triclofos sodium



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s85
trimethoprim / sulfamethoxazole ; .

DrugDDI.d282.s85.e0 0 11
drug
trimethoprim
DrugDDI.d282.s85.e1 13 28
drug
sulfamethoxazole



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s87
warfarin sodium overdosage.

DrugDDI.d282.s87.e0 8 13
drug
sodium



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s88
Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents , eg, tolbut-amide and chlorpropamide , by inhibiting their metabolism in the liver .

DrugDDI.d282.s88.e0 0 17
drug
Oral anticoagulants
DrugDDI.d282.s88.e1 34 51
drug
hypoglycemic action
DrugDDI.d282.s88.e2 54 71
drug
hypoglycemic agents
DrugDDI.d282.s88.e3 91 104
drug
chlorpropamide
DrugDDI.d282.s88.e4 138 142
drug
liver

interaction DrugDDI.d282.s88.e0 DrugDDI.d282.s88.e2

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s89
Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and pheny-toin are administered concurrently.

DrugDDI.d282.s89.e0 7 24
drug
oral anticoagulants
DrugDDI.d282.s89.e1 63 71
drug
phenytoin
DrugDDI.d282.s89.e2 89 102
drug
anticonvulsant
DrugDDI.d282.s89.e3 117 133
drug
oral anticoagulant

interaction DrugDDI.d282.s89.e0 DrugDDI.d282.s89.e1

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s90
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs , dipyridamole , hydrochloroquine, clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.

DrugDDI.d282.s90.e0 0 4
drug
Drugs
DrugDDI.d282.s90.e1 76 95
drug
antineoplastic agents
DrugDDI.d282.s90.e2 99 103
drug
drugs
DrugDDI.d282.s90.e3 136 142
drug
aspirin
DrugDDI.d282.s90.e4 151 185
drug
non-steroidal anti-inflammatory drugs
DrugDDI.d282.s90.e5 187 198
drug
dipyridamole
DrugDDI.d282.s90.e6 217 226
drug
clofibrate
DrugDDI.d282.s90.e7 228 234
drug
dextran
DrugDDI.d282.s90.e8 276 289
drug
anticoagulants

interaction DrugDDI.d282.s90.e1 DrugDDI.d282.s90.e8
interaction DrugDDI.d282.s90.e2 DrugDDI.d282.s90.e8
interaction DrugDDI.d282.s90.e4 DrugDDI.d282.s90.e8
interaction DrugDDI.d282.s90.e6 DrugDDI.d282.s90.e8

Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s91
The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.

DrugDDI.d282.s91.e0 85 97
drug
anticoagulant



Abstract Id: DrugDDI.d282
Sentence Id: DrugDDI.d282.s93
Drug /Laboratory Test Interferences: Dicu-marol and indanedione anticoagulant s, including anisindione , or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.

DrugDDI.d282.s93.e0 0 3
drug
Drug
DrugDDI.d282.s93.e1 46 69
drug
indanedione anticoagulant
DrugDDI.d282.s93.e2 81 91
drug
anisindione
DrugDDI.d282.s93.e3 100 110
drug
metabolites



Abstract Id: DrugDDI.d352
Sentence Id: DrugDDI.d352.s0
5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated .

DrugDDI.d352.s0.e0 76 86
drug
apomorphine
DrugDDI.d352.s0.e1 106 116
drug
ondansetron
DrugDDI.d352.s0.e2 137 147
drug
apomorphine
DrugDDI.d352.s0.e3 152 156
drug
drugs
DrugDDI.d352.s0.e4 203 213
drug
ondansetron
DrugDDI.d352.s0.e5 215 225
drug
granisetron
DrugDDI.d352.s0.e6 227 236
drug
dolasetron
DrugDDI.d352.s0.e7 238 249
drug
palonosetron
DrugDDI.d352.s0.e8 254 262
drug
alosetron

interaction DrugDDI.d352.s0.e0 DrugDDI.d352.s0.e1
interaction DrugDDI.d352.s0.e2 DrugDDI.d352.s0.e4
interaction DrugDDI.d352.s0.e2 DrugDDI.d352.s0.e6
interaction DrugDDI.d352.s0.e2 DrugDDI.d352.s0.e8

Abstract Id: DrugDDI.d352
Sentence Id: DrugDDI.d352.s1
Antihypertensive Medications and Vasodilators The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.

DrugDDI.d352.s1.e0 0 15
drug
Antihypertensive
DrugDDI.d352.s1.e1 30 41
drug
Vasodilators
DrugDDI.d352.s1.e2 124 139
drug
antihypertensive
DrugDDI.d352.s1.e3 153 164
drug
vasodilators
DrugDDI.d352.s1.e4 217 221
drug
drugs



Abstract Id: DrugDDI.d352
Sentence Id: DrugDDI.d352.s3
Dopamine Antagonists Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics (phenoth-iazines, butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .

DrugDDI.d352.s3.e0 0 18
drug
Dopamine Antagonists
DrugDDI.d352.s3.e1 24 34
drug
apomorphine
DrugDDI.d352.s3.e2 38 52
drug
dopamine agonist
DrugDDI.d352.s3.e3 70 88
drug
dopamine antagonists
DrugDDI.d352.s3.e4 99 110
drug
neuroleptics
DrugDDI.d352.s3.e5 128 141
drug
butyrophenones
DrugDDI.d352.s3.e6 143 155
drug
thioxanthenes
DrugDDI.d352.s3.e7 159 172
drug
metoclopramide
DrugDDI.d352.s3.e8 203 208
drug
APOKYN

interaction DrugDDI.d352.s3.e3 DrugDDI.d352.s3.e8
interaction DrugDDI.d352.s3.e5 DrugDDI.d352.s3.e8
interaction DrugDDI.d352.s3.e7 DrugDDI.d352.s3.e8

Abstract Id: DrugDDI.d352
Sentence Id: DrugDDI.d352.s4
Patients with major psychotic disorders, treated with neuroleptics , should be treated with dopamine agonists only if the potential benefits outweigh the risks.

DrugDDI.d352.s4.e0 47 58
drug
neuroleptics
DrugDDI.d352.s4.e1 79 94
drug
dopamine agonists



Abstract Id: DrugDDI.d352
Sentence Id: DrugDDI.d352.s5
Drugs Prolonging the QT/QTc Interval Caution should be exercised when prescribing apomorphine concomitantly with drugs that prolong the QT/QTc interval.

DrugDDI.d352.s5.e0 0 4
drug
Drugs
DrugDDI.d352.s5.e1 71 81
drug
apomorphine
DrugDDI.d352.s5.e2 99 103
drug
drugs

interaction DrugDDI.d352.s5.e1 DrugDDI.d352.s5.e2

Abstract Id: DrugDDI.d352
Sentence Id: DrugDDI.d352.s6
Drug /Laboratory Test Interactions There are no known interactions between APOKYN and laboratory tests.

DrugDDI.d352.s6.e0 0 3
drug
Drug
DrugDDI.d352.s6.e1 65 70
drug
APOKYN



Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s0
Apraclonidine should not be used in patients receiving MAO inhibitors ..

DrugDDI.d164.s0.e0 0 12
drug
Apraclonidine
DrugDDI.d164.s0.e1 47 59
drug
MAO inhibitors

interaction DrugDDI.d164.s0.e0 DrugDDI.d164.s0.e1

Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s1
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE@ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered.

DrugDDI.d164.s1.e0 53 57
drug
drugs
DrugDDI.d164.s1.e1 68 78
drug
medications
DrugDDI.d164.s1.e2 194 207
drug
CNS depressants
DrugDDI.d164.s1.e3 209 215
drug
alcohol
DrugDDI.d164.s1.e4 217 228
drug
barbiturates
DrugDDI.d164.s1.e5 230 236
drug
opiates
DrugDDI.d164.s1.e6 238 246
drug
sedatives
DrugDDI.d164.s1.e7 248 258
drug
anesthetics



Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s2
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine .

DrugDDI.d164.s2.e0 0 23
drug
Tricyclic antidepressants
DrugDDI.d164.s2.e1 77 85
drug
clonidine

interaction DrugDDI.d164.s2.e0 DrugDDI.d164.s2.e1

Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s3
It is not known whether the concurrent use of these agents with apraclonidine can lead to a reduction in IOP lowering effect.

DrugDDI.d164.s3.e0 52 64
drug
apraclonidine



Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s4
No data on the level of circulating catecholamines after apraclonidine withdrawal are available.

DrugDDI.d164.s4.e0 48 60
drug
apraclonidine



Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s5
Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

DrugDDI.d164.s5.e0 41 64
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s6
An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.

DrugDDI.d164.s6.e0 70 78
drug
clonidine



Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s7
Systemic clonidine may inhibit the production of catecholamines in response to insulin-induced hypoglycemia and mask the signs and symptoms of hypoglycemia.

DrugDDI.d164.s7.e0 8 16
drug
clonidine



Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s8
Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives , and cardiac glycosides is advised.

DrugDDI.d164.s8.e0 5 17
drug
apraclonidine
DrugDDI.d164.s8.e1 63 67
drug
drugs
DrugDDI.d164.s8.e2 74 86
drug
beta-blockers
DrugDDI.d164.s8.e3 111 127
drug
antihypertensives
DrugDDI.d164.s8.e4 132 148
drug
cardiac glycosides

interaction DrugDDI.d164.s8.e0 DrugDDI.d164.s8.e1
interaction DrugDDI.d164.s8.e0 DrugDDI.d164.s8.e3

Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s9
Patients using cardiovascular drugs concurrently with IOPIDINE 0 .5% Ophthalmic Solution should have pulse and blood pressures frequently monitored.

DrugDDI.d164.s9.e0 13 31
drug
cardiovascular drugs
DrugDDI.d164.s9.e1 48 56
drug
IOPIDINE 0

interaction DrugDDI.d164.s9.e0 DrugDDI.d164.s9.e1

Abstract Id: DrugDDI.d164
Sentence Id: DrugDDI.d164.s10
Caution should be exercised with simultaneous use of clonidine and other similar pharmacologic agents .

DrugDDI.d164.s10.e0 45 53
drug
clonidine



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s0
Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4 .

DrugDDI.d489.s0.e0 0 9
drug
Aprepitant
DrugDDI.d489.s0.e1 56 61
drug
CYP3A4

interaction DrugDDI.d489.s0.e0 DrugDDI.d489.s0.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s1
Aprepitant is also an inducer of CYP2C9 .

DrugDDI.d489.s1.e0 0 9
drug
Aprepitant
DrugDDI.d489.s1.e1 27 32
drug
CYP2C9

interaction DrugDDI.d489.s1.e0 DrugDDI.d489.s1.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s2
Effect of aprepitant on the pharmacokinetics of other agents .

DrugDDI.d489.s2.e0 8 17
drug
aprepitant



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s3
As a moderate inhibitor of CYP3A4 , aprepitant can increase plasma concentrations of coadministered medicinal product s that are metabolized through CYP3A4 .

DrugDDI.d489.s3.e0 22 27
drug
CYP3A4
DrugDDI.d489.s3.e1 29 38
drug
aprepitant
DrugDDI.d489.s3.e2 86 101
drug
medicinal product
DrugDDI.d489.s3.e3 128 133
drug
CYP3A4

interaction DrugDDI.d489.s3.e1 DrugDDI.d489.s3.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s4
Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide , which are metabolized through CYP2C9 .

DrugDDI.d489.s4.e0 0 9
drug
Aprepitant
DrugDDI.d489.s4.e1 49 56
drug
warfarin
DrugDDI.d489.s4.e2 60 70
drug
tolbutamide
DrugDDI.d489.s4.e3 98 103
drug
CYP2C9

interaction DrugDDI.d489.s4.e0 DrugDDI.d489.s4.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s5
Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9 , such as phenytoin , may result in lower plasma concentrations of these drugs .

DrugDDI.d489.s5.e0 18 27
drug
Aprepitant
DrugDDI.d489.s5.e1 37 41
drug
drugs
DrugDDI.d489.s5.e2 49 53
drug
drugs
DrugDDI.d489.s5.e3 83 88
drug
CYP2C9
DrugDDI.d489.s5.e4 96 104
drug
phenytoin
DrugDDI.d489.s5.e5 149 153
drug
drugs

interaction DrugDDI.d489.s5.e0 DrugDDI.d489.s5.e1
interaction DrugDDI.d489.s5.e0 DrugDDI.d489.s5.e4

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s6
Aprepitant is unlikely to interact with drugs that are substrates for the P- glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.

DrugDDI.d489.s6.e0 0 9
drug
Aprepitant
DrugDDI.d489.s6.e1 34 38
drug
drugs
DrugDDI.d489.s6.e2 64 75
drug
glycoprotein
DrugDDI.d489.s6.e3 126 135
drug
Aprepitant
DrugDDI.d489.s6.e4 140 146
drug
digoxin



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s7
5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron .

DrugDDI.d489.s7.e0 50 59
drug
aprepitant
DrugDDI.d489.s7.e1 119 129
drug
ondansetron
DrugDDI.d489.s7.e2 132 142
drug
granisetron



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s8
No clinical or drug interaction study was conducted with dolasetron .

DrugDDI.d489.s8.e0 48 57
drug
dolasetron



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s9
Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.

DrugDDI.d489.s9.e0 0 14
drug
Corticosteroids
DrugDDI.d489.s9.e1 16 28
drug
Dexamethasone
DrugDDI.d489.s9.e2 30 39
drug
Aprepitant
DrugDDI.d489.s9.e3 71 83
drug
dexamethasone
DrugDDI.d489.s9.e4 120 129
drug
Aprepitant
DrugDDI.d489.s9.e5 153 165
drug
dexamethasone
DrugDDI.d489.s9.e6 224 236
drug
dexamethasone
DrugDDI.d489.s9.e7 239 244
drug
CYP3A4

interaction DrugDDI.d489.s9.e2 DrugDDI.d489.s9.e3

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s10
The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant , to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant .

DrugDDI.d489.s10.e0 3 19
drug
oral dexamethasone
DrugDDI.d489.s10.e1 80 89
drug
Aprepitant
DrugDDI.d489.s10.e2 111 123
drug
dexamethasone
DrugDDI.d489.s10.e3 166 175
drug
Aprepitant

interaction DrugDDI.d489.s10.e0 DrugDDI.d489.s10.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s11
The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone .

DrugDDI.d489.s11.e0 14 26
drug
dexamethasone
DrugDDI.d489.s11.e1 60 69
drug
Aprepitant
DrugDDI.d489.s11.e2 114 126
drug
dexamethasone

interaction DrugDDI.d489.s11.e0 DrugDDI.d489.s11.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s12
Methylprednisolone .

DrugDDI.d489.s12.e0 0 17
drug
Methylprednisolone



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s13
Aprepitant , when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone , a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.

DrugDDI.d489.s13.e0 0 9
drug
Aprepitant
DrugDDI.d489.s13.e1 83 100
drug
methylprednisolone
DrugDDI.d489.s13.e2 103 108
drug
CYP3A4
DrugDDI.d489.s13.e3 160 177
drug
methylprednisolone

interaction DrugDDI.d489.s13.e0 DrugDDI.d489.s13.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s14
The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant .

DrugDDI.d489.s14.e0 5 22
drug
methylprednisolone
DrugDDI.d489.s14.e1 67 88
drug
oral methylprednisolone
DrugDDI.d489.s14.e2 148 157
drug
Aprepitant
DrugDDI.d489.s14.e3 178 195
drug
methylprednisolone
DrugDDI.d489.s14.e4 238 247
drug
Aprepitant

interaction DrugDDI.d489.s14.e0 DrugDDI.d489.s14.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s15
Warfarin : A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.

DrugDDI.d489.s15.e0 0 7
drug
Warfarin
DrugDDI.d489.s15.e1 28 37
drug
Aprepitant
DrugDDI.d489.s15.e2 124 131
drug
warfarin

interaction DrugDDI.d489.s15.e1 DrugDDI.d489.s15.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s16
Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-) warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant .

DrugDDI.d489.s16.e0 26 35
drug
Aprepitant
DrugDDI.d489.s16.e1 62 69
drug
warfarin
DrugDDI.d489.s16.e2 113 120
drug
warfarin
DrugDDI.d489.s16.e3 123 128
drug
CYP2C9
DrugDDI.d489.s16.e4 280 289
drug
Aprepitant



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s17
In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.

DrugDDI.d489.s17.e0 19 26
drug
warfarin
DrugDDI.d489.s17.e1 162 171
drug
Aprepitant



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s18
Tolbutamide : Aprepitant , when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.

DrugDDI.d489.s18.e0 0 10
drug
Tolbutamide
DrugDDI.d489.s18.e1 12 21
drug
Aprepitant
DrugDDI.d489.s18.e2 85 95
drug
tolbutamide
DrugDDI.d489.s18.e3 98 103
drug
CYP2C9
DrugDDI.d489.s18.e4 167 182
drug
tolbutamide 500 mg
DrugDDI.d489.s18.e5 248 257
drug
Aprepitant

interaction DrugDDI.d489.s18.e1 DrugDDI.d489.s18.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s19
Oral contraceptives : Aprepitant , when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone , decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%; .

DrugDDI.d489.s19.e0 0 17
drug
Oral contraceptives
DrugDDI.d489.s19.e1 19 28
drug
Aprepitant
DrugDDI.d489.s19.e2 79 95
drug
oral contraceptive
DrugDDI.d489.s19.e3 113 128
drug
ethinyl estradiol
DrugDDI.d489.s19.e4 137 149
drug
norethindrone
DrugDDI.d489.s19.e5 168 183
drug
ethinyl estradiol
DrugDDI.d489.s19.e6 210 222
drug
norethindrone

interaction DrugDDI.d489.s19.e1 DrugDDI.d489.s19.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s20
therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.

DrugDDI.d489.s20.e0 23 40
drug
oral contraceptives
DrugDDI.d489.s20.e1 63 72
drug
Aprepitant

interaction DrugDDI.d489.s20.e0 DrugDDI.d489.s20.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s21
Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.

DrugDDI.d489.s21.e0 23 32
drug
Aprepitant
DrugDDI.d489.s21.e1 55 72
drug
oral contraceptives



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s22
Midazolam : Aprepitant increased the AUC of midazolam , a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.

DrugDDI.d489.s22.e0 0 8
drug
Midazolam
DrugDDI.d489.s22.e1 10 19
drug
Aprepitant
DrugDDI.d489.s22.e2 37 45
drug
midazolam
DrugDDI.d489.s22.e3 57 62
drug
CYP3A4
DrugDDI.d489.s22.e4 128 136
drug
midazolam
DrugDDI.d489.s22.e5 182 196
drug
Aprepitant 125 mg

interaction DrugDDI.d489.s22.e1 DrugDDI.d489.s22.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s23
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant .

DrugDDI.d489.s23.e0 52 60
drug
midazolam
DrugDDI.d489.s23.e1 68 82
drug
benzodiazepines
DrugDDI.d489.s23.e2 97 102
drug
CYP3A4
DrugDDI.d489.s23.e3 104 113
drug
alprazolam
DrugDDI.d489.s23.e4 115 123
drug
triazolam
DrugDDI.d489.s23.e5 177 186
drug
Aprepitant

interaction DrugDDI.d489.s23.e0 DrugDDI.d489.s23.e5
interaction DrugDDI.d489.s23.e3 DrugDDI.d489.s23.e5

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s24
In another study with intravenous administration of midazolam , Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.

DrugDDI.d489.s24.e0 45 53
drug
midazolam
DrugDDI.d489.s24.e1 55 64
drug
Aprepitant
DrugDDI.d489.s24.e2 112 120
drug
midazolam
DrugDDI.d489.s24.e3 177 186
drug
Aprepitant



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s25
Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.

DrugDDI.d489.s25.e0 0 9
drug
Aprepitant
DrugDDI.d489.s25.e1 27 35
drug
midazolam
DrugDDI.d489.s25.e2 67 75
drug
midazolam
DrugDDI.d489.s25.e3 108 117
drug
Aprepitant

interaction DrugDDI.d489.s25.e0 DrugDDI.d489.s25.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s27
The AUC of midazolam on Day 15 was similar to that observed at baseline.

DrugDDI.d489.s27.e0 8 16
drug
midazolam



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s28
Effect of other agents on the pharmacokinefics of aprepitant .

DrugDDI.d489.s28.e0 42 51
drug
aprepitant



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s29
Aprepitant is a substrate for CYP3A4 ; .

DrugDDI.d489.s29.e0 0 9
drug
Aprepitant
DrugDDI.d489.s29.e1 25 30
drug
CYP3A4

interaction DrugDDI.d489.s29.e0 DrugDDI.d489.s29.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s30
therefore, coadministration of Aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant .

DrugDDI.d489.s30.e0 28 37
drug
Aprepitant
DrugDDI.d489.s30.e1 42 46
drug
drugs
DrugDDI.d489.s30.e2 58 63
drug
CYP3A4
DrugDDI.d489.s30.e3 114 123
drug
aprepitant

interaction DrugDDI.d489.s30.e0 DrugDDI.d489.s30.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s31
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution.

DrugDDI.d489.s31.e0 40 49
drug
Aprepitant
DrugDDI.d489.s31.e1 60 65
drug
CYP3A4
DrugDDI.d489.s31.e2 82 93
drug
ketoconazole
DrugDDI.d489.s31.e3 95 106
drug
itraconazole
DrugDDI.d489.s31.e4 108 117
drug
nefazodone
DrugDDI.d489.s31.e5 119 132
drug
troleandomycin
DrugDDI.d489.s31.e6 134 147
drug
clarithromycin
DrugDDI.d489.s31.e7 149 157
drug
ritonavir
DrugDDI.d489.s31.e8 159 168
drug
nelfinavir

interaction DrugDDI.d489.s31.e0 DrugDDI.d489.s31.e1
interaction DrugDDI.d489.s31.e0 DrugDDI.d489.s31.e3
interaction DrugDDI.d489.s31.e0 DrugDDI.d489.s31.e5
interaction DrugDDI.d489.s31.e0 DrugDDI.d489.s31.e7

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s32
Because moderate CYP3A4 inhibitors (e.g., diltiazem ) result in 2-fold increase in plasma concentrations of aprepitant , concomitant administration should also be approached with caution.

DrugDDI.d489.s32.e0 15 20
drug
CYP3A4
DrugDDI.d489.s32.e1 37 45
drug
diltiazem
DrugDDI.d489.s32.e2 93 102
drug
aprepitant

interaction DrugDDI.d489.s32.e0 DrugDDI.d489.s32.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s33
Aprepitant is a substrate for CYP3A4 ; .

DrugDDI.d489.s33.e0 0 9
drug
Aprepitant
DrugDDI.d489.s33.e1 25 30
drug
CYP3A4

interaction DrugDDI.d489.s33.e0 DrugDDI.d489.s33.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s34
therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant .

DrugDDI.d489.s34.e0 28 37
drug
Aprepitant
DrugDDI.d489.s34.e1 42 46
drug
drugs
DrugDDI.d489.s34.e2 65 70
drug
CYP3A4
DrugDDI.d489.s34.e3 85 92
drug
rifampin
DrugDDI.d489.s34.e4 94 106
drug
carbamazepine
DrugDDI.d489.s34.e5 108 116
drug
phenytoin
DrugDDI.d489.s34.e6 158 167
drug
aprepitant
DrugDDI.d489.s34.e7 202 211
drug
Aprepitant

interaction DrugDDI.d489.s34.e0 DrugDDI.d489.s34.e1
interaction DrugDDI.d489.s34.e0 DrugDDI.d489.s34.e4

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s35
Ketoconazole : When a single 125-mg dose of Aprepitant was administered on Day5 of a .

DrugDDI.d489.s35.e0 0 11
drug
Ketoconazole
DrugDDI.d489.s35.e1 36 45
drug
Aprepitant



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s36
10-day regimen of 400 mg/day of ketoconazole , a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.

DrugDDI.d489.s36.e0 26 37
drug
ketoconazole
DrugDDI.d489.s36.e1 46 51
drug
CYP3A4
DrugDDI.d489.s36.e2 70 79
drug
aprepitant
DrugDDI.d489.s36.e3 137 146
drug
aprepitant

interaction DrugDDI.d489.s36.e0 DrugDDI.d489.s36.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s37
Concomitant administration of Aprepitant with strong CYP3A4 inhibitors should be approached cautiously.

DrugDDI.d489.s37.e0 27 36
drug
Aprepitant
DrugDDI.d489.s37.e1 47 52
drug
CYP3A4

interaction DrugDDI.d489.s37.e0 DrugDDI.d489.s37.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s38
Rifampin : When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin , a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.

DrugDDI.d489.s38.e0 0 7
drug
Rifampin
DrugDDI.d489.s38.e1 32 41
drug
Aprepitant
DrugDDI.d489.s38.e2 92 99
drug
rifampin
DrugDDI.d489.s38.e3 108 113
drug
CYP3A4
DrugDDI.d489.s38.e4 130 139
drug
aprepitant

interaction DrugDDI.d489.s38.e1 DrugDDI.d489.s38.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s39
Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant .

DrugDDI.d489.s39.e0 18 27
drug
Aprepitant
DrugDDI.d489.s39.e1 32 36
drug
drugs
DrugDDI.d489.s39.e2 47 52
drug
CYP3A4
DrugDDI.d489.s39.e3 121 130
drug
Aprepitant

interaction DrugDDI.d489.s39.e0 DrugDDI.d489.s39.e1

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s41
Diltiazem : In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.

DrugDDI.d489.s41.e0 0 8
drug
Diltiazem
DrugDDI.d489.s41.e1 67 76
drug
aprepitant
DrugDDI.d489.s41.e2 152 165
drug
diltiazem 120 mg
DrugDDI.d489.s41.e3 213 222
drug
aprepitant
DrugDDI.d489.s41.e4 260 268
drug
diltiazem

interaction DrugDDI.d489.s41.e1 DrugDDI.d489.s41.e2

Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s42
These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone.

DrugDDI.d489.s42.e0 125 133
drug
diltiazem



Abstract Id: DrugDDI.d489
Sentence Id: DrugDDI.d489.s43
Paroxetine : Coadministration of once daily doses of aprepitant , as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine .

DrugDDI.d489.s43.e0 0 9
drug
Paroxetine
DrugDDI.d489.s43.e1 45 54
drug
aprepitant
DrugDDI.d489.s43.e2 127 140
drug
paroxetine 20 mg
DrugDDI.d489.s43.e3 225 234
drug
aprepitant
DrugDDI.d489.s43.e4 238 247
drug
paroxetine

interaction DrugDDI.d489.s43.e1 DrugDDI.d489.s43.e2

Abstract Id: DrugDDI.d263
Sentence Id: DrugDDI.d263.s0
Beta-adrenergic blocking agents : concurrent use may blunt the response to arbutamine .

DrugDDI.d263.s0.e0 0 28
drug
Beta-adrenergic blocking agents
DrugDDI.d263.s0.e1 64 73
drug
arbutamine



Abstract Id: DrugDDI.d263
Sentence Id: DrugDDI.d263.s1
Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine -mediated stress test.

DrugDDI.d263.s1.e0 0 28
drug
Beta-adrenergic blocking agents
DrugDDI.d263.s1.e1 78 87
drug
arbutamine

interaction DrugDDI.d263.s1.e0 DrugDDI.d263.s1.e1

Abstract Id: DrugDDI.d263
Sentence Id: DrugDDI.d263.s2
Antiarrhythmic agent s, class I (such as flecainide , lidocaine , or quinidine ): concurrent use with arbutamine may have a proarrhythmic effect.

DrugDDI.d263.s2.e0 0 18
drug
Antiarrhythmic agent
DrugDDI.d263.s2.e1 34 43
drug
flecainide
DrugDDI.d263.s2.e2 45 53
drug
lidocaine
DrugDDI.d263.s2.e3 57 65
drug
quinidine
DrugDDI.d263.s2.e4 85 94
drug
arbutamine



Abstract Id: DrugDDI.d263
Sentence Id: DrugDDI.d263.s3
Antidepressants (tricyclic), atropine or other anticholinergic agents , or digitalis glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.

DrugDDI.d263.s3.e0 0 14
drug
Antidepressants
DrugDDI.d263.s3.e1 27 34
drug
atropine
DrugDDI.d263.s3.e2 42 62
drug
anticholinergic agents
DrugDDI.d263.s3.e3 66 84
drug
digitalis glycosides
DrugDDI.d263.s3.e4 103 112
drug
arbutamine



Abstract Id: DrugDDI.d446
Sentence Id: DrugDDI.d446.s0
Anticoagulants including coumarin derivatives, indandione derivatives , and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .

DrugDDI.d446.s0.e0 0 13
drug
Anticoagulants
DrugDDI.d446.s0.e1 23 30
drug
coumarin
DrugDDI.d446.s0.e2 53 63
drug
derivatives
DrugDDI.d446.s0.e3 68 96
drug
platelet aggregation inhibitors
DrugDDI.d446.s0.e4 103 136
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d446.s0.e5 138 143
drug
NSAIDs
DrugDDI.d446.s0.e6 149 155
drug
aspirin
DrugDDI.d446.s0.e7 217 225
drug
ardeparin

interaction DrugDDI.d446.s0.e0 DrugDDI.d446.s0.e7
interaction DrugDDI.d446.s0.e2 DrugDDI.d446.s0.e7
interaction DrugDDI.d446.s0.e4 DrugDDI.d446.s0.e7
interaction DrugDDI.d446.s0.e6 DrugDDI.d446.s0.e7

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s0
If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.

DrugDDI.d578.s0.e0 12 26
drug
adrenergic drugs



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s1
When paroxetine , a potent inhibitor of CYP2D6 , was co-administered with BROVANA at steady-state, exposure to either drug was not altered.

DrugDDI.d578.s1.e0 4 13
drug
paroxetine
DrugDDI.d578.s1.e1 33 38
drug
CYP2D6
DrugDDI.d578.s1.e2 100 103
drug
drug



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s2
Dosage adjustments of BROVANA are not necessary when the drug is given concomitantly with potent CYP2D6 inhibitors.

DrugDDI.d578.s2.e0 48 51
drug
drug
DrugDDI.d578.s2.e1 82 87
drug
CYP2D6



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s3
Concomitant treatment with methylxanthines ( aminophylline , theophylline ), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists .

DrugDDI.d578.s3.e0 24 38
drug
methylxanthines
DrugDDI.d578.s3.e1 40 52
drug
aminophylline
DrugDDI.d578.s3.e2 54 65
drug
theophylline
DrugDDI.d578.s3.e3 79 87
drug
diuretics
DrugDDI.d578.s3.e4 123 140
drug
adrenergic agonists

interaction DrugDDI.d578.s3.e0 DrugDDI.d578.s3.e4
interaction DrugDDI.d578.s3.e2 DrugDDI.d578.s3.e4

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s4
The ECG changes and/or hypokalemia that may result from the administration of non- potassium sparing diuretics (such as loop or thiazide diuretics ) can be acutely worsened by beta- agonists , especially when the recommended dose of the beta- agonist is exceeded.

DrugDDI.d578.s4.e0 70 94
drug
potassium sparing diuretics
DrugDDI.d578.s4.e1 108 124
drug
thiazide diuretics
DrugDDI.d578.s4.e2 153 160
drug
agonists
DrugDDI.d578.s4.e3 204 210
drug
agonist



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s5
Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta- agonists with non- potassium sparing diuretics .

DrugDDI.d578.s5.e0 101 108
drug
agonists
DrugDDI.d578.s5.e1 117 141
drug
potassium sparing diuretics

interaction DrugDDI.d578.s5.e0 DrugDDI.d578.s5.e1

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s6
BROVANA, as with other beta2- agonists , should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors , tricyclic antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

DrugDDI.d578.s6.e0 25 32
drug
agonists
DrugDDI.d578.s6.e1 98 123
drug
monoamine oxidase inhibitors
DrugDDI.d578.s6.e2 125 148
drug
tricyclic antidepressants
DrugDDI.d578.s6.e3 152 156
drug
drugs
DrugDDI.d578.s6.e4 203 220
drug
adrenergic agonists

interaction DrugDDI.d578.s6.e0 DrugDDI.d578.s6.e1
interaction DrugDDI.d578.s6.e0 DrugDDI.d578.s6.e3

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s7
Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.

DrugDDI.d578.s7.e0 0 4
drug
Drugs



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s8
The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline , theophylline ) by patients receiving BROVANA has not been completely evaluated.

DrugDDI.d578.s8.e0 51 65
drug
methylxanthines
DrugDDI.d578.s8.e1 72 84
drug
aminophylline
DrugDDI.d578.s8.e2 86 97
drug
theophylline



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s9
In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.

DrugDDI.d578.s9.e0 168 179
drug
theophylline



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s10
In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.

DrugDDI.d578.s10.e0 117 128
drug
theophylline



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s11
In these trials, heart rate and systolic blood pressure were approximately 2-3 bpm and 6-8 mm Hg higher, respectively, in subjects on concomitant theophylline compared with the overall population.

DrugDDI.d578.s11.e0 123 134
drug
theophylline



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s12
Beta-adrenergic receptor antagonists ( beta-blockers ) and BROVANA may interfere with the effect of each other when administered concurrently.

DrugDDI.d578.s12.e0 0 22
drug
Beta-adrenergic receptor
DrugDDI.d578.s12.e1 35 47
drug
beta-blockers



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s13
Beta-blockers not only block the therapeutic effects of beta- agonists , but may produce severe bronchospasm in COPD patients.

DrugDDI.d578.s13.e0 0 12
drug
Beta-blockers
DrugDDI.d578.s13.e1 53 60
drug
agonists

interaction DrugDDI.d578.s13.e0 DrugDDI.d578.s13.e1

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s14
Therefore, patients with COPD should not normally be treated with beta-blockers .

DrugDDI.d578.s14.e0 56 68
drug
beta-blockers



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s15
However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD.

DrugDDI.d578.s15.e0 122 134
drug
beta-blockers



Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s16
In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

DrugDDI.d578.s16.e0 14 41
drug
cardioselective beta-blockers



Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s0
Heparin : Since heparin is contraindicated in patients with heparin -induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.

DrugDDI.d508.s0.e0 0 6
drug
Heparin
DrugDDI.d508.s0.e1 13 19
drug
heparin
DrugDDI.d508.s0.e2 51 57
drug
heparin
DrugDDI.d508.s0.e3 105 114
drug
Argatroban
DrugDDI.d508.s0.e4 118 124
drug
heparin

interaction DrugDDI.d508.s0.e1 DrugDDI.d508.s0.e3

Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s1
However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparin s effect on the aPTT to decrease prior to initiation of Argatroban therapy.

DrugDDI.d508.s1.e0 10 19
drug
Argatroban
DrugDDI.d508.s1.e1 88 94
drug
heparin
DrugDDI.d508.s1.e2 140 149
drug
Argatroban

interaction DrugDDI.d508.s1.e0 DrugDDI.d508.s1.e1

Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s2
Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1 @g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5 @g/kg/min. over 18 hours).

DrugDDI.d508.s2.e0 0 6
drug
Aspirin
DrugDDI.d508.s2.e1 8 20
drug
Acetaminophen
DrugDDI.d508.s2.e2 105 114
drug
Argatroban
DrugDDI.d508.s2.e3 143 149
drug
aspirin
DrugDDI.d508.s2.e4 199 208
drug
Argatroban
DrugDDI.d508.s2.e5 233 245
drug
acetaminophen
DrugDDI.d508.s2.e6 324 333
drug
Argatroban

interaction DrugDDI.d508.s2.e2 DrugDDI.d508.s2.e3

Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s3
Oral anticoagulant agents : Pharmacokinetic drug-drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated.

DrugDDI.d508.s3.e0 4 22
drug
anticoagulant agents
DrugDDI.d508.s3.e1 67 76
drug
Argatroban
DrugDDI.d508.s3.e2 80 87
drug
warfarin



Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s4
However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).

DrugDDI.d508.s4.e0 27 36
drug
Argatroban
DrugDDI.d508.s4.e1 40 47
drug
warfarin

interaction DrugDDI.d508.s4.e0 DrugDDI.d508.s4.e1

Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s5
Thrombolytic agents : The safety and effectiveness of Argatroban with thrombolytic agents have not been established.

DrugDDI.d508.s5.e0 0 17
drug
Thrombolytic agents
DrugDDI.d508.s5.e1 46 55
drug
Argatroban
DrugDDI.d508.s5.e2 60 77
drug
thrombolytic agents



Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s6
Co-administration: Concomitant use of Argatroban with antiplatelet agents , thrombolytic s, and other anticoagulants may increase the risk of bleeding.

DrugDDI.d508.s6.e0 34 43
drug
Argatroban
DrugDDI.d508.s6.e1 48 65
drug
antiplatelet agents
DrugDDI.d508.s6.e2 67 78
drug
thrombolytic
DrugDDI.d508.s6.e3 89 102
drug
anticoagulants

interaction DrugDDI.d508.s6.e0 DrugDDI.d508.s6.e1
interaction DrugDDI.d508.s6.e0 DrugDDI.d508.s6.e3

Abstract Id: DrugDDI.d508
Sentence Id: DrugDDI.d508.s7
Drug-drug interactions have not been observed between Argatroban and digoxin or erythromycin .

DrugDDI.d508.s7.e0 47 56
drug
Argatroban
DrugDDI.d508.s7.e1 60 66
drug
digoxin
DrugDDI.d508.s7.e2 69 80
drug
erythromycin



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s0
Drug-Drug Interactions Given the primary CNS effects of aripiprazole , caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol .

DrugDDI.d115.s0.e0 48 59
drug
aripiprazole
DrugDDI.d115.s0.e1 84 90
drug
ABILIFY
DrugDDI.d115.s0.e2 120 139
drug
centrally acting drugs
DrugDDI.d115.s0.e3 143 149
drug
alcohol

interaction DrugDDI.d115.s0.e1 DrugDDI.d115.s0.e2

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s2
1- adrenergic receptor antagonism , aripiprazole has the potential to enhance the effect of certain antihypertensive agents .

DrugDDI.d115.s2.e0 0 29
drug
1- adrenergic receptor antagonism
DrugDDI.d115.s2.e1 31 42
drug
aripiprazole
DrugDDI.d115.s2.e2 85 106
drug
antihypertensive agents

interaction DrugDDI.d115.s2.e1 DrugDDI.d115.s2.e2

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s3
Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1 , CYP1A2 , CYP2A6 , CYP2B6 , CYP2C8 , CYP2C9 , CYP2C19 , or CYP2E1 enzymes.

DrugDDI.d115.s3.e0 17 21
drug
Drugs
DrugDDI.d115.s3.e1 30 36
drug
ABILIFY
DrugDDI.d115.s3.e2 66 71
drug
CYP1A1
DrugDDI.d115.s3.e3 73 78
drug
CYP1A2
DrugDDI.d115.s3.e4 80 85
drug
CYP2A6
DrugDDI.d115.s3.e5 87 92
drug
CYP2B6
DrugDDI.d115.s3.e6 94 99
drug
CYP2C8
DrugDDI.d115.s3.e7 101 106
drug
CYP2C9
DrugDDI.d115.s3.e8 108 114
drug
CYP2C19
DrugDDI.d115.s3.e9 118 123
drug
CYP2E1



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s4
Aripiprazole also does not undergo direct glucuronidation.

DrugDDI.d115.s4.e0 0 11
drug
Aripiprazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s5
This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.

DrugDDI.d115.s5.e0 31 42
drug
aripiprazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s6
Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism.

DrugDDI.d115.s6.e0 4 9
drug
CYP3A4
DrugDDI.d115.s6.e1 13 18
drug
CYP2D6
DrugDDI.d115.s6.e2 36 47
drug
aripiprazole

interaction DrugDDI.d115.s6.e0 DrugDDI.d115.s6.e2

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s7
Agents that induce CYP3A4 (eg, carbamazepine ) could cause an increase in aripiprazole clearance and lower blood levels.

DrugDDI.d115.s7.e0 16 21
drug
CYP3A4
DrugDDI.d115.s7.e1 26 38
drug
carbamazepine
DrugDDI.d115.s7.e2 62 73
drug
aripiprazole

interaction DrugDDI.d115.s7.e0 DrugDDI.d115.s7.e1

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s8
Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels.

DrugDDI.d115.s8.e0 12 17
drug
CYP3A4
DrugDDI.d115.s8.e1 22 33
drug
ketoconazole
DrugDDI.d115.s8.e2 37 42
drug
CYP2D6
DrugDDI.d115.s8.e3 47 55
drug
quinidine
DrugDDI.d115.s8.e4 57 66
drug
fluoxetine
DrugDDI.d115.s8.e5 70 79
drug
paroxetine
DrugDDI.d115.s8.e6 91 102
drug
aripiprazole

interaction DrugDDI.d115.s8.e0 DrugDDI.d115.s8.e6
interaction DrugDDI.d115.s8.e2 DrugDDI.d115.s8.e6
interaction DrugDDI.d115.s8.e4 DrugDDI.d115.s8.e6

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s9
Ketoconazole : Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.

DrugDDI.d115.s9.e0 0 11
drug
Ketoconazole
DrugDDI.d115.s9.e1 31 42
drug
ketoconazole
DrugDDI.d115.s9.e2 85 96
drug
aripiprazole
DrugDDI.d115.s9.e3 114 125
drug
aripiprazole
DrugDDI.d115.s9.e4 132 147
drug
active metabolite

interaction DrugDDI.d115.s9.e1 DrugDDI.d115.s9.e2

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s10
The effect of a higher ketoconazole dose (400 mg/day) has not been studied.

DrugDDI.d115.s10.e0 18 29
drug
ketoconazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s11
When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.

DrugDDI.d115.s11.e0 31 42
drug
ketoconazole
DrugDDI.d115.s11.e1 47 58
drug
aripiprazole
DrugDDI.d115.s11.e2 66 77
drug
aripiprazole

interaction DrugDDI.d115.s11.e0 DrugDDI.d115.s11.e1

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s12
Other strong inhibitors of CYP3A4 ( itraconazole ) would be expected to have similar effects and need similar dose reductions; .

DrugDDI.d115.s12.e0 23 28
drug
CYP3A4
DrugDDI.d115.s12.e1 30 41
drug
itraconazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s13
weaker inhibitors ( erythromycin , grapefruit juice) have not been studied.

DrugDDI.d115.s13.e0 17 28
drug
erythromycin



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s14
When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.

DrugDDI.d115.s14.e0 7 12
drug
CYP3A4
DrugDDI.d115.s14.e1 59 70
drug
aripiprazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s15
Quinidine : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6 , increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite , dehydroaripiprazole, by 35%.

DrugDDI.d115.s15.e0 0 8
drug
Quinidine
DrugDDI.d115.s15.e1 46 57
drug
aripiprazole
DrugDDI.d115.s15.e2 62 70
drug
quinidine
DrugDDI.d115.s15.e3 110 115
drug
CYP2D6
DrugDDI.d115.s15.e4 134 145
drug
aripiprazole
DrugDDI.d115.s15.e5 175 190
drug
active metabolite

interaction DrugDDI.d115.s15.e1 DrugDDI.d115.s15.e2

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s16
Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.

DrugDDI.d115.s16.e0 0 11
drug
Aripiprazole
DrugDDI.d115.s16.e1 87 95
drug
quinidine
DrugDDI.d115.s16.e2 100 111
drug
aripiprazole

interaction DrugDDI.d115.s16.e1 DrugDDI.d115.s16.e2

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s17
Other significant inhibitors of CYP2D6 , such as fluoxetine or paroxetine , would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.

DrugDDI.d115.s17.e0 28 33
drug
CYP2D6
DrugDDI.d115.s17.e1 41 50
drug
fluoxetine
DrugDDI.d115.s17.e2 53 62
drug
paroxetine



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s18
When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.

DrugDDI.d115.s18.e0 7 12
drug
CYP2D6
DrugDDI.d115.s18.e1 59 70
drug
aripiprazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s19
Carbamazepine : Coadministration of carbamazepine (200 mg BID ), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite , dehydro- aripiprazole .

DrugDDI.d115.s19.e0 0 12
drug
Carbamazepine
DrugDDI.d115.s19.e1 32 44
drug
carbamazepine
DrugDDI.d115.s19.e2 51 53
drug
BID
DrugDDI.d115.s19.e3 63 68
drug
CYP3A4
DrugDDI.d115.s19.e4 81 92
drug
aripiprazole
DrugDDI.d115.s19.e5 159 170
drug
aripiprazole
DrugDDI.d115.s19.e6 177 192
drug
active metabolite
DrugDDI.d115.s19.e7 202 213
drug
aripiprazole

interaction DrugDDI.d115.s19.e1 DrugDDI.d115.s19.e4

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s20
When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.

DrugDDI.d115.s20.e0 4 16
drug
carbamazepine
DrugDDI.d115.s20.e1 26 37
drug
aripiprazole
DrugDDI.d115.s20.e2 46 57
drug
aripiprazole

interaction DrugDDI.d115.s20.e0 DrugDDI.d115.s20.e1

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s22
When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.

DrugDDI.d115.s22.e0 4 16
drug
carbamazepine
DrugDDI.d115.s22.e1 54 65
drug
aripiprazole

interaction DrugDDI.d115.s22.e0 DrugDDI.d115.s22.e1

Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s23
No clinically significant effect of famotidine , valproate , or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).

DrugDDI.d115.s23.e0 31 40
drug
famotidine
DrugDDI.d115.s23.e1 42 50
drug
valproate
DrugDDI.d115.s23.e2 54 60
drug
lithium
DrugDDI.d115.s23.e3 91 102
drug
aripiprazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s24
Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.

DrugDDI.d115.s24.e0 12 18
drug
ABILIFY
DrugDDI.d115.s24.e1 32 36
drug
Drugs
DrugDDI.d115.s24.e2 116 120
drug
drugs
DrugDDI.d115.s24.e3 134 147
drug
cytochrome P450



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s25
In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates.

DrugDDI.d115.s25.e0 37 48
drug
aripiprazole
DrugDDI.d115.s25.e1 85 90
drug
CYP2D6
DrugDDI.d115.s25.e2 92 107
drug
dextromethorphan
DrugDDI.d115.s25.e3 110 115
drug
CYP2C9
DrugDDI.d115.s25.e4 117 124
drug
warfarin
DrugDDI.d115.s25.e5 127 133
drug
CYP2C19
DrugDDI.d115.s25.e6 135 144
drug
omeprazole
DrugDDI.d115.s25.e7 146 153
drug
warfarin
DrugDDI.d115.s25.e8 159 164
drug
CYP3A4
DrugDDI.d115.s25.e9 166 181
drug
dextromethorphan



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s26
Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.

DrugDDI.d115.s26.e0 13 24
drug
aripiprazole



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s27
Alcohol : There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.

DrugDDI.d115.s27.e0 0 6
drug
Alcohol
DrugDDI.d115.s27.e1 46 57
drug
aripiprazole
DrugDDI.d115.s27.e2 76 82
drug
ethanol
DrugDDI.d115.s27.e3 111 117
drug
ethanol



Abstract Id: DrugDDI.d115
Sentence Id: DrugDDI.d115.s28
As with most psychoactive medications , patients should be advised to avoid alcohol while taking ABILIFY .

DrugDDI.d115.s28.e0 22 32
drug
medications
DrugDDI.d115.s28.e1 64 70
drug
alcohol
DrugDDI.d115.s28.e2 82 88
drug
ABILIFY

interaction DrugDDI.d115.s28.e1 DrugDDI.d115.s28.e2

Abstract Id: DrugDDI.d96
Sentence Id: DrugDDI.d96.s1
Caution is advised when TRISENOX@ is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin B ).

DrugDDI.d96.s1.e0 54 64
drug
medications
DrugDDI.d96.s1.e1 104 118
drug
antiarrhythmics
DrugDDI.d96.s1.e2 121 132
drug
thioridazine
DrugDDI.d96.s1.e3 173 181
drug
diuretics
DrugDDI.d96.s1.e4 184 196
drug
amphotericin B



Abstract Id: DrugDDI.d258
Sentence Id: DrugDDI.d258.s0
Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.

DrugDDI.d258.s0.e0 41 46
drug
ELSPAR
DrugDDI.d258.s0.e1 78 89
drug
methotrexate
DrugDDI.d258.s0.e2 121 132
drug
methotrexate

interaction DrugDDI.d258.s0.e0 DrugDDI.d258.s0.e1

Abstract Id: DrugDDI.d258
Sentence Id: DrugDDI.d258.s1
These results would seem to dictate against the clinical use of methotrexate with ELSPAR , or during the period following ELSPAR therapy when plasma asparagine levels are below normal.

DrugDDI.d258.s1.e0 53 64
drug
methotrexate
DrugDDI.d258.s1.e1 69 74
drug
ELSPAR
DrugDDI.d258.s1.e2 102 107
drug
ELSPAR



Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s0
Uricosuric Agents : Aspirin may decrease the effects of probenecid , sulfinpyrazone , and phenylbutazone .

DrugDDI.d345.s0.e0 0 15
drug
Uricosuric Agents
DrugDDI.d345.s0.e1 17 23
drug
Aspirin
DrugDDI.d345.s0.e2 47 56
drug
probenecid
DrugDDI.d345.s0.e3 58 71
drug
sulfinpyrazone
DrugDDI.d345.s0.e4 76 89
drug
phenylbutazone

interaction DrugDDI.d345.s0.e1 DrugDDI.d345.s0.e2
interaction DrugDDI.d345.s0.e1 DrugDDI.d345.s0.e3
interaction DrugDDI.d345.s0.e1 DrugDDI.d345.s0.e4

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s1
Alcohol : Has a synergistic effect with aspirin in causing gastrointestinal bleeding.

DrugDDI.d345.s1.e0 0 6
drug
Alcohol
DrugDDI.d345.s1.e1 33 39
drug
aspirin

interaction DrugDDI.d345.s1.e0 DrugDDI.d345.s1.e1

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s2
Corticosteroids : Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.

DrugDDI.d345.s2.e0 0 14
drug
Corticosteroids
DrugDDI.d345.s2.e1 45 51
drug
aspirin

interaction DrugDDI.d345.s2.e0 DrugDDI.d345.s2.e1

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s3
Pyrazolone Derivatives ( phenylbutazone , oxyphenbutazone , and possibly dipyrone ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.

DrugDDI.d345.s3.e0 0 9
drug
Pyrazolone
DrugDDI.d345.s3.e1 22 35
drug
phenylbutazone
DrugDDI.d345.s3.e2 37 51
drug
oxyphenbutazone
DrugDDI.d345.s3.e3 64 71
drug
dipyrone
DrugDDI.d345.s3.e4 103 109
drug
aspirin

interaction DrugDDI.d345.s3.e0 DrugDDI.d345.s3.e4
interaction DrugDDI.d345.s3.e1 DrugDDI.d345.s3.e4
interaction DrugDDI.d345.s3.e2 DrugDDI.d345.s3.e4
interaction DrugDDI.d345.s3.e3 DrugDDI.d345.s3.e4

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s4
Nonsteroidal Antiinflammatory Agents : Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents .

DrugDDI.d345.s4.e0 0 33
drug
Nonsteroidal Antiinflammatory Agents
DrugDDI.d345.s4.e1 35 41
drug
Aspirin
DrugDDI.d345.s4.e2 91 125
drug
nonsteroidal anti-inflammatory agents

interaction DrugDDI.d345.s4.e1 DrugDDI.d345.s4.e2

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s5
Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.

DrugDDI.d345.s5.e0 0 6
drug
Urinary
DrugDDI.d345.s5.e1 28 34
drug
aspirin
DrugDDI.d345.s5.e2 69 78
drug
salicylate

interaction DrugDDI.d345.s5.e0 DrugDDI.d345.s5.e1

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s6
Phenobarbital : Decreases aspirin effectiveness by enzyme induction.

DrugDDI.d345.s6.e0 0 12
drug
Phenobarbital
DrugDDI.d345.s6.e1 23 29
drug
aspirin

interaction DrugDDI.d345.s6.e0 DrugDDI.d345.s6.e1

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s7
Phenytoin : Serum phenytoin level s may be increased by aspirin .

DrugDDI.d345.s7.e0 0 8
drug
Phenytoin
DrugDDI.d345.s7.e1 10 28
drug
Serum phenytoin level
DrugDDI.d345.s7.e2 46 52
drug
aspirin

interaction DrugDDI.d345.s7.e1 DrugDDI.d345.s7.e2

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s8
Propranolol : May decrease aspirin s anti-inflammatory action by competing for the same receptors .

DrugDDI.d345.s8.e0 0 10
drug
Propranolol
DrugDDI.d345.s8.e1 23 29
drug
aspirin
DrugDDI.d345.s8.e2 75 83
drug
receptors

interaction DrugDDI.d345.s8.e0 DrugDDI.d345.s8.e1

Abstract Id: DrugDDI.d345
Sentence Id: DrugDDI.d345.s9
Antacids : Enteric Coated Aspirin should not be given concurrently with antacids , since an increase in the pH of the stomach may effect the enteric coating of the tablets.

DrugDDI.d345.s9.e0 0 7
drug
Antacids
DrugDDI.d345.s9.e1 16 28
drug
Coated Aspirin
DrugDDI.d345.s9.e2 61 68
drug
antacids

interaction DrugDDI.d345.s9.e1 DrugDDI.d345.s9.e2

Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s0
Catecholamine-depleting drugs (eg, reserpine ) may have an additive effect when given with beta-blocking agent s.

DrugDDI.d41.s0.e0 23 27
drug
drugs
DrugDDI.d41.s0.e1 32 40
drug
reserpine
DrugDDI.d41.s0.e2 78 95
drug
beta-blocking agent

interaction DrugDDI.d41.s0.e0 DrugDDI.d41.s0.e2

Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s1
Patients treated with TENORMIN plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.

DrugDDI.d41.s1.e0 19 26
drug
TENORMIN



Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s2
Calcium channel blockers may also have an additive effect when given with TENORMIN .

DrugDDI.d41.s2.e0 0 21
drug
Calcium channel blockers
DrugDDI.d41.s2.e1 62 69
drug
TENORMIN

interaction DrugDDI.d41.s2.e0 DrugDDI.d41.s2.e1

Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s3
Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine .

DrugDDI.d41.s3.e0 0 11
drug
Beta blockers
DrugDDI.d41.s3.e1 76 84
drug
clonidine

interaction DrugDDI.d41.s3.e0 DrugDDI.d41.s3.e1

Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s4
If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine .

DrugDDI.d41.s4.e0 8 12
drug
drugs
DrugDDI.d41.s4.e1 34 44
drug
beta blocker
DrugDDI.d41.s4.e2 101 109
drug
clonidine

interaction DrugDDI.d41.s4.e1 DrugDDI.d41.s4.e2

Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s5
If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.

DrugDDI.d41.s5.e0 11 19
drug
clonidine
DrugDDI.d41.s5.e1 22 33
drug
beta-blocker
DrugDDI.d41.s5.e2 59 70
drug
beta blockers
DrugDDI.d41.s5.e3 105 113
drug
clonidine



Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s6
Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin , may decrease the hypotensive effects of beta blockers .

DrugDDI.d41.s6.e0 16 36
drug
prostaglandin synthase
DrugDDI.d41.s6.e1 56 67
drug
indomethacin
DrugDDI.d41.s6.e2 103 114
drug
beta blockers

interaction DrugDDI.d41.s6.e0 DrugDDI.d41.s6.e2

Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s7
Information on concurrent usage of atenolol and aspirin is limited.

DrugDDI.d41.s7.e0 30 37
drug
atenolol
DrugDDI.d41.s7.e1 41 47
drug
aspirin



Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s8
Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.

DrugDDI.d41.s8.e0 91 97
drug
aspirin
DrugDDI.d41.s8.e1 101 112
drug
beta blockers



Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s9
While taking beta blockers , patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic.

DrugDDI.d41.s9.e0 11 22
drug
beta blockers



Abstract Id: DrugDDI.d41
Sentence Id: DrugDDI.d41.s10
Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.

DrugDDI.d41.s10.e0 46 56
drug
epinephrine



Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s0
Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.

DrugDDI.d450.s0.e0 21 29
drug
Albuterol
DrugDDI.d450.s0.e1 141 149
drug
albuterol
DrugDDI.d450.s0.e2 163 170
drug
agonists
DrugDDI.d450.s0.e3 190 198
drug
albuterol

interaction DrugDDI.d450.s0.e0 DrugDDI.d450.s0.e1

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s1
CYP2D6 inhibitors - Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine.

DrugDDI.d450.s1.e0 17 27
drug
Atomoxetine
DrugDDI.d450.s1.e1 55 60
drug
CYP2D6

interaction DrugDDI.d450.s1.e0 DrugDDI.d450.s1.e1

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s2
In EMs, selective inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs.

DrugDDI.d450.s2.e0 41 51
drug
atomoxetine



Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s3
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine , fluoxetine , and quinidine .

DrugDDI.d450.s3.e0 18 26
drug
STRATTERA
DrugDDI.d450.s3.e1 63 68
drug
CYP2D6
DrugDDI.d450.s3.e2 85 94
drug
paroxetine
DrugDDI.d450.s3.e3 96 105
drug
fluoxetine
DrugDDI.d450.s3.e4 110 118
drug
quinidine

interaction DrugDDI.d450.s3.e0 DrugDDI.d450.s3.e1
interaction DrugDDI.d450.s3.e0 DrugDDI.d450.s3.e3

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s4
In EM individuals treated with paroxetine or fluoxetine , the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.

DrugDDI.d450.s4.e0 26 35
drug
paroxetine
DrugDDI.d450.s4.e1 38 47
drug
fluoxetine
DrugDDI.d450.s4.e2 57 67
drug
atomoxetine
DrugDDI.d450.s4.e3 131 141
drug
atomoxetine

interaction DrugDDI.d450.s4.e0 DrugDDI.d450.s4.e2

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s5
In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine .

DrugDDI.d450.s5.e0 43 56
drug
cytochrome P450
DrugDDI.d450.s5.e1 112 122
drug
atomoxetine



Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s6
Pressor agents - Because of possible effects on blood pressure, STRATTERA should be used cautiously with pressor agents .

DrugDDI.d450.s6.e0 0 12
drug
Pressor agents
DrugDDI.d450.s6.e1 54 62
drug
STRATTERA
DrugDDI.d450.s6.e2 89 101
drug
pressor agents

interaction DrugDDI.d450.s6.e1 DrugDDI.d450.s6.e2

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s0
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , fibric acid derivatives , niacin ( nicotinic acid ), erythromycin , azole antifungals .

DrugDDI.d356.s0.e0 36 40
drug
drugs
DrugDDI.d356.s0.e1 93 104
drug
cyclosporine
DrugDDI.d356.s0.e2 116 126
drug
derivatives
DrugDDI.d356.s0.e3 128 133
drug
niacin
DrugDDI.d356.s0.e4 135 147
drug
nicotinic acid
DrugDDI.d356.s0.e5 150 161
drug
erythromycin
DrugDDI.d356.s0.e6 163 178
drug
azole antifungals

interaction DrugDDI.d356.s0.e0 DrugDDI.d356.s0.e1
interaction DrugDDI.d356.s0.e0 DrugDDI.d356.s0.e3
interaction DrugDDI.d356.s0.e0 DrugDDI.d356.s0.e5

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s1
Antacid : When atorvastatin and Maalox@ TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.

DrugDDI.d356.s1.e0 0 6
drug
Antacid
DrugDDI.d356.s1.e1 12 23
drug
atorvastatin
DrugDDI.d356.s1.e2 87 98
drug
atorvastatin



Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s3
Antipyrine : Because atorvastatin does not affect the pharmacokinetics of antipyrine , interactions with other drugs metabolized via the same cytochrome isozymes are not expected.

DrugDDI.d356.s3.e0 0 9
drug
Antipyrine
DrugDDI.d356.s3.e1 18 29
drug
atorvastatin
DrugDDI.d356.s3.e2 64 73
drug
antipyrine
DrugDDI.d356.s3.e3 96 100
drug
drugs
DrugDDI.d356.s3.e4 132 139
drug
isozymes



Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s4
Colestipol : Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.

DrugDDI.d356.s4.e0 0 9
drug
Colestipol
DrugDDI.d356.s4.e1 33 44
drug
atorvastatin
DrugDDI.d356.s4.e2 74 83
drug
colestipol
DrugDDI.d356.s4.e3 87 98
drug
atorvastatin

interaction DrugDDI.d356.s4.e2 DrugDDI.d356.s4.e3

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s5
However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.

DrugDDI.d356.s5.e0 36 47
drug
atorvastatin
DrugDDI.d356.s5.e1 51 60
drug
colestipol
DrugDDI.d356.s5.e2 93 96
drug
drug

interaction DrugDDI.d356.s5.e0 DrugDDI.d356.s5.e1

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s6
Cimetidine : Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine .

DrugDDI.d356.s6.e0 0 9
drug
Cimetidine
DrugDDI.d356.s6.e1 11 22
drug
Atorvastatin
DrugDDI.d356.s6.e2 94 103
drug
cimetidine

interaction DrugDDI.d356.s6.e1 DrugDDI.d356.s6.e2

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s7
Digoxin : When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.

DrugDDI.d356.s7.e0 0 6
drug
Digoxin
DrugDDI.d356.s7.e1 27 38
drug
atorvastatin
DrugDDI.d356.s7.e2 42 48
drug
digoxin
DrugDDI.d356.s7.e3 86 92
drug
digoxin

interaction DrugDDI.d356.s7.e1 DrugDDI.d356.s7.e2

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s8
Patients taking digoxin should be monitored appropriately.

DrugDDI.d356.s8.e0 14 20
drug
digoxin



Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s9
Erythromycin : In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin , a known inhibitor of cytochrome P450 3A4 .

DrugDDI.d356.s9.e0 0 11
drug
Erythromycin
DrugDDI.d356.s9.e1 56 67
drug
atorvastatin
DrugDDI.d356.s9.e2 115 126
drug
atorvastatin
DrugDDI.d356.s9.e3 130 141
drug
erythromycin
DrugDDI.d356.s9.e4 160 176
drug
cytochrome P450 3A4

interaction DrugDDI.d356.s9.e2 DrugDDI.d356.s9.e3

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s10
Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.

DrugDDI.d356.s10.e0 0 17
drug
Oral Contraceptives
DrugDDI.d356.s10.e1 37 48
drug
atorvastatin
DrugDDI.d356.s10.e2 54 70
drug
oral contraceptive
DrugDDI.d356.s10.e3 92 104
drug
norethindrone
DrugDDI.d356.s10.e4 108 123
drug
ethinyl estradiol

interaction DrugDDI.d356.s10.e1 DrugDDI.d356.s10.e2

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s11
These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin .

DrugDDI.d356.s11.e0 47 63
drug
oral contraceptive
DrugDDI.d356.s11.e1 79 90
drug
atorvastatin

interaction DrugDDI.d356.s11.e0 DrugDDI.d356.s11.e1

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s12
Warfarin : Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.

DrugDDI.d356.s12.e0 0 7
drug
Warfarin
DrugDDI.d356.s12.e1 9 20
drug
Atorvastatin



Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s13
Endocrine Function HMG-CoA reductase inhibitors interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.

DrugDDI.d356.s13.e0 17 42
drug
HMG-CoA reductase inhibitors
DrugDDI.d356.s13.e1 56 66
drug
cholesterol
DrugDDI.d356.s13.e2 102 108
drug
adrenal

interaction DrugDDI.d356.s13.e0 DrugDDI.d356.s13.e1

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s14
Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve.

DrugDDI.d356.s14.e0 28 39
drug
atorvastatin
DrugDDI.d356.s14.e1 64 71
drug
cortisol
DrugDDI.d356.s14.e2 93 99
drug
adrenal



Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s15
The effects of HMG-CoA reductase inhibitors on male fertility have not been studied in adequate numbers of patients.

DrugDDI.d356.s15.e0 12 37
drug
HMG-CoA reductase inhibitors



Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s17
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole , spironolactone , and cimetidine .

DrugDDI.d356.s17.e0 28 52
drug
HMG-CoA reductase inhibitor
DrugDDI.d356.s17.e1 84 88
drug
drugs
DrugDDI.d356.s17.e2 157 168
drug
ketoconazole
DrugDDI.d356.s17.e3 170 183
drug
spironolactone
DrugDDI.d356.s17.e4 188 197
drug
cimetidine

interaction DrugDDI.d356.s17.e0 DrugDDI.d356.s17.e1
interaction DrugDDI.d356.s17.e0 DrugDDI.d356.s17.e3

Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s20
The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day.

DrugDDI.d356.s20.e0 65 75
drug
human plasma



Abstract Id: DrugDDI.d356
Sentence Id: DrugDDI.d356.s25
A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.

DrugDDI.d356.s25.e0 18 21
drug
drug



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; .

DrugDDI.d494.s0.e0 0 4
drug
Drugs
DrugDDI.d494.s0.e1 52 59
drug
TRACRIUM
DrugDDI.d494.s0.e2 68 76
drug
enflurane

interaction DrugDDI.d494.s0.e0 DrugDDI.d494.s0.e1
interaction DrugDDI.d494.s0.e1 DrugDDI.d494.s0.e2

Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s1
isoflurane ; .

DrugDDI.d494.s1.e0 0 9
drug
isoflurane



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s2
halothane ; .

DrugDDI.d494.s2.e0 0 8
drug
halothane



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s3
certain antibiotics , especially the aminoglycosides and polymyxins ; .

DrugDDI.d494.s3.e0 7 17
drug
antibiotics
DrugDDI.d494.s3.e1 32 46
drug
aminoglycosides
DrugDDI.d494.s3.e2 50 59
drug
polymyxins



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s4
lithium ; .

DrugDDI.d494.s4.e0 0 6
drug
lithium



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s5
magnesium salt s; .

DrugDDI.d494.s5.e0 0 12
drug
magnesium salt



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s6
procainamide ; .

DrugDDI.d494.s6.e0 0 11
drug
procainamide



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s7
and quinidine .

DrugDDI.d494.s7.e0 3 11
drug
quinidine



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s8
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

DrugDDI.d494.s8.e0 7 21
drug
muscle relaxants



Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s9
The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM .

DrugDDI.d494.s9.e0 24 38
drug
succinylcholine
DrugDDI.d494.s9.e1 136 143
drug
TRACRIUM

interaction DrugDDI.d494.s9.e0 DrugDDI.d494.s9.e1

Abstract Id: DrugDDI.d494
Sentence Id: DrugDDI.d494.s10
TRACRIUM should not be administered until a patient has recovered from succinylcholine -induced neuromuscular block.

DrugDDI.d494.s10.e0 0 7
drug
TRACRIUM
DrugDDI.d494.s10.e1 60 74
drug
succinylcholine

interaction DrugDDI.d494.s10.e0 DrugDDI.d494.s10.e1

Abstract Id: DrugDDI.d535
Sentence Id: DrugDDI.d535.s0
Auranofin should be avoided by patients with a history of serious reaction to any gold medication , including Solganal and Myochrysine .

DrugDDI.d535.s0.e0 0 8
drug
Auranofin
DrugDDI.d535.s0.e1 72 81
drug
medication
DrugDDI.d535.s0.e2 92 99
drug
Solganal
DrugDDI.d535.s0.e3 103 113
drug
Myochrysine

interaction DrugDDI.d535.s0.e0 DrugDDI.d535.s0.e1
interaction DrugDDI.d535.s0.e0 DrugDDI.d535.s0.e3

Abstract Id: DrugDDI.d535
Sentence Id: DrugDDI.d535.s1
Auranofin should not be used together with penicillamine ( Depen , Cuprimine ), another arthritis medication .

DrugDDI.d535.s1.e0 0 8
drug
Auranofin
DrugDDI.d535.s1.e1 36 48
drug
penicillamine
DrugDDI.d535.s1.e2 50 54
drug
Depen
DrugDDI.d535.s1.e3 56 64
drug
Cuprimine
DrugDDI.d535.s1.e4 74 92
drug
arthritis medication

interaction DrugDDI.d535.s1.e0 DrugDDI.d535.s1.e1
interaction DrugDDI.d535.s1.e0 DrugDDI.d535.s1.e3

Abstract Id: DrugDDI.d535
Sentence Id: DrugDDI.d535.s2
It should also be avoided in patients with blood, liver or kidney diseases, recent radiation treatment, or uncontrolled diabetes.

DrugDDI.d535.s2.e0 41 45
drug
liver



Abstract Id: DrugDDI.d535
Sentence Id: DrugDDI.d535.s3
Patients should report to their practitioners any new rashes, itching, mouth sores, or unusual taste while taking auranofin .

DrugDDI.d535.s3.e0 97 105
drug
auranofin



Abstract Id: DrugDDI.d535
Sentence Id: DrugDDI.d535.s4
Gold is excreted slowly from the body.

DrugDDI.d535.s4.e0 0 3
drug
Gold



Abstract Id: DrugDDI.d364
Sentence Id: DrugDDI.d364.s0
No formal assessments of drug-drug interactions between Vidaza and other agents have been conducted .

DrugDDI.d364.s0.e0 49 54
drug
Vidaza



Abstract Id: DrugDDI.d293
Sentence Id: DrugDDI.d293.s0
MAO inhibitors prolong and intensify the effects of antihistamines .

DrugDDI.d293.s0.e0 0 12
drug
MAO inhibitors
DrugDDI.d293.s0.e1 44 57
drug
antihistamines

interaction DrugDDI.d293.s0.e0 DrugDDI.d293.s0.e1

Abstract Id: DrugDDI.d293
Sentence Id: DrugDDI.d293.s1
Concomitant use of antihistamines with alcohol , tricyclic antidepressants , barbiturates , or other central nervous system depressants may have an additive effect.

DrugDDI.d293.s1.e0 16 29
drug
antihistamines
DrugDDI.d293.s1.e1 34 40
drug
alcohol
DrugDDI.d293.s1.e2 42 65
drug
tricyclic antidepressants
DrugDDI.d293.s1.e3 67 78
drug
barbiturates
DrugDDI.d293.s1.e4 87 117
drug
central nervous system depressants

interaction DrugDDI.d293.s1.e0 DrugDDI.d293.s1.e1
interaction DrugDDI.d293.s1.e0 DrugDDI.d293.s1.e3

Abstract Id: DrugDDI.d293
Sentence Id: DrugDDI.d293.s2
When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors , hypertensive reactions, including hypertensive crises, may occur.

DrugDDI.d293.s2.e0 4 23
drug
sympathomimetic drugs
DrugDDI.d293.s2.e1 51 76
drug
monoamine oxidase inhibitors

interaction DrugDDI.d293.s2.e0 DrugDDI.d293.s2.e1

Abstract Id: DrugDDI.d293
Sentence Id: DrugDDI.d293.s3
The antihypertensive effects of methyldopa , mecamylamine , reserpine , and veratrum alkaloids may be reduced by sympathomimetics .

DrugDDI.d293.s3.e0 3 18
drug
antihypertensive
DrugDDI.d293.s3.e1 28 37
drug
methyldopa
DrugDDI.d293.s3.e2 39 50
drug
mecamylamine
DrugDDI.d293.s3.e3 52 60
drug
reserpine
DrugDDI.d293.s3.e4 65 81
drug
veratrum alkaloids
DrugDDI.d293.s3.e5 96 111
drug
sympathomimetics

interaction DrugDDI.d293.s3.e0 DrugDDI.d293.s3.e5
interaction DrugDDI.d293.s3.e2 DrugDDI.d293.s3.e5
interaction DrugDDI.d293.s3.e4 DrugDDI.d293.s3.e5

Abstract Id: DrugDDI.d293
Sentence Id: DrugDDI.d293.s4
Beta-adrenergic blocking agents may also interact with sympathomimetics .

DrugDDI.d293.s4.e0 0 28
drug
Beta-adrenergic blocking agents
DrugDDI.d293.s4.e1 48 63
drug
sympathomimetics

interaction DrugDDI.d293.s4.e0 DrugDDI.d293.s4.e1

Abstract Id: DrugDDI.d293
Sentence Id: DrugDDI.d293.s5
Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis .

DrugDDI.d293.s5.e0 45 59
drug
pseudoephedrine
DrugDDI.d293.s5.e1 83 91
drug
digitalis

interaction DrugDDI.d293.s5.e0 DrugDDI.d293.s5.e1

Abstract Id: DrugDDI.d293
Sentence Id: DrugDDI.d293.s6
Antacids increase the rate of absorption of pseudoephedrine , while kaolin decreases it.

DrugDDI.d293.s6.e0 0 7
drug
Antacids
DrugDDI.d293.s6.e1 37 51
drug
pseudoephedrine
DrugDDI.d293.s6.e2 58 63
drug
kaolin

interaction DrugDDI.d293.s6.e0 DrugDDI.d293.s6.e1
interaction DrugDDI.d293.s6.e1 DrugDDI.d293.s6.e2

Abstract Id: DrugDDI.d252
Sentence Id: DrugDDI.d252.s0
Use with Allopurinol : The principal pathway for detoxification of azathioprine is inhibited by allopurinol .

DrugDDI.d252.s0.e0 7 17
drug
Allopurinol
DrugDDI.d252.s0.e1 57 68
drug
azathioprine
DrugDDI.d252.s0.e2 82 92
drug
allopurinol

interaction DrugDDI.d252.s0.e1 DrugDDI.d252.s0.e2

Abstract Id: DrugDDI.d252
Sentence Id: DrugDDI.d252.s1
Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine , to approximately 1/3 to 1/4 the usual dose.

DrugDDI.d252.s1.e0 17 28
drug
azathioprine
DrugDDI.d252.s1.e1 32 42
drug
allopurinol
DrugDDI.d252.s1.e2 82 93
drug
azathioprine

interaction DrugDDI.d252.s1.e0 DrugDDI.d252.s1.e1

Abstract Id: DrugDDI.d252
Sentence Id: DrugDDI.d252.s2
Use with Other Agents Affecting Myelopoesis: Drugs which may affect leukocyte production, including co-trimoxazole , may lead to exaggerated leukopenia, especially in renal transplant recipients.

DrugDDI.d252.s2.e0 39 43
drug
Drugs
DrugDDI.d252.s2.e1 87 100
drug
co-trimoxazole



Abstract Id: DrugDDI.d252
Sentence Id: DrugDDI.d252.s3
Use with Angiotensln Converting Enzyme Inhibitors : The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.

DrugDDI.d252.s3.e0 28 43
drug
Enzyme Inhibitors
DrugDDI.d252.s3.e1 53 79
drug
angiotensin converting enzyme
DrugDDI.d252.s3.e2 123 134
drug
azathioprine

interaction DrugDDI.d252.s3.e1 DrugDDI.d252.s3.e2

Abstract Id: DrugDDI.d172
Sentence Id: DrugDDI.d172.s0
No drug interaction studies have been conducted for COLAZAL , however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.

DrugDDI.d172.s0.e0 44 50
drug
COLAZAL
DrugDDI.d172.s0.e1 141 150
drug
mesalamine



Abstract Id: DrugDDI.d501
Sentence Id: DrugDDI.d501.s0
No dose adjustment is necessary when Simulect@ is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate mofetil .

DrugDDI.d501.s0.e0 90 101
drug
cyclosporine
DrugDDI.d501.s0.e1 103 117
drug
corticosteroids
DrugDDI.d501.s0.e2 128 139
drug
azathioprine
DrugDDI.d501.s0.e3 142 161
drug
mycophenolate mofetil



Abstract Id: DrugDDI.d501
Sentence Id: DrugDDI.d501.s3
Total body clearance of Simulect@ was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids .

DrugDDI.d501.s3.e0 63 74
drug
azathioprine
DrugDDI.d501.s3.e1 78 97
drug
mycophenolate mofetil
DrugDDI.d501.s3.e2 143 154
drug
cyclosporine
DrugDDI.d501.s3.e3 172 186
drug
corticosteroids



Abstract Id: DrugDDI.d501
Sentence Id: DrugDDI.d501.s4
Nonetheless, the range of individual Simulect@ clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).

DrugDDI.d501.s4.e0 71 82
drug
azathioprine
DrugDDI.d501.s4.e1 96 115
drug
mycophenolate mofetil



Abstract Id: DrugDDI.d501
Sentence Id: DrugDDI.d501.s5
The following medications have been administered in clinical trials with Simulect@ with no increase in adverse reactions: ATG /ALG, azathioprine , corticosteroids , cyclosporine , mycophenolate mofetil , and muromonab-CD3 .

DrugDDI.d501.s5.e0 12 22
drug
medications
DrugDDI.d501.s5.e1 105 107
drug
ATG
DrugDDI.d501.s5.e2 113 124
drug
azathioprine
DrugDDI.d501.s5.e3 126 140
drug
corticosteroids
DrugDDI.d501.s5.e4 142 153
drug
cyclosporine
DrugDDI.d501.s5.e5 155 174
drug
mycophenolate mofetil
DrugDDI.d501.s5.e6 179 191
drug
muromonab-CD3



Abstract Id: DrugDDI.d200
Sentence Id: DrugDDI.d200.s0
It is not known if REGRANEX Gel interacts with other topical medications applied to the ulcer site.

DrugDDI.d200.s0.e0 14 21
drug
REGRANEX
DrugDDI.d200.s0.e1 50 60
drug
medications



Abstract Id: DrugDDI.d200
Sentence Id: DrugDDI.d200.s1
The use of REGRANEX Gel with other topical drugs has not been studied.

DrugDDI.d200.s1.e0 8 15
drug
REGRANEX
DrugDDI.d200.s1.e1 35 39
drug
drugs



Abstract Id: DrugDDI.d114
Sentence Id: DrugDDI.d114.s0
Albuterol , Antihistamines , antidiabetic drugs , diuretics , digitalis .

DrugDDI.d114.s0.e0 0 8
drug
Albuterol
DrugDDI.d114.s0.e1 10 23
drug
Antihistamines
DrugDDI.d114.s0.e2 25 41
drug
antidiabetic drugs
DrugDDI.d114.s0.e3 43 51
drug
diuretics
DrugDDI.d114.s0.e4 53 61
drug
digitalis



Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s0
Diuretics Patients on diuretics , especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin .

DrugDDI.d361.s0.e0 0 8
drug
Diuretics
DrugDDI.d361.s0.e1 19 27
drug
diuretics
DrugDDI.d361.s0.e2 175 182
drug
Lotensin

interaction DrugDDI.d361.s0.e1 DrugDDI.d361.s0.e2

Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s1
The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin .

DrugDDI.d361.s1.e0 38 45
drug
Lotensin
DrugDDI.d361.s1.e1 84 91
drug
diuretic
DrugDDI.d361.s1.e2 149 156
drug
Lotensin

interaction DrugDDI.d361.s1.e0 DrugDDI.d361.s1.e1

Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s3
Potassium Supplement s and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics .

DrugDDI.d361.s3.e0 0 18
drug
Potassium Supplement
DrugDDI.d361.s3.e1 23 48
drug
Potassium-Sparing Diuretics
DrugDDI.d361.s3.e2 69 77
drug
potassium
DrugDDI.d361.s3.e3 90 106
drug
thiazide diuretics

interaction DrugDDI.d361.s3.e0 DrugDDI.d361.s3.e2
interaction DrugDDI.d361.s3.e1 DrugDDI.d361.s3.e3

Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s4
Potassium-sparing diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplement s can increase the risk of hyperkalemia.

DrugDDI.d361.s4.e0 0 25
drug
Potassium-sparing diuretics
DrugDDI.d361.s4.e1 27 40
drug
spironolactone
DrugDDI.d361.s4.e2 42 50
drug
amiloride
DrugDDI.d361.s4.e3 52 62
drug
triamterene
DrugDDI.d361.s4.e4 76 94
drug
potassium supplement



Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s6
Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants .

DrugDDI.d361.s6.e0 0 17
drug
Oral Anticoagulants
DrugDDI.d361.s6.e1 40 47
drug
warfarin
DrugDDI.d361.s6.e2 51 63
drug
acenocoumarol
DrugDDI.d361.s6.e3 157 170
drug
anticoagulants



Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s7
Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium .

DrugDDI.d361.s7.e0 0 6
drug
Lithium
DrugDDI.d361.s7.e1 97 109
drug
ACE inhibitors
DrugDDI.d361.s7.e2 127 133
drug
lithium

interaction DrugDDI.d361.s7.e1 DrugDDI.d361.s7.e2

Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s8
These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.

DrugDDI.d361.s8.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s9
If a diuretic is also used, the risk of lithium toxicity may be increased.

DrugDDI.d361.s9.e0 3 10
drug
diuretic



Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s10
Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine .

DrugDDI.d361.s10.e0 65 72
drug
Lotensin
DrugDDI.d361.s10.e1 105 123
drug
hydrochlorothiazide
DrugDDI.d361.s10.e2 125 138
drug
chlorthalidone
DrugDDI.d361.s10.e3 140 149
drug
furosemide
DrugDDI.d361.s10.e4 151 157
drug
digoxin
DrugDDI.d361.s10.e5 159 169
drug
propranolol
DrugDDI.d361.s10.e6 171 178
drug
atenolol
DrugDDI.d361.s10.e7 180 187
drug
naproxen
DrugDDI.d361.s10.e8 191 200
drug
cimetidine



Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s11
Lotensin has been used concomitantly with beta-adrenergic-blocking agents , calcium-channel-blocking agents , diuretics , digoxin , and hydralazine , without evidence of clinically important adverse interactions.

DrugDDI.d361.s11.e0 0 7
drug
Lotensin
DrugDDI.d361.s11.e1 36 65
drug
beta-adrenergic-blocking agents
DrugDDI.d361.s11.e2 67 96
drug
calcium-channel-blocking agents
DrugDDI.d361.s11.e3 98 106
drug
diuretics
DrugDDI.d361.s11.e4 108 114
drug
digoxin
DrugDDI.d361.s11.e5 119 129
drug
hydralazine



Abstract Id: DrugDDI.d361
Sentence Id: DrugDDI.d361.s12
Benazepril , like other ACE inhibitors , has had less than additive effects with beta-adrenergic blockers , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system .

DrugDDI.d361.s12.e0 0 9
drug
Benazepril
DrugDDI.d361.s12.e1 20 32
drug
ACE inhibitors
DrugDDI.d361.s12.e2 67 89
drug
beta-adrenergic blockers
DrugDDI.d361.s12.e3 112 116
drug
drugs

interaction DrugDDI.d361.s12.e0 DrugDDI.d361.s12.e2
interaction DrugDDI.d361.s12.e1 DrugDDI.d361.s12.e2

Abstract Id: DrugDDI.d342
Sentence Id: DrugDDI.d342.s0
May interact with the following: cholestyramine , colestipol (use with thiazide diuretics may prevent the diuretic from working properly; .

DrugDDI.d342.s0.e0 28 41
drug
cholestyramine
DrugDDI.d342.s0.e1 43 52
drug
colestipol
DrugDDI.d342.s0.e2 61 77
drug
thiazide diuretics
DrugDDI.d342.s0.e3 81 87
drug
prevent
DrugDDI.d342.s0.e4 91 98
drug
diuretic



Abstract Id: DrugDDI.d342
Sentence Id: DrugDDI.d342.s1
take the diuretic at least 1 hour before or 4 hours after cholestyramine or colestipol ), digitalis glycosides (use with thiazide diuretics may cause high blood levels of digoxin , which may increase the chance of side effects), and lithium (use with thiazide diuretics may cause high blood levels of lithium , which may increase the chance of side effects).

DrugDDI.d342.s1.e0 7 14
drug
diuretic
DrugDDI.d342.s1.e1 46 59
drug
cholestyramine
DrugDDI.d342.s1.e2 62 71
drug
colestipol
DrugDDI.d342.s1.e3 74 92
drug
digitalis glycosides
DrugDDI.d342.s1.e4 101 117
drug
thiazide diuretics
DrugDDI.d342.s1.e5 143 149
drug
digoxin
DrugDDI.d342.s1.e6 194 200
drug
lithium
DrugDDI.d342.s1.e7 209 225
drug
thiazide diuretics
DrugDDI.d342.s1.e8 251 257
drug
lithium

interaction DrugDDI.d342.s1.e3 DrugDDI.d342.s1.e4
interaction DrugDDI.d342.s1.e6 DrugDDI.d342.s1.e7

Abstract Id: DrugDDI.d531
Sentence Id: DrugDDI.d531.s0
May interact with other creams, lotions, or skin medicines when placed on the same areas of your skin that you are using bentoquatam .

DrugDDI.d531.s0.e0 41 49
drug
medicines
DrugDDI.d531.s0.e1 99 109
drug
bentoquatam



Abstract Id: DrugDDI.d216
Sentence Id: DrugDDI.d216.s0
Antipsychotic drugs such as phenothiazines or haloperidol ; .

DrugDDI.d216.s0.e0 0 17
drug
Antipsychotic drugs
DrugDDI.d216.s0.e1 24 37
drug
phenothiazines
DrugDDI.d216.s0.e2 40 50
drug
haloperidol



Abstract Id: DrugDDI.d216
Sentence Id: DrugDDI.d216.s1
tricyclic antidepressants .

DrugDDI.d216.s1.e0 0 23
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s0
Nitrates : The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.

DrugDDI.d71.s0.e0 0 7
drug
Nitrates
DrugDDI.d71.s0.e1 28 35
drug
Bepridil
DrugDDI.d71.s0.e2 60 67
drug
nitrates



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s1
Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.

DrugDDI.d71.s1.e0 10 22
drug
nitroglycerin
DrugDDI.d71.s1.e1 83 90
drug
Bepridil



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s2
Beta-blocking Agent s: The concomitant use of Bepridil and beta-blocking agent s has been well tolerated in patients with stable angina.

DrugDDI.d71.s2.e0 0 17
drug
Beta-blocking Agent
DrugDDI.d71.s2.e1 39 46
drug
Bepridil
DrugDDI.d71.s2.e2 50 67
drug
beta-blocking agent



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s3
Available data are not sufficient, however, to predict the effects of concomitant medication on patients with impaired ventricular function or cardiac conduction abnormalities.

DrugDDI.d71.s3.e0 70 79
drug
medication



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s4
Digoxin : In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.

DrugDDI.d71.s4.e0 0 6
drug
Digoxin
DrugDDI.d71.s4.e1 47 67
drug
bepridil hydrochloride
DrugDDI.d71.s4.e2 169 175
drug
digoxin

interaction DrugDDI.d71.s4.e1 DrugDDI.d71.s4.e2

Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s5
Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.

DrugDDI.d71.s5.e0 55 75
drug
bepridil hydrochloride
DrugDDI.d71.s5.e1 79 85
drug
digoxin



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s6
Available data are neither sufficient to rule out possible increases in serum digoxin with concomitant treatment in some patients, nor other possible interactions, particularly in patients with cardiac conduction abnormalities (Also see WARNINGS Congestive Heart Failure).

DrugDDI.d71.s6.e0 66 72
drug
digoxin



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s7
Oral Hypoglycemics : Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents .

DrugDDI.d71.s7.e0 0 16
drug
Oral Hypoglycemics
DrugDDI.d71.s7.e1 18 25
drug
Bepridil
DrugDDI.d71.s7.e2 134 140
drug
insulin
DrugDDI.d71.s7.e3 147 164
drug
hypoglycemic agents



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s8
General Interactions: Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride .

DrugDDI.d71.s8.e0 27 31
drug
drugs
DrugDDI.d71.s8.e1 96 116
drug
bepridil hydrochloride

interaction DrugDDI.d71.s8.e0 DrugDDI.d71.s8.e1

Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s9
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as quinidine and procainamide , cardiac glycosides and tricyclic anti-depressants .

DrugDDI.d71.s9.e0 18 22
drug
drugs
DrugDDI.d71.s9.e1 72 92
drug
bepridil hydrochloride
DrugDDI.d71.s9.e2 103 123
drug
anti-arrhythmic agents
DrugDDI.d71.s9.e3 130 138
drug
quinidine
DrugDDI.d71.s9.e4 142 153
drug
procainamide
DrugDDI.d71.s9.e5 155 171
drug
cardiac glycosides
DrugDDI.d71.s9.e6 175 199
drug
tricyclic anti-depressants



Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s10
Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride .

DrugDDI.d71.s10.e0 0 15
drug
Anti-arrhythmics
DrugDDI.d71.s10.e1 19 43
drug
tricyclic anti-depressants
DrugDDI.d71.s10.e2 101 121
drug
bepridil hydrochloride

interaction DrugDDI.d71.s10.e0 DrugDDI.d71.s10.e2

Abstract Id: DrugDDI.d71
Sentence Id: DrugDDI.d71.s11
Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride .

DrugDDI.d71.s11.e0 0 16
drug
Cardiac glycosides
DrugDDI.d71.s11.e1 76 96
drug
bepridil hydrochloride

interaction DrugDDI.d71.s11.e0 DrugDDI.d71.s11.e1

Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s0
The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine , nifedipine , chlorthalidone , and hydrochlorothiazide .

DrugDDI.d123.s0.e0 12 16
drug
drugs
DrugDDI.d123.s0.e1 43 49
drug
Kerlone
DrugDDI.d123.s0.e2 87 96
drug
cimetidine
DrugDDI.d123.s0.e3 98 107
drug
nifedipine
DrugDDI.d123.s0.e4 109 122
drug
chlorthalidone
DrugDDI.d123.s0.e5 127 145
drug
hydrochlorothiazide



Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s1
Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin .

DrugDDI.d123.s1.e0 27 33
drug
Kerlone
DrugDDI.d123.s1.e1 41 65
drug
oral anticoagulant warfarin
DrugDDI.d123.s1.e2 117 124
drug
warfarin



Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s2
Catecholamine-depleting drugs (e.g., reserpine ) may have an additive effect when given with beta-blocking agent s.

DrugDDI.d123.s2.e0 23 27
drug
drugs
DrugDDI.d123.s2.e1 34 42
drug
reserpine
DrugDDI.d123.s2.e2 80 97
drug
beta-blocking agent

interaction DrugDDI.d123.s2.e0 DrugDDI.d123.s2.e2

Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s3
Patients treated with a beta-adrenergic receptor blocking agent plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

DrugDDI.d123.s3.e0 20 55
drug
beta-adrenergic receptor blocking agent



Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s4
Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine .

DrugDDI.d123.s4.e0 56 68
drug
beta-blockers
DrugDDI.d123.s4.e1 72 80
drug
clonidine
DrugDDI.d123.s4.e2 97 108
drug
beta-blocker
DrugDDI.d123.s4.e3 178 186
drug
clonidine

interaction DrugDDI.d123.s4.e0 DrugDDI.d123.s4.e1

Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s5
Literature reports suggest that oral calcium antagonist s may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.

DrugDDI.d123.s5.e0 32 48
drug
calcium antagonist
DrugDDI.d123.s5.e1 76 104
drug
beta-adrenergic blocking agents



Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s6
Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.

DrugDDI.d123.s6.e0 101 129
drug
beta-adrenergic blocking agents
DrugDDI.d123.s6.e1 140 156
drug
calcium antagonist

interaction DrugDDI.d123.s6.e0 DrugDDI.d123.s6.e1

Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s7
Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem .

DrugDDI.d123.s7.e0 36 52
drug
calcium antagonist
DrugDDI.d123.s7.e1 58 72
drug
dihydropyridine
DrugDDI.d123.s7.e2 89 98
drug
nifedipine
DrugDDI.d123.s7.e3 214 222
drug
verapamil
DrugDDI.d123.s7.e4 225 233
drug
diltiazem



Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s8
Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.

DrugDDI.d123.s8.e0 58 70
drug
beta-blockers
DrugDDI.d123.s8.e1 88 98
drug
epinephrine
DrugDDI.d123.s8.e2 133 145
drug
beta-blockers



Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s9
Severe allergic reactions including anaphylaxis have been reported in patients exposed to a variety of allergens either by repeated challenge, or accidental contact, and with diagnostic or therapeutic agents while receiving beta-blockers .

DrugDDI.d123.s9.e0 162 178
drug
therapeutic agents
DrugDDI.d123.s9.e1 193 205
drug
beta-blockers



Abstract Id: DrugDDI.d123
Sentence Id: DrugDDI.d123.s10
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

DrugDDI.d123.s10.e0 46 56
drug
epinephrine



Abstract Id: DrugDDI.d423
Sentence Id: DrugDDI.d423.s0
Special care is required if this drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur.

DrugDDI.d423.s0.e0 27 30
drug
drug



Abstract Id: DrugDDI.d5
Sentence Id: DrugDDI.d5.s0
No formal studies to evaluate drug interactions with bexarotene have been conducted.

DrugDDI.d5.s0.e0 45 54
drug
bexarotene



Abstract Id: DrugDDI.d5
Sentence Id: DrugDDI.d5.s1
Bexarotene oxidative metabolites appear to be formed by cytochrome P450 3A4 .

DrugDDI.d5.s1.e0 0 9
drug
Bexarotene
DrugDDI.d5.s1.e1 48 64
drug
cytochrome P450 3A4



Abstract Id: DrugDDI.d5
Sentence Id: DrugDDI.d5.s2
On the basis of the metabolism of bexarotene by cytochrome P450 3A4 , ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.

DrugDDI.d5.s2.e0 27 36
drug
bexarotene
DrugDDI.d5.s2.e1 39 55
drug
cytochrome P450 3A4
DrugDDI.d5.s2.e2 57 68
drug
ketoconazole
DrugDDI.d5.s2.e3 70 81
drug
itraconazole
DrugDDI.d5.s2.e4 83 94
drug
erythromycin
DrugDDI.d5.s2.e5 96 106
drug
gemfibrozil
DrugDDI.d5.s2.e6 144 160
drug
cytochrome P450 3A4
DrugDDI.d5.s2.e7 202 211
drug
bexarotene

interaction DrugDDI.d5.s2.e2 DrugDDI.d5.s2.e7
interaction DrugDDI.d5.s2.e4 DrugDDI.d5.s2.e7
interaction DrugDDI.d5.s2.e6 DrugDDI.d5.s2.e7

Abstract Id: DrugDDI.d5
Sentence Id: DrugDDI.d5.s3
Furthermore, rifampin , phenytoin , phenobarbital , and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.

DrugDDI.d5.s3.e0 12 19
drug
rifampin
DrugDDI.d5.s3.e1 21 29
drug
phenytoin
DrugDDI.d5.s3.e2 31 43
drug
phenobarbital
DrugDDI.d5.s3.e3 63 79
drug
cytochrome P450 3A4
DrugDDI.d5.s3.e4 106 115
drug
bexarotene

interaction DrugDDI.d5.s3.e0 DrugDDI.d5.s3.e4
interaction DrugDDI.d5.s3.e1 DrugDDI.d5.s3.e4
interaction DrugDDI.d5.s3.e2 DrugDDI.d5.s3.e4

Abstract Id: DrugDDI.d5
Sentence Id: DrugDDI.d5.s4
Concomitant administration of Targretin @ capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil .

DrugDDI.d5.s4.e0 27 35
drug
Targretin
DrugDDI.d5.s4.e1 48 58
drug
gemfibrozil
DrugDDI.d5.s4.e2 113 122
drug
bexarotene
DrugDDI.d5.s4.e3 157 173
drug
cytochrome P450 3A4
DrugDDI.d5.s4.e4 186 196
drug
gemfibrozil

interaction DrugDDI.d5.s4.e0 DrugDDI.d5.s4.e1
interaction DrugDDI.d5.s4.e0 DrugDDI.d5.s4.e2
interaction DrugDDI.d5.s4.e1 DrugDDI.d5.s4.e2
interaction DrugDDI.d5.s4.e2 DrugDDI.d5.s4.e4

Abstract Id: DrugDDI.d5
Sentence Id: DrugDDI.d5.s5
Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.

DrugDDI.d5.s5.e0 23 32
drug
bexarotene
DrugDDI.d5.s5.e1 75 86
drug
atorvastatin



Abstract Id: DrugDDI.d5
Sentence Id: DrugDDI.d5.s6
Concomitant administration of gemfibrozil with Targretin @ capsules is not recommended.

DrugDDI.d5.s6.e0 27 37
drug
gemfibrozil
DrugDDI.d5.s6.e1 42 50
drug
Targretin

interaction DrugDDI.d5.s6.e0 DrugDDI.d5.s6.e1

Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s0
When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.

DrugDDI.d213.s0.e0 4 10
drug
Bezalip
DrugDDI.d213.s0.e1 13 19
drug
Bezalip
DrugDDI.d213.s0.e2 52 60
drug
medicines
DrugDDI.d213.s0.e3 121 127
drug
Bezalip
DrugDDI.d213.s0.e4 131 137
drug
Bezalip
DrugDDI.d213.s0.e5 165 178
drug
anticoagulants
DrugDDI.d213.s0.e6 184 191
drug
coumarin

interaction DrugDDI.d213.s0.e3 DrugDDI.d213.s0.e5
interaction DrugDDI.d213.s0.e3 DrugDDI.d213.s0.e6
interaction DrugDDI.d213.s0.e4 DrugDDI.d213.s0.e5
interaction DrugDDI.d213.s0.e4 DrugDDI.d213.s0.e6

Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s1
For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters .

DrugDDI.d213.s1.e0 26 38
drug
anticoagulant
DrugDDI.d213.s1.e1 87 93
drug
Bezalip
DrugDDI.d213.s1.e2 96 102
drug
Bezalip

interaction DrugDDI.d213.s1.e0 DrugDDI.d213.s1.e1
interaction DrugDDI.d213.s1.e0 DrugDDI.d213.s1.e2

Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s3
- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.

DrugDDI.d213.s3.e0 12 25
drug
sulphonylureas
DrugDDI.d213.s3.e1 29 35
drug
insulin
DrugDDI.d213.s3.e2 51 57
drug
Bezalip
DrugDDI.d213.s3.e3 60 66
drug
Bezalip

interaction DrugDDI.d213.s3.e0 DrugDDI.d213.s3.e2
interaction DrugDDI.d213.s3.e0 DrugDDI.d213.s3.e3
interaction DrugDDI.d213.s3.e1 DrugDDI.d213.s3.e2
interaction DrugDDI.d213.s3.e1 DrugDDI.d213.s3.e3

Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s4
This may be due to an improved glucose utilization with simultaneous reduction in insulin requirement .

DrugDDI.d213.s4.e0 24 30
drug
glucose
DrugDDI.d213.s4.e1 69 75
drug
insulin



Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s6
- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate .

DrugDDI.d213.s6.e0 220 230
drug
bezafibrate



Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s7
Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, bezafibrate should, if necessary, be discontinued .

DrugDDI.d213.s7.e0 129 139
drug
bezafibrate



Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s9
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines , since the absorption of Bezalip or Bezalip retard is impaired .

DrugDDI.d213.s9.e0 5 11
drug
Bezalip
DrugDDI.d213.s9.e1 14 20
drug
Bezalip
DrugDDI.d213.s9.e2 49 68
drug
anion-exchange resins
DrugDDI.d213.s9.e3 147 155
drug
medicines
DrugDDI.d213.s9.e4 177 183
drug
Bezalip
DrugDDI.d213.s9.e5 186 192
drug
Bezalip



Abstract Id: DrugDDI.d213
Sentence Id: DrugDDI.d213.s11
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.

DrugDDI.d213.s11.e0 1 26
drug
Perhexiline hydrogen maleate
DrugDDI.d213.s11.e1 29 42
drug
MAO-inhibitors
DrugDDI.d213.s11.e2 102 108
drug
Bezalip
DrugDDI.d213.s11.e3 111 117
drug
Bezalip

interaction DrugDDI.d213.s11.e0 DrugDDI.d213.s11.e2
interaction DrugDDI.d213.s11.e0 DrugDDI.d213.s11.e3
interaction DrugDDI.d213.s11.e1 DrugDDI.d213.s11.e2
interaction DrugDDI.d213.s11.e1 DrugDDI.d213.s11.e3

Abstract Id: DrugDDI.d10
Sentence Id: DrugDDI.d10.s0
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .

DrugDDI.d10.s0.e0 62 82
drug
anticholinergic agents
DrugDDI.d10.s0.e1 89 96
drug
AKINETON
DrugDDI.d10.s0.e2 129 133
drug
drugs
DrugDDI.d10.s0.e3 151 165
drug
anticholinergic
DrugDDI.d10.s0.e4 186 203
drug
narcotic analgesics
DrugDDI.d10.s0.e5 210 219
drug
meperidine
DrugDDI.d10.s0.e6 224 237
drug
phenothiazines
DrugDDI.d10.s0.e7 246 259
drug
antipsychotics
DrugDDI.d10.s0.e8 261 284
drug
tricyclic antidepressants
DrugDDI.d10.s0.e9 293 307
drug
antiarrhythmics
DrugDDI.d10.s0.e10 317 325
drug
quinidine
DrugDDI.d10.s0.e11 335 348
drug
antihistamines



Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s0
ZEBETA should not be combined with other beta-blocking agent s.

DrugDDI.d381.s0.e0 0 5
drug
ZEBETA
DrugDDI.d381.s0.e1 34 51
drug
beta-blocking agent

interaction DrugDDI.d381.s0.e0 DrugDDI.d381.s0.e1

Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s1
Patients receiving catecholamine-depleting drugs , such as reserpine or guanethidine , should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.

DrugDDI.d381.s1.e0 40 44
drug
drugs
DrugDDI.d381.s1.e1 52 60
drug
reserpine
DrugDDI.d381.s1.e2 63 74
drug
guanethidine
DrugDDI.d381.s1.e3 147 152
drug
ZEBETA

interaction DrugDDI.d381.s1.e0 DrugDDI.d381.s1.e3
interaction DrugDDI.d381.s1.e1 DrugDDI.d381.s1.e3
interaction DrugDDI.d381.s1.e2 DrugDDI.d381.s1.e3

Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s2
In patients receiving concurrent therapy with clonidine , if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine .

DrugDDI.d381.s2.e0 40 48
drug
clonidine
DrugDDI.d381.s2.e1 95 100
drug
ZEBETA
DrugDDI.d381.s2.e2 150 158
drug
clonidine

interaction DrugDDI.d381.s2.e1 DrugDDI.d381.s2.e2

Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s3
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonist s (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic agent s, such as disopyramide , are used concurrently.

DrugDDI.d381.s3.e0 0 5
drug
ZEBETA
DrugDDI.d381.s3.e1 30 50
drug
myocardial depressants
DrugDDI.d381.s3.e2 91 107
drug
calcium antagonist
DrugDDI.d381.s3.e3 144 152
drug
verapamil
DrugDDI.d381.s3.e4 173 181
drug
diltiazem
DrugDDI.d381.s3.e5 194 212
drug
antiarrhythmic agent
DrugDDI.d381.s3.e6 221 232
drug
disopyramide

interaction DrugDDI.d381.s3.e0 DrugDDI.d381.s3.e1
interaction DrugDDI.d381.s3.e0 DrugDDI.d381.s3.e3
interaction DrugDDI.d381.s3.e0 DrugDDI.d381.s3.e5

Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s4
Concurrent use of rifampin increases the metabolic clearance of ZEBETA , resulting in a shortened elimination half-life of ZEBETA .

DrugDDI.d381.s4.e0 15 22
drug
rifampin
DrugDDI.d381.s4.e1 55 60
drug
ZEBETA
DrugDDI.d381.s4.e2 105 110
drug
ZEBETA

interaction DrugDDI.d381.s4.e0 DrugDDI.d381.s4.e1

Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s6
Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics , digoxin , and cimetidine .

DrugDDI.d381.s6.e0 105 121
drug
thiazide diuretics
DrugDDI.d381.s6.e1 123 129
drug
digoxin
DrugDDI.d381.s6.e2 134 143
drug
cimetidine



Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s7
There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin .

DrugDDI.d381.s7.e0 18 23
drug
ZEBETA
DrugDDI.d381.s7.e1 66 73
drug
warfarin



Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s8
Risk of Anaphylactic Reaction: While taking beta-blockers , patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.

DrugDDI.d381.s8.e0 38 50
drug
beta-blockers



Abstract Id: DrugDDI.d381
Sentence Id: DrugDDI.d381.s9
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.

DrugDDI.d381.s9.e0 46 56
drug
epinephrine



Abstract Id: DrugDDI.d161
Sentence Id: DrugDDI.d161.s0
Use of MAO inhibitors may cause an excessive increase in blood pressure and heart stimulation.

DrugDDI.d161.s0.e0 5 17
drug
MAO inhibitors



Abstract Id: DrugDDI.d161
Sentence Id: DrugDDI.d161.s1
If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.

DrugDDI.d161.s1.e0 37 46
drug
bitolterol



Abstract Id: DrugDDI.d161
Sentence Id: DrugDDI.d161.s2
This allows bitolterol to open air passages, increasing the effectiveness of the steroid.

DrugDDI.d161.s2.e0 10 19
drug
bitolterol



Abstract Id: DrugDDI.d487
Sentence Id: DrugDDI.d487.s0
Angiomax does not exhibit binding to plasma proteins (other than thrombin ) or red blood cells .

DrugDDI.d487.s0.e0 0 7
drug
Angiomax
DrugDDI.d487.s0.e1 31 44
drug
plasma proteins
DrugDDI.d487.s0.e2 55 62
drug
thrombin
DrugDDI.d487.s0.e3 66 78
drug
red blood cells



Abstract Id: DrugDDI.d487
Sentence Id: DrugDDI.d487.s1
In clinical trials in patients undergoing PTCA/ PCI , co-administration of Angiomax with heparin , warfarin , thrombolytic s or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .

DrugDDI.d487.s1.e0 41 43
drug
PCI
DrugDDI.d487.s1.e1 64 71
drug
Angiomax
DrugDDI.d487.s1.e2 76 82
drug
heparin
DrugDDI.d487.s1.e3 84 91
drug
warfarin
DrugDDI.d487.s1.e4 93 104
drug
thrombolytic
DrugDDI.d487.s1.e5 108 119
drug
glycoprotein
DrugDDI.d487.s1.e6 236 246
drug
medications

interaction DrugDDI.d487.s1.e1 DrugDDI.d487.s1.e2
interaction DrugDDI.d487.s1.e1 DrugDDI.d487.s1.e3
interaction DrugDDI.d487.s1.e1 DrugDDI.d487.s1.e4
interaction DrugDDI.d487.s1.e1 DrugDDI.d487.s1.e5

Abstract Id: DrugDDI.d487
Sentence Id: DrugDDI.d487.s2
There is no experience with co-administration of Angiomax and plasma expander s such as dextran .

DrugDDI.d487.s2.e0 42 49
drug
Angiomax
DrugDDI.d487.s2.e1 53 66
drug
plasma expander
DrugDDI.d487.s2.e2 74 80
drug
dextran



Abstract Id: DrugDDI.d487
Sentence Id: DrugDDI.d487.s3
Angiomax should be used with caution in patients with disease states associated with an increased risk of bleeding.

DrugDDI.d487.s3.e0 0 7
drug
Angiomax



Abstract Id: DrugDDI.d487
Sentence Id: DrugDDI.d487.s4
Immunogenicity/Re-exposure: In in vitro studies, Angiomax exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.

DrugDDI.d487.s4.e0 44 51
drug
Angiomax



Abstract Id: DrugDDI.d487
Sentence Id: DrugDDI.d487.s5
Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies , 2 subjects had treatment-emergent positive bivalirudin antibody tests.

DrugDDI.d487.s5.e0 27 34
drug
Angiomax
DrugDDI.d487.s5.e1 67 76
drug
antibodies
DrugDDI.d487.s5.e2 116 126
drug
bivalirudin



Abstract Id: DrugDDI.d52
Sentence Id: DrugDDI.d52.s0
Certain antibiotic , cisplatin , cyclosporine , diuretic , foscarnet, and vaccines .

DrugDDI.d52.s0.e0 7 16
drug
antibiotic
DrugDDI.d52.s0.e1 18 26
drug
cisplatin
DrugDDI.d52.s0.e2 28 39
drug
cyclosporine
DrugDDI.d52.s0.e3 41 48
drug
diuretic
DrugDDI.d52.s0.e4 63 70
drug
vaccines



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s0
Bosentan is metabolized by CYP2C9 and CYP3A4 .

DrugDDI.d127.s0.e0 0 7
drug
Bosentan
DrugDDI.d127.s0.e1 23 28
drug
CYP2C9
DrugDDI.d127.s0.e2 32 37
drug
CYP3A4

interaction DrugDDI.d127.s0.e0 DrugDDI.d127.s0.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s1
Inhibition of these isoenzymes may increase the plasma concentration of bosentan .

DrugDDI.d127.s1.e0 17 26
drug
isoenzymes
DrugDDI.d127.s1.e1 62 69
drug
bosentan

interaction DrugDDI.d127.s1.e0 DrugDDI.d127.s1.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s2
Bosentan is an inducer of CYP3A4 and CYP2C9 .

DrugDDI.d127.s2.e0 0 7
drug
Bosentan
DrugDDI.d127.s2.e1 21 26
drug
CYP3A4
DrugDDI.d127.s2.e2 30 35
drug
CYP2C9

interaction DrugDDI.d127.s2.e0 DrugDDI.d127.s2.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s3
Consequently, plasma concentrations of drugs metabolized by these two isoenzymes will be decreased when TRACLEER@ is co-administered.

DrugDDI.d127.s3.e0 35 39
drug
drugs
DrugDDI.d127.s3.e1 61 70
drug
isoenzymes



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s4
Bosentan had no relevant inhibitory effect on any CYP isoenzymes tested ( CYP1A2 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4 ).

DrugDDI.d127.s4.e0 0 7
drug
Bosentan
DrugDDI.d127.s4.e1 45 54
drug
isoenzymes
DrugDDI.d127.s4.e2 62 67
drug
CYP1A2
DrugDDI.d127.s4.e3 69 74
drug
CYP2C9
DrugDDI.d127.s4.e4 76 82
drug
CYP2C19
DrugDDI.d127.s4.e5 84 89
drug
CYP2D6
DrugDDI.d127.s4.e6 91 96
drug
CYP3A4



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s5
Consequently, TRACLEER@ is not expected to increase the plasma concentrations of drugs metabolized by these enzymes.

DrugDDI.d127.s5.e0 70 74
drug
drugs



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s6
Hormonal Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum@ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.

DrugDDI.d127.s6.e0 8 21
drug
Contraceptives
DrugDDI.d127.s6.e1 74 87
drug
Contraceptives
DrugDDI.d127.s6.e2 142 149
drug
bosentan
DrugDDI.d127.s6.e3 156 192
drug
oral hormonal contraceptive Ortho-Novum@
DrugDDI.d127.s6.e4 219 231
drug
norethindrone
DrugDDI.d127.s6.e5 235 250
drug
ethinyl estradiol

interaction DrugDDI.d127.s6.e2 DrugDDI.d127.s6.e3

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s8
Therefore, hormonal contraceptives , including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER@ is co-administered.

DrugDDI.d127.s8.e0 18 31
drug
contraceptives



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s10
Specific interaction studies have demonstrated the following: Cyclosporine A : During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold.

DrugDDI.d127.s10.e0 55 67
drug
Cyclosporine A
DrugDDI.d127.s10.e1 136 143
drug
bosentan



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s11
Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A .

DrugDDI.d127.s11.e0 12 19
drug
bosentan
DrugDDI.d127.s11.e1 78 90
drug
cyclosporine A

interaction DrugDDI.d127.s11.e0 DrugDDI.d127.s11.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s12
The concomitant administration of bosentan and cyclosporine A is contraindicated.

DrugDDI.d127.s12.e0 30 37
drug
bosentan
DrugDDI.d127.s12.e1 41 53
drug
cyclosporine A

interaction DrugDDI.d127.s12.e0 DrugDDI.d127.s12.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s13
Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.

DrugDDI.d127.s13.e0 19 26
drug
bosentan
DrugDDI.d127.s13.e1 61 73
drug
cyclosporine A
DrugDDI.d127.s13.e2 76 81
drug
CYP3A4

interaction DrugDDI.d127.s13.e0 DrugDDI.d127.s13.e1
interaction DrugDDI.d127.s13.e0 DrugDDI.d127.s13.e2

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s14
Tacrolimus : Co-administration of tacrolimus and bosentan has not been studied in man.

DrugDDI.d127.s14.e0 0 9
drug
Tacrolimus
DrugDDI.d127.s14.e1 30 39
drug
tacrolimus
DrugDDI.d127.s14.e2 43 50
drug
bosentan



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s15
Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.

DrugDDI.d127.s15.e0 19 28
drug
tacrolimus
DrugDDI.d127.s15.e1 32 39
drug
bosentan
DrugDDI.d127.s15.e2 89 96
drug
bosentan

interaction DrugDDI.d127.s15.e0 DrugDDI.d127.s15.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s16
Caution should be exercised if tacrolimus and bosentan are used together.

DrugDDI.d127.s16.e0 26 35
drug
tacrolimus
DrugDDI.d127.s16.e1 39 46
drug
bosentan

interaction DrugDDI.d127.s16.e0 DrugDDI.d127.s16.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s17
Glyburide : An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide .

DrugDDI.d127.s17.e0 0 8
drug
Glyburide
DrugDDI.d127.s17.e1 40 56
drug
aminotransferases
DrugDDI.d127.s17.e2 109 117
drug
glyburide



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s18
Therefore, the concomitant administration of TRACLEER@ and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.

DrugDDI.d127.s18.e0 52 60
drug
glyburide
DrugDDI.d127.s18.e1 93 110
drug
hypoglycemic agents



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s19
Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.

DrugDDI.d127.s19.e0 19 26
drug
bosentan
DrugDDI.d127.s19.e1 61 69
drug
glyburide

interaction DrugDDI.d127.s19.e0 DrugDDI.d127.s19.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s20
The plasma concentrations of bosentan were also decreased by approximately 30%.

DrugDDI.d127.s20.e0 25 32
drug
bosentan



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s21
Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4 .

DrugDDI.d127.s21.e0 0 7
drug
Bosentan
DrugDDI.d127.s21.e1 61 78
drug
hypoglycemic agents
DrugDDI.d127.s21.e2 112 117
drug
CYP2C9
DrugDDI.d127.s21.e3 120 125
drug
CYP3A4

interaction DrugDDI.d127.s21.e0 DrugDDI.d127.s21.e1

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s23
Ketoconazole : Co-administration of bosentan 125 mg b.i.d. and ketoconazole , a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.

DrugDDI.d127.s23.e0 0 11
drug
Ketoconazole
DrugDDI.d127.s23.e1 32 44
drug
bosentan 125 mg
DrugDDI.d127.s23.e2 54 65
drug
ketoconazole
DrugDDI.d127.s23.e3 74 79
drug
CYP3A4
DrugDDI.d127.s23.e4 124 131
drug
bosentan

interaction DrugDDI.d127.s23.e1 DrugDDI.d127.s23.e4

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s24
No dose adjustment of bosentan is necessary, but increased effects of bosentan should be considered.

DrugDDI.d127.s24.e0 18 25
drug
bosentan
DrugDDI.d127.s24.e1 59 66
drug
bosentan



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s25
Simvastatin and Other Statins : Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active @ -hydroxy acid metabolite , by approximately 50%.

DrugDDI.d127.s25.e0 0 10
drug
Simvastatin
DrugDDI.d127.s25.e1 19 25
drug
Statins
DrugDDI.d127.s25.e2 46 53
drug
bosentan
DrugDDI.d127.s25.e3 88 98
drug
simvastatin
DrugDDI.d127.s25.e4 101 106
drug
CYP3A4
DrugDDI.d127.s25.e5 131 152
drug
-hydroxy acid metabolite

interaction DrugDDI.d127.s25.e2 DrugDDI.d127.s25.e3
interaction DrugDDI.d127.s25.e2 DrugDDI.d127.s25.e5

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s26
The plasma concentrations of bosentan were not affected.

DrugDDI.d127.s26.e0 25 32
drug
bosentan



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s27
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4 , such as lovastatin and atorvastatin .

DrugDDI.d127.s27.e0 0 7
drug
Bosentan
DrugDDI.d127.s27.e1 57 63
drug
statins
DrugDDI.d127.s27.e2 95 100
drug
CYP3A4
DrugDDI.d127.s27.e3 108 117
drug
lovastatin
DrugDDI.d127.s27.e4 121 132
drug
atorvastatin

interaction DrugDDI.d127.s27.e0 DrugDDI.d127.s27.e1
interaction DrugDDI.d127.s27.e0 DrugDDI.d127.s27.e3
interaction DrugDDI.d127.s27.e0 DrugDDI.d127.s27.e4

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s29
Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER@ is initiated to see whether the statin dose needs adjustment.

DrugDDI.d127.s29.e0 30 36
drug
statins



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s30
Warfarin : Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S- warfarin (a CYP2C9 substrate) and R- warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.

DrugDDI.d127.s30.e0 0 7
drug
Warfarin
DrugDDI.d127.s30.e1 28 35
drug
bosentan
DrugDDI.d127.s30.e2 95 102
drug
warfarin
DrugDDI.d127.s30.e3 105 110
drug
CYP2C9
DrugDDI.d127.s30.e4 126 133
drug
warfarin
DrugDDI.d127.s30.e5 136 141
drug
CYP3A4

interaction DrugDDI.d127.s30.e1 DrugDDI.d127.s30.e2

Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s31
Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients.

DrugDDI.d127.s31.e0 49 56
drug
bosentan
DrugDDI.d127.s31.e1 60 67
drug
warfarin
DrugDDI.d127.s31.e2 302 309
drug
bosentan



Abstract Id: DrugDDI.d127
Sentence Id: DrugDDI.d127.s32
Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan .

DrugDDI.d127.s32.e0 0 6
drug
Digoxin
DrugDDI.d127.s32.e1 8 17
drug
Nimodipine
DrugDDI.d127.s32.e2 21 28
drug
Losartan
DrugDDI.d127.s32.e3 30 37
drug
Bosentan
DrugDDI.d127.s32.e4 85 91
drug
digoxin
DrugDDI.d127.s32.e5 95 104
drug
nimodipine
DrugDDI.d127.s32.e6 109 116
drug
losartan
DrugDDI.d127.s32.e7 155 162
drug
bosentan



Abstract Id: DrugDDI.d304
Sentence Id: DrugDDI.d304.s0
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare -like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

DrugDDI.d304.s0.e0 19 25
drug
MYOBLOC
DrugDDI.d304.s0.e1 29 43
drug
aminoglycosides
DrugDDI.d304.s0.e2 103 108
drug
curare
DrugDDI.d304.s0.e3 172 176
drug
toxin

interaction DrugDDI.d304.s0.e0 DrugDDI.d304.s0.e1

Abstract Id: DrugDDI.d304
Sentence Id: DrugDDI.d304.s1
The effect of administering different botulinum neurotoxin serotypes at the same time or within less than 4 months of each other is unknown.

DrugDDI.d304.s1.e0 33 51
drug
botulinum neurotoxin



Abstract Id: DrugDDI.d304
Sentence Id: DrugDDI.d304.s2
However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes .

DrugDDI.d304.s2.e0 103 125
drug
botulinum toxin serotypes



Abstract Id: DrugDDI.d17
Sentence Id: DrugDDI.d17.s0
Although specific drug interaction studies have not been conducted with ALPHAGAN@ P, the possibility of an additive or potentiating effect with CNS depressants ( alcohol , barbiturates , opiates , sedatives , or anesthetics ) should be considered.

DrugDDI.d17.s0.e0 123 136
drug
CNS depressants
DrugDDI.d17.s0.e1 138 144
drug
alcohol
DrugDDI.d17.s0.e2 146 157
drug
barbiturates
DrugDDI.d17.s0.e3 159 165
drug
opiates
DrugDDI.d17.s0.e4 167 175
drug
sedatives
DrugDDI.d17.s0.e5 179 189
drug
anesthetics



Abstract Id: DrugDDI.d17
Sentence Id: DrugDDI.d17.s1
Alpha- agonists , as a class, may reduce pulse and blood pressure.

DrugDDI.d17.s1.e0 6 13
drug
agonists



Abstract Id: DrugDDI.d17
Sentence Id: DrugDDI.d17.s2
Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.

DrugDDI.d17.s2.e0 25 29
drug
drugs
DrugDDI.d17.s2.e1 36 48
drug
beta-blockers
DrugDDI.d17.s2.e2 73 90
drug
anti-hypertensives
DrugDDI.d17.s2.e3 97 113
drug
cardiac glycosides



Abstract Id: DrugDDI.d17
Sentence Id: DrugDDI.d17.s3
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine .It is not known whether the concurrent use of these agents with ALPHAGAN@ P in humans can lead to resulting interference with the IOP lowering effect.

DrugDDI.d17.s3.e0 0 23
drug
Tricyclic antidepressants
DrugDDI.d17.s3.e1 77 85
drug
clonidine

interaction DrugDDI.d17.s3.e0 DrugDDI.d17.s3.e1

Abstract Id: DrugDDI.d17
Sentence Id: DrugDDI.d17.s5
Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

DrugDDI.d17.s5.e0 41 64
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d307
Sentence Id: DrugDDI.d307.s0
AZOPT ( brinzolamide ophthalmic suspension ) 1% contains a carbonic anhydrase inhibitor .

DrugDDI.d307.s0.e0 0 4
drug
AZOPT
DrugDDI.d307.s0.e1 6 37
drug
brinzolamide ophthalmic suspension
DrugDDI.d307.s0.e2 50 75
drug
carbonic anhydrase inhibitor



Abstract Id: DrugDDI.d307
Sentence Id: DrugDDI.d307.s1
Acid-base and electrolyte alterations were not reported in the clinical trials with brinzolamide .

DrugDDI.d307.s1.e0 72 83
drug
brinzolamide



Abstract Id: DrugDDI.d307
Sentence Id: DrugDDI.d307.s2
However, in patients treated with oral carbonic anhydrase inhibitors , rare instances of drug interactions have occurred with high-dose salicylate therapy.

DrugDDI.d307.s2.e0 33 59
drug
carbonic anhydrase inhibitors
DrugDDI.d307.s2.e1 117 126
drug
salicylate

interaction DrugDDI.d307.s2.e0 DrugDDI.d307.s2.e1

Abstract Id: DrugDDI.d307
Sentence Id: DrugDDI.d307.s3
Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT ( brinzolamide ophthalmic suspension ) 1%.

DrugDDI.d307.s3.e0 81 85
drug
AZOPT
DrugDDI.d307.s3.e1 87 118
drug
brinzolamide ophthalmic suspension



Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s0
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate .

DrugDDI.d411.s0.e0 14 34
drug
bromocriptine mesylate
DrugDDI.d411.s0.e1 57 61
drug
drugs
DrugDDI.d411.s0.e2 99 105
drug
alcohol
DrugDDI.d411.s0.e3 135 155
drug
bromocriptine mesylate

interaction DrugDDI.d411.s0.e2 DrugDDI.d411.s0.e3

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s1
Bromocriptine mesylate may interact with dopamine antagonists , butyrophenones , and certain other agents.

DrugDDI.d411.s1.e0 0 20
drug
Bromocriptine mesylate
DrugDDI.d411.s1.e1 36 54
drug
dopamine antagonists
DrugDDI.d411.s1.e2 56 69
drug
butyrophenones

interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e1
interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e2

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s2
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate : phenothiazines , haloperidol , metoclopramide , pimozide .

DrugDDI.d411.s2.e0 54 74
drug
bromocriptine mesylate
DrugDDI.d411.s2.e1 76 89
drug
phenothiazines
DrugDDI.d411.s2.e2 91 101
drug
haloperidol
DrugDDI.d411.s2.e3 103 116
drug
metoclopramide
DrugDDI.d411.s2.e4 118 125
drug
pimozide

interaction DrugDDI.d411.s2.e0 DrugDDI.d411.s2.e1
interaction DrugDDI.d411.s2.e0 DrugDDI.d411.s2.e2
interaction DrugDDI.d411.s2.e0 DrugDDI.d411.s2.e3
interaction DrugDDI.d411.s2.e0 DrugDDI.d411.s2.e4

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s3
Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.

DrugDDI.d411.s3.e0 16 36
drug
bromocriptine mesylate
DrugDDI.d411.s3.e1 46 59
drug
ergot alkaloids

interaction DrugDDI.d411.s3.e0 DrugDDI.d411.s3.e1

Abstract Id: DrugDDI.d490
Sentence Id: DrugDDI.d490.s0
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).

DrugDDI.d490.s0.e0 0 17
drug
Dexbrompheniramine
DrugDDI.d490.s0.e1 33 39
drug
alcohol
DrugDDI.d490.s0.e2 47 60
drug
CNS depressants
DrugDDI.d490.s0.e3 78 90
drug
CNS depressant
DrugDDI.d490.s0.e4 111 121
drug
medications
DrugDDI.d490.s0.e5 124 137
drug
antihistamines
DrugDDI.d490.s0.e6 140 155
drug
anticholinergics
DrugDDI.d490.s0.e7 158 173
drug
other medications
DrugDDI.d490.s0.e8 178 192
drug
anticholinergic
DrugDDI.d490.s0.e9 202 216
drug
anticholinergic
DrugDDI.d490.s0.e10 249 259
drug
medications
DrugDDI.d490.s0.e11 283 296
drug
antihistamines
DrugDDI.d490.s0.e12 302 317
drug
monoamine oxidase
DrugDDI.d490.s0.e13 351 364
drug
antihistamines
DrugDDI.d490.s0.e14 390 404
drug
anticholinergic
DrugDDI.d490.s0.e15 408 420
drug
CNS depressant
DrugDDI.d490.s0.e16 430 443
drug
antihistamines



Abstract Id: DrugDDI.d457
Sentence Id: DrugDDI.d457.s0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine oxidase ( MAO ) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).

DrugDDI.d457.s0.e0 4 7
drug
drug
DrugDDI.d457.s0.e1 23 29
drug
alcohol
DrugDDI.d457.s0.e2 37 50
drug
CNS depressants
DrugDDI.d457.s0.e3 68 80
drug
CNS depressant
DrugDDI.d457.s0.e4 101 111
drug
medications
DrugDDI.d457.s0.e5 114 127
drug
antihistamines
DrugDDI.d457.s0.e6 130 145
drug
anticholinergics
DrugDDI.d457.s0.e7 148 163
drug
other medications
DrugDDI.d457.s0.e8 168 182
drug
anticholinergic
DrugDDI.d457.s0.e9 192 206
drug
anticholinergic
DrugDDI.d457.s0.e10 239 249
drug
medications
DrugDDI.d457.s0.e11 273 286
drug
antihistamines
DrugDDI.d457.s0.e12 292 307
drug
monoamine oxidase
DrugDDI.d457.s0.e13 309 311
drug
MAO
DrugDDI.d457.s0.e14 341 354
drug
antihistamines
DrugDDI.d457.s0.e15 380 394
drug
anticholinergic
DrugDDI.d457.s0.e16 398 410
drug
CNS depressant
DrugDDI.d457.s0.e17 420 433
drug
antihistamines

interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e1
interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e2
interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e4
interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e5
interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e6
interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e7
interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e12
interaction DrugDDI.d457.s0.e0 DrugDDI.d457.s0.e13
interaction DrugDDI.d457.s0.e10 DrugDDI.d457.s0.e11

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s0
- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.

DrugDDI.d187.s0.e0 1 5
drug
Drugs
DrugDDI.d187.s0.e1 107 116
drug
bumetanide
DrugDDI.d187.s0.e2 133 157
drug
aminoglycoside antibiotics

interaction DrugDDI.d187.s0.e1 DrugDDI.d187.s0.e2

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s1
- Drugs with nephrotoxic potential: There has been no experience on the concurrent use of bumetanide with drugs known to have a nephrotoxic potential.

DrugDDI.d187.s1.e0 1 5
drug
Drugs
DrugDDI.d187.s1.e1 75 84
drug
bumetanide
DrugDDI.d187.s1.e2 89 93
drug
drugs



Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s2
Therefore, the simultaneous administration of these drugs should be avoided.

DrugDDI.d187.s2.e0 46 50
drug
drugs



Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s3
- Lithium : Lithium should generally not be given with diuretics (such as bumetanide ) because they reduce its renal clearance and add a high risk of lithium toxicity.

DrugDDI.d187.s3.e0 1 7
drug
Lithium
DrugDDI.d187.s3.e1 9 15
drug
Lithium
DrugDDI.d187.s3.e2 45 53
drug
diuretics
DrugDDI.d187.s3.e3 61 70
drug
bumetanide

interaction DrugDDI.d187.s3.e1 DrugDDI.d187.s3.e2
interaction DrugDDI.d187.s3.e1 DrugDDI.d187.s3.e3

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s4
- Probenecid : Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide .

DrugDDI.d187.s4.e0 1 10
drug
Probenecid
DrugDDI.d187.s4.e1 28 37
drug
probenecid
DrugDDI.d187.s4.e2 90 99
drug
bumetanide

interaction DrugDDI.d187.s4.e1 DrugDDI.d187.s4.e2

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s5
This antagonistic effect of probenecid on bu-metanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide .

DrugDDI.d187.s5.e0 24 33
drug
probenecid
DrugDDI.d187.s5.e1 83 88
drug
sodium
DrugDDI.d187.s5.e2 166 175
drug
bumetanide

interaction DrugDDI.d187.s5.e0 DrugDDI.d187.s5.e2

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s6
Thus, probenecid should not be administered concurrently with bumetanide .

DrugDDI.d187.s6.e0 5 14
drug
probenecid
DrugDDI.d187.s6.e1 54 63
drug
bumetanide

interaction DrugDDI.d187.s6.e0 DrugDDI.d187.s6.e1

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s7
- Indomethacin : Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide -induced increase in plasma renin activity.

DrugDDI.d187.s7.e0 1 12
drug
Indomethacin
DrugDDI.d187.s7.e1 14 25
drug
Indomethacin
DrugDDI.d187.s7.e2 60 65
drug
sodium
DrugDDI.d187.s7.e3 118 127
drug
bumetanide

interaction DrugDDI.d187.s7.e1 DrugDDI.d187.s7.e3

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s8
Concurrent therapy with bumetanide is thus not recommended.

DrugDDI.d187.s8.e0 21 30
drug
bumetanide



Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s9
- Antihypertensives : Bumetanide may potentiate the effect of various antihypertensive drugs , necessitating a reduction in the dosage of these drugs .

DrugDDI.d187.s9.e0 1 17
drug
Antihypertensives
DrugDDI.d187.s9.e1 19 28
drug
Bumetanide
DrugDDI.d187.s9.e2 60 80
drug
antihypertensive drugs
DrugDDI.d187.s9.e3 123 127
drug
drugs

interaction DrugDDI.d187.s9.e1 DrugDDI.d187.s9.e2

Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s10
- Digoxin : Interaction studies in humans have shown no effect on digoxin blood levels.

DrugDDI.d187.s10.e0 1 7
drug
Digoxin



Abstract Id: DrugDDI.d187
Sentence Id: DrugDDI.d187.s11
- Anticoagulants : Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.

DrugDDI.d187.s11.e0 1 14
drug
Anticoagulants
DrugDDI.d187.s11.e1 51 60
drug
bumetanide
DrugDDI.d187.s11.e2 77 84
drug
warfarin



Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s0
Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4.

DrugDDI.d228.s0.e0 0 12
drug
Buprenorphine
DrugDDI.d228.s0.e1 46 55
drug
cytochrome

interaction DrugDDI.d228.s0.e0 DrugDDI.d228.s0.e1

Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s1
Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine , patients already on CYP 3A4 inhibitors such as azole antifungals (e.g.

DrugDDI.d228.s1.e0 7 9
drug
CYP
DrugDDI.d228.s1.e1 56 68
drug
buprenorphine
DrugDDI.d228.s1.e2 87 89
drug
CYP
DrugDDI.d228.s1.e3 109 124
drug
azole antifungals

interaction DrugDDI.d228.s1.e0 DrugDDI.d228.s1.e1
interaction DrugDDI.d228.s1.e1 DrugDDI.d228.s1.e3

Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s2
ketoconazole ), macrolide antibiotics (e.g. erythromycin ), and HIV protease inhibitors (e.g. ritonavir , indi-navir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted.

DrugDDI.d228.s2.e0 0 11
drug
ketoconazole
DrugDDI.d228.s2.e1 14 33
drug
macrolide antibiotics
DrugDDI.d228.s2.e2 39 50
drug
erythromycin
DrugDDI.d228.s2.e3 56 76
drug
HIV protease inhibitors
DrugDDI.d228.s2.e4 82 90
drug
ritonavir
DrugDDI.d228.s2.e5 105 114
drug
saquinavir
DrugDDI.d228.s2.e6 137 143
drug
SUBUTEX
DrugDDI.d228.s2.e7 146 153
drug
SUBOXONE



Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s3
Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines .

DrugDDI.d228.s3.e0 54 66
drug
buprenorphine
DrugDDI.d228.s3.e1 70 84
drug
benzodiazepines

interaction DrugDDI.d228.s3.e0 DrugDDI.d228.s3.e1

Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s4
There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.

DrugDDI.d228.s4.e0 119 131
drug
buprenorphine
DrugDDI.d228.s4.e1 135 149
drug
benzodiazepines

interaction DrugDDI.d228.s4.e0 DrugDDI.d228.s4.e1

Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s5
In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.

DrugDDI.d228.s5.e0 19 31
drug
buprenorphine
DrugDDI.d228.s5.e1 67 73
drug
SUBUTEX

interaction DrugDDI.d228.s5.e0 DrugDDI.d228.s5.e1

Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s6
SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.

DrugDDI.d228.s6.e0 0 6
drug
SUBUTEX
DrugDDI.d228.s6.e1 10 17
drug
SUBOXONE
DrugDDI.d228.s6.e2 59 73
drug
benzodiazepines
DrugDDI.d228.s6.e3 81 85
drug
drugs
DrugDDI.d228.s6.e4 143 147
drug
drugs
DrugDDI.d228.s6.e5 191 195
drug
drugs

interaction DrugDDI.d228.s6.e0 DrugDDI.d228.s6.e2
interaction DrugDDI.d228.s6.e1 DrugDDI.d228.s6.e3

Abstract Id: DrugDDI.d228
Sentence Id: DrugDDI.d228.s7
Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX .

DrugDDI.d228.s7.e0 79 93
drug
benzodiazepines
DrugDDI.d228.s7.e1 117 124
drug
SUBOXONE
DrugDDI.d228.s7.e2 127 133
drug
SUBUTEX

interaction DrugDDI.d228.s7.e0 DrugDDI.d228.s7.e1
interaction DrugDDI.d228.s7.e0 DrugDDI.d228.s7.e2

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s0
Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs .

DrugDDI.d170.s0.e0 49 58
drug
WELLBUTRIN
DrugDDI.d170.s0.e1 102 106
drug
drugs
DrugDDI.d170.s0.e2 162 171
drug
WELLBUTRIN
DrugDDI.d170.s0.e3 194 198
drug
drugs



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s1
Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity.

DrugDDI.d170.s1.e0 7 15
drug
bupropion
DrugDDI.d170.s1.e1 67 71
drug
drugs

interaction DrugDDI.d170.s1.e0 DrugDDI.d170.s1.e1

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s2
In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme .

DrugDDI.d170.s2.e0 26 34
drug
bupropion
DrugDDI.d170.s2.e1 59 74
drug
hydroxybupropion
DrugDDI.d170.s2.e2 80 94
drug
CYP2B6 isoenzyme

interaction DrugDDI.d170.s2.e0 DrugDDI.d170.s2.e1

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s3
Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide ).

DrugDDI.d170.s3.e0 54 63
drug
WELLBUTRIN
DrugDDI.d170.s3.e1 67 71
drug
drugs
DrugDDI.d170.s3.e2 85 99
drug
CYP2B6 isoenzyme
DrugDDI.d170.s3.e3 106 117
drug
orphenadrine
DrugDDI.d170.s3.e4 121 136
drug
cyclophosphamide

interaction DrugDDI.d170.s3.e0 DrugDDI.d170.s3.e1
interaction DrugDDI.d170.s3.e0 DrugDDI.d170.s3.e3
interaction DrugDDI.d170.s3.e0 DrugDDI.d170.s3.e4
interaction DrugDDI.d170.s3.e3 DrugDDI.d170.s3.e4

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s4
The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.

DrugDDI.d170.s4.e0 3 31
drug
threohydrobupropion metabolite
DrugDDI.d170.s4.e1 34 42
drug
bupropion
DrugDDI.d170.s4.e2 73 86
drug
cytochrome P450



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s5
The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.

DrugDDI.d170.s5.e0 39 48
drug
cimetidine
DrugDDI.d170.s5.e1 72 80
drug
bupropion
DrugDDI.d170.s5.e2 93 103
drug
metabolites

interaction DrugDDI.d170.s5.e0 DrugDDI.d170.s5.e1

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s6
Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine , the pharmacokinetics of bupropion and hydroxybupropion were unaffected.

DrugDDI.d170.s6.e0 83 92
drug
cimetidine
DrugDDI.d170.s6.e1 115 123
drug
bupropion
DrugDDI.d170.s6.e2 127 142
drug
hydroxybupropion



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s8
While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine , phenobarbital , phenytoin ).

DrugDDI.d170.s8.e0 37 41
drug
drugs
DrugDDI.d170.s8.e1 66 74
drug
bupropion
DrugDDI.d170.s8.e2 81 93
drug
carbamazepine
DrugDDI.d170.s8.e3 95 107
drug
phenobarbital
DrugDDI.d170.s8.e4 109 117
drug
phenytoin

interaction DrugDDI.d170.s8.e0 DrugDDI.d170.s8.e1
interaction DrugDDI.d170.s8.e1 DrugDDI.d170.s8.e2
interaction DrugDDI.d170.s8.e1 DrugDDI.d170.s8.e3
interaction DrugDDI.d170.s8.e1 DrugDDI.d170.s8.e4

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s9
Animal data indicated that bupropion may be an inducer of drug -metabolizing enzymes in humans.

DrugDDI.d170.s9.e0 23 31
drug
bupropion
DrugDDI.d170.s9.e1 48 51
drug
drug

interaction DrugDDI.d170.s9.e0 DrugDDI.d170.s9.e1

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s10
In one study, following chronic administration of bupropion , 100 mg 3 times daily to 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism.

DrugDDI.d170.s10.e0 43 51
drug
bupropion



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s11
Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs .

DrugDDI.d170.s11.e0 97 101
drug
drugs



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s12
Drugs Metabolized by Cytochrome P450IID6 ( CYP2D6 ): Many drugs , including most antidepressants (SSRIs, many tricyclics ), beta-blockers , antiarrhythmics , and antipsychotics are metabolized by the CYP2D6 isoenzyme .

DrugDDI.d170.s12.e0 0 4
drug
Drugs
DrugDDI.d170.s12.e1 18 27
drug
Cytochrome
DrugDDI.d170.s12.e2 37 42
drug
CYP2D6
DrugDDI.d170.s12.e3 49 53
drug
drugs
DrugDDI.d170.s12.e4 68 82
drug
antidepressants
DrugDDI.d170.s12.e5 94 103
drug
tricyclics
DrugDDI.d170.s12.e6 106 118
drug
beta-blockers
DrugDDI.d170.s12.e7 120 134
drug
antiarrhythmics
DrugDDI.d170.s12.e8 139 152
drug
antipsychotics
DrugDDI.d170.s12.e9 172 186
drug
CYP2D6 isoenzyme

interaction DrugDDI.d170.s12.e3 DrugDDI.d170.s12.e9
interaction DrugDDI.d170.s12.e5 DrugDDI.d170.s12.e9
interaction DrugDDI.d170.s12.e7 DrugDDI.d170.s12.e9

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s13
Although bupropion is not metabolized by this isoenzyme , bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.

DrugDDI.d170.s13.e0 8 16
drug
bupropion
DrugDDI.d170.s13.e1 39 47
drug
isoenzyme
DrugDDI.d170.s13.e2 49 57
drug
bupropion
DrugDDI.d170.s13.e3 61 76
drug
hydroxybupropion
DrugDDI.d170.s13.e4 95 109
drug
CYP2D6 isoenzyme

interaction DrugDDI.d170.s13.e0 DrugDDI.d170.s13.e4
interaction DrugDDI.d170.s13.e3 DrugDDI.d170.s13.e4

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s14
In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme , daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1 /2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.

DrugDDI.d170.s14.e0 74 88
drug
CYP2D6 isoenzyme
DrugDDI.d170.s14.e1 102 110
drug
bupropion
DrugDDI.d170.s14.e2 160 170
drug
desipramine
DrugDDI.d170.s14.e3 195 196
drug
t1
DrugDDI.d170.s14.e4 201 211
drug
desipramine

interaction DrugDDI.d170.s14.e1 DrugDDI.d170.s14.e2

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s15
The effect was present for at least 7 days after the last dose of bupropion .

DrugDDI.d170.s15.e0 52 60
drug
bupropion



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s16
Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.

DrugDDI.d170.s16.e0 16 24
drug
bupropion
DrugDDI.d170.s16.e1 34 38
drug
drugs
DrugDDI.d170.s16.e2 52 57
drug
CYP2D6



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s17
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e.g., haloperidol , risperidone , thioridazine ), beta-blockers (e.g., metoprolol ), and Type 1C antiarrhythmics (e.g., propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .

DrugDDI.d170.s17.e0 29 37
drug
bupropion
DrugDDI.d170.s17.e1 42 46
drug
drugs
DrugDDI.d170.s17.e2 67 81
drug
CYP2D6 isoenzyme
DrugDDI.d170.s17.e3 98 112
drug
antidepressants
DrugDDI.d170.s17.e4 119 131
drug
nortriptyline
DrugDDI.d170.s17.e5 133 142
drug
imipramine
DrugDDI.d170.s17.e6 144 154
drug
desipramine
DrugDDI.d170.s17.e7 156 165
drug
paroxetine
DrugDDI.d170.s17.e8 167 176
drug
fluoxetine
DrugDDI.d170.s17.e9 178 187
drug
sertraline
DrugDDI.d170.s17.e10 190 203
drug
antipsychotics
DrugDDI.d170.s17.e11 210 220
drug
haloperidol
DrugDDI.d170.s17.e12 222 232
drug
risperidone
DrugDDI.d170.s17.e13 234 245
drug
thioridazine
DrugDDI.d170.s17.e14 248 260
drug
beta-blockers
DrugDDI.d170.s17.e15 267 276
drug
metoprolol
DrugDDI.d170.s17.e16 288 302
drug
antiarrhythmics
DrugDDI.d170.s17.e17 309 319
drug
propafenone
DrugDDI.d170.s17.e18 321 330
drug
flecainide
DrugDDI.d170.s17.e19 425 434
drug
medication

interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e1
interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e4
interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e6
interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e8
interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e10
interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e12
interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e14
interaction DrugDDI.d170.s17.e0 DrugDDI.d170.s17.e16

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s18
If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6 , the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index.

DrugDDI.d170.s18.e0 2 10
drug
bupropion
DrugDDI.d170.s18.e1 66 69
drug
drug
DrugDDI.d170.s18.e2 83 88
drug
CYP2D6
DrugDDI.d170.s18.e3 127 136
drug
medication
DrugDDI.d170.s18.e4 187 197
drug
medications

interaction DrugDDI.d170.s18.e0 DrugDDI.d170.s18.e1

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s19
MAO Inhibitors : Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .

DrugDDI.d170.s19.e0 0 12
drug
MAO Inhibitors
DrugDDI.d170.s19.e1 63 71
drug
bupropion
DrugDDI.d170.s19.e2 87 98
drug
MAO inhibitor

interaction DrugDDI.d170.s19.e1 DrugDDI.d170.s19.e2

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s20
Levodopa and Amantadine : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine .

DrugDDI.d170.s20.e0 0 7
drug
Levodopa
DrugDDI.d170.s20.e1 11 20
drug
Amantadine
DrugDDI.d170.s20.e2 103 111
drug
bupropion
DrugDDI.d170.s20.e3 134 141
drug
levodopa
DrugDDI.d170.s20.e4 144 153
drug
amantadine

interaction DrugDDI.d170.s20.e2 DrugDDI.d170.s20.e3
interaction DrugDDI.d170.s20.e2 DrugDDI.d170.s20.e4

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s21
Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.

DrugDDI.d170.s21.e0 16 32
drug
WELLBUTRIN Tablets
DrugDDI.d170.s21.e1 58 65
drug
levodopa
DrugDDI.d170.s21.e2 68 77
drug
amantadine

interaction DrugDDI.d170.s21.e0 DrugDDI.d170.s21.e1
interaction DrugDDI.d170.s21.e0 DrugDDI.d170.s21.e2

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s22
Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics , other antidepressants , theophylline , systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.

DrugDDI.d170.s22.e0 0 4
drug
Drugs
DrugDDI.d170.s22.e1 57 66
drug
WELLBUTRIN
DrugDDI.d170.s22.e2 82 95
drug
antipsychotics
DrugDDI.d170.s22.e3 102 116
drug
antidepressants
DrugDDI.d170.s22.e4 118 129
drug
theophylline
DrugDDI.d170.s22.e5 131 138
drug
systemic

interaction DrugDDI.d170.s22.e1 DrugDDI.d170.s22.e2
interaction DrugDDI.d170.s22.e1 DrugDDI.d170.s22.e3
interaction DrugDDI.d170.s22.e1 DrugDDI.d170.s22.e4
interaction DrugDDI.d170.s22.e1 DrugDDI.d170.s22.e5

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s24
Nicotine Transdermal System: .

DrugDDI.d170.s24.e0 0 7
drug
Nicotine



Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s25
Alcohol : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN .

DrugDDI.d170.s25.e0 0 6
drug
Alcohol
DrugDDI.d170.s25.e1 132 146
drug
drinking alcohol
DrugDDI.d170.s25.e2 166 175
drug
WELLBUTRIN

interaction DrugDDI.d170.s25.e1 DrugDDI.d170.s25.e2

Abstract Id: DrugDDI.d170
Sentence Id: DrugDDI.d170.s26
The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS) .

DrugDDI.d170.s26.e0 16 22
drug
alcohol
DrugDDI.d170.s26.e1 42 51
drug
WELLBUTRIN

interaction DrugDDI.d170.s26.e0 DrugDDI.d170.s26.e1

Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s0
It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.

DrugDDI.d515.s0.e0 19 40
drug
buspirone hydrochloride
DrugDDI.d515.s0.e1 67 79
drug
MAO inhibitors
DrugDDI.d515.s0.e2 126 137
drug
buspirone HCl
DrugDDI.d515.s0.e3 151 167
drug
psychotropic drugs
DrugDDI.d515.s0.e4 206 217
drug
buspirone HCl
DrugDDI.d515.s0.e5 227 241
drug
CNS-active drugs

interaction DrugDDI.d515.s0.e0 DrugDDI.d515.s0.e1

Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s1
There is one report suggesting that the concomitant use of trazodone hydrochloride ( Desyrel ) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.

DrugDDI.d515.s1.e0 49 70
drug
trazodone hydrochloride
DrugDDI.d515.s1.e1 72 78
drug
Desyrel
DrugDDI.d515.s1.e2 83 94
drug
buspirone HCl

interaction DrugDDI.d515.s1.e0 DrugDDI.d515.s1.e2
interaction DrugDDI.d515.s1.e1 DrugDDI.d515.s1.e2

Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s2
In a similar study, attempting to replicate this finding, no interactive effect on hepatic transaminases was identified.

DrugDDI.d515.s2.e0 77 89
drug
transaminases



Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s3
In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.

DrugDDI.d515.s3.e0 54 65
drug
buspirone HCl
DrugDDI.d515.s3.e1 69 79
drug
haloperidol
DrugDDI.d515.s3.e2 104 114
drug
haloperidol

interaction DrugDDI.d515.s3.e0 DrugDDI.d515.s3.e1

Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s5
In vitro, buspirone does not displace tightly bound drugs like phenytoin , propranolol , and warfarin from serum proteins .

DrugDDI.d515.s5.e0 8 16
drug
buspirone
DrugDDI.d515.s5.e1 53 61
drug
phenytoin
DrugDDI.d515.s5.e2 63 73
drug
propranolol
DrugDDI.d515.s5.e3 78 85
drug
warfarin
DrugDDI.d515.s5.e4 90 102
drug
serum proteins



Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s6
However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin .

DrugDDI.d515.s6.e0 59 67
drug
buspirone
DrugDDI.d515.s6.e1 109 116
drug
warfarin

interaction DrugDDI.d515.s6.e0 DrugDDI.d515.s6.e1

Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s7
The patient was also chronically receiving phenytoin , phenobarbital , digoxin , and levothyroxine sodium .

DrugDDI.d515.s7.e0 37 45
drug
phenytoin
DrugDDI.d515.s7.e1 47 59
drug
phenobarbital
DrugDDI.d515.s7.e2 61 67
drug
digoxin
DrugDDI.d515.s7.e3 72 90
drug
levothyroxine sodium



Abstract Id: DrugDDI.d515
Sentence Id: DrugDDI.d515.s8
In vitro, buspirone may displace less firmly bound drugs like digoxin .

DrugDDI.d515.s8.e0 8 16
drug
buspirone
DrugDDI.d515.s8.e1 52 58
drug
digoxin

interaction DrugDDI.d515.s8.e0 DrugDDI.d515.s8.e1

Abstract Id: DrugDDI.d368
Sentence Id: DrugDDI.d368.s0
Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500 @M@min in some patients.

DrugDDI.d368.s0.e0 0 11
drug
Itraconazole
DrugDDI.d368.s0.e1 21 28
drug
busulfan

interaction DrugDDI.d368.s0.e0 DrugDDI.d368.s0.e1

Abstract Id: DrugDDI.d368
Sentence Id: DrugDDI.d368.s1
Fluconazole , and the 5-HT3 antiemetics odansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX .

DrugDDI.d368.s1.e0 0 10
drug
Fluconazole
DrugDDI.d368.s1.e1 23 33
drug
antiemetics
DrugDDI.d368.s1.e2 45 50
drug
Zofran
DrugDDI.d368.s1.e3 55 65
drug
granisetron
DrugDDI.d368.s1.e4 67 72
drug
Kytril
DrugDDI.d368.s1.e5 93 100
drug
BUSULFEX



Abstract Id: DrugDDI.d368
Sentence Id: DrugDDI.d368.s2
Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase .

DrugDDI.d368.s2.e0 0 8
drug
Phenytoin
DrugDDI.d368.s2.e1 32 39
drug
busulfan
DrugDDI.d368.s2.e2 79 103
drug
glutathione-S-transferase

interaction DrugDDI.d368.s2.e0 DrugDDI.d368.s2.e1

Abstract Id: DrugDDI.d368
Sentence Id: DrugDDI.d368.s3
Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin , the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin .

DrugDDI.d368.s3.e0 26 33
drug
BUSULFEX
DrugDDI.d368.s3.e1 66 74
drug
phenytoin
DrugDDI.d368.s3.e2 90 97
drug
BUSULFEX
DrugDDI.d368.s3.e3 174 182
drug
phenytoin

interaction DrugDDI.d368.s3.e0 DrugDDI.d368.s3.e1

Abstract Id: DrugDDI.d368
Sentence Id: DrugDDI.d368.s4
Because busulfan is eliminated from the body via conjugation with glutathione , use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.

DrugDDI.d368.s4.e0 7 14
drug
busulfan
DrugDDI.d368.s4.e1 56 66
drug
glutathione
DrugDDI.d368.s4.e2 73 85
drug
acetaminophen
DrugDDI.d368.s4.e3 118 125
drug
BUSULFEX
DrugDDI.d368.s4.e4 144 151
drug
busulfan
DrugDDI.d368.s4.e5 188 200
drug
acetaminophen
DrugDDI.d368.s4.e6 211 221
drug
glutathione

interaction DrugDDI.d368.s4.e0 DrugDDI.d368.s4.e2
interaction DrugDDI.d368.s4.e0 DrugDDI.d368.s4.e3

Abstract Id: DrugDDI.d440
Sentence Id: DrugDDI.d440.s0
Interactions may occur with the following: adrenocorticoids ( cortisone -like medicine ), anticoagulants ( blood thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines ), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control ).

DrugDDI.d440.s0.e0 54 62
drug
cortisone
DrugDDI.d440.s0.e1 68 75
drug
medicine
DrugDDI.d440.s0.e2 78 91
drug
anticoagulants
DrugDDI.d440.s0.e3 93 104
drug
blood thinner
DrugDDI.d440.s0.e4 108 120
drug
carbamazepine
DrugDDI.d440.s0.e5 122 134
drug
corticotropin
DrugDDI.d440.s0.e6 136 147
drug
barbiturates
DrugDDI.d440.s0.e7 176 184
drug
medicines
DrugDDI.d440.s0.e8 234 242
drug
medicines
DrugDDI.d440.s0.e9 247 258
drug
barbiturates
DrugDDI.d440.s0.e10 279 291
drug
CNS depressant
DrugDDI.d440.s0.e11 301 316
drug
divalproex sodium
DrugDDI.d440.s0.e12 318 329
drug
valproic acid
DrugDDI.d440.s0.e13 341 349
drug
medicines
DrugDDI.d440.s0.e14 354 365
drug
barbiturates
DrugDDI.d440.s0.e15 392 399
drug
medicine
DrugDDI.d440.s0.e16 422 439
drug
oral contraceptives
DrugDDI.d440.s0.e17 450 458
drug
estrogens
DrugDDI.d440.s0.e18 460 471
drug
barbiturates
DrugDDI.d440.s0.e19 506 523
drug
oral contraceptives
DrugDDI.d440.s0.e20 564 575
drug
birth control

interaction DrugDDI.d440.s0.e4 DrugDDI.d440.s0.e6
interaction DrugDDI.d440.s0.e5 DrugDDI.d440.s0.e6
interaction DrugDDI.d440.s0.e9 DrugDDI.d440.s0.e10
interaction DrugDDI.d440.s0.e11 DrugDDI.d440.s0.e14
interaction DrugDDI.d440.s0.e12 DrugDDI.d440.s0.e14
interaction DrugDDI.d440.s0.e16 DrugDDI.d440.s0.e18

Abstract Id: DrugDDI.d243
Sentence Id: DrugDDI.d243.s0
Potential drug interactions between Mentax@ ( butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.

DrugDDI.d243.s0.e0 40 52
drug
butenafine HCl
DrugDDI.d243.s0.e1 76 80
drug
drugs



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s0
Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central nervous system depressant effects.

DrugDDI.d219.s0.e0 15 25
drug
butorphanol
DrugDDI.d219.s0.e1 30 60
drug
central nervous system depressants
DrugDDI.d219.s0.e2 67 73
drug
alcohol
DrugDDI.d219.s0.e3 75 86
drug
barbiturates
DrugDDI.d219.s0.e4 88 100
drug
tranquilizers
DrugDDI.d219.s0.e5 105 118
drug
antihistamines
DrugDDI.d219.s0.e6 140 169
drug
central nervous system depressant

interaction DrugDDI.d219.s0.e0 DrugDDI.d219.s0.e1
interaction DrugDDI.d219.s0.e0 DrugDDI.d219.s0.e2
interaction DrugDDI.d219.s0.e0 DrugDDI.d219.s0.e3
interaction DrugDDI.d219.s0.e0 DrugDDI.d219.s0.e4
interaction DrugDDI.d219.s0.e0 DrugDDI.d219.s0.e5

Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s1
When used concurrently with such drugs , the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids .

DrugDDI.d219.s1.e0 28 32
drug
drugs
DrugDDI.d219.s1.e1 43 53
drug
butorphanol
DrugDDI.d219.s1.e2 165 169
drug
drugs
DrugDDI.d219.s1.e3 195 201
drug
opioids

interaction DrugDDI.d219.s1.e1 DrugDDI.d219.s1.e3

Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s2
In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan .

DrugDDI.d219.s2.e0 52 62
drug
butorphanol
DrugDDI.d219.s2.e1 77 84
drug
STADOL NS
DrugDDI.d219.s2.e2 152 162
drug
sumatriptan



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s3
However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray .

DrugDDI.d219.s3.e0 63 73
drug
butorphanol
DrugDDI.d219.s3.e1 151 158
drug
STADOL NS
DrugDDI.d219.s3.e2 198 218
drug
sumatriptan nasal spray

interaction DrugDDI.d219.s3.e1 DrugDDI.d219.s3.e2

Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s4
(The two drugs were administered in opposite nostrils.) .

DrugDDI.d219.s4.e0 7 11
drug
drugs



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s5
When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray , the AUC of butorphanol increased 11% and Cmax decreased 18%.

DrugDDI.d219.s5.e0 7 14
drug
STADOL NS
DrugDDI.d219.s5.e1 47 67
drug
sumatriptan nasal spray
DrugDDI.d219.s5.e2 77 87
drug
butorphanol

interaction DrugDDI.d219.s5.e0 DrugDDI.d219.s5.e1

Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s6
In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL NS .

DrugDDI.d219.s6.e0 38 48
drug
sumatriptan
DrugDDI.d219.s6.e1 79 86
drug
STADOL NS



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s7
These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray , but by 30 minutes any such reduction in effect should be minimal.

DrugDDI.d219.s7.e0 43 50
drug
STADOL NS
DrugDDI.d219.s7.e1 98 118
drug
sumatriptan nasal spray

interaction DrugDDI.d219.s7.e0 DrugDDI.d219.s7.e1

Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s8
The safety of using STADOL NS and IMITREX@ ( sumatriptan ) Nasal Spray during the same episode of migraine has not been established.

DrugDDI.d219.s8.e0 16 23
drug
STADOL NS
DrugDDI.d219.s8.e1 36 46
drug
sumatriptan



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s10
The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).

DrugDDI.d219.s10.e0 32 42
drug
butorphanol
DrugDDI.d219.s10.e1 57 64
drug
STADOL NS
DrugDDI.d219.s10.e2 103 112
drug
cimetidine



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s11
Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine .

DrugDDI.d219.s11.e0 30 37
drug
STADOL NS
DrugDDI.d219.s11.e1 42 52
drug
butorphanol
DrugDDI.d219.s11.e2 102 111
drug
cimetidine



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s12
It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs ( erythromycin , etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.

DrugDDI.d219.s12.e0 26 36
drug
butorphanol
DrugDDI.d219.s12.e1 60 70
drug
medications
DrugDDI.d219.s12.e2 100 104
drug
drugs
DrugDDI.d219.s12.e3 106 117
drug
erythromycin

interaction DrugDDI.d219.s12.e0 DrugDDI.d219.s12.e1

Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s13
The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor ( oxymetazoline ), but the rate of absorption is decreased.

DrugDDI.d219.s13.e0 13 20
drug
STADOL NS
DrugDDI.d219.s13.e1 74 93
drug
nasal vasoconstrictor
DrugDDI.d219.s13.e2 95 107
drug
oxymetazoline



Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s14
Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor .

DrugDDI.d219.s14.e0 40 47
drug
STADOL NS
DrugDDI.d219.s14.e1 104 123
drug
nasal vasoconstrictor

interaction DrugDDI.d219.s14.e0 DrugDDI.d219.s14.e1

Abstract Id: DrugDDI.d219
Sentence Id: DrugDDI.d219.s15
No information is available about the use of butorphanol concurrently with MAO inhibitors .

DrugDDI.d219.s15.e0 37 47
drug
butorphanol
DrugDDI.d219.s15.e1 64 76
drug
MAO inhibitors



Abstract Id: DrugDDI.d251
Sentence Id: DrugDDI.d251.s0
Cytochrome P450 1A2 ( CYP1A2 ) is known to be the major enzyme involved in the metabolism of caffeine .

DrugDDI.d251.s0.e0 0 16
drug
Cytochrome P450 1A2
DrugDDI.d251.s0.e1 18 23
drug
CYP1A2
DrugDDI.d251.s0.e2 75 82
drug
caffeine

interaction DrugDDI.d251.s0.e0 DrugDDI.d251.s0.e2

Abstract Id: DrugDDI.d251
Sentence Id: DrugDDI.d251.s1
Therefore, caffeine has the potential to interact with drugs that are substrates for CYP1A2 , inhibit CYP1A2 , or induce CYP1A2 .

DrugDDI.d251.s1.e0 10 17
drug
caffeine
DrugDDI.d251.s1.e1 47 51
drug
drugs
DrugDDI.d251.s1.e2 72 77
drug
CYP1A2
DrugDDI.d251.s1.e3 86 91
drug
CYP1A2
DrugDDI.d251.s1.e4 101 106
drug
CYP1A2

interaction DrugDDI.d251.s1.e0 DrugDDI.d251.s1.e1
interaction DrugDDI.d251.s1.e0 DrugDDI.d251.s1.e4

Abstract Id: DrugDDI.d251
Sentence Id: DrugDDI.d251.s2
Few data exist on drug interactions with caffeine in preterm neonates.

DrugDDI.d251.s2.e0 34 41
drug
caffeine



Abstract Id: DrugDDI.d251
Sentence Id: DrugDDI.d251.s3
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin ).

DrugDDI.d251.s3.e0 29 36
drug
caffeine
DrugDDI.d251.s3.e1 75 79
drug
drugs
DrugDDI.d251.s3.e2 106 113
drug
caffeine
DrugDDI.d251.s3.e3 131 140
drug
cimetidine
DrugDDI.d251.s3.e4 144 155
drug
ketoconazole
DrugDDI.d251.s3.e5 166 173
drug
caffeine
DrugDDI.d251.s3.e6 217 221
drug
drugs
DrugDDI.d251.s3.e7 234 241
drug
caffeine
DrugDDI.d251.s3.e8 259 271
drug
phenobarbital
DrugDDI.d251.s3.e9 275 283
drug
phenytoin

interaction DrugDDI.d251.s3.e0 DrugDDI.d251.s3.e1
interaction DrugDDI.d251.s3.e0 DrugDDI.d251.s3.e3
interaction DrugDDI.d251.s3.e0 DrugDDI.d251.s3.e4
interaction DrugDDI.d251.s3.e5 DrugDDI.d251.s3.e6
interaction DrugDDI.d251.s3.e5 DrugDDI.d251.s3.e8
interaction DrugDDI.d251.s3.e5 DrugDDI.d251.s3.e9

Abstract Id: DrugDDI.d251
Sentence Id: DrugDDI.d251.s4
Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.

DrugDDI.d251.s4.e0 0 7
drug
Caffeine
DrugDDI.d251.s4.e1 36 45
drug
ketoprofen

interaction DrugDDI.d251.s4.e0 DrugDDI.d251.s4.e1

Abstract Id: DrugDDI.d251
Sentence Id: DrugDDI.d251.s6
Interconversion between caffeine and theophylline has been reported in preterm neonates.

DrugDDI.d251.s6.e0 22 29
drug
caffeine
DrugDDI.d251.s6.e1 33 44
drug
theophylline



Abstract Id: DrugDDI.d251
Sentence Id: DrugDDI.d251.s7
The concurrent use of these drugs is not recommended.

DrugDDI.d251.s7.e0 23 27
drug
drugs



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s0
Interactions for vitamin D analogues ( Vitamin D2 , Vitamin D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; .

DrugDDI.d496.s0.e0 33 41
drug
Vitamin D2
DrugDDI.d496.s0.e1 43 51
drug
Vitamin D3
DrugDDI.d496.s0.e2 53 62
drug
Calcitriol
DrugDDI.d496.s0.e3 67 75
drug
Calcidiol
DrugDDI.d496.s0.e4 78 91
drug
Cholestyramine
DrugDDI.d496.s0.e5 93 106
drug
Cholestyramine



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s1
as such it may impair intestinal absorption of any of vitamin D .

DrugDDI.d496.s1.e0 44 51
drug
vitamin D



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s2
Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism.

DrugDDI.d496.s2.e0 0 8
drug
Phenytoin
DrugDDI.d496.s2.e1 10 22
drug
Phenobarbital
DrugDDI.d496.s2.e2 45 53
drug
phenytoin
DrugDDI.d496.s2.e3 56 68
drug
phenobarbital
DrugDDI.d496.s2.e4 104 111
drug
vitamin D
DrugDDI.d496.s2.e5 149 158
drug
calcitriol

interaction DrugDDI.d496.s2.e2 DrugDDI.d496.s2.e5
interaction DrugDDI.d496.s2.e3 DrugDDI.d496.s2.e5

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s3
Since blood level of calcitriol /ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.

DrugDDI.d496.s3.e0 17 26
drug
calcitriol
DrugDDI.d496.s3.e1 69 77
drug
Rocaltrol
DrugDDI.d496.s3.e2 99 103
drug
drugs

interaction DrugDDI.d496.s3.e0 DrugDDI.d496.s3.e1

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s4
Thiazides : Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.

DrugDDI.d496.s4.e0 0 8
drug
Thiazides
DrugDDI.d496.s4.e1 10 18
drug
Thiazides
DrugDDI.d496.s4.e2 64 70
drug
calcium



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s5
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.

DrugDDI.d496.s5.e0 54 62
drug
thiazides
DrugDDI.d496.s5.e1 67 74
drug
vitamin D

interaction DrugDDI.d496.s5.e0 DrugDDI.d496.s5.e1

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s7
Digitalis : Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis , as hypercalcemia in such patients may precipitate cardiac arrhythmias.

DrugDDI.d496.s7.e0 0 8
drug
Digitalis
DrugDDI.d496.s7.e1 10 17
drug
Vitamin D
DrugDDI.d496.s7.e2 81 89
drug
digitalis

interaction DrugDDI.d496.s7.e1 DrugDDI.d496.s7.e2

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s8
Ketoconazole : Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D .

DrugDDI.d496.s8.e0 0 11
drug
Ketoconazole
DrugDDI.d496.s8.e1 13 24
drug
Ketoconazole
DrugDDI.d496.s8.e2 69 76
drug
vitamin D

interaction DrugDDI.d496.s8.e1 DrugDDI.d496.s8.e2

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s9
Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.

DrugDDI.d496.s9.e0 114 125
drug
ketoconazole



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s10
However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.

DrugDDI.d496.s10.e0 38 49
drug
ketoconazole
DrugDDI.d496.s10.e1 54 61
drug
vitamin D



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s11
Corticosteroids : A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids , which inhibit calcium absorption.

DrugDDI.d496.s11.e0 0 14
drug
Corticosteroids
DrugDDI.d496.s11.e1 94 100
drug
calcium
DrugDDI.d496.s11.e2 115 129
drug
corticosteroids
DrugDDI.d496.s11.e3 143 149
drug
calcium



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s12
Phosphate-Binding Agents : Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.

DrugDDI.d496.s12.e0 0 22
drug
Phosphate-Binding Agents
DrugDDI.d496.s12.e1 29 36
drug
vitamin D
DrugDDI.d496.s12.e2 114 136
drug
phosphate-binding agents

interaction DrugDDI.d496.s12.e1 DrugDDI.d496.s12.e2

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s13
Vitamin D : The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.

DrugDDI.d496.s13.e0 0 7
drug
Vitamin D



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s14
Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.

DrugDDI.d496.s14.e0 0 6
drug
Calcium
DrugDDI.d496.s14.e1 49 78
drug
calcium-containing preparations



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s15
Magnesium : Magnesium-containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.

DrugDDI.d496.s15.e0 0 8
drug
Magnesium
DrugDDI.d496.s15.e1 10 41
drug
Magnesium-containing preparations
DrugDDI.d496.s15.e2 46 53
drug
antacids
DrugDDI.d496.s15.e3 123 130
drug
vitamin D

interaction DrugDDI.d496.s15.e1 DrugDDI.d496.s15.e3

Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s0
Interactions for vitamin D analogues ( Vitamin D2 , Vitamin D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; .

DrugDDI.d436.s0.e0 33 41
drug
Vitamin D2
DrugDDI.d436.s0.e1 43 51
drug
Vitamin D3
DrugDDI.d436.s0.e2 53 62
drug
Calcitriol
DrugDDI.d436.s0.e3 67 75
drug
Calcidiol
DrugDDI.d436.s0.e4 78 91
drug
Cholestyramine
DrugDDI.d436.s0.e5 93 106
drug
Cholestyramine



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s1
as such it may impair intestinal absorption of any of vitamin D .

DrugDDI.d436.s1.e0 44 51
drug
vitamin D



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s2
Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism.

DrugDDI.d436.s2.e0 0 8
drug
Phenytoin
DrugDDI.d436.s2.e1 10 22
drug
Phenobarbital
DrugDDI.d436.s2.e2 45 53
drug
phenytoin
DrugDDI.d436.s2.e3 56 68
drug
phenobarbital
DrugDDI.d436.s2.e4 104 111
drug
vitamin D
DrugDDI.d436.s2.e5 149 158
drug
calcitriol

interaction DrugDDI.d436.s2.e2 DrugDDI.d436.s2.e5
interaction DrugDDI.d436.s2.e3 DrugDDI.d436.s2.e5

Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s3
Since blood level of calcitriol /ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.

DrugDDI.d436.s3.e0 17 26
drug
calcitriol
DrugDDI.d436.s3.e1 69 77
drug
Rocaltrol
DrugDDI.d436.s3.e2 99 103
drug
drugs

interaction DrugDDI.d436.s3.e0 DrugDDI.d436.s3.e1

Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s4
Thiazides : Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.

DrugDDI.d436.s4.e0 0 8
drug
Thiazides
DrugDDI.d436.s4.e1 10 18
drug
Thiazides
DrugDDI.d436.s4.e2 64 70
drug
calcium



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s5
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.

DrugDDI.d436.s5.e0 54 62
drug
thiazides
DrugDDI.d436.s5.e1 67 74
drug
vitamin D

interaction DrugDDI.d436.s5.e0 DrugDDI.d436.s5.e1

Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s7
Digitalis : Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis , as hypercalcemia in such patients may precipitate cardiac arrhythmias.

DrugDDI.d436.s7.e0 0 8
drug
Digitalis
DrugDDI.d436.s7.e1 10 17
drug
Vitamin D
DrugDDI.d436.s7.e2 81 89
drug
digitalis

interaction DrugDDI.d436.s7.e1 DrugDDI.d436.s7.e2

Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s8
Ketoconazole : Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D .

DrugDDI.d436.s8.e0 0 11
drug
Ketoconazole
DrugDDI.d436.s8.e1 13 24
drug
Ketoconazole
DrugDDI.d436.s8.e2 69 76
drug
vitamin D

interaction DrugDDI.d436.s8.e1 DrugDDI.d436.s8.e2

Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s9
Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.

DrugDDI.d436.s9.e0 114 125
drug
ketoconazole



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s10
However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.

DrugDDI.d436.s10.e0 38 49
drug
ketoconazole
DrugDDI.d436.s10.e1 54 61
drug
vitamin D



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s11
Corticosteroids : A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids , which inhibit calcium absorption.

DrugDDI.d436.s11.e0 0 14
drug
Corticosteroids
DrugDDI.d436.s11.e1 94 100
drug
calcium
DrugDDI.d436.s11.e2 115 129
drug
corticosteroids
DrugDDI.d436.s11.e3 143 149
drug
calcium



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s12
Phosphate-Binding Agents : Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.

DrugDDI.d436.s12.e0 0 22
drug
Phosphate-Binding Agents
DrugDDI.d436.s12.e1 29 36
drug
vitamin D
DrugDDI.d436.s12.e2 114 136
drug
phosphate-binding agents

interaction DrugDDI.d436.s12.e1 DrugDDI.d436.s12.e2

Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s13
Vitamin D : The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.

DrugDDI.d436.s13.e0 0 7
drug
Vitamin D



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s14
Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.

DrugDDI.d436.s14.e0 0 6
drug
Calcium
DrugDDI.d436.s14.e1 49 78
drug
calcium-containing preparations



Abstract Id: DrugDDI.d436
Sentence Id: DrugDDI.d436.s15
Magnesium : Magnesium-containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.

DrugDDI.d436.s15.e0 0 8
drug
Magnesium
DrugDDI.d436.s15.e1 10 41
drug
Magnesium-containing preparations
DrugDDI.d436.s15.e2 46 53
drug
antacids
DrugDDI.d436.s15.e3 123 130
drug
vitamin D

interaction DrugDDI.d436.s15.e1 DrugDDI.d436.s15.e3

Abstract Id: DrugDDI.d247
Sentence Id: DrugDDI.d247.s0
Concomitant use with other calcium -containing medicines (including antacids ) may cause too much calcium in the blood or urine, which may increase the chance of side effects.

DrugDDI.d247.s0.e0 23 29
drug
calcium
DrugDDI.d247.s0.e1 60 67
drug
antacids
DrugDDI.d247.s0.e2 84 90
drug
calcium



Abstract Id: DrugDDI.d247
Sentence Id: DrugDDI.d247.s1
Using calcium acetate with digitalis glycosides ( heart medicine ) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.

DrugDDI.d247.s1.e0 5 18
drug
calcium acetate
DrugDDI.d247.s1.e1 23 41
drug
digitalis glycosides
DrugDDI.d247.s1.e2 43 55
drug
heart medicine
DrugDDI.d247.s1.e3 86 92
drug
calcium

interaction DrugDDI.d247.s1.e0 DrugDDI.d247.s1.e1
interaction DrugDDI.d247.s1.e0 DrugDDI.d247.s1.e2

Abstract Id: DrugDDI.d326
Sentence Id: DrugDDI.d326.s0
May interact with cefamandole naftate , cephalothin sodium , magnesium sulfate , prednisolone sodium succi@nate, and prochlorperazine edisylate .

DrugDDI.d326.s0.e0 15 32
drug
cefamandole naftate
DrugDDI.d326.s0.e1 34 50
drug
cephalothin sodium
DrugDDI.d326.s0.e2 52 67
drug
magnesium sulfate
DrugDDI.d326.s0.e3 69 80
drug
prednisolone
DrugDDI.d326.s0.e4 101 125
drug
prochlorperazine edisylate



Abstract Id: DrugDDI.d50
Sentence Id: DrugDDI.d50.s0
Antacid The effect of an aluminum hydroxide - and magnesium hydroxide-containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.

DrugDDI.d50.s0.e0 20 36
drug
aluminum hydroxide
DrugDDI.d50.s0.e1 41 76
drug
magnesium hydroxide-containing antacid
DrugDDI.d50.s0.e2 78 83
drug
Maalox
DrugDDI.d50.s0.e3 109 120
drug
capecitabine



Abstract Id: DrugDDI.d50
Sentence Id: DrugDDI.d50.s1
There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR); .

DrugDDI.d50.s1.e0 46 57
drug
capecitabine
DrugDDI.d50.s1.e1 64 73
drug
metabolite



Abstract Id: DrugDDI.d50
Sentence Id: DrugDDI.d50.s2
there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL ).

DrugDDI.d50.s2.e0 27 37
drug
metabolites
DrugDDI.d50.s2.e1 46 49
drug
5-FU
DrugDDI.d50.s2.e2 53 56
drug
FBAL



Abstract Id: DrugDDI.d50
Sentence Id: DrugDDI.d50.s3
Coumarin Anticoagulant s Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon .

DrugDDI.d50.s3.e0 0 20
drug
Coumarin Anticoagulant
DrugDDI.d50.s3.e1 96 107
drug
capecitabine
DrugDDI.d50.s3.e2 125 157
drug
coumarin-derivative anticoagulants
DrugDDI.d50.s3.e3 164 171
drug
warfarin
DrugDDI.d50.s3.e4 175 187
drug
phenprocoumon

interaction DrugDDI.d50.s3.e1 DrugDDI.d50.s3.e2
interaction DrugDDI.d50.s3.e1 DrugDDI.d50.s3.e4

Abstract Id: DrugDDI.d50
Sentence Id: DrugDDI.d50.s4
Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).

DrugDDI.d50.s4.e0 14 46
drug
coumarin-derivative anticoagulants
DrugDDI.d50.s4.e1 64 75
drug
capecitabine

interaction DrugDDI.d50.s4.e0 DrugDDI.d50.s4.e1

Abstract Id: DrugDDI.d50
Sentence Id: DrugDDI.d50.s5
Leucovorin The concentration of 5- fluorouracil is increased and its toxicity may be enhanced by leucovorin .

DrugDDI.d50.s5.e0 0 9
drug
Leucovorin
DrugDDI.d50.s5.e1 30 41
drug
fluorouracil
DrugDDI.d50.s5.e2 82 91
drug
leucovorin

interaction DrugDDI.d50.s5.e1 DrugDDI.d50.s5.e2

Abstract Id: DrugDDI.d50
Sentence Id: DrugDDI.d50.s6
Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil .

DrugDDI.d50.s6.e0 101 110
drug
leucovorin
DrugDDI.d50.s6.e1 114 125
drug
fluorouracil

interaction DrugDDI.d50.s6.e0 DrugDDI.d50.s6.e1

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s0
Hypotension @ Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril .

DrugDDI.d8.s0.e0 48 56
drug
diuretics
DrugDDI.d8.s0.e1 146 149
drug
salt
DrugDDI.d8.s0.e2 288 296
drug
captopril

interaction DrugDDI.d8.s0.e0 DrugDDI.d8.s0.e2

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s1
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril ( captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).

DrugDDI.d8.s1.e0 38 46
drug
captopril
DrugDDI.d8.s1.e1 85 92
drug
diuretic
DrugDDI.d8.s1.e2 170 178
drug
captopril
DrugDDI.d8.s1.e3 180 188
drug
captopril

interaction DrugDDI.d8.s1.e0 DrugDDI.d8.s1.e1

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s3
If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline .

DrugDDI.d8.s3.e0 107 118
drug
normal saline



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s5
Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available; .

DrugDDI.d8.s5.e0 12 22
drug
Vasodilator
DrugDDI.d8.s5.e1 70 81
drug
vasodilators
DrugDDI.d8.s5.e2 101 109
drug
captopril



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s6
therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril .

DrugDDI.d8.s6.e0 10 22
drug
nitroglycerin
DrugDDI.d8.s6.e1 30 37
drug
nitrates
DrugDDI.d8.s6.e2 74 78
drug
drugs
DrugDDI.d8.s6.e3 85 95
drug
vasodilator
DrugDDI.d8.s6.e4 150 158
drug
captopril

interaction DrugDDI.d8.s6.e0 DrugDDI.d8.s6.e4
interaction DrugDDI.d8.s6.e2 DrugDDI.d8.s6.e4

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s7
If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage.

DrugDDI.d8.s7.e0 15 23
drug
captopril



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s8
Agents Causing Renin Release Captopril@ s effect will be augmented by antihypertensive agents that cause renin release.

DrugDDI.d8.s8.e0 35 41
drug
s effect
DrugDDI.d8.s8.e1 59 80
drug
antihypertensive agents
DrugDDI.d8.s8.e2 90 94
drug
renin



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s9
For example, diuretics (e.g., thiazides ) may activate the renin-angiotensin-aldosterone system.

DrugDDI.d8.s9.e0 11 19
drug
diuretics
DrugDDI.d8.s9.e1 26 34
drug
thiazides



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s10
Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics .

DrugDDI.d8.s10.e0 129 137
drug
captopril
DrugDDI.d8.s10.e1 149 157
drug
diuretics

interaction DrugDDI.d8.s10.e0 DrugDDI.d8.s10.e1

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s11
Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents ) should be used with caution.

DrugDDI.d8.s11.e0 50 73
drug
ganglionic blocking agents
DrugDDI.d8.s11.e1 76 105
drug
adrenergic neuron blocking agents



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s12
Beta- adrenergic blocking drugs add some further antihypertensive effect to captopril , but the overall response is less than additive.

DrugDDI.d8.s12.e0 5 27
drug
adrenergic blocking drugs
DrugDDI.d8.s12.e1 42 57
drug
antihypertensive
DrugDDI.d8.s12.e2 66 74
drug
captopril

interaction DrugDDI.d8.s12.e0 DrugDDI.d8.s12.e2

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s13
Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.

DrugDDI.d8.s13.e0 35 43
drug
captopril
DrugDDI.d8.s13.e1 53 63
drug
aldosterone

interaction DrugDDI.d8.s13.e0 DrugDDI.d8.s13.e1

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s14
Potassium-sparing diuretics such as spironolactone , triamterene , or amiloride , or potassium supplement s should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.

DrugDDI.d8.s14.e0 0 25
drug
Potassium-sparing diuretics
DrugDDI.d8.s14.e1 32 45
drug
spironolactone
DrugDDI.d8.s14.e2 47 57
drug
triamterene
DrugDDI.d8.s14.e3 61 69
drug
amiloride
DrugDDI.d8.s14.e4 73 91
drug
potassium supplement



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s15
Salt substitutes containing potassium should also be used with caution.

DrugDDI.d8.s15.e0 0 3
drug
Salt
DrugDDI.d8.s15.e1 25 33
drug
potassium



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s16
Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril , especially in cases of low renin hypertension.

DrugDDI.d8.s16.e0 22 34
drug
Prostaglandin
DrugDDI.d8.s16.e1 65 76
drug
indomethacin
DrugDDI.d8.s16.e2 89 104
drug
antihypertensive
DrugDDI.d8.s16.e3 113 121
drug
captopril

interaction DrugDDI.d8.s16.e1 DrugDDI.d8.s16.e3

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s17
Other nonsteroidal anti-inflammatory agents (e.g., aspirin ) may also have this effect.

DrugDDI.d8.s17.e0 5 39
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d8.s17.e1 46 52
drug
aspirin



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s18
Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.

DrugDDI.d8.s18.e0 0 6
drug
Lithium
DrugDDI.d8.s18.e1 108 114
drug
lithium
DrugDDI.d8.s18.e2 118 129
drug
ACE inhibitor

interaction DrugDDI.d8.s18.e1 DrugDDI.d8.s18.e2

Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s19
These drugs should be coad-ministered with caution and frequent monitoring of serum lithium levels is recommended.

DrugDDI.d8.s19.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s20
If a diuretic is also used, it may increase the risk of lithium toxicity.

DrugDDI.d8.s20.e0 3 10
drug
diuretic



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s21
Cardiac Glycosides In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril -digoxin interaction could be found.

DrugDDI.d8.s21.e0 0 16
drug
Cardiac Glycosides
DrugDDI.d8.s21.e1 85 93
drug
captopril



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s22
Loop Diuretics : Furosemide administered concurrently with cap-topril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.

DrugDDI.d8.s22.e0 0 12
drug
Loop Diuretics
DrugDDI.d8.s22.e1 14 23
drug
Furosemide
DrugDDI.d8.s22.e2 95 103
drug
captopril



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s23
Allopurinol In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allop-urinol were administered concomitantly for 6 days.

DrugDDI.d8.s23.e0 0 10
drug
Allopurinol
DrugDDI.d8.s23.e1 93 101
drug
captopril



Abstract Id: DrugDDI.d8
Sentence Id: DrugDDI.d8.s24
Drug /Laboratory Test Interaction Captopril may cause a false-positive urine test for acetone .

DrugDDI.d8.s24.e0 0 3
drug
Drug
DrugDDI.d8.s24.e1 30 38
drug
Captopril
DrugDDI.d8.s24.e2 74 80
drug
acetone

interaction DrugDDI.d8.s24.e1 DrugDDI.d8.s24.e2

Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s0
Clinically meaningful drug interactions have occurred with concomitant medications and include, but are not limited to the following: Agents Highly Bound to Plasma Protein Carbamazepine is not highly bound to plasma proteins ; .

DrugDDI.d366.s0.e0 63 73
drug
medications
DrugDDI.d366.s0.e1 135 147
drug
Plasma Protein
DrugDDI.d366.s0.e2 179 192
drug
plasma proteins



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s1
therefore, administration of EQUETROTM to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug .

DrugDDI.d366.s1.e0 26 34
drug
EQUETROTM
DrugDDI.d366.s1.e1 58 61
drug
drug
DrugDDI.d366.s1.e2 74 80
drug
protein
DrugDDI.d366.s1.e3 137 140
drug
drug



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s2
Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase Carbamazepine is metabolized mainly by cytochrome P450 ( CYP ) 3A4 to the active carbamazepine 10 ,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase .

DrugDDI.d366.s2.e0 17 30
drug
Cytochrome P450
DrugDDI.d366.s2.e1 47 62
drug
Epoxide Hydrolase
DrugDDI.d366.s2.e2 97 110
drug
cytochrome P450
DrugDDI.d366.s2.e3 112 114
drug
CYP
DrugDDI.d366.s2.e4 130 144
drug
carbamazepine 10
DrugDDI.d366.s2.e5 199 214
drug
epoxide hydrolase



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s3
Therefore, the potential exists for interaction between carbamazepine and any agent that inhibits CYP3A4 and/or epoxide hydrolase .

DrugDDI.d366.s3.e0 49 61
drug
carbamazepine
DrugDDI.d366.s3.e1 85 90
drug
CYP3A4
DrugDDI.d366.s3.e2 97 112
drug
epoxide hydrolase

interaction DrugDDI.d366.s3.e0 DrugDDI.d366.s3.e1

Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s4
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton .

DrugDDI.d366.s4.e0 13 18
drug
CYP3A4
DrugDDI.d366.s4.e1 85 93
drug
EQUETROTM
DrugDDI.d366.s4.e2 110 122
drug
Acetazolamide
DrugDDI.d366.s4.e3 124 139
drug
azole antifungals
DrugDDI.d366.s4.e4 141 150
drug
cimetidine
DrugDDI.d366.s4.e5 152 165
drug
clarithromycin
DrugDDI.d366.s4.e6 170 181
drug
dalfopristin
DrugDDI.d366.s4.e7 183 189
drug
danazol
DrugDDI.d366.s4.e8 191 201
drug
delavirdine
DrugDDI.d366.s4.e9 203 211
drug
diltiazem
DrugDDI.d366.s4.e10 213 224
drug
erythromycin
DrugDDI.d366.s4.e11 229 238
drug
fluoxetine
DrugDDI.d366.s4.e12 240 250
drug
fluvoxamine
DrugDDI.d366.s4.e13 268 276
drug
isoniazid
DrugDDI.d366.s4.e14 278 289
drug
itraconazole
DrugDDI.d366.s4.e15 291 302
drug
ketoconazole
DrugDDI.d366.s4.e16 304 313
drug
loratadine
DrugDDI.d366.s4.e17 315 324
drug
nefazodone
DrugDDI.d366.s4.e18 326 336
drug
niacinamide
DrugDDI.d366.s4.e19 338 349
drug
nicotinamide
DrugDDI.d366.s4.e20 351 368
drug
protease inhibitors
DrugDDI.d366.s4.e21 370 381
drug
propoxyphene
DrugDDI.d366.s4.e22 383 389
drug
quinine
DrugDDI.d366.s4.e23 391 402
drug
quinupristin
DrugDDI.d366.s4.e24 404 417
drug
troleandomycin
DrugDDI.d366.s4.e25 419 427
drug
valproate
DrugDDI.d366.s4.e26 432 440
drug
verapamil
DrugDDI.d366.s4.e27 442 449
drug
zileuton



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s5
Thus, if a patient has been titrated to a stable dosage of EQUETROTM , and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for EQUETROTM may be necessary.

DrugDDI.d366.s5.e0 47 55
drug
EQUETROTM
DrugDDI.d366.s5.e1 102 107
drug
CYP3A4
DrugDDI.d366.s5.e2 110 125
drug
epoxide hydrolase
DrugDDI.d366.s5.e3 180 188
drug
EQUETROTM



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s6
Agents that Induce Cytochrome P450 Isoenzymes Carbamazepine is metabolized by CYP3A4 .

DrugDDI.d366.s6.e0 16 29
drug
Cytochrome P450
DrugDDI.d366.s6.e1 68 73
drug
CYP3A4



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s7
Therefore, the potential exists for interaction between carbamazepine and any agent that induces CYP3A4 .

DrugDDI.d366.s7.e0 49 61
drug
carbamazepine
DrugDDI.d366.s7.e1 84 89
drug
CYP3A4

interaction DrugDDI.d366.s7.e0 DrugDDI.d366.s7.e1

Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s8
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.

DrugDDI.d366.s8.e0 13 15
drug
CYP
DrugDDI.d366.s8.e1 80 88
drug
EQUETROTM
DrugDDI.d366.s8.e2 105 113
drug
Cisplatin
DrugDDI.d366.s8.e3 115 128
drug
doxorubicin HCL
DrugDDI.d366.s8.e4 130 138
drug
felbamate
DrugDDI.d366.s8.e5 140 147
drug
rifampin
DrugDDI.d366.s8.e6 149 161
drug
phenobarbital
DrugDDI.d366.s8.e7 163 171
drug
Phenytoin
DrugDDI.d366.s8.e8 176 184
drug
primidone
DrugDDI.d366.s8.e9 186 197
drug
methsuximide
DrugDDI.d366.s8.e10 202 213
drug
theophylline
DrugDDI.d366.s8.e11 261 269
drug
EQUETROTM
DrugDDI.d366.s8.e12 316 321
drug
CYP3A4
DrugDDI.d366.s8.e13 373 381
drug
EQUETROTM



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s9
Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes Carbamazepine is known to induce CYP1A2 and CYP3A4 .

DrugDDI.d366.s9.e0 40 52
drug
Carbamazepine
DrugDDI.d366.s9.e1 69 82
drug
Cytochrome P450
DrugDDI.d366.s9.e2 118 123
drug
CYP1A2
DrugDDI.d366.s9.e3 127 132
drug
CYP3A4



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s10
Therefore, the potential exists for interaction between carbamazepine and any agent metabolized by one (or more) of these enzymes.

DrugDDI.d366.s10.e0 49 61
drug
carbamazepine



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s11
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen , alprazolam , amitriptyline , bupropion , buspirone , citalopram , clobazam , clonazepam , clozapine , cyclosporin , delavirdine , desipramine , diazepam , dicumarol , doxycycline , ethosuximide , felbamate , felodipine , glucocorticoids, haloperidol , itraconazole , lamotrigine , levothyroxine , lorazepam , methadone , midazolam , mirtazapine , nortriptyline , olanzapine , oral contraceptives (3), oxcarbazepine , Phenytoin (4), praziquantel , protease inhibitors , quetiapine , risperidone , theophylline , topiramate , tiagabine , tramadol , triazolam , valproate , warfarin (5) , ziprasidone , and zonisamide .

DrugDDI.d366.s11.e0 79 87
drug
EQUETROTM
DrugDDI.d366.s11.e1 104 106
drug
CYP
DrugDDI.d366.s11.e2 130 142
drug
Acetaminophen
DrugDDI.d366.s11.e3 144 153
drug
alprazolam
DrugDDI.d366.s11.e4 155 167
drug
amitriptyline
DrugDDI.d366.s11.e5 169 177
drug
bupropion
DrugDDI.d366.s11.e6 179 187
drug
buspirone
DrugDDI.d366.s11.e7 189 198
drug
citalopram
DrugDDI.d366.s11.e8 200 207
drug
clobazam
DrugDDI.d366.s11.e9 209 218
drug
clonazepam
DrugDDI.d366.s11.e10 220 228
drug
clozapine
DrugDDI.d366.s11.e11 230 240
drug
cyclosporin
DrugDDI.d366.s11.e12 242 252
drug
delavirdine
DrugDDI.d366.s11.e13 254 264
drug
desipramine
DrugDDI.d366.s11.e14 266 273
drug
diazepam
DrugDDI.d366.s11.e15 275 283
drug
dicumarol
DrugDDI.d366.s11.e16 285 295
drug
doxycycline
DrugDDI.d366.s11.e17 297 308
drug
ethosuximide
DrugDDI.d366.s11.e18 310 318
drug
felbamate
DrugDDI.d366.s11.e19 320 329
drug
felodipine
DrugDDI.d366.s11.e20 347 357
drug
haloperidol
DrugDDI.d366.s11.e21 359 370
drug
itraconazole
DrugDDI.d366.s11.e22 372 382
drug
lamotrigine
DrugDDI.d366.s11.e23 384 396
drug
levothyroxine
DrugDDI.d366.s11.e24 398 406
drug
lorazepam
DrugDDI.d366.s11.e25 408 416
drug
methadone
DrugDDI.d366.s11.e26 418 426
drug
midazolam
DrugDDI.d366.s11.e27 428 438
drug
mirtazapine
DrugDDI.d366.s11.e28 440 452
drug
nortriptyline
DrugDDI.d366.s11.e29 454 463
drug
olanzapine
DrugDDI.d366.s11.e30 465 482
drug
oral contraceptives
DrugDDI.d366.s11.e31 487 499
drug
oxcarbazepine
DrugDDI.d366.s11.e32 501 509
drug
Phenytoin
DrugDDI.d366.s11.e33 514 525
drug
praziquantel
DrugDDI.d366.s11.e34 527 544
drug
protease inhibitors
DrugDDI.d366.s11.e35 546 555
drug
quetiapine
DrugDDI.d366.s11.e36 557 567
drug
risperidone
DrugDDI.d366.s11.e37 569 580
drug
theophylline
DrugDDI.d366.s11.e38 582 591
drug
topiramate
DrugDDI.d366.s11.e39 593 601
drug
tiagabine
DrugDDI.d366.s11.e40 603 610
drug
tramadol
DrugDDI.d366.s11.e41 612 620
drug
triazolam
DrugDDI.d366.s11.e42 622 630
drug
valproate
DrugDDI.d366.s11.e43 632 639
drug
warfarin
DrugDDI.d366.s11.e44 644 654
drug
ziprasidone
DrugDDI.d366.s11.e45 659 668
drug
zonisamide



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s12
Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM , it is reasonable to expect that a dose increase for the concomitant agent may be necessary.

DrugDDI.d366.s12.e0 111 119
drug
EQUETROTM



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s13
Agents with Increased Levels in the Presence of Carbamazepine : EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.

DrugDDI.d366.s13.e0 40 52
drug
Carbamazepine
DrugDDI.d366.s13.e1 54 62
drug
EQUETROTM
DrugDDI.d366.s13.e2 108 119
drug
Clomipramine
DrugDDI.d366.s13.e3 124 132
drug
Phenytoin
DrugDDI.d366.s13.e4 140 148
drug
primidone
DrugDDI.d366.s13.e5 263 271
drug
EQUETROTM

interaction DrugDDI.d366.s13.e1 DrugDDI.d366.s13.e2
interaction DrugDDI.d366.s13.e2 DrugDDI.d366.s13.e3
interaction DrugDDI.d366.s13.e2 DrugDDI.d366.s13.e4

Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s14
Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.

DrugDDI.d366.s14.e0 47 59
drug
Carbamazepine
DrugDDI.d366.s14.e1 87 99
drug
carbamazepine
DrugDDI.d366.s14.e2 103 109
drug
lithium

interaction DrugDDI.d366.s14.e1 DrugDDI.d366.s14.e2

Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s15
Given the anticonvulsant properties of carbamazepine , EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants .

DrugDDI.d366.s15.e0 8 21
drug
anticonvulsant
DrugDDI.d366.s15.e1 34 46
drug
carbamazepine
DrugDDI.d366.s15.e2 48 56
drug
EQUETROTM
DrugDDI.d366.s15.e3 110 124
drug
anticonvulsants



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s16
Additionally, anti-malarial drugs , such as chloroquine and mefloquine , may antagonize the activity of carbamazepine .

DrugDDI.d366.s16.e0 13 30
drug
anti-malarial drugs
DrugDDI.d366.s16.e1 38 48
drug
chloroquine
DrugDDI.d366.s16.e2 52 61
drug
mefloquine
DrugDDI.d366.s16.e3 89 101
drug
carbamazepine

interaction DrugDDI.d366.s16.e0 DrugDDI.d366.s16.e3
interaction DrugDDI.d366.s16.e1 DrugDDI.d366.s16.e3
interaction DrugDDI.d366.s16.e2 DrugDDI.d366.s16.e3

Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s17
Thus if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM , it is reasonable to expect that a dose adjustment may be necessary.

DrugDDI.d366.s17.e0 110 118
drug
EQUETROTM



Abstract Id: DrugDDI.d366
Sentence Id: DrugDDI.d366.s18
Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol .

DrugDDI.d366.s18.e0 52 60
drug
EQUETROTM
DrugDDI.d366.s18.e1 77 96
drug
centrally acting drugs
DrugDDI.d366.s18.e2 100 106
drug
alcohol



Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s0
Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa-levodopa combination products.

DrugDDI.d370.s0.e0 40 44
drug
drugs
DrugDDI.d370.s0.e1 77 83
drug
LODOSYN
DrugDDI.d370.s0.e2 85 93
drug
Carbidopa
DrugDDI.d370.s0.e3 104 111
drug
levodopa
DrugDDI.d370.s0.e4 114 131
drug
carbidopa-levodopa

interaction DrugDDI.d370.s0.e0 DrugDDI.d370.s0.e1
interaction DrugDDI.d370.s0.e0 DrugDDI.d370.s0.e3

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s1
Symptomatic postural hypotension has occurred when LODOSYN , given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs .

DrugDDI.d370.s1.e0 45 51
drug
LODOSYN
DrugDDI.d370.s1.e1 62 69
drug
levodopa
DrugDDI.d370.s1.e2 72 89
drug
carbidopa-levodopa
DrugDDI.d370.s1.e3 151 171
drug
antihypertensive drugs

interaction DrugDDI.d370.s1.e0 DrugDDI.d370.s1.e3
interaction DrugDDI.d370.s1.e2 DrugDDI.d370.s1.e3

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s2
Therefore, when therapy with LODOSYN , given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.

DrugDDI.d370.s2.e0 25 31
drug
LODOSYN
DrugDDI.d370.s2.e1 51 58
drug
levodopa
DrugDDI.d370.s2.e2 61 78
drug
carbidopa-levodopa
DrugDDI.d370.s2.e3 130 149
drug
antihypertensive drug

interaction DrugDDI.d370.s2.e0 DrugDDI.d370.s2.e3
interaction DrugDDI.d370.s2.e2 DrugDDI.d370.s2.e3

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s3
For patients receiving monoamine oxidase inhibitors , see CONTRAINDICATIONS.

DrugDDI.d370.s3.e0 20 45
drug
monoamine oxidase inhibitors



Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s4
Concomitant therapy with selegiline and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone.

DrugDDI.d370.s4.e0 22 31
drug
selegiline
DrugDDI.d370.s4.e1 35 52
drug
carbidopa-levodopa
DrugDDI.d370.s4.e2 117 134
drug
carbidopa-levodopa

interaction DrugDDI.d370.s4.e0 DrugDDI.d370.s4.e1

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s5
There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations .

DrugDDI.d370.s5.e0 110 133
drug
tricyclic antidepressants
DrugDDI.d370.s5.e1 137 166
drug
carbidopa-levodopa preparations

interaction DrugDDI.d370.s5.e0 DrugDDI.d370.s5.e1

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s6
Dopamine D2 receptor antagonists (e.g., phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa .

DrugDDI.d370.s6.e0 0 28
drug
Dopamine D2 receptor antagonists
DrugDDI.d370.s6.e1 35 48
drug
phenothiazines
DrugDDI.d370.s6.e2 50 63
drug
butyrophenones
DrugDDI.d370.s6.e3 65 75
drug
risperidone
DrugDDI.d370.s6.e4 80 88
drug
isoniazid
DrugDDI.d370.s6.e5 121 128
drug
levodopa

interaction DrugDDI.d370.s6.e0 DrugDDI.d370.s6.e5
interaction DrugDDI.d370.s6.e1 DrugDDI.d370.s6.e5
interaction DrugDDI.d370.s6.e2 DrugDDI.d370.s6.e5
interaction DrugDDI.d370.s6.e3 DrugDDI.d370.s6.e5
interaction DrugDDI.d370.s6.e4 DrugDDI.d370.s6.e5

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s7
In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine .

DrugDDI.d370.s7.e0 33 40
drug
levodopa
DrugDDI.d370.s7.e1 90 98
drug
phenytoin
DrugDDI.d370.s7.e2 102 111
drug
papaverine

interaction DrugDDI.d370.s7.e0 DrugDDI.d370.s7.e1

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s8
Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.

DrugDDI.d370.s8.e0 19 23
drug
drugs
DrugDDI.d370.s8.e1 28 34
drug
LODOSYN
DrugDDI.d370.s8.e2 38 45
drug
levodopa
DrugDDI.d370.s8.e3 48 65
drug
carbidopa-levodopa

interaction DrugDDI.d370.s8.e0 DrugDDI.d370.s8.e1
interaction DrugDDI.d370.s8.e0 DrugDDI.d370.s8.e3

Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s9
Iron salts may reduce the bioavailability of carbidopa and levodopa .

DrugDDI.d370.s9.e0 38 46
drug
carbidopa
DrugDDI.d370.s9.e1 50 57
drug
levodopa



Abstract Id: DrugDDI.d370
Sentence Id: DrugDDI.d370.s11
Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.

DrugDDI.d370.s11.e0 8 21
drug
metoclopramide
DrugDDI.d370.s11.e1 53 60
drug
levodopa
DrugDDI.d370.s11.e2 89 102
drug
metoclopramide
DrugDDI.d370.s11.e3 144 171
drug
dopamine receptor antagonistic

interaction DrugDDI.d370.s11.e0 DrugDDI.d370.s11.e1
interaction DrugDDI.d370.s11.e2 DrugDDI.d370.s11.e3

Abstract Id: DrugDDI.d227
Sentence Id: DrugDDI.d227.s0
Antihistamines may enhance the effects of tricyclic antidepressants , barbiturates , alcohol , and other CNS depressants .

DrugDDI.d227.s0.e0 0 13
drug
Antihistamines
DrugDDI.d227.s0.e1 36 59
drug
tricyclic antidepressants
DrugDDI.d227.s0.e2 61 72
drug
barbiturates
DrugDDI.d227.s0.e3 74 80
drug
alcohol
DrugDDI.d227.s0.e4 90 103
drug
CNS depressants

interaction DrugDDI.d227.s0.e0 DrugDDI.d227.s0.e1
interaction DrugDDI.d227.s0.e0 DrugDDI.d227.s0.e2
interaction DrugDDI.d227.s0.e0 DrugDDI.d227.s0.e3
interaction DrugDDI.d227.s0.e0 DrugDDI.d227.s0.e4

Abstract Id: DrugDDI.d227
Sentence Id: DrugDDI.d227.s1
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines .

DrugDDI.d227.s1.e0 0 12
drug
MAO inhibitors
DrugDDI.d227.s1.e1 35 49
drug
anticholinergic
DrugDDI.d227.s1.e2 59 72
drug
antihistamines

interaction DrugDDI.d227.s1.e0 DrugDDI.d227.s1.e2

Abstract Id: DrugDDI.d227
Sentence Id: DrugDDI.d227.s2
Sympathomimetic amines may reduce the antihypertensive effects of reserpine , veratrum alkaloids , methyldopa and mecamylamine .

DrugDDI.d227.s2.e0 0 20
drug
Sympathomimetic amines
DrugDDI.d227.s2.e1 33 48
drug
antihypertensive
DrugDDI.d227.s2.e2 58 66
drug
reserpine
DrugDDI.d227.s2.e3 68 84
drug
veratrum alkaloids
DrugDDI.d227.s2.e4 86 95
drug
methyldopa
DrugDDI.d227.s2.e5 99 110
drug
mecamylamine

interaction DrugDDI.d227.s2.e0 DrugDDI.d227.s2.e2
interaction DrugDDI.d227.s2.e0 DrugDDI.d227.s2.e3
interaction DrugDDI.d227.s2.e0 DrugDDI.d227.s2.e4
interaction DrugDDI.d227.s2.e0 DrugDDI.d227.s2.e5

Abstract Id: DrugDDI.d227
Sentence Id: DrugDDI.d227.s3
Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers .

DrugDDI.d227.s3.e0 9 24
drug
sympathomimetics
DrugDDI.d227.s3.e1 41 53
drug
MAO inhibitors
DrugDDI.d227.s3.e2 57 78
drug
beta adrenergic blockers

interaction DrugDDI.d227.s3.e0 DrugDDI.d227.s3.e1
interaction DrugDDI.d227.s3.e0 DrugDDI.d227.s3.e2

Abstract Id: DrugDDI.d317
Sentence Id: DrugDDI.d317.s0
HEMABATE may augment the activity of other oxytocic agents .

DrugDDI.d317.s0.e0 0 7
drug
HEMABATE
DrugDDI.d317.s0.e1 36 49
drug
oxytocic agents



Abstract Id: DrugDDI.d317
Sentence Id: DrugDDI.d317.s1
Concomitant use with other oxytocic agents is not recommended .

DrugDDI.d317.s1.e0 23 36
drug
oxytocic agents



Abstract Id: DrugDDI.d355
Sentence Id: DrugDDI.d355.s0
Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.

DrugDDI.d355.s0.e0 0 7
drug
Ocupress
DrugDDI.d355.s0.e1 57 84
drug
beta-adrenergic blocking agent

interaction DrugDDI.d355.s0.e0 DrugDDI.d355.s0.e1

Abstract Id: DrugDDI.d355
Sentence Id: DrugDDI.d355.s1
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

DrugDDI.d355.s1.e0 46 57
drug
beta-blocker
DrugDDI.d355.s1.e1 114 118
drug
drugs
DrugDDI.d355.s1.e2 125 133
drug
reserpine

interaction DrugDDI.d355.s1.e0 DrugDDI.d355.s1.e2

Abstract Id: DrugDDI.d108
Sentence Id: DrugDDI.d108.s0
Drug /Laboratory Test Interactions Positive direct Coombs@ tests have been reported during treatment with the cephalosporin antibiotics .

DrugDDI.d108.s0.e0 0 3
drug
Drug
DrugDDI.d108.s0.e1 95 118
drug
cephalosporin antibiotics



Abstract Id: DrugDDI.d108
Sentence Id: DrugDDI.d108.s1
In hematologic studies or in transfusion cross-matching procedures when anti-globulin tests are performed on the minor side or in Coombs@ testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs@ test may be due to the drug .

DrugDDI.d108.s1.e0 159 182
drug
cephalosporin antibiotics
DrugDDI.d108.s1.e1 258 261
drug
drug



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s0
Antacids (aluminum- or magnesium -containing) Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox@ TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.

DrugDDI.d240.s0.e0 0 7
drug
Antacids
DrugDDI.d240.s0.e1 20 28
drug
magnesium
DrugDDI.d240.s0.e2 74 81
drug
cefdinir



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s2
There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir .

DrugDDI.d240.s2.e0 30 37
drug
cefdinir
DrugDDI.d240.s2.e1 59 65
drug
antacid
DrugDDI.d240.s2.e2 105 112
drug
cefdinir



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s3
If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid .

DrugDDI.d240.s3.e0 2 9
drug
antacids
DrugDDI.d240.s3.e1 27 33
drug
OMNICEF
DrugDDI.d240.s3.e2 42 48
drug
OMNICEF
DrugDDI.d240.s3.e3 91 97
drug
antacid

interaction DrugDDI.d240.s3.e2 DrugDDI.d240.s3.e3

Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s4
Probenecid As with other b span class= c233 -lactam antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.

DrugDDI.d240.s4.e0 0 9
drug
Probenecid
DrugDDI.d240.s4.e1 32 53
drug
c233 -lactam antibiotics
DrugDDI.d240.s4.e2 55 64
drug
probenecid
DrugDDI.d240.s4.e3 92 99
drug
cefdinir
DrugDDI.d240.s4.e4 157 164
drug
cefdinir

interaction DrugDDI.d240.s4.e2 DrugDDI.d240.s4.e3

Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s5
Iron Supplement s and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.

DrugDDI.d240.s5.e0 0 13
drug
Iron Supplement
DrugDDI.d240.s5.e1 36 39
drug
Iron
DrugDDI.d240.s5.e2 67 74
drug
cefdinir
DrugDDI.d240.s5.e3 91 104
drug
iron supplement
DrugDDI.d240.s5.e4 121 133
drug
elemental iron
DrugDDI.d240.s5.e5 145 152
drug
vitamins
DrugDDI.d240.s5.e6 175 187
drug
elemental iron

interaction DrugDDI.d240.s5.e2 DrugDDI.d240.s5.e3
interaction DrugDDI.d240.s5.e2 DrugDDI.d240.s5.e5

Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s6
If iron supplement s are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.

DrugDDI.d240.s6.e0 2 15
drug
iron supplement
DrugDDI.d240.s6.e1 34 40
drug
OMNICEF
DrugDDI.d240.s6.e2 49 55
drug
OMNICEF



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s7
The effect of foods highly fortified with elemental iron (primarily iron -fortified breakfast cereals) on cefdinir absorption has not been studied.

DrugDDI.d240.s7.e0 35 47
drug
elemental iron
DrugDDI.d240.s7.e1 58 61
drug
iron
DrugDDI.d240.s7.e2 91 98
drug
cefdinir



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s8
Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron /6 oz) has no significant effect on cefdinir pharmacokinetics.

DrugDDI.d240.s8.e0 58 70
drug
elemental iron
DrugDDI.d240.s8.e1 100 107
drug
cefdinir



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s9
Therefore, OMNICEF for Oral Suspension can be administered with iron -fortified infant formula.

DrugDDI.d240.s9.e0 10 16
drug
OMNICEF
DrugDDI.d240.s9.e1 55 58
drug
iron



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s10
There have been rare reports of reddish stools in patients who have received cefdinir in Japan.

DrugDDI.d240.s10.e0 64 71
drug
cefdinir



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s11
The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.

DrugDDI.d240.s11.e0 64 71
drug
cefdinir
DrugDDI.d240.s11.e1 97 100
drug
iron



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s12
Drug /Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside , but not with those using nitroferricyanide .

DrugDDI.d240.s12.e0 0 3
drug
Drug
DrugDDI.d240.s12.e1 96 108
drug
nitroprusside
DrugDDI.d240.s12.e2 130 146
drug
nitroferricyanide



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s13
The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest@, Benedict@s solution, or Fehlings solution.

DrugDDI.d240.s13.e0 19 26
drug
cefdinir
DrugDDI.d240.s13.e1 64 70
drug
glucose



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s14
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix@ or Tes-Tape@) be used.

DrugDDI.d240.s14.e0 47 60
drug
glucose oxidase



Abstract Id: DrugDDI.d240
Sentence Id: DrugDDI.d240.s15
Cephalosporins are known to occasionally induce a positive direct Coombs@ test.

DrugDDI.d240.s15.e0 0 13
drug
Cephalosporins



Abstract Id: DrugDDI.d271
Sentence Id: DrugDDI.d271.s0
Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics .

DrugDDI.d271.s0.e0 52 66
drug
aminoglycosides
DrugDDI.d271.s0.e1 90 97
drug
MAXIPIME
DrugDDI.d271.s0.e2 160 184
drug
aminoglycoside antibiotics

interaction DrugDDI.d271.s0.e0 DrugDDI.d271.s0.e1

Abstract Id: DrugDDI.d271
Sentence Id: DrugDDI.d271.s1
Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide .

DrugDDI.d271.s1.e0 70 83
drug
cephalosporins
DrugDDI.d271.s1.e1 94 102
drug
diuretics
DrugDDI.d271.s1.e2 109 118
drug
furosemide

interaction DrugDDI.d271.s1.e0 DrugDDI.d271.s1.e1

Abstract Id: DrugDDI.d271
Sentence Id: DrugDDI.d271.s2
Drug /Laboratory Test Interactions The administration of cefepime may result in a false-positive reaction for glucose in the urine when using Clinitest@ tablets.

DrugDDI.d271.s2.e0 0 3
drug
Drug
DrugDDI.d271.s2.e1 50 57
drug
cefepime
DrugDDI.d271.s2.e2 95 101
drug
glucose



Abstract Id: DrugDDI.d271
Sentence Id: DrugDDI.d271.s3
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix@ or Tes-Tape@ ) be used.

DrugDDI.d271.s3.e0 47 60
drug
glucose oxidase



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s0
Carbamazepine : Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.

DrugDDI.d398.s0.e0 0 12
drug
Carbamazepine
DrugDDI.d398.s0.e1 86 91
drug
SUPRAX



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s1
Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.

DrugDDI.d398.s1.e0 55 67
drug
carbamazepine



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s2
Warfarin and Anticoagulants : Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.

DrugDDI.d398.s2.e0 0 7
drug
Warfarin
DrugDDI.d398.s2.e1 11 24
drug
Anticoagulants
DrugDDI.d398.s2.e2 100 107
drug
cefixime



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s3
Drug /Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide .

DrugDDI.d398.s3.e0 0 3
drug
Drug
DrugDDI.d398.s3.e1 96 108
drug
nitroprusside
DrugDDI.d398.s3.e2 129 145
drug
nitroferricyanide



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s4
The administration of SUPRAX may result in a false-positive reaction for glucose in the urine using Clinitest@**, Benedict@s solution, or Fehling@s solution.

DrugDDI.d398.s4.e0 19 24
drug
SUPRAX
DrugDDI.d398.s4.e1 62 68
drug
glucose



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s5
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix@** or Tes-Tape@**) be used.

DrugDDI.d398.s5.e0 47 60
drug
glucose oxidase



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s6
A false-positive direct Coombs test has been reported during treatment with other cephalosporin antibiotics ; .

DrugDDI.d398.s6.e0 70 93
drug
cephalosporin antibiotics



Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s7
therefore, it should be recognized that a positive Coombs test may be due to the drug .

DrugDDI.d398.s7.e0 66 69
drug
drug



Abstract Id: DrugDDI.d154
Sentence Id: DrugDDI.d154.s0
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics .

DrugDDI.d154.s0.e0 74 87
drug
cephalosporins
DrugDDI.d154.s0.e1 91 115
drug
aminoglycoside antibiotics

interaction DrugDDI.d154.s0.e0 DrugDDI.d154.s0.e1

Abstract Id: DrugDDI.d154
Sentence Id: DrugDDI.d154.s1
Drug /Laboratory Test Interactions Cephalosporins , including cefotaxime sodium , are known to occasionally induce a positive direct Coombs test.

DrugDDI.d154.s1.e0 0 3
drug
Drug
DrugDDI.d154.s1.e1 31 44
drug
Cephalosporins
DrugDDI.d154.s1.e2 55 70
drug
cefotaxime sodium



Abstract Id: DrugDDI.d54
Sentence Id: DrugDDI.d54.s0
Increases in serum creatinine have occurred when CEFOTAN was given alone.

DrugDDI.d54.s0.e0 42 48
drug
CEFOTAN



Abstract Id: DrugDDI.d54
Sentence Id: DrugDDI.d54.s1
If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.

DrugDDI.d54.s1.e0 2 8
drug
CEFOTAN
DrugDDI.d54.s1.e1 14 27
drug
aminoglycoside

interaction DrugDDI.d54.s1.e0 DrugDDI.d54.s1.e1

Abstract Id: DrugDDI.d54
Sentence Id: DrugDDI.d54.s2
Drug /Laboratory Test Interactions: The administration of CEFOTAN may result in a false positive reaction for glucose in the urine using Clinitest@@, Benedicts solution, or Fehlings solution.

DrugDDI.d54.s2.e0 0 3
drug
Drug
DrugDDI.d54.s2.e1 51 57
drug
CEFOTAN
DrugDDI.d54.s2.e2 94 100
drug
glucose



Abstract Id: DrugDDI.d54
Sentence Id: DrugDDI.d54.s3
It is recommended that glucose tests based on enzymatic glucose oxidase be used.

DrugDDI.d54.s3.e0 47 60
drug
glucose oxidase



Abstract Id: DrugDDI.d54
Sentence Id: DrugDDI.d54.s4
As with other cephalosporins , high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe@ reaction and produce false increases in the levels of creatinine reported.

DrugDDI.d54.s4.e0 11 24
drug
cephalosporins
DrugDDI.d54.s4.e1 46 54
drug
cefotetan
DrugDDI.d54.s4.e2 166 175
drug
creatinine

interaction DrugDDI.d54.s4.e1 DrugDDI.d54.s4.e2

Abstract Id: DrugDDI.d185
Sentence Id: DrugDDI.d185.s0
Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics .

DrugDDI.d185.s0.e0 65 89
drug
aminoglycoside antibiotics
DrugDDI.d185.s0.e1 93 116
drug
cephalosporin antibiotics



Abstract Id: DrugDDI.d185
Sentence Id: DrugDDI.d185.s1
Concomitant administration of probenecid doubled the AUC for cefprozil .

DrugDDI.d185.s1.e0 27 36
drug
probenecid
DrugDDI.d185.s1.e1 53 61
drug
cefprozil



Abstract Id: DrugDDI.d185
Sentence Id: DrugDDI.d185.s2
The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid .

DrugDDI.d185.s2.e0 43 51
drug
cefprozil
DrugDDI.d185.s2.e1 101 107
drug
antacid



Abstract Id: DrugDDI.d226
Sentence Id: DrugDDI.d226.s0
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide .

DrugDDI.d226.s0.e0 65 78
drug
cephalosporins
DrugDDI.d226.s0.e1 83 107
drug
aminoglycoside antibiotics
DrugDDI.d226.s0.e2 116 124
drug
diuretics
DrugDDI.d226.s0.e3 131 140
drug
furosemide



Abstract Id: DrugDDI.d226
Sentence Id: DrugDDI.d226.s1
Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics .

DrugDDI.d226.s1.e0 70 84
drug
aminoglycosides
DrugDDI.d226.s1.e1 193 203
drug
antibiotics



Abstract Id: DrugDDI.d226
Sentence Id: DrugDDI.d226.s2
Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials.

DrugDDI.d226.s2.e0 44 54
drug
ceftazidime



Abstract Id: DrugDDI.d226
Sentence Id: DrugDDI.d226.s3
Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotic s, including ceftazidime , based on in vitro studies and time kill curves with enteric gram-negative bacilli.

DrugDDI.d226.s3.e0 0 14
drug
Chloramphenicol
DrugDDI.d226.s3.e1 45 65
drug
beta-lactam antibiotic
DrugDDI.d226.s3.e2 77 87
drug
ceftazidime



Abstract Id: DrugDDI.d226
Sentence Id: DrugDDI.d226.s4
Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided.

DrugDDI.d226.s4.e0 88 91
drug
drug



Abstract Id: DrugDDI.d226
Sentence Id: DrugDDI.d226.s5
Drug /Laboratory Test Interactions The administration of ceftazidime may result in a false-positive reaction for glucose in the urine when using CLINITEST@ tablets, Benedicts solution, or Fehlings solution.

DrugDDI.d226.s5.e0 0 3
drug
Drug
DrugDDI.d226.s5.e1 50 60
drug
ceftazidime
DrugDDI.d226.s5.e2 98 104
drug
glucose



Abstract Id: DrugDDI.d226
Sentence Id: DrugDDI.d226.s6
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX@ or TES-TAPE@) be used.

DrugDDI.d226.s6.e0 47 60
drug
glucose oxidase



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s0
Theophylline : Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.

DrugDDI.d72.s0.e0 0 11
drug
Theophylline



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s1
With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).

DrugDDI.d72.s1.e0 20 29
drug
ceftibuten
DrugDDI.d72.s1.e1 86 97
drug
theophylline



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s2
The pharmacokinetics of theophylline were not altered.

DrugDDI.d72.s2.e0 21 32
drug
theophylline



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s3
The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.

DrugDDI.d72.s3.e0 11 20
drug
ceftibuten
DrugDDI.d72.s3.e1 44 55
drug
theophylline



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s4
Antacids or H 2 -receptor antagonists : The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.

DrugDDI.d72.s4.e0 0 7
drug
Antacids
DrugDDI.d72.s4.e1 10 31
drug
H 2 -receptor antagonists
DrugDDI.d72.s4.e2 84 93
drug
ceftibuten



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s6
A single dose of liquid antacid did not affect the C max or AUC of ceftibuten ; .

DrugDDI.d72.s6.e0 19 25
drug
antacid
DrugDDI.d72.s6.e1 42 44
drug
max
DrugDDI.d72.s6.e2 52 61
drug
ceftibuten



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s7
however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.

DrugDDI.d72.s7.e0 15 24
drug
ranitidine
DrugDDI.d72.s7.e1 49 58
drug
ceftibuten
DrugDDI.d72.s7.e2 71 80
drug
ceftibuten

interaction DrugDDI.d72.s7.e0 DrugDDI.d72.s7.e1

Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s9
Drug /Laboratory Test Interactions: There have been no chemical or laboratory test interactions with ceftibuten noted to date.

DrugDDI.d72.s9.e0 0 3
drug
Drug
DrugDDI.d72.s9.e1 87 96
drug
ceftibuten



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s10
False-positive direct Coombs tests have been reported during treatment with other cephalosporins .

DrugDDI.d72.s10.e0 71 84
drug
cephalosporins



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s11
Therefore, it should be recognized that a positive Coombs test could be due to the drug .

DrugDDI.d72.s11.e0 68 71
drug
drug



Abstract Id: DrugDDI.d72
Sentence Id: DrugDDI.d72.s12
The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40 @g/mL.

DrugDDI.d72.s12.e0 68 77
drug
ceftibuten
DrugDDI.d72.s12.e1 142 151
drug
ceftibuten



Abstract Id: DrugDDI.d102
Sentence Id: DrugDDI.d102.s0
Although the occurrence has not been reported with Cefizox , nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides .

DrugDDI.d102.s0.e0 43 49
drug
Cefizox
DrugDDI.d102.s0.e1 121 134
drug
cephalosporins
DrugDDI.d102.s0.e2 138 152
drug
aminoglycosides



Abstract Id: DrugDDI.d21
Sentence Id: DrugDDI.d21.s0
Drug /Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict@s or Fehling@s solution or with Clinitest@ tablets) but not with enzyme-based tests for glycosuria.

DrugDDI.d21.s0.e0 0 3
drug
Drug
DrugDDI.d21.s0.e1 58 64
drug
glucose



Abstract Id: DrugDDI.d21
Sentence Id: DrugDDI.d21.s1
As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime .

DrugDDI.d21.s1.e0 81 94
drug
glucose oxidase
DrugDDI.d21.s1.e1 97 106
drug
hexokinase
DrugDDI.d21.s1.e2 173 182
drug
cefuroxime



Abstract Id: DrugDDI.d21
Sentence Id: DrugDDI.d21.s2
Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.

DrugDDI.d21.s2.e0 0 9
drug
Cefuroxime



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s0
General: Significant interactions may occur when celecoxib is administered together with drugs that inhibit P450 2C9.

DrugDDI.d53.s0.e0 43 51
drug
celecoxib
DrugDDI.d53.s0.e1 78 82
drug
drugs
DrugDDI.d53.s0.e2 94 97
drug
P450

interaction DrugDDI.d53.s0.e0 DrugDDI.d53.s0.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s1
Celecoxib metabolism is predominantly mediated via cytochrome P450 2C9 in the liver .

DrugDDI.d53.s1.e0 0 8
drug
Celecoxib
DrugDDI.d53.s1.e1 45 61
drug
cytochrome P450 2C9
DrugDDI.d53.s1.e2 67 71
drug
liver

interaction DrugDDI.d53.s1.e0 DrugDDI.d53.s1.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s2
Co-administration of celecoxib with drugs that are known to inhibit 2C9 should be done with caution.

DrugDDI.d53.s2.e0 19 27
drug
celecoxib
DrugDDI.d53.s2.e1 32 36
drug
drugs

interaction DrugDDI.d53.s2.e0 DrugDDI.d53.s2.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s3
In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9 , 2C19 or 3A4.

DrugDDI.d53.s3.e0 26 34
drug
celecoxib
DrugDDI.d53.s3.e1 53 69
drug
cytochrome P450 2C9



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s4
In vitro studies also indicate that celecoxib , although not a substrate, is an inhibitor of cytochrome P450 2D6 .

DrugDDI.d53.s4.e0 30 38
drug
celecoxib
DrugDDI.d53.s4.e1 77 93
drug
cytochrome P450 2D6

interaction DrugDDI.d53.s4.e0 DrugDDI.d53.s4.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s5
Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by P450 2D6 .

DrugDDI.d53.s5.e0 57 61
drug
drugs
DrugDDI.d53.s5.e1 82 88
drug
P450 2D6



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s6
Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium .

DrugDDI.d53.s6.e0 19 27
drug
celecoxib
DrugDDI.d53.s6.e1 80 90
drug
fluconazole
DrugDDI.d53.s6.e2 94 100
drug
lithium

interaction DrugDDI.d53.s6.e0 DrugDDI.d53.s6.e1
interaction DrugDDI.d53.s6.e0 DrugDDI.d53.s6.e2

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s7
Experience with nonsteroidal anti-inflammatory drugs ( NSAIDs ) suggests the potential for interactions with furosemide and ACE inhibitors .

DrugDDI.d53.s7.e0 14 47
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d53.s7.e1 49 54
drug
NSAIDs
DrugDDI.d53.s7.e2 95 104
drug
furosemide
DrugDDI.d53.s7.e3 108 120
drug
ACE inhibitors

interaction DrugDDI.d53.s7.e0 DrugDDI.d53.s7.e2
interaction DrugDDI.d53.s7.e0 DrugDDI.d53.s7.e3
interaction DrugDDI.d53.s7.e1 DrugDDI.d53.s7.e2
interaction DrugDDI.d53.s7.e1 DrugDDI.d53.s7.e3
interaction DrugDDI.d53.s7.e2 DrugDDI.d53.s7.e3

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s8
The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found.

DrugDDI.d53.s8.e0 10 18
drug
celecoxib
DrugDDI.d53.s8.e1 64 72
drug
glyburide
DrugDDI.d53.s8.e2 74 85
drug
ketoconazole
DrugDDI.d53.s8.e3 87 98
drug
methotrexate
DrugDDI.d53.s8.e4 100 108
drug
phenytoin
DrugDDI.d53.s8.e5 110 120
drug
tolbutamide
DrugDDI.d53.s8.e6 125 132
drug
warfarin



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s9
ACE inhibitors : Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.

DrugDDI.d53.s9.e0 0 12
drug
ACE inhibitors
DrugDDI.d53.s9.e1 32 37
drug
NSAIDs
DrugDDI.d53.s9.e2 52 67
drug
antihypertensive
DrugDDI.d53.s9.e3 76 102
drug
Angiotensin Converting Enzyme

interaction DrugDDI.d53.s9.e1 DrugDDI.d53.s9.e2
interaction DrugDDI.d53.s9.e1 DrugDDI.d53.s9.e3

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s10
This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors .

DrugDDI.d53.s10.e0 57 64
drug
CELEBREX
DrugDDI.d53.s10.e1 82 95
drug
ACE-inhibitors

interaction DrugDDI.d53.s10.e0 DrugDDI.d53.s10.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s11
Furosemide : Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.

DrugDDI.d53.s11.e0 0 9
drug
Furosemide
DrugDDI.d53.s11.e1 74 79
drug
NSAIDs
DrugDDI.d53.s11.e2 92 102
drug
natriuretic
DrugDDI.d53.s11.e3 111 120
drug
furosemide
DrugDDI.d53.s11.e4 124 132
drug
thiazides

interaction DrugDDI.d53.s11.e1 DrugDDI.d53.s11.e3
interaction DrugDDI.d53.s11.e1 DrugDDI.d53.s11.e4

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s12
This response has been attributed to inhibition of renal prostaglandin synthesis.

DrugDDI.d53.s12.e0 48 60
drug
prostaglandin



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s13
Aspirin : CELEBREX can be used with low dose aspirin .

DrugDDI.d53.s13.e0 0 6
drug
Aspirin
DrugDDI.d53.s13.e1 8 15
drug
CELEBREX
DrugDDI.d53.s13.e2 36 42
drug
aspirin



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s14
However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.

DrugDDI.d53.s14.e0 35 41
drug
aspirin
DrugDDI.d53.s14.e1 46 53
drug
CELEBREX
DrugDDI.d53.s14.e2 130 137
drug
CELEBREX

interaction DrugDDI.d53.s14.e0 DrugDDI.d53.s14.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s15
Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.

DrugDDI.d53.s15.e0 34 41
drug
CELEBREX
DrugDDI.d53.s15.e1 61 67
drug
aspirin



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s16
Fluconazole : Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.

DrugDDI.d53.s16.e0 0 10
drug
Fluconazole
DrugDDI.d53.s16.e1 39 49
drug
fluconazole
DrugDDI.d53.s16.e2 88 96
drug
celecoxib

interaction DrugDDI.d53.s16.e1 DrugDDI.d53.s16.e2

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s17
This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).

DrugDDI.d53.s17.e0 34 42
drug
celecoxib
DrugDDI.d53.s17.e1 56 59
drug
P450
DrugDDI.d53.s17.e2 65 75
drug
fluconazole

interaction DrugDDI.d53.s17.e0 DrugDDI.d53.s17.e2

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s18
CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole .

DrugDDI.d53.s18.e0 0 7
drug
CELEBREX
DrugDDI.d53.s18.e1 71 81
drug
fluconazole

interaction DrugDDI.d53.s18.e0 DrugDDI.d53.s18.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s19
Lithium : In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.

DrugDDI.d53.s19.e0 0 6
drug
Lithium
DrugDDI.d53.s19.e1 122 128
drug
lithium
DrugDDI.d53.s19.e2 141 148
drug
CELEBREX
DrugDDI.d53.s19.e3 186 192
drug
lithium

interaction DrugDDI.d53.s19.e1 DrugDDI.d53.s19.e2

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s20
Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.

DrugDDI.d53.s20.e0 10 16
drug
lithium
DrugDDI.d53.s20.e1 54 61
drug
CELEBREX

interaction DrugDDI.d53.s20.e0 DrugDDI.d53.s20.e1

Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s21
Methotrexate : In an interaction study of rheumatoid arthritis patients taking methotrexate , CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate .

DrugDDI.d53.s21.e0 0 11
drug
Methotrexate
DrugDDI.d53.s21.e1 68 79
drug
methotrexate
DrugDDI.d53.s21.e2 81 88
drug
CELEBREX
DrugDDI.d53.s21.e3 140 151
drug
methotrexate



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s22
Warfarin : The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin .

DrugDDI.d53.s22.e0 0 7
drug
Warfarin
DrugDDI.d53.s22.e1 20 28
drug
celecoxib
DrugDDI.d53.s22.e2 56 63
drug
warfarin
DrugDDI.d53.s22.e3 127 134
drug
warfarin



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s23
In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.

DrugDDI.d53.s23.e0 16 24
drug
celecoxib
DrugDDI.d53.s23.e1 60 67
drug
warfarin



Abstract Id: DrugDDI.d53
Sentence Id: DrugDDI.d53.s24
However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.

DrugDDI.d53.s24.e0 44 51
drug
CELEBREX
DrugDDI.d53.s24.e1 56 63
drug
warfarin

interaction DrugDDI.d53.s24.e0 DrugDDI.d53.s24.e1

Abstract Id: DrugDDI.d458
Sentence Id: DrugDDI.d458.s0
Metformin In healthy subjects given single 500 mg doses of cephalexin and metformin , plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.

DrugDDI.d458.s0.e0 0 8
drug
Metformin
DrugDDI.d458.s0.e1 49 58
drug
cephalexin
DrugDDI.d458.s0.e2 62 70
drug
metformin
DrugDDI.d458.s0.e3 78 86
drug
metformin
DrugDDI.d458.s0.e4 149 157
drug
metformin

interaction DrugDDI.d458.s0.e1 DrugDDI.d458.s0.e2

Abstract Id: DrugDDI.d458
Sentence Id: DrugDDI.d458.s1
No information is available about the interaction of cephalexin and metformin following multiple doses of either drug .

DrugDDI.d458.s1.e0 45 54
drug
cephalexin
DrugDDI.d458.s1.e1 58 66
drug
metformin
DrugDDI.d458.s1.e2 97 100
drug
drug



Abstract Id: DrugDDI.d458
Sentence Id: DrugDDI.d458.s2
Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.

DrugDDI.d458.s2.e0 89 98
drug
cephalexin
DrugDDI.d458.s2.e1 102 110
drug
metformin
DrugDDI.d458.s2.e2 144 158
drug
organic cationic

interaction DrugDDI.d458.s2.e0 DrugDDI.d458.s2.e1

Abstract Id: DrugDDI.d458
Sentence Id: DrugDDI.d458.s3
Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin .

DrugDDI.d458.s3.e0 55 63
drug
metformin
DrugDDI.d458.s3.e1 106 115
drug
cephalexin
DrugDDI.d458.s3.e2 119 127
drug
metformin

interaction DrugDDI.d458.s3.e1 DrugDDI.d458.s3.e2

Abstract Id: DrugDDI.d458
Sentence Id: DrugDDI.d458.s4
Probenecid As with other b- lactams , the renal excretion of cephalexin is inhibited by probenecid .

DrugDDI.d458.s4.e0 0 9
drug
Probenecid
DrugDDI.d458.s4.e1 23 29
drug
lactams
DrugDDI.d458.s4.e2 50 59
drug
cephalexin
DrugDDI.d458.s4.e3 73 82
drug
probenecid

interaction DrugDDI.d458.s4.e2 DrugDDI.d458.s4.e3

Abstract Id: DrugDDI.d458
Sentence Id: DrugDDI.d458.s5
Drug / Laboratory Test Interactions As a result of administration of Keflex , a false-positive reaction for glucose in the urine may occur.

DrugDDI.d458.s5.e0 0 3
drug
Drug
DrugDDI.d458.s5.e1 58 63
drug
Keflex
DrugDDI.d458.s5.e2 91 97
drug
glucose



Abstract Id: DrugDDI.d443
Sentence Id: DrugDDI.d443.s0
Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine , antipyrine , ketoconazole , erythromycin and azithromycin .

DrugDDI.d443.s0.e0 37 46
drug
cetirizine
DrugDDI.d443.s0.e1 72 86
drug
pseudoephedrine
DrugDDI.d443.s0.e2 88 97
drug
antipyrine
DrugDDI.d443.s0.e3 99 110
drug
ketoconazole
DrugDDI.d443.s0.e4 112 123
drug
erythromycin
DrugDDI.d443.s0.e5 127 138
drug
azithromycin



Abstract Id: DrugDDI.d443
Sentence Id: DrugDDI.d443.s2
In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.

DrugDDI.d443.s2.e0 22 33
drug
theophylline
DrugDDI.d443.s2.e1 61 70
drug
cetirizine
DrugDDI.d443.s2.e2 123 132
drug
cetirizine

interaction DrugDDI.d443.s2.e0 DrugDDI.d443.s2.e1

Abstract Id: DrugDDI.d443
Sentence Id: DrugDDI.d443.s3
The disposition of theophylline was not altered by concomitant cetirizine administration.

DrugDDI.d443.s3.e0 16 27
drug
theophylline
DrugDDI.d443.s3.e1 54 63
drug
cetirizine



Abstract Id: DrugDDI.d443
Sentence Id: DrugDDI.d443.s4
Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin , pseudoephedrine , ketoconazole , or erythromycin .

DrugDDI.d443.s4.e0 78 89
drug
theophylline
DrugDDI.d443.s4.e1 101 112
drug
azithromycin
DrugDDI.d443.s4.e2 114 128
drug
pseudoephedrine
DrugDDI.d443.s4.e3 130 141
drug
ketoconazole
DrugDDI.d443.s4.e4 145 156
drug
erythromycin



Abstract Id: DrugDDI.d443
Sentence Id: DrugDDI.d443.s5
There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline ; .

DrugDDI.d443.s5.e0 38 47
drug
cetirizine
DrugDDI.d443.s5.e1 69 80
drug
theophylline

interaction DrugDDI.d443.s5.e0 DrugDDI.d443.s5.e1

Abstract Id: DrugDDI.d363
Sentence Id: DrugDDI.d363.s0
A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan .

DrugDDI.d363.s0.e0 40 46
drug
ERBITUX
DrugDDI.d363.s0.e1 79 88
drug
irinotecan



Abstract Id: DrugDDI.d363
Sentence Id: DrugDDI.d363.s1
There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan .

DrugDDI.d363.s1.e0 57 63
drug
ERBITUX
DrugDDI.d363.s1.e1 67 76
drug
irinotecan



Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s0
Cevimeline should be administered with caution to patients taking beta adrenergic antagonists , because of the possibility of conduction disturbances.

DrugDDI.d539.s0.e0 0 9
drug
Cevimeline
DrugDDI.d539.s0.e1 57 81
drug
beta adrenergic antagonists

interaction DrugDDI.d539.s0.e0 DrugDDI.d539.s0.e1

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s1
Drugs with parasympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects.

DrugDDI.d539.s1.e0 0 4
drug
Drugs
DrugDDI.d539.s1.e1 9 27
drug
parasympathomimetic
DrugDDI.d539.s1.e2 63 72
drug
cevimeline

interaction DrugDDI.d539.s1.e0 DrugDDI.d539.s1.e2

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s2
Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.

DrugDDI.d539.s2.e0 0 9
drug
Cevimeline
DrugDDI.d539.s2.e1 37 50
drug
antimuscarinic
DrugDDI.d539.s2.e2 60 64
drug
drugs

interaction DrugDDI.d539.s2.e0 DrugDDI.d539.s2.e1
interaction DrugDDI.d539.s2.e0 DrugDDI.d539.s2.e2

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s3
Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline .

DrugDDI.d539.s3.e0 0 4
drug
Drugs
DrugDDI.d539.s3.e1 17 22
drug
CYP2D6
DrugDDI.d539.s3.e2 60 69
drug
cevimeline

interaction DrugDDI.d539.s3.e0 DrugDDI.d539.s3.e2

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s4
Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events.

DrugDDI.d539.s4.e0 0 9
drug
Cevimeline
DrugDDI.d539.s4.e1 77 82
drug
CYP2D6

interaction DrugDDI.d539.s4.e0 DrugDDI.d539.s4.e1

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s5
In an in vitro study, cytochrome P450 isozymes 1A2 , 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline .

DrugDDI.d539.s5.e0 17 41
drug
cytochrome P450 isozymes 1A2
DrugDDI.d539.s5.e1 98 107
drug
cevimeline



Abstract Id: DrugDDI.d262
Sentence Id: DrugDDI.d262.s0
There are no known drug /drug interactions with chlorambucil .

DrugDDI.d262.s0.e0 15 18
drug
drug
DrugDDI.d262.s0.e1 40 51
drug
chlorambucil



Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s0
Antacids and kaolin : Antacids and kaolin can reduce absorption of chloroquine ; .

DrugDDI.d561.s0.e0 0 7
drug
Antacids
DrugDDI.d561.s0.e1 11 16
drug
kaolin
DrugDDI.d561.s0.e2 18 25
drug
Antacids
DrugDDI.d561.s0.e3 29 34
drug
kaolin
DrugDDI.d561.s0.e4 56 66
drug
chloroquine

interaction DrugDDI.d561.s0.e2 DrugDDI.d561.s0.e4
interaction DrugDDI.d561.s0.e3 DrugDDI.d561.s0.e4

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s1
an interval of at least 4 hours between intake of these agents and chloroquine should be observed.

DrugDDI.d561.s1.e0 54 64
drug
chloroquine



Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s2
Cimetidine : Cimetidine can inhibit the metabolism of chloroquine , increasing its plasma level.

DrugDDI.d561.s2.e0 0 9
drug
Cimetidine
DrugDDI.d561.s2.e1 11 20
drug
Cimetidine
DrugDDI.d561.s2.e2 46 56
drug
chloroquine

interaction DrugDDI.d561.s2.e1 DrugDDI.d561.s2.e2

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s3
Concomitant use of cimetidine should be avoided.

DrugDDI.d561.s3.e0 16 25
drug
cimetidine



Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s4
Ampicillin : In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin .

DrugDDI.d561.s4.e0 0 9
drug
Ampicillin
DrugDDI.d561.s4.e1 39 49
drug
chloroquine
DrugDDI.d561.s4.e2 90 99
drug
ampicillin

interaction DrugDDI.d561.s4.e1 DrugDDI.d561.s4.e2

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s5
An interval of at least two hours between intake of this agent and chloroquine should be observed.

DrugDDI.d561.s5.e0 54 64
drug
chloroquine



Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s6
Cyclosporin : After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.

DrugDDI.d561.s6.e0 0 10
drug
Cyclosporin
DrugDDI.d561.s6.e1 31 41
drug
chloroquine



Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s7
Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.

DrugDDI.d561.s7.e0 77 87
drug
chloroquine



Abstract Id: DrugDDI.d482
Sentence Id: DrugDDI.d482.s0
Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin .

DrugDDI.d482.s0.e0 0 15
drug
Chlorotrianisene
DrugDDI.d482.s0.e1 31 45
drug
antidepressants
DrugDDI.d482.s0.e2 47 53
drug
aspirin
DrugDDI.d482.s0.e3 55 66
drug
barbiturates
DrugDDI.d482.s0.e4 68 80
drug
bromocriptine
DrugDDI.d482.s0.e5 82 88
drug
calcium
DrugDDI.d482.s0.e6 101 115
drug
corticosteroids
DrugDDI.d482.s0.e7 117 129
drug
corticotropin
DrugDDI.d482.s0.e8 131 142
drug
cyclosporine
DrugDDI.d482.s0.e9 144 153
drug
dantrolene
DrugDDI.d482.s0.e10 155 162
drug
nicotine
DrugDDI.d482.s0.e11 164 173
drug
somatropin
DrugDDI.d482.s0.e12 175 183
drug
tamoxifen
DrugDDI.d482.s0.e13 188 195
drug
warfarin

interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e1
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e2
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e3
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e4
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e5
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e6
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e7
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e8
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e9
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e10
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e11
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e12
interaction DrugDDI.d482.s0.e0 DrugDDI.d482.s0.e13

Abstract Id: DrugDDI.d358
Sentence Id: DrugDDI.d358.s0
Substrate of CYP2D6 (minor), 3A4 (major); .

DrugDDI.d358.s0.e0 11 16
drug
CYP2D6



Abstract Id: DrugDDI.d358
Sentence Id: DrugDDI.d358.s1
Inhibits CYP2D6 (weak).

DrugDDI.d358.s1.e0 8 13
drug
CYP2D6



Abstract Id: DrugDDI.d358
Sentence Id: DrugDDI.d358.s2
Increased toxicity (CNS depression): CNS depressants , MAO inhibitors , tricyclic antidepressants , phenothiazines .

DrugDDI.d358.s2.e0 33 46
drug
CNS depressants
DrugDDI.d358.s2.e1 48 60
drug
MAO inhibitors
DrugDDI.d358.s2.e2 62 85
drug
tricyclic antidepressants
DrugDDI.d358.s2.e3 87 100
drug
phenothiazines



Abstract Id: DrugDDI.d358
Sentence Id: DrugDDI.d358.s3
CYP3A4 inhibitors: May increase the levels/effects of chlorpheniramine .

DrugDDI.d358.s3.e0 0 5
drug
CYP3A4
DrugDDI.d358.s3.e1 47 62
drug
chlorpheniramine



Abstract Id: DrugDDI.d358
Sentence Id: DrugDDI.d358.s4
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .

DrugDDI.d358.s4.e0 24 39
drug
azole antifungals
DrugDDI.d358.s4.e1 41 53
drug
ciprofloxacin
DrugDDI.d358.s4.e2 55 68
drug
clarithromycin
DrugDDI.d358.s4.e3 70 79
drug
diclofenac
DrugDDI.d358.s4.e4 81 91
drug
doxycycline
DrugDDI.d358.s4.e5 93 104
drug
erythromycin
DrugDDI.d358.s4.e6 106 113
drug
imatinib
DrugDDI.d358.s4.e7 115 123
drug
isoniazid
DrugDDI.d358.s4.e8 125 134
drug
nefazodone
DrugDDI.d358.s4.e9 136 146
drug
nicardipine
DrugDDI.d358.s4.e10 148 155
drug
propofol
DrugDDI.d358.s4.e11 157 174
drug
protease inhibitors
DrugDDI.d358.s4.e12 176 184
drug
quinidine
DrugDDI.d358.s4.e13 189 197
drug
verapamil



Abstract Id: DrugDDI.d524
Sentence Id: DrugDDI.d524.s0
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine ), an antiparkinsonian drug (eg, trihexyphenidyl ), and/or a tricyclic antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.

DrugDDI.d524.s0.e0 27 31
drug
drugs
DrugDDI.d524.s0.e1 36 50
drug
anticholinergic
DrugDDI.d524.s0.e2 69 85
drug
antipsychotic drug
DrugDDI.d524.s0.e3 90 103
drug
chlorpromazine
DrugDDI.d524.s0.e4 108 127
drug
antiparkinsonian drug
DrugDDI.d524.s0.e5 132 146
drug
trihexyphenidyl
DrugDDI.d524.s0.e6 156 178
drug
tricyclic antidepressant
DrugDDI.d524.s0.e7 183 195
drug
amitriptyline
DrugDDI.d524.s0.e8 225 239
drug
anticholinergic

interaction DrugDDI.d524.s0.e2 DrugDDI.d524.s0.e4
interaction DrugDDI.d524.s0.e2 DrugDDI.d524.s0.e5
interaction DrugDDI.d524.s0.e2 DrugDDI.d524.s0.e6
interaction DrugDDI.d524.s0.e2 DrugDDI.d524.s0.e7
interaction DrugDDI.d524.s0.e3 DrugDDI.d524.s0.e4
interaction DrugDDI.d524.s0.e3 DrugDDI.d524.s0.e5
interaction DrugDDI.d524.s0.e3 DrugDDI.d524.s0.e7
interaction DrugDDI.d524.s0.e4 DrugDDI.d524.s0.e7
interaction DrugDDI.d524.s0.e5 DrugDDI.d524.s0.e6
interaction DrugDDI.d524.s0.e5 DrugDDI.d524.s0.e7

Abstract Id: DrugDDI.d524
Sentence Id: DrugDDI.d524.s1
Interactions may also occur with the following: anti-depressants / anti-anxiety drugs , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e.g., codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine ), any other drugs that may make you drowsy.

DrugDDI.d524.s1.e0 41 56
drug
anti-depressants
DrugDDI.d524.s1.e1 58 74
drug
anti-anxiety drugs
DrugDDI.d524.s1.e2 76 80
drug
drugs
DrugDDI.d524.s1.e3 112 124
drug
beta-blockers
DrugDDI.d524.s1.e4 131 141
drug
propranolol
DrugDDI.d524.s1.e5 144 155
drug
sparfloxacin
DrugDDI.d524.s1.e6 157 169
drug
grepafloxacin
DrugDDI.d524.s1.e7 171 182
drug
guanethidine
DrugDDI.d524.s1.e8 184 192
drug
guanadrel
DrugDDI.d524.s1.e9 194 204
drug
metrizamide
DrugDDI.d524.s1.e10 206 216
drug
cabergoline
DrugDDI.d524.s1.e11 218 224
drug
lithium
DrugDDI.d524.s1.e12 226 233
drug
narcotic
DrugDDI.d524.s1.e13 254 260
drug
codeine
DrugDDI.d524.s1.e14 263 267
drug
drugs
DrugDDI.d524.s1.e15 301 314
drug
antihistamines
DrugDDI.d524.s1.e16 321 335
drug
diphenhydramine
DrugDDI.d524.s1.e17 346 350
drug
drugs



Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s0
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .

DrugDDI.d137.s0.e0 3 20
drug
hypoglycemic action
DrugDDI.d137.s0.e1 23 34
drug
sulfonylurea
DrugDDI.d137.s0.e2 60 64
drug
drugs
DrugDDI.d137.s0.e3 74 108
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d137.s0.e4 117 121
drug
drugs
DrugDDI.d137.s0.e5 135 141
drug
protein
DrugDDI.d137.s0.e6 148 158
drug
salicylates
DrugDDI.d137.s0.e7 160 171
drug
sulfonamides
DrugDDI.d137.s0.e8 173 187
drug
chloramphenicol
DrugDDI.d137.s0.e9 189 198
drug
probenecid
DrugDDI.d137.s0.e10 200 208
drug
coumarins
DrugDDI.d137.s0.e11 210 235
drug
monoamine oxidase inhibitors
DrugDDI.d137.s0.e12 240 267
drug
beta adrenergic blocking agents

interaction DrugDDI.d137.s0.e0 DrugDDI.d137.s0.e2
interaction DrugDDI.d137.s0.e0 DrugDDI.d137.s0.e4
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e3
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e6
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e7
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e8
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e9
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e10
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e11
interaction DrugDDI.d137.s0.e1 DrugDDI.d137.s0.e12

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s1
When such drugs are administered to a patient receiving DIABINESE , the patient should be observed closely for hypoglycemia.

DrugDDI.d137.s1.e0 8 12
drug
drugs
DrugDDI.d137.s1.e1 47 55
drug
DIABINESE

interaction DrugDDI.d137.s1.e0 DrugDDI.d137.s1.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s2
When such drugs are withdrawn from a patient receiving DIABINESE , the patient should be observed closely for loss of control.

DrugDDI.d137.s2.e0 8 12
drug
drugs
DrugDDI.d137.s2.e1 46 54
drug
DIABINESE

interaction DrugDDI.d137.s2.e0 DrugDDI.d137.s2.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s3
Certain drugs tend to produce hyperglycemia and may lead to loss of control.

DrugDDI.d137.s3.e0 7 11
drug
drugs



Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s4
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .

DrugDDI.d137.s4.e0 5 9
drug
drugs
DrugDDI.d137.s4.e1 20 28
drug
thiazides
DrugDDI.d137.s4.e2 37 45
drug
diuretics
DrugDDI.d137.s4.e3 47 61
drug
corticosteroids
DrugDDI.d137.s4.e4 63 76
drug
phenothiazines
DrugDDI.d137.s4.e5 78 84
drug
thyroid
DrugDDI.d137.s4.e6 94 102
drug
estrogens
DrugDDI.d137.s4.e7 104 121
drug
oral contraceptives
DrugDDI.d137.s4.e8 123 131
drug
phenytoin
DrugDDI.d137.s4.e9 133 145
drug
nicotinic acid
DrugDDI.d137.s4.e10 147 162
drug
sympathomimetics
DrugDDI.d137.s4.e11 164 190
drug
calcium channel blocking drugs
DrugDDI.d137.s4.e12 195 203
drug
isoniazid

interaction DrugDDI.d137.s4.e0 DrugDDI.d137.s4.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s5
When such drugs are administered to a patient receiving DIABINESE , the patient should be closely observed for loss of control.

DrugDDI.d137.s5.e0 8 12
drug
drugs
DrugDDI.d137.s5.e1 47 55
drug
DIABINESE

interaction DrugDDI.d137.s5.e0 DrugDDI.d137.s5.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s6
When such drugs are withdrawn from a patient receiving DIABINESE , the patient should be observed closely for hypoglycemia.

DrugDDI.d137.s6.e0 8 12
drug
drugs
DrugDDI.d137.s6.e1 46 54
drug
DIABINESE

interaction DrugDDI.d137.s6.e0 DrugDDI.d137.s6.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s7
Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide , barbiturates should be employed with caution.

DrugDDI.d137.s7.e0 40 51
drug
barbiturates
DrugDDI.d137.s7.e1 79 92
drug
chlorpropamide
DrugDDI.d137.s7.e2 94 105
drug
barbiturates

interaction DrugDDI.d137.s7.e0 DrugDDI.d137.s7.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s8
In some patients, a disulfiram -like reaction may be produced by the ingestion of alcohol .

DrugDDI.d137.s8.e0 16 25
drug
disulfiram
DrugDDI.d137.s8.e1 68 74
drug
alcohol

interaction DrugDDI.d137.s8.e0 DrugDDI.d137.s8.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s9
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.

DrugDDI.d137.s9.e0 28 41
drug
oral miconazole
DrugDDI.d137.s9.e1 49 66
drug
hypoglycemic agents

interaction DrugDDI.d137.s9.e0 DrugDDI.d137.s9.e1

Abstract Id: DrugDDI.d137
Sentence Id: DrugDDI.d137.s10
Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

DrugDDI.d137.s10.e0 82 91
drug
miconazole



Abstract Id: DrugDDI.d330
Sentence Id: DrugDDI.d330.s0
Chlorprothixene may increase the plasma-level of concomitantly given lithium .

DrugDDI.d330.s0.e0 0 14
drug
Chlorprothixene
DrugDDI.d330.s0.e1 61 67
drug
lithium

interaction DrugDDI.d330.s0.e0 DrugDDI.d330.s0.e1

Abstract Id: DrugDDI.d330
Sentence Id: DrugDDI.d330.s2
If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.

DrugDDI.d330.s2.e0 2 16
drug
chlorprothixene
DrugDDI.d330.s2.e1 41 47
drug
opioids
DrugDDI.d330.s2.e2 52 57
drug
opioid
DrugDDI.d330.s2.e3 99 113
drug
chlorprothixene
DrugDDI.d330.s2.e4 161 167
drug
opioids

interaction DrugDDI.d330.s2.e0 DrugDDI.d330.s2.e1

Abstract Id: DrugDDI.d330
Sentence Id: DrugDDI.d330.s3
Avoid the concomitant use of chlorprothixene and tramadol ( Ultram ).

DrugDDI.d330.s3.e0 24 38
drug
chlorprothixene
DrugDDI.d330.s3.e1 42 49
drug
tramadol
DrugDDI.d330.s3.e2 51 56
drug
Ultram

interaction DrugDDI.d330.s3.e0 DrugDDI.d330.s3.e1

Abstract Id: DrugDDI.d330
Sentence Id: DrugDDI.d330.s5
Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.

DrugDDI.d330.s5.e0 16 23
drug
sedative
DrugDDI.d330.s5.e1 62 76
drug
chlorprothixene
DrugDDI.d330.s5.e2 88 102
drug
benzodiazepines

interaction DrugDDI.d330.s5.e1 DrugDDI.d330.s5.e2

Abstract Id: DrugDDI.d330
Sentence Id: DrugDDI.d330.s6
Choose particular low doses of these drugs .

DrugDDI.d330.s6.e0 31 35
drug
drugs



Abstract Id: DrugDDI.d330
Sentence Id: DrugDDI.d330.s7
Exert particular caution in combining chlorprothixene with other anticholinergic drugs ( tricyclic antidepressants and antiparkinsonian agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.

DrugDDI.d330.s7.e0 33 47
drug
chlorprothixene
DrugDDI.d330.s7.e1 57 76
drug
anticholinergic drugs
DrugDDI.d330.s7.e2 78 101
drug
tricyclic antidepressants
DrugDDI.d330.s7.e3 105 126
drug
antiparkinsonian agents

interaction DrugDDI.d330.s7.e0 DrugDDI.d330.s7.e1
interaction DrugDDI.d330.s7.e0 DrugDDI.d330.s7.e3

Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s0
Chlorthalidone may add to or potentiate the action of other antihypertensive drugs .

DrugDDI.d143.s0.e0 0 13
drug
Chlorthalidone
DrugDDI.d143.s0.e1 50 70
drug
antihypertensive drugs

interaction DrugDDI.d143.s0.e0 DrugDDI.d143.s0.e1

Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s1
Potentiation occurs with ganglionic peripheral adrenergic blocking drugs .

DrugDDI.d143.s1.e0 32 64
drug
peripheral adrenergic blocking drugs



Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s2
Medication such as digitalis may also influence serum electrolytes.

DrugDDI.d143.s2.e0 0 9
drug
Medication
DrugDDI.d143.s2.e1 16 24
drug
digitalis



Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s4
Insulin requirements in diabetic patients may be increased, decreased, or unchanged.

DrugDDI.d143.s4.e0 0 6
drug
Insulin



Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s5
Higher dosage of oral hypoglycemic agents may be required.

DrugDDI.d143.s5.e0 18 35
drug
hypoglycemic agents



Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s6
Latent diabetes mellitus may become manifest during chlorthalidone administration.

DrugDDI.d143.s6.e0 45 58
drug
chlorthalidone



Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s7
Chlorthalidone and related drugs may increase the responsiveness to tubocurarine .

DrugDDI.d143.s7.e0 0 13
drug
Chlorthalidone
DrugDDI.d143.s7.e1 24 28
drug
drugs
DrugDDI.d143.s7.e2 59 70
drug
tubocurarine

interaction DrugDDI.d143.s7.e0 DrugDDI.d143.s7.e2
interaction DrugDDI.d143.s7.e1 DrugDDI.d143.s7.e2

Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s8
Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine .

DrugDDI.d143.s8.e0 0 13
drug
Chlorthalidone
DrugDDI.d143.s8.e1 24 28
drug
drugs
DrugDDI.d143.s8.e2 64 77
drug
norepinephrine

interaction DrugDDI.d143.s8.e0 DrugDDI.d143.s8.e2
interaction DrugDDI.d143.s8.e1 DrugDDI.d143.s8.e2

Abstract Id: DrugDDI.d143
Sentence Id: DrugDDI.d143.s9
This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

DrugDDI.d143.s9.e0 57 68
drug
pressor agent



Abstract Id: DrugDDI.d558
Sentence Id: DrugDDI.d558.s0
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.

DrugDDI.d558.s0.e0 19 25
drug
alcohol
DrugDDI.d558.s0.e1 33 63
drug
central nervous system depressants

interaction DrugDDI.d558.s0.e0 DrugDDI.d558.s0.e1

Abstract Id: DrugDDI.d4
Sentence Id: DrugDDI.d4.s0
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital , thyroid and thyroxine preparation s, estrogens and progestins , and digitalis .

DrugDDI.d4.s0.e0 0 13
drug
Cholestyramine
DrugDDI.d4.s0.e1 14 18
drug
resin
DrugDDI.d4.s0.e2 81 94
drug
phenylbutazone
DrugDDI.d4.s0.e3 96 103
drug
warfarin
DrugDDI.d4.s0.e4 105 121
drug
thiazide diuretics
DrugDDI.d4.s0.e5 132 142
drug
propranolol
DrugDDI.d4.s0.e6 159 170
drug
tetracycline
DrugDDI.d4.s0.e7 183 195
drug
phenobarbital
DrugDDI.d4.s0.e8 197 203
drug
thyroid
DrugDDI.d4.s0.e9 207 226
drug
thyroxine preparation
DrugDDI.d4.s0.e10 229 237
drug
estrogens
DrugDDI.d4.s0.e11 241 250
drug
progestins
DrugDDI.d4.s0.e12 255 263
drug
digitalis

interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e2
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e3
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e4
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e5
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e6
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e7
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e8
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e9
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e10
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e11
interaction DrugDDI.d4.s0.e0 DrugDDI.d4.s0.e12

Abstract Id: DrugDDI.d4
Sentence Id: DrugDDI.d4.s1
Interference with the absorption of oral phosphate supplements has been observed with another positively-charged bile acid sequestrant .

DrugDDI.d4.s1.e0 31 54
drug
oral phosphate supplements
DrugDDI.d4.s1.e1 81 117
drug
positively-charged bile acid sequestrant

interaction DrugDDI.d4.s1.e0 DrugDDI.d4.s1.e1

Abstract Id: DrugDDI.d4
Sentence Id: DrugDDI.d4.s2
Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin .

DrugDDI.d4.s2.e0 0 13
drug
Cholestyramine
DrugDDI.d4.s2.e1 56 60
drug
drugs
DrugDDI.d4.s2.e2 116 129
drug
cholestyramine
DrugDDI.d4.s2.e3 178 181
drug
drug
DrugDDI.d4.s2.e4 188 196
drug
digitalis
DrugDDI.d4.s2.e5 256 269
drug
cholestyramine
DrugDDI.d4.s2.e6 270 274
drug
resin

interaction DrugDDI.d4.s2.e0 DrugDDI.d4.s2.e1
interaction DrugDDI.d4.s2.e4 DrugDDI.d4.s2.e5

Abstract Id: DrugDDI.d4
Sentence Id: DrugDDI.d4.s3
Because cholestyramine binds bile acids , cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.

DrugDDI.d4.s3.e0 7 20
drug
cholestyramine
DrugDDI.d4.s3.e1 26 34
drug
bile acids
DrugDDI.d4.s3.e2 36 49
drug
cholestyramine
DrugDDI.d4.s3.e3 112 118
drug
prevent



Abstract Id: DrugDDI.d4
Sentence Id: DrugDDI.d4.s4
When cholestyramine resin is given for long periods of time, concomitant supplementation with water -miscible (or parenteral) forms of fat-soluble vitamins should be considered.

DrugDDI.d4.s4.e0 4 17
drug
cholestyramine
DrugDDI.d4.s4.e1 18 22
drug
resin
DrugDDI.d4.s4.e2 81 85
drug
water



Abstract Id: DrugDDI.d4
Sentence Id: DrugDDI.d4.s5
SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.

DrugDDI.d4.s5.e0 5 23
drug
CHOLESTYRAMINE RESIN
DrugDDI.d4.s5.e1 36 40
drug
DRUGS
DrugDDI.d4.s5.e2 95 99
drug
DRUGS
DrugDDI.d4.s5.e3 134 152
drug
CHOLESTYRAMINE RESIN



Abstract Id: DrugDDI.d165
Sentence Id: DrugDDI.d165.s0
Based on in vitro studies in human liver microsomes, des -ciclesonide appears to have no inhibitory or induction potential on the metabolism of other drugs metabolized by CYP 450 enzymes.

DrugDDI.d165.s0.e0 44 46
drug
des
DrugDDI.d165.s0.e1 126 130
drug
drugs
DrugDDI.d165.s0.e2 144 146
drug
CYP



Abstract Id: DrugDDI.d165
Sentence Id: DrugDDI.d165.s1
The inhibitory potential of ciclesonide on CYP450 isoenzymes has not been studied.

DrugDDI.d165.s1.e0 24 34
drug
ciclesonide
DrugDDI.d165.s1.e1 43 52
drug
isoenzymes



Abstract Id: DrugDDI.d165
Sentence Id: DrugDDI.d165.s2
In vitro studies demonstrated that the plasma protein binding of des -ciclesonide was not affected by warfarin or salicylic acid , indicating no potential for protein binding-based drug interactions.

DrugDDI.d165.s2.e0 33 45
drug
plasma protein
DrugDDI.d165.s2.e1 55 57
drug
des
DrugDDI.d165.s2.e2 86 93
drug
warfarin
DrugDDI.d165.s2.e3 96 108
drug
salicylic acid



Abstract Id: DrugDDI.d165
Sentence Id: DrugDDI.d165.s3
In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4 , had no effect on the pharmacokinetics of either des -ciclesonide or erythromycin .

DrugDDI.d165.s3.e0 56 66
drug
ciclesonide
DrugDDI.d165.s3.e1 100 116
drug
cytochrome P450 3A4
DrugDDI.d165.s3.e2 158 160
drug
des
DrugDDI.d165.s3.e3 175 186
drug
erythromycin



Abstract Id: DrugDDI.d165
Sentence Id: DrugDDI.d165.s4
In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole , a potent inhibitor of cytochrome P450 3A4 , increased the exposure (AUC) of des -ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.

DrugDDI.d165.s4.e0 62 72
drug
ciclesonide
DrugDDI.d165.s4.e1 80 91
drug
ketoconazole
DrugDDI.d165.s4.e2 111 127
drug
cytochrome P450 3A4
DrugDDI.d165.s4.e3 156 158
drug
des
DrugDDI.d165.s4.e4 221 231
drug
ciclesonide

interaction DrugDDI.d165.s4.e0 DrugDDI.d165.s4.e1

Abstract Id: DrugDDI.d165
Sentence Id: DrugDDI.d165.s5
Therefore, ketoconazole should be administered with caution with intranasal ciclesonide .

DrugDDI.d165.s5.e0 10 21
drug
ketoconazole
DrugDDI.d165.s5.e1 67 77
drug
ciclesonide

interaction DrugDDI.d165.s5.e0 DrugDDI.d165.s5.e1

Abstract Id: DrugDDI.d92
Sentence Id: DrugDDI.d92.s0
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen , acyclovir , angiotensin-converting enzyme inhibitors , aminosalicylic acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal anti-inflammatory agents , theophylline , and zidovudine ).

DrugDDI.d92.s0.e0 0 9
drug
Probenecid
DrugDDI.d92.s0.e1 11 20
drug
Probenecid
DrugDDI.d92.s0.e2 84 88
drug
drugs
DrugDDI.d92.s0.e3 95 107
drug
acetaminophen
DrugDDI.d92.s0.e4 109 117
drug
acyclovir
DrugDDI.d92.s0.e5 119 156
drug
angiotensin-converting enzyme inhibitors
DrugDDI.d92.s0.e6 158 175
drug
aminosalicylic acid
DrugDDI.d92.s0.e7 177 188
drug
barbiturates
DrugDDI.d92.s0.e8 190 204
drug
benzodiazepines
DrugDDI.d92.s0.e9 206 215
drug
bumetanide
DrugDDI.d92.s0.e10 217 226
drug
clofibrate
DrugDDI.d92.s0.e11 228 239
drug
methotrexate
DrugDDI.d92.s0.e12 241 250
drug
famotidine
DrugDDI.d92.s0.e13 252 261
drug
furosemide
DrugDDI.d92.s0.e14 263 297
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d92.s0.e15 299 310
drug
theophylline
DrugDDI.d92.s0.e16 315 324
drug
zidovudine

interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e2
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e3
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e4
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e5
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e6
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e7
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e8
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e9
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e10
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e11
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e12
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e13
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e14
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e15
interaction DrugDDI.d92.s0.e1 DrugDDI.d92.s0.e16

Abstract Id: DrugDDI.d92
Sentence Id: DrugDDI.d92.s1
Concomitant medications should be carefully assessed.

DrugDDI.d92.s1.e0 11 21
drug
medications



Abstract Id: DrugDDI.d92
Sentence Id: DrugDDI.d92.s2
Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.

DrugDDI.d92.s2.e0 0 9
drug
Zidovudine
DrugDDI.d92.s2.e1 85 94
drug
probenecid
DrugDDI.d92.s2.e2 105 111
drug
VISTIDE

interaction DrugDDI.d92.s2.e0 DrugDDI.d92.s2.e1

Abstract Id: DrugDDI.d92
Sentence Id: DrugDDI.d92.s3
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin , gentamicin , and amikacin ), amphotericin B , foscarnet , intravenous pentamidin e, vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated.

DrugDDI.d92.s3.e0 45 51
drug
VISTIDE
DrugDDI.d92.s3.e1 102 116
drug
aminoglycosides
DrugDDI.d92.s3.e2 123 132
drug
tobramycin
DrugDDI.d92.s3.e3 134 143
drug
gentamicin
DrugDDI.d92.s3.e4 148 155
drug
amikacin
DrugDDI.d92.s3.e5 158 170
drug
amphotericin B
DrugDDI.d92.s3.e6 172 180
drug
foscarnet
DrugDDI.d92.s3.e7 193 202
drug
pentamidin
DrugDDI.d92.s3.e8 205 214
drug
vancomycin
DrugDDI.d92.s3.e9 219 254
drug
non-steroidal anti-inflammatory agents

interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e2
interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e3
interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e4
interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e5
interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e6
interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e7
interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e8
interaction DrugDDI.d92.s3.e0 DrugDDI.d92.s3.e9

Abstract Id: DrugDDI.d92
Sentence Id: DrugDDI.d92.s4
Such agents must be discontinued at least seven days prior to starting therapy with VISTIDE .

DrugDDI.d92.s4.e0 70 76
drug
VISTIDE



Abstract Id: DrugDDI.d320
Sentence Id: DrugDDI.d320.s0
Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole .

DrugDDI.d320.s0.e0 5 10
drug
PLETAL
DrugDDI.d320.s0.e1 37 51
drug
cytochrome P-450
DrugDDI.d320.s0.e2 91 96
drug
PLETAL
DrugDDI.d320.s0.e3 141 152
drug
ketoconazole
DrugDDI.d320.s0.e4 156 167
drug
erythromycin
DrugDDI.d320.s0.e5 182 188
drug
CYP2C19
DrugDDI.d320.s0.e6 195 204
drug
omeprazole

interaction DrugDDI.d320.s0.e2 DrugDDI.d320.s0.e3
interaction DrugDDI.d320.s0.e2 DrugDDI.d320.s0.e6

Abstract Id: DrugDDI.d320
Sentence Id: DrugDDI.d320.s1
Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites .

DrugDDI.d320.s1.e0 42 51
drug
omeprazole
DrugDDI.d320.s1.e1 55 66
drug
erythromycin
DrugDDI.d320.s1.e2 110 119
drug
cilostazol
DrugDDI.d320.s1.e3 134 144
drug
metabolites

interaction DrugDDI.d320.s1.e0 DrugDDI.d320.s1.e1
interaction DrugDDI.d320.s1.e0 DrugDDI.d320.s1.e2
interaction DrugDDI.d320.s1.e1 DrugDDI.d320.s1.e2

Abstract Id: DrugDDI.d320
Sentence Id: DrugDDI.d320.s2
Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem , an inhibitor of C.P.A..

DrugDDI.d320.s2.e0 60 69
drug
cilostazol
DrugDDI.d320.s2.e1 106 114
drug
diltiazem

interaction DrugDDI.d320.s2.e0 DrugDDI.d320.s2.e1

Abstract Id: DrugDDI.d320
Sentence Id: DrugDDI.d320.s3
Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4 , as it had no effect on lovastatin , a drug with metabolism very sensitive to C.P.A. inhibition.

DrugDDI.d320.s3.e0 0 5
drug
Pletal
DrugDDI.d320.s3.e1 57 61
drug
drugs
DrugDDI.d320.s3.e2 75 80
drug
CYP3A4
DrugDDI.d320.s3.e3 99 108
drug
lovastatin
DrugDDI.d320.s3.e4 111 114
drug
drug



Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s0
Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .

DrugDDI.d425.s0.e0 0 6
drug
Tagamet
DrugDDI.d425.s0.e1 42 57
drug
microsomal enzyme
DrugDDI.d425.s0.e2 124 137
drug
anticoagulants
DrugDDI.d425.s0.e3 139 147
drug
phenytoin
DrugDDI.d425.s0.e4 149 159
drug
propranolol
DrugDDI.d425.s0.e5 161 170
drug
nifedipine
DrugDDI.d425.s0.e6 172 187
drug
chlordiazepoxide
DrugDDI.d425.s0.e7 189 196
drug
diazepam
DrugDDI.d425.s0.e8 205 228
drug
tricyclic antidepressants
DrugDDI.d425.s0.e9 230 238
drug
lidocaine
DrugDDI.d425.s0.e10 240 251
drug
theophylline
DrugDDI.d425.s0.e11 255 267
drug
metronidazole
DrugDDI.d425.s0.e12 326 330
drug
drugs

interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e2
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e3
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e4
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e5
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e6
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e7
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e8
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e9
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e10
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e11

Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s1
Clinically significant effects have been reported with the warfarin anticoagulants ; .

DrugDDI.d425.s1.e0 59 72
drug
anticoagulants



Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s2
therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.

DrugDDI.d425.s2.e0 74 86
drug
anticoagulant
DrugDDI.d425.s2.e1 109 115
drug
Tagamet

interaction DrugDDI.d425.s2.e0 DrugDDI.d425.s2.e1

Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s3
Interaction with phenytoin , lidocaine and theophylline has also been reported to produce adverse clinical effects.

DrugDDI.d425.s3.e0 15 23
drug
phenytoin
DrugDDI.d425.s3.e1 25 33
drug
lidocaine
DrugDDI.d425.s3.e2 37 48
drug
theophylline



Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s4
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur@, Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.

DrugDDI.d425.s4.e0 55 64
drug
Tagamet 300
DrugDDI.d425.s4.e1 121 132
drug
theophylline
DrugDDI.d425.s4.e2 208 219
drug
theophylline

interaction DrugDDI.d425.s4.e0 DrugDDI.d425.s4.e1

Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s6
(Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.) .

DrugDDI.d425.s6.e0 26 37
drug
theophylline



Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s7
Dosage of the drugs mentioned above and other similarly metabolized drugs , particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels.

DrugDDI.d425.s7.e0 11 15
drug
drugs
DrugDDI.d425.s7.e1 58 62
drug
drugs
DrugDDI.d425.s7.e2 214 220
drug
Tagamet



Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s8
Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole ).

DrugDDI.d425.s8.e0 42 46
drug
drugs
DrugDDI.d425.s8.e1 53 64
drug
ketoconazole



Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s9
If these products are needed, they should be given at least 2 hours before cimetidine administration.

DrugDDI.d425.s9.e0 61 70
drug
cimetidine



Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s10
Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet .

DrugDDI.d425.s10.e0 42 46
drug
drugs
DrugDDI.d425.s10.e1 87 93
drug
Tagamet

interaction DrugDDI.d425.s10.e0 DrugDDI.d425.s10.e1

Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s0
and/or Drug /Laboratory Test Interactions See CLINICAL PHARMACOLOGY, Pharmacokinetics and Drug Interactions.

DrugDDI.d362.s0.e0 6 9
drug
Drug



Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s1
Effect of Sensipar on other drugs : Drugs metabolized by cytochrome P450 2D6 ( CYP2D6 ): Sensipar@ is a strong in vitro inhibitor of CYP2D6 .

DrugDDI.d362.s1.e0 8 15
drug
Sensipar
DrugDDI.d362.s1.e1 23 27
drug
drugs
DrugDDI.d362.s1.e2 29 33
drug
Drugs
DrugDDI.d362.s1.e3 47 63
drug
cytochrome P450 2D6
DrugDDI.d362.s1.e4 65 70
drug
CYP2D6
DrugDDI.d362.s1.e5 109 114
drug
CYP2D6

interaction DrugDDI.d362.s1.e2 DrugDDI.d362.s1.e3

Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s2
Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide , vinblastine , thioridazine and most tricyclic antidepressants ) may be required.

DrugDDI.d362.s2.e0 38 48
drug
medications
DrugDDI.d362.s2.e1 82 87
drug
CYP2D6
DrugDDI.d362.s2.e2 124 133
drug
flecainide
DrugDDI.d362.s2.e3 135 145
drug
vinblastine
DrugDDI.d362.s2.e4 147 158
drug
thioridazine
DrugDDI.d362.s2.e5 166 189
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s3
Amitriptyline : Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline ( active metabolite ) exposure by approximately 20% in CYP2D6 extensive metabolizers.

DrugDDI.d362.s3.e0 0 12
drug
Amitriptyline
DrugDDI.d362.s3.e1 51 60
drug
cinacalcet
DrugDDI.d362.s3.e2 69 81
drug
amitriptyline
DrugDDI.d362.s3.e3 91 103
drug
amitriptyline
DrugDDI.d362.s3.e4 115 127
drug
nortriptyline
DrugDDI.d362.s3.e5 129 144
drug
active metabolite
DrugDDI.d362.s3.e6 174 179
drug
CYP2D6

interaction DrugDDI.d362.s3.e1 DrugDDI.d362.s3.e2

Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s4
Effect of other drugs on Sensipar : Sensipar@ is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4 , CYP2D6 , and CYP1A2 .

DrugDDI.d362.s4.e0 13 17
drug
drugs
DrugDDI.d362.s4.e1 20 27
drug
Sensipar
DrugDDI.d362.s4.e2 61 74
drug
cytochrome P450
DrugDDI.d362.s4.e3 92 97
drug
CYP3A4
DrugDDI.d362.s4.e4 99 104
drug
CYP2D6
DrugDDI.d362.s4.e5 109 114
drug
CYP1A2



Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s5
Ketoconazole : Sensipar is metabolized in part by CYP3A4 .

DrugDDI.d362.s5.e0 0 11
drug
Ketoconazole
DrugDDI.d362.s5.e1 13 20
drug
Sensipar
DrugDDI.d362.s5.e2 42 47
drug
CYP3A4

interaction DrugDDI.d362.s5.e1 DrugDDI.d362.s5.e2

Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s6
Co-administration of ketoconazole , a strong inhibitor of CYP3A4 , increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.

DrugDDI.d362.s6.e0 19 30
drug
ketoconazole
DrugDDI.d362.s6.e1 50 55
drug
CYP3A4
DrugDDI.d362.s6.e2 66 75
drug
cinacalcet
DrugDDI.d362.s6.e3 110 117
drug
Sensipar

interaction DrugDDI.d362.s6.e0 DrugDDI.d362.s6.e3

Abstract Id: DrugDDI.d362
Sentence Id: DrugDDI.d362.s7
Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole , erythromycin , itraconazole ; .

DrugDDI.d362.s7.e0 16 23
drug
Sensipar
DrugDDI.d362.s7.e1 40 42
drug
PTH
DrugDDI.d362.s7.e2 147 152
drug
CYP3A4
DrugDDI.d362.s7.e3 168 179
drug
ketoconazole
DrugDDI.d362.s7.e4 181 192
drug
erythromycin
DrugDDI.d362.s7.e5 194 205
drug
itraconazole



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s0
Some quinolones , including ciprofloxacin , have also been shown to interfere with the metabolism of caffeine .

DrugDDI.d472.s0.e0 4 13
drug
quinolones
DrugDDI.d472.s0.e1 24 36
drug
ciprofloxacin
DrugDDI.d472.s0.e2 85 92
drug
caffeine

interaction DrugDDI.d472.s0.e0 DrugDDI.d472.s0.e2
interaction DrugDDI.d472.s0.e1 DrugDDI.d472.s0.e2

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s1
This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.

DrugDDI.d472.s1.e0 31 38
drug
caffeine



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s2
Some quinolones , including ciprofloxacin , have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

DrugDDI.d472.s2.e0 4 13
drug
quinolones
DrugDDI.d472.s2.e1 24 36
drug
ciprofloxacin
DrugDDI.d472.s2.e2 115 126
drug
cyclosporine

interaction DrugDDI.d472.s2.e0 DrugDDI.d472.s2.e2
interaction DrugDDI.d472.s2.e1 DrugDDI.d472.s2.e2

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s3
Glyburide The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.

DrugDDI.d472.s3.e0 0 8
drug
Glyburide
DrugDDI.d472.s3.e1 39 51
drug
ciprofloxacin
DrugDDI.d472.s3.e2 59 70
drug
sulfonylurea

interaction DrugDDI.d472.s3.e1 DrugDDI.d472.s3.e2

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s4
Histamine H2-receptor antagonists Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin .

DrugDDI.d472.s4.e0 0 30
drug
Histamine H2-receptor antagonists
DrugDDI.d472.s4.e1 115 127
drug
ciprofloxacin



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s5
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of methotrexate .

DrugDDI.d472.s5.e0 0 11
drug
Methotrexate
DrugDDI.d472.s5.e1 35 46
drug
methotrexate
DrugDDI.d472.s5.e2 90 102
drug
ciprofloxacin
DrugDDI.d472.s5.e3 147 158
drug
methotrexate

interaction DrugDDI.d472.s5.e1 DrugDDI.d472.s5.e2

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s6
This might increase the risk of methotrexate toxic reactions.

DrugDDI.d472.s6.e0 26 37
drug
methotrexate



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s7
Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.

DrugDDI.d472.s7.e0 23 34
drug
methotrexate
DrugDDI.d472.s7.e1 83 95
drug
ciprofloxacin

interaction DrugDDI.d472.s7.e0 DrugDDI.d472.s7.e1

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s8
Multivalent Cation -Containing Products Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation -containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/ buffer ed tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired.

DrugDDI.d472.s8.e0 11 16
drug
Cation
DrugDDI.d472.s8.e1 63 71
drug
quinolone
DrugDDI.d472.s8.e2 82 94
drug
ciprofloxacin
DrugDDI.d472.s8.e3 111 116
drug
cation
DrugDDI.d472.s8.e4 142 150
drug
magnesium
DrugDDI.d472.s8.e5 153 168
drug
aluminum antacids
DrugDDI.d472.s8.e6 170 179
drug
sucralfate
DrugDDI.d472.s8.e7 181 185
drug
VIDEX
DrugDDI.d472.s8.e8 195 200
drug
buffer
DrugDDI.d472.s8.e9 212 220
drug
pediatric
DrugDDI.d472.s8.e10 248 254
drug
calcium
DrugDDI.d472.s8.e11 256 259
drug
iron
DrugDDI.d472.s8.e12 263 266
drug
zinc
DrugDDI.d472.s8.e13 306 318
drug
ciprofloxacin

interaction DrugDDI.d472.s8.e0 DrugDDI.d472.s8.e3
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e3
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e4
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e5
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e6
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e7
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e9
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e11
interaction DrugDDI.d472.s8.e1 DrugDDI.d472.s8.e12
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e3
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e4
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e5
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e6
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e7
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e9
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e11
interaction DrugDDI.d472.s8.e2 DrugDDI.d472.s8.e12

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s10
This time window is different than for other oral formulations of ciprofloxacin , which are usually administered 2 hours before or 6 hours after antacids .

DrugDDI.d472.s10.e0 55 67
drug
ciprofloxacin
DrugDDI.d472.s10.e1 121 128
drug
antacids



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s11
Non-steroidal anti-inflammatory drugs (but not aspirin ) These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.

DrugDDI.d472.s11.e0 0 34
drug
Non-steroidal anti-inflammatory drugs
DrugDDI.d472.s11.e1 42 48
drug
aspirin
DrugDDI.d472.s11.e2 55 59
drug
drugs
DrugDDI.d472.s11.e3 92 101
drug
quinolones

interaction DrugDDI.d472.s11.e2 DrugDDI.d472.s11.e3

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s12
Omeprazole The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.

DrugDDI.d472.s12.e0 0 9
drug
Omeprazole
DrugDDI.d472.s12.e1 40 52
drug
ciprofloxacin
DrugDDI.d472.s12.e2 129 138
drug
omeprazole



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s13
Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..

DrugDDI.d472.s13.e0 0 9
drug
Omeprazole



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s14
Phenytoin Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin .

DrugDDI.d472.s14.e0 0 8
drug
Phenytoin
DrugDDI.d472.s14.e1 29 37
drug
phenytoin
DrugDDI.d472.s14.e2 107 119
drug
ciprofloxacin

interaction DrugDDI.d472.s14.e1 DrugDDI.d472.s14.e2

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s15
Probenecid Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.

DrugDDI.d472.s15.e0 0 9
drug
Probenecid
DrugDDI.d472.s15.e1 57 69
drug
ciprofloxacin
DrugDDI.d472.s15.e2 103 115
drug
ciprofloxacin

interaction DrugDDI.d472.s15.e0 DrugDDI.d472.s15.e1
interaction DrugDDI.d472.s15.e0 DrugDDI.d472.s15.e2

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s16
Theophylline As with some other quinolones , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.

DrugDDI.d472.s16.e0 0 11
drug
Theophylline
DrugDDI.d472.s16.e1 27 36
drug
quinolones
DrugDDI.d472.s16.e2 64 76
drug
ciprofloxacin
DrugDDI.d472.s16.e3 81 92
drug
theophylline
DrugDDI.d472.s16.e4 131 142
drug
theophylline

interaction DrugDDI.d472.s16.e2 DrugDDI.d472.s16.e3

Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s18
If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.

DrugDDI.d472.s18.e0 45 56
drug
theophylline



Abstract Id: DrugDDI.d472
Sentence Id: DrugDDI.d472.s19
Warfarin Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives .

DrugDDI.d472.s19.e0 8 17
drug
Quinolones
DrugDDI.d472.s19.e1 58 82
drug
oral anticoagulant warfarin
DrugDDI.d472.s19.e2 88 98
drug
derivatives

interaction DrugDDI.d472.s19.e0 DrugDDI.d472.s19.e1
interaction DrugDDI.d472.s19.e0 DrugDDI.d472.s19.e2

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s0
Cisapride is metabolized mainly via the cytochrome P450 3A4 enzyme.

DrugDDI.d428.s0.e0 0 8
drug
Cisapride
DrugDDI.d428.s0.e1 34 50
drug
cytochrome P450 3A4

interaction DrugDDI.d428.s0.e0 DrugDDI.d428.s0.e1

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s1
In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.

DrugDDI.d428.s1.e0 97 105
drug
cisapride
DrugDDI.d428.s1.e1 139 155
drug
cytochrome P450 3A4
DrugDDI.d428.s1.e2 180 188
drug
cisapride

interaction DrugDDI.d428.s1.e0 DrugDDI.d428.s1.e1

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s2
Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.

DrugDDI.d428.s2.e0 0 10
drug
Antibiotics
DrugDDI.d428.s2.e1 43 56
drug
clarithromycin
DrugDDI.d428.s2.e2 58 69
drug
erythromycin
DrugDDI.d428.s2.e3 74 87
drug
troleandomycin
DrugDDI.d428.s2.e4 118 126
drug
cisapride
DrugDDI.d428.s2.e5 162 170
drug
cisapride

interaction DrugDDI.d428.s2.e1 DrugDDI.d428.s2.e4
interaction DrugDDI.d428.s2.e2 DrugDDI.d428.s2.e4
interaction DrugDDI.d428.s2.e3 DrugDDI.d428.s2.e4

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s3
Anticholinergics : Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride .

DrugDDI.d428.s3.e0 0 15
drug
Anticholinergics
DrugDDI.d428.s3.e1 50 64
drug
anticholinergic
DrugDDI.d428.s3.e2 81 99
drug
belladonna alkaloids
DrugDDI.d428.s3.e3 103 113
drug
dicyclomine
DrugDDI.d428.s3.e4 164 172
drug
cisapride

interaction DrugDDI.d428.s3.e1 DrugDDI.d428.s3.e4
interaction DrugDDI.d428.s3.e3 DrugDDI.d428.s3.e4

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s4
Anticoagulants (Oral): In patients receiving oral anticoagulants , the coagulation times were increased in some cases.

DrugDDI.d428.s4.e0 0 13
drug
Anticoagulants
DrugDDI.d428.s4.e1 40 57
drug
oral anticoagulants



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s5
It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.

DrugDDI.d428.s5.e0 89 97
drug
cisapride
DrugDDI.d428.s5.e1 138 150
drug
anticoagulant



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s6
Antidepressants : In vitro data indicate that nefazodone inhibits the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.

DrugDDI.d428.s6.e0 0 14
drug
Antidepressants
DrugDDI.d428.s6.e1 39 48
drug
nefazodone
DrugDDI.d428.s6.e2 72 80
drug
cisapride
DrugDDI.d428.s6.e3 116 124
drug
cisapride

interaction DrugDDI.d428.s6.e1 DrugDDI.d428.s6.e2

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s7
Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.

DrugDDI.d428.s7.e0 0 10
drug
Antifungals
DrugDDI.d428.s7.e1 47 57
drug
fluconazole
DrugDDI.d428.s7.e2 59 70
drug
itraconazole
DrugDDI.d428.s7.e3 79 90
drug
ketoconazole
DrugDDI.d428.s7.e4 121 129
drug
cisapride
DrugDDI.d428.s7.e5 165 173
drug
cisapride

interaction DrugDDI.d428.s7.e1 DrugDDI.d428.s7.e4
interaction DrugDDI.d428.s7.e2 DrugDDI.d428.s7.e4
interaction DrugDDI.d428.s7.e3 DrugDDI.d428.s7.e4

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s8
Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride , resulting in a mean eight-fold increase in AUC of cisapride .

DrugDDI.d428.s8.e0 40 51
drug
ketoconazole
DrugDDI.d428.s8.e1 83 91
drug
cisapride
DrugDDI.d428.s8.e2 134 142
drug
cisapride

interaction DrugDDI.d428.s8.e0 DrugDDI.d428.s8.e1

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s9
A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.

DrugDDI.d428.s9.e0 69 77
drug
cisapride
DrugDDI.d428.s9.e1 81 92
drug
ketoconazole

interaction DrugDDI.d428.s9.e0 DrugDDI.d428.s9.e1

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s10
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on cisapride absorption when it is coadministered with ranitidine .

DrugDDI.d428.s10.e0 0 9
drug
H2 Receptor
DrugDDI.d428.s10.e1 22 31
drug
Cimetidine
DrugDDI.d428.s10.e2 97 105
drug
cisapride
DrugDDI.d428.s10.e3 124 132
drug
cisapride
DrugDDI.d428.s10.e4 169 178
drug
ranitidine

interaction DrugDDI.d428.s10.e1 DrugDDI.d428.s10.e2

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s11
The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride .

DrugDDI.d428.s11.e0 31 40
drug
cimetidine
DrugDDI.d428.s11.e1 44 53
drug
ranitidine
DrugDDI.d428.s11.e2 96 104
drug
cisapride

interaction DrugDDI.d428.s11.e0 DrugDDI.d428.s11.e2
interaction DrugDDI.d428.s11.e1 DrugDDI.d428.s11.e2

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s12
Protease Inhibitors : In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.

DrugDDI.d428.s12.e0 0 17
drug
Protease Inhibitors
DrugDDI.d428.s12.e1 42 50
drug
indinavir
DrugDDI.d428.s12.e2 54 62
drug
ritonavir
DrugDDI.d428.s12.e3 93 101
drug
cisapride
DrugDDI.d428.s12.e4 136 144
drug
cisapride

interaction DrugDDI.d428.s12.e1 DrugDDI.d428.s12.e3
interaction DrugDDI.d428.s12.e2 DrugDDI.d428.s12.e3

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s13
Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.

DrugDDI.d428.s13.e0 43 51
drug
cisapride
DrugDDI.d428.s13.e1 81 89
drug
cisapride



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s14
Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol ); .

DrugDDI.d428.s14.e0 0 8
drug
Cisapride
DrugDDI.d428.s14.e1 46 50
drug
drugs
DrugDDI.d428.s14.e2 86 100
drug
antiarrhythmics
DrugDDI.d428.s14.e3 132 140
drug
quinidine
DrugDDI.d428.s14.e4 144 155
drug
procainamide
DrugDDI.d428.s14.e5 175 181
drug
sotalol

interaction DrugDDI.d428.s14.e0 DrugDDI.d428.s14.e1

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s15
tricyclic antidepressants (such as amitriptyline ); .

DrugDDI.d428.s15.e0 0 23
drug
tricyclic antidepressants
DrugDDI.d428.s15.e1 31 43
drug
amitriptyline



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s16
certain tetracyclic antidepressant s (such as maprotilin e); .

DrugDDI.d428.s16.e0 7 31
drug
tetracyclic antidepressant
DrugDDI.d428.s16.e1 40 49
drug
maprotilin



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s17
certain antipsychotic medications (such as sertindole ); .

DrugDDI.d428.s17.e0 38 47
drug
sertindole



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s18
astemizole , bepridil , sparfloxacin , and terodiline .

DrugDDI.d428.s18.e0 0 9
drug
astemizole
DrugDDI.d428.s18.e1 11 18
drug
bepridil
DrugDDI.d428.s18.e2 20 31
drug
sparfloxacin
DrugDDI.d428.s18.e3 36 45
drug
terodiline



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s19
The preceding lists of drugs are not comprehensive.

DrugDDI.d428.s19.e0 19 23
drug
drugs



Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s20
The acceleration of gastric emptying by cisapride could affect the rate of absorption of other drugs .

DrugDDI.d428.s20.e0 34 42
drug
cisapride
DrugDDI.d428.s20.e1 80 84
drug
drugs

interaction DrugDDI.d428.s20.e0 DrugDDI.d428.s20.e1

Abstract Id: DrugDDI.d428
Sentence Id: DrugDDI.d428.s21
Patients receiving narrow therapeutic ratio drugs or other drugs that require careful titration should be followed closely; .

DrugDDI.d428.s21.e0 39 43
drug
drugs
DrugDDI.d428.s21.e1 51 55
drug
drugs



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s0
NIMBEX has been used safely following varying degrees of recovery from succinylcholine -induced neuromuscular block.

DrugDDI.d300.s0.e0 0 5
drug
NIMBEX
DrugDDI.d300.s0.e1 60 74
drug
succinylcholine



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s1
Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced @95% neuromuscular block.

DrugDDI.d300.s1.e0 33 38
drug
NIMBEX
DrugDDI.d300.s1.e1 84 98
drug
succinylcholine

interaction DrugDDI.d300.s1.e0 DrugDDI.d300.s1.e1

Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s2
The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine .

DrugDDI.d300.s2.e0 37 42
drug
NIMBEX
DrugDDI.d300.s2.e1 97 111
drug
succinylcholine



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s3
Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX .

DrugDDI.d300.s3.e0 21 35
drug
succinylcholine
DrugDDI.d300.s3.e1 121 126
drug
NIMBEX



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s4
Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.

DrugDDI.d300.s4.e0 22 27
drug
NIMBEX
DrugDDI.d300.s4.e1 50 64
drug
succinylcholine
DrugDDI.d300.s4.e2 83 88
drug
NIMBEX
DrugDDI.d300.s4.e3 130 144
drug
succinylcholine



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s5
The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.

DrugDDI.d300.s5.e0 8 13
drug
NIMBEX
DrugDDI.d300.s5.e1 20 34
drug
succinylcholine
DrugDDI.d300.s5.e2 68 82
drug
succinylcholine



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s6
Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium , pancuronium , or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX .

DrugDDI.d300.s6.e0 83 92
drug
vecuronium
DrugDDI.d300.s6.e1 94 104
drug
pancuronium
DrugDDI.d300.s6.e2 108 117
drug
atracurium
DrugDDI.d300.s6.e3 195 200
drug
NIMBEX



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s7
Isoflurane or enflurane administered with nitrous oxide / oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .

DrugDDI.d300.s7.e0 0 9
drug
Isoflurane
DrugDDI.d300.s7.e1 12 20
drug
enflurane
DrugDDI.d300.s7.e2 37 48
drug
nitrous oxide
DrugDDI.d300.s7.e3 50 55
drug
oxygen
DrugDDI.d300.s7.e4 180 185
drug
NIMBEX
DrugDDI.d300.s7.e5 222 227
drug
NIMBEX

interaction DrugDDI.d300.s7.e0 DrugDDI.d300.s7.e2
interaction DrugDDI.d300.s7.e1 DrugDDI.d300.s7.e2

Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s9
Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.

DrugDDI.d300.s9.e0 37 46
drug
isoflurane
DrugDDI.d300.s9.e1 49 57
drug
enflurane
DrugDDI.d300.s9.e2 112 117
drug
NIMBEX
DrugDDI.d300.s9.e3 180 185
drug
NIMBEX



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s10
In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.

DrugDDI.d300.s10.e0 30 38
drug
enflurane
DrugDDI.d300.s10.e1 41 50
drug
isoflurane
DrugDDI.d300.s10.e2 138 143
drug
NIMBEX

interaction DrugDDI.d300.s10.e0 DrugDDI.d300.s10.e2
interaction DrugDDI.d300.s10.e1 DrugDDI.d300.s10.e2

Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s12
In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX .

DrugDDI.d300.s12.e0 17 24
drug
propofol
DrugDDI.d300.s12.e1 80 85
drug
NIMBEX



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s13
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agent s such as NIMBEX include certain antibiotics (e. g., aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistemethate), magnesium salt s, lithium , local anesthetics , procainamide , and quinidine .

DrugDDI.d300.s13.e0 5 9
drug
drugs
DrugDDI.d300.s13.e1 57 76
drug
nondepolarizing agent
DrugDDI.d300.s13.e2 84 89
drug
NIMBEX
DrugDDI.d300.s13.e3 104 114
drug
antibiotics
DrugDDI.d300.s13.e4 121 135
drug
aminoglycosides
DrugDDI.d300.s13.e5 137 149
drug
tetracyclines
DrugDDI.d300.s13.e6 151 160
drug
bacitracin
DrugDDI.d300.s13.e7 162 171
drug
polymyxins
DrugDDI.d300.s13.e8 173 182
drug
lincomycin
DrugDDI.d300.s13.e9 184 194
drug
clindamycin
DrugDDI.d300.s13.e10 196 203
drug
colistin
DrugDDI.d300.s13.e11 208 213
drug
sodium
DrugDDI.d300.s13.e12 230 242
drug
magnesium salt
DrugDDI.d300.s13.e13 245 251
drug
lithium
DrugDDI.d300.s13.e14 253 268
drug
local anesthetics
DrugDDI.d300.s13.e15 270 281
drug
procainamide
DrugDDI.d300.s13.e16 286 294
drug
quinidine

interaction DrugDDI.d300.s13.e0 DrugDDI.d300.s13.e1

Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s14
Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .

DrugDDI.d300.s14.e0 59 85
drug
neuromuscular blocking agents
DrugDDI.d300.s14.e1 138 146
drug
phenytoin
DrugDDI.d300.s14.e2 149 161
drug
carbamazepine

interaction DrugDDI.d300.s14.e0 DrugDDI.d300.s14.e1

Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s15
While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.

DrugDDI.d300.s15.e0 24 32
drug
phenytoin
DrugDDI.d300.s15.e1 35 47
drug
carbamazepine
DrugDDI.d300.s15.e2 68 73
drug
NIMBEX



Abstract Id: DrugDDI.d300
Sentence Id: DrugDDI.d300.s16
Drug /Laboratory Test Interactions None known.

DrugDDI.d300.s16.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d529
Sentence Id: DrugDDI.d529.s0
There are no known drug interactions with LEUSTATIN Injection.

DrugDDI.d529.s0.e0 35 43
drug
LEUSTATIN



Abstract Id: DrugDDI.d529
Sentence Id: DrugDDI.d529.s1
Caution should be exercised if LEUSTATIN Injection is administered before, after, or in conjunction with other drugs known to cause immunosuppression or myelosuppression.

DrugDDI.d529.s1.e0 26 34
drug
LEUSTATIN
DrugDDI.d529.s1.e1 95 99
drug
drugs



Abstract Id: DrugDDI.d27
Sentence Id: DrugDDI.d27.s0
The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.

DrugDDI.d27.s0.e0 29 39
drug
allopurinol
DrugDDI.d27.s0.e1 43 52
drug
ampicillin
DrugDDI.d27.s0.e2 118 122
drug
drugs
DrugDDI.d27.s0.e3 152 161
drug
ampicillin

interaction DrugDDI.d27.s0.e0 DrugDDI.d27.s0.e1

Abstract Id: DrugDDI.d27
Sentence Id: DrugDDI.d27.s1
It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

DrugDDI.d27.s1.e0 37 46
drug
ampicillin
DrugDDI.d27.s1.e1 60 70
drug
allopurinol



Abstract Id: DrugDDI.d27
Sentence Id: DrugDDI.d27.s2
In controlled clinical trials of AUGMENTIN XR , 22 patients received concomitant allopurinol and AUGMENTIN XR .

DrugDDI.d27.s2.e0 28 38
drug
AUGMENTIN XR
DrugDDI.d27.s2.e1 69 79
drug
allopurinol
DrugDDI.d27.s2.e2 83 93
drug
AUGMENTIN XR



Abstract Id: DrugDDI.d27
Sentence Id: DrugDDI.d27.s4
However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.

DrugDDI.d27.s4.e0 104 114
drug
AUGMENTIN XR
DrugDDI.d27.s4.e1 118 128
drug
allopurinol



Abstract Id: DrugDDI.d27
Sentence Id: DrugDDI.d27.s5
In common with other broad-spectrum antibiotics , AUGMENTIN XR may reduce the efficacy of oral contraceptives .

DrugDDI.d27.s5.e0 31 41
drug
antibiotics
DrugDDI.d27.s5.e1 43 53
drug
AUGMENTIN XR
DrugDDI.d27.s5.e2 76 93
drug
oral contraceptives

interaction DrugDDI.d27.s5.e0 DrugDDI.d27.s5.e2
interaction DrugDDI.d27.s5.e1 DrugDDI.d27.s5.e2

Abstract Id: DrugDDI.d299
Sentence Id: DrugDDI.d299.s0
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates , tranquilizers , and alcohol .

DrugDDI.d299.s0.e0 33 46
drug
antihistamines
DrugDDI.d299.s0.e1 84 97
drug
CNS depressants
DrugDDI.d299.s0.e2 107 118
drug
barbiturates
DrugDDI.d299.s0.e3 120 132
drug
tranquilizers
DrugDDI.d299.s0.e4 137 143
drug
alcohol



Abstract Id: DrugDDI.d299
Sentence Id: DrugDDI.d299.s1
Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs .

DrugDDI.d299.s1.e0 17 30
drug
antihistamines
DrugDDI.d299.s1.e1 76 93
drug
CNS depressant drugs



Abstract Id: DrugDDI.d299
Sentence Id: DrugDDI.d299.s2
Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines .

DrugDDI.d299.s2.e0 0 15
drug
Monoamine oxidase
DrugDDI.d299.s2.e1 53 67
drug
anticholinergic
DrugDDI.d299.s2.e2 77 90
drug
antihistamines



Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s0
Caution should be exercised when anticoagulants are given in conjunction with Atromid-S .

DrugDDI.d190.s0.e0 28 41
drug
anticoagulants
DrugDDI.d190.s0.e1 67 75
drug
Atromid-S

interaction DrugDDI.d190.s0.e0 DrugDDI.d190.s0.e1

Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s1
Usually, the dosage of the anticoagulant should be reduced by one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications.

DrugDDI.d190.s1.e0 22 34
drug
anticoagulant
DrugDDI.d190.s1.e1 137 143
drug
prevent



Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s2
Frequent prothrombin determinations are advisable until it has been determined definitely that the prothrombin level has been stabilized.

DrugDDI.d190.s2.e0 8 18
drug
prothrombin



Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s3
Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.

DrugDDI.d190.s3.e0 0 8
drug
Atromid-S
DrugDDI.d190.s3.e1 26 30
drug
drugs
DrugDDI.d190.s3.e2 37 45
drug
phenytoin
DrugDDI.d190.s3.e3 48 58
drug
tolbutamide

interaction DrugDDI.d190.s3.e0 DrugDDI.d190.s3.e1
interaction DrugDDI.d190.s3.e0 DrugDDI.d190.s3.e3

Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s4
Caution should be exercised when treating patients with either of these drugs or other highly protein-bound drugs and Atromid-S .

DrugDDI.d190.s4.e0 61 65
drug
drugs
DrugDDI.d190.s4.e1 100 108
drug
Atromid-S



Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s5
The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.

DrugDDI.d190.s5.e0 3 20
drug
hypoglycemic effect
DrugDDI.d190.s5.e1 23 33
drug
tolbutamide
DrugDDI.d190.s5.e2 63 71
drug
Atromid-S

interaction DrugDDI.d190.s5.e1 DrugDDI.d190.s5.e2

Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s6
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.

DrugDDI.d190.s6.e0 96 102
drug
fibrate
DrugDDI.d190.s6.e1 106 115
drug
lovastatin



Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s7
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.

DrugDDI.d190.s7.e0 90 93
drug
drug
DrugDDI.d190.s7.e1 140 149
drug
lovastatin
DrugDDI.d190.s7.e2 154 160
drug
fibrate

interaction DrugDDI.d190.s7.e1 DrugDDI.d190.s7.e2

Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s8
While it is not known whether this interaction occurs with fibrates other than gemfibrozil , myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate .

DrugDDI.d190.s8.e0 49 56
drug
fibrates
DrugDDI.d190.s8.e1 66 76
drug
gemfibrozil
DrugDDI.d190.s8.e2 145 152
drug
fibrates
DrugDDI.d190.s8.e3 168 177
drug
clofibrate



Abstract Id: DrugDDI.d190
Sentence Id: DrugDDI.d190.s9
Therefore, the combined use of lovastatin with fibrates should generally be avoided.

DrugDDI.d190.s9.e0 26 35
drug
lovastatin
DrugDDI.d190.s9.e1 40 47
drug
fibrates

interaction DrugDDI.d190.s9.e0 DrugDDI.d190.s9.e1

Abstract Id: DrugDDI.d575
Sentence Id: DrugDDI.d575.s0
Drug interactions with clomiphene citrate tablets USP have not been documented.

DrugDDI.d575.s0.e0 20 43
drug
clomiphene citrate tablets



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s0
The risks of using Anafranil in combination with other drugs have not been systematically evaluated.

DrugDDI.d16.s0.e0 15 23
drug
Anafranil
DrugDDI.d16.s0.e1 46 50
drug
drugs



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s1
Given the primary CNS effects of Anafranil , caution is advised in using it concomitantly with other CNS-active drugs .

DrugDDI.d16.s1.e0 27 35
drug
Anafranil
DrugDDI.d16.s1.e1 84 98
drug
CNS-active drugs

interaction DrugDDI.d16.s1.e0 DrugDDI.d16.s1.e1

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s2
Anafranil should not be used with MAO inhibitors .

DrugDDI.d16.s2.e0 0 8
drug
Anafranil
DrugDDI.d16.s2.e1 28 40
drug
MAO inhibitors

interaction DrugDDI.d16.s2.e0 DrugDDI.d16.s2.e1

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s3
Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs .

DrugDDI.d16.s3.e0 59 67
drug
Anafranil
DrugDDI.d16.s3.e1 86 100
drug
anticholinergic
DrugDDI.d16.s3.e2 103 122
drug
sympathomimetic drugs

interaction DrugDDI.d16.s3.e0 DrugDDI.d16.s3.e1

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s4
Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants .

DrugDDI.d16.s4.e0 7 30
drug
tricyclic antidepressants
DrugDDI.d16.s4.e1 79 90
drug
guanethidine
DrugDDI.d16.s4.e2 92 100
drug
clonidine
DrugDDI.d16.s4.e3 195 218
drug
tricyclic antidepressants

interaction DrugDDI.d16.s4.e0 DrugDDI.d16.s4.e1

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s5
The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol ; .

DrugDDI.d16.s5.e0 87 97
drug
haloperidol



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s6
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well.

DrugDDI.d16.s6.e0 35 58
drug
tricyclic antidepressants
DrugDDI.d16.s6.e1 120 134
drug
methylphenidate
DrugDDI.d16.s6.e2 144 159
drug
enzyme inhibitors
DrugDDI.d16.s6.e3 166 175
drug
cimetidine
DrugDDI.d16.s6.e4 177 186
drug
fluoxetine
DrugDDI.d16.s6.e5 259 270
drug
barbiturates
DrugDDI.d16.s6.e6 272 280
drug
phenytoin

interaction DrugDDI.d16.s6.e0 DrugDDI.d16.s6.e1
interaction DrugDDI.d16.s6.e0 DrugDDI.d16.s6.e2
interaction DrugDDI.d16.s6.e0 DrugDDI.d16.s6.e5
interaction DrugDDI.d16.s6.e0 DrugDDI.d16.s6.e6
interaction DrugDDI.d16.s6.e1 DrugDDI.d16.s6.e3
interaction DrugDDI.d16.s6.e1 DrugDDI.d16.s6.e4

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s7
Administration of CMI has been reported to increase the plasma levels of phenobarbital , if given concomitantly.

DrugDDI.d16.s7.e0 61 73
drug
phenobarbital



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s8
Drugs Metabolized by P450 2D6 : The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 ( debrisoquin hydroxylase ) is reduced in a subset of the aucasian population (about 7%-10% of Caucasians are so-called poor metabolizers); .

DrugDDI.d16.s8.e0 0 4
drug
Drugs
DrugDDI.d16.s8.e1 18 24
drug
P450 2D6
DrugDDI.d16.s8.e2 53 56
drug
drug
DrugDDI.d16.s8.e3 94 115
drug
debrisoquin hydroxylase

interaction DrugDDI.d16.s8.e0 DrugDDI.d16.s8.e1

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s9
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.

DrugDDI.d16.s9.e0 41 54
drug
P450 2D6 isozyme



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s10
Poor metabolizers have higher than expected lasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

DrugDDI.d16.s10.e0 38 42
drug
lasma
DrugDDI.d16.s10.e1 59 82
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s11
Depending on the fraction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).

DrugDDI.d16.s11.e0 24 27
drug
drug
DrugDDI.d16.s11.e1 41 47
drug
P450 2D6



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s12
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.

DrugDDI.d16.s12.e0 18 22
drug
drugs
DrugDDI.d16.s12.e1 47 53
drug
isozyme

interaction DrugDDI.d16.s12.e0 DrugDDI.d16.s12.e1

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s13
An individual who is stable on a given dose of TCAmay become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

DrugDDI.d16.s13.e0 91 95
drug
drugs



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s14
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme ( quinidine ; .

DrugDDI.d16.s14.e0 3 7
drug
drugs
DrugDDI.d16.s14.e1 19 35
drug
cytochrome P450 2D6
DrugDDI.d16.s14.e2 80 88
drug
quinidine



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s15
cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and flecainide ).

DrugDDI.d16.s15.e0 0 9
drug
cimetidine
DrugDDI.d16.s15.e1 38 44
drug
P450 2D6
DrugDDI.d16.s15.e2 55 69
drug
antidepressants
DrugDDI.d16.s15.e3 71 84
drug
phenothiazines
DrugDDI.d16.s15.e4 113 123
drug
propafenone
DrugDDI.d16.s15.e5 127 136
drug
flecainide



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s16
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6 , they may vary in the extent of inhibition.

DrugDDI.d16.s16.e0 20 46
drug
serotonin reuptake inhibitors
DrugDDI.d16.s16.e1 60 69
drug
fluoxetine
DrugDDI.d16.s16.e2 71 80
drug
sertraline
DrugDDI.d16.s16.e3 82 91
drug
paroxetine
DrugDDI.d16.s16.e4 96 106
drug
fluvoxamine
DrugDDI.d16.s16.e5 115 121
drug
P450 2D6

interaction DrugDDI.d16.s16.e0 DrugDDI.d16.s16.e5
interaction DrugDDI.d16.s16.e2 DrugDDI.d16.s16.e5
interaction DrugDDI.d16.s16.e4 DrugDDI.d16.s16.e5

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s17
Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.

DrugDDI.d16.s17.e0 0 10
drug
Fluvoxamine
DrugDDI.d16.s17.e1 36 39
drug
P450
DrugDDI.d16.s17.e2 46 52
drug
isoform

interaction DrugDDI.d16.s17.e0 DrugDDI.d16.s17.e1

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s20
Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

DrugDDI.d16.s20.e0 103 112
drug
fluoxetine
DrugDDI.d16.s20.e1 149 164
drug
active metabolite



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s21
Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug .

DrugDDI.d16.s21.e0 27 49
drug
tricyclic antidepressant
DrugDDI.d16.s21.e1 69 77
drug
Anafranil
DrugDDI.d16.s21.e2 83 87
drug
drugs
DrugDDI.d16.s21.e3 102 118
drug
cytochrome P450 2D6
DrugDDI.d16.s21.e4 172 194
drug
tricyclic antidepressant
DrugDDI.d16.s21.e5 210 213
drug
drug

interaction DrugDDI.d16.s21.e0 DrugDDI.d16.s21.e2

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s22
Furthermore, whenever one of these drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant agent may be required.

DrugDDI.d16.s22.e0 30 34
drug
drugs
DrugDDI.d16.s22.e1 78 100
drug
tricyclic antidepressant



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s23
It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).

DrugDDI.d16.s23.e0 57 79
drug
tricyclic antidepressant
DrugDDI.d16.s23.e1 94 102
drug
Anafranil
DrugDDI.d16.s23.e2 140 143
drug
drug
DrugDDI.d16.s23.e3 166 172
drug
P450 2D6
DrugDDI.d16.s23.e4 180 183
drug
P450



Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s24
Because Anafranil is highly bound to serum protein , the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin , digoxin ) may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects.

DrugDDI.d16.s24.e0 7 15
drug
Anafranil
DrugDDI.d16.s24.e1 36 42
drug
protein
DrugDDI.d16.s24.e2 63 71
drug
Anafranil
DrugDDI.d16.s24.e3 93 97
drug
drugs
DrugDDI.d16.s24.e4 118 124
drug
protein
DrugDDI.d16.s24.e5 131 138
drug
warfarin
DrugDDI.d16.s24.e6 140 146
drug
digoxin
DrugDDI.d16.s24.e7 195 199
drug
drugs

interaction DrugDDI.d16.s24.e0 DrugDDI.d16.s24.e3
interaction DrugDDI.d16.s24.e0 DrugDDI.d16.s24.e5
interaction DrugDDI.d16.s24.e0 DrugDDI.d16.s24.e6

Abstract Id: DrugDDI.d16
Sentence Id: DrugDDI.d16.s25
Conversely, adverse effects may result from displacement of protein-bound Anafranil by other highly bound drugs.

DrugDDI.d16.s25.e0 65 73
drug
Anafranil



Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s0
Effect of Clonazepam on the Pharmacokinetics of Other Drugs : Clonazepam does not appear to alter the pharmacokinetics of phenytoin , carbamazepine , or phenobarbital .

DrugDDI.d70.s0.e0 8 17
drug
Clonazepam
DrugDDI.d70.s0.e1 46 50
drug
Drugs
DrugDDI.d70.s0.e2 52 61
drug
Clonazepam
DrugDDI.d70.s0.e3 103 111
drug
phenytoin
DrugDDI.d70.s0.e4 113 125
drug
carbamazepine
DrugDDI.d70.s0.e5 129 141
drug
phenobarbital



Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s1
The effect of clonazepam on the metabolism of other drugs has not been investigated.

DrugDDI.d70.s1.e0 11 20
drug
clonazepam
DrugDDI.d70.s1.e1 43 47
drug
drugs



Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s2
Effect of Other Drugs on the Pharmacokinetics of Clonazepam : Literature reports suggest that ranitidine , an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.

DrugDDI.d70.s2.e0 13 17
drug
Drugs
DrugDDI.d70.s2.e1 41 50
drug
Clonazepam
DrugDDI.d70.s2.e2 80 89
drug
ranitidine
DrugDDI.d70.s2.e3 145 154
drug
clonazepam



Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s3
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.

DrugDDI.d70.s3.e0 21 30
drug
clonazepam
DrugDDI.d70.s3.e1 86 98
drug
propantheline
DrugDDI.d70.s3.e2 102 121
drug
anticholinergic agent
DrugDDI.d70.s3.e3 182 191
drug
clonazepam
DrugDDI.d70.s3.e4 215 224
drug
clonazepam
DrugDDI.d70.s3.e5 281 293
drug
propantheline

interaction DrugDDI.d70.s3.e0 DrugDDI.d70.s3.e1

Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s4
Fluoxetine does not affect the pharmacokinetics of clonazepam .

DrugDDI.d70.s4.e0 0 9
drug
Fluoxetine
DrugDDI.d70.s4.e1 44 53
drug
clonazepam



Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s5
Cytochrome P-450 inducers, such as phenytoin , carbamazepine and phenobarbital , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.

DrugDDI.d70.s5.e0 0 14
drug
Cytochrome P-450
DrugDDI.d70.s5.e1 30 38
drug
phenytoin
DrugDDI.d70.s5.e2 40 52
drug
carbamazepine
DrugDDI.d70.s5.e3 56 68
drug
phenobarbital
DrugDDI.d70.s5.e4 76 85
drug
clonazepam

interaction DrugDDI.d70.s5.e0 DrugDDI.d70.s5.e4
interaction DrugDDI.d70.s5.e1 DrugDDI.d70.s5.e4
interaction DrugDDI.d70.s5.e2 DrugDDI.d70.s5.e4
interaction DrugDDI.d70.s5.e3 DrugDDI.d70.s5.e4

Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s6
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents , should be used cautiously in patients receiving clonazepam .

DrugDDI.d70.s6.e0 70 84
drug
cytochrome P-450
DrugDDI.d70.s6.e1 95 104
drug
clonazepam
DrugDDI.d70.s6.e2 156 171
drug
antifungal agents
DrugDDI.d70.s6.e3 214 223
drug
clonazepam

interaction DrugDDI.d70.s6.e2 DrugDDI.d70.s6.e3

Abstract Id: DrugDDI.d70
Sentence Id: DrugDDI.d70.s7
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate hypnotics , antianxiety agents , the phenothiazines , thioxanthene and butyrophenone classes of antipsychotic agents , monoamine oxidase inhibitors and the tricyclic antidepressants , and by other anticonvulsant drugs .

DrugDDI.d70.s7.e0 31 50
drug
CNS-depressant action
DrugDDI.d70.s7.e1 56 69
drug
benzodiazepine
DrugDDI.d70.s7.e2 77 81
drug
drugs
DrugDDI.d70.s7.e3 100 106
drug
alcohol
DrugDDI.d70.s7.e4 108 116
drug
narcotics
DrugDDI.d70.s7.e5 118 129
drug
barbiturates
DrugDDI.d70.s7.e6 145 153
drug
hypnotics
DrugDDI.d70.s7.e7 155 171
drug
antianxiety agents
DrugDDI.d70.s7.e8 176 189
drug
phenothiazines
DrugDDI.d70.s7.e9 191 202
drug
thioxanthene
DrugDDI.d70.s7.e10 206 218
drug
butyrophenone
DrugDDI.d70.s7.e11 228 246
drug
antipsychotic agents
DrugDDI.d70.s7.e12 248 273
drug
monoamine oxidase inhibitors
DrugDDI.d70.s7.e13 280 303
drug
tricyclic antidepressants
DrugDDI.d70.s7.e14 315 333
drug
anticonvulsant drugs

interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e3
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e4
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e5
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e6
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e7
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e8
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e9
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e10
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e12
interaction DrugDDI.d70.s7.e1 DrugDDI.d70.s7.e13

Abstract Id: DrugDDI.d514
Sentence Id: DrugDDI.d514.s0
Aspirin , warfarin , heparin , NSAIDs .

DrugDDI.d514.s0.e0 0 6
drug
Aspirin
DrugDDI.d514.s0.e1 8 15
drug
warfarin
DrugDDI.d514.s0.e2 17 23
drug
heparin
DrugDDI.d514.s0.e3 25 30
drug
NSAIDs



Abstract Id: DrugDDI.d322
Sentence Id: DrugDDI.d322.s0
If TRANXENE is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed.

DrugDDI.d322.s0.e0 2 9
drug
TRANXENE
DrugDDI.d322.s0.e1 33 37
drug
drugs



Abstract Id: DrugDDI.d322
Sentence Id: DrugDDI.d322.s1
Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition.

DrugDDI.d322.s1.e0 29 50
drug
clorazepate dipotassium
DrugDDI.d322.s1.e1 79 90
drug
hexobarbital
DrugDDI.d322.s1.e2 98 109
drug
ethyl alcohol
DrugDDI.d322.s1.e3 142 155
drug
chlorpromazine
DrugDDI.d322.s1.e4 174 189
drug
monoamine oxidase

interaction DrugDDI.d322.s1.e0 DrugDDI.d322.s1.e1
interaction DrugDDI.d322.s1.e0 DrugDDI.d322.s1.e2

Abstract Id: DrugDDI.d322
Sentence Id: DrugDDI.d322.s2
Clinical studies have shown increased sedation with concurrent hypnotic medications.

DrugDDI.d322.s2.e0 55 62
drug
hypnotic



Abstract Id: DrugDDI.d322
Sentence Id: DrugDDI.d322.s3
The actions of the benzodiazepines may be potentiated by barbiturates , narcotics , phenothiazines , monoamine oxidase inhibitors or other antidepressants .

DrugDDI.d322.s3.e0 15 29
drug
benzodiazepines
DrugDDI.d322.s3.e1 48 59
drug
barbiturates
DrugDDI.d322.s3.e2 61 69
drug
narcotics
DrugDDI.d322.s3.e3 71 84
drug
phenothiazines
DrugDDI.d322.s3.e4 86 111
drug
monoamine oxidase inhibitors
DrugDDI.d322.s3.e5 119 133
drug
antidepressants

interaction DrugDDI.d322.s3.e0 DrugDDI.d322.s3.e1
interaction DrugDDI.d322.s3.e0 DrugDDI.d322.s3.e2
interaction DrugDDI.d322.s3.e0 DrugDDI.d322.s3.e3
interaction DrugDDI.d322.s3.e0 DrugDDI.d322.s3.e4
interaction DrugDDI.d322.s3.e0 DrugDDI.d322.s3.e5

Abstract Id: DrugDDI.d322
Sentence Id: DrugDDI.d322.s4
If TRANXENE tablets are used to treat anxiety associated with somatic disease states, careful attention must be paid to possible drug interaction with concomitant medication .

DrugDDI.d322.s4.e0 2 9
drug
TRANXENE
DrugDDI.d322.s4.e1 139 148
drug
medication



Abstract Id: DrugDDI.d322
Sentence Id: DrugDDI.d322.s5
In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.

DrugDDI.d322.s5.e0 72 79
drug
antacids
DrugDDI.d322.s5.e1 147 154
drug
TRANXENE



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s0
The risks of using Clozapine in combination with other drugs have not been systematically evaluated.

DrugDDI.d175.s0.e0 15 23
drug
Clozapine
DrugDDI.d175.s0.e1 46 50
drug
drugs



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s1
Pharmacodynamic-related Interactions: The mechanism of Clozapine induced agranulocytosis is unknown; .

DrugDDI.d175.s1.e0 50 58
drug
Clozapine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s3
Therefore, Clozapine should not be used with other agents having a well-known potential to suppress bone marrow function.

DrugDDI.d175.s3.e0 10 18
drug
Clozapine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s4
Given the primary CNS effects of Clozapine , caution is advised in using it concomitantly with other CNS-active drugs or alcohol .

DrugDDI.d175.s4.e0 27 35
drug
Clozapine
DrugDDI.d175.s4.e1 84 98
drug
CNS-active drugs
DrugDDI.d175.s4.e2 101 107
drug
alcohol

interaction DrugDDI.d175.s4.e0 DrugDDI.d175.s4.e1

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s5
Orthostatic hypotension in patients taking clozapine can, in rare cases (approximately 1 case per 3,000 patients), be accompanied by profound collapse and respiratory and/or cardiac arrest.

DrugDDI.d175.s5.e0 38 46
drug
clozapine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s6
Some of the cases of collapse/respiratory arrest/cardiac arrest during initial treatment occurred in patients who were being administered benzodiazepines ; .

DrugDDI.d175.s6.e0 120 134
drug
benzodiazepines



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s7
similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.

DrugDDI.d175.s7.e0 50 66
drug
psychotropic drugs
DrugDDI.d175.s7.e1 73 81
drug
Clozapine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s8
Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug .

DrugDDI.d175.s8.e0 62 70
drug
Clozapine
DrugDDI.d175.s8.e1 74 88
drug
benzodiazepines
DrugDDI.d175.s8.e2 130 138
drug
clozapine
DrugDDI.d175.s8.e3 167 180
drug
benzodiazepine
DrugDDI.d175.s8.e4 191 206
drug
psychotropic drug

interaction DrugDDI.d175.s8.e2 DrugDDI.d175.s8.e3
interaction DrugDDI.d175.s8.e2 DrugDDI.d175.s8.e4

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s9
Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine -type drugs.

DrugDDI.d175.s9.e0 0 8
drug
Clozapine
DrugDDI.d175.s9.e1 45 65
drug
antihypertensive drugs
DrugDDI.d175.s9.e2 72 86
drug
anticholinergic
DrugDDI.d175.s9.e3 96 103
drug
atropine

interaction DrugDDI.d175.s9.e0 DrugDDI.d175.s9.e1
interaction DrugDDI.d175.s9.e0 DrugDDI.d175.s9.e3

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s10
The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.

DrugDDI.d175.s10.e0 19 29
drug
epinephrine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s11
Pharmacokinetic-related Interactions: Clozapine is a substrate for many CYP 450 isozymes , in particular 1A2, 2D6, and 3A4.

DrugDDI.d175.s11.e0 36 44
drug
Clozapine
DrugDDI.d175.s11.e1 70 77
drug
isozymes



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s12
The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized.

DrugDDI.d175.s12.e0 60 66
drug
isoform



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s13
Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.

DrugDDI.d175.s13.e0 80 84
drug
drugs



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s14
Concomitant administration of drugs known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine .

DrugDDI.d175.s14.e0 27 31
drug
drugs
DrugDDI.d175.s14.e1 45 58
drug
cytochrome P450
DrugDDI.d175.s14.e2 94 102
drug
clozapine

interaction DrugDDI.d175.s14.e0 DrugDDI.d175.s14.e2

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s15
Phenytoin , nicotine , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.

DrugDDI.d175.s15.e0 0 8
drug
Phenytoin
DrugDDI.d175.s15.e1 10 17
drug
nicotine
DrugDDI.d175.s15.e2 22 29
drug
rifampin



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s16
Concomitant administration of drugs known to inhibit the activity of cytochrome P450 isozymes may increase the plasma levels of clozapine .

DrugDDI.d175.s16.e0 27 31
drug
drugs
DrugDDI.d175.s16.e1 59 72
drug
cytochrome P450
DrugDDI.d175.s16.e2 109 117
drug
clozapine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s17
Cimetidine , caffeine , and erythromycin may increase plasma levels of Clozapine , potentially resulting in adverse effects.

DrugDDI.d175.s17.e0 0 9
drug
Cimetidine
DrugDDI.d175.s17.e1 11 18
drug
caffeine
DrugDDI.d175.s17.e2 23 34
drug
erythromycin
DrugDDI.d175.s17.e3 60 68
drug
Clozapine

interaction DrugDDI.d175.s17.e0 DrugDDI.d175.s17.e3
interaction DrugDDI.d175.s17.e1 DrugDDI.d175.s17.e3
interaction DrugDDI.d175.s17.e2 DrugDDI.d175.s17.e3

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s18
Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.

DrugDDI.d175.s18.e0 24 32
drug
Clozapine
DrugDDI.d175.s18.e1 36 48
drug
carbamazepine
DrugDDI.d175.s18.e2 113 125
drug
carbamazepine

interaction DrugDDI.d175.s18.e0 DrugDDI.d175.s18.e1

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s19
In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.

DrugDDI.d175.s19.e0 42 50
drug
clozapine
DrugDDI.d175.s19.e1 78 88
drug
fluvoxamine
DrugDDI.d175.s19.e2 91 100
drug
paroxetine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s20
After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites , N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.

DrugDDI.d175.s20.e0 57 65
drug
clozapine
DrugDDI.d175.s20.e1 72 82
drug
metabolites
DrugDDI.d175.s20.e2 84 103
drug
N-desmethylclozapine
DrugDDI.d175.s20.e3 140 150
drug
fluvoxamine

interaction DrugDDI.d175.s20.e2 DrugDDI.d175.s20.e3

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s21
Paroxetine produced only minor changes in the levels of clozapine and its metabolites .

DrugDDI.d175.s21.e0 0 9
drug
Paroxetine
DrugDDI.d175.s21.e1 47 55
drug
clozapine
DrugDDI.d175.s21.e2 62 72
drug
metabolites

interaction DrugDDI.d175.s21.e0 DrugDDI.d175.s21.e1

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s22
However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine , fluoxetine , and sertraline .

DrugDDI.d175.s22.e0 73 81
drug
clozapine
DrugDDI.d175.s22.e1 85 94
drug
metabolite
DrugDDI.d175.s22.e2 113 121
drug
clozapine
DrugDDI.d175.s22.e3 134 143
drug
paroxetine
DrugDDI.d175.s22.e4 145 154
drug
fluoxetine
DrugDDI.d175.s22.e5 159 168
drug
sertraline

interaction DrugDDI.d175.s22.e2 DrugDDI.d175.s22.e3
interaction DrugDDI.d175.s22.e2 DrugDDI.d175.s22.e4
interaction DrugDDI.d175.s22.e2 DrugDDI.d175.s22.e5

Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s23
Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs , particularly with fluvoxamine .

DrugDDI.d175.s23.e0 99 107
drug
Clozapine
DrugDDI.d175.s23.e1 127 131
drug
drugs
DrugDDI.d175.s23.e2 149 159
drug
fluvoxamine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s25
A subset (3%-10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isozyme P450 2D6 .

DrugDDI.d175.s25.e0 89 116
drug
cytochrome P450 isozyme P450 2D6



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s26
Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , the tricyclic antidepressants , and clozapine .

DrugDDI.d175.s26.e0 48 52
drug
drugs
DrugDDI.d175.s26.e1 59 69
drug
debrisoquin
DrugDDI.d175.s26.e2 71 86
drug
dextromethorphan
DrugDDI.d175.s26.e3 91 114
drug
tricyclic antidepressants
DrugDDI.d175.s26.e4 119 127
drug
clozapine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s27
These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.

DrugDDI.d175.s27.e0 66 74
drug
clozapine



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s28
In addition, certain drugs that are metabolized by this isozyme , including many antidepressants ( clozapine , selective serotonin reuptake inhibitors , and others), may inhibit the activity of this isozyme , and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.

DrugDDI.d175.s28.e0 18 22
drug
drugs
DrugDDI.d175.s28.e1 47 53
drug
isozyme
DrugDDI.d175.s28.e2 68 82
drug
antidepressants
DrugDDI.d175.s28.e3 84 92
drug
clozapine
DrugDDI.d175.s28.e4 103 129
drug
serotonin reuptake inhibitors
DrugDDI.d175.s28.e5 169 175
drug
isozyme
DrugDDI.d175.s28.e6 272 276
drug
drugs



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s29
Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug .

DrugDDI.d175.s29.e0 16 24
drug
clozapine
DrugDDI.d175.s29.e1 34 38
drug
drugs
DrugDDI.d175.s29.e2 52 68
drug
cytochrome P450 2D6
DrugDDI.d175.s29.e3 119 127
drug
clozapine
DrugDDI.d175.s29.e4 138 141
drug
drug



Abstract Id: DrugDDI.d175
Sentence Id: DrugDDI.d175.s30
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme , including antidepressants , phenothiazines , carbamazepine , and Type 1C antiarrhythmics (e.g., propafenone , flecainide and encainide ), or that inhibit this enzyme (e.g., quinidine ), should be approached with caution.

DrugDDI.d175.s30.e0 29 37
drug
clozapine
DrugDDI.d175.s30.e1 47 51
drug
drugs
DrugDDI.d175.s30.e2 76 82
drug
isozyme
DrugDDI.d175.s30.e3 93 107
drug
antidepressants
DrugDDI.d175.s30.e4 109 122
drug
phenothiazines
DrugDDI.d175.s30.e5 124 136
drug
carbamazepine
DrugDDI.d175.s30.e6 147 161
drug
antiarrhythmics
DrugDDI.d175.s30.e7 168 178
drug
propafenone
DrugDDI.d175.s30.e8 180 189
drug
flecainide
DrugDDI.d175.s30.e9 193 201
drug
encainide
DrugDDI.d175.s30.e10 233 241
drug
quinidine

interaction DrugDDI.d175.s30.e0 DrugDDI.d175.s30.e3
interaction DrugDDI.d175.s30.e0 DrugDDI.d175.s30.e4
interaction DrugDDI.d175.s30.e0 DrugDDI.d175.s30.e5
interaction DrugDDI.d175.s30.e0 DrugDDI.d175.s30.e7
interaction DrugDDI.d175.s30.e0 DrugDDI.d175.s30.e8
interaction DrugDDI.d175.s30.e0 DrugDDI.d175.s30.e9
interaction DrugDDI.d175.s30.e0 DrugDDI.d175.s30.e10

Abstract Id: DrugDDI.d570
Sentence Id: DrugDDI.d570.s0
The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.

DrugDDI.d570.s0.e0 37 45
drug
NovoSeven
DrugDDI.d570.s0.e1 49 65
drug
coagulation factor



Abstract Id: DrugDDI.d570
Sentence Id: DrugDDI.d570.s1
Simultaneous use of activated prothrombin complex concentrate s or prothrombin complex concentrates should be avoided.

DrugDDI.d570.s1.e0 17 54
drug
activated prothrombin complex concentrate
DrugDDI.d570.s1.e1 58 87
drug
prothrombin complex concentrates



Abstract Id: DrugDDI.d570
Sentence Id: DrugDDI.d570.s2
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid , aminocaproic acid ) and NovoSeven .

DrugDDI.d570.s2.e0 144 157
drug
tranexamic acid
DrugDDI.d570.s2.e1 159 174
drug
aminocaproic acid
DrugDDI.d570.s2.e2 179 187
drug
NovoSeven

interaction DrugDDI.d570.s2.e0 DrugDDI.d570.s2.e2
interaction DrugDDI.d570.s2.e1 DrugDDI.d570.s2.e2

Abstract Id: DrugDDI.d570
Sentence Id: DrugDDI.d570.s3
NovoSeven should not be mixed with infusion solutions until clinical data are available to direct this use.

DrugDDI.d570.s3.e0 0 8
drug
NovoSeven



Abstract Id: DrugDDI.d22
Sentence Id: DrugDDI.d22.s0
Codeine in combination with other narcotic analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS depressants (including alcohol ) has additive depressant effects.

DrugDDI.d22.s0.e0 0 6
drug
Codeine
DrugDDI.d22.s0.e1 24 45
drug
other narcotic analgesic
DrugDDI.d22.s0.e2 48 65
drug
general anesthetics
DrugDDI.d22.s0.e3 67 80
drug
phenothiazines
DrugDDI.d22.s0.e4 82 94
drug
tranquilizers
DrugDDI.d22.s0.e5 96 113
drug
sedative-hypnotics
DrugDDI.d22.s0.e6 122 135
drug
CNS depressants
DrugDDI.d22.s0.e7 146 152
drug
alcohol



Abstract Id: DrugDDI.d272
Sentence Id: DrugDDI.d272.s0
WelChol@ has been studied in several human drug interaction studies in which it was administered with a meal and the test drug .

DrugDDI.d272.s0.e0 101 104
drug
drug



Abstract Id: DrugDDI.d272
Sentence Id: DrugDDI.d272.s1
WelChol@ was found to have no significant effect on the bioavailability of digoxin , lovastatin , metoprolol , quinidine , valproic acid , and warfarin .

DrugDDI.d272.s1.e0 63 69
drug
digoxin
DrugDDI.d272.s1.e1 71 80
drug
lovastatin
DrugDDI.d272.s1.e2 82 91
drug
metoprolol
DrugDDI.d272.s1.e3 93 101
drug
quinidine
DrugDDI.d272.s1.e4 103 114
drug
valproic acid
DrugDDI.d272.s1.e5 119 126
drug
warfarin



Abstract Id: DrugDDI.d272
Sentence Id: DrugDDI.d272.s2
WelChol@ decreased the Cmax and AUC of sustained-release verapamil ( Calan SR@) by approximately 31% and 11%, respectively.

DrugDDI.d272.s2.e0 49 57
drug
verapamil
DrugDDI.d272.s2.e1 59 63
drug
Calan



Abstract Id: DrugDDI.d272
Sentence Id: DrugDDI.d272.s3
Since there is a high degree of variability in the bioavailability of verapamil , the clinical significance of this finding is unclear.

DrugDDI.d272.s3.e0 58 66
drug
verapamil



Abstract Id: DrugDDI.d272
Sentence Id: DrugDDI.d272.s4
In clinical studies, coadministration of WelChol@ with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor .

DrugDDI.d272.s4.e0 48 59
drug
atorvastatin
DrugDDI.d272.s4.e1 61 70
drug
lovastatin
DrugDDI.d272.s4.e2 74 84
drug
simvastatin
DrugDDI.d272.s4.e3 134 158
drug
HMG-CoA reductase inhibitor



Abstract Id: DrugDDI.d272
Sentence Id: DrugDDI.d272.s5
Other drugs have not been studied.

DrugDDI.d272.s5.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d272
Sentence Id: DrugDDI.d272.s6
When administering other drugs for which alterations in blood levels could have a clinically significant effect on safety or efficacy, physicians should consider monitoring drug levels or effects.

DrugDDI.d272.s6.e0 22 26
drug
drugs



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s0
Since colestipol hydrochloride is an anion exchange resin , it may have a strong affinity for anions other than the bile acids .

DrugDDI.d159.s0.e0 5 27
drug
colestipol hydrochloride
DrugDDI.d159.s0.e1 32 49
drug
anion exchange resin
DrugDDI.d159.s0.e2 96 104
drug
bile acids



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s1
In vitro studies have indicated that colestipol hydrochloride binds a number of drugs .

DrugDDI.d159.s1.e0 31 53
drug
colestipol hydrochloride
DrugDDI.d159.s1.e1 68 72
drug
drugs



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s3
The interval between the administration of COLESTID Tablets and any other medication should be as long as possible.

DrugDDI.d159.s3.e0 37 44
drug
COLESTID
DrugDDI.d159.s3.e1 63 72
drug
medication



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s4
Patients should take other drugs at least one hour before or four hours after COLESTID Tablets to avoid impeding their absorption.

DrugDDI.d159.s4.e0 23 27
drug
drugs
DrugDDI.d159.s4.e1 64 71
drug
COLESTID



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s5
Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.

DrugDDI.d159.s5.e0 15 37
drug
colestipol hydrochloride
DrugDDI.d159.s5.e1 63 73
drug
propranolol
DrugDDI.d159.s5.e2 113 123
drug
propranolol



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s6
However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption; .

DrugDDI.d159.s6.e0 69 91
drug
colestipol hydrochloride
DrugDDI.d159.s6.e1 95 105
drug
propranolol
DrugDDI.d159.s6.e2 177 187
drug
propranolol



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s8
Effects on the absorption of other beta-blockers have not been determined.

DrugDDI.d159.s8.e0 29 41
drug
beta-blockers



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s9
Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.

DrugDDI.d159.s9.e0 20 30
drug
propranolol
DrugDDI.d159.s9.e1 51 58
drug
COLESTID



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s10
Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride .

DrugDDI.d159.s10.e0 38 51
drug
chlorothiazide
DrugDDI.d159.s10.e1 133 155
drug
colestipol hydrochloride



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s11
The absorption of tetracycline , furosemide , penicillin G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride ; .

DrugDDI.d159.s11.e0 15 26
drug
tetracycline
DrugDDI.d159.s11.e1 28 37
drug
furosemide
DrugDDI.d159.s11.e2 39 49
drug
penicillin G
DrugDDI.d159.s11.e3 51 69
drug
hydrochlorothiazide
DrugDDI.d159.s11.e4 74 84
drug
gemfibrozil
DrugDDI.d159.s11.e5 137 159
drug
colestipol hydrochloride



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s12
these drugs were not tested to determine the effect of administration one hour before colestipol hydrochloride .

DrugDDI.d159.s12.e0 5 9
drug
drugs
DrugDDI.d159.s12.e1 72 94
drug
colestipol hydrochloride



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s13
No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs : aspirin , clindamycin , clofibrate , methyldopa , nicotinic acid ( niacin ), tolbutamide , phenytoin or warfarin .

DrugDDI.d159.s13.e0 51 73
drug
colestipol hydrochloride
DrugDDI.d159.s13.e1 110 114
drug
drugs
DrugDDI.d159.s13.e2 116 122
drug
aspirin
DrugDDI.d159.s13.e3 124 134
drug
clindamycin
DrugDDI.d159.s13.e4 136 145
drug
clofibrate
DrugDDI.d159.s13.e5 147 156
drug
methyldopa
DrugDDI.d159.s13.e6 158 170
drug
nicotinic acid
DrugDDI.d159.s13.e7 172 177
drug
niacin
DrugDDI.d159.s13.e8 180 190
drug
tolbutamide
DrugDDI.d159.s13.e9 192 200
drug
phenytoin
DrugDDI.d159.s13.e10 203 210
drug
warfarin



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s14
Particular caution should be observed with digitalis preparation s since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin .

DrugDDI.d159.s14.e0 37 56
drug
digitalis preparation
DrugDDI.d159.s14.e1 103 125
drug
colestipol hydrochloride
DrugDDI.d159.s14.e2 145 151
drug
digoxin
DrugDDI.d159.s14.e3 155 163
drug
digitoxin



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s15
The potential for binding of these drugs if given concomitantly is present.

DrugDDI.d159.s15.e0 29 33
drug
drugs



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s16
Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride .

DrugDDI.d159.s16.e0 13 35
drug
colestipol hydrochloride
DrugDDI.d159.s16.e1 79 82
drug
drug
DrugDDI.d159.s16.e2 112 116
drug
resin
DrugDDI.d159.s16.e3 175 197
drug
colestipol hydrochloride



Abstract Id: DrugDDI.d159
Sentence Id: DrugDDI.d159.s17
Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone .

DrugDDI.d159.s17.e0 0 7
drug
Bile acid
DrugDDI.d159.s17.e1 56 79
drug
oral phosphate supplements
DrugDDI.d159.s17.e2 83 96
drug
hydrocortisone

interaction DrugDDI.d159.s17.e0 DrugDDI.d159.s17.e1
interaction DrugDDI.d159.s17.e0 DrugDDI.d159.s17.e2

Abstract Id: DrugDDI.d321
Sentence Id: DrugDDI.d321.s0
Certain other antibiotics ( aminoglycosides and polymyxin ) have also been reported to interfere with the nerve transmission at the neuromuscular junction.

DrugDDI.d321.s0.e0 7 22
drug
other antibiotics
DrugDDI.d321.s0.e1 24 38
drug
aminoglycosides
DrugDDI.d321.s0.e2 42 50
drug
polymyxin



Abstract Id: DrugDDI.d321
Sentence Id: DrugDDI.d321.s1
Based on this reported activity, they should not be given concomitantly with Coly-Mycin M Parenteral except with the greatest caution.

DrugDDI.d321.s1.e0 65 85
drug
Coly-Mycin M Parenteral



Abstract Id: DrugDDI.d321
Sentence Id: DrugDDI.d321.s2
Curariform muscle relaxants (eg, tubocurarine ) and other drugs , including ether , succinylcholine , gallamine , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral .

DrugDDI.d321.s2.e0 0 24
drug
Curariform muscle relaxants
DrugDDI.d321.s2.e1 29 40
drug
tubocurarine
DrugDDI.d321.s2.e2 50 54
drug
drugs
DrugDDI.d321.s2.e3 65 69
drug
ether
DrugDDI.d321.s2.e4 71 85
drug
succinylcholine
DrugDDI.d321.s2.e5 87 95
drug
gallamine
DrugDDI.d321.s2.e6 97 109
drug
decamethonium
DrugDDI.d321.s2.e7 113 125
drug
sodium citrate
DrugDDI.d321.s2.e8 226 246
drug
Coly-Mycin M Parenteral

interaction DrugDDI.d321.s2.e0 DrugDDI.d321.s2.e8
interaction DrugDDI.d321.s2.e1 DrugDDI.d321.s2.e8
interaction DrugDDI.d321.s2.e2 DrugDDI.d321.s2.e8
interaction DrugDDI.d321.s2.e3 DrugDDI.d321.s2.e8
interaction DrugDDI.d321.s2.e4 DrugDDI.d321.s2.e8
interaction DrugDDI.d321.s2.e5 DrugDDI.d321.s2.e8
interaction DrugDDI.d321.s2.e6 DrugDDI.d321.s2.e8
interaction DrugDDI.d321.s2.e7 DrugDDI.d321.s2.e8

Abstract Id: DrugDDI.d321
Sentence Id: DrugDDI.d321.s3
Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral .

DrugDDI.d321.s3.e0 0 16
drug
Sodium cephalothin
DrugDDI.d321.s3.e1 46 66
drug
Coly-Mycin M Parenteral

interaction DrugDDI.d321.s3.e0 DrugDDI.d321.s3.e1

Abstract Id: DrugDDI.d321
Sentence Id: DrugDDI.d321.s4
The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.

DrugDDI.d321.s4.e0 19 35
drug
sodium cephalothin
DrugDDI.d321.s4.e1 39 59
drug
Coly-Mycin M Parenteral

interaction DrugDDI.d321.s4.e0 DrugDDI.d321.s4.e1

Abstract Id: DrugDDI.d544
Sentence Id: DrugDDI.d544.s0
Digoxin Coadministration of digoxin , a P- glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.

DrugDDI.d544.s0.e0 0 6
drug
Digoxin
DrugDDI.d544.s0.e1 25 31
drug
digoxin
DrugDDI.d544.s0.e2 36 47
drug
glycoprotein
DrugDDI.d544.s0.e3 66 75
drug
conivaptan
DrugDDI.d544.s0.e4 122 128
drug
digoxin

interaction DrugDDI.d544.s0.e1 DrugDDI.d544.s0.e3

Abstract Id: DrugDDI.d544
Sentence Id: DrugDDI.d544.s1
Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.

DrugDDI.d544.s1.e0 12 18
drug
digoxin



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s0
DRUG /LABORATORY TEST INTERACTIONS 1.

DrugDDI.d434.s0.e0 0 3
drug
DRUG



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s3
increased factors II , VII antigen , VIII antigen , VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin ; .

DrugDDI.d434.s3.e0 9 17
drug
factors II
DrugDDI.d434.s3.e1 22 28
drug
antigen
DrugDDI.d434.s3.e2 34 40
drug
antigen
DrugDDI.d434.s3.e3 42 54
drug
VIII coagulant
DrugDDI.d434.s3.e4 105 124
drug
beta-thromboglobulin



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s4
decreased levels of anti-factor Xa and antithrombin III , decreased antithrombin III activity; .

DrugDDI.d434.s4.e0 17 29
drug
anti-factor Xa
DrugDDI.d434.s4.e1 33 47
drug
antithrombin III
DrugDDI.d434.s4.e2 58 72
drug
antithrombin III



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s5
increased levels of fibrinogen and fibrinogen activity; .

DrugDDI.d434.s5.e0 17 26
drug
fibrinogen



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s8
Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.

DrugDDI.d434.s8.e0 109 127
drug
protein-bound iodine



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s11
Patients on thyroid replacement therapy may require higher doses of thyroid hormone .

DrugDDI.d434.s11.e0 10 16
drug
thyroid
DrugDDI.d434.s11.e1 58 71
drug
thyroid hormone



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s13
Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin ( CBG ), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively.

DrugDDI.d434.s13.e0 5 19
drug
binding proteins
DrugDDI.d434.s13.e1 47 75
drug
corticosteroid binding globulin
DrugDDI.d434.s13.e2 77 79
drug
CBG
DrugDDI.d434.s13.e3 92 106
drug
binding globulin
DrugDDI.d434.s13.e4 148 162
drug
corticosteroids



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s15
Other plasma proteins may be increased ( angiotensinogen /renin substrate , alpha-1-antitrypsin , ceruloplasmin ).

DrugDDI.d434.s15.e0 5 18
drug
plasma proteins
DrugDDI.d434.s15.e1 34 48
drug
angiotensinogen
DrugDDI.d434.s15.e2 49 63
drug
/renin substrate
DrugDDI.d434.s15.e3 65 83
drug
alpha-1-antitrypsin
DrugDDI.d434.s15.e4 85 97
drug
ceruloplasmin



Abstract Id: DrugDDI.d434
Sentence Id: DrugDDI.d434.s17
Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.

DrugDDI.d434.s17.e0 25 35
drug
cholesterol
DrugDDI.d434.s17.e1 69 82
drug
LDL cholesterol



Abstract Id: DrugDDI.d203
Sentence Id: DrugDDI.d203.s0
Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.

DrugDDI.d203.s0.e0 0 12
drug
Corticotropin



Abstract Id: DrugDDI.d206
Sentence Id: DrugDDI.d206.s0
Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.

DrugDDI.d206.s0.e0 17 27
drug
antibiotics
DrugDDI.d206.s0.e1 29 40
drug
methotrexate
DrugDDI.d206.s0.e2 44 56
drug
pyrimethamine
DrugDDI.d206.s0.e3 67 75
drug
folic acid
DrugDDI.d206.s0.e4 79 88
drug
vitamin B12



Abstract Id: DrugDDI.d206
Sentence Id: DrugDDI.d206.s1
Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12 .

DrugDDI.d206.s1.e0 0 9
drug
Colchicine
DrugDDI.d206.s1.e1 98 107
drug
vitamin B12

interaction DrugDDI.d206.s1.e0 DrugDDI.d206.s1.e1

Abstract Id: DrugDDI.d367
Sentence Id: DrugDDI.d367.s0
Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.

DrugDDI.d367.s0.e0 17 27
drug
antibiotics
DrugDDI.d367.s0.e1 29 40
drug
methotrexate
DrugDDI.d367.s0.e2 44 56
drug
pyrimethamine
DrugDDI.d367.s0.e3 67 75
drug
folic acid
DrugDDI.d367.s0.e4 79 88
drug
vitamin B12



Abstract Id: DrugDDI.d367
Sentence Id: DrugDDI.d367.s1
Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12 .

DrugDDI.d367.s1.e0 0 9
drug
Colchicine
DrugDDI.d367.s1.e1 98 107
drug
vitamin B12



Abstract Id: DrugDDI.d68
Sentence Id: DrugDDI.d68.s0
FLEXERIL may have life-threatening interactions with MAO inhibitors .

DrugDDI.d68.s0.e0 0 7
drug
FLEXERIL
DrugDDI.d68.s0.e1 47 59
drug
MAO inhibitors

interaction DrugDDI.d68.s0.e0 DrugDDI.d68.s0.e1

Abstract Id: DrugDDI.d68
Sentence Id: DrugDDI.d68.s1
FLEXERIL may enhance the effects of alcohol , barbiturates , and other CNS depressants .

DrugDDI.d68.s1.e0 0 7
drug
FLEXERIL
DrugDDI.d68.s1.e1 30 36
drug
alcohol
DrugDDI.d68.s1.e2 38 49
drug
barbiturates
DrugDDI.d68.s1.e3 59 72
drug
CNS depressants

interaction DrugDDI.d68.s1.e0 DrugDDI.d68.s1.e1
interaction DrugDDI.d68.s1.e0 DrugDDI.d68.s1.e2
interaction DrugDDI.d68.s1.e0 DrugDDI.d68.s1.e3

Abstract Id: DrugDDI.d68
Sentence Id: DrugDDI.d68.s2
Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

DrugDDI.d68.s2.e0 0 23
drug
Tricyclic antidepressants
DrugDDI.d68.s2.e1 35 50
drug
antihypertensive
DrugDDI.d68.s2.e2 59 70
drug
guanethidine

interaction DrugDDI.d68.s2.e0 DrugDDI.d68.s2.e2

Abstract Id: DrugDDI.d68
Sentence Id: DrugDDI.d68.s3
Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol .

DrugDDI.d68.s3.e0 0 23
drug
Tricyclic antidepressants
DrugDDI.d68.s3.e1 64 71
drug
tramadol

interaction DrugDDI.d68.s3.e0 DrugDDI.d68.s3.e1

Abstract Id: DrugDDI.d104
Sentence Id: DrugDDI.d104.s0
Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine ; .

DrugDDI.d104.s0.e0 0 13
drug
Cyclopentolate
DrugDDI.d104.s0.e1 54 62
drug
carbachol
DrugDDI.d104.s0.e2 65 75
drug
pilocarpine

interaction DrugDDI.d104.s0.e0 DrugDDI.d104.s0.e1
interaction DrugDDI.d104.s0.e0 DrugDDI.d104.s0.e2

Abstract Id: DrugDDI.d104
Sentence Id: DrugDDI.d104.s1
also, concurrent use of this medication may antagonise the anti-glaucoma and miotic actions of ophthalmic cholinesterase inhibitors .

DrugDDI.d104.s1.e0 24 33
drug
medication
DrugDDI.d104.s1.e1 66 71
drug
miotic
DrugDDI.d104.s1.e2 91 114
drug
cholinesterase inhibitors

interaction DrugDDI.d104.s1.e0 DrugDDI.d104.s1.e2

Abstract Id: DrugDDI.d1
Sentence Id: DrugDDI.d1.s0
The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital .

DrugDDI.d1.s0.e0 45 60
drug
cyclophosphamide
DrugDDI.d1.s0.e1 119 131
drug
phenobarbital

interaction DrugDDI.d1.s0.e0 DrugDDI.d1.s0.e1

Abstract Id: DrugDDI.d1
Sentence Id: DrugDDI.d1.s1
The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs , including other cytotoxic drugs .

DrugDDI.d1.s1.e0 88 103
drug
cyclophosphamide
DrugDDI.d1.s1.e1 114 129
drug
cyclophosphamide
DrugDDI.d1.s1.e2 174 178
drug
drugs
DrugDDI.d1.s1.e3 189 207
drug
other cytotoxic drugs



Abstract Id: DrugDDI.d1
Sentence Id: DrugDDI.d1.s2
Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride .

DrugDDI.d1.s2.e0 114 136
drug
succinylcholine chloride



Abstract Id: DrugDDI.d1
Sentence Id: DrugDDI.d1.s3
If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.

DrugDDI.d1.s3.e0 28 43
drug
cyclophosphamide



Abstract Id: DrugDDI.d7
Sentence Id: DrugDDI.d7.s0
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines .

DrugDDI.d7.s0.e0 0 12
drug
MAO inhibitors
DrugDDI.d7.s0.e1 35 49
drug
anticholinergic
DrugDDI.d7.s0.e2 59 72
drug
antihistamines



Abstract Id: DrugDDI.d7
Sentence Id: DrugDDI.d7.s1
Antihistamines may have additive effects with alcohol and other CNS depressants , e.g., hypnotics , sedatives , tranquilizers , antianxiety agents .

DrugDDI.d7.s1.e0 0 13
drug
Antihistamines
DrugDDI.d7.s1.e1 40 46
drug
alcohol
DrugDDI.d7.s1.e2 55 68
drug
CNS depressants
DrugDDI.d7.s1.e3 75 83
drug
hypnotics
DrugDDI.d7.s1.e4 85 93
drug
sedatives
DrugDDI.d7.s1.e5 95 107
drug
tranquilizers
DrugDDI.d7.s1.e6 109 125
drug
antianxiety agents



Abstract Id: DrugDDI.d176
Sentence Id: DrugDDI.d176.s0
Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide , vincristine , and prednisone with or without cytarabine or procarbazine .

DrugDDI.d176.s0.e0 39 45
drug
digoxin
DrugDDI.d176.s0.e1 68 76
drug
glycoside
DrugDDI.d176.s0.e2 128 134
drug
digoxin
DrugDDI.d176.s0.e3 168 183
drug
cyclophosphamide
DrugDDI.d176.s0.e4 185 195
drug
vincristine
DrugDDI.d176.s0.e5 200 209
drug
prednisone
DrugDDI.d176.s0.e6 223 232
drug
cytarabine
DrugDDI.d176.s0.e7 235 246
drug
procarbazine

interaction DrugDDI.d176.s0.e2 DrugDDI.d176.s0.e3
interaction DrugDDI.d176.s0.e2 DrugDDI.d176.s0.e4
interaction DrugDDI.d176.s0.e2 DrugDDI.d176.s0.e5

Abstract Id: DrugDDI.d176
Sentence Id: DrugDDI.d176.s1
Steady state plasma digitoxin concentrations did not appear to change.

DrugDDI.d176.s1.e0 17 25
drug
digitoxin



Abstract Id: DrugDDI.d176
Sentence Id: DrugDDI.d176.s3
The utilization of digitoxin for such patients may be considered as an alternative.

DrugDDI.d176.s3.e0 16 24
drug
digitoxin



Abstract Id: DrugDDI.d176
Sentence Id: DrugDDI.d176.s4
Also flucytosine .

DrugDDI.d176.s4.e0 4 14
drug
flucytosine



Abstract Id: DrugDDI.d202
Sentence Id: DrugDDI.d202.s0
Drug /LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.

DrugDDI.d202.s0.e0 0 3
drug
Drug
DrugDDI.d202.s0.e1 31 42
drug
Dactinomycin
DrugDDI.d202.s0.e2 98 114
drug
antibacterial drug



Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s0
Dantrium is metabolized by the liver , and it is theoretically possible that its metabolism may be enhanced by drugs known to induce hepatic microsomal enzymes .

DrugDDI.d471.s0.e0 0 7
drug
Dantrium
DrugDDI.d471.s0.e1 26 30
drug
liver
DrugDDI.d471.s0.e2 92 96
drug
drugs
DrugDDI.d471.s0.e3 117 133
drug
microsomal enzymes

interaction DrugDDI.d471.s0.e0 DrugDDI.d471.s0.e2

Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s1
However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.

DrugDDI.d471.s1.e0 15 27
drug
phenobarbital
DrugDDI.d471.s1.e1 31 38
drug
diazepam
DrugDDI.d471.s1.e2 54 61
drug
Dantrium



Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s2
Binding to plasma protein is not significantly altered by diazepam , diphenylhydantoin , or phenylbutazone .

DrugDDI.d471.s2.e0 9 21
drug
plasma protein
DrugDDI.d471.s2.e1 49 56
drug
diazepam
DrugDDI.d471.s2.e2 58 74
drug
diphenylhydantoin
DrugDDI.d471.s2.e3 78 91
drug
phenylbutazone



Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s3
Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide .

DrugDDI.d471.s3.e0 9 22
drug
plasma proteins
DrugDDI.d471.s3.e1 34 41
drug
warfarin
DrugDDI.d471.s3.e2 69 79
drug
tolbutamide



Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s4
Cardiovascular collapse in patients treated simultaneously with varapamil and dantrolene sodium is rare.

DrugDDI.d471.s4.e0 69 84
drug
dantrolene sodium



Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s5
The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane / span class= c35 a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.

DrugDDI.d471.s5.e0 45 60
drug
dantrolene sodium
DrugDDI.d471.s5.e1 64 72
drug
verapamil
DrugDDI.d471.s5.e2 75 83
drug
halothane

interaction DrugDDI.d471.s5.e0 DrugDDI.d471.s5.e1

Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s6
It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers , such as verapamil , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.

DrugDDI.d471.s6.e0 46 61
drug
dantrolene sodium
DrugDDI.d471.s6.e1 65 86
drug
calcium channel blockers
DrugDDI.d471.s6.e2 94 102
drug
verapamil

interaction DrugDDI.d471.s6.e0 DrugDDI.d471.s6.e1
interaction DrugDDI.d471.s6.e0 DrugDDI.d471.s6.e2

Abstract Id: DrugDDI.d471
Sentence Id: DrugDDI.d471.s7
Administration of dantrolene may potentiate vecuronium -induced neuromuscular block.

DrugDDI.d471.s7.e0 16 25
drug
dantrolene
DrugDDI.d471.s7.e1 39 48
drug
vecuronium

interaction DrugDDI.d471.s7.e0 DrugDDI.d471.s7.e1

Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s0
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim / sulfamethoxazole ( TMP /SMX).

DrugDDI.d536.s0.e0 111 122
drug
trimethoprim
DrugDDI.d536.s0.e1 124 139
drug
sulfamethoxazole
DrugDDI.d536.s0.e2 141 143
drug
TMP



Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s1
During co-administration, systemic levels of TMP and SMX were essentially unchanged.

DrugDDI.d536.s1.e0 40 42
drug
TMP



Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s2
However, levels of dapsone and its metabolites increased in the presence of TMP /SMX.

DrugDDI.d536.s2.e0 16 22
drug
dapsone
DrugDDI.d536.s2.e1 29 39
drug
metabolites
DrugDDI.d536.s2.e2 64 66
drug
TMP

interaction DrugDDI.d536.s2.e0 DrugDDI.d536.s2.e2
interaction DrugDDI.d536.s2.e1 DrugDDI.d536.s2.e2

Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s3
Systemic exposure (AUC0-12) of dapsone and N-acetyl- dapsone ( NAD ) were increased by about 40% and 20% respectively in presence of TMP /SMX.

DrugDDI.d536.s3.e0 27 33
drug
dapsone
DrugDDI.d536.s3.e1 46 52
drug
dapsone
DrugDDI.d536.s3.e2 54 56
drug
NAD
DrugDDI.d536.s3.e3 111 113
drug
TMP

interaction DrugDDI.d536.s3.e0 DrugDDI.d536.s3.e3
interaction DrugDDI.d536.s3.e1 DrugDDI.d536.s3.e3

Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s4
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP /SMX.

DrugDDI.d536.s4.e0 35 54
drug
dapsone hydroxylamine
DrugDDI.d536.s4.e1 93 95
drug
TMP

interaction DrugDDI.d536.s4.e0 DrugDDI.d536.s4.e1

Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s5
Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP /SMX.

DrugDDI.d536.s5.e0 97 99
drug
TMP



Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s6
Certain concomitant medications (such as rifampin , anticonvulsants , St.

DrugDDI.d536.s6.e0 18 28
drug
medications
DrugDDI.d536.s6.e1 36 43
drug
rifampin
DrugDDI.d536.s6.e2 45 59
drug
anticonvulsants



Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s7
John@s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis.

DrugDDI.d536.s7.e0 58 67
drug
metabolite
DrugDDI.d536.s7.e1 70 76
drug
dapsone



Abstract Id: DrugDDI.d536
Sentence Id: DrugDDI.d536.s8
With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions .

DrugDDI.d536.s8.e0 8 14
drug
dapsone
DrugDDI.d536.s8.e1 25 44
drug
folic acid antagonists
DrugDDI.d536.s8.e2 51 63
drug
pyrimethamine

interaction DrugDDI.d536.s8.e0 DrugDDI.d536.s8.e1
interaction DrugDDI.d536.s8.e0 DrugDDI.d536.s8.e2

Abstract Id: DrugDDI.d441
Sentence Id: DrugDDI.d441.s0
The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole , itraconazole , ritonavir , nelfinavir , clarithromycin and nefazadone) .

DrugDDI.d441.s0.e0 14 20
drug
ENABLEX
DrugDDI.d441.s0.e1 69 74
drug
CYP3A4
DrugDDI.d441.s0.e2 91 102
drug
ketoconazole
DrugDDI.d441.s0.e3 104 115
drug
itraconazole
DrugDDI.d441.s0.e4 117 125
drug
ritonavir
DrugDDI.d441.s0.e5 127 136
drug
nelfinavir
DrugDDI.d441.s0.e6 138 151
drug
clarithromycin

interaction DrugDDI.d441.s0.e0 DrugDDI.d441.s0.e1
interaction DrugDDI.d441.s0.e0 DrugDDI.d441.s0.e2
interaction DrugDDI.d441.s0.e0 DrugDDI.d441.s0.e3
interaction DrugDDI.d441.s0.e0 DrugDDI.d441.s0.e4
interaction DrugDDI.d441.s0.e0 DrugDDI.d441.s0.e5
interaction DrugDDI.d441.s0.e0 DrugDDI.d441.s0.e6

Abstract Id: DrugDDI.d441
Sentence Id: DrugDDI.d441.s1
Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide , thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).

DrugDDI.d441.s1.e0 24 30
drug
ENABLEX
DrugDDI.d441.s1.e1 54 64
drug
medications
DrugDDI.d441.s1.e2 98 103
drug
CYP2D6
DrugDDI.d441.s1.e3 147 156
drug
flecainide
DrugDDI.d441.s1.e4 158 169
drug
thioridazine
DrugDDI.d441.s1.e5 173 196
drug
tricyclic antidepressants

interaction DrugDDI.d441.s1.e0 DrugDDI.d441.s1.e1
interaction DrugDDI.d441.s1.e0 DrugDDI.d441.s1.e3
interaction DrugDDI.d441.s1.e0 DrugDDI.d441.s1.e4
interaction DrugDDI.d441.s1.e0 DrugDDI.d441.s1.e5

Abstract Id: DrugDDI.d441
Sentence Id: DrugDDI.d441.s2
The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.

DrugDDI.d441.s2.e0 19 25
drug
ENABLEX
DrugDDI.d441.s2.e1 35 55
drug
anticholinergic agents
DrugDDI.d441.s2.e2 138 152
drug
anticholinergic

interaction DrugDDI.d441.s2.e0 DrugDDI.d441.s2.e1

Abstract Id: DrugDDI.d441
Sentence Id: DrugDDI.d441.s3
Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.

DrugDDI.d441.s3.e0 0 20
drug
Anticholinergic agents
DrugDDI.d441.s3.e1 84 88
drug
drugs

interaction DrugDDI.d441.s3.e0 DrugDDI.d441.s3.e1

Abstract Id: DrugDDI.d441
Sentence Id: DrugDDI.d441.s4
Drug Laboratory Test Interactions Interactions between darifenacin and laboratory tests have not been studied.

DrugDDI.d441.s4.e0 49 59
drug
darifenacin



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s0
Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.

DrugDDI.d407.s0.e0 0 4
drug
Drugs
DrugDDI.d407.s0.e1 49 54
drug
CYP3A4
DrugDDI.d407.s0.e2 78 83
drug
CYP3A4



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s1
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided.

DrugDDI.d407.s1.e0 26 30
drug
drugs
DrugDDI.d407.s1.e1 42 47
drug
CYP3A4
DrugDDI.d407.s1.e2 52 63
drug
ketoconazole
DrugDDI.d407.s1.e3 65 76
drug
itraconazole
DrugDDI.d407.s1.e4 78 89
drug
erythromycin
DrugDDI.d407.s1.e5 91 104
drug
clarithromycin
DrugDDI.d407.s1.e6 106 114
drug
ritonavir
DrugDDI.d407.s1.e7 116 125
drug
atazanavir
DrugDDI.d407.s1.e8 127 135
drug
indinavir
DrugDDI.d407.s1.e9 137 146
drug
nefazodone
DrugDDI.d407.s1.e10 148 157
drug
nelfinavir
DrugDDI.d407.s1.e11 159 168
drug
saquinavir
DrugDDI.d407.s1.e12 170 182
drug
telithromycin



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s2
In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.

DrugDDI.d407.s2.e0 141 146
drug
CYP3A4



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s3
Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.

DrugDDI.d407.s3.e0 0 4
drug
Drugs
DrugDDI.d407.s3.e1 49 54
drug
CYP3A4
DrugDDI.d407.s3.e2 64 68
drug
Drugs
DrugDDI.d407.s3.e3 79 84
drug
CYP3A4



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s4
In patients in whom CYP3A4 inducers (eg, dexamethasone , phenytoin , carbamazepine , rifampicin , phenobarbital ) are indicated, alternative agents with less enzyme induction potential should be used.

DrugDDI.d407.s4.e0 16 21
drug
CYP3A4
DrugDDI.d407.s4.e1 34 46
drug
dexamethasone
DrugDDI.d407.s4.e2 48 56
drug
phenytoin
DrugDDI.d407.s4.e3 58 70
drug
carbamazepine
DrugDDI.d407.s4.e4 72 81
drug
rifampicin
DrugDDI.d407.s4.e5 83 95
drug
phenobarbital



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s5
If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.

DrugDDI.d407.s5.e0 32 37
drug
CYP3A4



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s6
St. Johns wort ( Hypericum perforatum ) may decrease SPRYCEL plasma concentrations unpredictably.

DrugDDI.d407.s6.e0 0 11
drug
St. Johns wort
DrugDDI.d407.s6.e1 13 31
drug
Hypericum perforatum



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s7
Patients receiving SPRYCEL should not take St. Johns wort .

DrugDDI.d407.s7.e0 37 48
drug
St. Johns wort



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s8
Antacids : Nonclinical data demonstrate that the solubility of dasatinib is pH dependent.

DrugDDI.d407.s8.e0 0 7
drug
Antacids



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s9
Simultaneous administration of SPRYCEL with antacids should be avoided.

DrugDDI.d407.s9.e0 39 46
drug
antacids



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s10
If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.

DrugDDI.d407.s10.e0 28 34
drug
antacid



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s11
H2 Blockers / Proton Pump Inhibitors : Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure.

DrugDDI.d407.s11.e0 0 9
drug
H2 Blockers
DrugDDI.d407.s11.e1 11 30
drug
Proton Pump Inhibitors
DrugDDI.d407.s11.e2 76 85
drug
H2 blockers
DrugDDI.d407.s11.e3 88 107
drug
proton pump inhibitors
DrugDDI.d407.s11.e4 112 121
drug
famotidine
DrugDDI.d407.s11.e5 125 134
drug
omeprazole



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s12
The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.

DrugDDI.d407.s12.e0 19 28
drug
H2 blockers
DrugDDI.d407.s12.e1 31 50
drug
proton pump inhibitors



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s13
The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.

DrugDDI.d407.s13.e0 8 15
drug
antacids
DrugDDI.d407.s13.e1 43 52
drug
H2 blockers
DrugDDI.d407.s13.e2 55 74
drug
proton pump inhibitors



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s14
Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4 .

DrugDDI.d407.s14.e0 0 4
drug
Drugs
DrugDDI.d407.s14.e1 58 63
drug
CYP3A4
DrugDDI.d407.s14.e2 112 117
drug
CYP3A4



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s15
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL.

DrugDDI.d407.s15.e0 10 15
drug
CYP3A4
DrugDDI.d407.s15.e1 66 75
drug
alfentanil
DrugDDI.d407.s15.e2 77 86
drug
astemizole
DrugDDI.d407.s15.e3 88 98
drug
terfenadine
DrugDDI.d407.s15.e4 100 108
drug
cisapride
DrugDDI.d407.s15.e5 110 121
drug
cyclosporine
DrugDDI.d407.s15.e6 123 130
drug
fentanyl
DrugDDI.d407.s15.e7 132 139
drug
pimozide
DrugDDI.d407.s15.e8 141 149
drug
quinidine
DrugDDI.d407.s15.e9 151 159
drug
sirolimus
DrugDDI.d407.s15.e10 161 170
drug
tacrolimus
DrugDDI.d407.s15.e11 174 187
drug
ergot alkaloids
DrugDDI.d407.s15.e12 189 198
drug
ergotamine
DrugDDI.d407.s15.e13 200 216
drug
dihydroergotamine



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s16
Hepatic Impairment There are currently no clinical studies with SPRYCEL in patients with impaired liver function (clinical studies have excluded patients with ALT and/or AST  2.5 times the upper limit of the normal range and/or total bilirubin  2 times the upper limit of the normal range).

DrugDDI.d407.s16.e0 146 148
drug
AST
DrugDDI.d407.s16.e1 192 205
drug
total bilirubin



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s19
Renal Impairment There are currently no clinical studies with SPRYCEL in patients with impaired renal function (clinical studies have excluded patients with serum creatinine concentration  1.5 times the upper limit of the normal range).

DrugDDI.d407.s19.e0 140 149
drug
creatinine



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s20
Dasatinib and its metabolites are minimally excreted via the kidney.

DrugDDI.d407.s20.e0 15 25
drug
metabolites



Abstract Id: DrugDDI.d407
Sentence Id: DrugDDI.d407.s21
Since the renal excretion of unchanged dasatinib and its metabolites is  4%, a decrease in total body clearance is not expected in patients with renal insufficiency.

DrugDDI.d407.s21.e0 48 58
drug
metabolites



Abstract Id: DrugDDI.d277
Sentence Id: DrugDDI.d277.s0
Potentially fatal drug interactions may occur when coadministered with digoxin , as this may enhance cardiovascular depression and bradyarrhythmias may occur.

DrugDDI.d277.s0.e0 62 68
drug
digoxin



Abstract Id: DrugDDI.d277
Sentence Id: DrugDDI.d277.s1
Anticholinesterases (neostgmine, physostigmine ), lignocaine , quinine , procainamide can enhance toxicity and cause cardio respiratory depression.

DrugDDI.d277.s1.e0 0 18
drug
Anticholinesterases
DrugDDI.d277.s1.e1 31 43
drug
physostigmine
DrugDDI.d277.s1.e2 46 55
drug
lignocaine
DrugDDI.d277.s1.e3 57 63
drug
quinine
DrugDDI.d277.s1.e4 65 76
drug
procainamide



Abstract Id: DrugDDI.d277
Sentence Id: DrugDDI.d277.s2
In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium carbonate , and terbutaline .

DrugDDI.d277.s2.e0 50 67
drug
general anesthetics
DrugDDI.d277.s2.e1 69 84
drug
local anesthetics
DrugDDI.d277.s2.e2 89 97
drug
lidocaine
DrugDDI.d277.s2.e3 99 106
drug
procaine
DrugDDI.d277.s2.e4 108 120
drug
beta-blockers
DrugDDI.d277.s2.e5 122 135
drug
metaclopramide
DrugDDI.d277.s2.e6 137 152
drug
lithium carbonate
DrugDDI.d277.s2.e7 157 167
drug
terbutaline



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s0
The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.

DrugDDI.d139.s0.e0 30 35
drug
Exjade
DrugDDI.d139.s0.e1 39 76
drug
aluminum-containing antacid preparations



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s1
Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum-containing antacid preparations .

DrugDDI.d139.s1.e0 8 18
drug
deferasirox
DrugDDI.d139.s1.e1 54 57
drug
iron
DrugDDI.d139.s1.e2 59 64
drug
Exjade
DrugDDI.d139.s1.e3 85 122
drug
aluminum-containing antacid preparations



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s2
In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin .

DrugDDI.d139.s2.e0 20 25
drug
Exjade
DrugDDI.d139.s2.e1 60 66
drug
digoxin



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s3
The effect of digoxin on Exjade pharmacokinetics has not been studied.

DrugDDI.d139.s3.e0 11 17
drug
digoxin
DrugDDI.d139.s3.e1 20 25
drug
Exjade



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s4
The concomitant administration of Exjade and vitamin C has not been formally studied.

DrugDDI.d139.s4.e0 30 35
drug
Exjade
DrugDDI.d139.s4.e1 39 46
drug
vitamin C



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s5
Doses of vitamin C up to 200 mg were allowed in clinical studies without negative consequences.

DrugDDI.d139.s5.e0 7 14
drug
vitamin C



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s6
The interaction of Exjade with hydroxyurea has not been formally studied.

DrugDDI.d139.s6.e0 16 21
drug
Exjade
DrugDDI.d139.s6.e1 26 36
drug
hydroxyurea



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s7
No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.

DrugDDI.d139.s7.e0 14 24
drug
deferasirox
DrugDDI.d139.s7.e1 37 47
drug
hydroxyurea



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s8
Exjade should not be combined with other iron chelator therapies , as safety of such combinations has not been established.

DrugDDI.d139.s8.e0 0 5
drug
Exjade
DrugDDI.d139.s8.e1 34 54
drug
iron chelator therapies



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s9
Drug /Food Interactions The bioavailability (AUC) of deferasirox was variably increased when taken with a meal.

DrugDDI.d139.s9.e0 0 3
drug
Drug
DrugDDI.d139.s9.e1 46 56
drug
deferasirox



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s10
Deferasirox should be taken on an empty stomach 30 minutes before eating.

DrugDDI.d139.s10.e0 0 10
drug
Deferasirox



Abstract Id: DrugDDI.d139
Sentence Id: DrugDDI.d139.s11
Exjade tablets for oral suspension can be dispersed in water , orange juice, or apple juice.

DrugDDI.d139.s11.e0 0 5
drug
Exjade
DrugDDI.d139.s11.e1 46 50
drug
water



Abstract Id: DrugDDI.d73
Sentence Id: DrugDDI.d73.s0
Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir .

DrugDDI.d73.s0.e0 9 22
drug
clarithromycin
DrugDDI.d73.s0.e1 24 33
drug
Didanosine
DrugDDI.d73.s0.e2 35 45
drug
Fluconazole
DrugDDI.d73.s0.e3 47 56
drug
Fluoxetine
DrugDDI.d73.s0.e4 68 79
drug
Ketoconazole
DrugDDI.d73.s0.e5 81 89
drug
Phenytoin
DrugDDI.d73.s0.e6 105 117
drug
carbamazepine
DrugDDI.d73.s0.e7 119 127
drug
Rifabutin
DrugDDI.d73.s0.e8 129 136
drug
Rifampin
DrugDDI.d73.s0.e9 148 157
drug
Saquinavir



Abstract Id: DrugDDI.d419
Sentence Id: DrugDDI.d419.s0
Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents .

DrugDDI.d419.s0.e0 26 33
drug
HUMORSOL
DrugDDI.d419.s0.e1 38 52
drug
succinylcholine
DrugDDI.d419.s0.e2 64 87
drug
anticholinesterase agents

interaction DrugDDI.d419.s0.e0 DrugDDI.d419.s0.e1
interaction DrugDDI.d419.s0.e0 DrugDDI.d419.s0.e2

Abstract Id: DrugDDI.d173
Sentence Id: DrugDDI.d173.s1
However, in a single in vivo rodent study denileukin diftitox had no effect on P450 levels.

DrugDDI.d173.s1.e0 34 51
drug
denileukin diftitox
DrugDDI.d173.s1.e1 65 68
drug
P450



Abstract Id: DrugDDI.d513
Sentence Id: DrugDDI.d513.s0
Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.

DrugDDI.d513.s0.e0 7 23
drug
rauwolfia alkaloid
DrugDDI.d513.s0.e1 63 75
drug
MAO inhibitors

interaction DrugDDI.d513.s0.e0 DrugDDI.d513.s0.e1

Abstract Id: DrugDDI.d163
Sentence Id: DrugDDI.d163.s0
No clinically significant adverse interactions with commonly used preanesthetic drugs , or drugs used during anesthesia ( muscle relaxants , intravenous agents, and local anesthetic agents ) were reported in clinical trials.

DrugDDI.d163.s0.e0 71 75
drug
drugs
DrugDDI.d163.s0.e1 79 83
drug
drugs
DrugDDI.d163.s0.e2 105 119
drug
muscle relaxants
DrugDDI.d163.s0.e3 147 162
drug
anesthetic agents



Abstract Id: DrugDDI.d163
Sentence Id: DrugDDI.d163.s1
The effect of desflurane on the disposition of other drugs has not been determined.

DrugDDI.d163.s1.e0 11 20
drug
desflurane
DrugDDI.d163.s1.e1 44 48
drug
drugs



Abstract Id: DrugDDI.d163
Sentence Id: DrugDDI.d163.s2
Like isoflurane , desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.

DrugDDI.d163.s2.e0 4 13
drug
isoflurane
DrugDDI.d163.s2.e1 15 24
drug
desflurane
DrugDDI.d163.s2.e2 108 118
drug
epinephrine



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s0
In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7 .5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.

DrugDDI.d237.s0.e0 82 89
drug
nd female
DrugDDI.d237.s0.e1 118 131
drug
desloratadine 7
DrugDDI.d237.s0.e2 188 204
drug
erythromycin 500 mg
DrugDDI.d237.s0.e3 218 234
drug
ketoconazole 200 mg



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s1
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.

DrugDDI.d237.s1.e0 67 79
drug
desloratadine
DrugDDI.d237.s1.e1 127 143
drug
azithromycin 500 mg
DrugDDI.d237.s1.e2 188 201
drug
fluoxetine 20 mg
DrugDDI.d237.s1.e3 252 261
drug
fluoxetine
DrugDDI.d237.s1.e4 274 288
drug
cimetidine 600 mg



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s2
Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine , as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.

DrugDDI.d237.s2.e0 39 41
drug
max
DrugDDI.d237.s2.e1 58 70
drug
desloratadine
DrugDDI.d237.s2.e2 165 177
drug
desloratadine



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s3
Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers .

DrugDDI.d237.s3.e0 15 27
drug
Desloratadine



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s5
Desloratadine 3-Hydroxydesloratadine .

DrugDDI.d237.s5.e0 0 12
drug
Desloratadine



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s8
Erythromycin .

DrugDDI.d237.s8.e0 0 11
drug
Erythromycin



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s11
Ketoconazole .

DrugDDI.d237.s11.e0 0 11
drug
Ketoconazole



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s14
Azithromycin .

DrugDDI.d237.s14.e0 0 11
drug
Azithromycin



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s15
(500 mg day 1, 250 mg QD @ 4 days) .

DrugDDI.d237.s15.e0 11 13
drug
250



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s17
Fluoxetine .

DrugDDI.d237.s17.e0 0 9
drug
Fluoxetine



Abstract Id: DrugDDI.d237
Sentence Id: DrugDDI.d237.s20
Cimetidine .

DrugDDI.d237.s20.e0 0 9
drug
Cimetidine



Abstract Id: DrugDDI.d405
Sentence Id: DrugDDI.d405.s0
Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.

DrugDDI.d405.s0.e0 11 17
drug
pressor
DrugDDI.d405.s0.e1 28 39
drug
Desmopressin
DrugDDI.d405.s0.e2 62 73
drug
antidiuretic
DrugDDI.d405.s0.e3 95 106
drug
Desmopressin
DrugDDI.d405.s0.e4 135 147
drug
pressor agents



Abstract Id: DrugDDI.d94
Sentence Id: DrugDDI.d94.s0
Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin .

DrugDDI.d94.s0.e0 122 129
drug
rifampin



Abstract Id: DrugDDI.d94
Sentence Id: DrugDDI.d94.s1
A similar association, though less marked, has been suggested with barbiturates , phenyl -butazone, phenytoin sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72) .

DrugDDI.d94.s1.e0 57 68
drug
barbiturates
DrugDDI.d94.s1.e1 70 75
drug
phenyl
DrugDDI.d94.s1.e2 86 100
drug
phenytoin sodium
DrugDDI.d94.s1.e3 102 114
drug
carbamazepine
DrugDDI.d94.s1.e4 130 141
drug
griseofulvin
DrugDDI.d94.s1.e5 143 152
drug
ampicillin
DrugDDI.d94.s1.e6 157 169
drug
tetracyclines



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s0
Aminoglutethimide : Aminoglutethimide may diminish adrenal suppression by corticosteroids .

DrugDDI.d421.s0.e0 0 16
drug
Aminoglutethimide
DrugDDI.d421.s0.e1 18 34
drug
Aminoglutethimide
DrugDDI.d421.s0.e2 66 80
drug
corticosteroids

interaction DrugDDI.d421.s0.e1 DrugDDI.d421.s0.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s1
Amphotericin B injection and potassium -depleting agents: When corticosteroids are administered concomitantly with potassium -depleting agents (e.g., amphotericin B , diuretics ), patients should be observed closely for development of hypokalemia.

DrugDDI.d421.s1.e0 0 12
drug
Amphotericin B
DrugDDI.d421.s1.e1 25 33
drug
potassium
DrugDDI.d421.s1.e2 55 69
drug
corticosteroids
DrugDDI.d421.s1.e3 102 110
drug
potassium
DrugDDI.d421.s1.e4 133 145
drug
amphotericin B
DrugDDI.d421.s1.e5 147 155
drug
diuretics

interaction DrugDDI.d421.s1.e2 DrugDDI.d421.s1.e3

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s2
In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.

DrugDDI.d421.s2.e0 60 72
drug
amphotericin B
DrugDDI.d421.s2.e1 76 89
drug
hydrocortisone

interaction DrugDDI.d421.s2.e0 DrugDDI.d421.s2.e1

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s3
Antibiotics : Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.

DrugDDI.d421.s3.e0 0 10
drug
Antibiotics
DrugDDI.d421.s3.e1 12 31
drug
Macrolide antibiotics
DrugDDI.d421.s3.e2 77 90
drug
corticosteroid

interaction DrugDDI.d421.s3.e1 DrugDDI.d421.s3.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s4
Anticholinesterases : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.

DrugDDI.d421.s4.e0 0 18
drug
Anticholinesterases
DrugDDI.d421.s4.e1 36 59
drug
anticholinesterase agents
DrugDDI.d421.s4.e2 63 77
drug
corticosteroids

interaction DrugDDI.d421.s4.e1 DrugDDI.d421.s4.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s5
If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.

DrugDDI.d421.s5.e0 11 34
drug
anticholinesterase agents



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s6
Anticoagulants , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin , although there have been some conflicting reports.

DrugDDI.d421.s6.e0 0 13
drug
Anticoagulants
DrugDDI.d421.s6.e1 39 53
drug
corticosteroids
DrugDDI.d421.s6.e2 57 64
drug
warfarin
DrugDDI.d421.s6.e3 103 110
drug
warfarin

interaction DrugDDI.d421.s6.e1 DrugDDI.d421.s6.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s8
Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.

DrugDDI.d421.s8.e0 0 12
drug
Antidiabetics
DrugDDI.d421.s8.e1 21 35
drug
corticosteroids
DrugDDI.d421.s8.e2 93 110
drug
antidiabetic agents

interaction DrugDDI.d421.s8.e1 DrugDDI.d421.s8.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s9
Antitubercular drugs : Serum concentrations of isoniazid may be decreased.

DrugDDI.d421.s9.e0 0 18
drug
Antitubercular drugs
DrugDDI.d421.s9.e1 41 49
drug
isoniazid



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s10
Cholestyramine : Cholestyramine may increase the clearance of corticosteroids .

DrugDDI.d421.s10.e0 0 13
drug
Cholestyramine
DrugDDI.d421.s10.e1 15 28
drug
Cholestyramine
DrugDDI.d421.s10.e2 54 68
drug
corticosteroids

interaction DrugDDI.d421.s10.e1 DrugDDI.d421.s10.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s11
Cyclosporine : Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.

DrugDDI.d421.s11.e0 0 11
drug
Cyclosporine
DrugDDI.d421.s11.e1 36 47
drug
cyclosporine
DrugDDI.d421.s11.e2 51 65
drug
corticosteroids

interaction DrugDDI.d421.s11.e1 DrugDDI.d421.s11.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s13
Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported.

DrugDDI.d421.s13.e0 119 130
drug
indomethacin



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s15
Digitalis glycosides : Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.

DrugDDI.d421.s15.e0 0 18
drug
Digitalis glycosides
DrugDDI.d421.s15.e1 30 48
drug
digitalis glycosides



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s16
Ephedrine : Ephedrine may enhance the metabolic clearance of corticosteroids , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.

DrugDDI.d421.s16.e0 0 8
drug
Ephedrine
DrugDDI.d421.s16.e1 10 18
drug
Ephedrine
DrugDDI.d421.s16.e2 52 66
drug
corticosteroids
DrugDDI.d421.s16.e3 155 168
drug
corticosteroid

interaction DrugDDI.d421.s16.e1 DrugDDI.d421.s16.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s17
Estrogens , including oral contraceptives : Estrogens may decrease the hepatic metabolism of certain corticosteroids , thereby increasing their effect.

DrugDDI.d421.s17.e0 0 8
drug
Estrogens
DrugDDI.d421.s17.e1 19 36
drug
oral contraceptives
DrugDDI.d421.s17.e2 38 46
drug
Estrogens
DrugDDI.d421.s17.e3 87 101
drug
corticosteroids

interaction DrugDDI.d421.s17.e2 DrugDDI.d421.s17.e3

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s18
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 ( CYP 3A4) enzyme activity (e.g., barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.

DrugDDI.d421.s18.e0 46 50
drug
Drugs
DrugDDI.d421.s18.e1 62 78
drug
cytochrome P450 3A4
DrugDDI.d421.s18.e2 80 82
drug
CYP
DrugDDI.d421.s18.e3 107 118
drug
barbiturates
DrugDDI.d421.s18.e4 120 128
drug
phenytoin
DrugDDI.d421.s18.e5 130 142
drug
carbamazepine
DrugDDI.d421.s18.e6 144 151
drug
rifampin
DrugDDI.d421.s18.e7 178 192
drug
corticosteroids
DrugDDI.d421.s18.e8 221 234
drug
corticosteroid

interaction DrugDDI.d421.s18.e0 DrugDDI.d421.s18.e7
interaction DrugDDI.d421.s18.e3 DrugDDI.d421.s18.e7
interaction DrugDDI.d421.s18.e4 DrugDDI.d421.s18.e7
interaction DrugDDI.d421.s18.e5 DrugDDI.d421.s18.e7
interaction DrugDDI.d421.s18.e6 DrugDDI.d421.s18.e7

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s19
Drugs which inhibit CYP 3A4 (e.g., ketoconazole , macrolide antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids .

DrugDDI.d421.s19.e0 0 4
drug
Drugs
DrugDDI.d421.s19.e1 17 19
drug
CYP
DrugDDI.d421.s19.e2 29 40
drug
ketoconazole
DrugDDI.d421.s19.e3 42 61
drug
macrolide antibiotics
DrugDDI.d421.s19.e4 68 79
drug
erythromycin
DrugDDI.d421.s19.e5 138 152
drug
corticosteroids

interaction DrugDDI.d421.s19.e0 DrugDDI.d421.s19.e5
interaction DrugDDI.d421.s19.e2 DrugDDI.d421.s19.e5
interaction DrugDDI.d421.s19.e4 DrugDDI.d421.s19.e5

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s20
Dexamethasone is a moderate inducer of CYP 3A4.

DrugDDI.d421.s20.e0 0 12
drug
Dexamethasone
DrugDDI.d421.s20.e1 33 35
drug
CYP



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s21
Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir , erythromycin ) may increase their clearance, resulting in decreased plasma concentration.

DrugDDI.d421.s21.e0 26 30
drug
drugs
DrugDDI.d421.s21.e1 51 53
drug
CYP
DrugDDI.d421.s21.e2 63 71
drug
indinavir
DrugDDI.d421.s21.e3 73 84
drug
erythromycin



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s22
Ketoconazole : Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.

DrugDDI.d421.s22.e0 0 11
drug
Ketoconazole
DrugDDI.d421.s22.e1 13 24
drug
Ketoconazole
DrugDDI.d421.s22.e2 72 86
drug
corticosteroids
DrugDDI.d421.s22.e3 121 134
drug
corticosteroid

interaction DrugDDI.d421.s22.e1 DrugDDI.d421.s22.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s23
In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.

DrugDDI.d421.s23.e0 11 22
drug
ketoconazole
DrugDDI.d421.s23.e1 45 58
drug
corticosteroid
DrugDDI.d421.s23.e2 105 118
drug
corticosteroid

interaction DrugDDI.d421.s23.e0 DrugDDI.d421.s23.e1
interaction DrugDDI.d421.s23.e0 DrugDDI.d421.s23.e2

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s24
Nonsteroidal anti-inflammatory agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents ) and corticosteroids increases the risk of gastrointestinal side effects.

DrugDDI.d421.s24.e0 0 34
drug
Nonsteroidal anti-inflammatory agents
DrugDDI.d421.s24.e1 36 41
drug
NSAIDS
DrugDDI.d421.s24.e2 60 66
drug
aspirin
DrugDDI.d421.s24.e3 75 108
drug
nonsteroidal antiinflammatory agents
DrugDDI.d421.s24.e4 113 127
drug
corticosteroids

interaction DrugDDI.d421.s24.e2 DrugDDI.d421.s24.e4
interaction DrugDDI.d421.s24.e3 DrugDDI.d421.s24.e4

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s25
Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

DrugDDI.d421.s25.e0 0 6
drug
Aspirin
DrugDDI.d421.s25.e1 46 60
drug
corticosteroids

interaction DrugDDI.d421.s25.e0 DrugDDI.d421.s25.e1

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s26
The clearance of salicylates may be increased with concurrent use of corticosteroids .

DrugDDI.d421.s26.e0 14 24
drug
salicylates
DrugDDI.d421.s26.e1 58 72
drug
corticosteroids

interaction DrugDDI.d421.s26.e0 DrugDDI.d421.s26.e1

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s27
Phenytoin : In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.

DrugDDI.d421.s27.e0 0 8
drug
Phenytoin
DrugDDI.d421.s27.e1 105 117
drug
dexamethasone



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s28
Skin tests: Corticosteroids may suppress reactions to skin tests.

DrugDDI.d421.s28.e0 10 24
drug
Corticosteroids



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s29
Thalidomide : Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.

DrugDDI.d421.s29.e0 0 10
drug
Thalidomide
DrugDDI.d421.s29.e1 33 43
drug
thalidomide



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s30
Vaccines : Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.

DrugDDI.d421.s30.e0 0 7
drug
Vaccines
DrugDDI.d421.s30.e1 71 77
drug
toxoids
DrugDDI.d421.s30.e2 87 105
drug
inactivated vaccines



Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s31
Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines .

DrugDDI.d421.s31.e0 0 14
drug
Corticosteroids
DrugDDI.d421.s31.e1 72 93
drug
live attenuated vaccines

interaction DrugDDI.d421.s31.e0 DrugDDI.d421.s31.e1

Abstract Id: DrugDDI.d421
Sentence Id: DrugDDI.d421.s32
Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.

DrugDDI.d421.s32.e0 23 30
drug
vaccines
DrugDDI.d421.s32.e1 33 39
drug
toxoids



Abstract Id: DrugDDI.d36
Sentence Id: DrugDDI.d36.s0
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).

DrugDDI.d36.s0.e0 0 17
drug
Dexbrompheniramine
DrugDDI.d36.s0.e1 33 39
drug
alcohol
DrugDDI.d36.s0.e2 47 60
drug
CNS depressants
DrugDDI.d36.s0.e3 78 90
drug
CNS depressant
DrugDDI.d36.s0.e4 111 121
drug
medications
DrugDDI.d36.s0.e5 124 137
drug
antihistamines
DrugDDI.d36.s0.e6 140 155
drug
anticholinergics
DrugDDI.d36.s0.e7 158 173
drug
other medications
DrugDDI.d36.s0.e8 178 192
drug
anticholinergic
DrugDDI.d36.s0.e9 202 216
drug
anticholinergic
DrugDDI.d36.s0.e10 249 259
drug
medications
DrugDDI.d36.s0.e11 283 296
drug
antihistamines
DrugDDI.d36.s0.e12 302 317
drug
monoamine oxidase
DrugDDI.d36.s0.e13 351 364
drug
antihistamines
DrugDDI.d36.s0.e14 390 404
drug
anticholinergic
DrugDDI.d36.s0.e15 408 420
drug
CNS depressant
DrugDDI.d36.s0.e16 430 443
drug
antihistamines

interaction DrugDDI.d36.s0.e0 DrugDDI.d36.s0.e1
interaction DrugDDI.d36.s0.e0 DrugDDI.d36.s0.e2
interaction DrugDDI.d36.s0.e0 DrugDDI.d36.s0.e3
interaction DrugDDI.d36.s0.e0 DrugDDI.d36.s0.e5
interaction DrugDDI.d36.s0.e0 DrugDDI.d36.s0.e6
interaction DrugDDI.d36.s0.e0 DrugDDI.d36.s0.e7

Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s0
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride ) in combination with serotoninergic agents (e.g., fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.

DrugDDI.d131.s0.e0 31 56
drug
monoamine oxidase inhibitors
DrugDDI.d131.s0.e1 70 92
drug
selegiline hydrochloride
DrugDDI.d131.s0.e2 137 146
drug
fluoxetine
DrugDDI.d131.s0.e3 148 158
drug
fluvoxamine
DrugDDI.d131.s0.e4 160 169
drug
paroxetine
DrugDDI.d131.s0.e5 171 180
drug
sertraline
DrugDDI.d131.s0.e6 182 192
drug
venlafaxine



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s1
Because dexfenfluramine is a serotonin releaser and reuptake inhibitor , dexfenfluramine should not be used concomitantly with a MAO inhibitor .

DrugDDI.d131.s1.e0 7 21
drug
dexfenfluramine
DrugDDI.d131.s1.e1 45 61
drug
reuptake inhibitor
DrugDDI.d131.s1.e2 63 77
drug
dexfenfluramine
DrugDDI.d131.s1.e3 111 122
drug
MAO inhibitor



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s2
At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine .

DrugDDI.d131.s2.e0 50 61
drug
MAO inhibitor
DrugDDI.d131.s2.e1 90 104
drug
dexfenfluramine



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s3
At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor .

DrugDDI.d131.s3.e0 49 63
drug
dexfenfluramine
DrugDDI.d131.s3.e1 93 104
drug
MAO inhibitor



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s4
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex ( sumatriptan succinate ) and dihydroergotamine .

DrugDDI.d131.s4.e0 112 138
drug
serotonin reuptake inhibitors
DrugDDI.d131.s4.e1 180 186
drug
Imitrex
DrugDDI.d131.s4.e2 188 207
drug
sumatriptan succinate
DrugDDI.d131.s4.e3 212 228
drug
dihydroergotamine



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s6
Dexfenfluramine should not be administered with other serotoninergic agents.

DrugDDI.d131.s6.e0 0 14
drug
Dexfenfluramine



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s7
The appropriate interval between administration of these agents and dexfenfluramine has not been established.

DrugDDI.d131.s7.e0 59 73
drug
dexfenfluramine



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s8
The use of dexfenfluramine with other CNS-active drugs has not been systematically evaluated; .

DrugDDI.d131.s8.e0 8 22
drug
dexfenfluramine
DrugDDI.d131.s8.e1 32 46
drug
CNS-active drugs



Abstract Id: DrugDDI.d131
Sentence Id: DrugDDI.d131.s9
consequently, caution is advised if dexfenfluramine and such drugs are prescribed concurrently.

DrugDDI.d131.s9.e0 31 45
drug
dexfenfluramine
DrugDDI.d131.s9.e1 53 57
drug
drugs



Abstract Id: DrugDDI.d128
Sentence Id: DrugDDI.d128.s0
ZINECARD does not influence the pharmacokinetics of doxorubicin .

DrugDDI.d128.s0.e0 0 7
drug
ZINECARD
DrugDDI.d128.s0.e1 45 55
drug
doxorubicin



Abstract Id: DrugDDI.d128
Sentence Id: DrugDDI.d128.s1
Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term carcinogenicity studies have been carried out with dexrazoxane in animals.

DrugDDI.d128.s1.e0 103 113
drug
dexrazoxane



Abstract Id: DrugDDI.d128
Sentence Id: DrugDDI.d128.s2
Dexrazoxane was not mutagenic in the Ame s test but was found to be clastogenic to human lymphocytes in vitro and to mouse bone marrow erythrocytes in vivo (micronucleus test).

DrugDDI.d128.s2.e0 0 10
drug
Dexrazoxane
DrugDDI.d128.s2.e1 31 33
drug
Ame



Abstract Id: DrugDDI.d128
Sentence Id: DrugDDI.d128.s3
The possible adverse effects of ZINECARD on the fertility of humans and experimental animals, male or female, have not been adequately studied.

DrugDDI.d128.s3.e0 27 34
drug
ZINECARD



Abstract Id: DrugDDI.d128
Sentence Id: DrugDDI.d128.s4
Testicular atrophy was seen with dexrazoxane administration at doses as low as 30 mg/kg weekly for 6 weeks in rats (1/3 the human dose on a mg/m 2 basis) and as low as 20 mg/kg weekly for 13 weeks in dogs (approximately equal to the human dose on a mg/m 2 basis).

DrugDDI.d128.s4.e0 28 38
drug
dexrazoxane



Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s0
Acidifying agents : Gastrointestinal acidifying agents ( guanethidine , reserpine , glutamic acid HCl , ascorbic acid , fruit juices, etc.) lower absorption of amphetamines .

DrugDDI.d205.s0.e0 0 15
drug
Acidifying agents
DrugDDI.d205.s0.e1 17 48
drug
Gastrointestinal acidifying agents
DrugDDI.d205.s0.e2 50 61
drug
guanethidine
DrugDDI.d205.s0.e3 63 71
drug
reserpine
DrugDDI.d205.s0.e4 73 87
drug
glutamic acid HCl
DrugDDI.d205.s0.e5 89 100
drug
ascorbic acid
DrugDDI.d205.s0.e6 136 147
drug
amphetamines

interaction DrugDDI.d205.s0.e1 DrugDDI.d205.s0.e6
interaction DrugDDI.d205.s0.e2 DrugDDI.d205.s0.e6
interaction DrugDDI.d205.s0.e3 DrugDDI.d205.s0.e6
interaction DrugDDI.d205.s0.e4 DrugDDI.d205.s0.e6
interaction DrugDDI.d205.s0.e5 DrugDDI.d205.s0.e6

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s1
Urinary acidifying agents ( ammonium chloride , sodium acid phosphate , etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.

DrugDDI.d205.s1.e0 7 22
drug
acidifying agents
DrugDDI.d205.s1.e1 24 39
drug
ammonium chloride
DrugDDI.d205.s1.e2 41 59
drug
sodium acid phosphate
DrugDDI.d205.s1.e3 114 124
drug
amphetamine

interaction DrugDDI.d205.s1.e0 DrugDDI.d205.s1.e3
interaction DrugDDI.d205.s1.e1 DrugDDI.d205.s1.e3
interaction DrugDDI.d205.s1.e2 DrugDDI.d205.s1.e3

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s2
Both groups of agents lower blood levels and efficacy of amphetamines .

DrugDDI.d205.s2.e0 47 58
drug
amphetamines



Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s3
Adrenergic blockers : Adrenergic blockers are inhibited by amphetamines .

DrugDDI.d205.s3.e0 0 17
drug
Adrenergic blockers
DrugDDI.d205.s3.e1 19 36
drug
Adrenergic blockers
DrugDDI.d205.s3.e2 51 62
drug
amphetamines

interaction DrugDDI.d205.s3.e1 DrugDDI.d205.s3.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s4
Alkalinizing agents : Gastrointestinal alkalinizing agents ( sodium bicarbonate , etc.) increase absorption of amphetamines .

DrugDDI.d205.s4.e0 0 17
drug
Alkalinizing agents
DrugDDI.d205.s4.e1 19 52
drug
Gastrointestinal alkalinizing agents
DrugDDI.d205.s4.e2 54 70
drug
sodium bicarbonate
DrugDDI.d205.s4.e3 97 108
drug
amphetamines

interaction DrugDDI.d205.s4.e1 DrugDDI.d205.s4.e3
interaction DrugDDI.d205.s4.e2 DrugDDI.d205.s4.e3

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s5
Urinary alkalinizing agents ( acetazolamide , some thiazides ) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.

DrugDDI.d205.s5.e0 7 24
drug
alkalinizing agents
DrugDDI.d205.s5.e1 26 38
drug
acetazolamide
DrugDDI.d205.s5.e2 44 52
drug
thiazides
DrugDDI.d205.s5.e3 106 116
drug
amphetamine

interaction DrugDDI.d205.s5.e0 DrugDDI.d205.s5.e3
interaction DrugDDI.d205.s5.e1 DrugDDI.d205.s5.e3
interaction DrugDDI.d205.s5.e2 DrugDDI.d205.s5.e3

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s6
Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines .

DrugDDI.d205.s6.e0 71 82
drug
amphetamines



Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s7
Antidepressants , tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents ; .

DrugDDI.d205.s7.e0 0 14
drug
Antidepressants
DrugDDI.d205.s7.e1 26 37
drug
Amphetamines
DrugDDI.d205.s7.e2 72 92
drug
sympathomimetic agents

interaction DrugDDI.d205.s7.e1 DrugDDI.d205.s7.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s8
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; .

DrugDDI.d205.s8.e0 0 12
drug
d-amphetamine
DrugDDI.d205.s8.e1 17 27
drug
desipramine
DrugDDI.d205.s8.e2 30 42
drug
protriptyline
DrugDDI.d205.s8.e3 59 68
drug
tricyclics
DrugDDI.d205.s8.e4 123 135
drug
d-amphetamine

interaction DrugDDI.d205.s8.e0 DrugDDI.d205.s8.e1
interaction DrugDDI.d205.s8.e0 DrugDDI.d205.s8.e2
interaction DrugDDI.d205.s8.e0 DrugDDI.d205.s8.e3

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s10
MAO inhibitors : MAOI antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism.

DrugDDI.d205.s10.e0 0 12
drug
MAO inhibitors
DrugDDI.d205.s10.e1 18 32
drug
antidepressants
DrugDDI.d205.s10.e2 43 52
drug
metabolite
DrugDDI.d205.s10.e3 55 66
drug
furazolidone
DrugDDI.d205.s10.e4 72 82
drug
amphetamine

interaction DrugDDI.d205.s10.e1 DrugDDI.d205.s10.e4
interaction DrugDDI.d205.s10.e3 DrugDDI.d205.s10.e4

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s11
This slowing potentiates amphetamines , increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; .

DrugDDI.d205.s11.e0 22 33
drug
amphetamines
DrugDDI.d205.s11.e1 70 83
drug
norepinephrine

interaction DrugDDI.d205.s11.e0 DrugDDI.d205.s11.e1

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s14
Antihistamines : Amphetamines may counteract the sedative effect of antihistamines .

DrugDDI.d205.s14.e0 0 13
drug
Antihistamines
DrugDDI.d205.s14.e1 15 26
drug
Amphetamines
DrugDDI.d205.s14.e2 43 50
drug
sedative
DrugDDI.d205.s14.e3 59 72
drug
antihistamines

interaction DrugDDI.d205.s14.e1 DrugDDI.d205.s14.e3

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s15
Antihypertensives : Amphetamines may antagonize the hypotensive effects of antihypertensives .

DrugDDI.d205.s15.e0 0 16
drug
Antihypertensives
DrugDDI.d205.s15.e1 18 29
drug
Amphetamines
DrugDDI.d205.s15.e2 66 82
drug
antihypertensives

interaction DrugDDI.d205.s15.e1 DrugDDI.d205.s15.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s16
Chlorpromazine : Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines , and can be used to treat amphetamine poisoning.

DrugDDI.d205.s16.e0 0 13
drug
Chlorpromazine
DrugDDI.d205.s16.e1 15 28
drug
Chlorpromazine
DrugDDI.d205.s16.e2 35 42
drug
dopamine
DrugDDI.d205.s16.e3 46 59
drug
norepinephrine
DrugDDI.d205.s16.e4 86 101
drug
central stimulant
DrugDDI.d205.s16.e5 111 122
drug
amphetamines

interaction DrugDDI.d205.s16.e1 DrugDDI.d205.s16.e2
interaction DrugDDI.d205.s16.e1 DrugDDI.d205.s16.e3
interaction DrugDDI.d205.s16.e1 DrugDDI.d205.s16.e5

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s17
Ethosuximide : Amphetamines may delay intestinal absorption of ethosuximide .

DrugDDI.d205.s17.e0 0 11
drug
Ethosuximide
DrugDDI.d205.s17.e1 13 24
drug
Amphetamines
DrugDDI.d205.s17.e2 55 66
drug
ethosuximide

interaction DrugDDI.d205.s17.e1 DrugDDI.d205.s17.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s18
Haloperidol : Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines .

DrugDDI.d205.s18.e0 0 10
drug
Haloperidol
DrugDDI.d205.s18.e1 12 22
drug
Haloperidol
DrugDDI.d205.s18.e2 29 36
drug
dopamine
DrugDDI.d205.s18.e3 40 53
drug
norepinephrine
DrugDDI.d205.s18.e4 80 95
drug
central stimulant
DrugDDI.d205.s18.e5 105 116
drug
amphetamines

interaction DrugDDI.d205.s18.e1 DrugDDI.d205.s18.e2
interaction DrugDDI.d205.s18.e1 DrugDDI.d205.s18.e3
interaction DrugDDI.d205.s18.e1 DrugDDI.d205.s18.e5

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s19
Lithium carbonate : The stimulatory effects of amphetamines may be inhibited by lithium carbonate .

DrugDDI.d205.s19.e0 0 15
drug
Lithium carbonate
DrugDDI.d205.s19.e1 40 51
drug
amphetamines
DrugDDI.d205.s19.e2 68 83
drug
lithium carbonate

interaction DrugDDI.d205.s19.e1 DrugDDI.d205.s19.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s20
Meperidine : Amphetamines potentiate the analgesic effect of meperidine .

DrugDDI.d205.s20.e0 0 9
drug
Meperidine
DrugDDI.d205.s20.e1 11 22
drug
Amphetamines
DrugDDI.d205.s20.e2 53 62
drug
meperidine

interaction DrugDDI.d205.s20.e1 DrugDDI.d205.s20.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s21
Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.

DrugDDI.d205.s21.e0 0 10
drug
Methenamine
DrugDDI.d205.s21.e1 37 48
drug
amphetamines
DrugDDI.d205.s21.e2 84 99
drug
acidifying agents
DrugDDI.d205.s21.e3 106 116
drug
methenamine

interaction DrugDDI.d205.s21.e1 DrugDDI.d205.s21.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s22
Norepinephrine : Amphetamines enhance the adrenergic effect of norepinephrine .

DrugDDI.d205.s22.e0 0 13
drug
Norepinephrine
DrugDDI.d205.s22.e1 15 26
drug
Amphetamines
DrugDDI.d205.s22.e2 55 68
drug
norepinephrine

interaction DrugDDI.d205.s22.e1 DrugDDI.d205.s22.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s23
Phenobarbital : Amphetamines may delay intestinal absorption of phenobarbital ; .

DrugDDI.d205.s23.e0 0 12
drug
Phenobarbital
DrugDDI.d205.s23.e1 14 25
drug
Amphetamines
DrugDDI.d205.s23.e2 56 68
drug
phenobarbital

interaction DrugDDI.d205.s23.e1 DrugDDI.d205.s23.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s24
co-administration of phenobarbital may produce a synergistic anticonvulsant action.

DrugDDI.d205.s24.e0 19 31
drug
phenobarbital
DrugDDI.d205.s24.e1 54 67
drug
anticonvulsant



Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s25
Phenytoin : Amphetamines may delay intestinal absorption of phenytoin ; .

DrugDDI.d205.s25.e0 0 8
drug
Phenytoin
DrugDDI.d205.s25.e1 10 21
drug
Amphetamines
DrugDDI.d205.s25.e2 52 60
drug
phenytoin

interaction DrugDDI.d205.s25.e1 DrugDDI.d205.s25.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s26
co-administration of phenytoin may produce a synergistic anticonvulsant action.

DrugDDI.d205.s26.e0 19 27
drug
phenytoin
DrugDDI.d205.s26.e1 50 63
drug
anticonvulsant



Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s27
Propoxyphene : In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.

DrugDDI.d205.s27.e0 0 11
drug
Propoxyphene
DrugDDI.d205.s27.e1 22 33
drug
propoxyphene
DrugDDI.d205.s27.e2 45 58
drug
amphetamine CNS

interaction DrugDDI.d205.s27.e1 DrugDDI.d205.s27.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s28
Veratrum alkaloids : Amphetamines inhibit the hypotensive effect of veratrum alkaloids .

DrugDDI.d205.s28.e0 0 16
drug
Veratrum alkaloids
DrugDDI.d205.s28.e1 18 29
drug
Amphetamines
DrugDDI.d205.s28.e2 59 75
drug
veratrum alkaloids

interaction DrugDDI.d205.s28.e1 DrugDDI.d205.s28.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s29
Drug /Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.

DrugDDI.d205.s29.e0 0 3
drug
Drug
DrugDDI.d205.s29.e1 32 43
drug
Amphetamines
DrugDDI.d205.s29.e2 81 94
drug
corticosteroid

interaction DrugDDI.d205.s29.e1 DrugDDI.d205.s29.e2

Abstract Id: DrugDDI.d205
Sentence Id: DrugDDI.d205.s31
Amphetamines may interfere with urinary steroid determinations.

DrugDDI.d205.s31.e0 0 11
drug
Amphetamines



Abstract Id: DrugDDI.d532
Sentence Id: DrugDDI.d532.s0
Additive depressant effect when used with general anesthetics , sedatives , antianxiety drugs , hypnotics , alcohol , and other opiate analgesics.

DrugDDI.d532.s0.e0 36 53
drug
general anesthetics
DrugDDI.d532.s0.e1 55 63
drug
sedatives
DrugDDI.d532.s0.e2 65 80
drug
antianxiety drugs
DrugDDI.d532.s0.e3 82 90
drug
hypnotics
DrugDDI.d532.s0.e4 92 98
drug
alcohol
DrugDDI.d532.s0.e5 108 113
drug
opiate



Abstract Id: DrugDDI.d160
Sentence Id: DrugDDI.d160.s0
May interact with thyroid medication (e.g., levothyroxine ), iodine-containing products, antacids , H2-antagonists (e.g., famotidine , ranitidine ), and proton pump inhibitors (e.g., lansoprazole , omeprazole ).

DrugDDI.d160.s0.e0 15 31
drug
thyroid medication
DrugDDI.d160.s0.e1 38 50
drug
levothyroxine
DrugDDI.d160.s0.e2 53 69
drug
iodine-containing
DrugDDI.d160.s0.e3 79 86
drug
antacids
DrugDDI.d160.s0.e4 108 117
drug
famotidine
DrugDDI.d160.s0.e5 119 128
drug
ranitidine
DrugDDI.d160.s0.e6 134 153
drug
proton pump inhibitors
DrugDDI.d160.s0.e7 160 171
drug
lansoprazole
DrugDDI.d160.s0.e8 173 182
drug
omeprazole



Abstract Id: DrugDDI.d268
Sentence Id: DrugDDI.d268.s0
Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors , as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.

DrugDDI.d268.s0.e0 55 61
drug
aspirin
DrugDDI.d268.s0.e1 65 91
drug
carbonic anhydrase inhibitors

interaction DrugDDI.d268.s0.e0 DrugDDI.d268.s0.e1

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s0
Aspirin : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations, peak plasma levels, and AUC values.

DrugDDI.d284.s0.e0 0 6
drug
Aspirin
DrugDDI.d284.s0.e1 35 44
drug
diclofenac
DrugDDI.d284.s0.e2 48 54
drug
aspirin
DrugDDI.d284.s0.e3 78 87
drug
diclofenac
DrugDDI.d284.s0.e4 154 160
drug
aspirin

interaction DrugDDI.d284.s0.e1 DrugDDI.d284.s0.e2

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s1
Anticoagulants : While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs .

DrugDDI.d284.s1.e0 0 13
drug
Anticoagulants
DrugDDI.d284.s1.e1 39 48
drug
diclofenac
DrugDDI.d284.s1.e2 63 76
drug
anticoagulants
DrugDDI.d284.s1.e3 82 89
drug
warfarin
DrugDDI.d284.s1.e4 170 175
drug
NSAIDs

interaction DrugDDI.d284.s1.e1 DrugDDI.d284.s1.e4

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s2
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.

DrugDDI.d284.s2.e0 7 20
drug
prostaglandins
DrugDDI.d284.s2.e1 56 61
drug
NSAIDs
DrugDDI.d284.s2.e2 115 120
drug
NSAIDs
DrugDDI.d284.s2.e3 131 140
drug
diclofenac
DrugDDI.d284.s2.e4 145 152
drug
warfarin
DrugDDI.d284.s2.e5 216 228
drug
anticoagulant



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s3
Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs .

DrugDDI.d284.s3.e0 0 6
drug
Digoxin
DrugDDI.d284.s3.e1 8 19
drug
Methotrexate
DrugDDI.d284.s3.e2 21 32
drug
Cyclosporine
DrugDDI.d284.s3.e3 34 43
drug
Diclofenac
DrugDDI.d284.s3.e4 54 59
drug
NSAIDs
DrugDDI.d284.s3.e5 75 88
drug
prostaglandins
DrugDDI.d284.s3.e6 120 124
drug
drugs

interaction DrugDDI.d284.s3.e3 DrugDDI.d284.s3.e5
interaction DrugDDI.d284.s3.e3 DrugDDI.d284.s3.e6
interaction DrugDDI.d284.s3.e4 DrugDDI.d284.s3.e5
interaction DrugDDI.d284.s3.e4 DrugDDI.d284.s3.e6

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s4
Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine@s nephrotoxicity.

DrugDDI.d284.s4.e0 11 20
drug
diclofenac
DrugDDI.d284.s4.e1 53 59
drug
digoxin
DrugDDI.d284.s4.e2 63 74
drug
methotrexate

interaction DrugDDI.d284.s4.e0 DrugDDI.d284.s4.e1
interaction DrugDDI.d284.s4.e0 DrugDDI.d284.s4.e2

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s5
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs .

DrugDDI.d284.s5.e0 22 31
drug
diclofenac
DrugDDI.d284.s5.e1 50 59
drug
diclofenac
DrugDDI.d284.s5.e2 74 78
drug
NSAID
DrugDDI.d284.s5.e3 90 96
drug
digoxin
DrugDDI.d284.s5.e4 98 109
drug
methotrexate
DrugDDI.d284.s5.e5 113 124
drug
cyclosporine
DrugDDI.d284.s5.e6 166 170
drug
drugs

interaction DrugDDI.d284.s5.e0 DrugDDI.d284.s5.e3
interaction DrugDDI.d284.s5.e0 DrugDDI.d284.s5.e4
interaction DrugDDI.d284.s5.e0 DrugDDI.d284.s5.e5
interaction DrugDDI.d284.s5.e2 DrugDDI.d284.s5.e3
interaction DrugDDI.d284.s5.e2 DrugDDI.d284.s5.e4
interaction DrugDDI.d284.s5.e2 DrugDDI.d284.s5.e5

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s7
In the case of digoxin , serum levels should be monitored.

DrugDDI.d284.s7.e0 11 17
drug
digoxin



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s8
Lithium : Diclofenac decreases lithium renal clearance and increases lithium plasma levels.

DrugDDI.d284.s8.e0 0 6
drug
Lithium
DrugDDI.d284.s8.e1 8 17
drug
Diclofenac



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s9
In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.

DrugDDI.d284.s9.e0 16 25
drug
diclofenac
DrugDDI.d284.s9.e1 29 35
drug
lithium

interaction DrugDDI.d284.s9.e0 DrugDDI.d284.s9.e1

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s10
Oral Hypoglycemics : Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents .

DrugDDI.d284.s10.e0 0 16
drug
Oral Hypoglycemics
DrugDDI.d284.s10.e1 18 27
drug
Diclofenac
DrugDDI.d284.s10.e2 103 120
drug
hypoglycemic agents



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s11
There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.

DrugDDI.d284.s11.e0 73 79
drug
insulin
DrugDDI.d284.s11.e1 86 103
drug
hypoglycemic agents
DrugDDI.d284.s11.e2 119 128
drug
diclofenac

interaction DrugDDI.d284.s11.e0 DrugDDI.d284.s11.e2
interaction DrugDDI.d284.s11.e1 DrugDDI.d284.s11.e2

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s13
A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient@s response to insulin or oral hypoglycemic agents .

DrugDDI.d284.s13.e0 92 101
drug
diclofenac
DrugDDI.d284.s13.e1 138 144
drug
insulin
DrugDDI.d284.s13.e2 151 168
drug
hypoglycemic agents

interaction DrugDDI.d284.s13.e0 DrugDDI.d284.s13.e1
interaction DrugDDI.d284.s13.e0 DrugDDI.d284.s13.e2

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s14
Diuretics : Diclofenac and other NSAIDs can inhibit the activity of diuretics .

DrugDDI.d284.s14.e0 0 8
drug
Diuretics
DrugDDI.d284.s14.e1 10 19
drug
Diclofenac
DrugDDI.d284.s14.e2 28 33
drug
NSAIDs
DrugDDI.d284.s14.e3 57 65
drug
diuretics

interaction DrugDDI.d284.s14.e1 DrugDDI.d284.s14.e3
interaction DrugDDI.d284.s14.e2 DrugDDI.d284.s14.e3

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s15
Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.

DrugDDI.d284.s15.e0 24 49
drug
potassium-sparing diuretics



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s16
Other Drugs : In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .

DrugDDI.d284.s16.e0 5 9
drug
Drugs
DrugDDI.d284.s16.e1 88 99
drug
azathioprine
DrugDDI.d284.s16.e2 101 104
drug
gold
DrugDDI.d284.s16.e3 106 116
drug
chloroquine
DrugDDI.d284.s16.e4 118 132
drug
D-penicillamine
DrugDDI.d284.s16.e5 134 145
drug
prednisolone
DrugDDI.d284.s16.e6 147 157
drug
doxycycline
DrugDDI.d284.s16.e7 161 169
drug
digitoxin
DrugDDI.d284.s16.e8 222 231
drug
diclofenac



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s17
Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.

DrugDDI.d284.s17.e0 115 124
drug
diclofenac



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s18
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide , prednisolone (10% decrease in binding), or warfarin .

DrugDDI.d284.s18.e0 22 31
drug
diclofenac
DrugDDI.d284.s18.e1 84 96
drug
salicylic acid
DrugDDI.d284.s18.e2 120 130
drug
tolbutamide
DrugDDI.d284.s18.e3 132 143
drug
prednisolone
DrugDDI.d284.s18.e4 169 176
drug
warfarin

interaction DrugDDI.d284.s18.e0 DrugDDI.d284.s18.e1
interaction DrugDDI.d284.s18.e0 DrugDDI.d284.s18.e2
interaction DrugDDI.d284.s18.e0 DrugDDI.d284.s18.e3
interaction DrugDDI.d284.s18.e0 DrugDDI.d284.s18.e4

Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s19
Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.

DrugDDI.d284.s19.e0 0 15
drug
Benzylpenicillin
DrugDDI.d284.s19.e1 17 26
drug
ampicillin
DrugDDI.d284.s19.e2 28 36
drug
oxacillin
DrugDDI.d284.s19.e3 38 54
drug
chlortetracycline
DrugDDI.d284.s19.e4 56 66
drug
doxycycline
DrugDDI.d284.s19.e5 68 78
drug
cephalothin
DrugDDI.d284.s19.e6 80 91
drug
erythromycin
DrugDDI.d284.s19.e7 96 111
drug
sulfamethoxazole
DrugDDI.d284.s19.e8 155 164
drug
diclofenac



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s20
Drug /Laboratory Test Interactions Effect on Blood Coagulation: Diclofenac increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen, or factors V and VII to XII.

DrugDDI.d284.s20.e0 0 3
drug
Drug
DrugDDI.d284.s20.e1 56 65
drug
Diclofenac
DrugDDI.d284.s20.e2 173 180
drug
factors V



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s21
Statistically significant changes in prothrombin and partial thromboplastin times have been reported in normal volunteers.

DrugDDI.d284.s21.e0 33 43
drug
prothrombin



Abstract Id: DrugDDI.d284
Sentence Id: DrugDDI.d284.s23
Diclofenac is a prostaglandin synthetase inhibitor , however, and all drugs that inhibit prostaglandin synthesis interfere with platelet function to some degree; .

DrugDDI.d284.s23.e0 0 9
drug
Diclofenac
DrugDDI.d284.s23.e1 13 44
drug
prostaglandin synthetase inhibitor
DrugDDI.d284.s23.e2 60 64
drug
drugs
DrugDDI.d284.s23.e3 76 88
drug
prostaglandin



Abstract Id: DrugDDI.d259
Sentence Id: DrugDDI.d259.s0
Tetracycline , a bacteriostat ic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.

DrugDDI.d259.s0.e0 0 11
drug
Tetracycline
DrugDDI.d259.s0.e1 14 25
drug
bacteriostat
DrugDDI.d259.s0.e2 74 83
drug
penicillin
DrugDDI.d259.s0.e3 107 111
drug
drugs

interaction DrugDDI.d259.s0.e0 DrugDDI.d259.s0.e1
interaction DrugDDI.d259.s0.e0 DrugDDI.d259.s0.e2

Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s0
The following agents may increase certain actions or side effects of anticholinergic drugs . amantadine antiarrhythmic agents of class (e.g. quinidine ), antihistamines antipsychotic agents (e.g. phenothiazines ), benzodiazepines .

DrugDDI.d35.s0.e0 58 77
drug
anticholinergic drugs
DrugDDI.d35.s0.e1 79 88
drug
amantadine
DrugDDI.d35.s0.e2 121 129
drug
quinidine
DrugDDI.d35.s0.e3 132 145
drug
antihistamines
DrugDDI.d35.s0.e4 146 164
drug
antipsychotic agents
DrugDDI.d35.s0.e5 170 183
drug
phenothiazines
DrugDDI.d35.s0.e6 186 200
drug
benzodiazepines

interaction DrugDDI.d35.s0.e0 DrugDDI.d35.s0.e1
interaction DrugDDI.d35.s0.e0 DrugDDI.d35.s0.e2
interaction DrugDDI.d35.s0.e0 DrugDDI.d35.s0.e3
interaction DrugDDI.d35.s0.e0 DrugDDI.d35.s0.e5
interaction DrugDDI.d35.s0.e0 DrugDDI.d35.s0.e6

Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s1
MAO inhibitors , narcotic analgesics (e.g., meperidine ), nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity.

DrugDDI.d35.s1.e0 0 12
drug
MAO inhibitors
DrugDDI.d35.s1.e1 14 31
drug
narcotic analgesics
DrugDDI.d35.s1.e2 38 47
drug
meperidine
DrugDDI.d35.s1.e3 50 57
drug
nitrates
DrugDDI.d35.s1.e4 61 68
drug
nitrites
DrugDDI.d35.s1.e5 70 90
drug
sympathomimetic agents
DrugDDI.d35.s1.e6 92 115
drug
tricyclic antidepressants
DrugDDI.d35.s1.e7 125 129
drug
drugs
DrugDDI.d35.s1.e8 136 150
drug
anticholinergic



Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s2
Anticholinergics antagonize the effects of antiglaucoma agents.

DrugDDI.d35.s2.e0 0 15
drug
Anticholinergics



Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s3
Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corti costeroids..

DrugDDI.d35.s3.e0 0 19
drug
Anticholinergic drugs



Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s4
Anticholinergic agents may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of digoxin ; .

DrugDDI.d35.s4.e0 0 20
drug
Anticholinergic agents
DrugDDI.d35.s4.e1 65 69
drug
drugs
DrugDDI.d35.s4.e2 106 112
drug
digoxin

interaction DrugDDI.d35.s4.e0 DrugDDI.d35.s4.e1
interaction DrugDDI.d35.s4.e0 DrugDDI.d35.s4.e2

Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s5
increased serum digoxin concentrations may result.

DrugDDI.d35.s5.e0 14 20
drug
digoxin



Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s6
Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide .

DrugDDI.d35.s6.e0 0 19
drug
Anticholinergic drugs
DrugDDI.d35.s6.e1 48 52
drug
drugs
DrugDDI.d35.s6.e2 93 106
drug
metoclopramide

interaction DrugDDI.d35.s6.e0 DrugDDI.d35.s6.e1
interaction DrugDDI.d35.s6.e0 DrugDDI.d35.s6.e2

Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s7
Because antacids may interfere with the absorption of anticholinergic agents , simultaneous use of these drugs should be avoided.

DrugDDI.d35.s7.e0 7 14
drug
antacids
DrugDDI.d35.s7.e1 46 66
drug
anticholinergic agents
DrugDDI.d35.s7.e2 90 94
drug
drugs

interaction DrugDDI.d35.s7.e0 DrugDDI.d35.s7.e1

Abstract Id: DrugDDI.d35
Sentence Id: DrugDDI.d35.s8
The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.

DrugDDI.d35.s8.e0 22 41
drug
anticholinergic drugs



Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s0
Coadministration of VIDEX with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS) and should be done with extreme caution, only if other alternatives are not available, and only if clearly indicated.

DrugDDI.d248.s0.e0 18 22
drug
VIDEX
DrugDDI.d248.s0.e1 27 31
drug
drugs

interaction DrugDDI.d248.s0.e0 DrugDDI.d248.s0.e1

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s1
Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine , and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS).

DrugDDI.d248.s1.e0 102 110
drug
stavudine
DrugDDI.d248.s1.e1 166 170
drug
VIDEX



Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s2
Allopurinol : The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).

DrugDDI.d248.s2.e0 0 10
drug
Allopurinol
DrugDDI.d248.s2.e1 20 29
drug
didanosine
DrugDDI.d248.s2.e2 57 67
drug
allopurinol
DrugDDI.d248.s2.e3 119 123
drug
VIDEX

interaction DrugDDI.d248.s2.e2 DrugDDI.d248.s2.e3

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s3
The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.

DrugDDI.d248.s3.e0 12 22
drug
allopurinol
DrugDDI.d248.s3.e1 25 34
drug
didanosine



Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s4
Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/ Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.

DrugDDI.d248.s4.e0 0 7
drug
Antacids
DrugDDI.d248.s4.e1 36 43
drug
antacids
DrugDDI.d248.s4.e2 54 62
drug
magnesium
DrugDDI.d248.s4.e3 77 81
drug
VIDEX
DrugDDI.d248.s4.e4 91 116
drug
Dispersible Buffered Tablets
DrugDDI.d248.s4.e5 119 127
drug
Pediatric
DrugDDI.d248.s4.e6 192 198
drug
antacid

interaction DrugDDI.d248.s4.e1 DrugDDI.d248.s4.e3
interaction DrugDDI.d248.s4.e1 DrugDDI.d248.s4.e4
interaction DrugDDI.d248.s4.e1 DrugDDI.d248.s4.e5

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s5
Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX .

DrugDDI.d248.s5.e0 0 4
drug
Drugs
DrugDDI.d248.s5.e1 65 69
drug
Drugs
DrugDDI.d248.s5.e2 76 87
drug
ketoconazole
DrugDDI.d248.s5.e3 91 102
drug
itraconazole
DrugDDI.d248.s5.e4 153 157
drug
VIDEX



Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s6
Ganciclovir : Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).

DrugDDI.d248.s6.e0 0 10
drug
Ganciclovir
DrugDDI.d248.s6.e1 28 32
drug
VIDEX
DrugDDI.d248.s6.e2 66 76
drug
ganciclovir
DrugDDI.d248.s6.e3 134 143
drug
didanosine

interaction DrugDDI.d248.s6.e1 DrugDDI.d248.s6.e2

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s7
A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir , but not when the two drugs were administered simultaneously (n = 12).

DrugDDI.d248.s7.e0 38 48
drug
ganciclovir
DrugDDI.d248.s7.e1 64 68
drug
VIDEX
DrugDDI.d248.s7.e2 97 107
drug
ganciclovir
DrugDDI.d248.s7.e3 125 129
drug
drugs

interaction DrugDDI.d248.s7.e1 DrugDDI.d248.s7.e2

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s8
Quinolone Antibiotic s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum.

DrugDDI.d248.s8.e0 0 18
drug
Quinolone Antibiotic
DrugDDI.d248.s8.e1 21 25
drug
VIDEX
DrugDDI.d248.s8.e2 88 100
drug
ciprofloxacin
DrugDDI.d248.s8.e3 130 142
drug
ciprofloxacin
DrugDDI.d248.s8.e4 175 182
drug
antacids
DrugDDI.d248.s8.e5 193 201
drug
magnesium
DrugDDI.d248.s8.e6 203 209
drug
calcium

interaction DrugDDI.d248.s8.e1 DrugDDI.d248.s8.e2
interaction DrugDDI.d248.s8.e3 DrugDDI.d248.s8.e4

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s9
In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/ dispersible tablet formulation of VIDEX .

DrugDDI.d248.s9.e0 48 60
drug
ciprofloxacin
DrugDDI.d248.s9.e1 106 118
drug
ciprofloxacin
DrugDDI.d248.s9.e2 165 181
drug
dispersible tablet
DrugDDI.d248.s9.e3 195 199
drug
VIDEX

interaction DrugDDI.d248.s9.e1 DrugDDI.d248.s9.e2

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s10
The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine -placebo tablets concurrently.

DrugDDI.d248.s10.e0 8 20
drug
ciprofloxacin
DrugDDI.d248.s10.e1 75 87
drug
ciprofloxacin
DrugDDI.d248.s10.e2 91 100
drug
didanosine

interaction DrugDDI.d248.s10.e1 DrugDDI.d248.s10.e2

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s11
In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine -placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.

DrugDDI.d248.s11.e0 30 42
drug
ciprofloxacin
DrugDDI.d248.s11.e1 61 70
drug
didanosine
DrugDDI.d248.s11.e2 121 133
drug
ciprofloxacin

interaction DrugDDI.d248.s11.e0 DrugDDI.d248.s11.e1

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s12
Plasma concentrations of quinolone antibiotic s are decreased when administered with antacids containing magnesium , calcium , or aluminum.

DrugDDI.d248.s12.e0 22 40
drug
quinolone antibiotic
DrugDDI.d248.s12.e1 74 81
drug
antacids
DrugDDI.d248.s12.e2 92 100
drug
magnesium
DrugDDI.d248.s12.e3 102 108
drug
calcium

interaction DrugDDI.d248.s12.e0 DrugDDI.d248.s12.e1
interaction DrugDDI.d248.s12.e0 DrugDDI.d248.s12.e2
interaction DrugDDI.d248.s12.e0 DrugDDI.d248.s12.e3

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s13
The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.

DrugDDI.d248.s13.e0 47 51
drug
VIDEX
DrugDDI.d248.s13.e1 96 104
drug
quinolone



Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s14
Interactions with Other Antiretroviral Drugs : Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX .

DrugDDI.d248.s14.e0 35 39
drug
Drugs
DrugDDI.d248.s14.e1 71 81
drug
delavirdine
DrugDDI.d248.s14.e2 90 98
drug
indinavir
DrugDDI.d248.s14.e3 164 168
drug
VIDEX

interaction DrugDDI.d248.s14.e1 DrugDDI.d248.s14.e3
interaction DrugDDI.d248.s14.e2 DrugDDI.d248.s14.e3

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s15
To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX .

DrugDDI.d248.s15.e0 23 33
drug
delavirdine
DrugDDI.d248.s15.e1 36 44
drug
indinavir
DrugDDI.d248.s15.e2 80 84
drug
VIDEX

interaction DrugDDI.d248.s15.e0 DrugDDI.d248.s15.e2
interaction DrugDDI.d248.s15.e1 DrugDDI.d248.s15.e2

Abstract Id: DrugDDI.d248
Sentence Id: DrugDDI.d248.s16
The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX .

DrugDDI.d248.s16.e0 21 30
drug
nelfinavir
DrugDDI.d248.s16.e1 118 122
drug
VIDEX



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s0
Drug / Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen -containing oral contraceptives .

DrugDDI.d233.s0.e0 0 3
drug
Drug
DrugDDI.d233.s0.e1 83 90
drug
estrogen
DrugDDI.d233.s0.e2 102 119
drug
oral contraceptives



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s1
The following similar changes may be expected with larger doses of estrogen : - Increased sulfobromophthalein retention .

DrugDDI.d233.s1.e0 56 63
drug
estrogen



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s3
- Increased prothrombin and factors VII , VIII, IX, and X; .

DrugDDI.d233.s3.e0 10 20
drug
prothrombin
DrugDDI.d233.s3.e1 24 33
drug
factors VII



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s4
decreased antithrombin 3; .

DrugDDI.d233.s4.e0 9 20
drug
antithrombin



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s5
increased norepinephrine -induced platelet aggregability .

DrugDDI.d233.s5.e0 9 22
drug
norepinephrine



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s7
- Increased thyroid-binding globulin (TBG) leading to in-creased circulating total thyroid hormone ; .

DrugDDI.d233.s7.e0 73 86
drug
thyroid hormone



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s8
as measured by PBI, T4 by column, or T4 by radioimmunoassay.

DrugDDI.d233.s8.e0 16 17
drug
T4
DrugDDI.d233.s8.e1 29 30
drug
T4



Abstract Id: DrugDDI.d233
Sentence Id: DrugDDI.d233.s20
- Increased serum triglyceride and phospholipid concentration.

DrugDDI.d233.s20.e0 30 41
drug
phospholipid



Abstract Id: DrugDDI.d546
Sentence Id: DrugDDI.d546.s0
Antidiabetic drug requirements (i.e., insulin ) may be altered.

DrugDDI.d546.s0.e0 0 15
drug
Antidiabetic drug
DrugDDI.d546.s0.e1 34 40
drug
insulin



Abstract Id: DrugDDI.d546
Sentence Id: DrugDDI.d546.s1
Concurrent use with general anesthetics may result in arrhythmias.

DrugDDI.d546.s1.e0 17 34
drug
general anesthetics



Abstract Id: DrugDDI.d546
Sentence Id: DrugDDI.d546.s2
The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; .

DrugDDI.d546.s2.e0 3 16
drug
pressor effects
DrugDDI.d546.s2.e1 19 32
drug
diethylpropion
DrugDDI.d546.s2.e2 48 52
drug
drugs
DrugDDI.d546.s2.e3 73 77
drug
drugs

interaction DrugDDI.d546.s2.e1 DrugDDI.d546.s2.e2

Abstract Id: DrugDDI.d546
Sentence Id: DrugDDI.d546.s3
conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine , a- methyldopa ).

DrugDDI.d546.s3.e0 11 24
drug
diethylpropion
DrugDDI.d546.s3.e1 41 61
drug
antihypertensive drugs
DrugDDI.d546.s3.e2 68 79
drug
guanethidine
DrugDDI.d546.s3.e3 83 92
drug
methyldopa

interaction DrugDDI.d546.s3.e0 DrugDDI.d546.s3.e2
interaction DrugDDI.d546.s3.e0 DrugDDI.d546.s3.e3

Abstract Id: DrugDDI.d546
Sentence Id: DrugDDI.d546.s4
Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion .

DrugDDI.d546.s4.e0 15 28
drug
phenothiazines
DrugDDI.d546.s4.e1 62 75
drug
diethylpropion

interaction DrugDDI.d546.s4.e0 DrugDDI.d546.s4.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s0
Oral Anticoagulants : In some normal volunteers, the concomitant administration of diflunisal and warfarin , acenocoumarol , or phenprocoumon resulted in prolongation of prothrombin time.

DrugDDI.d279.s0.e0 0 17
drug
Oral Anticoagulants
DrugDDI.d279.s0.e1 72 81
drug
diflunisal
DrugDDI.d279.s0.e2 85 92
drug
warfarin
DrugDDI.d279.s0.e3 94 106
drug
acenocoumarol
DrugDDI.d279.s0.e4 110 122
drug
phenprocoumon

interaction DrugDDI.d279.s0.e1 DrugDDI.d279.s0.e2
interaction DrugDDI.d279.s0.e1 DrugDDI.d279.s0.e3
interaction DrugDDI.d279.s0.e1 DrugDDI.d279.s0.e4

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s1
This may occur because diflunisal competitively displaces coumarins from protein binding sites.

DrugDDI.d279.s1.e0 19 28
drug
diflunisal
DrugDDI.d279.s1.e1 51 59
drug
coumarins
DrugDDI.d279.s1.e2 64 70
drug
protein

interaction DrugDDI.d279.s1.e0 DrugDDI.d279.s1.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s2
Accordingly, when diflunisal is administered with oral anticoagulants , the prothrombin time should be closely monitored during and for several days after concomitant drug administration.

DrugDDI.d279.s2.e0 16 25
drug
diflunisal
DrugDDI.d279.s2.e1 44 61
drug
oral anticoagulants



Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s3
Adjustment of dosage of oral anticoagulants may be required.

DrugDDI.d279.s3.e0 20 37
drug
oral anticoagulants



Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s4
Tolbutamide : In diabetic patients receiving diflunisal and tolbutamide , no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.

DrugDDI.d279.s4.e0 0 10
drug
Tolbutamide
DrugDDI.d279.s4.e1 39 48
drug
diflunisal
DrugDDI.d279.s4.e2 52 62
drug
tolbutamide
DrugDDI.d279.s4.e3 94 104
drug
tolbutamide



Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s5
Hydrochlorothiazide : In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide .

DrugDDI.d279.s5.e0 0 18
drug
Hydrochlorothiazide
DrugDDI.d279.s5.e1 66 75
drug
diflunisal
DrugDDI.d279.s5.e2 79 97
drug
hydrochlorothiazide
DrugDDI.d279.s5.e3 144 162
drug
hydrochlorothiazide

interaction DrugDDI.d279.s5.e1 DrugDDI.d279.s5.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s6
Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide .

DrugDDI.d279.s6.e0 0 9
drug
Diflunisal
DrugDDI.d279.s6.e1 43 61
drug
hydrochlorothiazide

interaction DrugDDI.d279.s6.e0 DrugDDI.d279.s6.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s7
Furosemide : In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide .

DrugDDI.d279.s7.e0 0 9
drug
Furosemide
DrugDDI.d279.s7.e1 60 69
drug
diflunisal
DrugDDI.d279.s7.e2 73 82
drug
furosemide
DrugDDI.d279.s7.e3 99 106
drug
diuretic
DrugDDI.d279.s7.e4 117 126
drug
furosemide



Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s8
Diflunisal decreased the hyperuricemic effect of furosemide .

DrugDDI.d279.s8.e0 0 9
drug
Diflunisal
DrugDDI.d279.s8.e1 43 52
drug
furosemide

interaction DrugDDI.d279.s8.e0 DrugDDI.d279.s8.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s9
Antacids : Concomitant administration of antacids may reduce plasma levels of diflunisal .

DrugDDI.d279.s9.e0 0 7
drug
Antacids
DrugDDI.d279.s9.e1 36 43
drug
antacids
DrugDDI.d279.s9.e2 67 76
drug
diflunisal

interaction DrugDDI.d279.s9.e1 DrugDDI.d279.s9.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s10
This effect is small with occasional doses of antacids , but may be clinically significant when antacids are used on a continuous schedule.

DrugDDI.d279.s10.e0 38 45
drug
antacids
DrugDDI.d279.s10.e1 80 87
drug
antacids



Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s11
Acetaminophen : In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen .

DrugDDI.d279.s11.e0 0 12
drug
Acetaminophen
DrugDDI.d279.s11.e1 60 69
drug
diflunisal
DrugDDI.d279.s11.e2 73 85
drug
acetaminophen
DrugDDI.d279.s11.e3 136 148
drug
acetaminophen

interaction DrugDDI.d279.s11.e1 DrugDDI.d279.s11.e3

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s12
Acetaminophen had no effect on plasma levels of diflunisal .

DrugDDI.d279.s12.e0 0 12
drug
Acetaminophen
DrugDDI.d279.s12.e1 40 49
drug
diflunisal



Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s13
Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.

DrugDDI.d279.s13.e0 5 17
drug
acetaminophen
DrugDDI.d279.s13.e1 92 101
drug
diflunisal
DrugDDI.d279.s13.e2 105 117
drug
acetaminophen

interaction DrugDDI.d279.s13.e1 DrugDDI.d279.s13.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s14
Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal / acetaminophen ) resulted in greater gastrointestinal toxicity than when either drug was administered alone.

DrugDDI.d279.s14.e0 27 36
drug
diflunisal
DrugDDI.d279.s14.e1 40 52
drug
acetaminophen
DrugDDI.d279.s14.e2 159 168
drug
diflunisal
DrugDDI.d279.s14.e3 170 182
drug
acetaminophen
DrugDDI.d279.s14.e4 239 242
drug
drug

interaction DrugDDI.d279.s14.e0 DrugDDI.d279.s14.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s16
Methotrexate : Caution should be used if diflunisal is administered concomitantly with methotrexate .

DrugDDI.d279.s16.e0 0 11
drug
Methotrexate
DrugDDI.d279.s16.e1 34 43
drug
diflunisal
DrugDDI.d279.s16.e2 75 86
drug
methotrexate

interaction DrugDDI.d279.s16.e1 DrugDDI.d279.s16.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s17
Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.

DrugDDI.d279.s17.e0 0 33
drug
Nonsteroidal anti-inflammatory drugs
DrugDDI.d279.s17.e1 81 92
drug
methotrexate

interaction DrugDDI.d279.s17.e0 DrugDDI.d279.s17.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s18
Cyclosporine : Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin .

DrugDDI.d279.s18.e0 0 11
drug
Cyclosporine
DrugDDI.d279.s18.e1 29 61
drug
nonsteroial anti-inflammatory drugs
DrugDDI.d279.s18.e2 79 90
drug
cyclosporine
DrugDDI.d279.s18.e3 191 202
drug
prostacyclin

interaction DrugDDI.d279.s18.e1 DrugDDI.d279.s18.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s19
NSAIDs should be used with caution in patients taking cyclosporine , and renal function should be carefully monitored.

DrugDDI.d279.s19.e0 0 5
drug
NSAIDs
DrugDDI.d279.s19.e1 45 56
drug
cyclosporine

interaction DrugDDI.d279.s19.e0 DrugDDI.d279.s19.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s20
Nonsteroidal Anti-Inflammatory Drugs The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin .

DrugDDI.d279.s20.e0 0 33
drug
Nonsteroidal Anti-Inflammatory Drugs
DrugDDI.d279.s20.e1 53 62
drug
diflunisal
DrugDDI.d279.s20.e2 90 101
drug
indomethacin
DrugDDI.d279.s20.e3 170 181
drug
indomethacin

interaction DrugDDI.d279.s20.e1 DrugDDI.d279.s20.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s21
In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.

DrugDDI.d279.s21.e0 30 41
drug
indomethacin
DrugDDI.d279.s21.e1 45 54
drug
diflunisal

interaction DrugDDI.d279.s21.e0 DrugDDI.d279.s21.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s22
Therefore, indomethacin and diflunisal should not be used concomitantly.

DrugDDI.d279.s22.e0 10 21
drug
indomethacin
DrugDDI.d279.s22.e1 25 34
drug
diflunisal

interaction DrugDDI.d279.s22.e0 DrugDDI.d279.s22.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s23
The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.

DrugDDI.d279.s23.e0 19 28
drug
diflunisal
DrugDDI.d279.s23.e1 44 49
drug
NSAIDs

interaction DrugDDI.d279.s23.e0 DrugDDI.d279.s23.e1

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s25
Aspirin : In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.

DrugDDI.d279.s25.e0 0 6
drug
Aspirin
DrugDDI.d279.s25.e1 43 52
drug
diflunisal
DrugDDI.d279.s25.e2 89 98
drug
diflunisal
DrugDDI.d279.s25.e3 102 108
drug
aspirin

interaction DrugDDI.d279.s25.e2 DrugDDI.d279.s25.e3

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s26
Sulindac : The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.

DrugDDI.d279.s26.e0 0 7
drug
Sulindac
DrugDDI.d279.s26.e1 39 48
drug
diflunisal
DrugDDI.d279.s26.e2 52 59
drug
sulindac
DrugDDI.d279.s26.e3 124 148
drug
sulindac sulfide metabolite

interaction DrugDDI.d279.s26.e1 DrugDDI.d279.s26.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s27
Naproxen : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .

DrugDDI.d279.s27.e0 0 7
drug
Naproxen
DrugDDI.d279.s27.e1 39 48
drug
diflunisal
DrugDDI.d279.s27.e2 52 59
drug
naproxen
DrugDDI.d279.s27.e3 108 115
drug
naproxen
DrugDDI.d279.s27.e4 163 170
drug
naproxen
DrugDDI.d279.s27.e5 177 197
drug
glucuronide metabolite

interaction DrugDDI.d279.s27.e1 DrugDDI.d279.s27.e2

Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s28
Naproxen had no effect on plasma levels of diflunisal .

DrugDDI.d279.s28.e0 0 7
drug
Naproxen
DrugDDI.d279.s28.e1 35 44
drug
diflunisal



Abstract Id: DrugDDI.d279
Sentence Id: DrugDDI.d279.s29
Drug laboratory Test Interactions Serum Salicylate Assays: Caution should be used in interpreting the results of serum salicylate assays when diflunisal is present.

DrugDDI.d279.s29.e0 35 44
drug
Salicylate
DrugDDI.d279.s29.e1 102 111
drug
salicylate
DrugDDI.d279.s29.e2 122 131
drug
diflunisal

interaction DrugDDI.d279.s29.e1 DrugDDI.d279.s29.e2

Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s0
Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.

DrugDDI.d82.s0.e0 0 27
drug
Potassium-depleting diuretics



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s1
Calcium , particularly if administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients.

DrugDDI.d82.s1.e0 0 6
drug
Calcium



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s2
Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that digitalis intoxication may result.

DrugDDI.d82.s2.e0 0 8
drug
Quinidine
DrugDDI.d82.s2.e1 10 18
drug
verapamil
DrugDDI.d82.s2.e2 20 29
drug
amiodarone
DrugDDI.d82.s2.e3 31 41
drug
propafenone
DrugDDI.d82.s2.e4 43 54
drug
indomethacin
DrugDDI.d82.s2.e5 56 67
drug
itraconazole
DrugDDI.d82.s2.e6 69 78
drug
alprazolam
DrugDDI.d82.s2.e7 83 96
drug
spironolactone
DrugDDI.d82.s2.e8 110 116
drug
digoxin
DrugDDI.d82.s2.e9 189 192
drug
drug

interaction DrugDDI.d82.s2.e0 DrugDDI.d82.s2.e8
interaction DrugDDI.d82.s2.e1 DrugDDI.d82.s2.e8
interaction DrugDDI.d82.s2.e2 DrugDDI.d82.s2.e8
interaction DrugDDI.d82.s2.e3 DrugDDI.d82.s2.e8
interaction DrugDDI.d82.s2.e4 DrugDDI.d82.s2.e8
interaction DrugDDI.d82.s2.e5 DrugDDI.d82.s2.e8
interaction DrugDDI.d82.s2.e6 DrugDDI.d82.s2.e8
interaction DrugDDI.d82.s2.e7 DrugDDI.d82.s2.e8

Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s3
Erythromycin and clarithromycin (and possibly other macrolide antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.

DrugDDI.d82.s3.e0 0 11
drug
Erythromycin
DrugDDI.d82.s3.e1 15 28
drug
clarithromycin
DrugDDI.d82.s3.e2 46 65
drug
macrolide antibiotics
DrugDDI.d82.s3.e3 70 81
drug
tetracycline
DrugDDI.d82.s3.e4 93 99
drug
digoxin
DrugDDI.d82.s3.e5 133 139
drug
digoxin

interaction DrugDDI.d82.s3.e0 DrugDDI.d82.s3.e4
interaction DrugDDI.d82.s3.e1 DrugDDI.d82.s3.e4
interaction DrugDDI.d82.s3.e2 DrugDDI.d82.s3.e4
interaction DrugDDI.d82.s3.e3 DrugDDI.d82.s3.e4

Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s4
The risk of this interaction may be reduced if digoxin is given as capsules.

DrugDDI.d82.s4.e0 38 44
drug
digoxin



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s5
Propantheline and diphenoxylate , by decreasing gut motility, may increase digoxin absorption.

DrugDDI.d82.s5.e0 0 12
drug
Propantheline
DrugDDI.d82.s5.e1 16 28
drug
diphenoxylate
DrugDDI.d82.s5.e2 65 71
drug
digoxin

interaction DrugDDI.d82.s5.e0 DrugDDI.d82.s5.e2
interaction DrugDDI.d82.s5.e1 DrugDDI.d82.s5.e2

Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s6
Antacids , kaolin-pectin , sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.

DrugDDI.d82.s6.e0 0 7
drug
Antacids
DrugDDI.d82.s6.e1 9 21
drug
kaolin-pectin
DrugDDI.d82.s6.e2 23 35
drug
sulfasalazine
DrugDDI.d82.s6.e3 37 44
drug
neomycin
DrugDDI.d82.s6.e4 46 59
drug
cholestyramine
DrugDDI.d82.s6.e5 87 100
drug
metoclopramide
DrugDDI.d82.s6.e6 127 133
drug
digoxin

interaction DrugDDI.d82.s6.e0 DrugDDI.d82.s6.e6
interaction DrugDDI.d82.s6.e1 DrugDDI.d82.s6.e6
interaction DrugDDI.d82.s6.e2 DrugDDI.d82.s6.e6
interaction DrugDDI.d82.s6.e3 DrugDDI.d82.s6.e6
interaction DrugDDI.d82.s6.e4 DrugDDI.d82.s6.e6
interaction DrugDDI.d82.s6.e5 DrugDDI.d82.s6.e6

Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s7
Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin .

DrugDDI.d82.s7.e0 0 7
drug
Rifampin
DrugDDI.d82.s7.e1 24 30
drug
digoxin
DrugDDI.d82.s7.e2 121 127
drug
digoxin

interaction DrugDDI.d82.s7.e0 DrugDDI.d82.s7.e1

Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s8
There have been inconsistent reports regarding the effects of other drugs (e.g., quinine , penicillamine ) on serum digoxin concentration.

DrugDDI.d82.s8.e0 58 62
drug
drugs
DrugDDI.d82.s8.e1 69 75
drug
quinine
DrugDDI.d82.s8.e2 77 89
drug
penicillamine
DrugDDI.d82.s8.e3 98 104
drug
digoxin



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s9
Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin .

DrugDDI.d82.s9.e0 0 6
drug
Thyroid
DrugDDI.d82.s9.e1 85 91
drug
digoxin



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s10
Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.

DrugDDI.d82.s10.e0 16 22
drug
digoxin
DrugDDI.d82.s10.e1 26 41
drug
sympathomimetics

interaction DrugDDI.d82.s10.e0 DrugDDI.d82.s10.e1

Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s11
Succinylcholine may cause a sudden extrusion of potassium from muscle cells, and may thereby cause arrhythmias in digitalized patients.

DrugDDI.d82.s11.e0 0 14
drug
Succinylcholine
DrugDDI.d82.s11.e1 41 49
drug
potassium



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s12
Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.

DrugDDI.d82.s12.e0 8 30
drug
beta-adrenergic blockers
DrugDDI.d82.s12.e1 33 54
drug
calcium channel blockers
DrugDDI.d82.s12.e2 58 64
drug
digoxin



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s13
Due to the considerable variability of these interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently.

DrugDDI.d82.s13.e0 62 68
drug
digoxin
DrugDDI.d82.s13.e1 115 125
drug
medications



Abstract Id: DrugDDI.d82
Sentence Id: DrugDDI.d82.s14
Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin .

DrugDDI.d82.s14.e0 49 55
drug
digoxin
DrugDDI.d82.s14.e1 63 66
drug
drug
DrugDDI.d82.s14.e2 196 202
drug
digoxin

interaction DrugDDI.d82.s14.e0 DrugDDI.d82.s14.e1

Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s0
Vasoconstrictors : D.H.E. 45@ ( dihydroergotamine mesylate ) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.

DrugDDI.d26.s0.e0 0 15
drug
Vasoconstrictors
DrugDDI.d26.s0.e1 27 51
drug
dihydroergotamine mesylate
DrugDDI.d26.s0.e2 95 110
drug
vasoconstrictors

interaction DrugDDI.d26.s0.e1 DrugDDI.d26.s0.e2

Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s1
Sumatriptan : Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45@ ( dihydroergotamine mesylate ) Injection, USP.

DrugDDI.d26.s1.e0 0 10
drug
Sumatriptan
DrugDDI.d26.s1.e1 12 22
drug
Sumatriptan
DrugDDI.d26.s1.e2 110 134
drug
dihydroergotamine mesylate

interaction DrugDDI.d26.s1.e1 DrugDDI.d26.s1.e2

Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s2
Sumatriptan and D.H.E. 45@ ( dihydroergotamine mesylate ) Injection, USP should not be taken within 24 hours of each other..

DrugDDI.d26.s2.e0 0 10
drug
Sumatriptan
DrugDDI.d26.s2.e1 24 48
drug
dihydroergotamine mesylate



Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s3
Beta Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45@ ( dihydroergotamine mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine .

DrugDDI.d26.s3.e0 0 11
drug
Beta Blockers
DrugDDI.d26.s3.e1 116 140
drug
dihydroergotamine mesylate
DrugDDI.d26.s3.e2 181 191
drug
propranolol
DrugDDI.d26.s3.e3 217 227
drug
propranolol
DrugDDI.d26.s3.e4 268 277
drug
ergotamine
DrugDDI.d26.s3.e5 313 323
drug
epinephrine

interaction DrugDDI.d26.s3.e3 DrugDDI.d26.s3.e4

Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s4
Nicotine : Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.

DrugDDI.d26.s4.e0 0 7
drug
Nicotine
DrugDDI.d26.s4.e1 9 16
drug
Nicotine
DrugDDI.d26.s4.e2 98 102
drug
ergot



Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s5
Macrolide Antibiotics (e. g. erythromycin and troleandomycin ): Agents of the ergot alkaloid class, of which D.H.E. 45@ ( dihydroergotamine mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.

DrugDDI.d26.s5.e0 0 19
drug
Macrolide Antibiotics
DrugDDI.d26.s5.e1 25 36
drug
erythromycin
DrugDDI.d26.s5.e2 40 53
drug
troleandomycin
DrugDDI.d26.s5.e3 67 79
drug
ergot alkaloid
DrugDDI.d26.s5.e4 103 127
drug
dihydroergotamine mesylate
DrugDDI.d26.s5.e5 179 189
drug
antibiotics
DrugDDI.d26.s5.e6 195 203
drug
macrolide

interaction DrugDDI.d26.s5.e3 DrugDDI.d26.s5.e5
interaction DrugDDI.d26.s5.e3 DrugDDI.d26.s5.e6
interaction DrugDDI.d26.s5.e4 DrugDDI.d26.s5.e5
interaction DrugDDI.d26.s5.e4 DrugDDI.d26.s5.e6

Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s6
Vasospastic reactions have been reported with therapeutic doses of ergotamine -containing drugs when co-administered with these antibiotics .

DrugDDI.d26.s6.e0 58 67
drug
ergotamine
DrugDDI.d26.s6.e1 112 122
drug
antibiotics

interaction DrugDDI.d26.s6.e0 DrugDDI.d26.s6.e1

Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s7
SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.

DrugDDI.d26.s7.e0 71 83
drug
5-HT1 agonists



Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s8
fluoxetine , fluvoxamine , paroxetine , sertraline ).

DrugDDI.d26.s8.e0 0 9
drug
fluoxetine
DrugDDI.d26.s8.e1 11 21
drug
fluvoxamine
DrugDDI.d26.s8.e2 23 32
drug
paroxetine
DrugDDI.d26.s8.e3 34 43
drug
sertraline



Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s9
There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45@ ( dihydroergotamine mesylate ) Injection, USP.

DrugDDI.d26.s9.e0 92 116
drug
dihydroergotamine mesylate



Abstract Id: DrugDDI.d26
Sentence Id: DrugDDI.d26.s10
Oral Contraceptives : The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45@ ( dihydroergotamine mesylate ) Injection, USP has not been studied.

DrugDDI.d26.s10.e0 0 17
drug
Oral Contraceptives
DrugDDI.d26.s10.e1 30 47
drug
oral contraceptives
DrugDDI.d26.s10.e2 81 105
drug
dihydroergotamine mesylate



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s0
Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction.

DrugDDI.d519.s0.e0 93 114
drug
diltiazem hydrochloride



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s1
Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac .

DrugDDI.d519.s1.e0 90 102
drug
beta-blockers
DrugDDI.d519.s1.e1 105 113
drug
digitalis
DrugDDI.d519.s1.e2 131 136
drug
Tiazac

interaction DrugDDI.d519.s1.e0 DrugDDI.d519.s1.e2
interaction DrugDDI.d519.s1.e1 DrugDDI.d519.s1.e2

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s2
As with all drugs , care should be exercised when treating patients with multiple medications .

DrugDDI.d519.s2.e0 9 13
drug
drugs
DrugDDI.d519.s2.e1 68 78
drug
medications



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s3
Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system.

DrugDDI.d519.s3.e0 0 8
drug
Diltiazem
DrugDDI.d519.s3.e1 44 61
drug
cytochrome P-450 3A4



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s4
Other drugs that are specific substrates, inhibitors, or inducers of the enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem .

DrugDDI.d519.s4.e0 5 9
drug
drugs
DrugDDI.d519.s4.e1 134 142
drug
diltiazem

interaction DrugDDI.d519.s4.e0 DrugDDI.d519.s4.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s5
Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.

DrugDDI.d519.s5.e0 19 23
drug
drugs
DrugDDI.d519.s5.e1 177 185
drug
diltiazem

interaction DrugDDI.d519.s5.e0 DrugDDI.d519.s5.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s6
Beta Blockers .

DrugDDI.d519.s6.e0 0 11
drug
Beta Blockers



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s7
Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.

DrugDDI.d519.s7.e0 67 88
drug
diltiazem hydrochloride
DrugDDI.d519.s7.e1 92 104
drug
beta-blockers



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s8
Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.

DrugDDI.d519.s8.e0 16 37
drug
diltiazem hydrochloride
DrugDDI.d519.s8.e1 55 65
drug
propranolol
DrugDDI.d519.s8.e2 107 117
drug
propranolol
DrugDDI.d519.s8.e3 157 167
drug
propranolol

interaction DrugDDI.d519.s8.e0 DrugDDI.d519.s8.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s9
In vitro, propranolol appears to be displaced from its binding sites by diltiazem .

DrugDDI.d519.s9.e0 8 18
drug
propranolol
DrugDDI.d519.s9.e1 60 68
drug
diltiazem

interaction DrugDDI.d519.s9.e0 DrugDDI.d519.s9.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s10
If combination therapy is initiated or withdrawn in conjunction with propranolol , an adjustment in the propranolol dose may be warranted.

DrugDDI.d519.s10.e0 59 69
drug
propranolol



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s11
Cimetidine .

DrugDDI.d519.s11.e0 0 9
drug
Cimetidine



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s12
A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.

DrugDDI.d519.s12.e0 62 70
drug
diltiazem
DrugDDI.d519.s12.e1 119 128
drug
cimetidine
DrugDDI.d519.s12.e2 155 163
drug
diltiazem

interaction DrugDDI.d519.s12.e1 DrugDDI.d519.s12.e2

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s13
Ranitidine produced smaller, nonsignificant increases.

DrugDDI.d519.s13.e0 0 9
drug
Ranitidine



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s14
The effect may be mediated by cimetidine s known inhibition of hepatic cytochrome P-450 , the enzyme system responsible for the first-pass metabolism of diltiazem .

DrugDDI.d519.s14.e0 24 33
drug
cimetidine
DrugDDI.d519.s14.e1 59 73
drug
cytochrome P-450
DrugDDI.d519.s14.e2 129 137
drug
diltiazem



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s15
Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine .

DrugDDI.d519.s15.e0 26 34
drug
diltiazem
DrugDDI.d519.s15.e1 142 151
drug
cimetidine

interaction DrugDDI.d519.s15.e0 DrugDDI.d519.s15.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s16
An adjustment in the diltiazem dose may be warranted.

DrugDDI.d519.s16.e0 17 25
drug
diltiazem



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s17
Digitalis .

DrugDDI.d519.s17.e0 0 8
drug
Digitalis



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s18
Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.

DrugDDI.d519.s18.e0 16 37
drug
diltiazem hydrochloride
DrugDDI.d519.s18.e1 42 48
drug
digoxin
DrugDDI.d519.s18.e2 87 93
drug
digoxin

interaction DrugDDI.d519.s18.e0 DrugDDI.d519.s18.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s20
Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.

DrugDDI.d519.s20.e0 154 175
drug
diltiazem hydrochloride



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s21
Anesthetics .

DrugDDI.d519.s21.e0 0 10
drug
Anesthetics



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s22
The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers .

DrugDDI.d519.s22.e0 105 115
drug
anesthetics
DrugDDI.d519.s22.e1 134 155
drug
calcium channel blockers

interaction DrugDDI.d519.s22.e0 DrugDDI.d519.s22.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s23
When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.

DrugDDI.d519.s23.e0 22 32
drug
anesthetics
DrugDDI.d519.s23.e1 36 57
drug
calcium channel blockers

interaction DrugDDI.d519.s23.e0 DrugDDI.d519.s23.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s24
Cyclosporine .

DrugDDI.d519.s24.e0 0 11
drug
Cyclosporine



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s25
A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.

DrugDDI.d519.s25.e0 34 42
drug
diltiazem
DrugDDI.d519.s25.e1 46 57
drug
cyclosporine

interaction DrugDDI.d519.s25.e0 DrugDDI.d519.s25.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s26
In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem .

DrugDDI.d519.s26.e0 50 61
drug
cyclosporine
DrugDDI.d519.s26.e1 107 118
drug
cyclosporine
DrugDDI.d519.s26.e2 177 185
drug
diltiazem



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s27
If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.

DrugDDI.d519.s27.e0 45 56
drug
cyclosporine
DrugDDI.d519.s27.e1 103 111
drug
diltiazem

interaction DrugDDI.d519.s27.e0 DrugDDI.d519.s27.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s28
The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.

DrugDDI.d519.s28.e0 11 22
drug
cyclosporine
DrugDDI.d519.s28.e1 25 33
drug
diltiazem



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s29
Carbamazepine .

DrugDDI.d519.s29.e0 0 12
drug
Carbamazepine



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s30
Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.

DrugDDI.d519.s30.e0 27 35
drug
diltiazem
DrugDDI.d519.s30.e1 40 52
drug
carbamazepine
DrugDDI.d519.s30.e2 99 111
drug
carbamazepine

interaction DrugDDI.d519.s30.e0 DrugDDI.d519.s30.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s31
Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

DrugDDI.d519.s31.e0 22 26
drug
drugs



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s32
Benzodiazepines .

DrugDDI.d519.s32.e0 0 14
drug
Benzodiazepines



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s33
Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.

DrugDDI.d519.s33.e0 17 25
drug
diltiazem
DrugDDI.d519.s33.e1 43 51
drug
midazolam
DrugDDI.d519.s33.e2 55 63
drug
triazolam

interaction DrugDDI.d519.s33.e0 DrugDDI.d519.s33.e1
interaction DrugDDI.d519.s33.e0 DrugDDI.d519.s33.e2

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s34
The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem .

DrugDDI.d519.s34.e0 24 32
drug
midazolam
DrugDDI.d519.s34.e1 36 44
drug
triazolam
DrugDDI.d519.s34.e2 97 105
drug
diltiazem

interaction DrugDDI.d519.s34.e0 DrugDDI.d519.s34.e2
interaction DrugDDI.d519.s34.e1 DrugDDI.d519.s34.e2

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s35
These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam .

DrugDDI.d519.s35.e0 37 45
drug
diltiazem
DrugDDI.d519.s35.e1 127 135
drug
midazolam
DrugDDI.d519.s35.e2 139 147
drug
triazolam

interaction DrugDDI.d519.s35.e0 DrugDDI.d519.s35.e1
interaction DrugDDI.d519.s35.e0 DrugDDI.d519.s35.e2

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s36
Lovastatin .

DrugDDI.d519.s36.e0 0 9
drug
Lovastatin



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s37
In a ten-subject study, coadministration of diltiazem (120 mg bid ) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone; .

DrugDDI.d519.s37.e0 38 46
drug
diltiazem
DrugDDI.d519.s37.e1 53 55
drug
bid
DrugDDI.d519.s37.e2 61 70
drug
lovastatin
DrugDDI.d519.s37.e3 104 113
drug
lovastatin
DrugDDI.d519.s37.e4 127 136
drug
lovastatin

interaction DrugDDI.d519.s37.e0 DrugDDI.d519.s37.e2

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s38
no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.

DrugDDI.d519.s38.e0 10 20
drug
pravastatin
DrugDDI.d519.s38.e1 48 56
drug
diltiazem



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s39
Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin .

DrugDDI.d519.s39.e0 0 8
drug
Diltiazem
DrugDDI.d519.s39.e1 51 60
drug
lovastatin
DrugDDI.d519.s39.e2 63 73
drug
pravastatin



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s40
Rifampin .

DrugDDI.d519.s40.e0 0 7
drug
Rifampin



Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s41
Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.

DrugDDI.d519.s41.e0 18 25
drug
rifampin
DrugDDI.d519.s41.e1 30 38
drug
diltiazem
DrugDDI.d519.s41.e2 49 57
drug
diltiazem

interaction DrugDDI.d519.s41.e0 DrugDDI.d519.s41.e1

Abstract Id: DrugDDI.d519
Sentence Id: DrugDDI.d519.s42
Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.

DrugDDI.d519.s42.e0 18 26
drug
diltiazem
DrugDDI.d519.s42.e1 31 38
drug
rifampin
DrugDDI.d519.s42.e2 49 54
drug
CYP3A4

interaction DrugDDI.d519.s42.e0 DrugDDI.d519.s42.e1
interaction DrugDDI.d519.s42.e0 DrugDDI.d519.s42.e2

Abstract Id: DrugDDI.d149
Sentence Id: DrugDDI.d149.s0
Dimenhydrinate may decrease emetic response to apomorphine .

DrugDDI.d149.s0.e0 0 13
drug
Dimenhydrinate
DrugDDI.d149.s0.e1 25 30
drug
emetic
DrugDDI.d149.s0.e2 41 51
drug
apomorphine

interaction DrugDDI.d149.s0.e0 DrugDDI.d149.s0.e2

Abstract Id: DrugDDI.d376
Sentence Id: DrugDDI.d376.s0
Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation; .

DrugDDI.d376.s0.e0 0 7
drug
Oxytocin
DrugDDI.d376.s0.e1 15 23
drug
oxytocics
DrugDDI.d376.s0.e2 42 50
drug
dinoprost



Abstract Id: DrugDDI.d579
Sentence Id: DrugDDI.d579.s0
PROSTIN E2 may augment the activity of other oxytocic drugs .

DrugDDI.d579.s0.e0 0 8
drug
PROSTIN E2
DrugDDI.d579.s0.e1 37 49
drug
oxytocic drugs



Abstract Id: DrugDDI.d579
Sentence Id: DrugDDI.d579.s1
Concomitant use with other oxytocic agents is not recommended.

DrugDDI.d579.s1.e0 23 36
drug
oxytocic agents



Abstract Id: DrugDDI.d403
Sentence Id: DrugDDI.d403.s0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).

DrugDDI.d403.s0.e0 4 7
drug
drug
DrugDDI.d403.s0.e1 23 29
drug
alcohol
DrugDDI.d403.s0.e2 37 50
drug
CNS depressants
DrugDDI.d403.s0.e3 68 80
drug
CNS depressant
DrugDDI.d403.s0.e4 101 111
drug
medications
DrugDDI.d403.s0.e5 114 127
drug
antihistamines
DrugDDI.d403.s0.e6 130 145
drug
anticholinergics
DrugDDI.d403.s0.e7 148 163
drug
other medications
DrugDDI.d403.s0.e8 168 182
drug
anticholinergic
DrugDDI.d403.s0.e9 192 206
drug
anticholinergic
DrugDDI.d403.s0.e10 239 249
drug
medications
DrugDDI.d403.s0.e11 273 286
drug
antihistamines
DrugDDI.d403.s0.e12 292 307
drug
monoamine oxidase
DrugDDI.d403.s0.e13 341 354
drug
antihistamines
DrugDDI.d403.s0.e14 380 394
drug
anticholinergic
DrugDDI.d403.s0.e15 398 410
drug
CNS depressant
DrugDDI.d403.s0.e16 420 433
drug
antihistamines



Abstract Id: DrugDDI.d417
Sentence Id: DrugDDI.d417.s0
No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE@ ( dipyridamole USP) Tablets.

DrugDDI.d417.s0.e0 73 84
drug
dipyridamole



Abstract Id: DrugDDI.d417
Sentence Id: DrugDDI.d417.s2
Adenosine : Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine .

DrugDDI.d417.s2.e0 0 8
drug
Adenosine
DrugDDI.d417.s2.e1 10 21
drug
Dipyridamole
DrugDDI.d417.s2.e2 88 96
drug
adenosine

interaction DrugDDI.d417.s2.e1 DrugDDI.d417.s2.e2

Abstract Id: DrugDDI.d417
Sentence Id: DrugDDI.d417.s3
Adjustment of adenosine dosage may be necessary.

DrugDDI.d417.s3.e0 12 20
drug
adenosine



Abstract Id: DrugDDI.d417
Sentence Id: DrugDDI.d417.s4
Cholinesterase Inhibitors : Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors , thereby potentially aggravating myasthenia gravis.

DrugDDI.d417.s4.e0 0 23
drug
Cholinesterase Inhibitors
DrugDDI.d417.s4.e1 25 36
drug
Dipyridamole
DrugDDI.d417.s4.e2 53 70
drug
anticholinesterase
DrugDDI.d417.s4.e3 79 102
drug
cholinesterase inhibitors

interaction DrugDDI.d417.s4.e1 DrugDDI.d417.s4.e3

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s0
Terfenadine In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of terfenadine .

DrugDDI.d545.s0.e0 0 10
drug
Terfenadine
DrugDDI.d545.s0.e1 66 78
drug
dirithromycin
DrugDDI.d545.s0.e2 106 116
drug
terfenadine



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s1
These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.

DrugDDI.d545.s1.e0 26 36
drug
terfenadine
DrugDDI.d545.s1.e1 77 87
drug
terfenadine
DrugDDI.d545.s1.e2 105 117
drug
dirithromycin



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s2
(Both drugs were thus dosed to steady state.) .

DrugDDI.d545.s2.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s3
The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin .

DrugDDI.d545.s3.e0 21 31
drug
terfenadine
DrugDDI.d545.s3.e1 38 51
drug
acid metabolite
DrugDDI.d545.s3.e2 123 133
drug
terfenadine
DrugDDI.d545.s3.e3 147 157
drug
terfenadine
DrugDDI.d545.s3.e4 162 174
drug
dirithromycin



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s4
In five men, terfenadine levels were undetectable ( 5 ng/mL) throughout the study; .

DrugDDI.d545.s4.e0 10 20
drug
terfenadine



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s5
in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin .

DrugDDI.d545.s5.e0 13 15
drug
max
DrugDDI.d545.s5.e1 18 28
drug
terfenadine
DrugDDI.d545.s5.e2 44 54
drug
terfenadine
DrugDDI.d545.s5.e3 75 85
drug
terfenadine
DrugDDI.d545.s5.e4 90 102
drug
dirithromycin



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s6
The mean C max , T max , and AUC of the acid metabolite of terfenadine were not significantly changed.

DrugDDI.d545.s6.e0 8 10
drug
max
DrugDDI.d545.s6.e1 13 15
drug
max
DrugDDI.d545.s6.e2 28 41
drug
acid metabolite
DrugDDI.d545.s6.e3 44 54
drug
terfenadine



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s7
The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin .

DrugDDI.d545.s7.e0 34 44
drug
terfenadine
DrugDDI.d545.s7.e1 60 70
drug
terfenadine
DrugDDI.d545.s7.e2 75 87
drug
dirithromycin



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s8
Also, in vitro experiments demonstrated a lack of interaction between dirithromycin and terfenadine .

DrugDDI.d545.s8.e0 60 72
drug
dirithromycin
DrugDDI.d545.s8.e1 76 86
drug
terfenadine



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s9
Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin .

DrugDDI.d545.s9.e0 34 45
drug
erythromycin
DrugDDI.d545.s9.e1 49 59
drug
terfenadine
DrugDDI.d545.s9.e2 76 88
drug
dirithromycin

interaction DrugDDI.d545.s9.e0 DrugDDI.d545.s9.e1

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s10
Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics .

DrugDDI.d545.s10.e0 79 89
drug
terfenadine
DrugDDI.d545.s10.e1 112 131
drug
macrolide antibiotics

interaction DrugDDI.d545.s10.e0 DrugDDI.d545.s10.e1

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s11
In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.

DrugDDI.d545.s11.e0 15 24
drug
macrolides
DrugDDI.d545.s11.e1 62 72
drug
terfenadine

interaction DrugDDI.d545.s11.e0 DrugDDI.d545.s11.e1

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s12
Theophylline Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.

DrugDDI.d545.s12.e0 0 11
drug
Theophylline
DrugDDI.d545.s12.e1 100 111
drug
theophylline
DrugDDI.d545.s12.e2 206 217
drug
theophylline



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s13
In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.

DrugDDI.d545.s13.e0 33 45
drug
dirithromycin
DrugDDI.d545.s13.e1 72 83
drug
theophylline
DrugDDI.d545.s13.e2 123 134
drug
theophylline
DrugDDI.d545.s13.e3 155 166
drug
theophylline



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s14
However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.

DrugDDI.d545.s14.e0 8 19
drug
theophylline
DrugDDI.d545.s14.e1 222 233
drug
theophylline



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s15
Antacids or H 2 receptor antagonists When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists , the absorption of dirithromycin is slightly enhanced.

DrugDDI.d545.s15.e0 0 7
drug
Antacids
DrugDDI.d545.s15.e1 10 30
drug
H 2 receptor antagonists
DrugDDI.d545.s15.e2 35 47
drug
dirithromycin
DrugDDI.d545.s15.e3 82 89
drug
antacids
DrugDDI.d545.s15.e4 92 113
drug
H 2 -receptor antagonists
DrugDDI.d545.s15.e5 130 142
drug
dirithromycin

interaction DrugDDI.d545.s15.e2 DrugDDI.d545.s15.e3
interaction DrugDDI.d545.s15.e2 DrugDDI.d545.s15.e4

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s16
The following drug interactions have been reported with erythromycin product s.

DrugDDI.d545.s16.e0 48 66
drug
erythromycin product



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s17
It is presently not known whether these same drug interactions occur with dirithromycin .

DrugDDI.d545.s17.e0 62 74
drug
dirithromycin



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s18
Until further data are available regarding the potential interaction of dirithromycin with these compounds, caution should be used during coadministration.

DrugDDI.d545.s18.e0 62 74
drug
dirithromycin



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s19
Triazolam Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam .

DrugDDI.d545.s19.e0 0 8
drug
Triazolam
DrugDDI.d545.s19.e1 60 68
drug
triazolam
DrugDDI.d545.s19.e2 113 121
drug
triazolam

interaction DrugDDI.d545.s19.e0 DrugDDI.d545.s19.e1

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s20
Digoxin Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.

DrugDDI.d545.s20.e0 0 6
drug
Digoxin
DrugDDI.d545.s20.e1 34 45
drug
erythromycin
DrugDDI.d545.s20.e2 49 55
drug
digoxin

interaction DrugDDI.d545.s20.e1 DrugDDI.d545.s20.e2

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s21
Anticoagulants There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.

DrugDDI.d545.s21.e0 0 13
drug
Anticoagulants
DrugDDI.d545.s21.e1 69 80
drug
erythromycin
DrugDDI.d545.s21.e2 84 101
drug
oral anticoagulants

interaction DrugDDI.d545.s21.e1 DrugDDI.d545.s21.e2

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s22
Increased anticoagulation effects due to a drug interaction with erythromycin may be more pronounced in the elderly.

DrugDDI.d545.s22.e0 56 67
drug
erythromycin



Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s23
Ergotamine Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

DrugDDI.d545.s23.e0 0 9
drug
Ergotamine
DrugDDI.d545.s23.e1 25 36
drug
erythromycin
DrugDDI.d545.s23.e2 40 49
drug
ergotamine
DrugDDI.d545.s23.e3 52 68
drug
dihydroergotamine
DrugDDI.d545.s23.e4 109 113
drug
ergot

interaction DrugDDI.d545.s23.e1 DrugDDI.d545.s23.e2
interaction DrugDDI.d545.s23.e1 DrugDDI.d545.s23.e3

Abstract Id: DrugDDI.d545
Sentence Id: DrugDDI.d545.s24
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications , including cyclosporine , hexobarbital , carbamazepine , alfentanil , disopyramide , phenytoin , bromocriptine , valproate , astemizole , and lovastatin .

DrugDDI.d545.s24.e0 73 84
drug
erythromycin
DrugDDI.d545.s24.e1 88 103
drug
other medications
DrugDDI.d545.s24.e2 114 125
drug
cyclosporine
DrugDDI.d545.s24.e3 127 138
drug
hexobarbital
DrugDDI.d545.s24.e4 140 152
drug
carbamazepine
DrugDDI.d545.s24.e5 154 163
drug
alfentanil
DrugDDI.d545.s24.e6 165 176
drug
disopyramide
DrugDDI.d545.s24.e7 178 186
drug
phenytoin
DrugDDI.d545.s24.e8 188 200
drug
bromocriptine
DrugDDI.d545.s24.e9 202 210
drug
valproate
DrugDDI.d545.s24.e10 212 221
drug
astemizole
DrugDDI.d545.s24.e11 226 235
drug
lovastatin

interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e1
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e2
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e3
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e4
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e5
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e6
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e7
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e8
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e9
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e10
interaction DrugDDI.d545.s24.e0 DrugDDI.d545.s24.e11

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s0
If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR , lower plasma levels of disopyramide may occur.

DrugDDI.d452.s0.e0 2 10
drug
phenytoin
DrugDDI.d452.s0.e1 63 69
drug
Norpace
DrugDDI.d452.s0.e2 72 80
drug
Norpace CR
DrugDDI.d452.s0.e3 101 112
drug
disopyramide

interaction DrugDDI.d452.s0.e0 DrugDDI.d452.s0.e1
interaction DrugDDI.d452.s0.e0 DrugDDI.d452.s0.e2

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s1
Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy.

DrugDDI.d452.s1.e0 12 23
drug
disopyramide



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s2
Other antiarrhythmic drugs (eg, quinidine , procainamide , lidocaine , propranolol ) have occasionally been used concurrently with Norpace .

DrugDDI.d452.s2.e0 5 23
drug
antiarrhythmic drugs
DrugDDI.d452.s2.e1 28 36
drug
quinidine
DrugDDI.d452.s2.e2 38 49
drug
procainamide
DrugDDI.d452.s2.e3 51 59
drug
lidocaine
DrugDDI.d452.s2.e4 61 71
drug
propranolol
DrugDDI.d452.s2.e5 113 119
drug
Norpace



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s4
In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam .

DrugDDI.d452.s4.e0 66 72
drug
Norpace
DrugDDI.d452.s4.e1 100 110
drug
propranolol
DrugDDI.d452.s4.e2 113 120
drug
diazepam



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s5
Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.

DrugDDI.d452.s5.e0 27 33
drug
Norpace
DrugDDI.d452.s5.e1 37 45
drug
quinidine
DrugDDI.d452.s5.e2 79 90
drug
disopyramide
DrugDDI.d452.s5.e3 123 131
drug
quinidine

interaction DrugDDI.d452.s5.e0 DrugDDI.d452.s5.e1

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s6
Norpace does not increase serum digoxin levels.

DrugDDI.d452.s6.e0 0 6
drug
Norpace



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s7
Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.

DrugDDI.d452.s7.e0 14 34
drug
disopyramide phosphate
DrugDDI.d452.s7.e1 38 49
drug
erythromycin
DrugDDI.d452.s7.e2 103 114
drug
disopyramide

interaction DrugDDI.d452.s7.e0 DrugDDI.d452.s7.e1

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s8
Patients taking disopyramide phosphate and hepatic enzyme inhibitors concomitantly should be closely monitored.

DrugDDI.d452.s8.e0 14 34
drug
disopyramide phosphate
DrugDDI.d452.s8.e1 45 60
drug
enzyme inhibitors

interaction DrugDDI.d452.s8.e0 DrugDDI.d452.s8.e1

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s9
Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.

DrugDDI.d452.s9.e0 38 46
drug
verapamil
DrugDDI.d452.s9.e1 50 70
drug
disopyramide phosphate
DrugDDI.d452.s9.e2 83 94
drug
disopyramide
DrugDDI.d452.s9.e3 151 159
drug
verapamil

interaction DrugDDI.d452.s9.e2 DrugDDI.d452.s9.e3

Abstract Id: DrugDDI.d242
Sentence Id: DrugDDI.d242.s0
Animal studies indicate that dobutamine may be ineffective if the patient has recently received a  span class= c65 b-blocking drug.

DrugDDI.d242.s0.e0 25 34
drug
dobutamine



Abstract Id: DrugDDI.d242
Sentence Id: DrugDDI.d242.s2
Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.

DrugDDI.d242.s2.e0 49 58
drug
dobutamine
DrugDDI.d242.s2.e1 62 74
drug
nitroprusside
DrugDDI.d242.s2.e2 158 161
drug
drug



Abstract Id: DrugDDI.d242
Sentence Id: DrugDDI.d242.s3
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs , including digitalis preparation s, furosemide , spironolactone , lidocaine , glyceryl trinitrate , isosorbide dinitrate , morphine , atropine , heparin , protamine , potassium chloride , folic acid , and acetaminophen .

DrugDDI.d242.s3.e0 60 69
drug
dobutamine
DrugDDI.d242.s3.e1 106 110
drug
drugs
DrugDDI.d242.s3.e2 121 140
drug
digitalis preparation
DrugDDI.d242.s3.e3 143 152
drug
furosemide
DrugDDI.d242.s3.e4 154 167
drug
spironolactone
DrugDDI.d242.s3.e5 169 177
drug
lidocaine
DrugDDI.d242.s3.e6 179 196
drug
glyceryl trinitrate
DrugDDI.d242.s3.e7 198 216
drug
isosorbide dinitrate
DrugDDI.d242.s3.e8 218 225
drug
morphine
DrugDDI.d242.s3.e9 227 234
drug
atropine
DrugDDI.d242.s3.e10 236 242
drug
heparin
DrugDDI.d242.s3.e11 244 252
drug
protamine
DrugDDI.d242.s3.e12 254 270
drug
potassium chloride
DrugDDI.d242.s3.e13 272 280
drug
folic acid
DrugDDI.d242.s3.e14 285 297
drug
acetaminophen



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s0
Drug /Laboratory Test Interactions None known.

DrugDDI.d308.s0.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s1
Drug-Drug Interactions Cimetidine : Concomitant use of cimetidine is contraindicated.

DrugDDI.d308.s1.e0 21 30
drug
Cimetidine
DrugDDI.d308.s1.e1 48 57
drug
cimetidine



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s2
Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID ) for 7 days has been shown to increase dofetilide plasma levels by 58%.

DrugDDI.d308.s2.e0 0 9
drug
Cimetidine
DrugDDI.d308.s2.e1 17 19
drug
BID
DrugDDI.d308.s2.e2 65 71
drug
TIKOSYN
DrugDDI.d308.s2.e3 79 81
drug
BID
DrugDDI.d308.s2.e4 113 122
drug
dofetilide

interaction DrugDDI.d308.s2.e0 DrugDDI.d308.s2.e2

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s3
Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).

DrugDDI.d308.s3.e0 0 9
drug
Cimetidine
DrugDDI.d308.s3.e1 24 26
drug
BID
DrugDDI.d308.s3.e2 60 69
drug
dofetilide

interaction DrugDDI.d308.s3.e0 DrugDDI.d308.s3.e2

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s4
No studies have been conducted at intermediate doses of cimetidine .

DrugDDI.d308.s4.e0 47 56
drug
cimetidine



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s5
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole , ranitidine , or antacids (aluminum and magnesium hydroxide s) be used as alternatives to cimetidine , as these agents have no effect on the pharmacokinetic profile of TIKOSYN .

DrugDDI.d308.s5.e0 18 24
drug
TIKOSYN
DrugDDI.d308.s5.e1 63 72
drug
omeprazole
DrugDDI.d308.s5.e2 74 83
drug
ranitidine
DrugDDI.d308.s5.e3 87 94
drug
antacids
DrugDDI.d308.s5.e4 107 124
drug
magnesium hydroxide
DrugDDI.d308.s5.e5 149 158
drug
cimetidine
DrugDDI.d308.s5.e6 214 220
drug
TIKOSYN

interaction DrugDDI.d308.s5.e0 DrugDDI.d308.s5.e5

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s6
Verapamil : Concomitant use of verapamil is contraindicated.

DrugDDI.d308.s6.e0 0 8
drug
Verapamil
DrugDDI.d308.s6.e1 26 34
drug
verapamil



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s7
Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.

DrugDDI.d308.s7.e0 19 25
drug
TIKOSYN
DrugDDI.d308.s7.e1 30 38
drug
verapamil
DrugDDI.d308.s7.e2 60 69
drug
dofetilide
DrugDDI.d308.s7.e3 117 126
drug
dofetilide

interaction DrugDDI.d308.s7.e0 DrugDDI.d308.s7.e1

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s8
In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.

DrugDDI.d308.s8.e0 102 110
drug
verapamil
DrugDDI.d308.s8.e1 115 124
drug
dofetilide

interaction DrugDDI.d308.s8.e0 DrugDDI.d308.s8.e1

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s9
Ketoconazole : Concomitant use of ketoconazole is contraindicated.

DrugDDI.d308.s9.e0 0 11
drug
Ketoconazole
DrugDDI.d308.s9.e1 29 40
drug
ketoconazole



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s10
Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID ) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.

DrugDDI.d308.s10.e0 0 11
drug
Ketoconazole
DrugDDI.d308.s10.e1 79 85
drug
TIKOSYN
DrugDDI.d308.s10.e2 93 95
drug
BID
DrugDDI.d308.s10.e3 127 136
drug
dofetilide

interaction DrugDDI.d308.s10.e0 DrugDDI.d308.s10.e1
interaction DrugDDI.d308.s10.e0 DrugDDI.d308.s10.e2

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s11
Trimethoprim Alone or in Combination with Sulfamethoxazole : Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.

DrugDDI.d308.s11.e0 0 11
drug
Trimethoprim
DrugDDI.d308.s11.e1 36 51
drug
Sulfamethoxazole
DrugDDI.d308.s11.e2 69 80
drug
trimethoprim
DrugDDI.d308.s11.e3 105 120
drug
sulfamethoxazole

interaction DrugDDI.d308.s11.e2 DrugDDI.d308.s11.e3

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s12
Trimethoprim 160 mg in combination with 800 mg sulfamethoxazole co-administered BID with TIKOSYN (500 mcg BID ) for 4 days has been shown to increase dofetilide AUC by 103% and Cmax by 93%.

DrugDDI.d308.s12.e0 0 16
drug
Trimethoprim 160 mg
DrugDDI.d308.s12.e1 39 54
drug
sulfamethoxazole
DrugDDI.d308.s12.e2 70 72
drug
BID
DrugDDI.d308.s12.e3 77 83
drug
TIKOSYN
DrugDDI.d308.s12.e4 91 93
drug
BID
DrugDDI.d308.s12.e5 125 134
drug
dofetilide

interaction DrugDDI.d308.s12.e2 DrugDDI.d308.s12.e3

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s13
Hydrochlorothiazide ( HCTZ ) Alone or in Combination with Triamterene : Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.

DrugDDI.d308.s13.e0 0 18
drug
Hydrochlorothiazide
DrugDDI.d308.s13.e1 20 23
drug
HCTZ
DrugDDI.d308.s13.e2 49 59
drug
Triamterene
DrugDDI.d308.s13.e3 77 80
drug
HCTZ
DrugDDI.d308.s13.e4 105 115
drug
triamterene

interaction DrugDDI.d308.s13.e3 DrugDDI.d308.s13.e4

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s14
HCTZ 50 mg QD or HCTZ /triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID ) for 5 days (following 2 days of diuretic use at half dose).

DrugDDI.d308.s14.e0 0 3
drug
HCTZ
DrugDDI.d308.s14.e1 12 15
drug
HCTZ
DrugDDI.d308.s14.e2 16 33
drug
/triamterene 50/100
DrugDDI.d308.s14.e3 60 66
drug
TIKOSYN
DrugDDI.d308.s14.e4 74 76
drug
BID
DrugDDI.d308.s14.e5 103 110
drug
diuretic



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s15
In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.

DrugDDI.d308.s15.e0 19 22
drug
HCTZ



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s17
In patients receiving HCTZ in combination with triamterene , dofetilide AUC increased by 30% and Cmax by 16%.

DrugDDI.d308.s17.e0 19 22
drug
HCTZ
DrugDDI.d308.s17.e1 40 50
drug
triamterene
DrugDDI.d308.s17.e2 52 61
drug
dofetilide

interaction DrugDDI.d308.s17.e0 DrugDDI.d308.s17.e1

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s19
The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium.

DrugDDI.d308.s19.e0 68 77
drug
dofetilide



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s20
In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics .

DrugDDI.d308.s20.e0 46 52
drug
TIKOSYN
DrugDDI.d308.s20.e1 56 64
drug
diuretics
DrugDDI.d308.s20.e2 149 157
drug
diuretics



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s21
Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).

DrugDDI.d308.s21.e0 22 48
drug
potassium depleting diuretics
DrugDDI.d308.s21.e1 72 82
drug
medications
DrugDDI.d308.s21.e2 115 121
drug
TIKOSYN



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s22
Potential Drug Interactions Dofetilide is eliminated in the kidney by cation ic secretion.

DrugDDI.d308.s22.e0 25 34
drug
Dofetilide
DrugDDI.d308.s22.e1 60 65
drug
cation



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s23
Inhibitors of renal cation ic secretion are contraindicated with TIKOSYN .

DrugDDI.d308.s23.e0 17 22
drug
cation
DrugDDI.d308.s23.e1 56 62
drug
TIKOSYN



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s24
In addition, drugs that are actively secreted via this route (e.g., triamterene , metformin and amiloride ) should be co-administered with care as they might increase dofetilide levels.

DrugDDI.d308.s24.e0 11 15
drug
drugs
DrugDDI.d308.s24.e1 57 67
drug
triamterene
DrugDDI.d308.s24.e2 69 77
drug
metformin
DrugDDI.d308.s24.e3 81 89
drug
amiloride
DrugDDI.d308.s24.e4 141 150
drug
dofetilide

interaction DrugDDI.d308.s24.e0 DrugDDI.d308.s24.e4
interaction DrugDDI.d308.s24.e1 DrugDDI.d308.s24.e4
interaction DrugDDI.d308.s24.e2 DrugDDI.d308.s24.e4
interaction DrugDDI.d308.s24.e3 DrugDDI.d308.s24.e4

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s25
Dofetilide is metabolized to a small extent by the CYP3A4 isoenzyme of the cytochrome P450 system.

DrugDDI.d308.s25.e0 0 9
drug
Dofetilide
DrugDDI.d308.s25.e1 42 56
drug
CYP3A4 isoenzyme
DrugDDI.d308.s25.e2 62 75
drug
cytochrome P450

interaction DrugDDI.d308.s25.e0 DrugDDI.d308.s25.e1

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s26
Inhibitors of the CYP3A4 isoenzyme could increase systemic dofetilide exposure.

DrugDDI.d308.s26.e0 15 29
drug
CYP3A4 isoenzyme
DrugDDI.d308.s26.e1 51 60
drug
dofetilide

interaction DrugDDI.d308.s26.e0 DrugDDI.d308.s26.e1

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s27
Inhibitors of this isoenzyme (e.g., macrolide antibiotics , azole antifungal agents , protease inhibitors , serotonin reuptake inhibitors , amiodarone , cannabinoids, diltiazem , grapefruit juice, nefazadone, norfloxacin , quinine , zafirlukast ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.

DrugDDI.d308.s27.e0 16 24
drug
isoenzyme
DrugDDI.d308.s27.e1 31 50
drug
macrolide antibiotics
DrugDDI.d308.s27.e2 57 72
drug
antifungal agents
DrugDDI.d308.s27.e3 74 91
drug
protease inhibitors
DrugDDI.d308.s27.e4 93 119
drug
serotonin reuptake inhibitors
DrugDDI.d308.s27.e5 121 130
drug
amiodarone
DrugDDI.d308.s27.e6 145 153
drug
diltiazem
DrugDDI.d308.s27.e7 182 192
drug
norfloxacin
DrugDDI.d308.s27.e8 194 200
drug
quinine
DrugDDI.d308.s27.e9 202 212
drug
zafirlukast
DrugDDI.d308.s27.e10 250 256
drug
TIKOSYN
DrugDDI.d308.s27.e11 285 294
drug
dofetilide

interaction DrugDDI.d308.s27.e1 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e2 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e3 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e4 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e5 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e6 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e7 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e8 DrugDDI.d308.s27.e10
interaction DrugDDI.d308.s27.e9 DrugDDI.d308.s27.e10

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s28
Dofetilide is not an inhibitor of CYP3A4 nor of other cytochrome P450 isoenzymes (e.g., CYP2C9 , CYP2D6 ) and is not expected to increase levels of drugs metabolized by CYP3A4 .

DrugDDI.d308.s28.e0 0 9
drug
Dofetilide
DrugDDI.d308.s28.e1 28 33
drug
CYP3A4
DrugDDI.d308.s28.e2 44 57
drug
cytochrome P450
DrugDDI.d308.s28.e3 74 79
drug
CYP2C9
DrugDDI.d308.s28.e4 81 86
drug
CYP2D6
DrugDDI.d308.s28.e5 122 126
drug
drugs
DrugDDI.d308.s28.e6 140 145
drug
CYP3A4



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s29
Other Drug Interaction Information Digoxin : Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin .

DrugDDI.d308.s29.e0 31 37
drug
Digoxin
DrugDDI.d308.s29.e1 78 84
drug
TIKOSYN
DrugDDI.d308.s29.e2 119 125
drug
digoxin



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s30
In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.

DrugDDI.d308.s30.e0 41 47
drug
digoxin
DrugDDI.d308.s30.e1 52 61
drug
dofetilide

interaction DrugDDI.d308.s30.e0 DrugDDI.d308.s30.e1

Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s31
It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin ; .

DrugDDI.d308.s31.e0 50 56
drug
TIKOSYN
DrugDDI.d308.s31.e1 116 122
drug
digoxin



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s33
No increase in mortality was observed in patients taking digoxin as concomitant medication .

DrugDDI.d308.s33.e0 48 54
drug
digoxin
DrugDDI.d308.s33.e1 68 77
drug
medication



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s34
Other Drugs : In healthy volunteers, amlodipine , phenytoin , glyburide , ranitidine , omeprazole , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone ), antacid (aluminum and magnesium hydroxide s) and theophylline did not affect the pharmacokinetics of TIKOSYN .

DrugDDI.d308.s34.e0 5 9
drug
Drugs
DrugDDI.d308.s34.e1 31 40
drug
amlodipine
DrugDDI.d308.s34.e2 42 50
drug
phenytoin
DrugDDI.d308.s34.e3 52 60
drug
glyburide
DrugDDI.d308.s34.e4 62 71
drug
ranitidine
DrugDDI.d308.s34.e5 73 82
drug
omeprazole
DrugDDI.d308.s34.e6 134 142
drug
estrogens
DrugDDI.d308.s34.e7 146 164
drug
medroxyprogesterone
DrugDDI.d308.s34.e8 167 173
drug
antacid
DrugDDI.d308.s34.e9 186 203
drug
magnesium hydroxide
DrugDDI.d308.s34.e10 209 220
drug
theophylline
DrugDDI.d308.s34.e11 254 260
drug
TIKOSYN



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s35
In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin , or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin , theophylline , or oral contraceptives .

DrugDDI.d308.s35.e0 50 56
drug
TIKOSYN
DrugDDI.d308.s35.e1 109 116
drug
warfarin
DrugDDI.d308.s35.e2 141 151
drug
propranolol
DrugDDI.d308.s35.e3 169 177
drug
phenytoin
DrugDDI.d308.s35.e4 179 190
drug
theophylline
DrugDDI.d308.s35.e5 194 211
drug
oral contraceptives



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s36
Population pharmacokinetic analyses were conducted on plasma concentration data from 1445 patients in clinical trials to examine the effects of concomitant medications on clearance or volume of distribution of dofetilide .

DrugDDI.d308.s36.e0 135 145
drug
medications
DrugDDI.d308.s36.e1 181 190
drug
dofetilide



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s37
Concomitant medications were grouped as ACE inhibitors , oral anticoagulants , calcium channel blockers , beta blockers , cardiac glycosides , inducers of CYP3A4 , substrates and inhibitors of CYP3A4 , substrates and inhibitors of P- glycoprotein , nitrates , sulphonylureas , loop diuretics , potassium sparing diuretics , thiazide diuretics , substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs .

DrugDDI.d308.s37.e0 11 21
drug
medications
DrugDDI.d308.s37.e1 35 47
drug
ACE inhibitors
DrugDDI.d308.s37.e2 49 66
drug
oral anticoagulants
DrugDDI.d308.s37.e3 68 89
drug
calcium channel blockers
DrugDDI.d308.s37.e4 91 102
drug
beta blockers
DrugDDI.d308.s37.e5 104 120
drug
cardiac glycosides
DrugDDI.d308.s37.e6 132 137
drug
CYP3A4
DrugDDI.d308.s37.e7 164 169
drug
CYP3A4
DrugDDI.d308.s37.e8 198 209
drug
glycoprotein
DrugDDI.d308.s37.e9 211 218
drug
nitrates
DrugDDI.d308.s37.e10 220 233
drug
sulphonylureas
DrugDDI.d308.s37.e11 235 247
drug
loop diuretics
DrugDDI.d308.s37.e12 249 273
drug
potassium sparing diuretics
DrugDDI.d308.s37.e13 275 291
drug
thiazide diuretics
DrugDDI.d308.s37.e14 365 369
drug
drugs



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s38
Differences in clearance between patients on these medications (at any occasion in the study) and those off medications varied between -16% and +3%.

DrugDDI.d308.s38.e0 44 54
drug
medications
DrugDDI.d308.s38.e1 91 101
drug
medications



Abstract Id: DrugDDI.d308
Sentence Id: DrugDDI.d308.s39
The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.

DrugDDI.d308.s39.e0 19 28
drug
dofetilide
DrugDDI.d308.s39.e1 59 75
drug
thiazide diuretics

interaction DrugDDI.d308.s39.e0 DrugDDI.d308.s39.e1

Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s0
The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.

DrugDDI.d433.s0.e0 64 73
drug
dolasetron
DrugDDI.d433.s0.e1 109 113
drug
drugs



Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s1
Blood levels of hydro dolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450 ) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450 ) for 7 days.

DrugDDI.d433.s1.e0 18 27
drug
dolasetron
DrugDDI.d433.s1.e1 75 84
drug
cimetidine
DrugDDI.d433.s1.e2 109 123
drug
cytochrome P-450
DrugDDI.d433.s1.e3 171 178
drug
rifampin
DrugDDI.d433.s1.e4 195 209
drug
cytochrome P-450

interaction DrugDDI.d433.s1.e0 DrugDDI.d433.s1.e1
interaction DrugDDI.d433.s1.e0 DrugDDI.d433.s1.e3

Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s2
Dolasetron has been safely coadministered with drugs used in chemotherapy and surgery.

DrugDDI.d433.s2.e0 0 9
drug
Dolasetron
DrugDDI.d433.s2.e1 41 45
drug
drugs



Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s3
As with other agents which prolong ECG intervals, caution should be exercised in patients taking drugs which prolong ECG intervals, particularly QTc.

DrugDDI.d433.s3.e0 82 86
drug
drugs



Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s4
In patients taking furosemide , nifedipine , diltiazem , ACE inhibitors , verapamil , glyburide , propranolol , and various chemotherapy agents , no effect was shown on the clearance of hydrodolasetron.

DrugDDI.d433.s4.e0 16 25
drug
furosemide
DrugDDI.d433.s4.e1 27 36
drug
nifedipine
DrugDDI.d433.s4.e2 38 46
drug
diltiazem
DrugDDI.d433.s4.e3 48 60
drug
ACE inhibitors
DrugDDI.d433.s4.e4 62 70
drug
verapamil
DrugDDI.d433.s4.e5 72 80
drug
glyburide
DrugDDI.d433.s4.e6 82 92
drug
propranolol
DrugDDI.d433.s4.e7 104 121
drug
chemotherapy agents



Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s5
Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol .

DrugDDI.d433.s5.e0 49 66
drug
dolasetron mesylate
DrugDDI.d433.s5.e1 112 119
drug
atenolol

interaction DrugDDI.d433.s5.e0 DrugDDI.d433.s5.e1

Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s6
Dolasetron does not influence anesthesia recovery time in patients.

DrugDDI.d433.s6.e0 0 9
drug
Dolasetron



Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s7
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agent s ( cisplatin , 5-fluorouracil , doxorubicin , cyclophosphamide ) in four murine models.

DrugDDI.d433.s7.e0 0 17
drug
Dolasetron mesylate
DrugDDI.d433.s7.e1 57 77
drug
chemotherapeutic agent
DrugDDI.d433.s7.e2 80 88
drug
cisplatin
DrugDDI.d433.s7.e3 90 103
drug
5-fluorouracil
DrugDDI.d433.s7.e4 105 115
drug
doxorubicin
DrugDDI.d433.s7.e5 117 132
drug
cyclophosphamide



Abstract Id: DrugDDI.d507
Sentence Id: DrugDDI.d507.s0
Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept .

DrugDDI.d507.s0.e0 0 4
drug
Drugs
DrugDDI.d507.s0.e1 24 29
drug
CYP 2D6
DrugDDI.d507.s0.e2 33 35
drug
CYP
DrugDDI.d507.s0.e3 66 72
drug
Aricept



Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s0
Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine .

DrugDDI.d305.s0.e0 7 14
drug
dopamine
DrugDDI.d305.s0.e1 30 45
drug
monoamine oxidase
DrugDDI.d305.s0.e2 107 114
drug
dopamine

interaction DrugDDI.d305.s0.e0 DrugDDI.d305.s0.e1

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s1
Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.

DrugDDI.d305.s1.e0 30 42
drug
MAO inhibitors
DrugDDI.d305.s1.e1 90 100
drug
dopamine HCl
DrugDDI.d305.s1.e2 128 138
drug
dopamine HCl



Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s2
Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.

DrugDDI.d305.s2.e0 34 44
drug
dopamine HCl
DrugDDI.d305.s2.e1 48 55
drug
diuretic

interaction DrugDDI.d305.s2.e0 DrugDDI.d305.s2.e1

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s3
Tricyclic antidepressants may potentiate the cardiovascular effects of adreneric agents.

DrugDDI.d305.s3.e0 0 23
drug
Tricyclic antidepressants



Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s4
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents , such as propranolol and metoprolol .

DrugDDI.d305.s4.e0 16 23
drug
dopamine
DrugDDI.d305.s4.e1 40 68
drug
beta-adrenergic blocking agents
DrugDDI.d305.s4.e2 76 86
drug
propranolol
DrugDDI.d305.s4.e3 90 99
drug
metoprolol

interaction DrugDDI.d305.s4.e0 DrugDDI.d305.s4.e1
interaction DrugDDI.d305.s4.e0 DrugDDI.d305.s4.e2
interaction DrugDDI.d305.s4.e0 DrugDDI.d305.s4.e3

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s5
The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents .

DrugDDI.d305.s5.e0 48 58
drug
dopamine HCl
DrugDDI.d305.s5.e1 74 103
drug
alpha-adrenergic blocking agents

interaction DrugDDI.d305.s5.e0 DrugDDI.d305.s5.e1

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s6
Dopamine -induced renal and mesenteric vasodilation is not antagonized by either alpha-or beta-adrenergic blocking agents .

DrugDDI.d305.s6.e0 0 7
drug
Dopamine
DrugDDI.d305.s6.e1 78 106
drug
beta-adrenergic blocking agents



Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s7
Butyrophenones (such as haloperidol ) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.

DrugDDI.d305.s7.e0 0 13
drug
Butyrophenones
DrugDDI.d305.s7.e1 21 31
drug
haloperidol
DrugDDI.d305.s7.e2 36 49
drug
phenothiazines
DrugDDI.d305.s7.e3 124 131
drug
dopamine

interaction DrugDDI.d305.s7.e0 DrugDDI.d305.s7.e3
interaction DrugDDI.d305.s7.e1 DrugDDI.d305.s7.e3
interaction DrugDDI.d305.s7.e2 DrugDDI.d305.s7.e3

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s8
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine .

DrugDDI.d305.s8.e0 0 11
drug
Cyclopropane
DrugDDI.d305.s8.e1 14 46
drug
halogenated hydrocarbon anesthetics
DrugDDI.d305.s8.e2 177 184
drug
dopamine

interaction DrugDDI.d305.s8.e0 DrugDDI.d305.s8.e2
interaction DrugDDI.d305.s8.e1 DrugDDI.d305.s8.e2

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s9
This interaction appears to be related both to pressor activity and to beta-adrenergic stimulating properties of these catecholamines and may produce ventricular arrhythmias and hypertension.

DrugDDI.d305.s9.e0 39 45
drug
pressor



Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s10
Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics .

DrugDDI.d305.s10.e0 58 68
drug
dopamine HCl
DrugDDI.d305.s10.e1 88 99
drug
cyclopropane
DrugDDI.d305.s10.e2 102 134
drug
halogenated hydrocarbon anesthetics

interaction DrugDDI.d305.s10.e0 DrugDDI.d305.s10.e1
interaction DrugDDI.d305.s10.e0 DrugDDI.d305.s10.e2

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s11
It has been reported that results of studies in animals indicate that dopamine -induced ventricular arrhythmias during anesthesia can be reversed by propranolol .

DrugDDI.d305.s11.e0 58 65
drug
dopamine
DrugDDI.d305.s11.e1 127 137
drug
propranolol

interaction DrugDDI.d305.s11.e0 DrugDDI.d305.s11.e1

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s12
The concomitant use of vasopressor s, vasoconstricting agents (such as ergonovine ) and some oxytocic drugs may result in severe hypertension.

DrugDDI.d305.s12.e0 19 29
drug
vasopressor
DrugDDI.d305.s12.e1 61 70
drug
ergonovine
DrugDDI.d305.s12.e2 79 91
drug
oxytocic drugs

interaction DrugDDI.d305.s12.e0 DrugDDI.d305.s12.e2
interaction DrugDDI.d305.s12.e1 DrugDDI.d305.s12.e2

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s13
Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.

DrugDDI.d305.s13.e0 16 24
drug
phenytoin
DrugDDI.d305.s13.e1 44 54
drug
dopamine HCl

interaction DrugDDI.d305.s13.e0 DrugDDI.d305.s13.e1

Abstract Id: DrugDDI.d305
Sentence Id: DrugDDI.d305.s14
It is suggested that in patients receiving dopamine HCl , alternatives to phenytoin should be used if anticonvulsant therapy is needed.

DrugDDI.d305.s14.e0 36 46
drug
dopamine HCl
DrugDDI.d305.s14.e1 62 70
drug
phenytoin



Abstract Id: DrugDDI.d162
Sentence Id: DrugDDI.d162.s0
Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide , these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).

DrugDDI.d162.s0.e0 81 91
drug
dorzolamide
DrugDDI.d162.s0.e1 134 160
drug
carbonic anhydrase inhibitors
DrugDDI.d162.s0.e2 248 257
drug
salicylate



Abstract Id: DrugDDI.d162
Sentence Id: DrugDDI.d162.s1
Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide .

DrugDDI.d162.s1.e0 82 92
drug
dorzolamide



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s0
Most (98%) of plasma doxazosin is protein bound.

DrugDDI.d257.s0.e0 17 25
drug
doxazosin
DrugDDI.d257.s0.e1 28 34
drug
protein



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s1
In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin , warfarin , phenytoin or indomethacin .

DrugDDI.d257.s1.e0 13 23
drug
human plasma
DrugDDI.d257.s1.e1 36 52
drug
doxazosin mesylate
DrugDDI.d257.s1.e2 82 88
drug
digoxin
DrugDDI.d257.s1.e3 90 97
drug
warfarin
DrugDDI.d257.s1.e4 99 107
drug
phenytoin
DrugDDI.d257.s1.e5 110 121
drug
indomethacin



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s2
There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding.

DrugDDI.d257.s2.e0 69 77
drug
doxazosin



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s3
Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics , beta-blocking agent s, and nonsteroidal anti-inflammatory drugs .

DrugDDI.d257.s3.e0 0 16
drug
Doxazosin mesylate
DrugDDI.d257.s3.e1 99 115
drug
thiazide diuretics
DrugDDI.d257.s3.e2 117 134
drug
beta-blocking agent
DrugDDI.d257.s3.e3 140 173
drug
nonsteroidal anti-inflammatory drugs



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s4
In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin .

DrugDDI.d257.s4.e0 80 88
drug
doxazosin
DrugDDI.d257.s4.e1 115 128
drug
oral cimetidine
DrugDDI.d257.s4.e2 179 187
drug
doxazosin
DrugDDI.d257.s4.e3 274 282
drug
doxazosin

interaction DrugDDI.d257.s4.e0 DrugDDI.d257.s4.e1

Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s5
The clinical significance of this increase in doxazosin AUC is unknown.

DrugDDI.d257.s5.e0 39 47
drug
doxazosin



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s6
In clinical trials, doxazosin mesylate tablets have been administered to patients on a variety of concomitant medications ; .

DrugDDI.d257.s6.e0 17 33
drug
doxazosin mesylate
DrugDDI.d257.s6.e1 94 104
drug
medications



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s8
Doxazosin mesylate tablets have been used with the following drugs or drug classes: 1.

DrugDDI.d257.s8.e0 0 16
drug
Doxazosin mesylate
DrugDDI.d257.s8.e1 52 56
drug
drugs
DrugDDI.d257.s8.e2 59 62
drug
drug



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s9
Analgesic /anti-inflammatory (e.g., acetaminophen , aspirin , codeine and codeine combinations, ibuprofen , indomethacin ).

DrugDDI.d257.s9.e0 0 8
drug
Analgesic
DrugDDI.d257.s9.e1 33 45
drug
acetaminophen
DrugDDI.d257.s9.e2 47 53
drug
aspirin
DrugDDI.d257.s9.e3 55 61
drug
codeine
DrugDDI.d257.s9.e4 65 71
drug
codeine
DrugDDI.d257.s9.e5 85 93
drug
ibuprofen
DrugDDI.d257.s9.e6 95 106
drug
indomethacin



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s11
Antibiotics (e.g., erythromycin , trimethoprim and sulfamethoxazole , amoxicillin ).

DrugDDI.d257.s11.e0 0 10
drug
Antibiotics
DrugDDI.d257.s11.e1 17 28
drug
erythromycin
DrugDDI.d257.s11.e2 30 41
drug
trimethoprim
DrugDDI.d257.s11.e3 45 60
drug
sulfamethoxazole
DrugDDI.d257.s11.e4 62 72
drug
amoxicillin



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s13
Antihistamines (e.g., chlorpheniramine ).

DrugDDI.d257.s13.e0 0 13
drug
Antihistamines
DrugDDI.d257.s13.e1 20 35
drug
chlorpheniramine



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s15
Cardiovascular agents (e.g., atenolol , hydrochlorothiazide , propranolol ).

DrugDDI.d257.s15.e0 0 19
drug
Cardiovascular agents
DrugDDI.d257.s15.e1 26 33
drug
atenolol
DrugDDI.d257.s15.e2 35 53
drug
hydrochlorothiazide
DrugDDI.d257.s15.e3 55 65
drug
propranolol



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s17
Corticosteroids .

DrugDDI.d257.s17.e0 0 14
drug
Corticosteroids



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s19
Gastrointestinal agents (e.g., antacids ).

DrugDDI.d257.s19.e0 0 21
drug
Gastrointestinal agents
DrugDDI.d257.s19.e1 28 35
drug
antacids



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s21
Hypoglycemics and endocrine drugs .

DrugDDI.d257.s21.e0 0 12
drug
Hypoglycemics
DrugDDI.d257.s21.e1 16 29
drug
endocrine drugs



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s23
Sedatives and tranquilizers (e.g., diazepam ).

DrugDDI.d257.s23.e0 0 8
drug
Sedatives
DrugDDI.d257.s23.e1 12 24
drug
tranquilizers
DrugDDI.d257.s23.e2 31 38
drug
diazepam



Abstract Id: DrugDDI.d257
Sentence Id: DrugDDI.d257.s25
Cold and flu remedies .

DrugDDI.d257.s25.e0 10 17
drug
remedies



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s0
Drugs Metabolized by P450 2D6 : The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 ( debrisoquin hydroxylase ) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called poor metabolizers); .

DrugDDI.d444.s0.e0 0 4
drug
Drugs
DrugDDI.d444.s0.e1 18 24
drug
P450 2D6
DrugDDI.d444.s0.e2 53 56
drug
drug
DrugDDI.d444.s0.e3 94 115
drug
debrisoquin hydroxylase



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s1
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.

DrugDDI.d444.s1.e0 41 54
drug
P450 2D6 isozyme



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s2
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

DrugDDI.d444.s2.e0 60 83
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s3
Depending on the fraction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).

DrugDDI.d444.s3.e0 24 27
drug
drug
DrugDDI.d444.s3.e1 41 47
drug
P450 2D6

interaction DrugDDI.d444.s3.e0 DrugDDI.d444.s3.e1

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s4
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.

DrugDDI.d444.s4.e0 18 22
drug
drugs
DrugDDI.d444.s4.e1 47 53
drug
isozyme

interaction DrugDDI.d444.s4.e0 DrugDDI.d444.s4.e1

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s5
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

DrugDDI.d444.s5.e0 91 95
drug
drugs



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s6
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme ( quinidine ; .

DrugDDI.d444.s6.e0 3 7
drug
drugs
DrugDDI.d444.s6.e1 19 35
drug
cytochrome P450 2D6
DrugDDI.d444.s6.e2 80 88
drug
quinidine



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s7
cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and flecainide ).

DrugDDI.d444.s7.e0 0 9
drug
cimetidine
DrugDDI.d444.s7.e1 38 44
drug
P450 2D6
DrugDDI.d444.s7.e2 55 69
drug
antidepressants
DrugDDI.d444.s7.e3 71 84
drug
phenothiazines
DrugDDI.d444.s7.e4 113 123
drug
propafenone
DrugDDI.d444.s7.e5 127 136
drug
flecainide



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s8
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram , escitalopram , fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition.

DrugDDI.d444.s8.e0 20 46
drug
serotonin reuptake inhibitors
DrugDDI.d444.s8.e1 60 69
drug
citalopram
DrugDDI.d444.s8.e2 71 82
drug
escitalopram
DrugDDI.d444.s8.e3 84 93
drug
fluoxetine
DrugDDI.d444.s8.e4 95 104
drug
sertraline
DrugDDI.d444.s8.e5 109 118
drug
paroxetine
DrugDDI.d444.s8.e6 127 133
drug
P450 2D6



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s11
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

DrugDDI.d444.s11.e0 103 112
drug
fluoxetine
DrugDDI.d444.s11.e1 149 164
drug
active metabolite



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s12
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

DrugDDI.d444.s12.e0 16 39
drug
tricyclic antidepressants
DrugDDI.d444.s12.e1 44 48
drug
drugs
DrugDDI.d444.s12.e2 63 79
drug
cytochrome P450 2D6
DrugDDI.d444.s12.e3 133 155
drug
tricyclic antidepressant
DrugDDI.d444.s12.e4 166 169
drug
drug

interaction DrugDDI.d444.s12.e0 DrugDDI.d444.s12.e1

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s13
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.

DrugDDI.d444.s13.e0 35 39
drug
drugs
DrugDDI.d444.s13.e1 83 105
drug
tricyclic antidepressant



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s14
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6 .

DrugDDI.d444.s14.e0 86 89
drug
drug
DrugDDI.d444.s14.e1 112 118
drug
P450 2D6



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s15
Doxepin is primarily metabolized by CYP2D6 (with CYP1A2  and  CYP3A4 as minor pathways).

DrugDDI.d444.s15.e0 0 6
drug
Doxepin
DrugDDI.d444.s15.e1 31 36
drug
CYP2D6
DrugDDI.d444.s15.e2 51 56
drug
CYP3A4



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s16
Inhibitors or substrates of CYP2D6 (i.e., quinidine , selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.

DrugDDI.d444.s16.e0 24 29
drug
CYP2D6
DrugDDI.d444.s16.e1 36 44
drug
quinidine
DrugDDI.d444.s16.e2 55 81
drug
serotonin reuptake inhibitors
DrugDDI.d444.s16.e3 125 131
drug
doxepin

interaction DrugDDI.d444.s16.e0 DrugDDI.d444.s16.e1
interaction DrugDDI.d444.s16.e1 DrugDDI.d444.s16.e3
interaction DrugDDI.d444.s16.e2 DrugDDI.d444.s16.e3

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s17
The extent of interaction depends on the variability of effect on CYP2D6 .

DrugDDI.d444.s17.e0 55 60
drug
CYP2D6



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s18
The clinical significance of this interaction with doxepin has not been systematically evaluated.

DrugDDI.d444.s18.e0 44 50
drug
doxepin



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s19
MAO Inhibitors : Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors .

DrugDDI.d444.s19.e0 0 12
drug
MAO Inhibitors
DrugDDI.d444.s19.e1 95 99
drug
drugs
DrugDDI.d444.s19.e2 104 116
drug
MAO inhibitors

interaction DrugDDI.d444.s19.e1 DrugDDI.d444.s19.e2

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s20
Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN .

DrugDDI.d444.s20.e0 10 22
drug
MAO inhibitors
DrugDDI.d444.s20.e1 99 106
drug
SINEQUAN

interaction DrugDDI.d444.s20.e0 DrugDDI.d444.s20.e1

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s21
The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved.

DrugDDI.d444.s21.e0 58 69
drug
MAO inhibitor



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s22
Cimetidine : Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants .

DrugDDI.d444.s22.e0 0 9
drug
Cimetidine
DrugDDI.d444.s22.e1 11 20
drug
Cimetidine
DrugDDI.d444.s22.e2 120 143
drug
tricyclic antidepressants

interaction DrugDDI.d444.s22.e1 DrugDDI.d444.s22.e2

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s23
Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.

DrugDDI.d444.s23.e0 7 21
drug
anticholinergic
DrugDDI.d444.s23.e1 134 156
drug
tricyclic antidepressant
DrugDDI.d444.s23.e2 161 170
drug
cimetidine

interaction DrugDDI.d444.s23.e1 DrugDDI.d444.s23.e2

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s24
Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine .

DrugDDI.d444.s24.e0 115 124
drug
cimetidine



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s25
In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.

DrugDDI.d444.s25.e0 49 72
drug
tricyclic antidepressants
DrugDDI.d444.s25.e1 92 101
drug
cimetidine
DrugDDI.d444.s25.e2 127 136
drug
cimetidine

interaction DrugDDI.d444.s25.e0 DrugDDI.d444.s25.e1

Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s26
Alcohol : It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.

DrugDDI.d444.s26.e0 0 6
drug
Alcohol
DrugDDI.d444.s26.e1 108 115
drug
SINEQUAN



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s27
This is especially important in patients who may use alcohol excessively.

DrugDDI.d444.s27.e0 44 50
drug
alcohol



Abstract Id: DrugDDI.d444
Sentence Id: DrugDDI.d444.s28
Tolazamide : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).

DrugDDI.d444.s28.e0 0 9
drug
Tolazamide
DrugDDI.d444.s28.e1 87 96
drug
tolazamide
DrugDDI.d444.s28.e2 130 136
drug
doxepin

interaction DrugDDI.d444.s28.e1 DrugDDI.d444.s28.e2

Abstract Id: DrugDDI.d64
Sentence Id: DrugDDI.d64.s1
Until specific compatibility data are available, it is not recommended that DOXIL@ be mixed with other drugs .

DrugDDI.d64.s1.e0 87 91
drug
drugs



Abstract Id: DrugDDI.d64
Sentence Id: DrugDDI.d64.s2
DOXIL@ may interact with drugs known to interact with the conventional formulation of doxorubicin HCl .

DrugDDI.d64.s2.e0 21 25
drug
drugs
DrugDDI.d64.s2.e1 73 86
drug
doxorubicin HCl



Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s0
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

DrugDDI.d294.s0.e0 7 19
drug
tetracyclines
DrugDDI.d294.s0.e1 139 151
drug
anticoagulant

interaction DrugDDI.d294.s0.e0 DrugDDI.d294.s0.e1

Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s1
Since bacteriostat ic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving tetracyclines in conjunction with penicillin .

DrugDDI.d294.s1.e0 5 16
drug
bacteriostat
DrugDDI.d294.s1.e1 63 72
drug
penicillin
DrugDDI.d294.s1.e2 100 112
drug
tetracyclines
DrugDDI.d294.s1.e3 130 139
drug
penicillin

interaction DrugDDI.d294.s1.e0 DrugDDI.d294.s1.e1
interaction DrugDDI.d294.s1.e2 DrugDDI.d294.s1.e3

Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s2
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium , or magnesium , and iron-containing preparations .

DrugDDI.d294.s2.e0 12 24
drug
tetracyclines
DrugDDI.d294.s2.e1 37 44
drug
antacids
DrugDDI.d294.s2.e2 64 70
drug
calcium
DrugDDI.d294.s2.e3 74 82
drug
magnesium
DrugDDI.d294.s2.e4 87 113
drug
iron-containing preparations

interaction DrugDDI.d294.s2.e0 DrugDDI.d294.s2.e1
interaction DrugDDI.d294.s2.e0 DrugDDI.d294.s2.e3
interaction DrugDDI.d294.s2.e0 DrugDDI.d294.s2.e4
interaction DrugDDI.d294.s2.e2 DrugDDI.d294.s2.e4

Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s3
Absorption of tetracycline is impaired by bismuth subsalicylate .

DrugDDI.d294.s3.e0 12 23
drug
tetracycline
DrugDDI.d294.s3.e1 36 55
drug
bismuth subsalicylate

interaction DrugDDI.d294.s3.e0 DrugDDI.d294.s3.e1

Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s4
Barbiturates , carbamazepine , and phenytoin decrease the half-life of doxycycline .

DrugDDI.d294.s4.e0 0 11
drug
Barbiturates
DrugDDI.d294.s4.e1 13 25
drug
carbamazepine
DrugDDI.d294.s4.e2 30 38
drug
phenytoin
DrugDDI.d294.s4.e3 61 71
drug
doxycycline

interaction DrugDDI.d294.s4.e0 DrugDDI.d294.s4.e3
interaction DrugDDI.d294.s4.e1 DrugDDI.d294.s4.e3
interaction DrugDDI.d294.s4.e2 DrugDDI.d294.s4.e3

Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s5
The concurrent use of tetracycline and Penthrane ( methoxyflurane ) has been reported to result in fatal renal toxicity.

DrugDDI.d294.s5.e0 18 29
drug
tetracycline
DrugDDI.d294.s5.e1 33 41
drug
Penthrane
DrugDDI.d294.s5.e2 43 56
drug
methoxyflurane

interaction DrugDDI.d294.s5.e0 DrugDDI.d294.s5.e1
interaction DrugDDI.d294.s5.e0 DrugDDI.d294.s5.e2

Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s6
Concurrent use of tetracycline may render oral contraceptives less effect ive.

DrugDDI.d294.s6.e0 15 26
drug
tetracycline
DrugDDI.d294.s6.e1 36 63
drug
oral contraceptives less effect



Abstract Id: DrugDDI.d294
Sentence Id: DrugDDI.d294.s7
Drug /Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

DrugDDI.d294.s7.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d121
Sentence Id: DrugDDI.d121.s0
Potential drug interactions for doxylamine include, increased seda@tion if doxylamine is combined with other CNS depressant drugs .

DrugDDI.d121.s0.e0 28 37
drug
doxylamine
DrugDDI.d121.s0.e1 66 75
drug
doxylamine
DrugDDI.d121.s0.e2 95 112
drug
CNS depressant drugs

interaction DrugDDI.d121.s0.e1 DrugDDI.d121.s0.e2

Abstract Id: DrugDDI.d121
Sentence Id: DrugDDI.d121.s1
Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin .

DrugDDI.d121.s1.e0 0 13
drug
Antihistamines
DrugDDI.d121.s1.e1 63 69
drug
heparin
DrugDDI.d121.s1.e2 72 79
drug
warfarin

interaction DrugDDI.d121.s1.e0 DrugDDI.d121.s1.e1
interaction DrugDDI.d121.s1.e0 DrugDDI.d121.s1.e2

Abstract Id: DrugDDI.d121
Sentence Id: DrugDDI.d121.s2
Doxylamine may enhance the effects of epinephrine .

DrugDDI.d121.s2.e0 0 9
drug
Doxylamine
DrugDDI.d121.s2.e1 32 42
drug
epinephrine

interaction DrugDDI.d121.s2.e0 DrugDDI.d121.s2.e1

Abstract Id: DrugDDI.d549
Sentence Id: DrugDDI.d549.s0
Androgens may increase sensitivity to oral anticoagulahts.

DrugDDI.d549.s0.e0 0 8
drug
Androgens



Abstract Id: DrugDDI.d549
Sentence Id: DrugDDI.d549.s1
Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.

DrugDDI.d549.s1.e0 11 23
drug
anticoagulant



Abstract Id: DrugDDI.d549
Sentence Id: DrugDDI.d549.s2
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone .

DrugDDI.d549.s2.e0 26 40
drug
oxyphenbutazone
DrugDDI.d549.s2.e1 44 52
drug
androgens
DrugDDI.d549.s2.e2 85 99
drug
oxyphenbutazone

interaction DrugDDI.d549.s2.e0 DrugDDI.d549.s2.e1

Abstract Id: DrugDDI.d549
Sentence Id: DrugDDI.d549.s3
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.

DrugDDI.d549.s3.e0 40 48
drug
androgens
DrugDDI.d549.s3.e1 85 91
drug
insulin

interaction DrugDDI.d549.s3.e0 DrugDDI.d549.s3.e1

Abstract Id: DrugDDI.d135
Sentence Id: DrugDDI.d135.s0
Other CNS depressant drugs (e.g. barbiturates , tranquilizers , opioids and general anesthetics ) have additive or potentiating effects with INAPSINE .

DrugDDI.d135.s0.e0 5 22
drug
CNS depressant drugs
DrugDDI.d135.s0.e1 28 39
drug
barbiturates
DrugDDI.d135.s0.e2 41 53
drug
tranquilizers
DrugDDI.d135.s0.e3 55 61
drug
opioids
DrugDDI.d135.s0.e4 65 82
drug
general anesthetics
DrugDDI.d135.s0.e5 121 128
drug
INAPSINE

interaction DrugDDI.d135.s0.e0 DrugDDI.d135.s0.e5
interaction DrugDDI.d135.s0.e1 DrugDDI.d135.s0.e5
interaction DrugDDI.d135.s0.e2 DrugDDI.d135.s0.e5
interaction DrugDDI.d135.s0.e3 DrugDDI.d135.s0.e5
interaction DrugDDI.d135.s0.e4 DrugDDI.d135.s0.e5

Abstract Id: DrugDDI.d135
Sentence Id: DrugDDI.d135.s1
When patients have received such drugs , the dose of INAPSINE required will be less than usual.

DrugDDI.d135.s1.e0 28 32
drug
drugs
DrugDDI.d135.s1.e1 43 50
drug
INAPSINE

interaction DrugDDI.d135.s1.e0 DrugDDI.d135.s1.e1

Abstract Id: DrugDDI.d135
Sentence Id: DrugDDI.d135.s2
Following the administration of INAPSINE , the dose of other CNS depressant drugs should be reduced.

DrugDDI.d135.s2.e0 28 35
drug
INAPSINE
DrugDDI.d135.s2.e1 51 68
drug
CNS depressant drugs

interaction DrugDDI.d135.s2.e0 DrugDDI.d135.s2.e1

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s0
Potential for Other Drugs to Affect Duloxetine : Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.

DrugDDI.d297.s0.e0 17 21
drug
Drugs
DrugDDI.d297.s0.e1 30 39
drug
Duloxetine
DrugDDI.d297.s0.e2 45 50
drug
CYP1A2
DrugDDI.d297.s0.e3 54 59
drug
CYP2D6
DrugDDI.d297.s0.e4 77 86
drug
duloxetine

interaction DrugDDI.d297.s0.e2 DrugDDI.d297.s0.e4
interaction DrugDDI.d297.s0.e3 DrugDDI.d297.s0.e4

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s1
Inhibitors of CYP1A2 : Concomitant use of duloxetine with fluvoxamine , an inhibitor of CYP1A2 , results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine .

DrugDDI.d297.s1.e0 12 17
drug
CYP1A2
DrugDDI.d297.s1.e1 35 44
drug
duloxetine
DrugDDI.d297.s1.e2 49 59
drug
fluvoxamine
DrugDDI.d297.s1.e3 74 79
drug
CYP1A2
DrugDDI.d297.s1.e4 156 165
drug
duloxetine

interaction DrugDDI.d297.s1.e1 DrugDDI.d297.s1.e2

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s2
Some quinolone antibiotic s would be expected to have similar effects and these combinations should be avoided.

DrugDDI.d297.s2.e0 4 22
drug
quinolone antibiotic



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s3
Inhibitors of CYP2D6 : Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine .

DrugDDI.d297.s3.e0 12 17
drug
CYP2D6
DrugDDI.d297.s3.e1 26 31
drug
CYP2D6
DrugDDI.d297.s3.e2 44 53
drug
duloxetine
DrugDDI.d297.s3.e3 81 90
drug
duloxetine
DrugDDI.d297.s3.e4 113 118
drug
CYP2D6
DrugDDI.d297.s3.e5 152 161
drug
duloxetine



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s4
Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine .

DrugDDI.d297.s4.e0 0 9
drug
Paroxetine
DrugDDI.d297.s4.e1 45 54
drug
duloxetine
DrugDDI.d297.s4.e2 131 140
drug
paroxetine

interaction DrugDDI.d297.s4.e0 DrugDDI.d297.s4.e1

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s5
Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine , quinidine ).

DrugDDI.d297.s5.e0 44 49
drug
CYP2D6
DrugDDI.d297.s5.e1 66 75
drug
fluoxetine
DrugDDI.d297.s5.e2 77 85
drug
quinidine



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s6
Potential for Duloxetine to Affect Other Drugs : Drugs Metabolized by CYP1A2 : In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.

DrugDDI.d297.s6.e0 12 21
drug
Duloxetine
DrugDDI.d297.s6.e1 35 39
drug
Drugs
DrugDDI.d297.s6.e2 41 45
drug
Drugs
DrugDDI.d297.s6.e3 59 64
drug
CYP1A2
DrugDDI.d297.s6.e4 110 119
drug
duloxetine
DrugDDI.d297.s6.e5 133 138
drug
CYP1A2
DrugDDI.d297.s6.e6 214 219
drug
CYP1A2



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s7
Drugs Metabolized by CYP2D6 : Duloxetine is a moderate inhibitor of CYP2D6 .

DrugDDI.d297.s7.e0 0 4
drug
Drugs
DrugDDI.d297.s7.e1 18 23
drug
CYP2D6
DrugDDI.d297.s7.e2 25 34
drug
Duloxetine
DrugDDI.d297.s7.e3 57 62
drug
CYP2D6

interaction DrugDDI.d297.s7.e2 DrugDDI.d297.s7.e3

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s8
When duloxetine was administered (at a dose of 60 mg BID ) in conjunction with a single 50-mg dose of desipramine , a CYP2D6 substrate, the AUC of desipramine increased 3-fold.

DrugDDI.d297.s8.e0 4 13
drug
duloxetine
DrugDDI.d297.s8.e1 43 45
drug
BID
DrugDDI.d297.s8.e2 82 92
drug
desipramine
DrugDDI.d297.s8.e3 95 100
drug
CYP2D6
DrugDDI.d297.s8.e4 119 129
drug
desipramine

interaction DrugDDI.d297.s8.e0 DrugDDI.d297.s8.e2

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s9
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants ( tricyclic antidepressants [TCAs], such as nortriptyline , amitriptyline , and imipramine ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone , flecainide ), should be approached with caution.

DrugDDI.d297.s9.e0 29 38
drug
Duloxetine
DrugDDI.d297.s9.e1 48 52
drug
drugs
DrugDDI.d297.s9.e2 88 94
drug
isozyme
DrugDDI.d297.s9.e3 147 161
drug
antidepressants
DrugDDI.d297.s9.e4 163 186
drug
tricyclic antidepressants
DrugDDI.d297.s9.e5 200 212
drug
nortriptyline
DrugDDI.d297.s9.e6 214 226
drug
amitriptyline
DrugDDI.d297.s9.e7 231 240
drug
imipramine
DrugDDI.d297.s9.e8 243 256
drug
phenothiazines
DrugDDI.d297.s9.e9 266 280
drug
antiarrhythmics
DrugDDI.d297.s9.e10 287 297
drug
propafenone
DrugDDI.d297.s9.e11 299 308
drug
flecainide

interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e1
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e3
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e4
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e5
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e6
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e7
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e8
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e9
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e10
interaction DrugDDI.d297.s9.e0 DrugDDI.d297.s9.e11

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s10
Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine .

DrugDDI.d297.s10.e0 106 115
drug
Duloxetine



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s11
Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine , Duloxetine and thioridazine should not be co-administered.

DrugDDI.d297.s11.e0 108 119
drug
thioridazine
DrugDDI.d297.s11.e1 121 130
drug
Duloxetine
DrugDDI.d297.s11.e2 134 145
drug
thioridazine

interaction DrugDDI.d297.s11.e1 DrugDDI.d297.s11.e2

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s12
Drugs Metabolized by CYP3A : Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity.

DrugDDI.d297.s12.e0 0 4
drug
Drugs
DrugDDI.d297.s12.e1 18 22
drug
CYP3A
DrugDDI.d297.s12.e2 62 71
drug
duloxetine
DrugDDI.d297.s12.e3 94 98
drug
CYP3A



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s13
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs : Alcohol : When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol .

DrugDDI.d297.s13.e0 0 9
drug
Duloxetine
DrugDDI.d297.s13.e1 69 73
drug
Drugs
DrugDDI.d297.s13.e2 75 81
drug
Alcohol
DrugDDI.d297.s13.e3 87 96
drug
Duloxetine
DrugDDI.d297.s13.e4 100 106
drug
ethanol
DrugDDI.d297.s13.e5 184 193
drug
Duloxetine
DrugDDI.d297.s13.e6 251 257
drug
alcohol

interaction DrugDDI.d297.s13.e0 DrugDDI.d297.s13.e1

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s14
In the Duloxetine clinical trials database, three Duloxetine -treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.

DrugDDI.d297.s14.e0 5 14
drug
Duloxetine
DrugDDI.d297.s14.e1 43 52
drug
Duloxetine
DrugDDI.d297.s14.e2 103 116
drug
total bilirubin



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s15
Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen.

DrugDDI.d297.s15.e0 23 29
drug
ethanol



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s16
CNS Acting Drugs : Given the primary CNS effects of Duloxetine , it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs , including those with a similar mechanism of action.

DrugDDI.d297.s16.e0 0 13
drug
CNS Acting Drugs
DrugDDI.d297.s16.e1 42 51
drug
Duloxetine
DrugDDI.d297.s16.e2 129 148
drug
centrally acting drugs



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s17
Potential for Interaction with Drugs that Affect Gastric Acidity: Duloxetine has an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5.

DrugDDI.d297.s17.e0 27 31
drug
Drugs
DrugDDI.d297.s17.e1 57 66
drug
Duloxetine



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s18
In extremely acidic conditions, Duloxetine , unprotected by the enteric coating, may undergo hydrolysis to form naphthol.

DrugDDI.d297.s18.e0 28 37
drug
Duloxetine



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s19
Caution is advised in using Duloxetine in patients with conditions that may slow gastric emptying (e.g., some diabetics).

DrugDDI.d297.s19.e0 23 32
drug
Duloxetine



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s20
Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine .

DrugDDI.d297.s20.e0 0 4
drug
Drugs
DrugDDI.d297.s20.e1 62 71
drug
duloxetine

interaction DrugDDI.d297.s20.e0 DrugDDI.d297.s20.e1

Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s21
However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine , had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.

DrugDDI.d297.s21.e0 27 36
drug
Duloxetine
DrugDDI.d297.s21.e1 53 80
drug
magnesium-containing antacids
DrugDDI.d297.s21.e2 90 99
drug
Duloxetine
DrugDDI.d297.s21.e3 104 113
drug
famotidine
DrugDDI.d297.s21.e4 156 165
drug
duloxetine



Abstract Id: DrugDDI.d297
Sentence Id: DrugDDI.d297.s22
It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.

DrugDDI.d297.s22.e0 48 67
drug
proton pump inhibitors
DrugDDI.d297.s22.e1 75 84
drug
duloxetine



Abstract Id: DrugDDI.d476
Sentence Id: DrugDDI.d476.s0
Synergism between xanthine bronchodilators (e.g., theophylline ), ephedrine , and other sympathomimetic bronchodilators has been reported.

DrugDDI.d476.s0.e0 16 38
drug
xanthine bronchodilators
DrugDDI.d476.s0.e1 45 56
drug
theophylline
DrugDDI.d476.s0.e2 59 67
drug
ephedrine
DrugDDI.d476.s0.e3 77 106
drug
sympathomimetic bronchodilators

interaction DrugDDI.d476.s0.e0 DrugDDI.d476.s0.e3
interaction DrugDDI.d476.s0.e1 DrugDDI.d476.s0.e3
interaction DrugDDI.d476.s0.e2 DrugDDI.d476.s0.e3

Abstract Id: DrugDDI.d476
Sentence Id: DrugDDI.d476.s2
Concurrent administration of dyphylline and probenecid , which compete s for tubular secretion, has been shown to increase the plasma half-life of dyphylline .

DrugDDI.d476.s2.e0 26 35
drug
dyphylline
DrugDDI.d476.s2.e1 39 48
drug
probenecid
DrugDDI.d476.s2.e2 55 61
drug
compete
DrugDDI.d476.s2.e3 125 134
drug
dyphylline

interaction DrugDDI.d476.s2.e0 DrugDDI.d476.s2.e1

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s0
Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticide s.

DrugDDI.d383.s0.e0 0 16
drug
Phospholine Iodide
DrugDDI.d383.s0.e1 33 56
drug
cholinesterase inhibitors
DrugDDI.d383.s0.e2 63 77
drug
succinylcholine
DrugDDI.d383.s0.e3 80 94
drug
organophosphate
DrugDDI.d383.s0.e4 98 117
drug
carbamate insecticide

interaction DrugDDI.d383.s0.e0 DrugDDI.d383.s0.e1
interaction DrugDDI.d383.s0.e0 DrugDDI.d383.s0.e2
interaction DrugDDI.d383.s0.e0 DrugDDI.d383.s0.e3
interaction DrugDDI.d383.s0.e0 DrugDDI.d383.s0.e4

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s1
Patients undergoing systemic anticholinesterase treatment should be warned of the possible additive effects of Phospholine Iodide .

DrugDDI.d383.s1.e0 97 113
drug
Phospholine Iodide



Abstract Id: DrugDDI.d498
Sentence Id: DrugDDI.d498.s0
Care should be given when administering this drug to patients with symptoms of myasthenic weakness who are also on anticholinesterase drugs .

DrugDDI.d498.s0.e0 38 41
drug
drug
DrugDDI.d498.s0.e1 96 118
drug
anticholinesterase drugs

interaction DrugDDI.d498.s0.e0 DrugDDI.d498.s0.e1

Abstract Id: DrugDDI.d498
Sentence Id: DrugDDI.d498.s1
Since symptoms of anticholinesterase overdose (cholinergic crisis) may mimic underdosage (myasthenic weakness), their condition may be worsened by the use of this drug .

DrugDDI.d498.s1.e0 141 144
drug
drug



Abstract Id: DrugDDI.d523
Sentence Id: DrugDDI.d523.s0
No formal drug interaction studies have been performed with RAPTIVA .

DrugDDI.d523.s0.e0 51 57
drug
RAPTIVA



Abstract Id: DrugDDI.d523
Sentence Id: DrugDDI.d523.s1
RAPTIVA should not be used with other immunosuppressive drugs.

DrugDDI.d523.s1.e0 0 6
drug
RAPTIVA
DrugDDI.d523.s1.e1 31 47
drug
immunosuppressive

interaction DrugDDI.d523.s1.e0 DrugDDI.d523.s1.e1

Abstract Id: DrugDDI.d523
Sentence Id: DrugDDI.d523.s2
Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.

DrugDDI.d523.s2.e0 17 39
drug
live-attenuated vaccines
DrugDDI.d523.s2.e1 69 75
drug
RAPTIVA

interaction DrugDDI.d523.s2.e0 DrugDDI.d523.s2.e1

Abstract Id: DrugDDI.d523
Sentence Id: DrugDDI.d523.s3
Drug /Laboratory Test Interactions Increases in lymphocyte counts related to the pharmacologic mechanism of action are frequently observed during RAPTIVA treatment.

DrugDDI.d523.s3.e0 0 3
drug
Drug
DrugDDI.d523.s3.e1 127 133
drug
RAPTIVA



Abstract Id: DrugDDI.d296
Sentence Id: DrugDDI.d296.s0
The potential for drug interactions with EMTRIVA has been studied in combination with indinavir , stavudine , famciclovir , and tenofovir disoproxil fumarate .

DrugDDI.d296.s0.e0 35 41
drug
EMTRIVA
DrugDDI.d296.s0.e1 73 81
drug
indinavir
DrugDDI.d296.s0.e2 83 91
drug
stavudine
DrugDDI.d296.s0.e3 93 103
drug
famciclovir
DrugDDI.d296.s0.e4 108 134
drug
tenofovir disoproxil fumarate



Abstract Id: DrugDDI.d296
Sentence Id: DrugDDI.d296.s1
There were no clinically significant drug interactions for any of these drugs .

DrugDDI.d296.s1.e0 61 65
drug
drugs



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s0
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat .

DrugDDI.d337.s0.e0 48 56
drug
diuretics
DrugDDI.d337.s0.e1 206 214
drug
enalapril
DrugDDI.d337.s0.e2 217 227
drug
enalaprilat

interaction DrugDDI.d337.s0.e0 DrugDDI.d337.s0.e1
interaction DrugDDI.d337.s0.e0 DrugDDI.d337.s0.e2

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s1
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .

DrugDDI.d337.s1.e0 38 46
drug
enalapril
DrugDDI.d337.s1.e1 49 59
drug
enalaprilat
DrugDDI.d337.s1.e2 98 105
drug
diuretic
DrugDDI.d337.s1.e3 163 171
drug
enalapril
DrugDDI.d337.s1.e4 174 184
drug
enalaprilat



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s2
If it is necessary to continue the diuretic , provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour..

DrugDDI.d337.s2.e0 28 35
drug
diuretic



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s3
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics ).

DrugDDI.d337.s3.e0 13 17
drug
Renin
DrugDDI.d337.s3.e1 29 44
drug
antihypertensive
DrugDDI.d337.s3.e2 53 61
drug
enalapril
DrugDDI.d337.s3.e3 65 73
drug
enalapril
DrugDDI.d337.s3.e4 89 110
drug
antihypertensive agents
DrugDDI.d337.s3.e5 120 124
drug
renin
DrugDDI.d337.s3.e6 138 146
drug
diuretics

interaction DrugDDI.d337.s3.e1 DrugDDI.d337.s3.e3
interaction DrugDDI.d337.s3.e2 DrugDDI.d337.s3.e4

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s4
Non-steroidal Anti-inflammatory Agents : In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs , the co-administration of enalapril may result in a further deterioration of renal function.

DrugDDI.d337.s4.e0 0 35
drug
Non-steroidal Anti-inflammatory Agents
DrugDDI.d337.s4.e1 101 134
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d337.s4.e2 158 166
drug
enalapril

interaction DrugDDI.d337.s4.e1 DrugDDI.d337.s4.e2

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s6
In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC .

DrugDDI.d337.s6.e0 29 40
drug
indomethacin
DrugDDI.d337.s6.e1 43 50
drug
sulindac
DrugDDI.d337.s6.e2 97 103
drug
VASOTEC



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s7
In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC .

DrugDDI.d337.s7.e0 45 60
drug
antihypertensive
DrugDDI.d337.s7.e1 69 75
drug
VASOTEC



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s8
However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors .

DrugDDI.d337.s8.e0 26 31
drug
NSAIDs
DrugDDI.d337.s8.e1 46 61
drug
antihypertensive
DrugDDI.d337.s8.e2 70 82
drug
ACE inhibitors

interaction DrugDDI.d337.s8.e0 DrugDDI.d337.s8.e2

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s9
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors .

DrugDDI.d337.s9.e0 57 62
drug
NSAIDs
DrugDDI.d337.s9.e1 80 92
drug
ACE inhibitors

interaction DrugDDI.d337.s9.e0 DrugDDI.d337.s9.e1

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s10
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium -blocking agents, hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions.

DrugDDI.d337.s10.e0 5 24
drug
Cardiovascular Agents
DrugDDI.d337.s10.e1 26 34
drug
Enalapril
DrugDDI.d337.s10.e2 38 46
drug
enalapril
DrugDDI.d337.s10.e3 78 106
drug
beta adrenergic-blocking agents
DrugDDI.d337.s10.e4 108 117
drug
methyldopa
DrugDDI.d337.s10.e5 119 126
drug
nitrates
DrugDDI.d337.s10.e6 128 134
drug
calcium
DrugDDI.d337.s10.e7 151 161
drug
hydralazine
DrugDDI.d337.s10.e8 163 170
drug
prazosin
DrugDDI.d337.s10.e9 174 180
drug
digoxin



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s11
Enalapril IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.

DrugDDI.d337.s11.e0 0 8
drug
Enalapril
DrugDDI.d337.s11.e1 39 47
drug
digitalis



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s12
Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics .

DrugDDI.d337.s12.e0 31 39
drug
Enalapril
DrugDDI.d337.s12.e1 43 51
drug
enalapril
DrugDDI.d337.s12.e2 63 71
drug
potassium
DrugDDI.d337.s12.e3 84 105
drug
thiazide-type diuretics



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s13
Potassium-sparing diuretics (e.g., spironolactone , triamterene , or amiloride ), potassium supplement s, or potassium-containing salt substitutes may lead to significant increases in serum potassium.

DrugDDI.d337.s13.e0 0 25
drug
Potassium-sparing diuretics
DrugDDI.d337.s13.e1 32 45
drug
spironolactone
DrugDDI.d337.s13.e2 47 57
drug
triamterene
DrugDDI.d337.s13.e3 61 69
drug
amiloride
DrugDDI.d337.s13.e4 72 90
drug
potassium supplement
DrugDDI.d337.s13.e5 95 129
drug
potassium-containing salt substitutes



Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s15
Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril .

DrugDDI.d337.s15.e0 0 8
drug
Potassium
DrugDDI.d337.s15.e1 81 89
drug
enalapril

interaction DrugDDI.d337.s15.e0 DrugDDI.d337.s15.e1

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s16
Lithium : Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium , including ACE inhibitors .

DrugDDI.d337.s16.e0 0 6
drug
Lithium
DrugDDI.d337.s16.e1 57 63
drug
lithium
DrugDDI.d337.s16.e2 81 85
drug
drugs
DrugDDI.d337.s16.e3 109 114
drug
sodium
DrugDDI.d337.s16.e4 125 137
drug
ACE inhibitors

interaction DrugDDI.d337.s16.e1 DrugDDI.d337.s16.e2
interaction DrugDDI.d337.s16.e1 DrugDDI.d337.s16.e4

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s17
A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril / enalapril IV and lithium and were reversible upon discontinuation of both drugs .

DrugDDI.d337.s17.e0 72 80
drug
enalapril
DrugDDI.d337.s17.e1 82 90
drug
enalapril
DrugDDI.d337.s17.e2 96 102
drug
lithium
DrugDDI.d337.s17.e3 145 149
drug
drugs

interaction DrugDDI.d337.s17.e0 DrugDDI.d337.s17.e2
interaction DrugDDI.d337.s17.e1 DrugDDI.d337.s17.e2

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s18
It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium .

DrugDDI.d337.s18.e0 60 68
drug
enalapril
DrugDDI.d337.s18.e1 100 106
drug
lithium

interaction DrugDDI.d337.s18.e0 DrugDDI.d337.s18.e1

Abstract Id: DrugDDI.d42
Sentence Id: DrugDDI.d42.s0
The action of nondepolarizing relaxants is augmented by Enflurane .

DrugDDI.d42.s0.e0 48 56
drug
Enflurane



Abstract Id: DrugDDI.d42
Sentence Id: DrugDDI.d42.s1
Less than the usual amounts of these medicines should be used.

DrugDDI.d42.s1.e0 30 38
drug
medicines



Abstract Id: DrugDDI.d42
Sentence Id: DrugDDI.d42.s2
If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.

DrugDDI.d42.s2.e0 122 130
drug
Enflurane
DrugDDI.d42.s2.e1 139 147
drug
halothane
DrugDDI.d42.s2.e2 150 161
drug
nitrous oxide



Abstract Id: DrugDDI.d80
Sentence Id: DrugDDI.d80.s0
CYP450 Metabolized Drugs Results from in vitro and in vivo studies suggest that enfuvirtide is unlikely to have significant drug interactions with concomitantly administered drugs metabolized by CYP450 enzymes.

DrugDDI.d80.s0.e0 17 21
drug
Drugs
DrugDDI.d80.s0.e1 67 77
drug
enfuvirtide
DrugDDI.d80.s0.e2 150 154
drug
drugs



Abstract Id: DrugDDI.d80
Sentence Id: DrugDDI.d80.s1
Antiretroviral Agents No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication .

DrugDDI.d80.s1.e0 0 19
drug
Antiretroviral Agents
DrugDDI.d80.s1.e1 47 71
drug
antiretroviral medications
DrugDDI.d80.s1.e2 127 137
drug
enfuvirtide
DrugDDI.d80.s1.e3 161 184
drug
antiretroviral medication



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s0
Bismuth: Bismuth subsalicylate , given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.

DrugDDI.d328.s0.e0 8 27
drug
Bismuth subsalicylate
DrugDDI.d328.s0.e1 51 58
drug
enoxacin
DrugDDI.d328.s0.e2 79 86
drug
enoxacin
DrugDDI.d328.s0.e3 111 118
drug
enoxacin

interaction DrugDDI.d328.s0.e0 DrugDDI.d328.s0.e1

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s1
Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.

DrugDDI.d328.s1.e0 32 39
drug
enoxacin
DrugDDI.d328.s1.e1 43 62
drug
bismuth subsalicylate

interaction DrugDDI.d328.s1.e0 DrugDDI.d328.s1.e1

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s2
Caffeine : Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines .

DrugDDI.d328.s2.e0 0 7
drug
Caffeine
DrugDDI.d328.s2.e1 9 16
drug
Enoxacin
DrugDDI.d328.s2.e2 40 54
drug
cytochrome P-450
DrugDDI.d328.s2.e3 92 106
drug
methylxanthines



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s3
In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine , thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine .

DrugDDI.d328.s3.e0 22 29
drug
enoxacin
DrugDDI.d328.s3.e1 88 95
drug
caffeine
DrugDDI.d328.s3.e2 128 135
drug
caffeine
DrugDDI.d328.s3.e3 200 207
drug
caffeine

interaction DrugDDI.d328.s3.e0 DrugDDI.d328.s3.e1

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s4
Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.

DrugDDI.d328.s4.e0 12 19
drug
enoxacin
DrugDDI.d328.s4.e1 47 54
drug
caffeine
DrugDDI.d328.s4.e2 58 65
drug
enoxacin

interaction DrugDDI.d328.s4.e1 DrugDDI.d328.s4.e2

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s5
Caffeine -related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin .

DrugDDI.d328.s5.e0 0 7
drug
Caffeine
DrugDDI.d328.s5.e1 61 68
drug
caffeine
DrugDDI.d328.s5.e2 87 94
drug
enoxacin

interaction DrugDDI.d328.s5.e1 DrugDDI.d328.s5.e2

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s6
Cyclosporine : Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class .

DrugDDI.d328.s6.e0 0 11
drug
Cyclosporine
DrugDDI.d328.s6.e1 34 45
drug
cyclosporine
DrugDDI.d328.s6.e2 82 93
drug
cyclosporine
DrugDDI.d328.s6.e3 115 128
drug
quinolone class

interaction DrugDDI.d328.s6.e2 DrugDDI.d328.s6.e3

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s7
Digoxin : Enoxacin may raise serum digoxin levels in some individuals.

DrugDDI.d328.s7.e0 0 6
drug
Digoxin
DrugDDI.d328.s7.e1 8 15
drug
Enoxacin



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s8
If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.

DrugDDI.d328.s8.e0 54 61
drug
enoxacin
DrugDDI.d328.s8.e1 65 71
drug
digoxin

interaction DrugDDI.d328.s8.e0 DrugDDI.d328.s8.e1

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s9
Non-steroidal anti-inflammatory agents : Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.

DrugDDI.d328.s9.e0 0 35
drug
Non-steroidal anti-inflammatory agents
DrugDDI.d328.s9.e1 77 84
drug
enoxacin
DrugDDI.d328.s9.e2 105 137
drug
nonsteroidal anti-inflammatory drug

interaction DrugDDI.d328.s9.e1 DrugDDI.d328.s9.e2

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s10
Animal studies also suggest an increased potential for seizures when these two drugs are given concomitantly.

DrugDDI.d328.s10.e0 67 71
drug
drugs



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s11
Fenbufen is not approved in the United States at this time.

DrugDDI.d328.s11.e0 0 7
drug
Fenbufen



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s12
Sucralfate and antacids : Quinolones form chelates with metal cations .

DrugDDI.d328.s12.e0 0 9
drug
Sucralfate
DrugDDI.d328.s12.e1 13 20
drug
antacids
DrugDDI.d328.s12.e2 22 31
drug
Quinolones
DrugDDI.d328.s12.e3 53 59
drug
cations



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s13
Therefore, administration of quinolones with antacids containing calcium , magnesium , or aluminum; .

DrugDDI.d328.s13.e0 26 35
drug
quinolones
DrugDDI.d328.s13.e1 40 47
drug
antacids
DrugDDI.d328.s13.e2 58 64
drug
calcium
DrugDDI.d328.s13.e3 66 74
drug
magnesium



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s14
with sucralfate ; .

DrugDDI.d328.s14.e0 4 13
drug
sucralfate



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s15
with divalent or trivalent cations such as iron ; .

DrugDDI.d328.s15.e0 23 29
drug
cations
DrugDDI.d328.s15.e1 36 39
drug
iron



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s16
or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.

DrugDDI.d328.s16.e0 6 18
drug
multivitamins
DrugDDI.d328.s16.e1 29 32
drug
zinc
DrugDDI.d328.s16.e2 108 122
drug
tissue quinolone



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s17
Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.

DrugDDI.d328.s17.e0 0 7
drug
Antacids
DrugDDI.d328.s17.e1 18 34
drug
aluminum hydroxide
DrugDDI.d328.s17.e2 38 55
drug
magnesium hydroxide
DrugDDI.d328.s17.e3 81 88
drug
enoxacin

interaction DrugDDI.d328.s17.e0 DrugDDI.d328.s17.e3
interaction DrugDDI.d328.s17.e1 DrugDDI.d328.s17.e3
interaction DrugDDI.d328.s17.e2 DrugDDI.d328.s17.e3

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s18
The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine .

DrugDDI.d328.s18.e0 24 31
drug
enoxacin
DrugDDI.d328.s18.e1 68 77
drug
ranitidine

interaction DrugDDI.d328.s18.e0 DrugDDI.d328.s18.e1

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s19
These agents should not be taken for 8 hours before or for 2 hours after enoxacin administration.

DrugDDI.d328.s19.e0 58 65
drug
enoxacin



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s20
Theophylline : Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines .

DrugDDI.d328.s20.e0 0 11
drug
Theophylline
DrugDDI.d328.s20.e1 13 20
drug
Enoxacin
DrugDDI.d328.s20.e2 44 58
drug
cytochrome P-450
DrugDDI.d328.s20.e3 96 110
drug
methylxanthines



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s21
Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.

DrugDDI.d328.s21.e0 0 7
drug
Enoxacin
DrugDDI.d328.s21.e1 37 48
drug
theophylline
DrugDDI.d328.s21.e2 91 102
drug
theophylline

interaction DrugDDI.d328.s21.e0 DrugDDI.d328.s21.e1

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s22
Theophylline -related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.

DrugDDI.d328.s22.e0 0 11
drug
Theophylline
DrugDDI.d328.s22.e1 60 71
drug
theophylline
DrugDDI.d328.s22.e2 75 82
drug
enoxacin

interaction DrugDDI.d328.s22.e1 DrugDDI.d328.s22.e2

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s23
Warfarin : Quinolones , including enoxacin , decrease the clearance of R- warfarin , the less active isomer of racemic warfarin .

DrugDDI.d328.s23.e0 0 7
drug
Warfarin
DrugDDI.d328.s23.e1 9 18
drug
Quinolones
DrugDDI.d328.s23.e2 29 36
drug
enoxacin
DrugDDI.d328.s23.e3 62 69
drug
warfarin
DrugDDI.d328.s23.e4 99 106
drug
warfarin

interaction DrugDDI.d328.s23.e1 DrugDDI.d328.s23.e2
interaction DrugDDI.d328.s23.e1 DrugDDI.d328.s23.e3

Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s24
Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.

DrugDDI.d328.s24.e0 0 7
drug
Enoxacin
DrugDDI.d328.s24.e1 100 107
drug
enoxacin
DrugDDI.d328.s24.e2 111 118
drug
warfarin



Abstract Id: DrugDDI.d328
Sentence Id: DrugDDI.d328.s25
Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.

DrugDDI.d328.s25.e0 82 89
drug
warfarin
DrugDDI.d328.s25.e1 95 105
drug
derivatives
DrugDDI.d328.s25.e2 109 116
drug
enoxacin

interaction DrugDDI.d328.s25.e0 DrugDDI.d328.s25.e2
interaction DrugDDI.d328.s25.e1 DrugDDI.d328.s25.e2

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s0
Unless really needed, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox Injection therapy.

DrugDDI.d392.s0.e0 98 104
drug
Lovenox



Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s1
These agents include medications such as: anticoagulants , platelet inhibitors including acetylsalicylic acid , sali- cylate s, NSAIDs (including ketorolac tromethamine ), dipyridamole , or sulfinpyrazone .

DrugDDI.d392.s1.e0 18 28
drug
medications
DrugDDI.d392.s1.e1 36 49
drug
anticoagulants
DrugDDI.d392.s1.e2 51 68
drug
platelet inhibitors
DrugDDI.d392.s1.e3 78 96
drug
acetylsalicylic acid
DrugDDI.d392.s1.e4 103 108
drug
cylate
DrugDDI.d392.s1.e5 111 116
drug
NSAIDs
DrugDDI.d392.s1.e6 127 147
drug
ketorolac tromethamine
DrugDDI.d392.s1.e7 150 161
drug
dipyridamole
DrugDDI.d392.s1.e8 165 178
drug
sulfinpyrazone



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s0
In vitro studies of human CYP enzymes showed that entacapone inhibited the CYP enzyme s 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A only at very high concentrations (IC50 from 200 to over 1000 uM; .

DrugDDI.d455.s0.e0 21 23
drug
CYP
DrugDDI.d455.s0.e1 41 50
drug
entacapone
DrugDDI.d455.s0.e2 63 71
drug
CYP enzyme



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s3
Protein Binding: Entacapone is highly protein bound (98%).

DrugDDI.d455.s3.e0 15 24
drug
Entacapone
DrugDDI.d455.s3.e1 33 39
drug
protein



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s4
In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin , salicylic acid , phenylbutazone , and diazepam .

DrugDDI.d455.s4.e0 51 60
drug
entacapone
DrugDDI.d455.s4.e1 92 99
drug
warfarin
DrugDDI.d455.s4.e2 101 113
drug
salicylic acid
DrugDDI.d455.s4.e3 115 128
drug
phenylbutazone
DrugDDI.d455.s4.e4 133 140
drug
diazepam



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s5
Drugs Metabolized by Catechol-O-methyltransferase (COMT): Hormone levels: Levodopa is known to depress prolactin secretion and increase growth hormone levels.

DrugDDI.d455.s5.e0 0 4
drug
Drugs
DrugDDI.d455.s5.e1 18 45
drug
Catechol-O-methyltransferase
DrugDDI.d455.s5.e2 67 74
drug
Levodopa
DrugDDI.d455.s5.e3 91 99
drug
prolactin



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s6
Treatment with entacapone coadministered with levodopa / dopa decarboxylase inhibitor does not change these effects.

DrugDDI.d455.s6.e0 13 22
drug
entacapone
DrugDDI.d455.s6.e1 41 48
drug
levodopa
DrugDDI.d455.s6.e2 50 75
drug
dopa decarboxylase inhibitor



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s7
No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa / dopa decarboxylase inhibitor (n=29).

DrugDDI.d455.s7.e0 28 41
drug
MAO-B inhibitor
DrugDDI.d455.s7.e1 92 101
drug
entacapone
DrugDDI.d455.s7.e2 124 131
drug
levodopa
DrugDDI.d455.s7.e3 133 158
drug
dopa decarboxylase inhibitor



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s8
More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa / dopa decarboxylase inhibitor .

DrugDDI.d455.s8.e0 60 69
drug
selegiline
DrugDDI.d455.s8.e1 87 96
drug
entacapone
DrugDDI.d455.s8.e2 100 107
drug
levodopa
DrugDDI.d455.s8.e3 109 134
drug
dopa decarboxylase inhibitor



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s9
As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone .

DrugDDI.d455.s9.e0 6 15
drug
entacapone
DrugDDI.d455.s9.e1 66 70
drug
drugs
DrugDDI.d455.s9.e2 137 154
drug
beta-glucuronidase
DrugDDI.d455.s9.e3 179 188
drug
entacapone

interaction DrugDDI.d455.s9.e1 DrugDDI.d455.s9.e3

Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s10
These include probenecid , cholestyramine , and some antibiotics (e.g. erythromycin , rifamipicin, ampicillin and chloramphenicol ).

DrugDDI.d455.s10.e0 12 21
drug
probenecid
DrugDDI.d455.s10.e1 23 36
drug
cholestyramine
DrugDDI.d455.s10.e2 45 55
drug
antibiotics
DrugDDI.d455.s10.e3 61 72
drug
erythromycin
DrugDDI.d455.s10.e4 86 95
drug
ampicillin
DrugDDI.d455.s10.e5 99 113
drug
chloramphenicol



Abstract Id: DrugDDI.d455
Sentence Id: DrugDDI.d455.s11
No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa / dopa-decarboxylase inhibitor .

DrugDDI.d455.s11.e0 20 42
drug
tricyclic antidepressant
DrugDDI.d455.s11.e1 84 93
drug
entacapone
DrugDDI.d455.s11.e2 115 122
drug
levodopa
DrugDDI.d455.s11.e3 124 150
drug
dopa-decarboxylase inhibitor



Abstract Id: DrugDDI.d58
Sentence Id: DrugDDI.d58.s0
Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug .

DrugDDI.d58.s0.e0 5 13
drug
entecavir
DrugDDI.d58.s0.e1 66 74
drug
BARACLUDE
DrugDDI.d58.s0.e2 79 83
drug
drugs
DrugDDI.d58.s0.e3 109 115
drug
compete
DrugDDI.d58.s0.e4 179 187
drug
entecavir
DrugDDI.d58.s0.e5 207 210
drug
drug

interaction DrugDDI.d58.s0.e1 DrugDDI.d58.s0.e2

Abstract Id: DrugDDI.d58
Sentence Id: DrugDDI.d58.s1
Coadministration of entecavir with lamivudine , adefovir dipivoxil ,or tenofovir disoproxil fumarate did not result in significant drug interactions.

DrugDDI.d58.s1.e0 18 26
drug
entecavir
DrugDDI.d58.s1.e1 31 40
drug
lamivudine
DrugDDI.d58.s1.e2 42 58
drug
adefovir dipivoxil
DrugDDI.d58.s1.e3 62 88
drug
tenofovir disoproxil fumarate



Abstract Id: DrugDDI.d58
Sentence Id: DrugDDI.d58.s2
The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs .

DrugDDI.d58.s2.e0 30 38
drug
BARACLUDE
DrugDDI.d58.s2.e1 48 52
drug
drugs
DrugDDI.d58.s2.e2 184 192
drug
BARACLUDE
DrugDDI.d58.s2.e3 217 221
drug
drugs

interaction DrugDDI.d58.s2.e2 DrugDDI.d58.s2.e3

Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s0
Epinephrine should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias.

DrugDDI.d402.s0.e0 0 10
drug
Epinephrine



Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s1
All vasopressor s should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.

DrugDDI.d402.s1.e0 3 13
drug
vasopressor
DrugDDI.d402.s1.e1 53 68
drug
monoamine oxidase

interaction DrugDDI.d402.s1.e0 DrugDDI.d402.s1.e1

Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s2
Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol ) because of possible additive effects and increased toxicity.

DrugDDI.d402.s2.e0 0 10
drug
Epinephrine
DrugDDI.d402.s2.e1 56 75
drug
sympathomimetic drugs
DrugDDI.d402.s2.e2 83 95
drug
isoproterenol

interaction DrugDDI.d402.s2.e0 DrugDDI.d402.s2.e1
interaction DrugDDI.d402.s2.e0 DrugDDI.d402.s2.e2

Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s4
They may be administered alternately when the preceding effect of other such drug has subsided.

DrugDDI.d402.s4.e0 65 68
drug
drug



Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s5
Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..

DrugDDI.d402.s5.e0 16 26
drug
epinephrine
DrugDDI.d402.s5.e1 46 57
drug
cyclopropane
DrugDDI.d402.s5.e2 60 99
drug
halogenated hydrocarbon general anesthetics
DrugDDI.d402.s5.e3 106 114
drug
halothane

interaction DrugDDI.d402.s5.e0 DrugDDI.d402.s5.e1
interaction DrugDDI.d402.s5.e0 DrugDDI.d402.s5.e2
interaction DrugDDI.d402.s5.e0 DrugDDI.d402.s5.e3

Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s6
When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug .

DrugDDI.d402.s6.e0 60 86
drug
beta-adrenergic blocking drug



Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s7
Epinephrine also should be used cautiously with other drugs (e.g., digitalis , glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs .

DrugDDI.d402.s7.e0 0 10
drug
Epinephrine
DrugDDI.d402.s7.e1 46 50
drug
drugs
DrugDDI.d402.s7.e2 57 65
drug
digitalis
DrugDDI.d402.s7.e3 118 137
drug
sympathomimetic drugs

interaction DrugDDI.d402.s7.e0 DrugDDI.d402.s7.e1
interaction DrugDDI.d402.s7.e0 DrugDDI.d402.s7.e2

Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s8
Diuretic agents may decrease vascular response to pressor drugs such as epinephrine .

DrugDDI.d402.s8.e0 0 7
drug
Diuretic
DrugDDI.d402.s8.e1 43 54
drug
pressor drugs
DrugDDI.d402.s8.e2 61 71
drug
epinephrine

interaction DrugDDI.d402.s8.e0 DrugDDI.d402.s8.e1
interaction DrugDDI.d402.s8.e0 DrugDDI.d402.s8.e2

Abstract Id: DrugDDI.d402
Sentence Id: DrugDDI.d402.s9
Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.

DrugDDI.d402.s9.e0 0 10
drug
Epinephrine
DrugDDI.d402.s9.e1 51 62
drug
guanethidine
DrugDDI.d402.s9.e2 83 98
drug
antihypertensive

interaction DrugDDI.d402.s9.e0 DrugDDI.d402.s9.e1

Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s0
ELLENCE when used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects.

DrugDDI.d406.s0.e0 0 6
drug
ELLENCE
DrugDDI.d406.s0.e1 32 50
drug
other cytotoxic drugs

interaction DrugDDI.d406.s0.e0 DrugDDI.d406.s0.e1

Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s1
Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers ), requires close monitoring of cardiac function throughout treatment.

DrugDDI.d406.s1.e0 16 22
drug
ELLENCE
DrugDDI.d406.s1.e1 85 106
drug
calcium channel blockers

interaction DrugDDI.d406.s1.e0 DrugDDI.d406.s1.e1

Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s2
There are few data regarding the coadministration of radiation therapy and epirubicin .

DrugDDI.d406.s2.e0 64 73
drug
epirubicin



Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s3
In adjuvant trials of epirubicin -containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed.

DrugDDI.d406.s3.e0 18 27
drug
epirubicin



Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s5
A small number of patients received epirubicin -based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities.

DrugDDI.d406.s5.e0 30 39
drug
epirubicin



Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s6
It is likely that use of epirubicin with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation.

DrugDDI.d406.s6.e0 19 28
drug
epirubicin



Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s7
Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation.

DrugDDI.d406.s7.e0 16 22
drug
ELLENCE



Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s8
Epirubicin is extensively metabolized by the liver .

DrugDDI.d406.s8.e0 0 9
drug
Epirubicin
DrugDDI.d406.s8.e1 39 43
drug
liver



Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s9
Changes in hepatic function induced by concomitant therapies may affect epirubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity.

DrugDDI.d406.s9.e0 62 71
drug
epirubicin



Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s10
Cimetidine increased the AUC of epirubicin by 50%.

DrugDDI.d406.s10.e0 0 9
drug
Cimetidine
DrugDDI.d406.s10.e1 27 36
drug
epirubicin

interaction DrugDDI.d406.s10.e0 DrugDDI.d406.s10.e1

Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s11
Cimetidine treatment should be stopped during treatment with ELLENCE .

DrugDDI.d406.s11.e0 0 9
drug
Cimetidine
DrugDDI.d406.s11.e1 53 59
drug
ELLENCE

interaction DrugDDI.d406.s11.e0 DrugDDI.d406.s11.e1

Abstract Id: DrugDDI.d406
Sentence Id: DrugDDI.d406.s12
Drug-Laboratory Test Interactions There are no known interactions between ELLENCE and laboratory tests.

DrugDDI.d406.s12.e0 65 71
drug
ELLENCE



Abstract Id: DrugDDI.d547
Sentence Id: DrugDDI.d547.s0
No evidence of interaction of PROCRIT with other drugs was observed in the course of clinical trials. ?

DrugDDI.d547.s0.e0 25 31
drug
PROCRIT
DrugDDI.d547.s0.e1 41 45
drug
drugs



Abstract Id: DrugDDI.d435
Sentence Id: DrugDDI.d435.s0
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics , antihypertensive agents , or other vasodilators .

DrugDDI.d435.s0.e0 47 52
drug
FLOLAN
DrugDDI.d435.s0.e1 71 79
drug
diuretics
DrugDDI.d435.s0.e2 81 102
drug
antihypertensive agents
DrugDDI.d435.s0.e3 111 122
drug
vasodilators

interaction DrugDDI.d435.s0.e0 DrugDDI.d435.s0.e1
interaction DrugDDI.d435.s0.e0 DrugDDI.d435.s0.e2
interaction DrugDDI.d435.s0.e0 DrugDDI.d435.s0.e3

Abstract Id: DrugDDI.d435
Sentence Id: DrugDDI.d435.s1
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.

DrugDDI.d435.s1.e0 9 26
drug
antiplatelet agents
DrugDDI.d435.s1.e1 29 42
drug
anticoagulants
DrugDDI.d435.s1.e2 86 91
drug
FLOLAN

interaction DrugDDI.d435.s1.e0 DrugDDI.d435.s1.e2
interaction DrugDDI.d435.s1.e1 DrugDDI.d435.s1.e2

Abstract Id: DrugDDI.d435
Sentence Id: DrugDDI.d435.s2
However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.

DrugDDI.d435.s2.e0 36 41
drug
FLOLAN
DrugDDI.d435.s2.e1 74 87
drug
anticoagulants



Abstract Id: DrugDDI.d435
Sentence Id: DrugDDI.d435.s3
In clinical trials, FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen .In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.

DrugDDI.d435.s3.e0 17 22
drug
FLOLAN
DrugDDI.d435.s3.e1 34 40
drug
digoxin
DrugDDI.d435.s3.e2 42 50
drug
diuretics
DrugDDI.d435.s3.e3 52 65
drug
anticoagulants
DrugDDI.d435.s3.e4 71 82
drug
vasodilators
DrugDDI.d435.s3.e5 99 104
drug
oxygen
DrugDDI.d435.s3.e6 177 186
drug
furosemide
DrugDDI.d435.s3.e7 189 195
drug
digoxin
DrugDDI.d435.s3.e8 213 218
drug
FLOLAN
DrugDDI.d435.s3.e9 262 271
drug
furosemide
DrugDDI.d435.s3.e10 281 287
drug
digoxin

interaction DrugDDI.d435.s3.e6 DrugDDI.d435.s3.e8
interaction DrugDDI.d435.s3.e7 DrugDDI.d435.s3.e8

Abstract Id: DrugDDI.d435
Sentence Id: DrugDDI.d435.s4
The change in furosemide clearance value is not likely to be clinically significant.

DrugDDI.d435.s4.e0 11 20
drug
furosemide



Abstract Id: DrugDDI.d435
Sentence Id: DrugDDI.d435.s5
However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN , which may be clinically significant in patients prone to digoxin toxicity.

DrugDDI.d435.s5.e0 18 24
drug
digoxin
DrugDDI.d435.s5.e1 44 50
drug
digoxin
DrugDDI.d435.s5.e2 93 98
drug
FLOLAN

interaction DrugDDI.d435.s5.e0 DrugDDI.d435.s5.e2

Abstract Id: DrugDDI.d486
Sentence Id: DrugDDI.d486.s0
Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide .

DrugDDI.d486.s0.e0 0 9
drug
Eprosartan
DrugDDI.d486.s0.e1 59 65
drug
digoxin
DrugDDI.d486.s0.e2 90 97
drug
warfarin
DrugDDI.d486.s0.e3 101 109
drug
glyburide



Abstract Id: DrugDDI.d486
Sentence Id: DrugDDI.d486.s2
Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.

DrugDDI.d486.s2.e0 7 16
drug
eprosartan
DrugDDI.d486.s2.e1 38 51
drug
cytochrome P450
DrugDDI.d486.s2.e2 126 137
drug
ketoconazole
DrugDDI.d486.s2.e3 141 151
drug
fluconazole
DrugDDI.d486.s2.e4 171 175
drug
CYP3A
DrugDDI.d486.s2.e5 225 234
drug
eprosartan



Abstract Id: DrugDDI.d486
Sentence Id: DrugDDI.d486.s3
Ranitidine also has no effect on eprosartan pharmacokinetics.

DrugDDI.d486.s3.e0 0 9
drug
Ranitidine
DrugDDI.d486.s3.e1 27 36
drug
eprosartan



Abstract Id: DrugDDI.d486
Sentence Id: DrugDDI.d486.s4
Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic ( hydrochlorothiazide ).

DrugDDI.d486.s4.e0 0 9
drug
Eprosartan
DrugDDI.d486.s4.e1 79 94
drug
thiazide diuretic
DrugDDI.d486.s4.e2 96 114
drug
hydrochlorothiazide



Abstract Id: DrugDDI.d486
Sentence Id: DrugDDI.d486.s5
Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine ) with no clinically significant adverse interactions.

DrugDDI.d486.s5.e0 0 9
drug
Eprosartan
DrugDDI.d486.s5.e1 84 105
drug
calcium channel blockers
DrugDDI.d486.s5.e2 124 133
drug
nifedipine



Abstract Id: DrugDDI.d477
Sentence Id: DrugDDI.d477.s0
Enoxaparin dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of eptifibatide or the level of platelet aggregation in healthy adults.

DrugDDI.d477.s0.e0 0 9
drug
Enoxaparin
DrugDDI.d477.s0.e1 95 106
drug
eptifibatide



Abstract Id: DrugDDI.d525
Sentence Id: DrugDDI.d525.s0
Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations .

DrugDDI.d525.s0.e0 0 9
drug
Mineral oil
DrugDDI.d525.s0.e1 68 87
drug
vitamin D preparations

interaction DrugDDI.d525.s0.e0 DrugDDI.d525.s0.e1

Abstract Id: DrugDDI.d525
Sentence Id: DrugDDI.d525.s1
Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.

DrugDDI.d525.s1.e0 16 32
drug
thiazide diuretics
DrugDDI.d525.s1.e1 92 105
drug
ergocalciferol

interaction DrugDDI.d525.s1.e0 DrugDDI.d525.s1.e1

Abstract Id: DrugDDI.d214
Sentence Id: DrugDDI.d214.s0
The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine .

DrugDDI.d214.s0.e0 12 18
drug
ERGOMAR
DrugDDI.d214.s0.e1 37 57
drug
triacetyloleandomycin
DrugDDI.d214.s0.e2 86 95
drug
ergotamine

interaction DrugDDI.d214.s0.e0 DrugDDI.d214.s0.e1

Abstract Id: DrugDDI.d214
Sentence Id: DrugDDI.d214.s1
The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.

DrugDDI.d214.s1.e0 3 16
drug
pressor effects
DrugDDI.d214.s1.e1 19 25
drug
ERGOMAR
DrugDDI.d214.s1.e2 34 53
drug
vasoconstrictor drugs

interaction DrugDDI.d214.s1.e1 DrugDDI.d214.s1.e2

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s0
Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.

DrugDDI.d393.s0.e0 0 11
drug
Erythromycin
DrugDDI.d393.s0.e1 51 62
drug
theophylline

interaction DrugDDI.d393.s0.e0 DrugDDI.d393.s0.e1

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s1
In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.

DrugDDI.d393.s1.e0 8 19
drug
theophylline
DrugDDI.d393.s1.e1 139 150
drug
erythromycin

interaction DrugDDI.d393.s1.e0 DrugDDI.d393.s1.e1

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s2
Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.

DrugDDI.d393.s2.e0 27 38
drug
erythromycin
DrugDDI.d393.s2.e1 42 48
drug
digoxin

interaction DrugDDI.d393.s2.e0 DrugDDI.d393.s2.e1

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s3
There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.

DrugDDI.d393.s3.e0 55 66
drug
erythromycin
DrugDDI.d393.s3.e1 70 87
drug
oral anticoagulants

interaction DrugDDI.d393.s3.e0 DrugDDI.d393.s3.e1

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s4
Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulents may be more pronounced in the elderly.

DrugDDI.d393.s4.e0 50 61
drug
erythromycin



Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s5
Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

DrugDDI.d393.s5.e0 15 26
drug
erythromycin
DrugDDI.d393.s5.e1 30 39
drug
ergotamine
DrugDDI.d393.s5.e2 42 58
drug
dihydroergotamine
DrugDDI.d393.s5.e3 99 103
drug
ergot

interaction DrugDDI.d393.s5.e0 DrugDDI.d393.s5.e1
interaction DrugDDI.d393.s5.e0 DrugDDI.d393.s5.e2

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s6
Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines .

DrugDDI.d393.s6.e0 0 11
drug
Erythromycin
DrugDDI.d393.s6.e1 51 59
drug
triazolam
DrugDDI.d393.s6.e2 63 71
drug
midazolam
DrugDDI.d393.s6.e3 119 133
drug
benzodiazepines

interaction DrugDDI.d393.s6.e0 DrugDDI.d393.s6.e1
interaction DrugDDI.d393.s6.e0 DrugDDI.d393.s6.e2
interaction DrugDDI.d393.s6.e0 DrugDDI.d393.s6.e3

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s7
The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs .

DrugDDI.d393.s7.e0 8 19
drug
erythromycin
DrugDDI.d393.s7.e1 48 52
drug
drugs
DrugDDI.d393.s7.e2 69 82
drug
cytochrome P450
DrugDDI.d393.s7.e3 143 147
drug
drugs

interaction DrugDDI.d393.s7.e0 DrugDDI.d393.s7.e1

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s8
There have been reports of interactions of erythromycin with carbamazepine , cyclosporine , tacrolimus , hexobarbital , phenytoin , alfentanil , cisapride , disopyramide , lovastatin , bromocriptine , valproate , terfenadine , and astemizole .

DrugDDI.d393.s8.e0 36 47
drug
erythromycin
DrugDDI.d393.s8.e1 52 64
drug
carbamazepine
DrugDDI.d393.s8.e2 66 77
drug
cyclosporine
DrugDDI.d393.s8.e3 79 88
drug
tacrolimus
DrugDDI.d393.s8.e4 90 101
drug
hexobarbital
DrugDDI.d393.s8.e5 103 111
drug
phenytoin
DrugDDI.d393.s8.e6 113 122
drug
alfentanil
DrugDDI.d393.s8.e7 124 132
drug
cisapride
DrugDDI.d393.s8.e8 134 145
drug
disopyramide
DrugDDI.d393.s8.e9 147 156
drug
lovastatin
DrugDDI.d393.s8.e10 158 170
drug
bromocriptine
DrugDDI.d393.s8.e11 172 180
drug
valproate
DrugDDI.d393.s8.e12 182 192
drug
terfenadine
DrugDDI.d393.s8.e13 197 206
drug
astemizole

interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e1
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e2
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e3
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e4
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e5
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e6
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e7
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e8
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e9
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e10
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e11
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e12
interaction DrugDDI.d393.s8.e0 DrugDDI.d393.s8.e13

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s9
Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin .

DrugDDI.d393.s9.e0 21 25
drug
drugs
DrugDDI.d393.s9.e1 42 55
drug
cytochrome P450
DrugDDI.d393.s9.e2 117 128
drug
erythromycin

interaction DrugDDI.d393.s9.e0 DrugDDI.d393.s9.e2

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s10
Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.

DrugDDI.d393.s10.e0 0 11
drug
Erythromycin
DrugDDI.d393.s10.e1 73 86
drug
antihistamines
DrugDDI.d393.s10.e2 101 110
drug
astemizole

interaction DrugDDI.d393.s10.e0 DrugDDI.d393.s10.e1
interaction DrugDDI.d393.s10.e0 DrugDDI.d393.s10.e2

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s12
In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin .

DrugDDI.d393.s12.e0 70 80
drug
terfenadine
DrugDDI.d393.s12.e1 84 95
drug
erythromycin

interaction DrugDDI.d393.s12.e0 DrugDDI.d393.s12.e1

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s13
There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride , resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin .

DrugDDI.d393.s13.e0 55 66
drug
erythromycin
DrugDDI.d393.s13.e1 87 95
drug
cisapride
DrugDDI.d393.s13.e2 252 260
drug
cisapride
DrugDDI.d393.s13.e3 263 274
drug
erythromycin

interaction DrugDDI.d393.s13.e0 DrugDDI.d393.s13.e1

Abstract Id: DrugDDI.d393
Sentence Id: DrugDDI.d393.s15
Patients receiving concomitant lovastatin and erythromycin should be carefully monitored; .

DrugDDI.d393.s15.e0 28 37
drug
lovastatin
DrugDDI.d393.s15.e1 41 52
drug
erythromycin

interaction DrugDDI.d393.s15.e0 DrugDDI.d393.s15.e1

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s0
CNS Drug s - Given the primary CNS effects of escitalopram , caution should be used when it is taken in combination with other centrally acting drugs .

DrugDDI.d413.s0.e0 0 6
drug
CNS Drug
DrugDDI.d413.s0.e1 36 47
drug
escitalopram
DrugDDI.d413.s0.e2 103 122
drug
centrally acting drugs

interaction DrugDDI.d413.s0.e1 DrugDDI.d413.s0.e2

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s1
Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications , the use of alcohol by patients taking LEXAPRO is not recommended.

DrugDDI.d413.s1.e0 0 6
drug
Alcohol
DrugDDI.d413.s1.e1 16 22
drug
LEXAPRO
DrugDDI.d413.s1.e2 68 74
drug
alcohol
DrugDDI.d413.s1.e3 103 125
drug
psychotropic medications
DrugDDI.d413.s1.e4 135 141
drug
alcohol
DrugDDI.d413.s1.e5 158 164
drug
LEXAPRO

interaction DrugDDI.d413.s1.e1 DrugDDI.d413.s1.e4

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s2
Monoamine Oxidase Inhibitors (MAOIs) - See Contraindications and  a href= lexapro _wcp.htm#W Warnings.

DrugDDI.d413.s2.e0 0 25
drug
Monoamine Oxidase Inhibitors
DrugDDI.d413.s2.e1 63 69
drug
lexapro



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s3
Drugs That Interfere With Hemostasis ( NSAIDs , Aspirin , Warfarin , etc.) .

DrugDDI.d413.s3.e0 0 4
drug
Drugs
DrugDDI.d413.s3.e1 33 38
drug
NSAIDs
DrugDDI.d413.s3.e2 40 46
drug
Aspirin
DrugDDI.d413.s3.e3 48 55
drug
Warfarin



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s5
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.

DrugDDI.d413.s5.e0 99 115
drug
psychotropic drugs
DrugDDI.d413.s5.e1 231 235
drug
NSAID
DrugDDI.d413.s5.e2 238 244
drug
aspirin

interaction DrugDDI.d413.s5.e0 DrugDDI.d413.s5.e1
interaction DrugDDI.d413.s5.e0 DrugDDI.d413.s5.e2

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s6
Thus, patients should be cautioned about the use of such drugs concurrently with LEXAPRO .

DrugDDI.d413.s6.e0 47 51
drug
drugs
DrugDDI.d413.s6.e1 68 74
drug
LEXAPRO

interaction DrugDDI.d413.s6.e0 DrugDDI.d413.s6.e1

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s7
Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram , combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.

DrugDDI.d413.s7.e0 0 9
drug
Cimetidine
DrugDDI.d413.s7.e1 58 67
drug
citalopram
DrugDDI.d413.s7.e2 102 111
drug
cimetidine
DrugDDI.d413.s7.e3 142 151
drug
citalopram

interaction DrugDDI.d413.s7.e1 DrugDDI.d413.s7.e2

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s9
Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram , combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin .

DrugDDI.d413.s9.e0 0 6
drug
Digoxin
DrugDDI.d413.s9.e1 55 64
drug
citalopram
DrugDDI.d413.s9.e2 90 99
drug
citalopram
DrugDDI.d413.s9.e3 103 109
drug
digoxin
DrugDDI.d413.s9.e4 179 188
drug
citalopram
DrugDDI.d413.s9.e5 191 197
drug
digoxin



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s10
Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium .

DrugDDI.d413.s10.e0 0 6
drug
Lithium
DrugDDI.d413.s10.e1 33 42
drug
citalopram
DrugDDI.d413.s10.e2 65 71
drug
lithium
DrugDDI.d413.s10.e3 137 146
drug
citalopram
DrugDDI.d413.s10.e4 149 155
drug
lithium



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s12
Because lithium may enhance the serotonergic effects of escitalopram , caution should be exercised when LEXAPRO and lithium are coadministered.

DrugDDI.d413.s12.e0 7 13
drug
lithium
DrugDDI.d413.s12.e1 48 59
drug
escitalopram
DrugDDI.d413.s12.e2 89 95
drug
LEXAPRO
DrugDDI.d413.s12.e3 99 105
drug
lithium

interaction DrugDDI.d413.s12.e0 DrugDDI.d413.s12.e1
interaction DrugDDI.d413.s12.e2 DrugDDI.d413.s12.e3

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s13
Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.

DrugDDI.d413.s13.e0 0 7
drug
Pimozide
DrugDDI.d413.s13.e1 11 16
drug
Celexa
DrugDDI.d413.s13.e2 50 60
drug
pimozide 2 mg
DrugDDI.d413.s13.e3 87 100
drug
citalopram 40 mg
DrugDDI.d413.s13.e4 196 203
drug
pimozide

interaction DrugDDI.d413.s13.e2 DrugDDI.d413.s13.e3

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s14
Racemic citalopram did not alter the mean AUC or Cmax of pimozide .

DrugDDI.d413.s14.e0 7 16
drug
citalopram
DrugDDI.d413.s14.e1 46 53
drug
pimozide



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s16
Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan .

DrugDDI.d413.s16.e0 0 10
drug
Sumatriptan
DrugDDI.d413.s16.e1 138 163
drug
serotonin reuptake inhibitor
DrugDDI.d413.s16.e2 173 183
drug
sumatriptan

interaction DrugDDI.d413.s16.e1 DrugDDI.d413.s16.e2

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s17
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine , fluvoxamine , paroxetine , sertraline , citalopram , escitalopram ) is clinically warranted, appropriate observation of the patient is advised.

DrugDDI.d413.s17.e0 26 36
drug
sumatriptan
DrugDDI.d413.s17.e1 52 61
drug
fluoxetine
DrugDDI.d413.s17.e2 63 73
drug
fluvoxamine
DrugDDI.d413.s17.e3 75 84
drug
paroxetine
DrugDDI.d413.s17.e4 86 95
drug
sertraline
DrugDDI.d413.s17.e5 97 106
drug
citalopram
DrugDDI.d413.s17.e6 108 119
drug
escitalopram

interaction DrugDDI.d413.s17.e0 DrugDDI.d413.s17.e1
interaction DrugDDI.d413.s17.e0 DrugDDI.d413.s17.e2
interaction DrugDDI.d413.s17.e0 DrugDDI.d413.s17.e3
interaction DrugDDI.d413.s17.e0 DrugDDI.d413.s17.e4
interaction DrugDDI.d413.s17.e0 DrugDDI.d413.s17.e5
interaction DrugDDI.d413.s17.e0 DrugDDI.d413.s17.e6

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s18
Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline .

DrugDDI.d413.s18.e0 0 11
drug
Theophylline
DrugDDI.d413.s18.e1 44 53
drug
citalopram
DrugDDI.d413.s18.e2 94 105
drug
theophylline
DrugDDI.d413.s18.e3 158 169
drug
theophylline



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s19
The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.

DrugDDI.d413.s19.e0 11 22
drug
theophylline
DrugDDI.d413.s19.e1 46 55
drug
citalopram



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s20
Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin , a CYP3A4 substrate.

DrugDDI.d413.s20.e0 0 7
drug
Warfarin
DrugDDI.d413.s20.e1 40 49
drug
citalopram
DrugDDI.d413.s20.e2 92 99
drug
warfarin
DrugDDI.d413.s20.e3 102 107
drug
CYP3A4



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s22
Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine , a CYP3A4 substrate.

DrugDDI.d413.s22.e0 0 12
drug
Carbamazepine
DrugDDI.d413.s22.e1 45 54
drug
citalopram
DrugDDI.d413.s22.e2 77 89
drug
carbamazepine
DrugDDI.d413.s22.e3 166 178
drug
carbamazepine
DrugDDI.d413.s22.e4 181 186
drug
CYP3A4



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s23
Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine , the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.

DrugDDI.d413.s23.e0 14 23
drug
citalopram
DrugDDI.d413.s23.e1 86 98
drug
carbamazepine
DrugDDI.d413.s23.e2 118 130
drug
carbamazepine
DrugDDI.d413.s23.e3 158 169
drug
escitalopram
DrugDDI.d413.s23.e4 196 200
drug
drugs

interaction DrugDDI.d413.s23.e2 DrugDDI.d413.s23.e3

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s24
Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam .

DrugDDI.d413.s24.e0 0 8
drug
Triazolam
DrugDDI.d413.s24.e1 41 50
drug
citalopram
DrugDDI.d413.s24.e2 101 109
drug
triazolam
DrugDDI.d413.s24.e3 182 191
drug
citalopram
DrugDDI.d413.s24.e4 194 202
drug
triazolam



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s25
Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram .

DrugDDI.d413.s25.e0 0 11
drug
Ketoconazole
DrugDDI.d413.s25.e1 44 53
drug
citalopram
DrugDDI.d413.s25.e2 63 74
drug
ketoconazole
DrugDDI.d413.s25.e3 106 117
drug
ketoconazole
DrugDDI.d413.s25.e4 192 201
drug
citalopram

interaction DrugDDI.d413.s25.e1 DrugDDI.d413.s25.e2

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s26
Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4 , and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram .

DrugDDI.d413.s26.e0 0 8
drug
Ritonavir
DrugDDI.d413.s26.e1 47 55
drug
ritonavir
DrugDDI.d413.s26.e2 69 74
drug
CYP3A4
DrugDDI.d413.s26.e3 105 110
drug
CYP3A4
DrugDDI.d413.s26.e4 115 126
drug
escitalopram
DrugDDI.d413.s26.e5 172 180
drug
ritonavir
DrugDDI.d413.s26.e6 183 194
drug
escitalopram



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s27
CYP3A4 and -2C19 Inhibitors - In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram .

DrugDDI.d413.s27.e0 0 5
drug
CYP3A4
DrugDDI.d413.s27.e1 52 57
drug
CYP3A4
DrugDDI.d413.s27.e2 111 122
drug
escitalopram



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s28
However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4 , did not significantly affect the pharmacokinetics of escitalopram .

DrugDDI.d413.s28.e0 26 37
drug
escitalopram
DrugDDI.d413.s28.e1 47 55
drug
ritonavir
DrugDDI.d413.s28.e2 82 87
drug
CYP3A4
DrugDDI.d413.s28.e3 135 146
drug
escitalopram



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s29
Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.

DrugDDI.d413.s29.e0 7 18
drug
escitalopram
DrugDDI.d413.s29.e1 106 117
drug
escitalopram



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s30
Drugs Metabolized by Cytochrome P4502D6 - In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6 .

DrugDDI.d413.s30.e0 0 4
drug
Drugs
DrugDDI.d413.s30.e1 18 27
drug
Cytochrome
DrugDDI.d413.s30.e2 82 93
drug
escitalopram
DrugDDI.d413.s30.e3 96 101
drug
CYP2D6



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s31
In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram , suggesting that coadministration, with escitalopram , of a drug that inhibits CYP2D6 , is unlikely to have clinically significant effects on escitalopram metabolism.

DrugDDI.d413.s31.e0 37 46
drug
citalopram
DrugDDI.d413.s31.e1 106 111
drug
CYP2D6
DrugDDI.d413.s31.e2 158 167
drug
citalopram
DrugDDI.d413.s31.e3 204 215
drug
escitalopram
DrugDDI.d413.s31.e4 220 223
drug
drug
DrugDDI.d413.s31.e5 236 241
drug
CYP2D6
DrugDDI.d413.s31.e6 289 300
drug
escitalopram



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s32
However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram , i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6 , resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine .

DrugDDI.d413.s32.e0 50 55
drug
CYP2D6
DrugDDI.d413.s32.e1 75 86
drug
escitalopram
DrugDDI.d413.s32.e2 111 122
drug
escitalopram
DrugDDI.d413.s32.e3 149 171
drug
tricyclic antidepressant
DrugDDI.d413.s32.e4 215 220
drug
CYP2D6
DrugDDI.d413.s32.e5 273 283
drug
desipramine

interaction DrugDDI.d413.s32.e2 DrugDDI.d413.s32.e3

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s34
Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6 .

DrugDDI.d413.s34.e0 54 65
drug
escitalopram
DrugDDI.d413.s34.e1 69 73
drug
drugs
DrugDDI.d413.s34.e2 87 92
drug
CYP2D6

interaction DrugDDI.d413.s34.e0 DrugDDI.d413.s34.e1

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s35
Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).

DrugDDI.d413.s35.e0 0 9
drug
Metoprolol
DrugDDI.d413.s35.e1 35 41
drug
LEXAPRO
DrugDDI.d413.s35.e2 122 153
drug
beta-adrenergic blocker metoprolol

interaction DrugDDI.d413.s35.e1 DrugDDI.d413.s35.e2

Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s36
Increased metoprolol plasma levels have been associated with decreased cardioselectivity.

DrugDDI.d413.s36.e0 9 18
drug
metoprolol



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s37
Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.

DrugDDI.d413.s37.e0 18 24
drug
LEXAPRO
DrugDDI.d413.s37.e1 28 37
drug
metoprolol



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s38
Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of ECT and escitalopram .

DrugDDI.d413.s38.e0 79 90
drug
escitalopram



Abstract Id: DrugDDI.d413
Sentence Id: DrugDDI.d413.s39
Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram ( Celexa ), the two agents should not be coadministered.

DrugDDI.d413.s39.e0 36 45
drug
Citalopram
DrugDDI.d413.s39.e1 62 73
drug
escitalopram
DrugDDI.d413.s39.e2 100 109
drug
citalopram
DrugDDI.d413.s39.e3 111 116
drug
Celexa

interaction DrugDDI.d413.s39.e1 DrugDDI.d413.s39.e2

Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s0
Catecholamine-depleting drugs , e.g., reserpine , may have an additive effect when given with beta blocking agents .

DrugDDI.d78.s0.e0 23 27
drug
drugs
DrugDDI.d78.s0.e1 34 42
drug
reserpine
DrugDDI.d78.s0.e2 80 97
drug
beta blocking agents

interaction DrugDDI.d78.s0.e0 DrugDDI.d78.s0.e2
interaction DrugDDI.d78.s0.e1 DrugDDI.d78.s0.e2

Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s1
Patients treated concurrently with BREVIBLOC ( esmolol HCl ) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

DrugDDI.d78.s1.e0 31 39
drug
BREVIBLOC
DrugDDI.d78.s1.e1 41 50
drug
esmolol HCl



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s2
A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.

DrugDDI.d78.s2.e0 26 34
drug
BREVIBLOC
DrugDDI.d78.s2.e1 38 45
drug
warfarin
DrugDDI.d78.s2.e2 83 91
drug
BREVIBLOC
DrugDDI.d78.s2.e3 95 102
drug
warfarin
DrugDDI.d78.s2.e4 115 122
drug
warfarin



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s3
BREVIBLOC concentrations were equivocally higher when given with warfarin , but this is not likely to be clinically important.

DrugDDI.d78.s3.e0 0 8
drug
BREVIBLOC
DrugDDI.d78.s3.e1 57 64
drug
warfarin



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s4
When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.

DrugDDI.d78.s4.e0 4 10
drug
digoxin
DrugDDI.d78.s4.e1 14 22
drug
BREVIBLOC

interaction DrugDDI.d78.s4.e0 DrugDDI.d78.s4.e1

Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s5
Digoxin did not affect BREVIBLOC pharmacokinetics.

DrugDDI.d78.s5.e0 0 6
drug
Digoxin
DrugDDI.d78.s5.e1 19 27
drug
BREVIBLOC



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s6
When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine .

DrugDDI.d78.s6.e0 15 22
drug
morphine
DrugDDI.d78.s6.e1 26 34
drug
BREVIBLOC
DrugDDI.d78.s6.e2 91 98
drug
morphine
DrugDDI.d78.s6.e3 121 129
drug
BREVIBLOC
DrugDDI.d78.s6.e4 186 193
drug
morphine

interaction DrugDDI.d78.s6.e3 DrugDDI.d78.s6.e4

Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s8
The effect of BREVIBLOC on the duration of succinylcholine -induced neuromuscular blockade was studied in patients undergoing surgery.

DrugDDI.d78.s8.e0 11 19
drug
BREVIBLOC
DrugDDI.d78.s8.e1 35 49
drug
succinylcholine



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s9
The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC , but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.

DrugDDI.d78.s9.e0 33 47
drug
succinylcholine
DrugDDI.d78.s9.e1 63 71
drug
BREVIBLOC

interaction DrugDDI.d78.s9.e0 DrugDDI.d78.s9.e1

Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s10
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin , morphine , succinylcholine or warfarin .

DrugDDI.d78.s10.e0 86 94
drug
BREVIBLOC
DrugDDI.d78.s10.e1 160 166
drug
digoxin
DrugDDI.d78.s10.e2 168 175
drug
morphine
DrugDDI.d78.s10.e3 177 191
drug
succinylcholine
DrugDDI.d78.s10.e4 194 201
drug
warfarin

interaction DrugDDI.d78.s10.e0 DrugDDI.d78.s10.e1
interaction DrugDDI.d78.s10.e0 DrugDDI.d78.s10.e3
interaction DrugDDI.d78.s10.e0 DrugDDI.d78.s10.e4

Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s11
While taking beta blockers , patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.

DrugDDI.d78.s11.e0 11 22
drug
beta blockers



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s12
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

DrugDDI.d78.s12.e0 46 56
drug
epinephrine



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s13
Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.

DrugDDI.d78.s13.e0 47 55
drug
BREVIBLOC
DrugDDI.d78.s13.e1 59 67
drug
verapamil

interaction DrugDDI.d78.s13.e0 DrugDDI.d78.s13.e1

Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s14
Fatal cardiac arrests have occurred in patients receiving both drugs .

DrugDDI.d78.s14.e0 54 58
drug
drugs



Abstract Id: DrugDDI.d78
Sentence Id: DrugDDI.d78.s15
Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine , epinephrine , and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.

DrugDDI.d78.s15.e0 13 21
drug
BREVIBLOC
DrugDDI.d78.s15.e1 136 143
drug
dopamine
DrugDDI.d78.s15.e2 145 155
drug
epinephrine
DrugDDI.d78.s15.e3 160 173
drug
norepinephrine

interaction DrugDDI.d78.s15.e0 DrugDDI.d78.s15.e1
interaction DrugDDI.d78.s15.e0 DrugDDI.d78.s15.e2
interaction DrugDDI.d78.s15.e0 DrugDDI.d78.s15.e3

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s0
Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4 .

DrugDDI.d221.s0.e0 0 11
drug
Esomeprazole
DrugDDI.d221.s0.e1 41 45
drug
liver
DrugDDI.d221.s0.e2 48 54
drug
CYP2C19
DrugDDI.d221.s0.e3 58 63
drug
CYP3A4

interaction DrugDDI.d221.s0.e0 DrugDDI.d221.s0.e2
interaction DrugDDI.d221.s0.e0 DrugDDI.d221.s0.e3

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s1
In vitro and in vivo studies have shown that esomeprazole is not likely to inhibit CYPs 1A2 , 2A6, 2C9, 2D6, 2E1 and 3A4.

DrugDDI.d221.s1.e0 36 47
drug
esomeprazole
DrugDDI.d221.s1.e1 68 74
drug
CYPs 1A2



Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s2
No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected.

DrugDDI.d221.s2.e0 36 40
drug
drugs
DrugDDI.d221.s2.e1 59 61
drug
CYP



Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s3
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin , warfarin , quinidine , clarithromycin or amoxicillin .

DrugDDI.d221.s3.e0 35 46
drug
esomeprazole
DrugDDI.d221.s3.e1 98 106
drug
phenytoin
DrugDDI.d221.s3.e2 108 115
drug
warfarin
DrugDDI.d221.s3.e3 117 125
drug
quinidine
DrugDDI.d221.s3.e4 127 140
drug
clarithromycin
DrugDDI.d221.s3.e5 143 153
drug
amoxicillin



Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s4
Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.

DrugDDI.d221.s4.e0 32 42
drug
prothrombin
DrugDDI.d221.s4.e1 93 100
drug
warfarin
DrugDDI.d221.s4.e2 104 115
drug
esomeprazole

interaction DrugDDI.d221.s4.e1 DrugDDI.d221.s4.e2

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s6
Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.

DrugDDI.d221.s6.e0 19 38
drug
proton pump inhibitors
DrugDDI.d221.s6.e1 42 49
drug
warfarin

interaction DrugDDI.d221.s6.e0 DrugDDI.d221.s6.e1

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s7
Esomeprazole may potentially interfere with CYP2C19 , the major esomeprazole metabolizing enzyme.

DrugDDI.d221.s7.e0 0 11
drug
Esomeprazole
DrugDDI.d221.s7.e1 39 45
drug
CYP2C19

interaction DrugDDI.d221.s7.e0 DrugDDI.d221.s7.e1

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s8
Coadministration of esomeprazole 30 mg and diazepam , a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam .

DrugDDI.d221.s8.e0 18 29
drug
esomeprazole
DrugDDI.d221.s8.e1 37 44
drug
diazepam
DrugDDI.d221.s8.e2 47 53
drug
CYP2C19
DrugDDI.d221.s8.e3 99 106
drug
diazepam

interaction DrugDDI.d221.s8.e0 DrugDDI.d221.s8.e1

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s9
Increased plasma levels of diazepam were observed 12 hours after dosing and onwards.

DrugDDI.d221.s9.e0 23 30
drug
diazepam



Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s10
However, at that time, the plasma levels of diazepam were below the therapeutic interval, and thus this interaction is unlikely to be of clinical relevance.

DrugDDI.d221.s10.e0 36 43
drug
diazepam



Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s11
Esomeprazole inhibits gastric acid secretion.

DrugDDI.d221.s11.e0 0 11
drug
Esomeprazole



Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s12
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole , iron salts and digoxin ).

DrugDDI.d221.s12.e0 10 21
drug
esomeprazole
DrugDDI.d221.s12.e1 53 57
drug
drugs
DrugDDI.d221.s12.e2 117 128
drug
ketoconazole
DrugDDI.d221.s12.e3 142 148
drug
digoxin

interaction DrugDDI.d221.s12.e0 DrugDDI.d221.s12.e1
interaction DrugDDI.d221.s12.e0 DrugDDI.d221.s12.e2
interaction DrugDDI.d221.s12.e0 DrugDDI.d221.s12.e3

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s13
Coadministration of oral contraceptives , diazepam , phenytoin , or quinidine did not seem to change the pharmacokinetic profile of esomeprazole .

DrugDDI.d221.s13.e0 18 35
drug
oral contraceptives
DrugDDI.d221.s13.e1 37 44
drug
diazepam
DrugDDI.d221.s13.e2 46 54
drug
phenytoin
DrugDDI.d221.s13.e3 58 66
drug
quinidine
DrugDDI.d221.s13.e4 112 123
drug
esomeprazole



Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s14
Combination Therapy with Clarithromycin Co-administration of esomeprazole , clarithromycin , and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin .

DrugDDI.d221.s14.e0 22 35
drug
Clarithromycin
DrugDDI.d221.s14.e1 55 66
drug
esomeprazole
DrugDDI.d221.s14.e2 68 81
drug
clarithromycin
DrugDDI.d221.s14.e3 86 96
drug
amoxicillin
DrugDDI.d221.s14.e4 138 149
drug
esomeprazole
DrugDDI.d221.s14.e5 153 176
drug
14-hydroxyclarithromycin

interaction DrugDDI.d221.s14.e1 DrugDDI.d221.s14.e2
interaction DrugDDI.d221.s14.e1 DrugDDI.d221.s14.e3
interaction DrugDDI.d221.s14.e2 DrugDDI.d221.s14.e3

Abstract Id: DrugDDI.d221
Sentence Id: DrugDDI.d221.s15
Concomitant administration of clarithromycin with pimozide is contraindicated.

DrugDDI.d221.s15.e0 27 40
drug
clarithromycin
DrugDDI.d221.s15.e1 45 52
drug
pimozide

interaction DrugDDI.d221.s15.e0 DrugDDI.d221.s15.e1

Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s0
If ProSom is given concomitantly with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of all agents.

DrugDDI.d488.s0.e0 2 7
drug
ProSom
DrugDDI.d488.s0.e1 37 41
drug
drugs

interaction DrugDDI.d488.s0.e0 DrugDDI.d488.s0.e1

Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s1
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , monoamine oxidase inhibitors , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression.

DrugDDI.d488.s1.e0 14 28
drug
benzodiazepines
DrugDDI.d488.s1.e1 47 61
drug
anticonvulsants
DrugDDI.d488.s1.e2 63 76
drug
antihistamines
DrugDDI.d488.s1.e3 78 84
drug
alcohol
DrugDDI.d488.s1.e4 86 97
drug
barbiturates
DrugDDI.d488.s1.e5 99 124
drug
monoamine oxidase inhibitors
DrugDDI.d488.s1.e6 126 134
drug
narcotics
DrugDDI.d488.s1.e7 136 149
drug
phenothiazines
DrugDDI.d488.s1.e8 163 173
drug
medications
DrugDDI.d488.s1.e9 182 186
drug
drugs

interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e1
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e2
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e3
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e4
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e5
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e6
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e7
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e8
interaction DrugDDI.d488.s1.e0 DrugDDI.d488.s1.e9

Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s2
Smokers have an increased clearance of benzodiazepines as compared to nonsmokers; .

DrugDDI.d488.s2.e0 33 47
drug
benzodiazepines



Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s3
this was seen in studies with estazolam .

DrugDDI.d488.s3.e0 24 32
drug
estazolam



Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s4
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A , compounds that are potent CYP3A inducers (such as carbamazepine , phenytoin , rifampin , and barbiturates ) would be expected to decrease estazolam concentrations.

DrugDDI.d488.s4.e0 60 68
drug
estazolam
DrugDDI.d488.s4.e1 82 86
drug
CYP3A
DrugDDI.d488.s4.e2 110 114
drug
CYP3A
DrugDDI.d488.s4.e3 130 142
drug
carbamazepine
DrugDDI.d488.s4.e4 144 152
drug
phenytoin
DrugDDI.d488.s4.e5 154 161
drug
rifampin
DrugDDI.d488.s4.e6 166 177
drug
barbiturates
DrugDDI.d488.s4.e7 204 212
drug
estazolam

interaction DrugDDI.d488.s4.e0 DrugDDI.d488.s4.e2
interaction DrugDDI.d488.s4.e3 DrugDDI.d488.s4.e7
interaction DrugDDI.d488.s4.e4 DrugDDI.d488.s4.e7
interaction DrugDDI.d488.s4.e5 DrugDDI.d488.s4.e7
interaction DrugDDI.d488.s4.e6 DrugDDI.d488.s4.e7

Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s5
Estazolam Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A ( CYP3A ): The metabolism of estazolam to the major circulating metabolite 4-hydroxy- estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A .

DrugDDI.d488.s5.e0 0 8
drug
Estazolam
DrugDDI.d488.s5.e1 24 28
drug
Drugs
DrugDDI.d488.s5.e2 53 68
drug
Cytochrome P450 3A
DrugDDI.d488.s5.e3 70 74
drug
CYP3A
DrugDDI.d488.s5.e4 92 100
drug
estazolam
DrugDDI.d488.s5.e5 142 150
drug
estazolam
DrugDDI.d488.s5.e6 210 214
drug
CYP3A



Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s6
Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole , which are very potent inhibitors of CYP3A .

DrugDDI.d488.s6.e0 13 21
drug
estazolam
DrugDDI.d488.s6.e1 56 67
drug
ketoconazole
DrugDDI.d488.s6.e2 71 82
drug
itraconazole
DrugDDI.d488.s6.e3 114 118
drug
CYP3A

interaction DrugDDI.d488.s6.e0 DrugDDI.d488.s6.e1
interaction DrugDDI.d488.s6.e0 DrugDDI.d488.s6.e2

Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s7
With drugs inhibiting CYP3A to a lesser, but still significant degree, estazolam should be used only with caution and consideration of appropriate dosage reduction.

DrugDDI.d488.s7.e0 4 8
drug
drugs
DrugDDI.d488.s7.e1 19 23
drug
CYP3A
DrugDDI.d488.s7.e2 60 68
drug
estazolam

interaction DrugDDI.d488.s7.e0 DrugDDI.d488.s7.e2

Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s8
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : nefazodone , fluvoxamine , cimetidine , diltiazem , isoniazide , and some macrolide antibiotics .

DrugDDI.d488.s8.e0 25 29
drug
drugs
DrugDDI.d488.s8.e1 71 85
drug
benzodiazepines
DrugDDI.d488.s8.e2 116 120
drug
CYP3A
DrugDDI.d488.s8.e3 122 131
drug
nefazodone
DrugDDI.d488.s8.e4 133 143
drug
fluvoxamine
DrugDDI.d488.s8.e5 145 154
drug
cimetidine
DrugDDI.d488.s8.e6 156 164
drug
diltiazem
DrugDDI.d488.s8.e7 166 175
drug
isoniazide
DrugDDI.d488.s8.e8 184 203
drug
macrolide antibiotics

interaction DrugDDI.d488.s8.e0 DrugDDI.d488.s8.e1

Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s9
Drug Interaction with Fluoxetine : A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.

DrugDDI.d488.s9.e0 19 28
drug
Fluoxetine
DrugDDI.d488.s9.e1 80 93
drug
fluoxetine 20 mg
DrugDDI.d488.s9.e2 120 131
drug
estazolam 2 mg



Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s10
The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine , suggesting no clinically significant pharmacokinetic interaction.

DrugDDI.d488.s10.e0 21 29
drug
estazolam
DrugDDI.d488.s10.e1 76 85
drug
fluoxetine



Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s11
Estazolam Interaction with Other Drugs that are Metabolized by Cytochrome P450 ( CYP ): At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6@M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP2E1 , and CYP3A .

DrugDDI.d488.s11.e0 0 8
drug
Estazolam
DrugDDI.d488.s11.e1 29 33
drug
Drugs
DrugDDI.d488.s11.e2 54 67
drug
Cytochrome P450
DrugDDI.d488.s11.e3 69 71
drug
CYP
DrugDDI.d488.s11.e4 135 143
drug
estazolam
DrugDDI.d488.s11.e5 182 195
drug
cytochrome P450
DrugDDI.d488.s11.e6 211 216
drug
CYP2A6
DrugDDI.d488.s11.e7 218 223
drug
CYP2C9
DrugDDI.d488.s11.e8 225 231
drug
CYP2C19
DrugDDI.d488.s11.e9 233 238
drug
CYP2D6
DrugDDI.d488.s11.e10 240 245
drug
CYP2E1
DrugDDI.d488.s11.e11 250 254
drug
CYP3A



Abstract Id: DrugDDI.d488
Sentence Id: DrugDDI.d488.s12
Therefore, based on these in vitro data, estazolam is very unlikely to inhibit the biotransformation of other drugs metabolized by these CYP isoforms .

DrugDDI.d488.s12.e0 34 42
drug
estazolam
DrugDDI.d488.s12.e1 93 97
drug
drugs
DrugDDI.d488.s12.e2 119 126
drug
isoforms



Abstract Id: DrugDDI.d264
Sentence Id: DrugDDI.d264.s0
Milk, milk products, and calcium -rich foods or drugs may impair the absorption of EMCYT .

DrugDDI.d264.s0.e0 21 27
drug
calcium
DrugDDI.d264.s0.e1 40 44
drug
drugs
DrugDDI.d264.s0.e2 69 73
drug
EMCYT

interaction DrugDDI.d264.s0.e0 DrugDDI.d264.s0.e2
interaction DrugDDI.d264.s0.e1 DrugDDI.d264.s0.e2

Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s0
CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.

DrugDDI.d273.s0.e0 0 14
drug
CNS-Active Drugs
DrugDDI.d273.s0.e1 91 101
drug
eszopiclone
DrugDDI.d273.s0.e2 105 111
drug
ethanol
DrugDDI.d273.s0.e3 138 144
drug
ethanol

interaction DrugDDI.d273.s0.e1 DrugDDI.d273.s0.e2

Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s1
Paroxetine Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.

DrugDDI.d273.s1.e0 0 9
drug
Paroxetine
DrugDDI.d273.s1.e1 41 54
drug
eszopiclone 3 mg
DrugDDI.d273.s1.e2 58 71
drug
paroxetine 20 mg



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s2
Lorazepam Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug .

DrugDDI.d273.s2.e0 0 8
drug
Lorazepam
DrugDDI.d273.s2.e1 40 53
drug
eszopiclone 3 mg
DrugDDI.d273.s2.e2 57 68
drug
lorazepam 2 mg
DrugDDI.d273.s2.e3 151 154
drug
drug



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s3
Olanzapine Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.

DrugDDI.d273.s3.e0 0 9
drug
Olanzapine
DrugDDI.d273.s3.e1 28 41
drug
eszopiclone 3 mg
DrugDDI.d273.s3.e2 45 58
drug
olanzapine 10 mg

interaction DrugDDI.d273.s3.e1 DrugDDI.d273.s3.e2

Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s5
there was no alteration in the pharmacokinetics of either drug .

DrugDDI.d273.s5.e0 49 52
drug
drug



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s6
Drugs That Inhibit CYP3A4 ( Ketoconazole ) CYP3A4 is a major metabolic pathway for elimination of eszopiclone .

DrugDDI.d273.s6.e0 0 4
drug
Drugs
DrugDDI.d273.s6.e1 16 21
drug
CYP3A4
DrugDDI.d273.s6.e2 23 34
drug
Ketoconazole
DrugDDI.d273.s6.e3 36 41
drug
CYP3A4
DrugDDI.d273.s6.e4 82 92
drug
eszopiclone

interaction DrugDDI.d273.s6.e0 DrugDDI.d273.s6.e4

Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s7
The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole , a potent inhibitor of CYP3A4 , 400 mg daily for 5 days.

DrugDDI.d273.s7.e0 8 18
drug
eszopiclone
DrugDDI.d273.s7.e1 59 70
drug
ketoconazole
DrugDDI.d273.s7.e2 90 95
drug
CYP3A4

interaction DrugDDI.d273.s7.e0 DrugDDI.d273.s7.e1

Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s8
Cmax and t1 /2 were increased 1.4-fold and 1.3-fold, respectively.

DrugDDI.d273.s8.e0 7 8
drug
t1



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s9
Other strong inhibitors of CYP3A4 (e.g., itraconazole , clarithromycin , nefazodone , troleandomycin , ritonavir , nelfinavir ) would be expected to behave similarly.

DrugDDI.d273.s9.e0 23 28
drug
CYP3A4
DrugDDI.d273.s9.e1 35 46
drug
itraconazole
DrugDDI.d273.s9.e2 48 61
drug
clarithromycin
DrugDDI.d273.s9.e3 63 72
drug
nefazodone
DrugDDI.d273.s9.e4 74 87
drug
troleandomycin
DrugDDI.d273.s9.e5 89 97
drug
ritonavir
DrugDDI.d273.s9.e6 99 108
drug
nelfinavir



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s10
Drugs That Induce CYP3A4 ( Rifampicin ) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin , a potent inducer of CYP3A4 .

DrugDDI.d273.s10.e0 0 4
drug
Drugs
DrugDDI.d273.s10.e1 15 20
drug
CYP3A4
DrugDDI.d273.s10.e2 22 31
drug
Rifampicin
DrugDDI.d273.s10.e3 40 48
drug
zopiclone
DrugDDI.d273.s10.e4 90 99
drug
rifampicin
DrugDDI.d273.s10.e5 117 122
drug
CYP3A4

interaction DrugDDI.d273.s10.e2 DrugDDI.d273.s10.e3

Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s11
A similar effect would be expected with eszopiclone .

DrugDDI.d273.s11.e0 33 43
drug
eszopiclone



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s12
Drugs Highly Bound To Plasma Protein Eszopiclone is not highly bound to plasma proteins (52-59% bound); .

DrugDDI.d273.s12.e0 0 4
drug
Drugs
DrugDDI.d273.s12.e1 18 30
drug
Plasma Protein
DrugDDI.d273.s12.e2 60 73
drug
plasma proteins



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s13
therefore, the disposition of eszopiclone is not expected to be sensitive to alterations in protein binding.

DrugDDI.d273.s13.e0 26 36
drug
eszopiclone



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s14
Administration of eszopiclone 3 mg to a patient taking another drug that is highly protein -bound would not be expected to cause an alteration in the free concentration of either drug .

DrugDDI.d273.s14.e0 16 29
drug
eszopiclone 3 mg
DrugDDI.d273.s14.e1 53 56
drug
drug
DrugDDI.d273.s14.e2 69 75
drug
protein
DrugDDI.d273.s14.e3 149 152
drug
drug



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s15
Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.

DrugDDI.d273.s15.e0 0 4
drug
Drugs
DrugDDI.d273.s15.e1 52 65
drug
eszopiclone 3 mg
DrugDDI.d273.s15.e2 99 105
drug
digoxin



Abstract Id: DrugDDI.d273
Sentence Id: DrugDDI.d273.s16
Warfarin Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)- warfarin , nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin .

DrugDDI.d273.s16.e0 0 19
drug
Warfarin Eszopiclone 3
DrugDDI.d273.s16.e1 90 97
drug
warfarin
DrugDDI.d273.s16.e2 195 202
drug
warfarin



Abstract Id: DrugDDI.d369
Sentence Id: DrugDDI.d369.s0
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.

DrugDDI.d369.s0.e0 0 6
drug
Lithium
DrugDDI.d369.s0.e1 36 44
drug
diuretics

interaction DrugDDI.d369.s0.e0 DrugDDI.d369.s0.e1

Abstract Id: DrugDDI.d369
Sentence Id: DrugDDI.d369.s1
Read circulars for lithium preparation s before use of such concomitant therapy.

DrugDDI.d369.s1.e0 16 33
drug
lithium preparation



Abstract Id: DrugDDI.d369
Sentence Id: DrugDDI.d369.s2
EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics .

DrugDDI.d369.s2.e0 0 6
drug
EDECRIN
DrugDDI.d369.s2.e1 45 49
drug
drugs
DrugDDI.d369.s2.e2 56 69
drug
aminoglycoside
DrugDDI.d369.s2.e3 77 100
drug
cephalosporin antibiotics

interaction DrugDDI.d369.s2.e0 DrugDDI.d369.s2.e1
interaction DrugDDI.d369.s2.e0 DrugDDI.d369.s2.e2
interaction DrugDDI.d369.s2.e0 DrugDDI.d369.s2.e3

Abstract Id: DrugDDI.d369
Sentence Id: DrugDDI.d369.s4
A number of drugs , including ethacrynic acid , have been shown to displace warfarin from plasma protein ; .

DrugDDI.d369.s4.e0 9 13
drug
drugs
DrugDDI.d369.s4.e1 24 37
drug
ethacrynic acid
DrugDDI.d369.s4.e2 62 69
drug
warfarin
DrugDDI.d369.s4.e3 74 86
drug
plasma protein

interaction DrugDDI.d369.s4.e0 DrugDDI.d369.s4.e2
interaction DrugDDI.d369.s4.e1 DrugDDI.d369.s4.e2

Abstract Id: DrugDDI.d369
Sentence Id: DrugDDI.d369.s5
a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs .

DrugDDI.d369.s5.e0 20 32
drug
anticoagulant
DrugDDI.d369.s5.e1 75 79
drug
drugs



Abstract Id: DrugDDI.d369
Sentence Id: DrugDDI.d369.s6
In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium - sparing and thiazide diuretics .

DrugDDI.d369.s6.e0 35 68
drug
non- steroidal antiinflammatory agent
DrugDDI.d369.s6.e1 81 88
drug
diuretic
DrugDDI.d369.s6.e2 105 120
drug
antihypertensive
DrugDDI.d369.s6.e3 135 143
drug
potassium
DrugDDI.d369.s6.e4 155 171
drug
thiazide diuretics

interaction DrugDDI.d369.s6.e0 DrugDDI.d369.s6.e3
interaction DrugDDI.d369.s6.e0 DrugDDI.d369.s6.e4

Abstract Id: DrugDDI.d369
Sentence Id: DrugDDI.d369.s7
Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

DrugDDI.d369.s7.e0 14 20
drug
EDECRIN
DrugDDI.d369.s7.e1 28 59
drug
steroidal anti- inflammatory agents
DrugDDI.d369.s7.e2 148 155
drug
diuretic

interaction DrugDDI.d369.s7.e0 DrugDDI.d369.s7.e1

Abstract Id: DrugDDI.d24
Sentence Id: DrugDDI.d24.s0
The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.

DrugDDI.d24.s0.e0 38 47
drug
ethambutol
DrugDDI.d24.s0.e1 63 96
drug
aluminum hydroxide containing antacid
DrugDDI.d24.s0.e2 187 196
drug
ethambutol
DrugDDI.d24.s0.e3 268 277
drug
ethambutol
DrugDDI.d24.s0.e4 297 303
drug
antacid

interaction DrugDDI.d24.s0.e0 DrugDDI.d24.s0.e1
interaction DrugDDI.d24.s0.e3 DrugDDI.d24.s0.e4

Abstract Id: DrugDDI.d24
Sentence Id: DrugDDI.d24.s1
It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.

DrugDDI.d24.s1.e0 48 57
drug
ethambutol
DrugDDI.d24.s1.e1 62 96
drug
aluminum hydroxide containing antacids
DrugDDI.d24.s1.e2 122 131
drug
ethambutol

interaction DrugDDI.d24.s1.e0 DrugDDI.d24.s1.e1

Abstract Id: DrugDDI.d518
Sentence Id: DrugDDI.d518.s0
May interact with addictive medications , especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression@producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate ).

DrugDDI.d518.s0.e0 24 34
drug
medications
DrugDDI.d518.s0.e1 162 168
drug
alcohol
DrugDDI.d518.s0.e2 194 204
drug
medications
DrugDDI.d518.s0.e3 233 245
drug
CNS depressant
DrugDDI.d518.s0.e4 266 276
drug
medications
DrugDDI.d518.s0.e5 279 288
drug
ethinamate



Abstract Id: DrugDDI.d75
Sentence Id: DrugDDI.d75.s0
Trecator has been found to temporarily raise serum concentrations of isoniazid .

DrugDDI.d75.s0.e0 0 7
drug
Trecator
DrugDDI.d75.s0.e1 59 67
drug
isoniazid

interaction DrugDDI.d75.s0.e0 DrugDDI.d75.s0.e1

Abstract Id: DrugDDI.d75
Sentence Id: DrugDDI.d75.s1
Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.

DrugDDI.d75.s1.e0 0 7
drug
Trecator
DrugDDI.d75.s1.e1 45 64
drug
antituberculous drugs

interaction DrugDDI.d75.s1.e0 DrugDDI.d75.s1.e1

Abstract Id: DrugDDI.d75
Sentence Id: DrugDDI.d75.s2
In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs .

DrugDDI.d75.s2.e0 44 54
drug
ethionamide
DrugDDI.d75.s2.e1 73 83
drug
cycloserine
DrugDDI.d75.s2.e2 153 157
drug
drugs

interaction DrugDDI.d75.s2.e0 DrugDDI.d75.s2.e1

Abstract Id: DrugDDI.d75
Sentence Id: DrugDDI.d75.s3
Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported.

DrugDDI.d75.s3.e0 9 15
drug
ethanol



Abstract Id: DrugDDI.d136
Sentence Id: DrugDDI.d136.s0
Ethopropazine may interact with alcohol or other CNS depressants , causing increased sedative effects.

DrugDDI.d136.s0.e0 0 12
drug
Ethopropazine
DrugDDI.d136.s0.e1 28 34
drug
alcohol
DrugDDI.d136.s0.e2 42 55
drug
CNS depressants
DrugDDI.d136.s0.e3 73 80
drug
sedative

interaction DrugDDI.d136.s0.e0 DrugDDI.d136.s0.e1
interaction DrugDDI.d136.s0.e0 DrugDDI.d136.s0.e2

Abstract Id: DrugDDI.d136
Sentence Id: DrugDDI.d136.s1
It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.

DrugDDI.d136.s1.e0 21 30
drug
amantadine
DrugDDI.d136.s1.e1 38 57
drug
anticholinergic drugs
DrugDDI.d136.s1.e2 86 100
drug
anticholinergic



Abstract Id: DrugDDI.d136
Sentence Id: DrugDDI.d136.s2
Ethopropazine can interact with chlorpromazine , increasing the metabolism of chlorpromazine .

DrugDDI.d136.s2.e0 0 12
drug
Ethopropazine
DrugDDI.d136.s2.e1 28 41
drug
chlorpromazine
DrugDDI.d136.s2.e2 68 81
drug
chlorpromazine

interaction DrugDDI.d136.s2.e0 DrugDDI.d136.s2.e1

Abstract Id: DrugDDI.d314
Sentence Id: DrugDDI.d314.s0
Since Zarontin ( ethosuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).

DrugDDI.d314.s0.e0 5 12
drug
Zarontin
DrugDDI.d314.s0.e1 14 25
drug
ethosuximide
DrugDDI.d314.s0.e2 66 83
drug
antiepileptic drugs
DrugDDI.d314.s0.e3 124 128
drug
drugs
DrugDDI.d314.s0.e4 147 158
drug
ethosuximide
DrugDDI.d314.s0.e5 192 203
drug
valproic acid

interaction DrugDDI.d314.s0.e0 DrugDDI.d314.s0.e2
interaction DrugDDI.d314.s0.e2 DrugDDI.d314.s0.e4

Abstract Id: DrugDDI.d207
Sentence Id: DrugDDI.d207.s0
PEGANONE used in combination with other drugs known to adversely affect the hematopoietic system should be avoided if possible.

DrugDDI.d207.s0.e0 0 7
drug
PEGANONE
DrugDDI.d207.s0.e1 34 38
drug
drugs

interaction DrugDDI.d207.s0.e0 DrugDDI.d207.s0.e1

Abstract Id: DrugDDI.d207
Sentence Id: DrugDDI.d207.s1
Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone ( phenacemide ) since paranoid symptoms have been reported during therapy with this combination.

DrugDDI.d207.s1.e0 38 45
drug
PEGANONE
DrugDDI.d207.s1.e1 76 84
drug
Phenurone
DrugDDI.d207.s1.e2 86 96
drug
phenacemide

interaction DrugDDI.d207.s1.e0 DrugDDI.d207.s1.e1
interaction DrugDDI.d207.s1.e0 DrugDDI.d207.s1.e2

Abstract Id: DrugDDI.d207
Sentence Id: DrugDDI.d207.s2
A two-way interaction between the hydantoin antiepileptic , phenytoin, and the coumarin anticoagulant s has been suggested.

DrugDDI.d207.s2.e0 29 50
drug
hydantoin antiepileptic
DrugDDI.d207.s2.e1 68 88
drug
coumarin anticoagulant

interaction DrugDDI.d207.s2.e0 DrugDDI.d207.s2.e1

Abstract Id: DrugDDI.d207
Sentence Id: DrugDDI.d207.s3
Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulant s and increased prothrombin -proconvertin concentrations.

DrugDDI.d207.s3.e0 11 19
drug
phenytoin
DrugDDI.d207.s3.e1 107 127
drug
coumarin anticoagulant
DrugDDI.d207.s3.e2 141 151
drug
prothrombin

interaction DrugDDI.d207.s3.e0 DrugDDI.d207.s3.e1
interaction DrugDDI.d207.s3.e0 DrugDDI.d207.s3.e2

Abstract Id: DrugDDI.d207
Sentence Id: DrugDDI.d207.s4
Conversely, the coumarin anticoagulant s have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.

DrugDDI.d207.s4.e0 14 34
drug
coumarin anticoagulant
DrugDDI.d207.s4.e1 105 113
drug
phenytoin

interaction DrugDDI.d207.s4.e0 DrugDDI.d207.s4.e1

Abstract Id: DrugDDI.d207
Sentence Id: DrugDDI.d207.s5
Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulant s may occur.

DrugDDI.d207.s5.e0 63 70
drug
ethotoin
DrugDDI.d207.s5.e1 77 97
drug
coumarin anticoagulant

interaction DrugDDI.d207.s5.e0 DrugDDI.d207.s5.e1

Abstract Id: DrugDDI.d207
Sentence Id: DrugDDI.d207.s6
Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulant s.

DrugDDI.d207.s6.e0 42 49
drug
PEGANONE
DrugDDI.d207.s6.e1 69 89
drug
coumarin anticoagulant

interaction DrugDDI.d207.s6.e0 DrugDDI.d207.s6.e1

Abstract Id: DrugDDI.d422
Sentence Id: DrugDDI.d422.s0
Ethoxzolamide may increase the action of tricyclics , amphetamines , procainamide , and quinidine .

DrugDDI.d422.s0.e0 0 12
drug
Ethoxzolamide
DrugDDI.d422.s0.e1 35 44
drug
tricyclics
DrugDDI.d422.s0.e2 46 57
drug
amphetamines
DrugDDI.d422.s0.e3 59 70
drug
procainamide
DrugDDI.d422.s0.e4 75 83
drug
quinidine

interaction DrugDDI.d422.s0.e0 DrugDDI.d422.s0.e1
interaction DrugDDI.d422.s0.e0 DrugDDI.d422.s0.e2
interaction DrugDDI.d422.s0.e0 DrugDDI.d422.s0.e3
interaction DrugDDI.d422.s0.e0 DrugDDI.d422.s0.e4

Abstract Id: DrugDDI.d422
Sentence Id: DrugDDI.d422.s1
It may increase excretion of barbiturates , lithium , and ASA and may also increase the toxicity of salicylates .

DrugDDI.d422.s1.e0 24 35
drug
barbiturates
DrugDDI.d422.s1.e1 37 43
drug
lithium
DrugDDI.d422.s1.e2 82 92
drug
salicylates



Abstract Id: DrugDDI.d422
Sentence Id: DrugDDI.d422.s2
Coadministration of ethoxzolamide with other diuretics , amphotericin B , and corticosteroids may cause hypokalemia.

DrugDDI.d422.s2.e0 18 30
drug
ethoxzolamide
DrugDDI.d422.s2.e1 40 48
drug
diuretics
DrugDDI.d422.s2.e2 50 62
drug
amphotericin B
DrugDDI.d422.s2.e3 67 81
drug
corticosteroids

interaction DrugDDI.d422.s2.e0 DrugDDI.d422.s2.e1
interaction DrugDDI.d422.s2.e0 DrugDDI.d422.s2.e3

Abstract Id: DrugDDI.d19
Sentence Id: DrugDDI.d19.s0
There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.

DrugDDI.d19.s0.e0 86 95
drug
etidronate
DrugDDI.d19.s0.e1 106 113
drug
warfarin

interaction DrugDDI.d19.s0.e0 DrugDDI.d19.s0.e1

Abstract Id: DrugDDI.d19
Sentence Id: DrugDDI.d19.s2
Although the relevance of these reports and any mechanism of coagulation alterations is unclear, patients on warfarin should have their prothrombin time monitored.

DrugDDI.d19.s2.e0 93 100
drug
warfarin



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s0
ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors .

DrugDDI.d480.s0.e0 0 13
drug
ACE-inhibitors
DrugDDI.d480.s0.e1 32 37
drug
NSAIDs
DrugDDI.d480.s0.e2 52 67
drug
antihypertensive
DrugDDI.d480.s0.e3 76 89
drug
ACE-inhibitors

interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e3

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s1
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors .

DrugDDI.d480.s1.e0 57 62
drug
NSAIDs
DrugDDI.d480.s1.e1 80 93
drug
ACE-inhibitors

interaction DrugDDI.d480.s1.e0 DrugDDI.d480.s1.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s2
Antacids The concomitant administration of antacids has no apparent effect on the extent of absorption of Lodine .

DrugDDI.d480.s2.e0 0 7
drug
Antacids
DrugDDI.d480.s2.e1 38 45
drug
antacids
DrugDDI.d480.s2.e2 90 95
drug
Lodine



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s3
However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak.

DrugDDI.d480.s3.e0 8 15
drug
antacids



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s4
Aspirin When Lodine is administered with aspirin , its protein binding is reduced, although the clearance of free etodolac is not altered.

DrugDDI.d480.s4.e0 0 6
drug
Aspirin
DrugDDI.d480.s4.e1 11 16
drug
Lodine
DrugDDI.d480.s4.e2 35 41
drug
aspirin
DrugDDI.d480.s4.e3 96 103
drug
etodolac

interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e2

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s6
however, as with other NSAIDs , concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.

DrugDDI.d480.s6.e0 19 24
drug
NSAIDs
DrugDDI.d480.s6.e1 53 58
drug
Lodine
DrugDDI.d480.s6.e2 62 68
drug
aspirin

interaction DrugDDI.d480.s6.e1 DrugDDI.d480.s6.e2

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s7
Cyclosporine , Digoxin , Methotrexate Lodine, like other NSAIDs , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine , digoxin , methotrexate , and increased toxicity.

DrugDDI.d480.s7.e0 0 11
drug
Cyclosporine
DrugDDI.d480.s7.e1 13 19
drug
Digoxin
DrugDDI.d480.s7.e2 21 32
drug
Methotrexate
DrugDDI.d480.s7.e3 49 54
drug
NSAIDs
DrugDDI.d480.s7.e4 77 90
drug
prostaglandins
DrugDDI.d480.s7.e5 130 134
drug
drugs
DrugDDI.d480.s7.e6 165 176
drug
cyclosporine
DrugDDI.d480.s7.e7 178 184
drug
digoxin
DrugDDI.d480.s7.e8 186 197
drug
methotrexate

interaction DrugDDI.d480.s7.e0 DrugDDI.d480.s7.e4
interaction DrugDDI.d480.s7.e1 DrugDDI.d480.s7.e4
interaction DrugDDI.d480.s7.e2 DrugDDI.d480.s7.e4
interaction DrugDDI.d480.s7.e3 DrugDDI.d480.s7.e4

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s8
Nephrotoxicity associated with cyclosporine may also be enhanced.

DrugDDI.d480.s8.e0 28 39
drug
cyclosporine



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s9
Patients receiving these drugs who are given Lodine , or any other NSAID , and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs .

DrugDDI.d480.s9.e0 22 26
drug
drugs
DrugDDI.d480.s9.e1 38 43
drug
Lodine
DrugDDI.d480.s9.e2 55 59
drug
NSAID
DrugDDI.d480.s9.e3 177 181
drug
drugs

interaction DrugDDI.d480.s9.e0 DrugDDI.d480.s9.e1
interaction DrugDDI.d480.s9.e0 DrugDDI.d480.s9.e2

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s10
Diuretics Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide .

DrugDDI.d480.s10.e0 0 8
drug
Diuretics
DrugDDI.d480.s10.e1 76 85
drug
furosemide
DrugDDI.d480.s10.e2 88 106
drug
hydrochlorothiazide



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s11
Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.

DrugDDI.d480.s11.e0 75 80
drug
Lodine
DrugDDI.d480.s11.e1 93 103
drug
natriuretic
DrugDDI.d480.s11.e2 112 121
drug
furosemide
DrugDDI.d480.s11.e3 125 133
drug
thiazides

interaction DrugDDI.d480.s11.e0 DrugDDI.d480.s11.e2
interaction DrugDDI.d480.s11.e0 DrugDDI.d480.s11.e3

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s12
This response has been attributed to inhibition of renal prostaglandin synthesis.

DrugDDI.d480.s12.e0 48 60
drug
prostaglandin



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s13
During concomitant therapy with NSAIDs , the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.

DrugDDI.d480.s13.e0 28 33
drug
NSAIDs
DrugDDI.d480.s13.e1 107 114
drug
diuretic



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s14
Glyburide Etodolac has no apparent pharmacokinetic interaction when administered with glyburide .

DrugDDI.d480.s14.e0 0 8
drug
Glyburide
DrugDDI.d480.s14.e1 76 84
drug
glyburide



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s15
Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.

DrugDDI.d480.s15.e0 0 6
drug
Lithium
DrugDDI.d480.s15.e1 77 83
drug
lithium

interaction DrugDDI.d480.s15.e0 DrugDDI.d480.s15.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s16
The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.

DrugDDI.d480.s16.e0 14 20
drug
lithium



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s17
These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID .

DrugDDI.d480.s17.e0 49 61
drug
prostaglandin
DrugDDI.d480.s17.e1 76 80
drug
NSAID

interaction DrugDDI.d480.s17.e0 DrugDDI.d480.s17.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s18
Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

DrugDDI.d480.s18.e0 9 14
drug
NSAIDs
DrugDDI.d480.s18.e1 18 24
drug
lithium

interaction DrugDDI.d480.s18.e0 DrugDDI.d480.s18.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s19
Phenylbutazone Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac .

DrugDDI.d480.s19.e0 0 13
drug
Phenylbutazone
DrugDDI.d480.s19.e1 73 80
drug
etodolac

interaction DrugDDI.d480.s19.e0 DrugDDI.d480.s19.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s20
Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone , it is not recommended that they be coadministered.

DrugDDI.d480.s20.e0 43 50
drug
etodolac
DrugDDI.d480.s20.e1 89 102
drug
phenylbutazone

interaction DrugDDI.d480.s20.e0 DrugDDI.d480.s20.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s21
Phenytoin Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin .

DrugDDI.d480.s21.e0 9 16
drug
Etodolac
DrugDDI.d480.s21.e1 76 84
drug
phenytoin



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s22
Warfarin The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.

DrugDDI.d480.s22.e0 0 7
drug
Warfarin
DrugDDI.d480.s22.e1 20 27
drug
warfarin
DrugDDI.d480.s22.e2 31 36
drug
NSAIDs
DrugDDI.d480.s22.e3 83 87
drug
drugs
DrugDDI.d480.s22.e4 153 156
drug
drug

interaction DrugDDI.d480.s22.e1 DrugDDI.d480.s22.e2

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s23
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine@ ( etodolac capsules and tablets) results in reduced protein binding of warfarin , but there was no change in the clearance of free warfarin .

DrugDDI.d480.s23.e0 79 86
drug
warfarin
DrugDDI.d480.s23.e1 98 105
drug
etodolac
DrugDDI.d480.s23.e2 157 164
drug
warfarin
DrugDDI.d480.s23.e3 205 212
drug
warfarin

interaction DrugDDI.d480.s23.e0 DrugDDI.d480.s23.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s24
There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Lodine as measured by prothrombin time.

DrugDDI.d480.s24.e0 59 66
drug
warfarin
DrugDDI.d480.s24.e1 87 94
drug
warfarin
DrugDDI.d480.s24.e2 111 116
drug
Lodine



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s25
Thus, concomitant therapy with warfarin and Lodine should not require dosage adjustment of either drug .

DrugDDI.d480.s25.e0 27 34
drug
warfarin
DrugDDI.d480.s25.e1 38 43
drug
Lodine
DrugDDI.d480.s25.e2 84 87
drug
drug



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s26
However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac -treated patients receiving concomitant warfarin therapy.

DrugDDI.d480.s26.e0 126 133
drug
etodolac
DrugDDI.d480.s26.e1 170 177
drug
warfarin

interaction DrugDDI.d480.s26.e0 DrugDDI.d480.s26.e1

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s27
Drug /Laboratory Test Interactions The urine of patients who take Lodine can give a false-positive reaction for urinary bilirubin ( urobilin ) due to the presence of phenolic metabolite s of etodolac .

DrugDDI.d480.s27.e0 0 3
drug
Drug
DrugDDI.d480.s27.e1 56 61
drug
Lodine
DrugDDI.d480.s27.e2 112 119
drug
urobilin
DrugDDI.d480.s27.e3 139 156
drug
phenolic metabolite
DrugDDI.d480.s27.e4 160 167
drug
etodolac



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s28
Diagnostic dip-stick methodology, used to detect ketone bodies in urine, has resulted in false-positive findings in some patients treated with Lodine .

DrugDDI.d480.s28.e0 43 54
drug
ketone bodies
DrugDDI.d480.s28.e1 123 128
drug
Lodine



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s31
Lodine treatment is associated with a small decrease in serum uric acid levels.

DrugDDI.d480.s31.e0 0 5
drug
Lodine



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s32
In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving etodolac (600 mg to 1000 mg/day) after 4 weeks of therapy.

DrugDDI.d480.s32.e0 81 88
drug
etodolac



Abstract Id: DrugDDI.d193
Sentence Id: DrugDDI.d193.s0
The following drug interactions have been reported with etomidate .

DrugDDI.d193.s0.e0 48 56
drug
etomidate



Abstract Id: DrugDDI.d193
Sentence Id: DrugDDI.d193.s5
@@@Opioid analgesics @@@Decreased antinociceptive action .

DrugDDI.d193.s5.e0 9 18
drug
analgesics



Abstract Id: DrugDDI.d576
Sentence Id: DrugDDI.d576.s0
Etonogestrel may interact with the following medications : acetaminophen ( Tylenol ), antibiotics such as ampicillin and tetracycline , anticonvulsants ( Dilantin , Phenobarbital , Tegretol , Trileptal , Topamax , Felbatol ), antifungals ( Gris-PEG , Nizoral , Sporanox ), atorvastatin ( Lipitor ), clofibrate ( Atromid-S ), cyclosporine ( Neoral , Sandimmune ), HIV drugs classified as protease inhibitors ( Agenerase , Crixivan , Fortovase , Invirase , Kaletra , Norvir , Viracept ), morphine ( Astramorph , Kadian , MS Contin ), phenylbutazone , prednisolone ( Prelone ), rifadin ( rifampin ), St. Johns wort , temazepam , theophylline ( Theo-Dur ), and vitamin C .

DrugDDI.d576.s0.e0 0 11
drug
Etonogestrel
DrugDDI.d576.s0.e1 39 49
drug
medications
DrugDDI.d576.s0.e2 51 63
drug
acetaminophen
DrugDDI.d576.s0.e3 65 71
drug
Tylenol
DrugDDI.d576.s0.e4 74 84
drug
antibiotics
DrugDDI.d576.s0.e5 91 100
drug
ampicillin
DrugDDI.d576.s0.e6 104 115
drug
tetracycline
DrugDDI.d576.s0.e7 117 131
drug
anticonvulsants
DrugDDI.d576.s0.e8 133 140
drug
Dilantin
DrugDDI.d576.s0.e9 142 154
drug
Phenobarbital
DrugDDI.d576.s0.e10 156 163
drug
Tegretol
DrugDDI.d576.s0.e11 165 173
drug
Trileptal
DrugDDI.d576.s0.e12 175 181
drug
Topamax
DrugDDI.d576.s0.e13 183 190
drug
Felbatol
DrugDDI.d576.s0.e14 193 203
drug
antifungals
DrugDDI.d576.s0.e15 205 212
drug
Gris-PEG
DrugDDI.d576.s0.e16 214 220
drug
Nizoral
DrugDDI.d576.s0.e17 222 229
drug
Sporanox
DrugDDI.d576.s0.e18 232 243
drug
atorvastatin
DrugDDI.d576.s0.e19 245 251
drug
Lipitor
DrugDDI.d576.s0.e20 254 263
drug
clofibrate
DrugDDI.d576.s0.e21 265 273
drug
Atromid-S
DrugDDI.d576.s0.e22 276 287
drug
cyclosporine
DrugDDI.d576.s0.e23 289 294
drug
Neoral
DrugDDI.d576.s0.e24 296 305
drug
Sandimmune
DrugDDI.d576.s0.e25 311 315
drug
drugs
DrugDDI.d576.s0.e26 328 345
drug
protease inhibitors
DrugDDI.d576.s0.e27 347 355
drug
Agenerase
DrugDDI.d576.s0.e28 357 364
drug
Crixivan
DrugDDI.d576.s0.e29 366 374
drug
Fortovase
DrugDDI.d576.s0.e30 376 383
drug
Invirase
DrugDDI.d576.s0.e31 385 391
drug
Kaletra
DrugDDI.d576.s0.e32 393 398
drug
Norvir
DrugDDI.d576.s0.e33 400 407
drug
Viracept
DrugDDI.d576.s0.e34 410 417
drug
morphine
DrugDDI.d576.s0.e35 419 428
drug
Astramorph
DrugDDI.d576.s0.e36 430 435
drug
Kadian
DrugDDI.d576.s0.e37 437 444
drug
MS Contin
DrugDDI.d576.s0.e38 447 460
drug
phenylbutazone
DrugDDI.d576.s0.e39 462 473
drug
prednisolone
DrugDDI.d576.s0.e40 475 481
drug
Prelone
DrugDDI.d576.s0.e41 484 490
drug
rifadin
DrugDDI.d576.s0.e42 492 499
drug
rifampin
DrugDDI.d576.s0.e43 502 513
drug
St. Johns wort
DrugDDI.d576.s0.e44 515 523
drug
temazepam
DrugDDI.d576.s0.e45 525 536
drug
theophylline
DrugDDI.d576.s0.e46 538 545
drug
Theo-Dur
DrugDDI.d576.s0.e47 551 558
drug
vitamin C

interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e1
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e2
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e3
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e4
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e5
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e6
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e7
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e8
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e9
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e10
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e11
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e12
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e13
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e14
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e15
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e16
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e17
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e18
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e19
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e20
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e21
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e22
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e23
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e24
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e25
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e26
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e27
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e28
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e29
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e30
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e31
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e32
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e33
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e34
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e35
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e36
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e37
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e38
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e39
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e40
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e41
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e42
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e43
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e44
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e45
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e46
interaction DrugDDI.d576.s0.e0 DrugDDI.d576.s0.e47

Abstract Id: DrugDDI.d196
Sentence Id: DrugDDI.d196.s0
Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride ).

DrugDDI.d196.s0.e0 41 49
drug
ETOPOPHOS
DrugDDI.d196.s0.e1 54 58
drug
drugs
DrugDDI.d196.s0.e2 107 129
drug
levamisole hydrochloride

interaction DrugDDI.d196.s0.e0 DrugDDI.d196.s0.e1
interaction DrugDDI.d196.s0.e0 DrugDDI.d196.s0.e2

Abstract Id: DrugDDI.d196
Sentence Id: DrugDDI.d196.s1
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.

DrugDDI.d196.s1.e0 9 20
drug
cyclosporin A
DrugDDI.d196.s1.e1 80 88
drug
etoposide
DrugDDI.d196.s1.e2 112 120
drug
etoposide
DrugDDI.d196.s1.e3 167 175
drug
etoposide
DrugDDI.d196.s1.e4 186 194
drug
etoposide

interaction DrugDDI.d196.s1.e0 DrugDDI.d196.s1.e1

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s0
Exemestane is extensively metabolized by CYP 3A4, but coadministration of ketoconazole , a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics.

DrugDDI.d396.s0.e0 0 9
drug
Exemestane
DrugDDI.d396.s0.e1 36 38
drug
CYP
DrugDDI.d396.s0.e2 64 75
drug
ketoconazole
DrugDDI.d396.s0.e3 95 97
drug
CYP
DrugDDI.d396.s0.e4 126 135
drug
exemestane



Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s1
Significant pharmacokinetic interactions mediated by inhibition of CYP isoenzymes therefore appear unlikely.

DrugDDI.d396.s1.e0 63 72
drug
isoenzymes



Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s2
Co- medications that induce CYP 3A4 (e.g., rifampicin , phenytoin , carbamazepine , phenobarbital , or St. John@s wort) may significantly decrease exposure to exemestane .

DrugDDI.d396.s2.e0 3 13
drug
medications
DrugDDI.d396.s2.e1 24 26
drug
CYP
DrugDDI.d396.s2.e2 36 45
drug
rifampicin
DrugDDI.d396.s2.e3 47 55
drug
phenytoin
DrugDDI.d396.s2.e4 57 69
drug
carbamazepine
DrugDDI.d396.s2.e5 71 83
drug
phenobarbital
DrugDDI.d396.s2.e6 135 144
drug
exemestane

interaction DrugDDI.d396.s2.e1 DrugDDI.d396.s2.e6
interaction DrugDDI.d396.s2.e2 DrugDDI.d396.s2.e6
interaction DrugDDI.d396.s2.e3 DrugDDI.d396.s2.e6
interaction DrugDDI.d396.s2.e4 DrugDDI.d396.s2.e6
interaction DrugDDI.d396.s2.e5 DrugDDI.d396.s2.e6

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s3
Dose modification is recommended for patients who are also receiving a potent CYP 3A4 inducer.

DrugDDI.d396.s3.e0 66 68
drug
CYP



Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s4
Drug /Laboratory Tests Interactions No clinically relevant changes in the results of clinical laboratory tests have been observed.

DrugDDI.d396.s4.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d459
Sentence Id: DrugDDI.d459.s0
Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir .

DrugDDI.d459.s0.e0 17 26
drug
probenecid
DrugDDI.d459.s0.e1 34 38
drug
drugs
DrugDDI.d459.s0.e2 133 143
drug
penciclovir

interaction DrugDDI.d459.s0.e0 DrugDDI.d459.s0.e1
interaction DrugDDI.d459.s0.e0 DrugDDI.d459.s0.e2

Abstract Id: DrugDDI.d459
Sentence Id: DrugDDI.d459.s1
The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase .

DrugDDI.d459.s1.e0 22 32
drug
penciclovir
DrugDDI.d459.s1.e1 35 45
drug
penciclovir
DrugDDI.d459.s1.e2 59 73
drug
aldehyde oxidase



Abstract Id: DrugDDI.d459
Sentence Id: DrugDDI.d459.s2
Interactions with other drugs metabolized by this enzyme could potentially occur.

DrugDDI.d459.s2.e0 21 25
drug
drugs



Abstract Id: DrugDDI.d319
Sentence Id: DrugDDI.d319.s1
Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes , e.g., cytochrome P450 system.

DrugDDI.d319.s1.e0 11 20
drug
famotidine
DrugDDI.d319.s1.e1 138 154
drug
microsomal enzymes
DrugDDI.d319.s1.e2 161 174
drug
cytochrome P450



Abstract Id: DrugDDI.d319
Sentence Id: DrugDDI.d319.s2
Compounds tested in man include warfarin , theophylline , phenytoin , diazepam , aminopyrine and antipyrine .

DrugDDI.d319.s2.e0 27 34
drug
warfarin
DrugDDI.d319.s2.e1 36 47
drug
theophylline
DrugDDI.d319.s2.e2 49 57
drug
phenytoin
DrugDDI.d319.s2.e3 59 66
drug
diazepam
DrugDDI.d319.s2.e4 68 78
drug
aminopyrine
DrugDDI.d319.s2.e5 82 91
drug
antipyrine



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s1
Use in Conjunction with Other Antiepileptic Drugs : The addition of Felbatol@ to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.

DrugDDI.d215.s1.e0 25 42
drug
Antiepileptic Drugs
DrugDDI.d215.s1.e1 68 85
drug
antiepileptic drugs



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s4
Phenytoin @ ?

DrugDDI.d215.s4.e0 0 8
drug
Phenytoin



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s5
Valproate @ @** .

DrugDDI.d215.s5.e0 0 8
drug
Valproate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s6
Carbamazepine (CBZ) @ ?

DrugDDI.d215.s6.e0 0 12
drug
Carbamazepine



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s8
Phenobarbital @ ?

DrugDDI.d215.s8.e0 0 12
drug
Phenobarbital



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s9
*Not administered, but an active metabolite of carbamazepine .

DrugDDI.d215.s9.e0 22 37
drug
active metabolite
DrugDDI.d215.s9.e1 40 52
drug
carbamazepine



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s11
Specific Effects of Felbatol@ on Other Antiepileptic Drugs Phenytoin: Felbatol@ causes an increase in steady-state phenytoin plasma concentrations.

DrugDDI.d215.s11.e0 33 50
drug
Antiepileptic Drugs
DrugDDI.d215.s11.e1 100 108
drug
phenytoin



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s12
In 10 otherwise healthy subjects with epilepsy ingesting phenytoin , the steadystate trough (Cmin) phenytoin plasma concentration was 17@5 micrograms/mL.

DrugDDI.d215.s12.e0 49 57
drug
phenytoin
DrugDDI.d215.s12.e1 85 93
drug
phenytoin



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s13
The steady-state Cmin increased to 21@5 micrograms/mL when 1200 mg/day of felbamate was coadministered.

DrugDDI.d215.s13.e0 63 71
drug
felbamate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s14
Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25@7 micrograms/mL.

DrugDDI.d215.s14.e0 82 90
drug
phenytoin



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s17
Carbamazepine : Felbatol@ causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.

DrugDDI.d215.s17.e0 0 12
drug
Carbamazepine
DrugDDI.d215.s17.e1 55 67
drug
carbamazepine
DrugDDI.d215.s17.e2 118 137
drug
carbamazepine epoxide



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s18
In nine otherwise healthy subjects with epilepsy ingesting carbamazepine , the steady-state trough (Cmin) carbamazepine concentration was 8@2 micrograms/mL.

DrugDDI.d215.s18.e0 51 63
drug
carbamazepine
DrugDDI.d215.s18.e1 92 104
drug
carbamazepine



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s19
The carbamazepine steady-state Cmin decreased 31% to 5@1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.

DrugDDI.d215.s19.e0 3 15
drug
carbamazepine
DrugDDI.d215.s19.e1 66 74
drug
felbamate

interaction DrugDDI.d215.s19.e0 DrugDDI.d215.s19.e1

Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s20
Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0@0.3 to 1.6@0.4 micrograms/mL with the addition of felbamate .

DrugDDI.d215.s20.e0 0 19
drug
Carbamazepine epoxide
DrugDDI.d215.s20.e1 112 120
drug
felbamate

interaction DrugDDI.d215.s20.e0 DrugDDI.d215.s20.e1

Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s21
In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.

DrugDDI.d215.s21.e0 33 45
drug
carbamazepine
DrugDDI.d215.s21.e1 49 68
drug
carbamazepine epoxide



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s22
Valproate : Felbatol@ causes an increase in steady-state valproate concentrations.

DrugDDI.d215.s22.e0 0 8
drug
Valproate
DrugDDI.d215.s22.e1 49 57
drug
valproate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s23
In four subjects with epilepsy ingesting valproate , the steady-state trough (Cmin) valproate plasma concentration was 63@16 micrograms/mL.

DrugDDI.d215.s23.e0 35 43
drug
valproate
DrugDDI.d215.s23.e1 72 80
drug
valproate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s24
The steady-state Cmin increased to 78@14 micrograms/mL when 1200 mg/day of felbamate was coadministered.

DrugDDI.d215.s24.e0 64 72
drug
felbamate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s25
Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96@25 micrograms/mL.

DrugDDI.d215.s25.e0 61 69
drug
valproate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s27
The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol@, respectively.

DrugDDI.d215.s27.e0 27 35
drug
valproate
DrugDDI.d215.s27.e1 55 63
drug
valproate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s28
This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol@ Phenobarbital : Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital , the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.

DrugDDI.d215.s28.e0 36 44
drug
valproate
DrugDDI.d215.s28.e1 98 110
drug
Phenobarbital
DrugDDI.d215.s28.e2 130 138
drug
felbamate
DrugDDI.d215.s28.e3 143 155
drug
phenobarbital
DrugDDI.d215.s28.e4 174 186
drug
phenobarbital
DrugDDI.d215.s28.e5 251 263
drug
phenobarbital
DrugDDI.d215.s28.e6 292 304
drug
phenobarbital

interaction DrugDDI.d215.s28.e2 DrugDDI.d215.s28.e3

Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s29
The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.

DrugDDI.d215.s29.e0 76 84
drug
felbamate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s30
Effects of Other Antiepileptic Drugs on Felbatol@ Phenytoin : Phenytoin causes an approximate doubling of the clearance of Felbatol@ ( felbamate ) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol@ as compared to the same dose of Felbatol@ given as monotherapy.

DrugDDI.d215.s30.e0 14 31
drug
Antiepileptic Drugs
DrugDDI.d215.s30.e1 43 51
drug
Phenytoin
DrugDDI.d215.s30.e2 53 61
drug
Phenytoin
DrugDDI.d215.s30.e3 115 123
drug
felbamate
DrugDDI.d215.s30.e4 165 173
drug
phenytoin

interaction DrugDDI.d215.s30.e2 DrugDDI.d215.s30.e3

Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s31
Carbamazepine : Carbamazepine causes an approximate 50% increase in the clearance of Felbatol@ at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol@ as compared to the same dose of Felbatol@ given as monotherapy.

DrugDDI.d215.s31.e0 0 12
drug
Carbamazepine
DrugDDI.d215.s31.e1 14 26
drug
Carbamazepine
DrugDDI.d215.s31.e2 122 134
drug
carbamazepine



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s32
Valproate : Available data suggest that there is no significant effect of valproate on the clearance of Felbatol@ at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol@ ( felbamate ) plasma concentrations.

DrugDDI.d215.s32.e0 0 8
drug
Valproate
DrugDDI.d215.s32.e1 62 70
drug
valproate
DrugDDI.d215.s32.e2 133 141
drug
valproate
DrugDDI.d215.s32.e3 200 208
drug
felbamate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s33
Phenobarbital : It appears that phenobarbital may reduce plasma felbamate concentrations.

DrugDDI.d215.s33.e0 0 12
drug
Phenobarbital
DrugDDI.d215.s33.e1 27 39
drug
phenobarbital
DrugDDI.d215.s33.e2 55 63
drug
felbamate

interaction DrugDDI.d215.s33.e1 DrugDDI.d215.s33.e2

Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s34
Steady-state plasma felbamate concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of felbamate a day.

DrugDDI.d215.s34.e0 18 26
drug
felbamate
DrugDDI.d215.s34.e1 152 160
drug
felbamate



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s35
Effects of Antacids on Felbatol@ The rate and extent of absorption of a 2400 mg dose of Felbatol@ as monotherapy given as tablets was not affected when coadministered with antacids .

DrugDDI.d215.s35.e0 9 16
drug
Antacids
DrugDDI.d215.s35.e1 143 150
drug
antacids



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s36
Effects of Erythromycin on Felbatol@ The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.

DrugDDI.d215.s36.e0 9 20
drug
Erythromycin
DrugDDI.d215.s36.e1 53 64
drug
erythromycin



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s37
Effects of Felbatol@ on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.

DrugDDI.d215.s37.e0 20 56
drug
Low-Dose Combination Oral Contraceptives
DrugDDI.d215.s37.e1 121 137
drug
oral contraceptive
DrugDDI.d215.s37.e2 159 174
drug
ethinyl estradiol
DrugDDI.d215.s37.e3 182 190
drug
gestodene
DrugDDI.d215.s37.e4 228 236
drug
felbamate
DrugDDI.d215.s37.e5 289 305
drug
oral contraceptive



Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s38
Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol .

DrugDDI.d215.s38.e0 0 8
drug
Felbamate
DrugDDI.d215.s38.e1 45 53
drug
gestodene
DrugDDI.d215.s38.e2 134 149
drug
ethinyl estradiol

interaction DrugDDI.d215.s38.e0 DrugDDI.d215.s38.e1

Abstract Id: DrugDDI.d215
Sentence Id: DrugDDI.d215.s39
No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment.

DrugDDI.d215.s39.e0 96 104
drug
felbamate



Abstract Id: DrugDDI.d324
Sentence Id: DrugDDI.d324.s0
Drug Interactions with Beta-Blockers : Concomitant use of fenoldopam with beta-blockers should be avoided.

DrugDDI.d324.s0.e0 20 32
drug
Beta-Blockers
DrugDDI.d324.s0.e1 50 59
drug
fenoldopam
DrugDDI.d324.s0.e2 64 76
drug
beta-blockers

interaction DrugDDI.d324.s0.e1 DrugDDI.d324.s0.e2

Abstract Id: DrugDDI.d324
Sentence Id: DrugDDI.d324.s1
If the drugs are used together, caution should be exercised because unexpected hypotension could result from beta-blocker inhibition of the sympathetic reflex response to fenoldopam .

DrugDDI.d324.s1.e0 5 9
drug
drugs
DrugDDI.d324.s1.e1 93 104
drug
beta-blocker
DrugDDI.d324.s1.e2 147 156
drug
fenoldopam

interaction DrugDDI.d324.s1.e1 DrugDDI.d324.s1.e2

Abstract Id: DrugDDI.d324
Sentence Id: DrugDDI.d324.s2
Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin .

DrugDDI.d324.s2.e0 84 93
drug
fenoldopam
DrugDDI.d324.s2.e1 123 127
drug
drugs
DrugDDI.d324.s2.e2 134 142
drug
digitalis
DrugDDI.d324.s2.e3 156 168
drug
nitroglycerin



Abstract Id: DrugDDI.d324
Sentence Id: DrugDDI.d324.s3
There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers , ACE inhibitors , and diuretics (both thiazide -like and loop).

DrugDDI.d324.s3.e0 39 60
drug
antihypertensive agents
DrugDDI.d324.s3.e1 82 104
drug
calcium channel-blockers
DrugDDI.d324.s3.e2 106 118
drug
ACE inhibitors
DrugDDI.d324.s3.e3 123 131
drug
diuretics
DrugDDI.d324.s3.e4 137 144
drug
thiazide



Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s0
The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.

DrugDDI.d427.s0.e0 21 27
drug
aspirin
DrugDDI.d427.s0.e1 59 68
drug
fenoprofen
DrugDDI.d427.s0.e2 149 158
drug
fenoprofen

interaction DrugDDI.d427.s0.e0 DrugDDI.d427.s0.e1

Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s1
Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.

DrugDDI.d427.s1.e0 40 49
drug
fenoprofen
DrugDDI.d427.s1.e1 53 59
drug
aspirin
DrugDDI.d427.s1.e2 110 119
drug
fenoprofen
DrugDDI.d427.s1.e3 124 136
drug
plasma albumin



Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s2
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon , the concomitant use of Nalfon and salicylates is not recommended.

DrugDDI.d427.s2.e0 7 12
drug
Nalfon
DrugDDI.d427.s2.e1 78 84
drug
aspirin
DrugDDI.d427.s2.e2 100 106
drug
aspirin
DrugDDI.d427.s2.e3 136 141
drug
Nalfon
DrugDDI.d427.s2.e4 162 167
drug
Nalfon
DrugDDI.d427.s2.e5 171 181
drug
salicylates

interaction DrugDDI.d427.s2.e2 DrugDDI.d427.s2.e3
interaction DrugDDI.d427.s2.e4 DrugDDI.d427.s2.e5

Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s3
Chronic administration of phenobarbital , a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen .

DrugDDI.d427.s3.e0 23 35
drug
phenobarbital
DrugDDI.d427.s3.e1 107 116
drug
fenoprofen

interaction DrugDDI.d427.s3.e0 DrugDDI.d427.s3.e1

Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s4
When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.

DrugDDI.d427.s4.e0 4 16
drug
phenobarbital
DrugDDI.d427.s4.e1 69 74
drug
Nalfon

interaction DrugDDI.d427.s4.e0 DrugDDI.d427.s4.e1

Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s5
In vitro studies have shown that fenoprofen , because of its affinity for albumin , may displace from their binding sites other drugs that are also albumin bound, and this may lead to drug interaction.

DrugDDI.d427.s5.e0 27 36
drug
fenoprofen
DrugDDI.d427.s5.e1 61 67
drug
albumin
DrugDDI.d427.s5.e2 106 110
drug
drugs
DrugDDI.d427.s5.e3 122 128
drug
albumin

interaction DrugDDI.d427.s5.e0 DrugDDI.d427.s5.e2

Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s6
Theoretically, fenoprofen could likewise be displaced.

DrugDDI.d427.s6.e0 14 23
drug
fenoprofen



Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s7
Patients receiving hydantoins , sulfonamides , or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs .

DrugDDI.d427.s7.e0 17 26
drug
hydantoins
DrugDDI.d427.s7.e1 28 39
drug
sulfonamides
DrugDDI.d427.s7.e2 43 55
drug
sulfonylureas
DrugDDI.d427.s7.e3 99 103
drug
drugs
DrugDDI.d427.s7.e4 142 146
drug
drugs



Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s8
In patients receiving coumarin-type anticoagulants , the addition of Nalfon to therapy could prolong the prothrombin time.

DrugDDI.d427.s8.e0 19 45
drug
coumarin-type anticoagulants
DrugDDI.d427.s8.e1 60 65
drug
Nalfon

interaction DrugDDI.d427.s8.e0 DrugDDI.d427.s8.e1

Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s9
Patients receiving both drugs should be under careful observation.

DrugDDI.d427.s9.e0 21 25
drug
drugs



Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s10
Patients treated with Nalfon may be resistant to the effects of loop diuretics .

DrugDDI.d427.s10.e0 19 24
drug
Nalfon
DrugDDI.d427.s10.e1 53 65
drug
loop diuretics

interaction DrugDDI.d427.s10.e0 DrugDDI.d427.s10.e1

Abstract Id: DrugDDI.d427
Sentence Id: DrugDDI.d427.s11
In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.

DrugDDI.d427.s11.e0 19 24
drug
Nalfon



Abstract Id: DrugDDI.d292
Sentence Id: DrugDDI.d292.s0
Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system ( CYP3A4 ), therefore potential interactions may occur when DURAGESIC@ is given concurrently with agents that affect CYP3A4 activity.

DrugDDI.d292.s0.e0 15 31
drug
Cytochrome P450 3A4
DrugDDI.d292.s0.e1 85 101
drug
cytochrome P450 3A4
DrugDDI.d292.s0.e2 118 123
drug
CYP3A4
DrugDDI.d292.s0.e3 217 222
drug
CYP3A4



Abstract Id: DrugDDI.d292
Sentence Id: DrugDDI.d292.s2
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole , itraconazole , troleandomycin , clarithromycin , nelfinavir , and nefazadone may result in an increase in fentanyl plasma concentrations.

DrugDDI.d292.s2.e0 30 37
drug
fentanyl
DrugDDI.d292.s2.e1 42 50
drug
ritonavir
DrugDDI.d292.s2.e2 83 94
drug
ketoconazole
DrugDDI.d292.s2.e3 96 107
drug
itraconazole
DrugDDI.d292.s2.e4 109 122
drug
troleandomycin
DrugDDI.d292.s2.e5 124 137
drug
clarithromycin
DrugDDI.d292.s2.e6 139 148
drug
nelfinavir
DrugDDI.d292.s2.e7 186 193
drug
fentanyl

interaction DrugDDI.d292.s2.e0 DrugDDI.d292.s2.e1
interaction DrugDDI.d292.s2.e0 DrugDDI.d292.s2.e2
interaction DrugDDI.d292.s2.e0 DrugDDI.d292.s2.e3
interaction DrugDDI.d292.s2.e0 DrugDDI.d292.s2.e4
interaction DrugDDI.d292.s2.e0 DrugDDI.d292.s2.e5
interaction DrugDDI.d292.s2.e0 DrugDDI.d292.s2.e6

Abstract Id: DrugDDI.d292
Sentence Id: DrugDDI.d292.s3
The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.

DrugDDI.d292.s3.e0 24 29
drug
CYP3A4
DrugDDI.d292.s3.e1 46 54
drug
diltiazem
DrugDDI.d292.s3.e2 58 69
drug
erythromycin
DrugDDI.d292.s3.e3 85 92
drug
fentanyl
DrugDDI.d292.s3.e4 120 127
drug
fentanyl

interaction DrugDDI.d292.s3.e0 DrugDDI.d292.s3.e3
interaction DrugDDI.d292.s3.e1 DrugDDI.d292.s3.e3
interaction DrugDDI.d292.s3.e2 DrugDDI.d292.s3.e3

Abstract Id: DrugDDI.d292
Sentence Id: DrugDDI.d292.s5
Central Nervous System Depressants The concomitant use of DURAGESIC@ ( fentanyl transdermal system) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e.g., benzodiazepines ), general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.

DrugDDI.d292.s5.e0 0 30
drug
Central Nervous System Depressants
DrugDDI.d292.s5.e1 61 68
drug
fentanyl
DrugDDI.d292.s5.e2 96 126
drug
central nervous system depressants
DrugDDI.d292.s5.e3 157 163
drug
opioids
DrugDDI.d292.s5.e4 165 173
drug
sedatives
DrugDDI.d292.s5.e5 175 183
drug
hypnotics
DrugDDI.d292.s5.e6 185 197
drug
tranquilizers
DrugDDI.d292.s5.e7 204 218
drug
benzodiazepines
DrugDDI.d292.s5.e8 221 238
drug
general anesthetics
DrugDDI.d292.s5.e9 240 253
drug
phenothiazines
DrugDDI.d292.s5.e10 255 277
drug
skeletal muscle relaxants
DrugDDI.d292.s5.e11 282 288
drug
alcohol

interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e2
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e3
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e4
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e5
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e6
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e7
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e8
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e9
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e10
interaction DrugDDI.d292.s5.e1 DrugDDI.d292.s5.e11

Abstract Id: DrugDDI.d292
Sentence Id: DrugDDI.d292.s7
MAO Inhibitors DURAGESIC@ is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics .

DrugDDI.d292.s7.e0 0 12
drug
MAO Inhibitors
DrugDDI.d292.s7.e1 129 141
drug
MAO inhibitors
DrugDDI.d292.s7.e2 161 176
drug
opioid analgesics

interaction DrugDDI.d292.s7.e0 DrugDDI.d292.s7.e1
interaction DrugDDI.d292.s7.e1 DrugDDI.d292.s7.e2

Abstract Id: DrugDDI.d44
Sentence Id: DrugDDI.d44.s0
Drug interactions between NEUPOGEN@ and other drugs have not been fully evaluated.

DrugDDI.d44.s0.e0 40 44
drug
drugs



Abstract Id: DrugDDI.d44
Sentence Id: DrugDDI.d44.s1
Drugs which may potentiate the release of neutrophils, such as lithium , should be used with caution.

DrugDDI.d44.s1.e0 0 4
drug
Drugs
DrugDDI.d44.s1.e1 53 59
drug
lithium



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s1
Finasteride does not appear to affect the cytochrome P450 -linked drug-metabolizing enzyme system.

DrugDDI.d543.s1.e0 0 10
drug
Finasteride
DrugDDI.d543.s1.e1 35 48
drug
cytochrome P450



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s2
Compounds that have been tested in man include antipyrine , digoxin , propranolol , theophylline , and warfarin and no clinically meaningful interactions were found.

DrugDDI.d543.s2.e0 39 48
drug
antipyrine
DrugDDI.d543.s2.e1 50 56
drug
digoxin
DrugDDI.d543.s2.e2 58 68
drug
propranolol
DrugDDI.d543.s2.e3 70 81
drug
theophylline
DrugDDI.d543.s2.e4 86 93
drug
warfarin



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s3
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers, analgesics , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists, HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors (also referred to as NSAIDs ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.

DrugDDI.d543.s3.e0 74 84
drug
finasteride
DrugDDI.d543.s3.e1 143 155
drug
acetaminophen
DrugDDI.d543.s3.e2 157 175
drug
acetylsalicylic acid
DrugDDI.d543.s3.e3 188 197
drug
analgesics
DrugDDI.d543.s3.e4 199 226
drug
angiotensin-converting enzyme
DrugDDI.d543.s3.e5 243 257
drug
anticonvulsants
DrugDDI.d543.s3.e6 259 273
drug
benzodiazepines
DrugDDI.d543.s3.e7 275 286
drug
beta blockers
DrugDDI.d543.s3.e8 288 310
drug
calcium-channel blockers
DrugDDI.d543.s3.e9 319 326
drug
nitrates
DrugDDI.d543.s3.e10 328 336
drug
diuretics
DrugDDI.d543.s3.e11 352 377
drug
HMG-CoA reductase inhibitors
DrugDDI.d543.s3.e12 379 411
drug
prostaglandin synthetase inhibitors
DrugDDI.d543.s3.e13 429 434
drug
NSAIDs
DrugDDI.d543.s3.e14 440 463
drug
quinolone anti-infectives



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s4
Drug /Laboratory Test Interactions Finasteride had no effect on circulating levels of cortisol , thyroid-stimulating hormone , or thyroxine , nor did it affect the plasma lipid profile (e.g., total cholesterol, low-density lipoproteins , high-density lipoproteins and triglycerides ) or bone mineral density.

DrugDDI.d543.s4.e0 0 3
drug
Drug
DrugDDI.d543.s4.e1 31 41
drug
Finasteride
DrugDDI.d543.s4.e2 74 81
drug
cortisol
DrugDDI.d543.s4.e3 83 108
drug
thyroid-stimulating hormone
DrugDDI.d543.s4.e4 112 120
drug
thyroxine
DrugDDI.d543.s4.e5 180 202
drug
low-density lipoproteins
DrugDDI.d543.s4.e6 204 227
drug
high-density lipoproteins
DrugDDI.d543.s4.e7 231 243
drug
triglycerides



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s5
In studies with finasteride , no clinically meaningful changes in luteinizing hormone (LH), follicle-stimulating hormone ( FSH ) or prolactin were detected.

DrugDDI.d543.s5.e0 13 23
drug
finasteride
DrugDDI.d543.s5.e1 56 66
drug
luteinizing
DrugDDI.d543.s5.e2 79 98
drug
follicle-stimulating
DrugDDI.d543.s5.e3 107 109
drug
FSH
DrugDDI.d543.s5.e4 113 121
drug
prolactin



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s6
In healthy volunteers, treatment with finasteride did not alter the response of LH and FSH to gonadotropin-releasing hormone indicating that the hypothalamic-pituitary-testicular axis was not affected.

DrugDDI.d543.s6.e0 33 43
drug
finasteride
DrugDDI.d543.s6.e1 73 75
drug
FSH
DrugDDI.d543.s6.e2 78 99
drug
gonadotropin-releasing



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s7
In clinical studies with PROPECIA ( finasteride , 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.

DrugDDI.d543.s7.e0 21 28
drug
PROPECIA
DrugDDI.d543.s7.e1 30 40
drug
finasteride



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s8
Further, in clinical studies with PROSCAR ( finasteride , 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.

DrugDDI.d543.s8.e0 29 35
drug
PROSCAR
DrugDDI.d543.s8.e1 37 47
drug
finasteride



Abstract Id: DrugDDI.d543
Sentence Id: DrugDDI.d543.s9
These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride .

DrugDDI.d543.s9.e0 98 108
drug
finasteride



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s1
TAMBOCOR has been administered to patients receiving digitalis preparation s or beta-adrenergic blocking agents without adverse effects.

DrugDDI.d211.s1.e0 0 7
drug
TAMBOCOR
DrugDDI.d211.s1.e1 46 65
drug
digitalis preparation
DrugDDI.d211.s1.e2 69 97
drug
beta-adrenergic blocking agents



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s2
During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin , a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.

DrugDDI.d211.s2.e0 41 48
drug
TAMBOCOR
DrugDDI.d211.s2.e1 96 102
drug
digoxin

interaction DrugDDI.d211.s2.e0 DrugDDI.d211.s2.e1

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s3
In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.

DrugDDI.d211.s3.e0 41 48
drug
TAMBOCOR
DrugDDI.d211.s3.e1 52 62
drug
propranolol
DrugDDI.d211.s3.e2 82 91
drug
flecainide
DrugDDI.d211.s3.e3 122 132
drug
propranolol

interaction DrugDDI.d211.s3.e0 DrugDDI.d211.s3.e1

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s4
In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects; .

DrugDDI.d211.s4.e0 29 36
drug
TAMBOCOR
DrugDDI.d211.s4.e1 40 50
drug
propranolol

interaction DrugDDI.d211.s4.e0 DrugDDI.d211.s4.e1

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s5
when the drugs were administered together, the effects were additive.

DrugDDI.d211.s5.e0 7 11
drug
drugs



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s6
The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.

DrugDDI.d211.s6.e0 39 46
drug
TAMBOCOR
DrugDDI.d211.s6.e1 50 60
drug
propranolol

interaction DrugDDI.d211.s6.e0 DrugDDI.d211.s6.e1

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s7
In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects.

DrugDDI.d211.s7.e0 2 9
drug
TAMBOCOR
DrugDDI.d211.s7.e1 49 60
drug
beta blockers



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s8
Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.

DrugDDI.d211.s8.e0 63 74
drug
beta blockers
DrugDDI.d211.s8.e1 78 87
drug
flecainide

interaction DrugDDI.d211.s8.e0 DrugDDI.d211.s8.e1

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s9
Flecainide is not extensively bound to plasma proteins .

DrugDDI.d211.s9.e0 0 9
drug
Flecainide
DrugDDI.d211.s9.e1 33 46
drug
plasma proteins



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s10
In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less.

DrugDDI.d211.s10.e0 25 29
drug
drugs
DrugDDI.d211.s10.e1 86 95
drug
flecainide
DrugDDI.d211.s10.e2 110 123
drug
plasma proteins



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s11
Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected.

DrugDDI.d211.s11.e0 34 38
drug
drugs
DrugDDI.d211.s11.e1 53 59
drug
protein
DrugDDI.d211.s11.e2 71 84
drug
anticoagulants



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s12
TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction.

DrugDDI.d211.s12.e0 0 7
drug
TAMBOCOR
DrugDDI.d211.s12.e1 52 60
drug
diuretics



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s13
Limited data in patients receiving known enzyme inducers ( phenytoin , phenobarbital , carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.

DrugDDI.d211.s13.e0 50 58
drug
phenytoin
DrugDDI.d211.s13.e1 60 72
drug
phenobarbital
DrugDDI.d211.s13.e2 74 86
drug
carbamazepine
DrugDDI.d211.s13.e3 123 132
drug
flecainide

interaction DrugDDI.d211.s13.e0 DrugDDI.d211.s13.e3
interaction DrugDDI.d211.s13.e1 DrugDDI.d211.s13.e3
interaction DrugDDI.d211.s13.e2 DrugDDI.d211.s13.e3

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s14
In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.

DrugDDI.d211.s14.e0 26 35
drug
cimetidine
DrugDDI.d211.s14.e1 63 72
drug
flecainide

interaction DrugDDI.d211.s14.e0 DrugDDI.d211.s14.e1

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s15
When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.

DrugDDI.d211.s15.e0 4 13
drug
amiodarone
DrugDDI.d211.s15.e1 23 32
drug
flecainide
DrugDDI.d211.s15.e2 47 56
drug
flecainide
DrugDDI.d211.s15.e3 105 114
drug
flecainide

interaction DrugDDI.d211.s15.e0 DrugDDI.d211.s15.e1

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s16
Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy; .

DrugDDI.d211.s16.e0 0 4
drug
Drugs
DrugDDI.d211.s16.e1 16 25
drug
cytochrome
DrugDDI.d211.s16.e2 41 49
drug
quinidine
DrugDDI.d211.s16.e3 89 98
drug
flecainide
DrugDDI.d211.s16.e4 125 134
drug
flecainide

interaction DrugDDI.d211.s16.e0 DrugDDI.d211.s16.e3
interaction DrugDDI.d211.s16.e2 DrugDDI.d211.s16.e3

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s18
There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil .

DrugDDI.d211.s18.e0 53 60
drug
TAMBOCOR
DrugDDI.d211.s18.e1 70 81
drug
disopyramide
DrugDDI.d211.s18.e2 84 92
drug
verapamil



Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s19
Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.

DrugDDI.d211.s19.e0 18 22
drug
drugs
DrugDDI.d211.s19.e1 89 96
drug
TAMBOCOR
DrugDDI.d211.s19.e2 115 126
drug
disopyramide
DrugDDI.d211.s19.e3 130 138
drug
verapamil
DrugDDI.d211.s19.e4 175 182
drug
TAMBOCOR

interaction DrugDDI.d211.s19.e1 DrugDDI.d211.s19.e2
interaction DrugDDI.d211.s19.e2 DrugDDI.d211.s19.e3

Abstract Id: DrugDDI.d211
Sentence Id: DrugDDI.d211.s20
There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.

DrugDDI.d211.s20.e0 56 63
drug
TAMBOCOR
DrugDDI.d211.s20.e1 68 77
drug
nifedipine
DrugDDI.d211.s20.e2 80 88
drug
diltiazem



Abstract Id: DrugDDI.d232
Sentence Id: DrugDDI.d232.s0
Combination Therapy: Any form of therapy which adds to the stress of the patient, interferes with nutrition or depresses bone marrow function will increase the toxicity of Floxuridine .

DrugDDI.d232.s0.e0 49 54
drug
stress
DrugDDI.d232.s0.e1 145 155
drug
Floxuridine



Abstract Id: DrugDDI.d338
Sentence Id: DrugDDI.d338.s0
Cytosine arabinoside , a cytostatic agent , has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.

DrugDDI.d338.s0.e0 0 18
drug
Cytosine arabinoside
DrugDDI.d338.s0.e1 21 35
drug
cytostatic agent
DrugDDI.d338.s0.e2 67 76
drug
antifungal
DrugDDI.d338.s0.e3 87 97
drug
flucytosine

interaction DrugDDI.d338.s0.e0 DrugDDI.d338.s0.e3

Abstract Id: DrugDDI.d338
Sentence Id: DrugDDI.d338.s1
Drugs which impair glomerular filtration may prolong the biological half-life of flucytosine .

DrugDDI.d338.s1.e0 0 4
drug
Drugs
DrugDDI.d338.s1.e1 70 80
drug
flucytosine

interaction DrugDDI.d338.s1.e0 DrugDDI.d338.s1.e1

Abstract Id: DrugDDI.d338
Sentence Id: DrugDDI.d338.s2
Drug /Laboratory Test Interactions: Measurement of serum creatinine levels should be determined by the Jaffe reaction, since Ancobon does not interfere with the determination of creatinine values by this method.

DrugDDI.d338.s2.e0 0 3
drug
Drug
DrugDDI.d338.s2.e1 108 114
drug
Ancobon
DrugDDI.d338.s2.e2 153 162
drug
creatinine



Abstract Id: DrugDDI.d338
Sentence Id: DrugDDI.d338.s3
Most automated equipment for measurement of creatinine makes use of the Jaffe reaction.

DrugDDI.d338.s3.e0 38 47
drug
creatinine



Abstract Id: DrugDDI.d150
Sentence Id: DrugDDI.d150.s0
The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.

DrugDDI.d150.s0.e0 8 14
drug
FLUDARA
DrugDDI.d150.s0.e1 44 54
drug
pentostatin

interaction DrugDDI.d150.s0.e0 DrugDDI.d150.s0.e1

Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s0
When administered concurrently, the following drugs may interact with adrenal corticosteroids .

DrugDDI.d208.s0.e0 41 45
drug
drugs
DrugDDI.d208.s0.e1 68 82
drug
corticosteroids

interaction DrugDDI.d208.s0.e0 DrugDDI.d208.s0.e1

Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s1
Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs , ethacrynic acid and furosemide )@enhanced hypokalemia.

DrugDDI.d208.s1.e0 0 12
drug
Amphotericin B
DrugDDI.d208.s1.e1 15 42
drug
potassium-depleting diuretics
DrugDDI.d208.s1.e2 71 75
drug
drugs
DrugDDI.d208.s1.e3 77 90
drug
ethacrynic acid
DrugDDI.d208.s1.e4 94 103
drug
furosemide



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s3
use potassium supplements if necessary .

DrugDDI.d208.s3.e0 3 11
drug
potassium



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s4
Digitalis glycosides@enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia.

DrugDDI.d208.s4.e0 0 8
drug
Digitalis



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s6
use potassium supplements if necessary.

DrugDDI.d208.s6.e0 3 11
drug
potassium



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s8
Monitor prothrombin levels and adjust anticoagulant dosage accordingly.

DrugDDI.d208.s8.e0 33 45
drug
anticoagulant



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s9
Antidiabetic drugs (oral agents and insulin )@diminished antidiabetic effect.

DrugDDI.d208.s9.e0 0 16
drug
Antidiabetic drugs
DrugDDI.d208.s9.e1 31 37
drug
insulin
DrugDDI.d208.s9.e2 50 61
drug
antidiabetic



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s11
adjust dosage of antidiabetic drug upward if necessary.

DrugDDI.d208.s11.e0 14 29
drug
antidiabetic drug



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s13
decreased pharmacologic effect of aspirin .

DrugDDI.d208.s13.e0 30 36
drug
aspirin



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s14
Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.

DrugDDI.d208.s14.e0 88 94
drug
aspirin



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s15
Monitor salicylate levels or the therapeutic effect for which aspirin is given; .

DrugDDI.d208.s15.e0 53 59
drug
aspirin



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s16
adjust salicylate dosage accordingly if effect is altered.

DrugDDI.d208.s16.e0 6 15
drug
salicylate



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s17
Barbiturates , phenytoin , or rifampin@increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.

DrugDDI.d208.s17.e0 0 11
drug
Barbiturates
DrugDDI.d208.s17.e1 13 21
drug
phenytoin
DrugDDI.d208.s17.e2 63 84
drug
fludrocortisone acetate



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s19
Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone , methandrostenolone, norethandrolone , and similar compounds)@enhanced tendency toward edema.

DrugDDI.d208.s19.e0 0 15
drug
Anabolic steroids
DrugDDI.d208.s19.e1 42 50
drug
androgens
DrugDDI.d208.s19.e2 57 68
drug
oxymetholone
DrugDDI.d208.s19.e3 89 103
drug
norethandrolone



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s20
Use caution when giving these drugs together, especially in patients with hepatic or cardiac disease.

DrugDDI.d208.s20.e0 25 29
drug
drugs



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s22
Estrogen@increased levels of corticosteroid-binding globulin , thereby increasing the bound (inactive) fraction; .

DrugDDI.d208.s22.e0 26 55
drug
corticosteroid-binding globulin



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s23
this effect is at least balanced by decreased metabolism of corticosteroids .

DrugDDI.d208.s23.e0 50 64
drug
corticosteroids



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s24
When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.

DrugDDI.d208.s24.e0 43 56
drug
corticosteroid
DrugDDI.d208.s24.e1 113 120
drug
estrogen



Abstract Id: DrugDDI.d208
Sentence Id: DrugDDI.d208.s25
Drug /Laboratory Test Interactions Corticosteroids may affect the nitrobluetetrazolium test for bacterial infection and produce false-negative results .

DrugDDI.d208.s25.e0 0 3
drug
Drug
DrugDDI.d208.s25.e1 31 45
drug
Corticosteroids



Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s0
Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied; .

DrugDDI.d151.s0.e0 15 45
drug
central nervous system depressants
DrugDDI.d151.s0.e1 55 69
drug
benzodiazepines



Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s1
however, no deleterious interactions were seen when ROMAZICON was administered after narcotics , inhalational anesthetics , muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.

DrugDDI.d151.s1.e0 45 53
drug
ROMAZICON
DrugDDI.d151.s1.e1 74 82
drug
narcotics
DrugDDI.d151.s1.e2 84 106
drug
inhalational anesthetics
DrugDDI.d151.s1.e3 108 122
drug
muscle relaxants
DrugDDI.d151.s1.e4 126 139
drug
muscle relaxant



Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s2
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants ) may emerge with the reversal of the benzodiazepine effect by flumazenil .

DrugDDI.d151.s2.e0 37 45
drug
ROMAZICON
DrugDDI.d151.s2.e1 60 63
drug
drug
DrugDDI.d151.s2.e2 142 146
drug
drugs
DrugDDI.d151.s2.e3 179 193
drug
antidepressants
DrugDDI.d151.s2.e4 224 237
drug
benzodiazepine
DrugDDI.d151.s2.e5 246 255
drug
flumazenil

interaction DrugDDI.d151.s2.e0 DrugDDI.d151.s2.e1

Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s3
The use of ROMAZICON is not recommended in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period.

DrugDDI.d151.s3.e0 8 16
drug
ROMAZICON
DrugDDI.d151.s3.e1 72 85
drug
benzodiazepine

interaction DrugDDI.d151.s3.e0 DrugDDI.d151.s3.e1

Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s4
Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.

DrugDDI.d151.s4.e0 8 16
drug
ROMAZICON
DrugDDI.d151.s4.e1 39 52
drug
anticonvulsant
DrugDDI.d151.s4.e2 104 117
drug
benzodiazepine

interaction DrugDDI.d151.s4.e0 DrugDDI.d151.s4.e2

Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s5
ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.

DrugDDI.d151.s5.e0 0 8
drug
ROMAZICON
DrugDDI.d151.s5.e1 34 48
drug
benzodiazepines
DrugDDI.d151.s5.e2 78 85
drug
receptor

interaction DrugDDI.d151.s5.e0 DrugDDI.d151.s5.e1

Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s6
The effects of nonbenzodiazepine agonists at benzodiazepine receptors , such as zopiclone , triazolopyridazines and others, are also blocked by ROMAZICON .

DrugDDI.d151.s6.e0 29 36
drug
agonists
DrugDDI.d151.s6.e1 39 61
drug
benzodiazepine receptors
DrugDDI.d151.s6.e2 69 77
drug
zopiclone
DrugDDI.d151.s6.e3 124 132
drug
ROMAZICON

interaction DrugDDI.d151.s6.e0 DrugDDI.d151.s6.e1
interaction DrugDDI.d151.s6.e0 DrugDDI.d151.s6.e2
interaction DrugDDI.d151.s6.e0 DrugDDI.d151.s6.e3

Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s7
The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa.

DrugDDI.d151.s7.e0 21 35
drug
benzodiazepines
DrugDDI.d151.s7.e1 63 72
drug
flumazenil



Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s8
There is no pharmacokinetic interaction between ethanol and flumazenil .

DrugDDI.d151.s8.e0 42 48
drug
ethanol
DrugDDI.d151.s8.e1 52 61
drug
flumazenil



Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s9
Use in Ambulatory Patients The effects of ROMAZICON may wear off before a long-acting benzodiazepine is completely cleared from the body.

DrugDDI.d151.s9.e0 35 43
drug
ROMAZICON
DrugDDI.d151.s9.e1 61 85
drug
long-acting benzodiazepine

interaction DrugDDI.d151.s9.e0 DrugDDI.d151.s9.e1

Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s10
In general, if a patient shows no signs of sedation within 2 hours after a 1-mg dose of flumazenil , serious resedation at a later time is unlikely.

DrugDDI.d151.s10.e0 70 79
drug
flumazenil



Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s11
An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam ) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam ) have been used.

DrugDDI.d151.s11.e0 68 93
drug
long-acting benzodiazepines
DrugDDI.d151.s11.e1 101 108
drug
diazepam
DrugDDI.d151.s11.e2 124 150
drug
short-acting benzodiazepines
DrugDDI.d151.s11.e3 164 172
drug
midazolam



Abstract Id: DrugDDI.d151
Sentence Id: DrugDDI.d151.s12
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine , alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.

DrugDDI.d151.s12.e0 70 84
drug
benzodiazepines
DrugDDI.d151.s12.e1 183 196
drug
benzodiazepine
DrugDDI.d151.s12.e2 198 204
drug
alcohol
DrugDDI.d151.s12.e3 208 215
drug
sedative
DrugDDI.d151.s12.e4 271 279
drug
ROMAZICON

interaction DrugDDI.d151.s12.e1 DrugDDI.d151.s12.e4
interaction DrugDDI.d151.s12.e2 DrugDDI.d151.s12.e4
interaction DrugDDI.d151.s12.e3 DrugDDI.d151.s12.e4

Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s0
Do not take this medicine with thioridizine, or within 5 weeks of taking fluoxetine .

DrugDDI.d97.s0.e0 13 20
drug
medicine
DrugDDI.d97.s0.e1 60 69
drug
fluoxetine



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s1
Talk to your doctor if you are taking certain antibiotics such as erythromycin , clarithromycin or azithromycin .

DrugDDI.d97.s1.e0 37 47
drug
antibiotics
DrugDDI.d97.s1.e1 54 65
drug
erythromycin
DrugDDI.d97.s1.e2 67 80
drug
clarithromycin
DrugDDI.d97.s1.e3 83 94
drug
azithromycin



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s2
This medicine should not be taken with MAO inhibitors .

DrugDDI.d97.s2.e0 4 11
drug
medicine
DrugDDI.d97.s2.e1 32 44
drug
MAO inhibitors

interaction DrugDDI.d97.s2.e0 DrugDDI.d97.s2.e1

Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s3
Caution should be exercised when taking this medicine certain antibiotics , such as erythromycin , clarithromycin , or azithromycin .

DrugDDI.d97.s3.e0 53 63
drug
antibiotics
DrugDDI.d97.s3.e1 71 82
drug
erythromycin
DrugDDI.d97.s3.e2 84 97
drug
clarithromycin
DrugDDI.d97.s3.e3 101 112
drug
azithromycin

interaction DrugDDI.d97.s3.e0 DrugDDI.d97.s3.e1
interaction DrugDDI.d97.s3.e0 DrugDDI.d97.s3.e2
interaction DrugDDI.d97.s3.e0 DrugDDI.d97.s3.e3

Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s4
This medicine should not be taken with MAO inhibitors .

DrugDDI.d97.s4.e0 4 11
drug
medicine
DrugDDI.d97.s4.e1 32 44
drug
MAO inhibitors

interaction DrugDDI.d97.s4.e0 DrugDDI.d97.s4.e1

Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s5
If you think you are taking an MAO inhibitor talk to your doctor or pharmacist.

DrugDDI.d97.s5.e0 24 35
drug
MAO inhibitor



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s6
Do not take this medicine with St. Johns Wort because of the additive effects of sertonin.

DrugDDI.d97.s6.e0 13 20
drug
medicine
DrugDDI.d97.s6.e1 25 36
drug
St. Johns Wort

interaction DrugDDI.d97.s6.e0 DrugDDI.d97.s6.e1

Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s7
This medication should not be taken with MAO inhibitors .

DrugDDI.d97.s7.e0 4 13
drug
medication
DrugDDI.d97.s7.e1 34 46
drug
MAO inhibitors

interaction DrugDDI.d97.s7.e0 DrugDDI.d97.s7.e1

Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s8
Your doctor or pharmacist can give you more information on MAO inhibitors .

DrugDDI.d97.s8.e0 49 61
drug
MAO inhibitors



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s9
Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor .

DrugDDI.d97.s9.e0 23 34
drug
escitalopram
DrugDDI.d97.s9.e1 63 74
drug
MAO inhibitor



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s10
Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram .

DrugDDI.d97.s10.e0 25 36
drug
MAO inhibitor
DrugDDI.d97.s10.e1 51 62
drug
escitalopram



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s11
If you are taking medications for migraines such as Imitrex , talk to your doctor before starting this medicine .

DrugDDI.d97.s11.e0 43 49
drug
Imitrex
DrugDDI.d97.s11.e1 85 92
drug
medicine



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s12
If you are taking a tricyclic antidepressant , talk to your doctor before taking this medicine .

DrugDDI.d97.s12.e0 15 37
drug
tricyclic antidepressant
DrugDDI.d97.s12.e1 71 78
drug
medicine



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s13
St. John@@s Wort should be avoided while taking this medicine due to the additive effects of serotonin.

DrugDDI.d97.s13.e0 44 51
drug
medicine



Abstract Id: DrugDDI.d97
Sentence Id: DrugDDI.d97.s14
Tell your doctor if you are taking any of the following drugs : blood thinner s ( Coumadin ) other antidepressants metoprolol antihistamines carbamazepine ( Tegretol ) cimetidine ( Tagamet ) estrogens fluoxetine ( Prozac ) intraconazole ( Sporanox ) ketoconazole ( Nizoral ) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications .

DrugDDI.d97.s14.e0 45 49
drug
drugs
DrugDDI.d97.s14.e1 51 62
drug
blood thinner
DrugDDI.d97.s14.e2 65 72
drug
Coumadin
DrugDDI.d97.s14.e3 79 93
drug
antidepressants
DrugDDI.d97.s14.e4 104 117
drug
antihistamines
DrugDDI.d97.s14.e5 118 130
drug
carbamazepine
DrugDDI.d97.s14.e6 132 139
drug
Tegretol
DrugDDI.d97.s14.e7 141 150
drug
cimetidine
DrugDDI.d97.s14.e8 152 158
drug
Tagamet
DrugDDI.d97.s14.e9 160 168
drug
estrogens
DrugDDI.d97.s14.e10 180 185
drug
Prozac
DrugDDI.d97.s14.e11 201 208
drug
Sporanox
DrugDDI.d97.s14.e12 210 221
drug
ketoconazole
DrugDDI.d97.s14.e13 223 229
drug
Nizoral
DrugDDI.d97.s14.e14 231 238
drug
levodopa



Abstract Id: DrugDDI.d283
Sentence Id: DrugDDI.d283.s0
Drug Interactions: Flupenthixol may interact with some drugs , like: - Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants .

DrugDDI.d283.s0.e0 17 28
drug
Flupenthixol
DrugDDI.d283.s0.e1 48 52
drug
drugs
DrugDDI.d283.s0.e2 60 85
drug
Monoamine oxidase inhibitors
DrugDDI.d283.s0.e3 87 90
drug
MAOI
DrugDDI.d283.s0.e4 93 96
drug
MAOI
DrugDDI.d283.s0.e5 121 132
drug
flupenthixol
DrugDDI.d283.s0.e6 180 191
drug
Flupenthixol
DrugDDI.d283.s0.e7 195 201
drug
Ethanol
DrugDDI.d283.s0.e8 254 265
drug
Flupenthixol
DrugDDI.d283.s0.e9 286 309
drug
Tricyclic antidepressants

interaction DrugDDI.d283.s0.e0 DrugDDI.d283.s0.e1
interaction DrugDDI.d283.s0.e0 DrugDDI.d283.s0.e2
interaction DrugDDI.d283.s0.e0 DrugDDI.d283.s0.e3
interaction DrugDDI.d283.s0.e4 DrugDDI.d283.s0.e5
interaction DrugDDI.d283.s0.e8 DrugDDI.d283.s0.e9

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s0
Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.

DrugDDI.d485.s0.e0 67 74
drug
warfarin
DrugDDI.d485.s0.e1 87 95
drug
flutamide

interaction DrugDDI.d485.s0.e0 DrugDDI.d485.s0.e1

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s1
Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin .

DrugDDI.d485.s1.e0 73 85
drug
anticoagulant
DrugDDI.d485.s1.e1 108 122
drug
EULEXIN Capsules
DrugDDI.d485.s1.e2 155 162
drug
warfarin

interaction DrugDDI.d485.s1.e1 DrugDDI.d485.s1.e2

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s0
Potential for Interaction with Monoamine Oxidase Inhibitors .

DrugDDI.d129.s0.e0 27 52
drug
Monoamine Oxidase Inhibitors



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s1
In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.

DrugDDI.d129.s1.e0 26 51
drug
serotonin reuptake inhibitor
DrugDDI.d129.s1.e1 73 98
drug
monoamine oxidase inhibitors

interaction DrugDDI.d129.s1.e0 DrugDDI.d129.s1.e1

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s2
These reactions have also been reported in patients who have discontinued that drug and have been started on a MAOI.

DrugDDI.d129.s2.e0 67 70
drug
drug



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s4
Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.

DrugDDI.d129.s4.e0 29 39
drug
Fluvoxamine



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s5
After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.

DrugDDI.d129.s5.e0 13 23
drug
Fluvoxamine



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s6
Potential Terfenadine , Astemizole , and Cisapride Interactions .

DrugDDI.d129.s6.e0 9 19
drug
Terfenadine
DrugDDI.d129.s6.e1 21 30
drug
Astemizole
DrugDDI.d129.s6.e2 35 43
drug
Cisapride



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s7
Terfenadine , astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme , and it has been demonstrated that ketoconazole , a potent inhibitor of IIIA4, blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .

DrugDDI.d129.s7.e0 0 10
drug
Terfenadine
DrugDDI.d129.s7.e1 12 21
drug
astemizole
DrugDDI.d129.s7.e2 25 33
drug
cisapride
DrugDDI.d129.s7.e3 75 81
drug
isozyme
DrugDDI.d129.s7.e4 111 122
drug
ketoconazole
DrugDDI.d129.s7.e5 174 178
drug
drugs
DrugDDI.d129.s7.e6 228 231
drug
drug

interaction DrugDDI.d129.s7.e0 DrugDDI.d129.s7.e4
interaction DrugDDI.d129.s7.e1 DrugDDI.d129.s7.e4
interaction DrugDDI.d129.s7.e2 DrugDDI.d129.s7.e4
interaction DrugDDI.d129.s7.e4 DrugDDI.d129.s7.e5

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s8
Increased plasma concentrations of terfenadine , astemizole , and cisapride cause QT prolongation and have been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal.

DrugDDI.d129.s8.e0 31 41
drug
terfenadine
DrugDDI.d129.s8.e1 43 52
drug
astemizole
DrugDDI.d129.s8.e2 57 65
drug
cisapride



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s9
As noted below, a sub- for fluvoxamine in combination with alprazolam , a drug that is known to be metabolized by the IIIA4 isozyme .

DrugDDI.d129.s9.e0 21 31
drug
fluvoxamine
DrugDDI.d129.s9.e1 49 58
drug
alprazolam
DrugDDI.d129.s9.e2 61 64
drug
drug
DrugDDI.d129.s9.e3 101 107
drug
isozyme



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s10
Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam .

DrugDDI.d129.s10.e0 48 58
drug
fluvoxamine
DrugDDI.d129.s10.e1 130 140
drug
fluvoxamine
DrugDDI.d129.s10.e2 145 154
drug
alprazolam

interaction DrugDDI.d129.s10.e1 DrugDDI.d129.s10.e2

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s11
Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine , astemizole , or cisapride .

DrugDDI.d129.s11.e0 32 42
drug
fluvoxamine
DrugDDI.d129.s11.e1 75 85
drug
terbinafine
DrugDDI.d129.s11.e2 87 96
drug
astemizole
DrugDDI.d129.s11.e3 100 108
drug
cisapride

interaction DrugDDI.d129.s11.e0 DrugDDI.d129.s11.e1
interaction DrugDDI.d129.s11.e0 DrugDDI.d129.s11.e2
interaction DrugDDI.d129.s11.e0 DrugDDI.d129.s11.e3

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s12
Other Potentially Important Drug Interactions: Benzodiazepines : Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam , midazolam , triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine .

DrugDDI.d129.s12.e0 42 56
drug
Benzodiazepines
DrugDDI.d129.s12.e1 58 72
drug
Benzodiazepines
DrugDDI.d129.s12.e2 108 117
drug
alprazolam
DrugDDI.d129.s12.e3 119 127
drug
midazolam
DrugDDI.d129.s12.e4 129 137
drug
triazolam
DrugDDI.d129.s12.e5 192 196
drug
drugs
DrugDDI.d129.s12.e6 218 228
drug
fluvoxamine

interaction DrugDDI.d129.s12.e1 DrugDDI.d129.s12.e6
interaction DrugDDI.d129.s12.e2 DrugDDI.d129.s12.e6
interaction DrugDDI.d129.s12.e3 DrugDDI.d129.s12.e6
interaction DrugDDI.d129.s12.e4 DrugDDI.d129.s12.e6

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s13
The clearance of benzodiazepines metabolized by glucuronidation (e. g., lorazepam , oxazepam , temazepam ) is unlikely to be affected by fluvoxamine .

DrugDDI.d129.s13.e0 14 28
drug
benzodiazepines
DrugDDI.d129.s13.e1 63 71
drug
lorazepam
DrugDDI.d129.s13.e2 73 80
drug
oxazepam
DrugDDI.d129.s13.e3 82 90
drug
temazepam
DrugDDI.d129.s13.e4 116 126
drug
fluvoxamine



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s14
Alprazolam : When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1 /2,) of alprazolam were approximately twice those observed when alprazolam was administered alone; .

DrugDDI.d129.s14.e0 0 9
drug
Alprazolam
DrugDDI.d129.s14.e1 15 25
drug
fluvoxamine
DrugDDI.d129.s14.e2 45 54
drug
alprazolam
DrugDDI.d129.s14.e3 159 160
drug
T1
DrugDDI.d129.s14.e4 167 176
drug
alprazolam
DrugDDI.d129.s14.e5 216 225
drug
alprazolam

interaction DrugDDI.d129.s14.e1 DrugDDI.d129.s14.e2

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s16
The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory.

DrugDDI.d129.s16.e0 17 26
drug
alprazolam



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s17
This interaction, which has not been investigated using higher doses of fluvoxamine , may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.

DrugDDI.d129.s17.e0 61 71
drug
fluvoxamine
DrugDDI.d129.s17.e1 144 154
drug
fluvoxamine
DrugDDI.d129.s17.e2 219 228
drug
alprazolam
DrugDDI.d129.s17.e3 250 260
drug
Fluvoxamine
DrugDDI.d129.s17.e4 279 288
drug
alprazolam



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s18
No dosage adjustment is required for Fluvoxamine Tablets.

DrugDDI.d129.s18.e0 31 41
drug
Fluvoxamine



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s19
Diazepam : The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.

DrugDDI.d129.s19.e0 0 7
drug
Diazepam
DrugDDI.d129.s19.e1 31 41
drug
Fluvoxamine
DrugDDI.d129.s19.e2 52 59
drug
diazepam

interaction DrugDDI.d129.s19.e1 DrugDDI.d129.s19.e2

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s20
Because fluvoxamine reduces the clearance of both diazepam and its active metabolite , N- desmethyldiazepam , there is a strong likelihood of substantial accumulation of both species during chronic co-administration.

DrugDDI.d129.s20.e0 7 17
drug
fluvoxamine
DrugDDI.d129.s20.e1 43 50
drug
diazepam
DrugDDI.d129.s20.e2 57 72
drug
active metabolite
DrugDDI.d129.s20.e3 76 92
drug
desmethyldiazepam

interaction DrugDDI.d129.s20.e0 DrugDDI.d129.s20.e1
interaction DrugDDI.d129.s20.e0 DrugDDI.d129.s20.e2
interaction DrugDDI.d129.s20.e0 DrugDDI.d129.s20.e3

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s21
Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam .

DrugDDI.d129.s21.e0 65 75
drug
fluvoxamine
DrugDDI.d129.s21.e1 79 86
drug
diazepam
DrugDDI.d129.s21.e2 147 157
drug
fluvoxamine
DrugDDI.d129.s21.e3 197 204
drug
diazepam

interaction DrugDDI.d129.s21.e0 DrugDDI.d129.s21.e1

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s22
In these subjects (R= B), the clearance of diazepam was reduced by 65% and that of N- desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.

DrugDDI.d129.s22.e0 35 42
drug
diazepam
DrugDDI.d129.s22.e1 69 85
drug
desmethyldiazepam



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s23
It is likely that experience significantly underestimates the degree of accumulation that might occur with repealed diazepam administration.

DrugDDI.d129.s23.e0 100 107
drug
diazepam



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s24
Moreover, as noted with alprazolam , the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.

DrugDDI.d129.s24.e0 20 29
drug
alprazolam
DrugDDI.d129.s24.e1 42 52
drug
fluvoxamine

interaction DrugDDI.d129.s24.e0 DrugDDI.d129.s24.e1

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s25
Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.

DrugDDI.d129.s25.e0 12 19
drug
diazepam
DrugDDI.d129.s25.e1 23 33
drug
fluvoxamine

interaction DrugDDI.d129.s25.e0 DrugDDI.d129.s25.e1

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s26
Theophylline : The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.

DrugDDI.d129.s26.e0 0 11
drug
Theophylline
DrugDDI.d129.s26.e1 52 54
drug
bid
DrugDDI.d129.s26.e2 91 102
drug
Theophylline
DrugDDI.d129.s26.e3 117 129
drug
aminophylline



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s27
The clearance of theophylline was decreased approximately 3-fold.

DrugDDI.d129.s27.e0 14 25
drug
theophylline



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s28
Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.

DrugDDI.d129.s28.e0 12 23
drug
theophylline
DrugDDI.d129.s28.e1 45 55
drug
fluvoxamine
DrugDDI.d129.s28.e2 151 162
drug
theophylline

interaction DrugDDI.d129.s28.e0 DrugDDI.d129.s28.e1

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s29
No dosage adjustment is required for Fluvoxamine Tablets.

DrugDDI.d129.s29.e0 31 41
drug
Fluvoxamine



Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s30
Warfarin : When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.

DrugDDI.d129.s30.e0 0 7
drug
Warfarin
DrugDDI.d129.s30.e1 13 23
drug
fluvoxamine
DrugDDI.d129.s30.e2 72 79
drug
warfarin
DrugDDI.d129.s30.e3 92 99
drug
warfarin

interaction DrugDDI.d129.s30.e1 DrugDDI.d129.s30.e2

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s31
Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.

DrugDDI.d129.s31.e0 21 38
drug
oral anticoagulants
DrugDDI.d129.s31.e1 42 52
drug
Fluvoxamine
DrugDDI.d129.s31.e2 107 119
drug
anticoagulant

interaction DrugDDI.d129.s31.e0 DrugDDI.d129.s31.e1

Abstract Id: DrugDDI.d129
Sentence Id: DrugDDI.d129.s32
No dosage adjustment is required for Fluvoxamine Tablets.

DrugDDI.d129.s32.e0 31 41
drug
Fluvoxamine



Abstract Id: DrugDDI.d555
Sentence Id: DrugDDI.d555.s0
Medications that interfere with your bodys ability to use folate may also increase the need for this vitamin .

DrugDDI.d555.s0.e0 0 10
drug
Medications
DrugDDI.d555.s0.e1 84 90
drug
vitamin



Abstract Id: DrugDDI.d555
Sentence Id: DrugDDI.d555.s1
Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin , and primidone ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic ) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid .

DrugDDI.d555.s1.e0 0 10
drug
Medications
DrugDDI.d555.s1.e1 55 68
drug
anticonvulsant
DrugDDI.d555.s1.e2 87 95
drug
phenytoin
DrugDDI.d555.s1.e3 100 108
drug
primidone
DrugDDI.d555.s1.e4 110 118
drug
metformin
DrugDDI.d555.s1.e5 174 186
drug
sulfasalazine
DrugDDI.d555.s1.e6 261 271
drug
triamterene
DrugDDI.d555.s1.e7 274 281
drug
diuretic
DrugDDI.d555.s1.e8 283 294
drug
Methotrexate
DrugDDI.d555.s1.e9 340 349
drug
vitamin B12
DrugDDI.d555.s1.e10 353 361
drug
folic acid

interaction DrugDDI.d555.s1.e9 DrugDDI.d555.s1.e10

Abstract Id: DrugDDI.d555
Sentence Id: DrugDDI.d555.s2
Folic acid supplements can correct the anemia associated with vitamin B12 deficiency.

DrugDDI.d555.s2.e0 0 8
drug
Folic acid



Abstract Id: DrugDDI.d555
Sentence Id: DrugDDI.d555.s3
Unfortunately, folic acid will not correct changes in the nervous system that result from vitamin B12 deficiency.

DrugDDI.d555.s3.e0 14 22
drug
folic acid



Abstract Id: DrugDDI.d555
Sentence Id: DrugDDI.d555.s5
Therefore, intake of supplemental folic acid should not exceed 1000 micrograms (@g, sometimes mcg) per day to prevent folic acid from masking symptoms of vitamin B12 deficiency.

DrugDDI.d555.s5.e0 30 38
drug
folic acid
DrugDDI.d555.s5.e1 93 99
drug
prevent
DrugDDI.d555.s5.e2 100 108
drug
folic acid



Abstract Id: DrugDDI.d555
Sentence Id: DrugDDI.d555.s6
It is important for older adults to be aware of the relationship between folic acid and vitamin B12 because they are at greater risk of having a vitamin B12 deficiency.

DrugDDI.d555.s6.e0 60 68
drug
folic acid
DrugDDI.d555.s6.e1 72 81
drug
vitamin B12



Abstract Id: DrugDDI.d555
Sentence Id: DrugDDI.d555.s7
If you are 50 years of age or older, ask your physician to check your B12 status before you take a supplement that contains folic acid .

DrugDDI.d555.s7.e0 28 30
drug
ask
DrugDDI.d555.s7.e1 100 108
drug
folic acid



Abstract Id: DrugDDI.d309
Sentence Id: DrugDDI.d309.s0
No drug /drug interaction studies have been performed.

DrugDDI.d309.s0.e0 2 5
drug
drug



Abstract Id: DrugDDI.d146
Sentence Id: DrugDDI.d146.s0
Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.

DrugDDI.d146.s0.e0 11 17
drug
Antizol
DrugDDI.d146.s0.e1 34 53
drug
alcohol dehydrogenase
DrugDDI.d146.s0.e2 107 113
drug
ethanol

interaction DrugDDI.d146.s0.e0 DrugDDI.d146.s0.e2

Abstract Id: DrugDDI.d146
Sentence Id: DrugDDI.d146.s1
Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.

DrugDDI.d146.s1.e0 10 16
drug
ethanol
DrugDDI.d146.s1.e1 48 54
drug
Antizol

interaction DrugDDI.d146.s1.e0 DrugDDI.d146.s1.e1

Abstract Id: DrugDDI.d146
Sentence Id: DrugDDI.d146.s2
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin , carbamazepine , cimetidine , ketoconazole ), though this has not been studied .

DrugDDI.d146.s2.e0 50 56
drug
Antizol
DrugDDI.d146.s2.e1 60 64
drug
drugs
DrugDDI.d146.s2.e2 89 102
drug
cytochrome P450
DrugDDI.d146.s2.e3 115 123
drug
phenytoin
DrugDDI.d146.s2.e4 125 137
drug
carbamazepine
DrugDDI.d146.s2.e5 139 148
drug
cimetidine
DrugDDI.d146.s2.e6 150 161
drug
ketoconazole

interaction DrugDDI.d146.s2.e0 DrugDDI.d146.s2.e1
interaction DrugDDI.d146.s2.e0 DrugDDI.d146.s2.e4
interaction DrugDDI.d146.s2.e0 DrugDDI.d146.s2.e6

Abstract Id: DrugDDI.d339
Sentence Id: DrugDDI.d339.s0
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet inhibitors ( acetylsalicylic acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .

DrugDDI.d339.s0.e0 30 41
drug
Fondaparinux
DrugDDI.d339.s0.e1 62 79
drug
oral anticoagulants
DrugDDI.d339.s0.e2 81 88
drug
warfarin
DrugDDI.d339.s0.e3 91 108
drug
platelet inhibitors
DrugDDI.d339.s0.e4 110 128
drug
acetylsalicylic acid
DrugDDI.d339.s0.e5 131 136
drug
NSAIDs
DrugDDI.d339.s0.e6 138 146
drug
piroxicam
DrugDDI.d339.s0.e7 152 158
drug
digoxin
DrugDDI.d339.s0.e8 222 239
drug
fondaparinux sodium



Abstract Id: DrugDDI.d339
Sentence Id: DrugDDI.d339.s1
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state.

DrugDDI.d339.s1.e0 11 22
drug
Fondaparinux
DrugDDI.d339.s1.e1 61 68
drug
warfarin
DrugDDI.d339.s1.e2 70 88
drug
acetylsalicylic acid
DrugDDI.d339.s1.e3 90 98
drug
piroxicam
DrugDDI.d339.s1.e4 103 109
drug
digoxin
DrugDDI.d339.s1.e5 135 141
drug
digoxin



Abstract Id: DrugDDI.d339
Sentence Id: DrugDDI.d339.s2
Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of Fondaparinux therapy.

DrugDDI.d339.s2.e0 78 89
drug
Fondaparinux



Abstract Id: DrugDDI.d339
Sentence Id: DrugDDI.d339.s4
In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux ( 200 m m M i.e., 350 mg/L) was 17-28%.

DrugDDI.d339.s4.e0 51 56
drug
CYP2A6
DrugDDI.d339.s4.e1 72 79
drug
coumarin
DrugDDI.d339.s4.e2 82 93
drug
fondaparinux
DrugDDI.d339.s4.e3 95 97
drug
200

interaction DrugDDI.d339.s4.e1 DrugDDI.d339.s4.e2

Abstract Id: DrugDDI.d339
Sentence Id: DrugDDI.d339.s5
Inhibition of the other isozymes evaluated ( CYP s 2A1, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0-16%.

DrugDDI.d339.s5.e0 20 27
drug
isozymes
DrugDDI.d339.s5.e1 38 40
drug
CYP



Abstract Id: DrugDDI.d339
Sentence Id: DrugDDI.d339.s6
Since fondaparinux does not markedly inhibit CYP450s ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP2E1 , or CYP3A4 ) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes .

DrugDDI.d339.s6.e0 5 16
drug
fondaparinux
DrugDDI.d339.s6.e1 47 52
drug
CYP1A2
DrugDDI.d339.s6.e2 54 59
drug
CYP2A6
DrugDDI.d339.s6.e3 61 66
drug
CYP2C9
DrugDDI.d339.s6.e4 68 74
drug
CYP2C19
DrugDDI.d339.s6.e5 76 81
drug
CYP2D6
DrugDDI.d339.s6.e6 83 88
drug
CYP2E1
DrugDDI.d339.s6.e7 92 97
drug
CYP3A4
DrugDDI.d339.s6.e8 107 124
drug
fondaparinux sodium
DrugDDI.d339.s6.e9 170 174
drug
drugs
DrugDDI.d339.s6.e10 220 227
drug
isozymes



Abstract Id: DrugDDI.d339
Sentence Id: DrugDDI.d339.s7
Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected.

DrugDDI.d339.s7.e0 5 22
drug
fondaparinux sodium
DrugDDI.d339.s7.e1 49 62
drug
plasma proteins



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s0
Short-Acting @2- agonists : Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol .

DrugDDI.d29.s0.e0 15 22
drug
agonists
DrugDDI.d29.s0.e1 31 45
drug
bronchodilators
DrugDDI.d29.s0.e2 73 81
drug
stimulant
DrugDDI.d29.s0.e3 136 145
drug
formoterol



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s2
Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL .

DrugDDI.d29.s2.e0 32 52
drug
sympathomimetic agents
DrugDDI.d29.s2.e1 89 95
drug
FORADIL

interaction DrugDDI.d29.s2.e0 DrugDDI.d29.s2.e1

Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s3
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.

DrugDDI.d29.s3.e0 0 25
drug
Monoamine Oxidase Inhibitors
DrugDDI.d29.s3.e1 29 52
drug
Tricyclic Antidepressants
DrugDDI.d29.s3.e2 54 60
drug
FORADIL
DrugDDI.d29.s3.e3 125 150
drug
monoamine oxidase inhibitors
DrugDDI.d29.s3.e4 153 176
drug
tricyclic antidepressants
DrugDDI.d29.s3.e5 195 204
drug
formoterol

interaction DrugDDI.d29.s3.e2 DrugDDI.d29.s3.e3

Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s4
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of @2- agonists .

DrugDDI.d29.s4.e0 0 14
drug
Corticosteroids
DrugDDI.d29.s4.e1 16 30
drug
Methylxanthines
DrugDDI.d29.s4.e2 34 42
drug
Diuretics
DrugDDI.d29.s4.e3 68 75
drug
xanthine
DrugDDI.d29.s4.e4 99 107
drug
diuretics
DrugDDI.d29.s4.e5 152 159
drug
agonists

interaction DrugDDI.d29.s4.e4 DrugDDI.d29.s4.e5

Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s5
Hypokalemia may increase susceptibility to cardiac arrhythmias in patients treated with digitalis .

DrugDDI.d29.s5.e0 77 85
drug
digitalis



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s6
@- adrenergic Blockers : @- adrenergic blockers may weaken or antagonise the effect of FORADIL .

DrugDDI.d29.s6.e0 2 19
drug
adrenergic Blockers
DrugDDI.d29.s6.e1 23 40
drug
adrenergic blockers
DrugDDI.d29.s6.e2 73 79
drug
FORADIL

interaction DrugDDI.d29.s6.e1 DrugDDI.d29.s6.e2

Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s7
Therefore FORADIL should not be given together with @- adrenergic blockers (including eye drops) unless there are compelling reasons for their use.

DrugDDI.d29.s7.e0 9 15
drug
FORADIL
DrugDDI.d29.s7.e1 46 63
drug
adrenergic blockers

interaction DrugDDI.d29.s7.e0 DrugDDI.d29.s7.e1

Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s8
Other Drugs : Drugs such as quinidine , disopyramide , procainamide , phenothiazines , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.

DrugDDI.d29.s8.e0 5 9
drug
Drugs
DrugDDI.d29.s8.e1 11 15
drug
Drugs
DrugDDI.d29.s8.e2 22 30
drug
quinidine
DrugDDI.d29.s8.e3 32 43
drug
disopyramide
DrugDDI.d29.s8.e4 45 56
drug
procainamide
DrugDDI.d29.s8.e5 58 71
drug
phenothiazines
DrugDDI.d29.s8.e6 73 86
drug
antihistamines
DrugDDI.d29.s8.e7 91 114
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s10
It is important that patients understand how to use FORADIL@ ( formoterol fumarate ) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.

DrugDDI.d29.s10.e0 52 69
drug
formoterol fumarate
DrugDDI.d29.s10.e1 170 180
drug
medications



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s14
FORADIL is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.

DrugDDI.d29.s14.e0 0 6
drug
FORADIL



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s15
Acute symptoms should be treated with a short-acting, inhaled @2 - agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used).

DrugDDI.d29.s15.e0 56 62
drug
agonist
DrugDDI.d29.s15.e1 69 78
drug
salbutamol
DrugDDI.d29.s15.e2 123 132
drug
medication



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s17
The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously worsening asthma: @ Decreased effectiveness of short-acting, inhaled @2- agonists ; .

DrugDDI.d29.s17.e0 164 171
drug
agonists



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s18
@ Need for more inhalations than usual of short-acting, inhaled @2 - agonists .

DrugDDI.d29.s18.e0 12 22
drug
inhalations
DrugDDI.d29.s18.e1 57 64
drug
agonists



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s20
FORADIL should not be used as a substitute for oral or inhaled corticosteroids .

DrugDDI.d29.s20.e0 0 6
drug
FORADIL
DrugDDI.d29.s20.e1 51 65
drug
corticosteroids



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s21
The dosage of these medications should not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating treatment with FORADIL .

DrugDDI.d29.s21.e0 16 26
drug
medications
DrugDDI.d29.s21.e1 155 161
drug
FORADIL



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s24
In patients receiving FORADIL , other inhaled medications should be used only as directed by the physician.

DrugDDI.d29.s24.e0 19 25
drug
FORADIL
DrugDDI.d29.s24.e1 32 49
drug
inhaled medications



Abstract Id: DrugDDI.d29
Sentence Id: DrugDDI.d29.s26
Guardians of children who have been prescribed FORADIL should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of short-acting @2- agonists .

DrugDDI.d29.s26.e0 40 46
drug
FORADIL
DrugDDI.d29.s26.e1 184 191
drug
agonists



Abstract Id: DrugDDI.d301
Sentence Id: DrugDDI.d301.s0
A possible drug interaction of FOSCAVIR and intravenous pentamidin e has been described.

DrugDDI.d301.s0.e0 26 33
drug
FOSCAVIR
DrugDDI.d301.s0.e1 48 57
drug
pentamidin

interaction DrugDDI.d301.s0.e0 DrugDDI.d301.s0.e1

Abstract Id: DrugDDI.d301
Sentence Id: DrugDDI.d301.s1
Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidin e may have caused hypocalcemia; .

DrugDDI.d301.s1.e0 56 63
drug
FOSCAVIR
DrugDDI.d301.s1.e1 78 87
drug
pentamidin

interaction DrugDDI.d301.s1.e0 DrugDDI.d301.s1.e1

Abstract Id: DrugDDI.d301
Sentence Id: DrugDDI.d301.s3
Toxicity associated with concomitant use of aerosolized pentamidin e has not been reported.

DrugDDI.d301.s3.e0 49 58
drug
pentamidin



Abstract Id: DrugDDI.d301
Sentence Id: DrugDDI.d301.s4
Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin B and intravenous pentamidin e unless the potential benefits outweigh the risks to the patient.

DrugDDI.d301.s4.e0 9 17
drug
foscarnet
DrugDDI.d301.s4.e1 58 65
drug
FOSCAVIR
DrugDDI.d301.s4.e2 120 124
drug
drugs
DrugDDI.d301.s4.e3 131 145
drug
aminoglycosides
DrugDDI.d301.s4.e4 147 159
drug
amphotericin B
DrugDDI.d301.s4.e5 174 183
drug
pentamidin

interaction DrugDDI.d301.s4.e1 DrugDDI.d301.s4.e2
interaction DrugDDI.d301.s4.e1 DrugDDI.d301.s4.e4

Abstract Id: DrugDDI.d301
Sentence Id: DrugDDI.d301.s5
Abnormal renal function has been observed in clinical practice during the use of FASCAVIR and ritonavir , or FOSCAVIR , ritonavir , and saquinavir .

DrugDDI.d301.s5.e0 79 87
drug
ritonavir
DrugDDI.d301.s5.e1 91 98
drug
FOSCAVIR
DrugDDI.d301.s5.e2 100 108
drug
ritonavir
DrugDDI.d301.s5.e3 113 122
drug
saquinavir

interaction DrugDDI.d301.s5.e0 DrugDDI.d301.s5.e1

Abstract Id: DrugDDI.d301
Sentence Id: DrugDDI.d301.s6
Since FOSCAVIR decreases serum concentrations of ionized calcium , concurrent treatment with other drugs known to influence serum calcium concentrations should be used with particular caution.

DrugDDI.d301.s6.e0 5 12
drug
FOSCAVIR
DrugDDI.d301.s6.e1 43 56
drug
ionized calcium
DrugDDI.d301.s6.e2 86 90
drug
drugs

interaction DrugDDI.d301.s6.e0 DrugDDI.d301.s6.e2

Abstract Id: DrugDDI.d301
Sentence Id: DrugDDI.d301.s7
Ganciclovir The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.

DrugDDI.d301.s7.e0 0 10
drug
Ganciclovir
DrugDDI.d301.s7.e1 32 40
drug
foscarnet
DrugDDI.d301.s7.e2 44 54
drug
ganciclovir



Abstract Id: DrugDDI.d269
Sentence Id: DrugDDI.d269.s0
Metoclopramide : When coadministered with MONUROL , metoclopramide , a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin .

DrugDDI.d269.s0.e0 0 13
drug
Metoclopramide
DrugDDI.d269.s0.e1 37 43
drug
MONUROL
DrugDDI.d269.s0.e2 45 58
drug
metoclopramide
DrugDDI.d269.s0.e3 61 64
drug
drug
DrugDDI.d269.s0.e4 152 161
drug
fosfomycin

interaction DrugDDI.d269.s0.e1 DrugDDI.d269.s0.e4

Abstract Id: DrugDDI.d269
Sentence Id: DrugDDI.d269.s1
Other drugs that increase gastrointestinal motility may produce similar effects.

DrugDDI.d269.s1.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d269
Sentence Id: DrugDDI.d269.s2
Cimetidine : Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL .

DrugDDI.d269.s2.e0 0 9
drug
Cimetidine
DrugDDI.d269.s2.e1 11 20
drug
Cimetidine
DrugDDI.d269.s2.e2 55 64
drug
fosfomycin
DrugDDI.d269.s2.e3 87 93
drug
MONUROL



Abstract Id: DrugDDI.d512
Sentence Id: DrugDDI.d512.s0
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.

DrugDDI.d512.s0.e0 16 20
drug
drugs



Abstract Id: DrugDDI.d512
Sentence Id: DrugDDI.d512.s1
Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine -containing or ergot-type medications (like dihydroergotamine or methysergide ) and FROVA within 24 hours of each other should be avoided (see  a href= frova _od.htm#CI CONTRAINDICATIONS).

DrugDDI.d512.s1.e0 56 65
drug
ergotamine
DrugDDI.d512.s1.e1 89 99
drug
medications
DrugDDI.d512.s1.e2 105 121
drug
dihydroergotamine
DrugDDI.d512.s1.e3 124 135
drug
methysergide
DrugDDI.d512.s1.e4 140 144
drug
FROVA
DrugDDI.d512.s1.e5 194 198
drug
frova

interaction DrugDDI.d512.s1.e0 DrugDDI.d512.s1.e4
interaction DrugDDI.d512.s1.e2 DrugDDI.d512.s1.e4

Abstract Id: DrugDDI.d512
Sentence Id: DrugDDI.d512.s2
Concomitant use of other 5-HT1B/1D agonists within 24 hours of FROVA treatment is not recommended.

DrugDDI.d512.s2.e0 30 37
drug
agonists
DrugDDI.d512.s2.e1 53 57
drug
FROVA

interaction DrugDDI.d512.s2.e0 DrugDDI.d512.s2.e1

Abstract Id: DrugDDI.d512
Sentence Id: DrugDDI.d512.s3
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists .

DrugDDI.d512.s3.e0 9 35
drug
serotonin reuptake inhibitors
DrugDDI.d512.s3.e1 49 58
drug
fluoxetine
DrugDDI.d512.s3.e2 60 70
drug
fluvoxamine
DrugDDI.d512.s3.e3 72 81
drug
paroxetine
DrugDDI.d512.s3.e4 83 92
drug
sertraline
DrugDDI.d512.s3.e5 192 199
drug
agonists

interaction DrugDDI.d512.s3.e0 DrugDDI.d512.s3.e5
interaction DrugDDI.d512.s3.e2 DrugDDI.d512.s3.e5
interaction DrugDDI.d512.s3.e4 DrugDDI.d512.s3.e5

Abstract Id: DrugDDI.d512
Sentence Id: DrugDDI.d512.s4
If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.

DrugDDI.d512.s4.e0 26 37
drug
frovatriptan



Abstract Id: DrugDDI.d512
Sentence Id: DrugDDI.d512.s5
Drug /Laboratory Test Interactions FROVA is not known to interfere with commonly employed clinical laboratory tests.

DrugDDI.d512.s5.e0 0 3
drug
Drug
DrugDDI.d512.s5.e1 31 35
drug
FROVA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s0
Fulvestrant is metabolized by CYP 3A4 in vitro.

DrugDDI.d448.s0.e0 0 10
drug
Fulvestrant
DrugDDI.d448.s0.e1 26 28
drug
CYP



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s1
Clinical studies of the effect of strong CYP 3A4 inhibitors on the pharmacokinetics of fulvestrant have not been performed.

DrugDDI.d448.s1.e0 73 83
drug
fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s5
Induction of such tumors is consistent with the pharmacology-related endocrine feedback alterations in gonadotropin levels caused by an antiestrogen .

DrugDDI.d448.s5.e0 118 129
drug
antiestrogen



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s6
Fulvestrant was not mutagenic or clastogenic in multiple in vitro tests with and without the addition of a mammalian liver metabolic activation factor (bacterial mutation assay in strains of Salmonella typhimurium and Escherichia coli, in vitro cytogenetics study in human lymphocytes, mammalian cell mutation assay in mouse lymphoma cells and in vivo micronucleus test in rat.

DrugDDI.d448.s6.e0 0 10
drug
Fulvestrant
DrugDDI.d448.s6.e1 98 102
drug
liver



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s7
In female rats, fulvestrant administered at doses   0.01 mg/kg/day (approximately one-hundredth of the human recommended dose based on body surface area [ BSA ], for 2 weeks prior to and for 1 week following mating, caused a reduction in fertility and embryonic survival.

DrugDDI.d448.s7.e0 13 23
drug
fulvestrant
DrugDDI.d448.s7.e1 131 133
drug
BSA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s8
No adverse effects on female fertility and embryonic survival were evident in female animals dosed at 0.001 mg/kg/day (approximately one-thousandth of the human dose based on BSA ).

DrugDDI.d448.s8.e0 149 151
drug
BSA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s9
Restoration of female fertility to values similar to controls was evident following a 29-day withdrawal period after dosing at 2 mg/kg/day (twice the human dose based on BSA ).

DrugDDI.d448.s9.e0 143 145
drug
BSA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s10
The effects of fulvestrant on the fertility of female rats appear to be consistent with its anti-estrogenic activity.

DrugDDI.d448.s10.e0 12 22
drug
fulvestrant
DrugDDI.d448.s10.e1 76 90
drug
anti-estrogenic



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s11
The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.

DrugDDI.d448.s11.e0 21 31
drug
fulvestrant
DrugDDI.d448.s11.e1 189 199
drug
fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s13
These fulvestrant doses correspond to approximately 2-, 3-, and 3-fold the systemic exposure [AUC0-30 days] achieved in women.

DrugDDI.d448.s13.e0 5 15
drug
fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s16
approximately one-hundredth of the human recommended dose based on body surface area [ BSA ]), fulvestrant caused a reversible reduction in female fertility, as well as effects on embryo/fetal development consistent with its anti-estrogenic activity.

DrugDDI.d448.s16.e0 74 76
drug
BSA
DrugDDI.d448.s16.e1 80 90
drug
fulvestrant
DrugDDI.d448.s16.e2 192 206
drug
anti-estrogenic



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s17
Fulvestrant caused an increased incidence of fetal abnormalities in rats (tarsal flexure of the hind paw at 2 mg/kg/day IM; .

DrugDDI.d448.s17.e0 0 10
drug
Fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s18
twice the human dose on BSA ) and non-ossification of the odontoid and ventral tubercle of the first cervical vertebra at doses   0.1 mg/kg/day IM (approximately one-tenth of the human dose on BSA ) when administered during the period of organogenesis.

DrugDDI.d448.s18.e0 19 21
drug
BSA
DrugDDI.d448.s18.e1 159 161
drug
BSA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s19
Rabbits failed to maintain pregnancy when dosed with 1 mg/kg/day fulvestrant IM (twice the human dose on BSA ) during the period of organogenesis.

DrugDDI.d448.s19.e0 55 65
drug
fulvestrant
DrugDDI.d448.s19.e1 88 90
drug
BSA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s20
Further, in rabbits dosed at 0.25 mg/kg/day (about one-half the human dose on BSA ), increases in placental weight and post-implantation loss were observed but, there were no observed effects on fetal development.

DrugDDI.d448.s20.e0 65 67
drug
BSA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s21
Fulvestrant was associated with an increased incidence of fetal variations in rabbits (backwards displacement of the pelvic girdle, and 27 pre-sacral vertebrae at 0.25 mg/kg/day IM; .

DrugDDI.d448.s21.e0 0 10
drug
Fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s22
one-half the human dose on BSA ) when administered during the period of organogenesis.

DrugDDI.d448.s22.e0 22 24
drug
BSA



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s23
Because pregnancy could not be maintained in the rabbit following doses of fulvestrant of 1 mg/kg/day and above, this study was inadequate to fully define the possible adverse effects on fetal development at clinically relevant exposures.

DrugDDI.d448.s23.e0 63 73
drug
fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s24
Nursing Mothers Fulvestrant is found in rat milk at levels significantly higher (approximately 12-fold) than plasma after administration of 2 mg/kg.

DrugDDI.d448.s24.e0 14 24
drug
Fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s25
Drug exposure in rodent pups from fulvestrant -treated lactating dams was estimated as 10% of the administered dose.

DrugDDI.d448.s25.e0 28 38
drug
fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s26
It is not known if fulvestrant is excreted in human milk.

DrugDDI.d448.s26.e0 14 24
drug
fulvestrant



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s27
Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from FASLODEX in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.

DrugDDI.d448.s27.e0 11 15
drug
drugs
DrugDDI.d448.s27.e1 93 100
drug
FASLODEX
DrugDDI.d448.s27.e2 184 187
drug
drug
DrugDDI.d448.s27.e3 223 226
drug
drug



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s28
Pediatric Use The safety and efficacy of FASLODEX in pediatric patients have not been established.

DrugDDI.d448.s28.e0 0 8
drug
Pediatric
DrugDDI.d448.s28.e1 34 41
drug
FASLODEX



Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s29
Geriatric Use When tumor response was considered by age, objective responses were seen in 24% and 22% of patients under 65 years of age and in 16% and 11% of patients 65 years of age and older, who were treated with FASLODEX in the European and North American trials, respectively.

DrugDDI.d448.s29.e0 175 182
drug
FASLODEX



Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s0
Furosemide may increase the ototoxic potential of aminoglycoside antibiotics , especially in the presence of impaired renal function.

DrugDDI.d32.s0.e0 0 9
drug
Furosemide
DrugDDI.d32.s0.e1 43 67
drug
aminoglycoside antibiotics

interaction DrugDDI.d32.s0.e0 DrugDDI.d32.s0.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s2
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.

DrugDDI.d32.s2.e0 0 9
drug
Furosemide
DrugDDI.d32.s2.e1 42 55
drug
ethacrynic acid

interaction DrugDDI.d32.s2.e0 DrugDDI.d32.s2.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s3
Patients receiving high doses of salicylates concomitantly with furosemide , as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.

DrugDDI.d32.s3.e0 28 38
drug
salicylates
DrugDDI.d32.s3.e1 56 65
drug
furosemide

interaction DrugDDI.d32.s3.e0 DrugDDI.d32.s3.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s4
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine .

DrugDDI.d32.s4.e0 0 9
drug
Furosemide
DrugDDI.d32.s4.e1 67 78
drug
tubocurarine
DrugDDI.d32.s4.e2 106 120
drug
succinylcholine

interaction DrugDDI.d32.s4.e0 DrugDDI.d32.s4.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s5
Lithium generally should not be given with diuretics because they reduce lithium s renal clearance and add a high risk of lithium toxicity.

DrugDDI.d32.s5.e0 0 6
drug
Lithium
DrugDDI.d32.s5.e1 36 44
drug
diuretics
DrugDDI.d32.s5.e2 62 68
drug
lithium

interaction DrugDDI.d32.s5.e0 DrugDDI.d32.s5.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s6
Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs .

DrugDDI.d32.s6.e0 0 9
drug
Furosemide
DrugDDI.d32.s6.e1 57 77
drug
antihypertensive drugs

interaction DrugDDI.d32.s6.e0 DrugDDI.d32.s6.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s7
Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs .

DrugDDI.d32.s7.e0 44 66
drug
adrenergic blocking drugs



Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s8
Furosemide may decrease arterial responsiveness to norepinephrine .

DrugDDI.d32.s8.e0 0 9
drug
Furosemide
DrugDDI.d32.s8.e1 45 58
drug
norepinephrine

interaction DrugDDI.d32.s8.e0 DrugDDI.d32.s8.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s9
However, norepinephrine may still be used effectively.

DrugDDI.d32.s9.e0 8 21
drug
norepinephrine



Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s10
Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide .

DrugDDI.d32.s10.e0 35 44
drug
sucralfate
DrugDDI.d32.s10.e1 48 64
drug
furosemide tablets
DrugDDI.d32.s10.e2 77 87
drug
natriuretic
DrugDDI.d32.s10.e3 91 106
drug
antihypertensive
DrugDDI.d32.s10.e4 116 125
drug
furosemide

interaction DrugDDI.d32.s10.e0 DrugDDI.d32.s10.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s11
Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.

DrugDDI.d32.s11.e0 21 25
drug
drugs
DrugDDI.d32.s11.e1 72 79
drug
diuretic
DrugDDI.d32.s11.e2 86 101
drug
antihypertensive
DrugDDI.d32.s11.e3 110 119
drug
furosemide



Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s12
The intake of furosemide and sucralfate should be separated by at least two hours.

DrugDDI.d32.s12.e0 11 20
drug
furosemide
DrugDDI.d32.s12.e1 24 33
drug
sucralfate

interaction DrugDDI.d32.s12.e0 DrugDDI.d32.s12.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s13
Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.

DrugDDI.d32.s13.e0 86 95
drug
furosemide
DrugDDI.d32.s13.e1 99 117
drug
acetylsalicylic acid

interaction DrugDDI.d32.s13.e0 DrugDDI.d32.s13.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s14
There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs .

DrugDDI.d32.s14.e0 110 119
drug
furosemide
DrugDDI.d32.s14.e1 144 149
drug
NSAIDs

interaction DrugDDI.d32.s14.e0 DrugDDI.d32.s14.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s15
Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.

DrugDDI.d32.s15.e0 47 58
drug
indomethacin
DrugDDI.d32.s15.e1 71 81
drug
natriuretic
DrugDDI.d32.s15.e2 85 100
drug
antihypertensive
DrugDDI.d32.s15.e3 110 119
drug
furosemide
DrugDDI.d32.s15.e4 146 158
drug
prostaglandin

interaction DrugDDI.d32.s15.e0 DrugDDI.d32.s15.e3

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s16
Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.

DrugDDI.d32.s16.e0 0 11
drug
Indomethacin
DrugDDI.d32.s16.e1 43 53
drug
aldosterone
DrugDDI.d32.s16.e2 67 71
drug
renin

interaction DrugDDI.d32.s16.e0 DrugDDI.d32.s16.e1

Abstract Id: DrugDDI.d32
Sentence Id: DrugDDI.d32.s17
Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.

DrugDDI.d32.s17.e0 21 32
drug
indomethacin
DrugDDI.d32.s17.e1 36 45
drug
furosemide
DrugDDI.d32.s17.e2 92 99
drug
diuretic
DrugDDI.d32.s17.e3 106 121
drug
antihypertensive
DrugDDI.d32.s17.e4 130 139
drug
furosemide

interaction DrugDDI.d32.s17.e0 DrugDDI.d32.s17.e1

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s0
In vitro studies were conducted to investigate the potential of gabapentin to inhibit the major cytochrome P450 enzymes ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP2E1 , and CYP3A4 ) that mediate drug and xenobiotic metabolism using isoform selective marker substrates and human liver microsomal preparations .

DrugDDI.d144.s0.e0 54 63
drug
gabapentin
DrugDDI.d144.s0.e1 81 94
drug
cytochrome P450
DrugDDI.d144.s0.e2 103 108
drug
CYP1A2
DrugDDI.d144.s0.e3 110 115
drug
CYP2A6
DrugDDI.d144.s0.e4 117 122
drug
CYP2C9
DrugDDI.d144.s0.e5 124 130
drug
CYP2C19
DrugDDI.d144.s0.e6 132 137
drug
CYP2D6
DrugDDI.d144.s0.e7 139 144
drug
CYP2E1
DrugDDI.d144.s0.e8 149 154
drug
CYP3A4
DrugDDI.d144.s0.e9 167 170
drug
drug
DrugDDI.d144.s0.e10 199 205
drug
isoform
DrugDDI.d144.s0.e11 244 265
drug
microsomal preparations



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s3
1 mM) was a slight degree of inhibition (14%-30%) of isoform CYP2A6 observed.

DrugDDI.d144.s3.e0 43 55
drug
isoform CYP2A6



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s4
No inhibition of any of the other isoforms tested was observed at gabapentin concentrations up to 171 mg/mL (approximately 15 times the Cmax at 3600 mg/day).

DrugDDI.d144.s4.e0 27 34
drug
isoforms
DrugDDI.d144.s4.e1 54 63
drug
gabapentin



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s5
Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs .

DrugDDI.d144.s5.e0 0 9
drug
Gabapentin
DrugDDI.d144.s5.e1 96 113
drug
antiepileptic drugs



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s7
Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin span class= c11 @ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.

DrugDDI.d144.s7.e0 0 8
drug
Phenytoin
DrugDDI.d144.s7.e1 117 125
drug
phenytoin
DrugDDI.d144.s7.e2 155 164
drug
gabapentin
DrugDDI.d144.s7.e3 221 229
drug
phenytoin
DrugDDI.d144.s7.e4 233 241
drug
phenytoin
DrugDDI.d144.s7.e5 255 264
drug
gabapentin



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s8
Carbamazepine : Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID; .

DrugDDI.d144.s8.e0 0 12
drug
Carbamazepine
DrugDDI.d144.s8.e1 38 50
drug
carbamazepine
DrugDDI.d144.s8.e2 54 66
drug
carbamazepine
DrugDDI.d144.s8.e3 121 130
drug
gabapentin



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s10
Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.

DrugDDI.d144.s10.e0 9 18
drug
gabapentin
DrugDDI.d144.s10.e1 50 62
drug
carbamazepine



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s11
Valproic Acid : The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID; .

DrugDDI.d144.s11.e0 0 11
drug
Valproic Acid
DrugDDI.d144.s11.e1 43 54
drug
valproic acid
DrugDDI.d144.s11.e2 96 105
drug
gabapentin



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s12
N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic acid .

DrugDDI.d144.s12.e0 35 44
drug
gabapentin
DrugDDI.d144.s12.e1 80 91
drug
valproic acid



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s13
Phenobarbital : Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID; .

DrugDDI.d144.s13.e0 0 12
drug
Phenobarbital
DrugDDI.d144.s13.e1 65 77
drug
phenobarbital
DrugDDI.d144.s13.e2 80 89
drug
gabapentin



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s14
N=12) are identical whether the drugs are administered alone or together.

DrugDDI.d144.s14.e0 27 31
drug
drugs



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s15
Naproxen : Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin span class= c11 @ (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.

DrugDDI.d144.s15.e0 0 7
drug
Naproxen
DrugDDI.d144.s15.e1 33 46
drug
naproxen sodium
DrugDDI.d144.s15.e2 124 133
drug
gabapentin

interaction DrugDDI.d144.s15.e1 DrugDDI.d144.s15.e2

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s16
Gabapentin had no effect on naproxen pharmacokinetic parameters.

DrugDDI.d144.s16.e0 0 9
drug
Gabapentin
DrugDDI.d144.s16.e1 23 30
drug
naproxen



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s17
These doses are lower than the therapeutic doses for both drugs .

DrugDDI.d144.s17.e0 48 52
drug
drugs



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s18
The magnitude of interaction within the recommended dose ranges of either drug is not known.

DrugDDI.d144.s18.e0 63 66
drug
drug



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s19
Hydrocodone : Coadministration of Neurontin@ (125 to 500 mg; .

DrugDDI.d144.s19.e0 0 10
drug
Hydrocodone



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s20
N=48) decreases hydrocodone (10 mg; .

DrugDDI.d144.s20.e0 14 24
drug
hydrocodone



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s21
N=50) Cmax and AUC values in a dose-dependent manner relative to administration of hydrocodon e alone; .

DrugDDI.d144.s21.e0 70 79
drug
hydrocodon



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s24
Hydrocodone increases gabapentin AUC values by 14%.

DrugDDI.d144.s24.e0 0 10
drug
Hydrocodone
DrugDDI.d144.s24.e1 20 29
drug
gabapentin

interaction DrugDDI.d144.s24.e0 DrugDDI.d144.s24.e1

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s26
Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin@ capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine .

DrugDDI.d144.s26.e0 0 7
drug
Morphine
DrugDDI.d144.s26.e1 67 81
drug
morphine capsule
DrugDDI.d144.s26.e2 145 154
drug
gabapentin
DrugDDI.d144.s26.e3 182 191
drug
gabapentin
DrugDDI.d144.s26.e4 211 218
drug
morphine

interaction DrugDDI.d144.s26.e1 DrugDDI.d144.s26.e2

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s27
Morphine pharmacokinetic parameter values were not affected by administration of Neurontin@ 2 hours after morphine .

DrugDDI.d144.s27.e0 0 7
drug
Morphine
DrugDDI.d144.s27.e1 92 99
drug
morphine



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s29
Cimetidine : In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.

DrugDDI.d144.s29.e0 0 9
drug
Cimetidine
DrugDDI.d144.s29.e1 26 35
drug
cimetidine
DrugDDI.d144.s29.e2 82 91
drug
gabapentin

interaction DrugDDI.d144.s29.e1 DrugDDI.d144.s29.e2

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s30
Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine , an endogenous marker of renal function.

DrugDDI.d144.s30.e0 4 13
drug
cimetidine
DrugDDI.d144.s30.e1 52 61
drug
gabapentin
DrugDDI.d144.s30.e2 65 74
drug
creatinine

interaction DrugDDI.d144.s30.e0 DrugDDI.d144.s30.e1

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s31
This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.

DrugDDI.d144.s31.e0 30 39
drug
gabapentin
DrugDDI.d144.s31.e1 42 51
drug
cimetidine

interaction DrugDDI.d144.s31.e0 DrugDDI.d144.s31.e1

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s32
The effect of gabapentin on cimetidine was not evaluated.

DrugDDI.d144.s32.e0 11 20
drug
gabapentin
DrugDDI.d144.s32.e1 23 32
drug
cimetidine



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s33
Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID; .

DrugDDI.d144.s33.e0 0 16
drug
Oral Contraceptive
DrugDDI.d144.s33.e1 79 91
drug
norethindrone
DrugDDI.d144.s33.e2 95 110
drug
ethinyl estradiol
DrugDDI.d144.s33.e3 160 179
drug
norethindrone acetate
DrugDDI.d144.s33.e4 190 205
drug
ethinyl estradiol
DrugDDI.d144.s33.e5 249 258
drug
gabapentin



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s35
The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin ; .

DrugDDI.d144.s35.e0 9 21
drug
norethindrone
DrugDDI.d144.s35.e1 61 70
drug
gabapentin

interaction DrugDDI.d144.s35.e0 DrugDDI.d144.s35.e1

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s37
Antacid ( Maalox @): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.

DrugDDI.d144.s37.e0 0 6
drug
Antacid
DrugDDI.d144.s37.e1 8 13
drug
Maalox
DrugDDI.d144.s37.e2 50 59
drug
gabapentin

interaction DrugDDI.d144.s37.e1 DrugDDI.d144.s37.e2

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s38
This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox .

DrugDDI.d144.s38.e0 43 52
drug
gabapentin
DrugDDI.d144.s38.e1 79 84
drug
Maalox

interaction DrugDDI.d144.s38.e0 DrugDDI.d144.s38.e1

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s39
It is recommended that gabapentin be taken at least 2 hours following Maalox administration.

DrugDDI.d144.s39.e0 19 28
drug
gabapentin
DrugDDI.d144.s39.e1 58 63
drug
Maalox

interaction DrugDDI.d144.s39.e0 DrugDDI.d144.s39.e1

Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s40
Effect of Probenecid : Probenecid is a blocker of renal tubular secretion.

DrugDDI.d144.s40.e0 8 17
drug
Probenecid
DrugDDI.d144.s40.e1 19 28
drug
Probenecid



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s41
Gabapentin pharmacokinetic parameters without and with probenecid were comparable.

DrugDDI.d144.s41.e0 0 9
drug
Gabapentin
DrugDDI.d144.s41.e1 49 58
drug
probenecid



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s42
This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid .

DrugDDI.d144.s42.e0 17 26
drug
gabapentin
DrugDDI.d144.s42.e1 89 98
drug
probenecid



Abstract Id: DrugDDI.d144
Sentence Id: DrugDDI.d144.s43
Drug /Laboratory Tests Interactions Because false positive readings were reported with the Ame s N-Multistix SG span class= c11 @ dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs , the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein .

DrugDDI.d144.s43.e0 0 3
drug
Drug
DrugDDI.d144.s43.e1 79 81
drug
Ame
DrugDDI.d144.s43.e2 143 152
drug
gabapentin
DrugDDI.d144.s43.e3 168 185
drug
antiepileptic drugs
DrugDDI.d144.s43.e4 279 290
drug
urine protein



Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s0
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive product in healthy subjects.

DrugDDI.d478.s0.e0 29 35
drug
FACTIVE
DrugDDI.d478.s0.e1 80 91
drug
theophylline
DrugDDI.d478.s0.e2 93 99
drug
digoxin
DrugDDI.d478.s0.e3 104 119
drug
ethinylestradiol
DrugDDI.d478.s0.e4 135 151
drug
oral contraceptive



Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s1
Concomitant administration of FACTIVE and calcium carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance.

DrugDDI.d478.s1.e0 27 33
drug
FACTIVE
DrugDDI.d478.s1.e1 37 52
drug
calcium carbonate
DrugDDI.d478.s1.e2 54 63
drug
cimetidine
DrugDDI.d478.s1.e3 65 74
drug
omeprazole
DrugDDI.d478.s1.e4 80 87
drug
estrogen
DrugDDI.d478.s1.e5 89 100
drug
progesterone
DrugDDI.d478.s1.e6 161 172
drug
gemifloxacin



Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s2
Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin .

DrugDDI.d478.s2.e0 27 33
drug
FACTIVE
DrugDDI.d478.s2.e1 38 47
drug
probenecid
DrugDDI.d478.s2.e2 90 101
drug
gemifloxacin

interaction DrugDDI.d478.s2.e1 DrugDDI.d478.s2.e2

Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s3
FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.

DrugDDI.d478.s3.e0 0 6
drug
FACTIVE
DrugDDI.d478.s3.e1 55 62
drug
warfarin
DrugDDI.d478.s3.e2 88 95
drug
warfarin

interaction DrugDDI.d478.s3.e0 DrugDDI.d478.s3.e1

Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s4
However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives .

DrugDDI.d478.s4.e0 19 28
drug
quinolones
DrugDDI.d478.s4.e1 79 86
drug
warfarin
DrugDDI.d478.s4.e2 92 102
drug
derivatives
DrugDDI.d478.s4.e3 189 210
drug
quinolone antimicrobial
DrugDDI.d478.s4.e4 242 249
drug
warfarin
DrugDDI.d478.s4.e5 255 265
drug
derivatives

interaction DrugDDI.d478.s4.e0 DrugDDI.d478.s4.e1

Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s5
Quinolones form chelates with alkaline earth and transition metals.

DrugDDI.d478.s5.e0 0 9
drug
Quinolones



Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s6
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium .

DrugDDI.d478.s6.e0 19 30
drug
gemifloxacin
DrugDDI.d478.s6.e1 87 93
drug
antacid
DrugDDI.d478.s6.e2 115 123
drug
magnesium

interaction DrugDDI.d478.s6.e0 DrugDDI.d478.s6.e1

Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s7
Magnesium - and/or aluminum-containing antacids , products containing ferrous sulfate ( iron ), multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/ buffer ed tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .

DrugDDI.d478.s7.e0 0 8
drug
Magnesium
DrugDDI.d478.s7.e1 16 42
drug
aluminum-containing antacids
DrugDDI.d478.s7.e2 62 75
drug
ferrous sulfate
DrugDDI.d478.s7.e3 77 80
drug
iron
DrugDDI.d478.s7.e4 83 106
drug
multivitamin preparations
DrugDDI.d478.s7.e5 117 120
drug
zinc
DrugDDI.d478.s7.e6 133 139
drug
cations
DrugDDI.d478.s7.e7 143 147
drug
Videx
DrugDDI.d478.s7.e8 149 158
drug
didanosine
DrugDDI.d478.s7.e9 169 174
drug
buffer
DrugDDI.d478.s7.e10 189 197
drug
pediatric
DrugDDI.d478.s7.e11 266 272
drug
FACTIVE

interaction DrugDDI.d478.s7.e0 DrugDDI.d478.s7.e11
interaction DrugDDI.d478.s7.e2 DrugDDI.d478.s7.e11
interaction DrugDDI.d478.s7.e4 DrugDDI.d478.s7.e11
interaction DrugDDI.d478.s7.e7 DrugDDI.d478.s7.e11
interaction DrugDDI.d478.s7.e10 DrugDDI.d478.s7.e11

Abstract Id: DrugDDI.d478
Sentence Id: DrugDDI.d478.s8
Sucralfate should not be taken within 2 hours of FACTIVE .

DrugDDI.d478.s8.e0 0 9
drug
Sucralfate
DrugDDI.d478.s8.e1 40 46
drug
FACTIVE

interaction DrugDDI.d478.s8.e0 DrugDDI.d478.s8.e1

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s0
There have been no formal drug-interaction studies performed with Mylotarg .

DrugDDI.d467.s0.e0 57 64
drug
Mylotarg



Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s1
The potential for drug-drug interaction with drugs affected by cytochrome P450 enzymes may not be ruled out.

DrugDDI.d467.s1.e0 39 43
drug
drugs
DrugDDI.d467.s1.e1 54 67
drug
cytochrome P450



Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s3
Mylotarg is not known to interfere with any routine diagnostic tests.

DrugDDI.d467.s3.e0 0 7
drug
Mylotarg



Abstract Id: DrugDDI.d99
Sentence Id: DrugDDI.d99.s0
Interactions between COPAXONE@ and other drugs have not been fully evaluated.

DrugDDI.d99.s0.e0 36 40
drug
drugs



Abstract Id: DrugDDI.d99
Sentence Id: DrugDDI.d99.s1
Results from existing clinical trials suggest no significant interactions between COPAXONE@ and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days.

DrugDDI.d99.s1.e0 150 164
drug
corticosteroids



Abstract Id: DrugDDI.d99
Sentence Id: DrugDDI.d99.s2
COPAXONE@ has not been formally evaluated in combination with Interferon beta .

DrugDDI.d99.s2.e0 53 66
drug
Interferon beta



Abstract Id: DrugDDI.d99
Sentence Id: DrugDDI.d99.s3
However, 10 patients who switched from therapy with Interferon beta to COPAXONE@ did not report any serious and unexpected adverse reactions thought to be related to treatment.

DrugDDI.d99.s3.e0 44 57
drug
Interferon beta



Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s0
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .

DrugDDI.d195.s0.e0 3 20
drug
hypoglycemic action
DrugDDI.d195.s0.e1 23 35
drug
sulfonylureas
DrugDDI.d195.s0.e2 61 65
drug
drugs
DrugDDI.d195.s0.e3 75 109
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d195.s0.e4 118 122
drug
drugs
DrugDDI.d195.s0.e5 136 142
drug
protein
DrugDDI.d195.s0.e6 149 159
drug
salicylates
DrugDDI.d195.s0.e7 161 172
drug
sulfonamides
DrugDDI.d195.s0.e8 174 188
drug
chloramphenicol
DrugDDI.d195.s0.e9 190 199
drug
probenecid
DrugDDI.d195.s0.e10 201 209
drug
coumarins
DrugDDI.d195.s0.e11 211 236
drug
monoamine oxidase inhibitors
DrugDDI.d195.s0.e12 241 268
drug
beta adrenergic blocking agents

interaction DrugDDI.d195.s0.e1 DrugDDI.d195.s0.e2
interaction DrugDDI.d195.s0.e1 DrugDDI.d195.s0.e4
interaction DrugDDI.d195.s0.e1 DrugDDI.d195.s0.e7
interaction DrugDDI.d195.s0.e1 DrugDDI.d195.s0.e9
interaction DrugDDI.d195.s0.e1 DrugDDI.d195.s0.e11

Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s1
When such drugs are administered to a patient receiving MICRONASE , the patient should be observed closely for hypoglycemia.

DrugDDI.d195.s1.e0 8 12
drug
drugs
DrugDDI.d195.s1.e1 47 55
drug
MICRONASE

interaction DrugDDI.d195.s1.e0 DrugDDI.d195.s1.e1

Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s2
When such drugs are withdrawn from a patient receiving MICRONASE , the patient should be observed closely for loss of control.

DrugDDI.d195.s2.e0 8 12
drug
drugs
DrugDDI.d195.s2.e1 46 54
drug
MICRONASE

interaction DrugDDI.d195.s2.e0 DrugDDI.d195.s2.e1

Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s3
Certain drugs tend to produce hyperglycemia and may lead to loss of control.

DrugDDI.d195.s3.e0 7 11
drug
drugs



Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s4
These drugs include the thiazides and other diuretics , corticosteroids , phe -nothiazines, thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics, calcium channel blocking drugs , and isoniazid .

DrugDDI.d195.s4.e0 5 9
drug
drugs
DrugDDI.d195.s4.e1 20 28
drug
thiazides
DrugDDI.d195.s4.e2 37 45
drug
diuretics
DrugDDI.d195.s4.e3 47 61
drug
corticosteroids
DrugDDI.d195.s4.e4 63 65
drug
phe
DrugDDI.d195.s4.e5 79 85
drug
thyroid
DrugDDI.d195.s4.e6 95 103
drug
estrogens
DrugDDI.d195.s4.e7 105 122
drug
oral contraceptives
DrugDDI.d195.s4.e8 124 132
drug
phenytoin
DrugDDI.d195.s4.e9 134 146
drug
nicotinic acid
DrugDDI.d195.s4.e10 166 192
drug
calcium channel blocking drugs
DrugDDI.d195.s4.e11 197 205
drug
isoniazid



Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s5
When such drugs are administered to a patient receiving MICRONASE , the patient should be closely observed for loss of control.

DrugDDI.d195.s5.e0 8 12
drug
drugs
DrugDDI.d195.s5.e1 47 55
drug
MICRONASE

interaction DrugDDI.d195.s5.e0 DrugDDI.d195.s5.e1

Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s6
When such drugs are withdrawn from a patient receiving MICRONASE , the patient should be observed closely for hypoglycemia.

DrugDDI.d195.s6.e0 8 12
drug
drugs
DrugDDI.d195.s6.e1 46 54
drug
MICRONASE

interaction DrugDDI.d195.s6.e0 DrugDDI.d195.s6.e1

Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s7
A possible interaction between glyburide and ciprofloxacin , a fluoroquinolone antibiotic , has been reported, resulting in a potentiation of the hypoglycemic action of glyburide .

DrugDDI.d195.s7.e0 27 35
drug
glyburide
DrugDDI.d195.s7.e1 39 51
drug
ciprofloxacin
DrugDDI.d195.s7.e2 54 78
drug
fluoroquinolone antibiotic
DrugDDI.d195.s7.e3 125 142
drug
hypoglycemic action
DrugDDI.d195.s7.e4 145 153
drug
glyburide

interaction DrugDDI.d195.s7.e0 DrugDDI.d195.s7.e1

Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s9
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.

DrugDDI.d195.s9.e0 28 41
drug
oral miconazole
DrugDDI.d195.s9.e1 49 66
drug
hypoglycemic agents

interaction DrugDDI.d195.s9.e0 DrugDDI.d195.s9.e1

Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s10
Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.

DrugDDI.d195.s10.e0 81 90
drug
miconazole



Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s11
Metformin : In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.

DrugDDI.d195.s11.e0 0 8
drug
Metformin
DrugDDI.d195.s11.e1 67 75
drug
glyburide



Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s12
The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmaco-dynamic effects, makes the clinical significance of this interaction uncertain.

DrugDDI.d195.s12.e0 61 69
drug
glyburide



Abstract Id: DrugDDI.d195
Sentence Id: DrugDDI.d195.s13
Coadministration of gly -buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.

DrugDDI.d195.s13.e0 18 20
drug
gly
DrugDDI.d195.s13.e1 31 39
drug
metformin
DrugDDI.d195.s13.e2 72 80
drug
metformin



Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s0
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .

DrugDDI.d460.s0.e0 12 33
drug
Extended Release Tablets
DrugDDI.d460.s0.e1 57 69
drug
sulfonylureas
DrugDDI.d460.s0.e2 95 99
drug
drugs
DrugDDI.d460.s0.e3 109 143
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d460.s0.e4 163 167
drug
drugs
DrugDDI.d460.s0.e5 181 187
drug
protein
DrugDDI.d460.s0.e6 194 204
drug
salicylates
DrugDDI.d460.s0.e7 206 217
drug
sulfonamides
DrugDDI.d460.s0.e8 219 233
drug
chloramphenicol
DrugDDI.d460.s0.e9 235 244
drug
probenecid
DrugDDI.d460.s0.e10 246 254
drug
coumarins
DrugDDI.d460.s0.e11 256 281
drug
monoamine oxidase inhibitors
DrugDDI.d460.s0.e12 286 313
drug
beta adrenergic blocking agents

interaction DrugDDI.d460.s0.e1 DrugDDI.d460.s0.e2
interaction DrugDDI.d460.s0.e1 DrugDDI.d460.s0.e4
interaction DrugDDI.d460.s0.e1 DrugDDI.d460.s0.e7
interaction DrugDDI.d460.s0.e1 DrugDDI.d460.s0.e9
interaction DrugDDI.d460.s0.e1 DrugDDI.d460.s0.e11

Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s1
When such drugs are administered to a patient receiving glipizide , the patient should be observed closely for hypoglycemia.

DrugDDI.d460.s1.e0 8 12
drug
drugs
DrugDDI.d460.s1.e1 47 55
drug
glipizide

interaction DrugDDI.d460.s1.e0 DrugDDI.d460.s1.e1

Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s2
When such drugs are withdrawn from a patient receiving glipizide , the patient should be observed closely for loss of control.

DrugDDI.d460.s2.e0 8 12
drug
drugs
DrugDDI.d460.s2.e1 46 54
drug
glipizide

interaction DrugDDI.d460.s2.e0 DrugDDI.d460.s2.e1

Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s3
In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol .

DrugDDI.d460.s3.e0 30 42
drug
serum proteins
DrugDDI.d460.s3.e1 55 63
drug
glipizide
DrugDDI.d460.s3.e2 84 94
drug
tolbutamide
DrugDDI.d460.s3.e3 117 126
drug
salicylate
DrugDDI.d460.s3.e4 129 137
drug
dicumarol



Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s4
However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs .

DrugDDI.d460.s4.e0 93 101
drug
glipizide
DrugDDI.d460.s4.e1 111 115
drug
drugs

interaction DrugDDI.d460.s4.e0 DrugDDI.d460.s4.e1

Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s5
Certain drugs tend to produce hyperglycemia and may lead to loss of control.

DrugDDI.d460.s5.e0 7 11
drug
drugs



Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s6
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .

DrugDDI.d460.s6.e0 5 9
drug
drugs
DrugDDI.d460.s6.e1 20 28
drug
thiazides
DrugDDI.d460.s6.e2 37 45
drug
diuretics
DrugDDI.d460.s6.e3 47 61
drug
corticosteroids
DrugDDI.d460.s6.e4 63 76
drug
phenothiazines
DrugDDI.d460.s6.e5 78 84
drug
thyroid
DrugDDI.d460.s6.e6 94 102
drug
estrogens
DrugDDI.d460.s6.e7 104 121
drug
oral contraceptives
DrugDDI.d460.s6.e8 123 131
drug
phenytoin
DrugDDI.d460.s6.e9 133 145
drug
nicotinic acid
DrugDDI.d460.s6.e10 147 162
drug
sympathomimetics
DrugDDI.d460.s6.e11 164 190
drug
calcium channel blocking drugs
DrugDDI.d460.s6.e12 195 203
drug
isoniazid



Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s7
When such drugs are administered to a patient receiving glipizide , the patient should be closely observed for loss of control.

DrugDDI.d460.s7.e0 8 12
drug
drugs
DrugDDI.d460.s7.e1 47 55
drug
glipizide

interaction DrugDDI.d460.s7.e0 DrugDDI.d460.s7.e1

Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s8
When such drugs are withdrawn from a patient receiving glipizide , the patient should be observed closely for hypoglycemia.

DrugDDI.d460.s8.e0 8 12
drug
drugs
DrugDDI.d460.s8.e1 46 54
drug
glipizide

interaction DrugDDI.d460.s8.e0 DrugDDI.d460.s8.e1

Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s9
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.

DrugDDI.d460.s9.e0 28 41
drug
oral miconazole
DrugDDI.d460.s9.e1 49 66
drug
hypoglycemic agents

interaction DrugDDI.d460.s9.e0 DrugDDI.d460.s9.e1

Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s10
Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

DrugDDI.d460.s10.e0 82 91
drug
miconazole



Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s11
The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.

DrugDDI.d460.s11.e0 38 48
drug
fluconazole
DrugDDI.d460.s11.e1 52 60
drug
glipizide



Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s12
All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days.

DrugDDI.d460.s12.e0 19 27
drug
glipizide
DrugDDI.d460.s12.e1 65 75
drug
fluconazole



Abstract Id: DrugDDI.d460
Sentence Id: DrugDDI.d460.s13
The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).

DrugDDI.d460.s13.e0 30 38
drug
glipizide
DrugDDI.d460.s13.e1 47 57
drug
fluconazole

interaction DrugDDI.d460.s13.e0 DrugDDI.d460.s13.e1

Abstract Id: DrugDDI.d84
Sentence Id: DrugDDI.d84.s0
The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson drugs , or tricyclic antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.

DrugDDI.d84.s0.e0 18 24
drug
Robinul
DrugDDI.d84.s0.e1 43 58
drug
anticholinergics
DrugDDI.d84.s0.e2 61 71
drug
medications
DrugDDI.d84.s0.e3 76 90
drug
anticholinergic
DrugDDI.d84.s0.e4 106 119
drug
phenothiazines
DrugDDI.d84.s0.e5 121 138
drug
antiparkinson drugs
DrugDDI.d84.s0.e6 142 165
drug
tricyclic antidepressants
DrugDDI.d84.s0.e7 182 195
drug
antimuscarinic
DrugDDI.d84.s0.e8 229 243
drug
anticholinergic

interaction DrugDDI.d84.s0.e0 DrugDDI.d84.s0.e1
interaction DrugDDI.d84.s0.e0 DrugDDI.d84.s0.e4
interaction DrugDDI.d84.s0.e0 DrugDDI.d84.s0.e6

Abstract Id: DrugDDI.d84
Sentence Id: DrugDDI.d84.s1
Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride -induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.

DrugDDI.d84.s1.e0 27 33
drug
Robinul
DrugDDI.d84.s1.e1 46 62
drug
potassium chloride
DrugDDI.d84.s1.e2 66 68
drug
wax
DrugDDI.d84.s1.e3 99 115
drug
potassium chloride

interaction DrugDDI.d84.s1.e0 DrugDDI.d84.s1.e1

Abstract Id: DrugDDI.d33
Sentence Id: DrugDDI.d33.s0
The Factrel test should be conducted in the absence of other drugs which directly affect the pituitary secretion of the gonadotropins .

DrugDDI.d33.s0.e0 3 9
drug
Factrel
DrugDDI.d33.s0.e1 50 54
drug
drugs
DrugDDI.d33.s0.e2 77 85
drug
pituitary
DrugDDI.d33.s0.e3 100 112
drug
gonadotropins



Abstract Id: DrugDDI.d33
Sentence Id: DrugDDI.d33.s1
These would include a variety of preparations which contain androgens , estrogens , progestins , or glucocorticoids.

DrugDDI.d33.s1.e0 51 59
drug
androgens
DrugDDI.d33.s1.e1 61 69
drug
estrogens
DrugDDI.d33.s1.e2 71 80
drug
progestins



Abstract Id: DrugDDI.d33
Sentence Id: DrugDDI.d33.s2
The gonadotropin levels may be transiently elevated by spironolactone , minimally elevated by levodopa , and suppressed by oral contraceptives and digoxin .

DrugDDI.d33.s2.e0 47 60
drug
spironolactone
DrugDDI.d33.s2.e1 81 88
drug
levodopa
DrugDDI.d33.s2.e2 105 122
drug
oral contraceptives
DrugDDI.d33.s2.e3 126 132
drug
digoxin



Abstract Id: DrugDDI.d33
Sentence Id: DrugDDI.d33.s3
The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin .

DrugDDI.d33.s3.e0 13 19
drug
Factrel
DrugDDI.d33.s3.e1 34 47
drug
phenothiazines
DrugDDI.d33.s3.e2 51 69
drug
dopamine antagonists
DrugDDI.d33.s3.e3 87 95
drug
prolactin



Abstract Id: DrugDDI.d74
Sentence Id: DrugDDI.d74.s1
No confirmed interactions have been reported between ZOLADEX and other drugs .

DrugDDI.d74.s1.e0 46 52
drug
ZOLADEX
DrugDDI.d74.s1.e1 61 65
drug
drugs



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s0
Antacids , Sucralfate , Metal Cations , Multivitamins Quinolones form chelates with alkaline earth and transition metal cations .

DrugDDI.d105.s0.e0 0 7
drug
Antacids
DrugDDI.d105.s0.e1 9 18
drug
Sucralfate
DrugDDI.d105.s0.e2 25 31
drug
Cations
DrugDDI.d105.s0.e3 33 45
drug
Multivitamins
DrugDDI.d105.s0.e4 103 109
drug
cations



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s1
Administration of quinolones with antacids containing aluminum, magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/ buffer ed tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired.

DrugDDI.d105.s1.e0 16 25
drug
quinolones
DrugDDI.d105.s1.e1 30 37
drug
antacids
DrugDDI.d105.s1.e2 57 65
drug
magnesium
DrugDDI.d105.s1.e3 69 75
drug
calcium
DrugDDI.d105.s1.e4 81 90
drug
sucralfate
DrugDDI.d105.s1.e5 101 107
drug
cations
DrugDDI.d105.s1.e6 114 117
drug
iron
DrugDDI.d105.s1.e7 125 137
drug
multivitamins
DrugDDI.d105.s1.e8 148 151
drug
iron
DrugDDI.d105.s1.e9 154 157
drug
zinc
DrugDDI.d105.s1.e10 207 213
drug
cations
DrugDDI.d105.s1.e11 220 224
drug
VIDEX
DrugDDI.d105.s1.e12 226 235
drug
didanosine
DrugDDI.d105.s1.e13 246 251
drug
buffer
DrugDDI.d105.s1.e14 266 274
drug
pediatric
DrugDDI.d105.s1.e15 341 350
drug
quinolones

interaction DrugDDI.d105.s1.e0 DrugDDI.d105.s1.e1
interaction DrugDDI.d105.s1.e0 DrugDDI.d105.s1.e4
interaction DrugDDI.d105.s1.e0 DrugDDI.d105.s1.e7
interaction DrugDDI.d105.s1.e0 DrugDDI.d105.s1.e9
interaction DrugDDI.d105.s1.e0 DrugDDI.d105.s1.e14

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s2
These agents should not be taken within 4 hours before or 4 hours after grepafloxacin administration.

DrugDDI.d105.s2.e0 58 70
drug
grepafloxacin



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s3
Caffeine Theobromine Grepafloxacin, like other quinolones , may inhibit the metabolism of caffeine and theobromine .

DrugDDI.d105.s3.e0 0 7
drug
Caffeine
DrugDDI.d105.s3.e1 42 51
drug
quinolones
DrugDDI.d105.s3.e2 78 85
drug
caffeine
DrugDDI.d105.s3.e3 89 99
drug
theobromine

interaction DrugDDI.d105.s3.e0 DrugDDI.d105.s3.e2
interaction DrugDDI.d105.s3.e0 DrugDDI.d105.s3.e3

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s4
These stimulants are commonly found in coffee and tea, respectively.

DrugDDI.d105.s4.e0 5 14
drug
stimulants



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s5
In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of caffeine and theobromine .

DrugDDI.d105.s5.e0 95 102
drug
caffeine
DrugDDI.d105.s5.e1 106 116
drug
theobromine



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s6
Theophylline Grepafloxacin is a competitive inhibitor of the metabolism of theophylline .

DrugDDI.d105.s6.e0 0 11
drug
Theophylline
DrugDDI.d105.s6.e1 65 76
drug
theophylline

interaction DrugDDI.d105.s6.e0 DrugDDI.d105.s6.e1

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s7
Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline .

DrugDDI.d105.s7.e0 5 16
drug
theophylline
DrugDDI.d105.s7.e1 43 55
drug
grepafloxacin
DrugDDI.d105.s7.e2 89 100
drug
theophylline

interaction DrugDDI.d105.s7.e1 DrugDDI.d105.s7.e2

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s8
When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline , the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.

DrugDDI.d105.s8.e0 15 23
drug
multi-day
DrugDDI.d105.s8.e1 32 44
drug
grepafloxacin
DrugDDI.d105.s8.e2 67 78
drug
theophylline
DrugDDI.d105.s8.e3 153 165
drug
grepafloxacin
DrugDDI.d105.s8.e4 186 197
drug
theophylline

interaction DrugDDI.d105.s8.e1 DrugDDI.d105.s8.e2

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s9
Warfarin In subjects receiving warfarin , no significant change in clotting time was observed when grepafloxacin was coadministered.

DrugDDI.d105.s9.e0 0 7
drug
Warfarin
DrugDDI.d105.s9.e1 27 34
drug
warfarin
DrugDDI.d105.s9.e2 84 96
drug
grepafloxacin



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s10
However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives .

DrugDDI.d105.s10.e0 19 28
drug
quinolones
DrugDDI.d105.s10.e1 66 73
drug
warfarin
DrugDDI.d105.s10.e2 79 89
drug
derivatives
DrugDDI.d105.s10.e3 167 188
drug
quinolone antimicrobial
DrugDDI.d105.s10.e4 207 214
drug
warfarin
DrugDDI.d105.s10.e5 220 230
drug
derivatives

interaction DrugDDI.d105.s10.e3 DrugDDI.d105.s10.e4

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s11
Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2 .

DrugDDI.d105.s11.e0 0 4
drug
Drugs
DrugDDI.d105.s11.e1 18 31
drug
Cytochrome P450
DrugDDI.d105.s11.e2 83 95
drug
grepafloxacin
DrugDDI.d105.s11.e3 98 109
drug
theophylline
DrugDDI.d105.s11.e4 123 135
drug
grepafloxacin
DrugDDI.d105.s11.e5 144 155
drug
theophylline
DrugDDI.d105.s11.e6 184 189
drug
CYP1A2

interaction DrugDDI.d105.s11.e4 DrugDDI.d105.s11.e5

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s12
While no clinical studies have been conducted to evaluate the effect of grepafloxacin on the metabolism of C.P.A.

DrugDDI.d105.s12.e0 60 72
drug
grepafloxacin



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s13
substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism.

DrugDDI.d105.s13.e0 45 57
drug
grepafloxacin
DrugDDI.d105.s13.e1 60 65
drug
CYP3A4
DrugDDI.d105.s13.e2 87 98
drug
theophylline



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s14
In addition, other quinolones have been reported to decrease the CYP3A4 -mediated metabolism of cyclosporine .

DrugDDI.d105.s14.e0 16 25
drug
quinolones
DrugDDI.d105.s14.e1 55 60
drug
CYP3A4
DrugDDI.d105.s14.e2 82 93
drug
cyclosporine

interaction DrugDDI.d105.s14.e0 DrugDDI.d105.s14.e2

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s15
Other drugs metabolized by C.P.A.

DrugDDI.d105.s15.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s16
include terfenadine , astemizole , cisapride , midazolam , and triazolam .

DrugDDI.d105.s16.e0 7 17
drug
terfenadine
DrugDDI.d105.s16.e1 19 28
drug
astemizole
DrugDDI.d105.s16.e2 30 38
drug
cisapride
DrugDDI.d105.s16.e3 40 48
drug
midazolam
DrugDDI.d105.s16.e4 53 61
drug
triazolam



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s17
The clinical relevance of the potential effect of grepafloxacin on the metabolism of C.P.A. substrates is not known.

DrugDDI.d105.s17.e0 42 54
drug
grepafloxacin



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s18
Patients receiving concurrent administration of substrates of C.P.A. were not excluded from clinical trials of grepafloxacin .

DrugDDI.d105.s18.e0 96 108
drug
grepafloxacin



Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s19
Nonsteroidal Anti-inflammatory Drugs ( NSAIDs ) The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.

DrugDDI.d105.s19.e0 0 33
drug
Nonsteroidal Anti-inflammatory Drugs
DrugDDI.d105.s19.e1 35 40
drug
NSAIDs
DrugDDI.d105.s19.e2 73 104
drug
nonsteroidal anti inflammatory drug
DrugDDI.d105.s19.e3 110 118
drug
quinolone

interaction DrugDDI.d105.s19.e2 DrugDDI.d105.s19.e3

Abstract Id: DrugDDI.d105
Sentence Id: DrugDDI.d105.s20
Antidiabetic Agents Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent .

DrugDDI.d105.s20.e0 0 17
drug
Antidiabetic Agents
DrugDDI.d105.s20.e1 133 142
drug
quinolones
DrugDDI.d105.s20.e2 148 164
drug
antidiabetic agent

interaction DrugDDI.d105.s20.e1 DrugDDI.d105.s20.e2

Abstract Id: DrugDDI.d431
Sentence Id: DrugDDI.d431.s0
Patients on warfarin -type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.

DrugDDI.d431.s0.e0 10 17
drug
warfarin
DrugDDI.d431.s0.e1 74 86
drug
anticoagulant
DrugDDI.d431.s0.e2 101 112
drug
griseofulvin

interaction DrugDDI.d431.s0.e0 DrugDDI.d431.s0.e2

Abstract Id: DrugDDI.d431
Sentence Id: DrugDDI.d431.s1
Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.

DrugDDI.d431.s1.e0 16 27
drug
barbiturates
DrugDDI.d431.s1.e1 44 55
drug
griseofulvin

interaction DrugDDI.d431.s1.e0 DrugDDI.d431.s1.e1

Abstract Id: DrugDDI.d431
Sentence Id: DrugDDI.d431.s2
The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.

DrugDDI.d431.s2.e0 30 41
drug
griseofulvin
DrugDDI.d431.s2.e1 78 95
drug
oral contraceptives

interaction DrugDDI.d431.s2.e0 DrugDDI.d431.s2.e1

Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s0
The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.

DrugDDI.d31.s0.e0 36 45
drug
guanfacine
DrugDDI.d31.s0.e1 62 79
drug
CNS-depressant drug

interaction DrugDDI.d31.s0.e0 DrugDDI.d31.s0.e1

Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s1
The administration of guanfacine concomitantly with known microsomal enzyme inducer ( phenobarbital or phenytoin ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.

DrugDDI.d31.s1.e0 19 28
drug
guanfacine
DrugDDI.d31.s1.e1 51 66
drug
microsomal enzyme
DrugDDI.d31.s1.e2 75 87
drug
phenobarbital
DrugDDI.d31.s1.e3 90 98
drug
phenytoin

interaction DrugDDI.d31.s1.e0 DrugDDI.d31.s1.e2

Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s3
Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena.

DrugDDI.d31.s3.e0 10 19
drug
guanfacine



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s4
TCAs decrease the hypotensive effect of guanfacine .

DrugDDI.d31.s4.e0 34 43
drug
guanfacine



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s5
Noncardioselective beta-blockers ( nadolol ,porpranolol, timolol ) may exacerbate rebound hypertension when guanfacine is withdrawn.

DrugDDI.d31.s5.e0 0 30
drug
Noncardioselective beta-blockers
DrugDDI.d31.s5.e1 32 38
drug
nadolol
DrugDDI.d31.s5.e2 52 58
drug
timolol
DrugDDI.d31.s5.e3 96 105
drug
guanfacine

interaction DrugDDI.d31.s5.e0 DrugDDI.d31.s5.e3
interaction DrugDDI.d31.s5.e2 DrugDDI.d31.s5.e3

Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s6
The beta-blocker should be withdrawn first.

DrugDDI.d31.s6.e0 3 14
drug
beta-blocker



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s7
The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.

DrugDDI.d31.s7.e0 34 60
drug
cardioselective beta-blocker



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s8
Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine , 1-2 mg/day, for 4 weeks.

DrugDDI.d31.s8.e0 0 13
drug
Anticoagulants
DrugDDI.d31.s8.e1 44 61
drug
oral anticoagulants
DrugDDI.d31.s8.e2 71 80
drug
guanfacine



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s10
In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported.

DrugDDI.d31.s10.e0 32 41
drug
guanfacine
DrugDDI.d31.s10.e1 69 77
drug
diuretics



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s11
In the long-term safety studies, guanfacine was given concomitantly with many drugs without evidence of any interactions.

DrugDDI.d31.s11.e0 28 37
drug
guanfacine
DrugDDI.d31.s11.e1 67 71
drug
drugs



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s12
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilator s (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).

DrugDDI.d31.s12.e0 12 16
drug
drugs
DrugDDI.d31.s12.e1 58 74
drug
cardiac glycosides
DrugDDI.d31.s12.e2 81 89
drug
sedatives
DrugDDI.d31.s12.e3 93 101
drug
hypnotics
DrugDDI.d31.s12.e4 108 126
drug
coronary vasodilator
DrugDDI.d31.s12.e5 133 149
drug
oral hypoglycemics
DrugDDI.d31.s12.e6 184 189
drug
NSAIDs
DrugDDI.d31.s12.e7 195 213
drug
antihyperlipidemics
DrugDDI.d31.s12.e8 227 231
drug
drugs
DrugDDI.d31.s12.e9 237 254
drug
oral contraceptives
DrugDDI.d31.s12.e10 260 274
drug
bronchodilators
DrugDDI.d31.s12.e11 280 286
drug
insulin
DrugDDI.d31.s12.e12 295 306
drug
beta blockers



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s13
Laboratory Test In clinical trials, no clinically relevant laboratory test abnormalities were identified as causally related to drug during short-term treatment with guanfacine .

DrugDDI.d31.s13.e0 111 114
drug
drug
DrugDDI.d31.s13.e1 144 153
drug
guanfacine



Abstract Id: DrugDDI.d31
Sentence Id: DrugDDI.d31.s14
Drug /Laboratory Test Interactions No laboratory test abnormalities related to the use of guanfacine have been identified.

DrugDDI.d31.s14.e0 0 3
drug
Drug
DrugDDI.d31.s14.e1 77 86
drug
guanfacine



Abstract Id: DrugDDI.d550
Sentence Id: DrugDDI.d550.s0
An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL .

DrugDDI.d550.s0.e0 228 234
drug
lithium
DrugDDI.d550.s0.e1 239 244
drug
HALDOL

interaction DrugDDI.d550.s0.e0 DrugDDI.d550.s0.e1

Abstract Id: DrugDDI.d550
Sentence Id: DrugDDI.d550.s1
A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established; .

DrugDDI.d550.s1.e0 70 76
drug
lithium
DrugDDI.d550.s1.e1 80 85
drug
HALDOL



Abstract Id: DrugDDI.d550
Sentence Id: DrugDDI.d550.s3
As with other antipsychotic agents , it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics , opiates , and alcohol .

DrugDDI.d550.s3.e0 11 29
drug
antipsychotic agents
DrugDDI.d550.s3.e1 50 55
drug
HALDOL
DrugDDI.d550.s3.e2 82 95
drug
CNS depressants
DrugDDI.d550.s3.e3 102 112
drug
anesthetics
DrugDDI.d550.s3.e4 114 120
drug
opiates
DrugDDI.d550.s3.e5 125 131
drug
alcohol

interaction DrugDDI.d550.s3.e1 DrugDDI.d550.s3.e2
interaction DrugDDI.d550.s3.e1 DrugDDI.d550.s3.e4

Abstract Id: DrugDDI.d550
Sentence Id: DrugDDI.d550.s4
In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin , plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.

DrugDDI.d550.s4.e0 47 61
drug
oral haloperidol
DrugDDI.d550.s4.e1 65 72
drug
rifampin
DrugDDI.d550.s4.e2 80 90
drug
haloperidol

interaction DrugDDI.d550.s4.e0 DrugDDI.d550.s4.e1

Abstract Id: DrugDDI.d550
Sentence Id: DrugDDI.d550.s5
In 5 other schizophrenic patients treated with oral haloperidol and rifampin , discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.

DrugDDI.d550.s5.e0 40 54
drug
oral haloperidol
DrugDDI.d550.s5.e1 58 65
drug
rifampin
DrugDDI.d550.s5.e2 84 91
drug
rifampin
DrugDDI.d550.s5.e3 123 133
drug
haloperidol

interaction DrugDDI.d550.s5.e0 DrugDDI.d550.s5.e1

Abstract Id: DrugDDI.d550
Sentence Id: DrugDDI.d550.s6
Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol -treated patients.

DrugDDI.d550.s6.e0 53 60
drug
rifampin
DrugDDI.d550.s6.e1 91 101
drug
haloperidol

interaction DrugDDI.d550.s6.e0 DrugDDI.d550.s6.e1

Abstract Id: DrugDDI.d90
Sentence Id: DrugDDI.d90.s0
FLUOTHANE augments the action of non-depolarising muscle relaxant s and the muscle relaxant effects of aminoglycosides .

DrugDDI.d90.s0.e0 0 8
drug
FLUOTHANE
DrugDDI.d90.s0.e1 28 57
drug
non-depolarising muscle relaxant
DrugDDI.d90.s0.e2 65 78
drug
muscle relaxant
DrugDDI.d90.s0.e3 88 102
drug
aminoglycosides

interaction DrugDDI.d90.s0.e0 DrugDDI.d90.s0.e1

Abstract Id: DrugDDI.d90
Sentence Id: DrugDDI.d90.s1
FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine .

DrugDDI.d90.s1.e0 0 8
drug
FLUOTHANE
DrugDDI.d90.s1.e1 71 82
drug
tubocurarine

interaction DrugDDI.d90.s1.e0 DrugDDI.d90.s1.e1

Abstract Id: DrugDDI.d90
Sentence Id: DrugDDI.d90.s2
Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.

DrugDDI.d90.s2.e0 49 58
drug
adrenaline
DrugDDI.d90.s2.e1 86 94
drug
FLUOTHANE

interaction DrugDDI.d90.s2.e0 DrugDDI.d90.s2.e1

Abstract Id: DrugDDI.d90
Sentence Id: DrugDDI.d90.s3
For this reason the dose of adrenaline should be restricted and an antiarrhythmic agent administered as appropriate.

DrugDDI.d90.s3.e0 22 31
drug
adrenaline
DrugDDI.d90.s3.e1 55 73
drug
antiarrhythmic agent



Abstract Id: DrugDDI.d90
Sentence Id: DrugDDI.d90.s4
Caution should also be applied for other sympathomimetics , and for aminophylline and theophylline and tricyclic antidepressants , which may also precipitate arrhythmias.

DrugDDI.d90.s4.e0 34 49
drug
sympathomimetics
DrugDDI.d90.s4.e1 57 69
drug
aminophylline
DrugDDI.d90.s4.e2 73 84
drug
theophylline
DrugDDI.d90.s4.e3 88 111
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s0
Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral anticoagulants : Heparin sodium may prolong the one-stage prothrombin time.

DrugDDI.d360.s0.e0 19 23
drug
Drugs
DrugDDI.d360.s0.e1 33 39
drug
Heparin
DrugDDI.d360.s0.e2 47 64
drug
Oral anticoagulants
DrugDDI.d360.s0.e3 66 78
drug
Heparin sodium



Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s1
Therefore, when heparin sodium is given with dicumarol or warfarin sodium , a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.

DrugDDI.d360.s1.e0 14 26
drug
heparin sodium
DrugDDI.d360.s1.e1 38 46
drug
dicumarol
DrugDDI.d360.s1.e2 49 62
drug
warfarin sodium

interaction DrugDDI.d360.s1.e0 DrugDDI.d360.s1.e1

Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s2
Platelet inhibitors : Drugs such as acetylsalicylic acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium .

DrugDDI.d360.s2.e0 0 17
drug
Platelet inhibitors
DrugDDI.d360.s2.e1 19 23
drug
Drugs
DrugDDI.d360.s2.e2 30 48
drug
acetylsalicylic acid
DrugDDI.d360.s2.e3 50 56
drug
dextran
DrugDDI.d360.s2.e4 58 71
drug
phenylbutazone
DrugDDI.d360.s2.e5 73 81
drug
ibuprofen
DrugDDI.d360.s2.e6 83 94
drug
indomethacin
DrugDDI.d360.s2.e7 96 107
drug
dipyridamole
DrugDDI.d360.s2.e8 109 126
drug
hydroxychloroquine
DrugDDI.d360.s2.e9 190 199
drug
hemostatic
DrugDDI.d360.s2.e10 291 303
drug
heparin sodium

interaction DrugDDI.d360.s2.e1 DrugDDI.d360.s2.e10
interaction DrugDDI.d360.s2.e3 DrugDDI.d360.s2.e10
interaction DrugDDI.d360.s2.e5 DrugDDI.d360.s2.e10
interaction DrugDDI.d360.s2.e7 DrugDDI.d360.s2.e10
interaction DrugDDI.d360.s2.e9 DrugDDI.d360.s2.e10

Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s3
The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.

DrugDDI.d360.s3.e0 24 30
drug
heparin
DrugDDI.d360.s3.e1 66 80
drug
antithrombin III

interaction DrugDDI.d360.s3.e0 DrugDDI.d360.s3.e1

Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s4
Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).

DrugDDI.d360.s4.e0 42 48
drug
heparin
DrugDDI.d360.s4.e1 81 95
drug
antithrombin III

interaction DrugDDI.d360.s4.e0 DrugDDI.d360.s4.e1

Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s6
Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin sodium .

DrugDDI.d360.s6.e0 0 4
drug
Drugs
DrugDDI.d360.s6.e1 15 21
drug
Heparin
DrugDDI.d360.s6.e2 29 37
drug
Digitalis
DrugDDI.d360.s6.e3 39 51
drug
tetracyclines
DrugDDI.d360.s6.e4 53 60
drug
nicotine
DrugDDI.d360.s6.e5 64 77
drug
antihistamines
DrugDDI.d360.s6.e6 103 115
drug
anticoagulant
DrugDDI.d360.s6.e7 124 136
drug
heparin sodium

interaction DrugDDI.d360.s6.e2 DrugDDI.d360.s6.e7
interaction DrugDDI.d360.s6.e4 DrugDDI.d360.s6.e7

Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s7
Heparin Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form.

DrugDDI.d360.s7.e0 0 12
drug
Heparin Sodium
DrugDDI.d360.s7.e1 42 52
drug
doxorubicin
DrugDDI.d360.s7.e2 54 63
drug
droperidol
DrugDDI.d360.s7.e3 65 77
drug
ciprofloxacin
DrugDDI.d360.s7.e4 81 92
drug
mitoxantrone
DrugDDI.d360.s7.e5 125 129
drug
drugs
DrugDDI.d360.s7.e6 149 155
drug
heparin

interaction DrugDDI.d360.s7.e0 DrugDDI.d360.s7.e1
interaction DrugDDI.d360.s7.e0 DrugDDI.d360.s7.e3
interaction DrugDDI.d360.s7.e5 DrugDDI.d360.s7.e6

Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s8
Drug / Laboratory Tests Interactions Hyperaminotransferasemia: Significant elevations of aminotransferase (SGOT [S- AST ] and SGPT [S-ALT] ) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin sodium .

DrugDDI.d360.s8.e0 0 3
drug
Drug
DrugDDI.d360.s8.e1 80 95
drug
aminotransferase
DrugDDI.d360.s8.e2 104 106
drug
AST
DrugDDI.d360.s8.e3 111 121
drug
SGPT [S-ALT]
DrugDDI.d360.s8.e4 203 215
drug
heparin sodium

interaction DrugDDI.d360.s8.e3 DrugDDI.d360.s8.e4

Abstract Id: DrugDDI.d360
Sentence Id: DrugDDI.d360.s9
Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, rises that might be caused by drugs ( heparin sodium ) should be interpreted with caution.

DrugDDI.d360.s9.e0 5 20
drug
aminotransferase
DrugDDI.d360.s9.e1 127 131
drug
rises
DrugDDI.d360.s9.e2 151 155
drug
drugs
DrugDDI.d360.s9.e3 157 169
drug
heparin sodium



Abstract Id: DrugDDI.d47
Sentence Id: DrugDDI.d47.s0
Opioids are strong central nervous system depressants , but regular users develop physiological tolerance allowing gradually increased dosages.

DrugDDI.d47.s0.e0 0 6
drug
Opioids
DrugDDI.d47.s0.e1 16 46
drug
central nervous system depressants



Abstract Id: DrugDDI.d47
Sentence Id: DrugDDI.d47.s1
In combination with other central nervous system depressants , heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.

DrugDDI.d47.s1.e0 22 52
drug
central nervous system depressants
DrugDDI.d47.s1.e1 54 59
drug
heroin
DrugDDI.d47.s1.e2 126 129
drug
drug

interaction DrugDDI.d47.s1.e0 DrugDDI.d47.s1.e1

Abstract Id: DrugDDI.d47
Sentence Id: DrugDDI.d47.s2
Toxicology studies of heroin -related deaths reveal frequent involvement of other central nervous system depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone .

DrugDDI.d47.s2.e0 19 24
drug
heroin
DrugDDI.d47.s2.e1 71 101
drug
central nervous system depressants
DrugDDI.d47.s2.e2 112 118
drug
alcohol
DrugDDI.d47.s2.e3 120 134
drug
benzodiazepines
DrugDDI.d47.s2.e4 141 148
drug
diazepam
DrugDDI.d47.s2.e5 150 155
drug
Valium
DrugDDI.d47.s2.e6 178 186
drug
methadone

interaction DrugDDI.d47.s2.e0 DrugDDI.d47.s2.e2
interaction DrugDDI.d47.s2.e0 DrugDDI.d47.s2.e4
interaction DrugDDI.d47.s2.e0 DrugDDI.d47.s2.e6
interaction DrugDDI.d47.s2.e1 DrugDDI.d47.s2.e2

Abstract Id: DrugDDI.d47
Sentence Id: DrugDDI.d47.s3
Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms.

DrugDDI.d47.s3.e0 11 25
drug
benzodiazepines



Abstract Id: DrugDDI.d47
Sentence Id: DrugDDI.d47.s4
Cocaine sometimes proves to be fatal when used in combination with heroin .

DrugDDI.d47.s4.e0 0 6
drug
Cocaine
DrugDDI.d47.s4.e1 16 21
drug
proves
DrugDDI.d47.s4.e2 56 61
drug
heroin

interaction DrugDDI.d47.s4.e0 DrugDDI.d47.s4.e2

Abstract Id: DrugDDI.d365
Sentence Id: DrugDDI.d365.s0
Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .

DrugDDI.d365.s0.e0 0 11
drug
Barbiturates
DrugDDI.d365.s0.e1 41 58
drug
oral contraceptives
DrugDDI.d365.s0.e2 67 77
drug
antibiotics
DrugDDI.d365.s0.e3 79 87
drug
quinidine
DrugDDI.d365.s0.e4 89 100
drug
theophylline
DrugDDI.d365.s0.e5 102 116
drug
corticosteroids
DrugDDI.d365.s0.e6 118 131
drug
anticoagulants
DrugDDI.d365.s0.e7 136 147
drug
beta blockers

interaction DrugDDI.d365.s0.e0 DrugDDI.d365.s0.e1
interaction DrugDDI.d365.s0.e0 DrugDDI.d365.s0.e3
interaction DrugDDI.d365.s0.e0 DrugDDI.d365.s0.e5
interaction DrugDDI.d365.s0.e0 DrugDDI.d365.s0.e7

Abstract Id: DrugDDI.d46
Sentence Id: DrugDDI.d46.s0
MAO inhibitors should be used with caution in patients receiving hydralazine .

DrugDDI.d46.s0.e0 0 12
drug
MAO inhibitors
DrugDDI.d46.s0.e1 55 65
drug
hydralazine

interaction DrugDDI.d46.s0.e0 DrugDDI.d46.s0.e1

Abstract Id: DrugDDI.d46
Sentence Id: DrugDDI.d46.s1
When other potent parental antihypertensive drugs , such as diazoxide , are used in combination with hydralazine , patients should be continuously observed for several hours for any excessive fall in blood pressure.

DrugDDI.d46.s1.e0 23 43
drug
antihypertensive drugs
DrugDDI.d46.s1.e1 51 59
drug
diazoxide
DrugDDI.d46.s1.e2 85 95
drug
hydralazine

interaction DrugDDI.d46.s1.e0 DrugDDI.d46.s1.e2

Abstract Id: DrugDDI.d46
Sentence Id: DrugDDI.d46.s2
Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.

DrugDDI.d46.s2.e0 39 47
drug
diazoxide
DrugDDI.d46.s2.e1 60 70
drug
hydralazine

interaction DrugDDI.d46.s2.e0 DrugDDI.d46.s2.e1

Abstract Id: DrugDDI.d46
Sentence Id: DrugDDI.d46.s3
Beta-blockers ( metoprolol , propranolol ) serum concentrations and pharmacologic effects may be increased.

DrugDDI.d46.s3.e0 0 12
drug
Beta-blockers
DrugDDI.d46.s3.e1 14 23
drug
metoprolol
DrugDDI.d46.s3.e2 25 35
drug
propranolol



Abstract Id: DrugDDI.d46
Sentence Id: DrugDDI.d46.s5
Propranolol increases hydralazine s serum concentrations.

DrugDDI.d46.s5.e0 0 10
drug
Propranolol
DrugDDI.d46.s5.e1 20 30
drug
hydralazine

interaction DrugDDI.d46.s5.e0 DrugDDI.d46.s5.e1

Abstract Id: DrugDDI.d46
Sentence Id: DrugDDI.d46.s6
Acebutolol , atenolol , and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.

DrugDDI.d46.s6.e0 0 9
drug
Acebutolol
DrugDDI.d46.s6.e1 11 18
drug
atenolol
DrugDDI.d46.s6.e2 23 29
drug
nadolol



Abstract Id: DrugDDI.d46
Sentence Id: DrugDDI.d46.s7
NSAIDs may decrease the hemodynamic effects of hydralazine ; .

DrugDDI.d46.s7.e0 0 5
drug
NSAIDs
DrugDDI.d46.s7.e1 40 50
drug
hydralazine

interaction DrugDDI.d46.s7.e0 DrugDDI.d46.s7.e1

Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s0
When given concurrently the following drugs may interact with thiazide diuretics .

DrugDDI.d180.s0.e0 33 37
drug
drugs
DrugDDI.d180.s0.e1 53 69
drug
thiazide diuretics

interaction DrugDDI.d180.s0.e0 DrugDDI.d180.s0.e1

Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s1
Alcohol , barbiturates , or narcotics : potentiation of orthostatic hypotension may occur.

DrugDDI.d180.s1.e0 0 6
drug
Alcohol
DrugDDI.d180.s1.e1 8 19
drug
barbiturates
DrugDDI.d180.s1.e2 23 31
drug
narcotics



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s2
Antidiabetic drugs : (oral agents and insulin ) - dosage adjustment of the antidiabetic drug may be required.

DrugDDI.d180.s2.e0 0 16
drug
Antidiabetic drugs
DrugDDI.d180.s2.e1 32 38
drug
insulin
DrugDDI.d180.s2.e2 62 77
drug
antidiabetic drug



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s3
Other antihypertensive drugs : additive effect or potentiation.

DrugDDI.d180.s3.e0 5 25
drug
antihypertensive drugs



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s4
Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins .

DrugDDI.d180.s4.e0 0 13
drug
Cholestyramine
DrugDDI.d180.s4.e1 17 26
drug
colestipol
DrugDDI.d180.s4.e2 46 64
drug
hydrochlorothiazide
DrugDDI.d180.s4.e3 90 110
drug
anionic exchange resins



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s5
Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

DrugDDI.d180.s5.e0 19 32
drug
cholestyramine
DrugDDI.d180.s5.e1 35 44
drug
colestipol
DrugDDI.d180.s5.e2 58 76
drug
hydrochlorothiazide



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s6
Corticosteroids , ACTH : intensified electrolyte depletion, particularly hypokalemia.

DrugDDI.d180.s6.e0 0 14
drug
Corticosteroids
DrugDDI.d180.s6.e1 16 19
drug
ACTH



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s7
Pressor amines (e.g., norepinephrine ): possible decreased response to pressor amines but not sufficient to preclude their use.

DrugDDI.d180.s7.e0 0 12
drug
Pressor amines
DrugDDI.d180.s7.e1 19 32
drug
norepinephrine
DrugDDI.d180.s7.e2 62 74
drug
pressor amines



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s8
Skeletal muscle relaxants , nondepolarizing (e.g., tubocurarine ): possible increased responsiveness to the muscle relaxant .

DrugDDI.d180.s8.e0 0 22
drug
Skeletal muscle relaxants
DrugDDI.d180.s8.e1 45 56
drug
tubocurarine
DrugDDI.d180.s8.e2 95 108
drug
muscle relaxant



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s9
Lithium : generally should not be given with diuretics .

DrugDDI.d180.s9.e0 0 6
drug
Lithium
DrugDDI.d180.s9.e1 37 45
drug
diuretics

interaction DrugDDI.d180.s9.e0 DrugDDI.d180.s9.e1

Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s10
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.

DrugDDI.d180.s10.e0 0 7
drug
Diuretic
DrugDDI.d180.s10.e1 39 45
drug
lithium

interaction DrugDDI.d180.s10.e0 DrugDDI.d180.s10.e1

Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s11
Refer to the package insert for lithium preparation s before use of such preparations with Hydrochlorothiazide .

DrugDDI.d180.s11.e0 26 43
drug
lithium preparation
DrugDDI.d180.s11.e1 76 94
drug
Hydrochlorothiazide



Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s12
Non-steroidal Anti-inflammatory Drugs : In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium -sparing and thiazide diuretics .

DrugDDI.d180.s12.e0 0 34
drug
Non-steroidal Anti-inflammatory Drugs
DrugDDI.d180.s12.e1 71 105
drug
non-steroidal anti-inflammatory agent
DrugDDI.d180.s12.e2 118 125
drug
diuretic
DrugDDI.d180.s12.e3 142 157
drug
antihypertensive
DrugDDI.d180.s12.e4 172 180
drug
potassium
DrugDDI.d180.s12.e5 192 208
drug
thiazide diuretics

interaction DrugDDI.d180.s12.e1 DrugDDI.d180.s12.e5

Abstract Id: DrugDDI.d180
Sentence Id: DrugDDI.d180.s13
Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

DrugDDI.d180.s13.e0 14 32
drug
Hydrochlorothiazide
DrugDDI.d180.s13.e1 36 71
drug
non-steroidal anti-inflammatory agents
DrugDDI.d180.s13.e2 160 167
drug
diuretic

interaction DrugDDI.d180.s13.e0 DrugDDI.d180.s13.e1

Abstract Id: DrugDDI.d288
Sentence Id: DrugDDI.d288.s0
Patients receiving other narcotic analgesic s, antipsychotics , antianxiety agents , or other CNS depressants (including alcohol ) concomitantly with hydrocodon e and acetaminophen tablets may exhibit an additive CNS depression.

DrugDDI.d288.s0.e0 17 38
drug
other narcotic analgesic
DrugDDI.d288.s0.e1 41 54
drug
antipsychotics
DrugDDI.d288.s0.e2 56 72
drug
antianxiety agents
DrugDDI.d288.s0.e3 81 94
drug
CNS depressants
DrugDDI.d288.s0.e4 105 111
drug
alcohol
DrugDDI.d288.s0.e5 130 139
drug
hydrocodon
DrugDDI.d288.s0.e6 144 163
drug
acetaminophen tablets

interaction DrugDDI.d288.s0.e0 DrugDDI.d288.s0.e5
interaction DrugDDI.d288.s0.e1 DrugDDI.d288.s0.e6
interaction DrugDDI.d288.s0.e2 DrugDDI.d288.s0.e5
interaction DrugDDI.d288.s0.e3 DrugDDI.d288.s0.e6

Abstract Id: DrugDDI.d288
Sentence Id: DrugDDI.d288.s2
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparation s may increase the effect of either the antidepressant or hydrocodone .

DrugDDI.d288.s2.e0 8 20
drug
MAO inhibitors
DrugDDI.d288.s2.e1 23 46
drug
tricyclic antidepressants
DrugDDI.d288.s2.e2 51 72
drug
hydrocodone preparation
DrugDDI.d288.s2.e3 105 118
drug
antidepressant
DrugDDI.d288.s2.e4 121 131
drug
hydrocodone

interaction DrugDDI.d288.s2.e0 DrugDDI.d288.s2.e2

Abstract Id: DrugDDI.d288
Sentence Id: DrugDDI.d288.s3
The concurrent use of anticholinergics with hydrocodon e may produce paralytic ileus.

DrugDDI.d288.s3.e0 18 33
drug
anticholinergics
DrugDDI.d288.s3.e1 38 47
drug
hydrocodon

interaction DrugDDI.d288.s3.e0 DrugDDI.d288.s3.e1

Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s0
Anticoagulants , oral .

DrugDDI.d98.s0.e0 0 13
drug
Anticoagulants



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s1
(Effects may be decreased when used concurrently with thiazide diuretics ; .

DrugDDI.d98.s1.e0 46 62
drug
thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s3
Antigout medications .

DrugDDI.d98.s3.e0 8 18
drug
medications



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s4
( Thiazide diuretics may raise the level of blood uric acid; .

DrugDDI.d98.s4.e0 1 17
drug
Thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s5
dosage adjustment of antigout medications may be necessary to control hyperuricemia and gout.) .

DrugDDI.d98.s5.e0 26 36
drug
medications



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s6
Antihypertensive medications, other, especially diazoxide , or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants , nondepolarizing, used in surgery .

DrugDDI.d98.s6.e0 0 15
drug
Antihypertensive
DrugDDI.d98.s6.e1 44 52
drug
diazoxide
DrugDDI.d98.s6.e2 72 87
drug
anesthetic agents
DrugDDI.d98.s6.e3 103 126
drug
skeletal-muscle relaxants



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s7
(Effects may be potentiated when used concurrently with thiazide diuretics ; .

DrugDDI.d98.s7.e0 48 64
drug
thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s9
Amphotericin B or Corticosteroids or Corticotropin ( ACTH ) .

DrugDDI.d98.s9.e0 0 12
drug
Amphotericin B
DrugDDI.d98.s9.e1 15 29
drug
Corticosteroids
DrugDDI.d98.s9.e2 32 44
drug
Corticotropin
DrugDDI.d98.s9.e3 46 49
drug
ACTH



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s10
(Concurrent use with thiazide diuretics may intensify electrolyte imbalance, particularly hypokalemia.) .

DrugDDI.d98.s10.e0 18 34
drug
thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s11
Cardiac glycosides .

DrugDDI.d98.s11.e0 0 16
drug
Cardiac glycosides



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s12
(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.) .

DrugDDI.d98.s12.e0 18 34
drug
thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s13
Colestipol .

DrugDDI.d98.s13.e0 0 9
drug
Colestipol



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s14
(May inhibit gastrointestinal absorption of the thiazide diuretics ; .

DrugDDI.d98.s14.e0 42 58
drug
thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s15
administration 1 hour before or 4 hours after colestipol is recommended.) .

DrugDDI.d98.s15.e0 38 47
drug
colestipol



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s16
Hypoglycemics .

DrugDDI.d98.s16.e0 0 12
drug
Hypoglycemics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s17
( Thiazide diuretics may raise blood glucose levels; .

DrugDDI.d98.s17.e0 1 17
drug
Thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s18
for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy; .

DrugDDI.d98.s18.e0 42 64
drug
hypoglycemic medications
DrugDDI.d98.s18.e1 93 108
drug
thiazide diuretic

interaction DrugDDI.d98.s18.e0 DrugDDI.d98.s18.e1

Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s19
insulin requirements may be increased, decreased, or unchanged.) .

DrugDDI.d98.s19.e0 0 6
drug
insulin



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s20
Lithium salt s .

DrugDDI.d98.s20.e0 0 10
drug
Lithium salt



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s21
(Concurrent use with thiazide diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance.) .

DrugDDI.d98.s21.e0 18 34
drug
thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s22
Methenamine .

DrugDDI.d98.s22.e0 0 10
drug
Methenamine



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s23
(Effectiveness may be decreased when used concurrently with thiazide diuretics because of alkalinization of the urine.) .

DrugDDI.d98.s23.e0 52 68
drug
thiazide diuretics



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s24
Nonsteroidal anti-inflammatory agents .

DrugDDI.d98.s24.e0 0 34
drug
Nonsteroidal anti-inflammatory agents



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s25
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics .

DrugDDI.d98.s25.e0 19 49
drug
steroidal anti-inflammatory agent
DrugDDI.d98.s25.e1 62 69
drug
diuretic
DrugDDI.d98.s25.e2 86 101
drug
antihypertensive
DrugDDI.d98.s25.e3 116 124
drug
potassium
DrugDDI.d98.s25.e4 136 152
drug
thiazide diuretics

interaction DrugDDI.d98.s25.e0 DrugDDI.d98.s25.e4

Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s26
Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.) .

DrugDDI.d98.s26.e0 14 31
drug
hydroflumethiazide
DrugDDI.d98.s26.e1 35 69
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d98.s26.e2 158 165
drug
diuretic

interaction DrugDDI.d98.s26.e0 DrugDDI.d98.s26.e1

Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s27
Norepinephrine .

DrugDDI.d98.s27.e0 0 13
drug
Norepinephrine



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s28
( Thiazides may decrease arterial responsiveness to norepinephrine .

DrugDDI.d98.s28.e0 1 9
drug
Thiazides
DrugDDI.d98.s28.e1 45 58
drug
norepinephrine

interaction DrugDDI.d98.s28.e0 DrugDDI.d98.s28.e1

Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s29
This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.) .

DrugDDI.d98.s29.e0 57 68
drug
pressor agent



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s30
Tubocurarine .

DrugDDI.d98.s30.e0 0 11
drug
Tubocurarine



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s31
( Thiazide drugs may increase the responsiveness to tubocurarine .) .

DrugDDI.d98.s31.e0 1 8
drug
Thiazide
DrugDDI.d98.s31.e1 44 55
drug
tubocurarine

interaction DrugDDI.d98.s31.e0 DrugDDI.d98.s31.e1

Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s32
DIAGNOSTIC INTERFERENCE With expected physiologic effects: Blood and urine glucose levels (usually only in patients with a predisposition for glucose intolerance) and Serum bilirubin levels (by displacement from albumin binding) and Serum calcium levels ( thiazide diuretics should be discontinued before parathyroid -function tests are carried out) and Serum uric acid levels (may be increased) Serum magnesium, potassium , and sodium levels (may be decreased; .

DrugDDI.d98.s32.e0 66 72
drug
glucose
DrugDDI.d98.s32.e1 184 190
drug
albumin
DrugDDI.d98.s32.e2 221 237
drug
thiazide diuretics
DrugDDI.d98.s32.e3 264 274
drug
parathyroid
DrugDDI.d98.s32.e4 356 364
drug
potassium



Abstract Id: DrugDDI.d98
Sentence Id: DrugDDI.d98.s33
serum magnesium levels may increase in uremic patients) Serum protein-bound iodine (PBI) levels (may be decreased) Thiazides should be discontinued before carrying out tests for parathyroid function.

DrugDDI.d98.s33.e0 53 71
drug
protein-bound iodine
DrugDDI.d98.s33.e1 99 107
drug
Thiazides
DrugDDI.d98.s33.e2 153 163
drug
parathyroid



Abstract Id: DrugDDI.d120
Sentence Id: DrugDDI.d120.s0
Patients receiving other narcotic analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression.

DrugDDI.d120.s0.e0 17 38
drug
other narcotic analgesic
DrugDDI.d120.s0.e1 41 58
drug
general anesthetics
DrugDDI.d120.s0.e2 60 73
drug
phenothiazines
DrugDDI.d120.s0.e3 75 87
drug
tranquilizers
DrugDDI.d120.s0.e4 89 106
drug
sedative-hypnotics
DrugDDI.d120.s0.e5 108 131
drug
tricyclic antidepressants
DrugDDI.d120.s0.e6 139 152
drug
CNS depressants
DrugDDI.d120.s0.e7 163 169
drug
alcohol
DrugDDI.d120.s0.e8 188 195
drug
DILAUDID

interaction DrugDDI.d120.s0.e0 DrugDDI.d120.s0.e8
interaction DrugDDI.d120.s0.e2 DrugDDI.d120.s0.e8
interaction DrugDDI.d120.s0.e4 DrugDDI.d120.s0.e8
interaction DrugDDI.d120.s0.e6 DrugDDI.d120.s0.e8

Abstract Id: DrugDDI.d542
Sentence Id: DrugDDI.d542.s0
Prospective studies on the potential for hydroxyurea to interact with other drugs have not been performed.

DrugDDI.d542.s0.e0 35 45
drug
hydroxyurea
DrugDDI.d542.s0.e1 65 69
drug
drugs



Abstract Id: DrugDDI.d542
Sentence Id: DrugDDI.d542.s1
Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events.

DrugDDI.d542.s1.e0 15 25
drug
hydroxyurea



Abstract Id: DrugDDI.d542
Sentence Id: DrugDDI.d542.s2
Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary .

DrugDDI.d542.s2.e0 5 15
drug
hydroxyurea
DrugDDI.d542.s2.e1 64 83
drug
uricosuric medication

interaction DrugDDI.d542.s2.e0 DrugDDI.d542.s2.e1

Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s0
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC ANALGESICS AND BARBITURATES .

DrugDDI.d474.s0.e0 23 33
drug
HYDROXYZINE
DrugDDI.d474.s0.e1 57 60
drug
DRUG
DrugDDI.d474.s0.e2 84 114
drug
CENTRAL NERVOUS SYSTEM DEPRESSANTS
DrugDDI.d474.s0.e3 121 129
drug
NARCOTICS
DrugDDI.d474.s0.e4 131 152
drug
NON-NARCOTIC ANALGESICS
DrugDDI.d474.s0.e5 156 167
drug
BARBITURATES

interaction DrugDDI.d474.s0.e0 DrugDDI.d474.s0.e2
interaction DrugDDI.d474.s0.e0 DrugDDI.d474.s0.e4

Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s1
Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.

DrugDDI.d474.s1.e0 13 43
drug
central nervous system depressants
DrugDDI.d474.s1.e1 76 86
drug
hydroxyzine

interaction DrugDDI.d474.s1.e0 DrugDDI.d474.s1.e1

Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s2
Since drowsiness may occur with use of this drug , patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking Atarax .

DrugDDI.d474.s2.e0 36 39
drug
drug
DrugDDI.d474.s2.e1 150 155
drug
Atarax



Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s3
Patients should be advised against the simultaneous use of other CNS depressant drugs , and cautioned that the effect of alcohol may be increased.

DrugDDI.d474.s3.e0 55 72
drug
CNS depressant drugs
DrugDDI.d474.s3.e1 101 107
drug
alcohol

interaction DrugDDI.d474.s3.e0 DrugDDI.d474.s3.e1

Abstract Id: DrugDDI.d344
Sentence Id: DrugDDI.d344.s0
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinic s, amantadine , haloperidol , phenothiazines , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines .

DrugDDI.d344.s0.e0 66 71
drug
LEVSIN
DrugDDI.d344.s0.e1 108 121
drug
antimuscarinic
DrugDDI.d344.s0.e2 124 133
drug
amantadine
DrugDDI.d344.s0.e3 135 145
drug
haloperidol
DrugDDI.d344.s0.e4 147 160
drug
phenothiazines
DrugDDI.d344.s0.e5 162 177
drug
monoamine oxidase
DrugDDI.d344.s0.e6 194 217
drug
tricyclic antidepressants
DrugDDI.d344.s0.e7 224 237
drug
antihistamines

interaction DrugDDI.d344.s0.e0 DrugDDI.d344.s0.e1
interaction DrugDDI.d344.s0.e0 DrugDDI.d344.s0.e3
interaction DrugDDI.d344.s0.e0 DrugDDI.d344.s0.e6

Abstract Id: DrugDDI.d344
Sentence Id: DrugDDI.d344.s1
Antacids may interfere with the absorption of LEVSIN .

DrugDDI.d344.s1.e0 0 7
drug
Antacids
DrugDDI.d344.s1.e1 39 44
drug
LEVSIN

interaction DrugDDI.d344.s1.e0 DrugDDI.d344.s1.e1

Abstract Id: DrugDDI.d344
Sentence Id: DrugDDI.d344.s2
Administer LEVSIN before meals; .

DrugDDI.d344.s2.e0 10 15
drug
LEVSIN



Abstract Id: DrugDDI.d344
Sentence Id: DrugDDI.d344.s3
antacids after meals.

DrugDDI.d344.s3.e0 0 7
drug
antacids



Abstract Id: DrugDDI.d158
Sentence Id: DrugDDI.d158.s0
No formal drug interaction studies have been performed with ZEVALIN .

DrugDDI.d158.s0.e0 51 57
drug
ZEVALIN



Abstract Id: DrugDDI.d158
Sentence Id: DrugDDI.d158.s1
Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications which interfere with platelet function and/or anticoagulation should be weighed against the potential increased risks of bleeding and hemorrhage.

DrugDDI.d158.s1.e0 85 95
drug
medications



Abstract Id: DrugDDI.d158
Sentence Id: DrugDDI.d158.s2
Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia.

DrugDDI.d158.s2.e0 17 27
drug
medications



Abstract Id: DrugDDI.d158
Sentence Id: DrugDDI.d158.s4
Patients in clinical studies were prohibit ed from receiving growth factor treatment for 2 weeks prior to the ZEVALIN therapeutic regimen as well as for 2 weeks following completion of the regimen.

DrugDDI.d158.s4.e0 29 36
drug
prohibit
DrugDDI.d158.s4.e1 52 63
drug
growth factor
DrugDDI.d158.s4.e2 92 98
drug
ZEVALIN



Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s0
Coumarin-Type Anticoagulants : Several short-term controlled studies failed to wshow that ibuprofen significantly affected prothrombin times or a variety of other clotting factor s when administered to individuals on coumarin-type anticoagulants .

DrugDDI.d122.s0.e0 0 26
drug
Coumarin-Type Anticoagulants
DrugDDI.d122.s0.e1 79 87
drug
ibuprofen
DrugDDI.d122.s0.e2 142 155
drug
clotting factor
DrugDDI.d122.s0.e3 188 214
drug
coumarin-type anticoagulants

interaction DrugDDI.d122.s0.e1 DrugDDI.d122.s0.e3

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s1
However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants .

DrugDDI.d122.s1.e0 42 50
drug
ibuprofen
DrugDDI.d122.s1.e1 59 93
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d122.s1.e2 126 152
drug
coumarin-type anticoagulants
DrugDDI.d122.s1.e3 199 207
drug
ibuprofen
DrugDDI.d122.s1.e4 220 233
drug
anticoagulants

interaction DrugDDI.d122.s1.e0 DrugDDI.d122.s1.e2
interaction DrugDDI.d122.s1.e3 DrugDDI.d122.s1.e4

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s2
Aspirin : Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents , including ibuprofen , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.

DrugDDI.d122.s2.e0 0 6
drug
Aspirin
DrugDDI.d122.s2.e1 30 36
drug
aspirin
DrugDDI.d122.s2.e2 46 80
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d122.s2.e3 91 99
drug
ibuprofen
DrugDDI.d122.s2.e4 108 110
drug
net
DrugDDI.d122.s2.e5 173 183
drug
non-aspirin

interaction DrugDDI.d122.s2.e1 DrugDDI.d122.s2.e2

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s3
Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on ibuprofen blood levels.

DrugDDI.d122.s3.e0 77 83
drug
aspirin
DrugDDI.d122.s3.e1 86 94
drug
ibuprofen



Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s5
Methotrexate : Ibuprofen , as well as other nonsteroidal anti-inflammatory drugs , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.

DrugDDI.d122.s5.e0 0 11
drug
Methotrexate
DrugDDI.d122.s5.e1 13 21
drug
Ibuprofen
DrugDDI.d122.s5.e2 36 69
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d122.s5.e3 107 118
drug
methotrexate

interaction DrugDDI.d122.s5.e1 DrugDDI.d122.s5.e3

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s6
This may indicate that ibuprofen could enhance the toxicity of methotrexate .

DrugDDI.d122.s6.e0 19 27
drug
ibuprofen
DrugDDI.d122.s6.e1 53 64
drug
methotrexate

interaction DrugDDI.d122.s6.e0 DrugDDI.d122.s6.e1

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s7
Caution should be used if ibuprofen is administered concomitantly with methotrexate .

DrugDDI.d122.s7.e0 21 29
drug
ibuprofen
DrugDDI.d122.s7.e1 61 72
drug
methotrexate

interaction DrugDDI.d122.s7.e0 DrugDDI.d122.s7.e1

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s8
H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.

DrugDDI.d122.s8.e0 63 72
drug
cimetidine
DrugDDI.d122.s8.e1 75 84
drug
ranitidine
DrugDDI.d122.s8.e2 89 97
drug
ibuprofen
DrugDDI.d122.s8.e3 122 130
drug
ibuprofen



Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s9
Furosemide : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.

DrugDDI.d122.s9.e0 0 9
drug
Furosemide
DrugDDI.d122.s9.e1 67 75
drug
ibuprofen
DrugDDI.d122.s9.e2 88 98
drug
natriuretic
DrugDDI.d122.s9.e3 107 116
drug
furosemide
DrugDDI.d122.s9.e4 120 128
drug
thiazides

interaction DrugDDI.d122.s9.e1 DrugDDI.d122.s9.e3

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s10
This response has been attributed to inhibition of renal prostaglandin synthesis.

DrugDDI.d122.s10.e0 48 60
drug
prostaglandin



Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s11
During concomitant therapy with ibuprofen , the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.

DrugDDI.d122.s11.e0 28 36
drug
ibuprofen
DrugDDI.d122.s11.e1 110 117
drug
diuretic



Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s12
Lithium : Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.

DrugDDI.d122.s12.e0 0 6
drug
Lithium
DrugDDI.d122.s12.e1 8 16
drug
Ibuprofen
DrugDDI.d122.s12.e2 77 83
drug
lithium

interaction DrugDDI.d122.s12.e1 DrugDDI.d122.s12.e2

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s13
The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.

DrugDDI.d122.s13.e0 14 20
drug
lithium
DrugDDI.d122.s13.e1 68 74
drug
lithium



Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s14
This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen .

DrugDDI.d122.s14.e0 46 58
drug
prostaglandin
DrugDDI.d122.s14.e1 70 78
drug
ibuprofen



Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s15
Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

DrugDDI.d122.s15.e0 9 17
drug
ibuprofen
DrugDDI.d122.s15.e1 21 27
drug
lithium

interaction DrugDDI.d122.s15.e0 DrugDDI.d122.s15.e1

Abstract Id: DrugDDI.d122
Sentence Id: DrugDDI.d122.s16
(Read circulars for lithium preparation before use of such concurrent therapy).

DrugDDI.d122.s16.e0 17 34
drug
lithium preparation



Abstract Id: DrugDDI.d572
Sentence Id: DrugDDI.d572.s1
Digoxin : Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels.

DrugDDI.d572.s1.e0 0 6
drug
Digoxin



Abstract Id: DrugDDI.d572
Sentence Id: DrugDDI.d572.s3
Coadministration of digoxin did not have effects on either the safety or efficacy of ibutilide in the clinical trials.

DrugDDI.d572.s3.e0 18 24
drug
digoxin
DrugDDI.d572.s3.e1 71 79
drug
ibutilide



Abstract Id: DrugDDI.d572
Sentence Id: DrugDDI.d572.s4
Calcium channel blocking agents : Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.

DrugDDI.d572.s4.e0 0 27
drug
Calcium channel blocking agents
DrugDDI.d572.s4.e1 47 68
drug
calcium channel blockers
DrugDDI.d572.s4.e2 117 125
drug
ibutilide



Abstract Id: DrugDDI.d572
Sentence Id: DrugDDI.d572.s5
Beta-adrenergic blocking agents : Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.

DrugDDI.d572.s5.e0 0 28
drug
Beta-adrenergic blocking agents
DrugDDI.d572.s5.e1 48 76
drug
beta-adrenergic blocking agents
DrugDDI.d572.s5.e2 125 133
drug
ibutilide



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s0
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic ( Allium sativum ) and ginkgo ( Ginkgo biloba ).

DrugDDI.d503.s0.e0 27 29
drug
EPA
DrugDDI.d503.s0.e1 44 50
drug
aspirin
DrugDDI.d503.s0.e2 59 93
drug
non-steroidal anti-inflammatory drugs
DrugDDI.d503.s0.e3 108 113
drug
garlic
DrugDDI.d503.s0.e4 115 127
drug
Allium sativum
DrugDDI.d503.s0.e5 132 137
drug
ginkgo
DrugDDI.d503.s0.e6 139 150
drug
Ginkgo biloba



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s2
Most who take EPA supplements and the above drugs or herbs do not suffer from these problems and if they occur, they are rare.

DrugDDI.d503.s2.e0 11 13
drug
EPA
DrugDDI.d503.s2.e1 36 40
drug
drugs



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s3
If they do occur, the EPA dose should be lowered or discontinued.

DrugDDI.d503.s3.e0 17 19
drug
EPA



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s4
Conflicting results have been reported regarding the effects of EPA supplements on glycemic control in non-diabetics with glucose intolerance, and those with type 2 diabetes.

DrugDDI.d503.s4.e0 55 57
drug
EPA



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s5
Some early studies indicated that EPA supplements might have detrimental effects in those groups.

DrugDDI.d503.s5.e0 29 31
drug
EPA



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s7
There is no evidence that EPA supplements have detrimental effects on glucose tolerance, insulin secretion or insulin resistance in non-diabetic subjects.

DrugDDI.d503.s7.e0 21 23
drug
EPA



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s9
Diabetics who take EPA supplements should be monitored by their physicians.

DrugDDI.d503.s9.e0 16 18
drug
EPA



Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s0
Other medicines - Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.

DrugDDI.d379.s0.e0 5 13
drug
medicines
DrugDDI.d379.s0.e1 30 38
drug
medicines
DrugDDI.d379.s0.e2 92 100
drug
medicines



Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s2
When you are using idoxuridine , it is especially important that your health care professional know if you are using the following: Eye product containing boric acid .

DrugDDI.d379.s2.e0 15 25
drug
idoxuridine
DrugDDI.d379.s2.e1 130 138
drug
boric acid



Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s3
Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.

DrugDDI.d379.s3.e0 0 8
drug
Boric acid
DrugDDI.d379.s3.e1 27 48
drug
idoxuridine preparation
DrugDDI.d379.s3.e2 115 136
drug
idoxuridine preparation

interaction DrugDDI.d379.s3.e0 DrugDDI.d379.s3.e1

Abstract Id: DrugDDI.d138
Sentence Id: DrugDDI.d138.s0
In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine , diltiazem , or captopril .

DrugDDI.d138.s0.e0 82 89
drug
iloprost
DrugDDI.d138.s0.e1 99 108
drug
nifedipine
DrugDDI.d138.s0.e2 110 118
drug
diltiazem
DrugDDI.d138.s0.e3 122 130
drug
captopril



Abstract Id: DrugDDI.d138
Sentence Id: DrugDDI.d138.s1
However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents .

DrugDDI.d138.s1.e0 8 15
drug
iloprost
DrugDDI.d138.s1.e1 63 74
drug
vasodilators
DrugDDI.d138.s1.e2 78 99
drug
antihypertensive agents

interaction DrugDDI.d138.s1.e0 DrugDDI.d138.s1.e1

Abstract Id: DrugDDI.d138
Sentence Id: DrugDDI.d138.s2
Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants .

DrugDDI.d138.s2.e0 5 12
drug
iloprost
DrugDDI.d138.s2.e1 116 129
drug
anticoagulants

interaction DrugDDI.d138.s2.e0 DrugDDI.d138.s2.e1

Abstract Id: DrugDDI.d138
Sentence Id: DrugDDI.d138.s3
During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac glycosides , calcium channel blockers , analgesics , antipyretics , nonsteroidal antiinflammatories , corticosteroids , and other medications .

DrugDDI.d138.s3.e0 21 28
drug
iloprost
DrugDDI.d138.s3.e1 52 65
drug
anticoagulants
DrugDDI.d138.s3.e2 67 75
drug
diuretics
DrugDDI.d138.s3.e3 77 93
drug
cardiac glycosides
DrugDDI.d138.s3.e4 95 116
drug
calcium channel blockers
DrugDDI.d138.s3.e5 118 127
drug
analgesics
DrugDDI.d138.s3.e6 129 140
drug
antipyretics
DrugDDI.d138.s3.e7 154 171
drug
antiinflammatories
DrugDDI.d138.s3.e8 173 187
drug
corticosteroids
DrugDDI.d138.s3.e9 192 207
drug
other medications



Abstract Id: DrugDDI.d138
Sentence Id: DrugDDI.d138.s4
Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin .

DrugDDI.d138.s4.e0 21 28
drug
iloprost
DrugDDI.d138.s4.e1 63 69
drug
digoxin



Abstract Id: DrugDDI.d138
Sentence Id: DrugDDI.d138.s5
Acetylsalicylic acid did not alter the clearance (pharmacokinetics) of iloprost .

DrugDDI.d138.s5.e0 0 18
drug
Acetylsalicylic acid
DrugDDI.d138.s5.e1 62 69
drug
iloprost



Abstract Id: DrugDDI.d138
Sentence Id: DrugDDI.d138.s6
Although clinical studies have not been conducted, in vitro studies of iloprost indicate that no relevant inhibition of cytochrome P450 drug metabolism would be expected.

DrugDDI.d138.s6.e0 60 67
drug
iloprost
DrugDDI.d138.s6.e1 102 115
drug
cytochrome P450



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s0
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole , itraconazole , erythromycin , clarithromycin ).

DrugDDI.d343.s0.e0 0 4
drug
Drugs
DrugDDI.d343.s0.e1 17 24
drug
imatinib
DrugDDI.d343.s0.e2 65 72
drug
imatinib
DrugDDI.d343.s0.e3 131 137
drug
Gleevec
DrugDDI.d343.s0.e4 157 162
drug
CYP3A4
DrugDDI.d343.s0.e5 175 186
drug
ketoconazole
DrugDDI.d343.s0.e6 188 199
drug
itraconazole
DrugDDI.d343.s0.e7 201 212
drug
erythromycin
DrugDDI.d343.s0.e8 214 227
drug
clarithromycin

interaction DrugDDI.d343.s0.e3 DrugDDI.d343.s0.e5
interaction DrugDDI.d343.s0.e3 DrugDDI.d343.s0.e7

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s1
Substances that inhibit the cytochrome P450 isoenzyme ( CYP3A4 ) activity may decrease metabolism and increase imatinib concentrations.

DrugDDI.d343.s1.e0 24 37
drug
cytochrome P450
DrugDDI.d343.s1.e1 48 53
drug
CYP3A4
DrugDDI.d343.s1.e2 95 102
drug
imatinib



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s2
There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole ( CYP3A4 inhibitor).

DrugDDI.d343.s2.e0 39 46
drug
imatinib
DrugDDI.d343.s2.e1 51 57
drug
Gleevec
DrugDDI.d343.s2.e2 78 89
drug
ketoconazole
DrugDDI.d343.s2.e3 91 96
drug
CYP3A4

interaction DrugDDI.d343.s2.e1 DrugDDI.d343.s2.e2

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s3
Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.

DrugDDI.d343.s3.e0 0 4
drug
Drugs
DrugDDI.d343.s3.e1 20 27
drug
imatinib
DrugDDI.d343.s3.e2 76 81
drug
CYP3A4
DrugDDI.d343.s3.e3 122 129
drug
imatinib



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s4
Co- medications that induce CYP3A4 (e.g., dexamethasone , phenytoin , carbamazepine , rifampin , phenobarbital or St.

DrugDDI.d343.s4.e0 3 13
drug
medications
DrugDDI.d343.s4.e1 24 29
drug
CYP3A4
DrugDDI.d343.s4.e2 36 48
drug
dexamethasone
DrugDDI.d343.s4.e3 50 58
drug
phenytoin
DrugDDI.d343.s4.e4 60 72
drug
carbamazepine
DrugDDI.d343.s4.e5 74 81
drug
rifampin
DrugDDI.d343.s4.e6 83 95
drug
phenobarbital



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s5
Johns Wort) may significantly reduce exposure to Gleevec .

DrugDDI.d343.s5.e0 42 48
drug
Gleevec



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s6
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec , increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).

DrugDDI.d343.s6.e0 50 57
drug
rifampin
DrugDDI.d343.s6.e1 81 87
drug
Gleevec
DrugDDI.d343.s6.e2 98 104
drug
Gleevec

interaction DrugDDI.d343.s6.e0 DrugDDI.d343.s6.e1

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s7
In patients where rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered.

DrugDDI.d343.s7.e0 15 22
drug
rifampin
DrugDDI.d343.s7.e1 30 35
drug
CYP3A4
DrugDDI.d343.s7.e2 68 84
drug
therapeutic agents



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s8
Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin ( CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec .

DrugDDI.d343.s8.e0 0 4
drug
Drugs
DrugDDI.d343.s8.e1 49 55
drug
Gleevec
DrugDDI.d343.s8.e2 91 101
drug
simvastatin
DrugDDI.d343.s8.e3 103 108
drug
CYP3A4
DrugDDI.d343.s8.e4 173 178
drug
CYP3A4
DrugDDI.d343.s8.e5 181 187
drug
Gleevec

interaction DrugDDI.d343.s8.e1 DrugDDI.d343.s8.e2

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s9
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide ).

DrugDDI.d343.s9.e0 47 53
drug
Gleevec
DrugDDI.d343.s9.e1 58 63
drug
CYP3A4
DrugDDI.d343.s9.e2 112 123
drug
cyclosporine
DrugDDI.d343.s9.e3 126 133
drug
pimozide

interaction DrugDDI.d343.s9.e0 DrugDDI.d343.s9.e2

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s10
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo- benzodiazepines , dihydropyridine calcium channel blockers , certain HMG-CoA reductase inhibitors , etc.).

DrugDDI.d343.s10.e0 0 6
drug
Gleevec
DrugDDI.d343.s10.e1 62 66
drug
drugs
DrugDDI.d343.s10.e2 82 96
drug
benzodiazepines
DrugDDI.d343.s10.e3 113 134
drug
calcium channel blockers
DrugDDI.d343.s10.e4 143 168
drug
HMG-CoA reductase inhibitors

interaction DrugDDI.d343.s10.e0 DrugDDI.d343.s10.e1
interaction DrugDDI.d343.s10.e0 DrugDDI.d343.s10.e3

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s11
Because warfarin is metabolized by CYP2C9 and CYP3A4 , patients who require anticoagulation should receive low-molecular weight or standard heparin .

DrugDDI.d343.s11.e0 7 14
drug
warfarin
DrugDDI.d343.s11.e1 30 35
drug
CYP2C9
DrugDDI.d343.s11.e2 39 44
drug
CYP3A4
DrugDDI.d343.s11.e3 121 127
drug
heparin



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s12
in vitro, Gleevec inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity.

DrugDDI.d343.s12.e0 8 14
drug
Gleevec
DrugDDI.d343.s12.e1 26 54
drug
cytochrome P450 isoenzyme CYP2D6
DrugDDI.d343.s12.e2 96 101
drug
CYP3A4

interaction DrugDDI.d343.s12.e0 DrugDDI.d343.s12.e1

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s13
Systemic exposure to substrates of CYP2D6 is expected to be increased when coadministered with Gleevec .

DrugDDI.d343.s13.e0 30 35
drug
CYP2D6
DrugDDI.d343.s13.e1 81 87
drug
Gleevec



Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s15
in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5 @M) at therapeutic levels.

DrugDDI.d343.s15.e0 8 14
drug
Gleevec
DrugDDI.d343.s15.e1 23 35
drug
acetaminophen

interaction DrugDDI.d343.s15.e0 DrugDDI.d343.s15.e1

Abstract Id: DrugDDI.d343
Sentence Id: DrugDDI.d343.s16
Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec .

DrugDDI.d343.s16.e0 18 30
drug
acetaminophen
DrugDDI.d343.s16.e1 76 82
drug
Gleevec

interaction DrugDDI.d343.s16.e0 DrugDDI.d343.s16.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s0
Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4.

DrugDDI.d540.s0.e0 0 8
drug
Indinavir
DrugDDI.d540.s0.e1 27 40
drug
cytochrome P450



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s1
Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug , which could increase or prolong its therapeutic and adverse effects.

DrugDDI.d540.s1.e0 18 25
drug
CRIXIVAN
DrugDDI.d540.s1.e1 29 33
drug
drugs
DrugDDI.d540.s1.e2 56 61
drug
CYP3A4
DrugDDI.d540.s1.e3 112 115
drug
drug

interaction DrugDDI.d540.s1.e0 DrugDDI.d540.s1.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s2
Indinavir is metabolized by CYP3A4 .

DrugDDI.d540.s2.e0 0 8
drug
Indinavir
DrugDDI.d540.s2.e1 24 29
drug
CYP3A4



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s3
Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir , resulting in lowered plasma concentrations of indinavir .

DrugDDI.d540.s3.e0 0 4
drug
Drugs
DrugDDI.d540.s3.e1 15 20
drug
CYP3A4
DrugDDI.d540.s3.e2 68 76
drug
indinavir
DrugDDI.d540.s3.e3 118 126
drug
indinavir

interaction DrugDDI.d540.s3.e0 DrugDDI.d540.s3.e2

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s4
Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir .

DrugDDI.d540.s4.e0 18 25
drug
CRIXIVAN
DrugDDI.d540.s4.e1 34 38
drug
drugs
DrugDDI.d540.s4.e2 50 55
drug
CYP3A4
DrugDDI.d540.s4.e3 81 89
drug
indinavir
DrugDDI.d540.s4.e4 135 143
drug
indinavir

interaction DrugDDI.d540.s4.e0 DrugDDI.d540.s4.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s6
Drugs That Should Not Be Coadministered with CRIXIVAN .

DrugDDI.d540.s6.e0 0 4
drug
Drugs
DrugDDI.d540.s6.e1 38 45
drug
CRIXIVAN

interaction DrugDDI.d540.s6.e0 DrugDDI.d540.s6.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s7
Drug Class: Drug Name Clinical Comment .

DrugDDI.d540.s7.e0 0 3
drug
Drug
DrugDDI.d540.s7.e1 10 13
drug
Drug



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s8
Antiarrhythmics : amiodarone .

DrugDDI.d540.s8.e0 0 14
drug
Antiarrhythmics
DrugDDI.d540.s8.e1 16 25
drug
amiodarone



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s10
Ergot derivatives : dihydroergotamine , ergonovine , ergotamine , methylergonovine .

DrugDDI.d540.s10.e0 0 15
drug
Ergot derivatives
DrugDDI.d540.s10.e1 17 33
drug
dihydroergotamine
DrugDDI.d540.s10.e2 35 44
drug
ergonovine
DrugDDI.d540.s10.e3 46 55
drug
ergotamine
DrugDDI.d540.s10.e4 57 72
drug
methylergonovine



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s11
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.

DrugDDI.d540.s11.e0 81 85
drug
ergot



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s12
Sedative / hypnotics : midazolam , triazolam .

DrugDDI.d540.s12.e0 0 7
drug
Sedative
DrugDDI.d540.s12.e1 9 17
drug
hypnotics
DrugDDI.d540.s12.e2 19 27
drug
midazolam
DrugDDI.d540.s12.e3 29 37
drug
triazolam



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s14
GI motility agents: cisapride .

DrugDDI.d540.s14.e0 17 25
drug
cisapride



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s16
Neuroleptic : pimozide .

DrugDDI.d540.s16.e0 0 10
drug
Neuroleptic
DrugDDI.d540.s16.e1 12 19
drug
pimozide



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s18
Herbal products: St. John@s wort ( Hypericum perforatum ) .

DrugDDI.d540.s18.e0 29 47
drug
Hypericum perforatum



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s19
May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors .

DrugDDI.d540.s19.e0 55 62
drug
CRIXIVAN
DrugDDI.d540.s19.e1 77 94
drug
protease inhibitors



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s20
Antimycobacterial: rifampin .

DrugDDI.d540.s20.e0 18 25
drug
rifampin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s21
May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents .

DrugDDI.d540.s21.e0 55 62
drug
CRIXIVAN
DrugDDI.d540.s21.e1 77 94
drug
protease inhibitors
DrugDDI.d540.s21.e2 116 135
drug
antiretroviral agents



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s22
HMG-CoA Reductase inhibitors : lovastatin , simvastatin .

DrugDDI.d540.s22.e0 0 25
drug
HMG-CoA Reductase inhibitors
DrugDDI.d540.s22.e1 27 36
drug
lovastatin
DrugDDI.d540.s22.e2 38 48
drug
simvastatin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s24
Protease inhibitor : atazanavir .

DrugDDI.d540.s24.e0 0 16
drug
Protease inhibitor
DrugDDI.d540.s24.e1 18 27
drug
atazanavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s25
Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.

DrugDDI.d540.s25.e0 4 11
drug
CRIXIVAN
DrugDDI.d540.s25.e1 15 24
drug
atazanavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s26
Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.

DrugDDI.d540.s26.e0 19 23
drug
drugs
DrugDDI.d540.s26.e1 63 70
drug
CRIXIVAN
DrugDDI.d540.s26.e2 74 83
drug
atazanavir

interaction DrugDDI.d540.s26.e1 DrugDDI.d540.s26.e2

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s29
Drug Name .

DrugDDI.d540.s29.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s32
HIV Antiviral Agents .

DrugDDI.d540.s32.e0 3 17
drug
Antiviral Agents



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s33
Delavirdine .

DrugDDI.d540.s33.e0 0 10
drug
Delavirdine



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s34
@ indinavir concentration .

DrugDDI.d540.s34.e0 1 9
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s35
Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.

DrugDDI.d540.s35.e0 15 22
drug
CRIXIVAN
DrugDDI.d540.s35.e1 69 79
drug
delavirdine

interaction DrugDDI.d540.s35.e0 DrugDDI.d540.s35.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s36
Didanosine .

DrugDDI.d540.s36.e0 0 9
drug
Didanosine



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s37
Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.

DrugDDI.d540.s37.e0 0 8
drug
Indinavir
DrugDDI.d540.s37.e1 12 21
drug
didanosine
DrugDDI.d540.s37.e2 44 49
drug
buffer

interaction DrugDDI.d540.s37.e0 DrugDDI.d540.s37.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s38
Efavirenz .

DrugDDI.d540.s38.e0 0 8
drug
Efavirenz



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s40
The optimal dose of indinavir , when given in combination with efavirenz , is not known.

DrugDDI.d540.s40.e0 16 24
drug
indinavir
DrugDDI.d540.s40.e1 52 60
drug
efavirenz



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s41
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz .

DrugDDI.d540.s41.e0 13 21
drug
indinavir
DrugDDI.d540.s41.e1 77 85
drug
indinavir
DrugDDI.d540.s41.e2 101 109
drug
efavirenz



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s42
Nelfinavir .

DrugDDI.d540.s42.e0 0 9
drug
Nelfinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s43
@ indinavir concentration .

DrugDDI.d540.s43.e0 1 9
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s45
Nevirapine .

DrugDDI.d540.s45.e0 0 9
drug
Nevirapine



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s46
@ indinavir concentration .

DrugDDI.d540.s46.e0 1 9
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s47
Indinavir concentrations may be decreased in the presence of nevirapine .

DrugDDI.d540.s47.e0 0 8
drug
Indinavir
DrugDDI.d540.s47.e1 52 61
drug
nevirapine

interaction DrugDDI.d540.s47.e0 DrugDDI.d540.s47.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s49
Ritonavir .

DrugDDI.d540.s49.e0 0 8
drug
Ritonavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s50
@ indinavir concentration @ ritonavir concentration .

DrugDDI.d540.s50.e0 1 9
drug
indinavir
DrugDDI.d540.s50.e1 24 32
drug
ritonavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s52
Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.

DrugDDI.d540.s52.e0 90 98
drug
indinavir
DrugDDI.d540.s52.e1 116 124
drug
ritonavir
DrugDDI.d540.s52.e2 143 150
drug
CRIXIVAN

interaction DrugDDI.d540.s52.e0 DrugDDI.d540.s52.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s53
Saquinavir .

DrugDDI.d540.s53.e0 0 9
drug
Saquinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s54
@ saquinavir concentration .

DrugDDI.d540.s54.e0 1 10
drug
saquinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s57
Antiarrhythmics : bepridil , lidocaine (systemic) and quinidine .

DrugDDI.d540.s57.e0 0 14
drug
Antiarrhythmics
DrugDDI.d540.s57.e1 16 23
drug
bepridil
DrugDDI.d540.s57.e2 25 33
drug
lidocaine
DrugDDI.d540.s57.e3 47 55
drug
quinidine



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s58
@ antiarrhythmic agent s concentration .

DrugDDI.d540.s58.e0 1 19
drug
antiarrhythmic agent



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s59
Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN .

DrugDDI.d540.s59.e0 71 85
drug
antiarrhythmics
DrugDDI.d540.s59.e1 108 115
drug
CRIXIVAN

interaction DrugDDI.d540.s59.e0 DrugDDI.d540.s59.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s60
Anticonvulsants : carbamazepine , phenobarbital , phenytoin .

DrugDDI.d540.s60.e0 0 14
drug
Anticonvulsants
DrugDDI.d540.s60.e1 16 28
drug
carbamazepine
DrugDDI.d540.s60.e2 30 42
drug
phenobarbital
DrugDDI.d540.s60.e3 44 52
drug
phenytoin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s61
@ indinavir concentration .

DrugDDI.d540.s61.e0 1 9
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s63
CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.

DrugDDI.d540.s63.e0 0 7
drug
CRIXIVAN
DrugDDI.d540.s63.e1 39 47
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s64
Calcium Channel Blockers , Dihydropyridine : e.g., felodipine , nifedipine , nicardipine .

DrugDDI.d540.s64.e0 0 21
drug
Calcium Channel Blockers
DrugDDI.d540.s64.e1 23 37
drug
Dihydropyridine
DrugDDI.d540.s64.e2 44 53
drug
felodipine
DrugDDI.d540.s64.e3 55 64
drug
nifedipine
DrugDDI.d540.s64.e4 66 76
drug
nicardipine



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s65
@ dihydropyridine calcium channel blockers concentration .

DrugDDI.d540.s65.e0 16 37
drug
calcium channel blockers



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s67
Clarithromycin .

DrugDDI.d540.s67.e0 0 13
drug
Clarithromycin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s68
@ clarithromycin concentration @ indinavir concentration .

DrugDDI.d540.s68.e0 1 14
drug
clarithromycin
DrugDDI.d540.s68.e1 29 37
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s70
HMG-CoA Reductase Inhibitor : atorvastatin .

DrugDDI.d540.s70.e0 0 24
drug
HMG-CoA Reductase Inhibitor
DrugDDI.d540.s70.e1 26 37
drug
atorvastatin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s71
@ atorvastatin concentration .

DrugDDI.d540.s71.e0 1 12
drug
atorvastatin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s72
Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4 , such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN .

DrugDDI.d540.s72.e0 23 34
drug
atorvastatin
DrugDDI.d540.s72.e1 67 92
drug
HMG-CoA reductase inhibitors
DrugDDI.d540.s72.e2 125 130
drug
CYP3A4
DrugDDI.d540.s72.e3 138 148
drug
pravastatin
DrugDDI.d540.s72.e4 150 160
drug
fluvastatin
DrugDDI.d540.s72.e5 164 175
drug
rosuvastatin
DrugDDI.d540.s72.e6 193 200
drug
CRIXIVAN



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s73
Immunosuppressants : cyclosporine , tacrolimus , sirolimus .

DrugDDI.d540.s73.e0 0 17
drug
Immunosuppressants
DrugDDI.d540.s73.e1 19 30
drug
cyclosporine
DrugDDI.d540.s73.e2 32 41
drug
tacrolimus
DrugDDI.d540.s73.e3 43 51
drug
sirolimus



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s74
@ immunosuppressant agents concentration .

DrugDDI.d540.s74.e0 1 23
drug
immunosuppressant agents



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s75
Plasma concentrations may be increased by CRIXIVAN .

DrugDDI.d540.s75.e0 36 43
drug
CRIXIVAN



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s76
Itraconazole .

DrugDDI.d540.s76.e0 0 11
drug
Itraconazole



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s77
@ indinavir concentration .

DrugDDI.d540.s77.e0 1 9
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s78
Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.

DrugDDI.d540.s78.e0 15 22
drug
CRIXIVAN
DrugDDI.d540.s78.e1 71 82
drug
itraconazole

interaction DrugDDI.d540.s78.e0 DrugDDI.d540.s78.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s79
Ketoconazole .

DrugDDI.d540.s79.e0 0 11
drug
Ketoconazole



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s80
@ indinavir concentration .

DrugDDI.d540.s80.e0 1 9
drug
indinavir



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s81
Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered.

DrugDDI.d540.s81.e0 15 22
drug
CRIXIVAN



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s82
Rifabutin .

DrugDDI.d540.s82.e0 0 8
drug
Rifabutin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s83
@ indinavir concentration @ rifabutin concentration .

DrugDDI.d540.s83.e0 1 9
drug
indinavir
DrugDDI.d540.s83.e1 24 32
drug
rifabutin



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s84
Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.

DrugDDI.d540.s84.e0 15 23
drug
rifabutin
DrugDDI.d540.s84.e1 63 70
drug
CRIXIVAN
DrugDDI.d540.s84.e2 129 137
drug
rifabutin
DrugDDI.d540.s84.e3 141 148
drug
CRIXIVAN

interaction DrugDDI.d540.s84.e2 DrugDDI.d540.s84.e3

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s85
Sildenafil .

DrugDDI.d540.s85.e0 0 9
drug
Sildenafil



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s86
@ sildenafil concentration .

DrugDDI.d540.s86.e0 1 10
drug
sildenafil



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s87
Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.

DrugDDI.d540.s87.e0 0 9
drug
Sildenafil
DrugDDI.d540.s87.e1 89 97
drug
indinavir

interaction DrugDDI.d540.s87.e0 DrugDDI.d540.s87.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s88
Tadalafil .

DrugDDI.d540.s88.e0 0 8
drug
Tadalafil



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s89
@ tadalafil concentration .

DrugDDI.d540.s89.e0 1 9
drug
tadalafil



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s90
Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.

DrugDDI.d540.s90.e0 0 8
drug
Tadalafil
DrugDDI.d540.s90.e1 88 96
drug
indinavir

interaction DrugDDI.d540.s90.e0 DrugDDI.d540.s90.e1

Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s91
Vardenafil .

DrugDDI.d540.s91.e0 0 9
drug
Vardenafil



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s92
@ vardenafil concentration .

DrugDDI.d540.s92.e0 1 10
drug
vardenafil



Abstract Id: DrugDDI.d540
Sentence Id: DrugDDI.d540.s93
Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.

DrugDDI.d540.s93.e0 0 9
drug
Vardenafil
DrugDDI.d540.s93.e1 90 98
drug
indinavir



Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s0
Concurrent administration of etanercept (another TNF@-blocking agent) and anakinra (an interleukin-1 antagonist ) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal product s alone.

DrugDDI.d11.s0.e0 26 35
drug
etanercept
DrugDDI.d11.s0.e1 66 73
drug
anakinra
DrugDDI.d11.s0.e2 77 99
drug
interleukin-1 antagonist
DrugDDI.d11.s0.e3 223 238
drug
medicinal product

interaction DrugDDI.d11.s0.e0 DrugDDI.d11.s0.e1

Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s1
Other TNFa -blocking agents (including REMICADE ) used in combination with anakinra may also result in similar toxicities.

DrugDDI.d11.s1.e0 5 8
drug
TNFa
DrugDDI.d11.s1.e1 34 41
drug
REMICADE
DrugDDI.d11.s1.e2 64 71
drug
anakinra

interaction DrugDDI.d11.s1.e1 DrugDDI.d11.s1.e2

Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s2
Specific drug interaction studies, including interactions with MTX , have not been conducted.

DrugDDI.d11.s2.e0 56 58
drug
MTX



Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s3
The majority of patients in rheumatoid arthritis or Crohn@s disease clinical studies received one or more concomitant medications .

DrugDDI.d11.s3.e0 101 111
drug
medications



Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s4
In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents , folic acid , corticosteroids and/or narcotics .

DrugDDI.d11.s4.e0 33 43
drug
medications
DrugDDI.d11.s4.e1 51 53
drug
MTX
DrugDDI.d11.s4.e2 58 92
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d11.s4.e3 94 102
drug
folic acid
DrugDDI.d11.s4.e4 104 118
drug
corticosteroids
DrugDDI.d11.s4.e5 125 133
drug
narcotics



Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s5
Concomitant Crohn@s disease medications were antibiotics , antivirals , corticosteroids , 6-MP/AZA and aminosalicylate s.

DrugDDI.d11.s5.e0 25 35
drug
medications
DrugDDI.d11.s5.e1 40 50
drug
antibiotics
DrugDDI.d11.s5.e2 52 61
drug
antivirals
DrugDDI.d11.s5.e3 63 77
drug
corticosteroids
DrugDDI.d11.s5.e4 79 86
drug
6-MP/AZA
DrugDDI.d11.s5.e5 90 104
drug
aminosalicylate



Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s6
In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents , folic acid and corticosteroids .

DrugDDI.d11.s6.e0 46 56
drug
medications
DrugDDI.d11.s6.e1 65 67
drug
MTX
DrugDDI.d11.s6.e2 108 142
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d11.s6.e3 144 152
drug
folic acid
DrugDDI.d11.s6.e4 156 170
drug
corticosteroids



Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s7
Patients with Crohn@s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants .

DrugDDI.d11.s7.e0 37 54
drug
immunosuppressants
DrugDDI.d11.s7.e1 117 134
drug
immunosuppressants



Abstract Id: DrugDDI.d11
Sentence Id: DrugDDI.d11.s8
Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn@s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylate s.

DrugDDI.d11.s8.e0 5 14
drug
infliximab
DrugDDI.d11.s8.e1 66 76
drug
medications
DrugDDI.d11.s8.e2 117 131
drug
corticosteroids
DrugDDI.d11.s8.e3 133 143
drug
antibiotics
DrugDDI.d11.s8.e4 145 157
drug
metronidazole
DrugDDI.d11.s8.e5 160 172
drug
ciprofloxacin
DrugDDI.d11.s8.e6 177 191
drug
aminosalicylate



Abstract Id: DrugDDI.d239
Sentence Id: DrugDDI.d239.s0
A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.

DrugDDI.d239.s0.e0 55 61
drug
insulin



Abstract Id: DrugDDI.d239
Sentence Id: DrugDDI.d239.s1
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors , disopyramide , fibrates , fluoxetine , MAO inhibitors , propoxyphene , salicylates , somatostatin analog (e.g., octreotide ), sulfonamide antibiotics.

DrugDDI.d239.s1.e0 138 150
drug
ACE inhibitors
DrugDDI.d239.s1.e1 152 163
drug
disopyramide
DrugDDI.d239.s1.e2 165 172
drug
fibrates
DrugDDI.d239.s1.e3 174 183
drug
fluoxetine
DrugDDI.d239.s1.e4 185 197
drug
MAO inhibitors
DrugDDI.d239.s1.e5 199 210
drug
propoxyphene
DrugDDI.d239.s1.e6 212 222
drug
salicylates
DrugDDI.d239.s1.e7 224 241
drug
somatostatin analog
DrugDDI.d239.s1.e8 248 257
drug
octreotide
DrugDDI.d239.s1.e9 260 270
drug
sulfonamide



Abstract Id: DrugDDI.d239
Sentence Id: DrugDDI.d239.s2
The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic agents (e.g., epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens (e.g., in oral contraceptives ).

DrugDDI.d239.s2.e0 81 87
drug
insulin
DrugDDI.d239.s2.e1 89 103
drug
corticosteroids
DrugDDI.d239.s2.e2 105 111
drug
danazol
DrugDDI.d239.s2.e3 113 121
drug
diuretics
DrugDDI.d239.s2.e4 123 143
drug
sympathomimetic agents
DrugDDI.d239.s2.e5 150 160
drug
epinephrine
DrugDDI.d239.s2.e6 162 170
drug
albuterol
DrugDDI.d239.s2.e7 172 182
drug
terbutaline
DrugDDI.d239.s2.e8 185 193
drug
isoniazid
DrugDDI.d239.s2.e9 195 218
drug
phenothiazine derivatives
DrugDDI.d239.s2.e10 220 229
drug
somatropin
DrugDDI.d239.s2.e11 231 245
drug
thyroid hormones
DrugDDI.d239.s2.e12 247 255
drug
estrogens
DrugDDI.d239.s2.e13 257 268
drug
progestogens
DrugDDI.d239.s2.e14 277 294
drug
oral contraceptives



Abstract Id: DrugDDI.d239
Sentence Id: DrugDDI.d239.s3
Beta-blockers , clonidine , lithium salt s, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin .

DrugDDI.d239.s3.e0 0 12
drug
Beta-blockers
DrugDDI.d239.s3.e1 14 22
drug
clonidine
DrugDDI.d239.s3.e2 24 34
drug
lithium salt
DrugDDI.d239.s3.e3 40 46
drug
alcohol
DrugDDI.d239.s3.e4 107 113
drug
insulin

interaction DrugDDI.d239.s3.e0 DrugDDI.d239.s3.e4
interaction DrugDDI.d239.s3.e2 DrugDDI.d239.s3.e4

Abstract Id: DrugDDI.d239
Sentence Id: DrugDDI.d239.s4
Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.

DrugDDI.d239.s4.e0 0 10
drug
Pentamidine



Abstract Id: DrugDDI.d239
Sentence Id: DrugDDI.d239.s5
In addition, under the influence of sympatholytic medicinal products such as beta-blockers , clonidine , guanethidine , and reserpine , the signs of hypoglycemia may be reduced or absent.

DrugDDI.d239.s5.e0 30 42
drug
sympatholytic
DrugDDI.d239.s5.e1 66 78
drug
beta-blockers
DrugDDI.d239.s5.e2 80 88
drug
clonidine
DrugDDI.d239.s5.e3 90 101
drug
guanethidine
DrugDDI.d239.s5.e4 106 114
drug
reserpine



Abstract Id: DrugDDI.d87
Sentence Id: DrugDDI.d87.s0
Interactions between Betaseron and other drugs have not been fully evaluated.

DrugDDI.d87.s0.e0 19 27
drug
Betaseron
DrugDDI.d87.s0.e1 36 40
drug
drugs



Abstract Id: DrugDDI.d87
Sentence Id: DrugDDI.d87.s1
Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron .

DrugDDI.d87.s1.e0 78 91
drug
corticosteroid
DrugDDI.d87.s1.e1 94 97
drug
ACTH
DrugDDI.d87.s1.e2 184 192
drug
Betaseron



Abstract Id: DrugDDI.d87
Sentence Id: DrugDDI.d87.s2
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.

DrugDDI.d87.s2.e0 0 8
drug
Betaseron
DrugDDI.d87.s2.e1 106 115
drug
antipyrine
DrugDDI.d87.s2.e2 178 186
drug
Betaseron

interaction DrugDDI.d87.s2.e0 DrugDDI.d87.s2.e1

Abstract Id: DrugDDI.d399
Sentence Id: DrugDDI.d399.s0
ATROVENT Inhalation Aerosol has been used concomitantly with other drugs , including sympathomimetic bronchodilators , methylxanthines , and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.

DrugDDI.d399.s0.e0 0 24
drug
ATROVENT Inhalation Aerosol
DrugDDI.d399.s0.e1 58 62
drug
drugs
DrugDDI.d399.s0.e2 73 102
drug
sympathomimetic bronchodilators
DrugDDI.d399.s0.e3 104 118
drug
methylxanthines



Abstract Id: DrugDDI.d399
Sentence Id: DrugDDI.d399.s1
With the exception of albuterol , there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness.

DrugDDI.d399.s1.e0 18 26
drug
albuterol
DrugDDI.d399.s1.e1 89 113
drug
ATROVENT Inhalation Aerosol
DrugDDI.d399.s1.e2 122 126
drug
drugs



Abstract Id: DrugDDI.d399
Sentence Id: DrugDDI.d399.s2
Anticholinergic agents : Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.

DrugDDI.d399.s2.e0 0 20
drug
Anticholinergic agents
DrugDDI.d399.s2.e1 30 47
drug
ipratropium bromide
DrugDDI.d399.s2.e2 159 173
drug
anticholinergic

interaction DrugDDI.d399.s2.e1 DrugDDI.d399.s2.e2

Abstract Id: DrugDDI.d399
Sentence Id: DrugDDI.d399.s3
Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs .

DrugDDI.d399.s3.e0 48 72
drug
ATROVENT Inhalation Aerosol
DrugDDI.d399.s3.e1 82 112
drug
anticholinergic-containing drugs

interaction DrugDDI.d399.s3.e0 DrugDDI.d399.s3.e1

Abstract Id: DrugDDI.d506
Sentence Id: DrugDDI.d506.s0
Isocarboxazid should be administered with caution to patients receiving Antabuse ( disulfiram , Wyeth-Ayerst Laboratories).

DrugDDI.d506.s0.e0 0 12
drug
Isocarboxazid
DrugDDI.d506.s0.e1 63 70
drug
Antabuse
DrugDDI.d506.s0.e2 72 81
drug
disulfiram



Abstract Id: DrugDDI.d506
Sentence Id: DrugDDI.d506.s1
In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.

DrugDDI.d506.s1.e0 52 63
drug
MAO inhibitor
DrugDDI.d506.s1.e1 68 77
drug
disulfiram

interaction DrugDDI.d506.s1.e0 DrugDDI.d506.s1.e1

Abstract Id: DrugDDI.d506
Sentence Id: DrugDDI.d506.s2
Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.

DrugDDI.d506.s2.e0 16 28
drug
Isocarboxazid
DrugDDI.d506.s2.e1 37 54
drug
psychotropic agents

interaction DrugDDI.d506.s2.e0 DrugDDI.d506.s2.e1

Abstract Id: DrugDDI.d506
Sentence Id: DrugDDI.d506.s3
This is especially true in patients who may subject themselves to an overdosage of drugs .

DrugDDI.d506.s3.e0 69 73
drug
drugs



Abstract Id: DrugDDI.d506
Sentence Id: DrugDDI.d506.s5
The monoamine oxidase inhibitor y effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug , and this should be borne in mind when another drug is prescribed following Isocarboxazid .

DrugDDI.d506.s5.e0 3 27
drug
monoamine oxidase inhibitor
DrugDDI.d506.s5.e1 38 50
drug
Isocarboxazid
DrugDDI.d506.s5.e2 107 110
drug
drug
DrugDDI.d506.s5.e3 149 152
drug
drug
DrugDDI.d506.s5.e4 174 186
drug
Isocarboxazid



Abstract Id: DrugDDI.d506
Sentence Id: DrugDDI.d506.s6
To avoid potentiation, the physician wishing to terminate treatment with Isocarboxazid and begin therapy with another agent should allow for an interval of 10 days.

DrugDDI.d506.s6.e0 63 75
drug
Isocarboxazid



Abstract Id: DrugDDI.d66
Sentence Id: DrugDDI.d66.s0
May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide , quinidine , phenothiazines , and procainamide (these medicines may increase the risk of heart problems).

DrugDDI.d66.s0.e0 28 56
drug
beta-adrenergic blocking agents
DrugDDI.d66.s0.e1 63 71
drug
medicines
DrugDDI.d66.s0.e2 100 106
drug
prevent
DrugDDI.d66.s0.e3 120 134
drug
bronchodilators
DrugDDI.d66.s0.e4 158 169
drug
disopyramide
DrugDDI.d66.s0.e5 171 179
drug
quinidine
DrugDDI.d66.s0.e6 181 194
drug
phenothiazines
DrugDDI.d66.s0.e7 199 210
drug
procainamide
DrugDDI.d66.s0.e8 217 225
drug
medicines



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s0
Food: Isoniazid should not be administered with food.

DrugDDI.d409.s0.e0 5 13
drug
Isoniazid



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s1
Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food.

DrugDDI.d409.s1.e0 40 48
drug
isoniazid



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s2
Acetaminophen : A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid .

DrugDDI.d409.s2.e0 0 12
drug
Acetaminophen
DrugDDI.d409.s2.e1 80 88
drug
Isoniazid



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s3
It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.

DrugDDI.d409.s3.e0 87 95
drug
isoniazid
DrugDDI.d409.s3.e1 99 111
drug
acetaminophen

interaction DrugDDI.d409.s3.e0 DrugDDI.d409.s3.e1

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s4
However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites , in the liver .

DrugDDI.d409.s4.e0 35 43
drug
isoniazid
DrugDDI.d409.s4.e1 65 91
drug
mixed-function oxidase enzyme
DrugDDI.d409.s4.e2 121 131
drug
metabolites
DrugDDI.d409.s4.e3 138 142
drug
liver



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s5
Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites .

DrugDDI.d409.s5.e0 32 40
drug
isoniazid
DrugDDI.d409.s5.e1 84 88
drug
liver
DrugDDI.d409.s5.e2 143 155
drug
acetaminophen
DrugDDI.d409.s5.e3 180 190
drug
metabolites

interaction DrugDDI.d409.s5.e0 DrugDDI.d409.s5.e2

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s6
Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats.

DrugDDI.d409.s6.e0 43 51
drug
isoniazid



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s7
Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.

DrugDDI.d409.s7.e0 0 12
drug
Carbamazepine
DrugDDI.d409.s7.e1 14 22
drug
Isoniazid
DrugDDI.d409.s7.e2 51 63
drug
carbamazepine
DrugDDI.d409.s7.e3 89 101
drug
Carbamazepine
DrugDDI.d409.s7.e4 161 169
drug
isoniazid
DrugDDI.d409.s7.e5 270 283
drug
anticonvulsant

interaction DrugDDI.d409.s7.e1 DrugDDI.d409.s7.e2

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s8
Ketoconazole : Potential interaction of Ketoconazole and Isoniazid may exist.

DrugDDI.d409.s8.e0 0 11
drug
Ketoconazole
DrugDDI.d409.s8.e1 35 46
drug
Ketoconazole
DrugDDI.d409.s8.e2 50 58
drug
Isoniazid

interaction DrugDDI.d409.s8.e1 DrugDDI.d409.s8.e2

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s9
When Ketoconazole is given in combination with isoniazid and rifampin the AUC of ketoconazole is decreased by as much as 88% after 5 months of concurrent Isoniazid and Rifampin therapy.

DrugDDI.d409.s9.e0 4 15
drug
Ketoconazole
DrugDDI.d409.s9.e1 40 48
drug
isoniazid
DrugDDI.d409.s9.e2 52 59
drug
rifampin
DrugDDI.d409.s9.e3 68 79
drug
ketoconazole
DrugDDI.d409.s9.e4 128 136
drug
Isoniazid
DrugDDI.d409.s9.e5 140 147
drug
Rifampin

interaction DrugDDI.d409.s9.e0 DrugDDI.d409.s9.e1

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s10
Phenytoin : Isoniazid may increase serum levels of phenytoin .

DrugDDI.d409.s10.e0 0 8
drug
Phenytoin
DrugDDI.d409.s10.e1 10 18
drug
Isoniazid
DrugDDI.d409.s10.e2 43 51
drug
phenytoin

interaction DrugDDI.d409.s10.e1 DrugDDI.d409.s10.e2

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s11
To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.

DrugDDI.d409.s11.e0 55 68
drug
anticonvulsant



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s12
Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline , and in some instances a slight decrease in the elimination of isoniazid .

DrugDDI.d409.s12.e0 64 72
drug
isoniazid
DrugDDI.d409.s12.e1 76 87
drug
theophylline
DrugDDI.d409.s12.e2 118 129
drug
theophylline
DrugDDI.d409.s12.e3 182 190
drug
isoniazid

interaction DrugDDI.d409.s12.e0 DrugDDI.d409.s12.e1

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s13
Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.

DrugDDI.d409.s13.e0 26 37
drug
theophylline
DrugDDI.d409.s13.e1 127 138
drug
theophylline



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s14
Valproate : A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid .

DrugDDI.d409.s14.e0 0 8
drug
Valproate
DrugDDI.d409.s14.e1 69 77
drug
valproate
DrugDDI.d409.s14.e2 100 108
drug
isoniazid

interaction DrugDDI.d409.s14.e1 DrugDDI.d409.s14.e2

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s15
Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.

DrugDDI.d409.s15.e0 6 14
drug
valproate
DrugDDI.d409.s15.e1 49 57
drug
isoniazid
DrugDDI.d409.s15.e2 61 69
drug
valproate
DrugDDI.d409.s15.e3 121 129
drug
valproate

interaction DrugDDI.d409.s15.e1 DrugDDI.d409.s15.e2

Abstract Id: DrugDDI.d492
Sentence Id: DrugDDI.d492.s0
Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.

DrugDDI.d492.s0.e0 0 25
drug
Isoproterenol hydrochloride
DrugDDI.d492.s0.e1 38 48
drug
epinephrine
DrugDDI.d492.s0.e2 97 101
drug
drugs
DrugDDI.d492.s0.e3 111 127
drug
cardiac stimulants

interaction DrugDDI.d492.s0.e0 DrugDDI.d492.s0.e1

Abstract Id: DrugDDI.d492
Sentence Id: DrugDDI.d492.s1
The drugs may, however, be administered alternately provided a proper interval has elapsed between doses.

DrugDDI.d492.s1.e0 3 7
drug
drugs



Abstract Id: DrugDDI.d492
Sentence Id: DrugDDI.d492.s2
ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines .

DrugDDI.d492.s2.e0 0 6
drug
ISUPREL
DrugDDI.d492.s2.e1 49 71
drug
inhalational anesthetics
DrugDDI.d492.s2.e2 78 86
drug
halothane
DrugDDI.d492.s2.e3 151 171
drug
sympathomimetic amines

interaction DrugDDI.d492.s2.e0 DrugDDI.d492.s2.e1

Abstract Id: DrugDDI.d323
Sentence Id: DrugDDI.d323.s0
The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators .

DrugDDI.d323.s0.e0 24 44
drug
isosorbide mononitrate
DrugDDI.d323.s0.e1 74 85
drug
vasodilators

interaction DrugDDI.d323.s0.e0 DrugDDI.d323.s0.e1

Abstract Id: DrugDDI.d323
Sentence Id: DrugDDI.d323.s1
Alcohol , in particular, has been found to exhibit additive effects of this variety.

DrugDDI.d323.s1.e0 0 6
drug
Alcohol



Abstract Id: DrugDDI.d323
Sentence Id: DrugDDI.d323.s2
Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.

DrugDDI.d323.s2.e0 58 79
drug
calcium channel blockers
DrugDDI.d323.s2.e1 90 97
drug
nitrates



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s0
@ Vitamin A : Because of the relationship of Accutane to vitamin A , patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects .

DrugDDI.d18.s0.e0 1 8
drug
Vitamin A
DrugDDI.d18.s0.e1 36 43
drug
Accutane
DrugDDI.d18.s0.e2 46 53
drug
vitamin A
DrugDDI.d18.s0.e3 119 126
drug
vitamin A

interaction DrugDDI.d18.s0.e1 DrugDDI.d18.s0.e2

Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s2
@ Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines .

DrugDDI.d18.s2.e0 1 13
drug
Tetracyclines
DrugDDI.d18.s2.e1 39 46
drug
Accutane
DrugDDI.d18.s2.e2 50 62
drug
tetracyclines
DrugDDI.d18.s2.e3 85 92
drug
Accutane
DrugDDI.d18.s2.e4 219 231
drug
tetracyclines

interaction DrugDDI.d18.s2.e1 DrugDDI.d18.s2.e2

Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s4
@ Micro-dosed Progesterone Preparation s: Micro-dosed progesterone preparation s (minipills that do not contain an estrogen ) may be an inadequate method of contraception during Accutane therapy.

DrugDDI.d18.s4.e0 12 34
drug
Progesterone Preparation
DrugDDI.d18.s4.e1 48 70
drug
progesterone preparation
DrugDDI.d18.s4.e2 100 107
drug
estrogen
DrugDDI.d18.s4.e3 153 160
drug
Accutane

interaction DrugDDI.d18.s4.e1 DrugDDI.d18.s4.e3

Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s5
Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from women who have used combined oral contraceptives , as well as topical/injectable/implantable/insertable hormonal birth control products.

DrugDDI.d18.s5.e0 21 34
drug
contraceptives
DrugDDI.d18.s5.e1 113 130
drug
oral contraceptives
DrugDDI.d18.s5.e2 189 200
drug
birth control



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s7
It is not known if hormonal contraceptives differ in their effectiveness when used with Accutane .

DrugDDI.d18.s7.e0 22 35
drug
contraceptives
DrugDDI.d18.s7.e1 74 81
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s8
Therefore, it is critically important for women of childbearing potential to select and commit to use 2 forms of effective contraception simultaneously, at least 1 of which must be a primary form, unless absolute abstinence is the chosen method, or the patient has undergone a hysterectomy .

DrugDDI.d18.s8.e0 75 80
drug
commit



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s10
@ Phenytoin : Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.

DrugDDI.d18.s10.e0 1 9
drug
Phenytoin
DrugDDI.d18.s10.e1 11 18
drug
Accutane
DrugDDI.d18.s10.e2 62 70
drug
phenytoin



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s11
These results are consistent with the in vitro finding that neither isotretinoin nor its metabolites induce or inhibit the activity of the CYP 2C9 human hepatic P450 enzyme.

DrugDDI.d18.s11.e0 57 68
drug
isotretinoin
DrugDDI.d18.s11.e1 75 85
drug
metabolites
DrugDDI.d18.s11.e2 117 122
drug
CYP 2C9



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s12
Phenytoin is known to cause osteomalacia.

DrugDDI.d18.s12.e0 0 8
drug
Phenytoin



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s13
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and Accutane .

DrugDDI.d18.s13.e0 93 101
drug
phenytoin
DrugDDI.d18.s13.e1 105 112
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s14
Therefore, caution should be exercised when using these drugs together .

DrugDDI.d18.s14.e0 48 52
drug
drugs



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s16
@ Systemic Corticosteroids : Systemic corticosteroids are known to cause osteoporosis.

DrugDDI.d18.s16.e0 9 23
drug
Corticosteroids
DrugDDI.d18.s16.e1 33 47
drug
corticosteroids



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s17
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and Accutane .

DrugDDI.d18.s17.e0 101 115
drug
corticosteroids
DrugDDI.d18.s17.e1 119 126
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s18
Therefore, caution should be exercised when using these drugs together.

DrugDDI.d18.s18.e0 48 52
drug
drugs



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s19
Prescribers are advised to consult the package insert of medication administered concomitantly with hormonal contraceptives , since some medications may decrease the effectiveness of these birth control products.

DrugDDI.d18.s19.e0 48 57
drug
medication
DrugDDI.d18.s19.e1 95 108
drug
contraceptives
DrugDDI.d18.s19.e2 119 129
drug
medications
DrugDDI.d18.s19.e3 164 175
drug
birth control

interaction DrugDDI.d18.s19.e0 DrugDDI.d18.s19.e1

Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s20
Accutane use is associated with depression in some patients.

DrugDDI.d18.s20.e0 0 7
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s21
Patients should be prospectively cautioned not to self-medicate with the herbal supplement St. John@s Wort because a possible interaction has been suggested with hormonal contraceptives based on reports of breakthrough bleeding on oral contraceptives shortly after starting St. Johns Wort .

DrugDDI.d18.s21.e0 147 160
drug
contraceptives
DrugDDI.d18.s21.e1 199 216
drug
oral contraceptives
DrugDDI.d18.s21.e2 237 248
drug
St. Johns Wort

interaction DrugDDI.d18.s21.e1 DrugDDI.d18.s21.e2

Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s22
Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort .

DrugDDI.d18.s22.e0 52 65
drug
contraceptives
DrugDDI.d18.s22.e1 87 98
drug
St. Johns Wort

interaction DrugDDI.d18.s22.e0 DrugDDI.d18.s22.e1

Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s23
Laboratory Tests Pregnancy Test Female patients of childbearing potential must have negative results from 2 urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial Accutane prescription.

DrugDDI.d18.s23.e0 177 184
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s24
The first test is obtained by the prescriber when the decision is made to pursue qualification of the patient for Accutane (a screening test).

DrugDDI.d18.s24.e0 94 101
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s25
The second pregnancy test (a confirmation test) should be done during the first 5 days of the menstrual period immediately preceding the beginning of Accutane therapy.

DrugDDI.d18.s25.e0 126 133
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s31
After consumption of alcohol , at least 36 hours should elapse before these determinations are made.

DrugDDI.d18.s31.e0 18 24
drug
alcohol



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s32
It is recommended that these tests be performed at weekly or biweekly intervals until the lipid response to Accutane is established.

DrugDDI.d18.s32.e0 90 97
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s33
The incidence of hypertriglyceridemia is 1 patient in 4 on Accutane therapy .

DrugDDI.d18.s33.e0 49 56
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s35
@ Liver Function Tests: Since elevations of liver enzymes have been observed during clinical trials, and hepatitis has been reported, pretreatment and follow-up liver function tests should be performed at weekly or biweekly intervals until the response to Accutane has been established .

DrugDDI.d18.s35.e0 37 48
drug
liver enzymes
DrugDDI.d18.s35.e1 218 225
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s37
@ Glucose : Some patients receiving Accutane have experienced problems in the control of their blood sugar.

DrugDDI.d18.s37.e0 1 7
drug
Glucose
DrugDDI.d18.s37.e1 30 37
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s38
In addition, new cases of diabetes have been diagnosed during Accutane therapy, although no causal relationship has been established .

DrugDDI.d18.s38.e0 52 59
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s40
@ CPK: Some patients undergoing vigorous physical activity while on Accutane therapy have experienced elevated CPK levels; .

DrugDDI.d18.s40.e0 58 65
drug
Accutane



Abstract Id: DrugDDI.d18
Sentence Id: DrugDDI.d18.s43
In a clinical trial of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular acne, transient elevations in CPK were observed in 12% of patients, including those undergoing strenuous physical activity in association with reported musculoskeletal adverse events such as back pain, arthralgia, limb injury, or muscle sprain.

DrugDDI.d18.s43.e0 21 29
drug
pediatric



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s0
Nitroglycerin : DynaCirc@ ( isradipine ) has been safely coadministered with nitroglycerin .

DrugDDI.d183.s0.e0 0 12
drug
Nitroglycerin
DrugDDI.d183.s0.e1 24 33
drug
isradipine
DrugDDI.d183.s0.e2 66 78
drug
nitroglycerin



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s1
Hydrochlorothiazide : A study in normal healthy volunteers has shown that concomitant administration of DynaCirc@ ( isradipine ) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug .

DrugDDI.d183.s1.e0 0 18
drug
Hydrochlorothiazide
DrugDDI.d183.s1.e1 100 109
drug
isradipine
DrugDDI.d183.s1.e2 114 132
drug
hydrochlorothiazide
DrugDDI.d183.s1.e3 179 182
drug
drug



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s2
In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.

DrugDDI.d183.s2.e0 41 50
drug
isradipine
DrugDDI.d183.s2.e1 61 79
drug
hydrochlorothiazide
DrugDDI.d183.s2.e2 132 141
drug
isradipine
DrugDDI.d183.s2.e3 157 172
drug
antihypertensive



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s3
Propranolol : In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability.

DrugDDI.d183.s3.e0 0 10
drug
Propranolol
DrugDDI.d183.s3.e1 67 77
drug
propranolol
DrugDDI.d183.s3.e2 126 135
drug
isradipine



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s4
Significant increases In AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study.

DrugDDI.d183.s4.e0 67 77
drug
propranolol



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s5
However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d.

DrugDDI.d183.s5.e0 44 53
drug
isradipine



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s6
propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug@s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol , and between propranolol given singly and in combination with isradipine .

DrugDDI.d183.s6.e0 0 10
drug
propranolol
DrugDDI.d183.s6.e1 142 151
drug
isradipine
DrugDDI.d183.s6.e2 183 193
drug
propranolol
DrugDDI.d183.s6.e3 205 215
drug
propranolol
DrugDDI.d183.s6.e4 247 256
drug
isradipine



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s7
Cimetidine : In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).

DrugDDI.d183.s7.e0 0 9
drug
Cimetidine
DrugDDI.d183.s7.e1 56 65
drug
cimetidine
DrugDDI.d183.s7.e2 99 108
drug
isradipine
DrugDDI.d183.s7.e3 140 149
drug
isradipine

interaction DrugDDI.d183.s7.e1 DrugDDI.d183.s7.e2

Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s8
If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.

DrugDDI.d183.s8.e0 2 11
drug
isradipine
DrugDDI.d183.s8.e1 58 67
drug
cimetidine

interaction DrugDDI.d183.s8.e0 DrugDDI.d183.s8.e1

Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s9
Rifampicin : In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.

DrugDDI.d183.s9.e0 0 9
drug
Rifampicin
DrugDDI.d183.s9.e1 55 64
drug
rifampicin
DrugDDI.d183.s9.e2 102 111
drug
isradipine
DrugDDI.d183.s9.e3 134 143
drug
isradipine

interaction DrugDDI.d183.s9.e1 DrugDDI.d183.s9.e2

Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s10
If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine .

DrugDDI.d183.s10.e0 2 11
drug
rifampicin
DrugDDI.d183.s10.e1 30 39
drug
isradipine
DrugDDI.d183.s10.e2 169 178
drug
isradipine

interaction DrugDDI.d183.s10.e0 DrugDDI.d183.s10.e1

Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s11
Warfarin : In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine .

DrugDDI.d183.s11.e0 0 7
drug
Warfarin
DrugDDI.d183.s11.e1 107 116
drug
isradipine
DrugDDI.d183.s11.e2 127 134
drug
warfarin
DrugDDI.d183.s11.e3 166 173
drug
warfarin
DrugDDI.d183.s11.e4 258 267
drug
isradipine



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s12
Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug .

DrugDDI.d183.s12.e0 14 21
drug
warfarin
DrugDDI.d183.s12.e1 25 34
drug
isradipine
DrugDDI.d183.s12.e2 44 57
drug
plasma proteins
DrugDDI.d183.s12.e3 98 101
drug
drug



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s13
Digoxin : The concomitant administration of DynaCirc@ ( isradipine ) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin .

DrugDDI.d183.s13.e0 0 6
drug
Digoxin
DrugDDI.d183.s13.e1 48 57
drug
isradipine
DrugDDI.d183.s13.e2 62 68
drug
digoxin
DrugDDI.d183.s13.e3 152 158
drug
digoxin



Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s14
Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker .

DrugDDI.d183.s14.e0 0 7
drug
Fentanyl
DrugDDI.d183.s14.e1 57 64
drug
fentanyl
DrugDDI.d183.s14.e2 96 106
drug
beta blocker
DrugDDI.d183.s14.e3 111 131
drug
calcium channel blocker

interaction DrugDDI.d183.s14.e1 DrugDDI.d183.s14.e2

Abstract Id: DrugDDI.d183
Sentence Id: DrugDDI.d183.s15
Even though such interactions have not been seen in clinical studies with DynaCirc@ ( isradipine ), an increased volume of circulating fluids might be required if such an interaction were to occur.

DrugDDI.d183.s15.e0 72 81
drug
isradipine



Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s0
Both itraconazole and its major metabolite , hydroxyitraconazole , are inhibitors of the cytochrome P450 3A4 enzyme system.

DrugDDI.d313.s0.e0 4 15
drug
itraconazole
DrugDDI.d313.s0.e1 27 36
drug
metabolite
DrugDDI.d313.s0.e2 38 56
drug
hydroxyitraconazole
DrugDDI.d313.s0.e3 76 92
drug
cytochrome P450 3A4



Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s1
Coadministration of Itraconazole and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.

DrugDDI.d313.s1.e0 18 29
drug
Itraconazole
DrugDDI.d313.s1.e1 33 37
drug
drugs
DrugDDI.d313.s1.e2 63 79
drug
cytochrome P450 3A4
DrugDDI.d313.s1.e3 137 141
drug
drugs

interaction DrugDDI.d313.s1.e0 DrugDDI.d313.s1.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s3
Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine , resulting in rare instances of life- threatening cardiac dysrhythmias and one death.

DrugDDI.d313.s3.e0 18 28
drug
terfenadine
DrugDDI.d313.s3.e1 33 44
drug
Itraconazole
DrugDDI.d313.s3.e2 83 93
drug
terfenadine

interaction DrugDDI.d313.s3.e0 DrugDDI.d313.s3.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s4
Another oral azole antifungal , ketoconazole, inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.

DrugDDI.d313.s4.e0 11 25
drug
azole antifungal
DrugDDI.d313.s4.e1 63 72
drug
astemizole
DrugDDI.d313.s4.e2 115 124
drug
astemizole
DrugDDI.d313.s4.e3 131 146
drug
active metabolite

interaction DrugDDI.d313.s4.e0 DrugDDI.d313.s4.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s5
In vitro data suggest that itraconazole , when compared to ketoconazole , has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole .

DrugDDI.d313.s5.e0 22 33
drug
itraconazole
DrugDDI.d313.s5.e1 49 60
drug
ketoconazole
DrugDDI.d313.s5.e2 143 152
drug
astemizole



Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s6
Based on the chemical resemblance of itraconazole and ketoconazole , coadministration of astemizole with itraconazole is contraindicated.

DrugDDI.d313.s6.e0 31 42
drug
itraconazole
DrugDDI.d313.s6.e1 46 57
drug
ketoconazole
DrugDDI.d313.s6.e2 77 86
drug
astemizole
DrugDDI.d313.s6.e3 91 102
drug
itraconazole

interaction DrugDDI.d313.s6.e2 DrugDDI.d313.s6.e3

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s7
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride .

DrugDDI.d313.s7.e0 41 52
drug
ketoconazole
DrugDDI.d313.s7.e1 84 92
drug
cisapride
DrugDDI.d313.s7.e2 138 146
drug
cisapride

interaction DrugDDI.d313.s7.e0 DrugDDI.d313.s7.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s8
Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.

DrugDDI.d313.s8.e0 37 48
drug
ketoconazole
DrugDDI.d313.s8.e1 52 60
drug
cisapride

interaction DrugDDI.d313.s8.e0 DrugDDI.d313.s8.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s9
In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride ; .

DrugDDI.d313.s9.e0 22 33
drug
itraconazole
DrugDDI.d313.s9.e1 115 123
drug
cisapride

interaction DrugDDI.d313.s9.e0 DrugDDI.d313.s9.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s10
therefore concomitant administration of Itraconazole with cisapride is contraindicated.

DrugDDI.d313.s10.e0 36 47
drug
Itraconazole
DrugDDI.d313.s10.e1 52 60
drug
cisapride

interaction DrugDDI.d313.s10.e0 DrugDDI.d313.s10.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s11
Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs .

DrugDDI.d313.s11.e0 18 29
drug
Itraconazole
DrugDDI.d313.s11.e1 38 46
drug
midazolam
DrugDDI.d313.s11.e2 49 57
drug
triazolam
DrugDDI.d313.s11.e3 113 117
drug
drugs

interaction DrugDDI.d313.s11.e0 DrugDDI.d313.s11.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s12
This may potentiate and prolong hypnotic and sedative effects.

DrugDDI.d313.s12.e0 27 34
drug
hypnotic
DrugDDI.d313.s12.e1 38 45
drug
sedative



Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s13
These agents should not be used in patients treated with Itraconazole .

DrugDDI.d313.s13.e0 47 58
drug
Itraconazole



Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s14
If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.

DrugDDI.d313.s14.e0 2 10
drug
midazolam
DrugDDI.d313.s14.e1 73 80
drug
sedative



Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s15
Coadministration of Itraconazole and cyclosporine , tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs .

DrugDDI.d313.s15.e0 18 29
drug
Itraconazole
DrugDDI.d313.s15.e1 33 44
drug
cyclosporine
DrugDDI.d313.s15.e2 46 55
drug
tacrolimus
DrugDDI.d313.s15.e3 58 64
drug
digoxin
DrugDDI.d313.s15.e4 118 122
drug
drugs

interaction DrugDDI.d313.s15.e0 DrugDDI.d313.s15.e1
interaction DrugDDI.d313.s15.e0 DrugDDI.d313.s15.e3

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s16
Cyclosporine , tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug product s adjusted appropriately.

DrugDDI.d313.s16.e0 0 11
drug
Cyclosporine
DrugDDI.d313.s16.e1 13 22
drug
tacrolimus
DrugDDI.d313.s16.e2 26 32
drug
digoxin
DrugDDI.d313.s16.e3 81 92
drug
Itraconazole
DrugDDI.d313.s16.e4 146 156
drug
drug product

interaction DrugDDI.d313.s16.e0 DrugDDI.d313.s16.e3
interaction DrugDDI.d313.s16.e2 DrugDDI.d313.s16.e3

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s17
There have been rare reports of rhabdomyolysis involving renal transplant patients receiving the combination of Itraconazole , cyclosporine , and the HMG-CoA reductase inhibitors lovastatin or simvastatin .

DrugDDI.d313.s17.e0 97 108
drug
Itraconazole
DrugDDI.d313.s17.e1 110 121
drug
cyclosporine
DrugDDI.d313.s17.e2 129 154
drug
HMG-CoA reductase inhibitors
DrugDDI.d313.s17.e3 167 177
drug
simvastatin

interaction DrugDDI.d313.s17.e0 DrugDDI.d313.s17.e1
interaction DrugDDI.d313.s17.e0 DrugDDI.d313.s17.e3

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s18
Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine .

DrugDDI.d313.s18.e0 48 73
drug
HMG-CoA reductase inhibitors
DrugDDI.d313.s18.e1 132 148
drug
immunosuppressive
DrugDDI.d313.s18.e2 163 174
drug
cyclosporine

interaction DrugDDI.d313.s18.e0 DrugDDI.d313.s18.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s19
When Itraconazole was coadministered with phenytoin , rifampin , or H2antagonists, reduced plasma concentrations of itraconazole were reported.

DrugDDI.d313.s19.e0 4 15
drug
Itraconazole
DrugDDI.d313.s19.e1 37 45
drug
phenytoin
DrugDDI.d313.s19.e2 47 54
drug
rifampin
DrugDDI.d313.s19.e3 101 112
drug
itraconazole

interaction DrugDDI.d313.s19.e0 DrugDDI.d313.s19.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s20
The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.

DrugDDI.d313.s20.e0 55 66
drug
itraconazole
DrugDDI.d313.s20.e1 81 85
drug
drugs
DrugDDI.d313.s20.e2 128 139
drug
Itraconazole

interaction DrugDDI.d313.s20.e0 DrugDDI.d313.s20.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s21
Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin ; .

DrugDDI.d313.s21.e0 62 73
drug
Itraconazole
DrugDDI.d313.s21.e1 77 85
drug
phenytoin
DrugDDI.d313.s21.e2 109 117
drug
phenytoin

interaction DrugDDI.d313.s21.e0 DrugDDI.d313.s21.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s22
therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole .

DrugDDI.d313.s22.e0 32 40
drug
phenytoin
DrugDDI.d313.s22.e1 91 102
drug
Itraconazole

interaction DrugDDI.d313.s22.e0 DrugDDI.d313.s22.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s23
It has been reported that Itraconazole enhances the anticoagulant effect of coumarin -like drugs .

DrugDDI.d313.s23.e0 21 32
drug
Itraconazole
DrugDDI.d313.s23.e1 65 72
drug
coumarin
DrugDDI.d313.s23.e2 78 82
drug
drugs

interaction DrugDDI.d313.s23.e0 DrugDDI.d313.s23.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s24
Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin -like drugs simultaneously.

DrugDDI.d313.s24.e0 70 81
drug
Itraconazole
DrugDDI.d313.s24.e1 85 92
drug
coumarin
DrugDDI.d313.s24.e2 98 102
drug
drugs

interaction DrugDDI.d313.s24.e0 DrugDDI.d313.s24.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s25
Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid .

DrugDDI.d313.s25.e0 27 42
drug
antifungal agents
DrugDDI.d313.s25.e1 78 86
drug
isoniazid

interaction DrugDDI.d313.s25.e0 DrugDDI.d313.s25.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s26
Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.

DrugDDI.d313.s26.e0 0 11
drug
Itraconazole
DrugDDI.d313.s26.e1 53 64
drug
Itraconazole
DrugDDI.d313.s26.e2 68 76
drug
isoniazid

interaction DrugDDI.d313.s26.e1 DrugDDI.d313.s26.e2

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s27
Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents .

DrugDDI.d313.s27.e0 70 85
drug
antifungal agents
DrugDDI.d313.s27.e1 93 110
drug
hypoglycemic agents

interaction DrugDDI.d313.s27.e0 DrugDDI.d313.s27.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s28
Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.

DrugDDI.d313.s28.e0 56 67
drug
Itraconazole
DrugDDI.d313.s28.e1 75 92
drug
hypoglycemic agents

interaction DrugDDI.d313.s28.e0 DrugDDI.d313.s28.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s29
Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine .

DrugDDI.d313.s29.e0 75 86
drug
Itraconazole
DrugDDI.d313.s29.e1 90 98
drug
quinidine

interaction DrugDDI.d313.s29.e0 DrugDDI.d313.s29.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s30
Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers .

DrugDDI.d313.s30.e0 52 63
drug
Itraconazole
DrugDDI.d313.s30.e1 82 103
drug
calcium channel blockers

interaction DrugDDI.d313.s30.e0 DrugDDI.d313.s30.e1

Abstract Id: DrugDDI.d313
Sentence Id: DrugDDI.d313.s32
The results from a study in which eight HIV-infected individuals were treated with zidovudine , 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole , 100 mg b.i.d.

DrugDDI.d313.s32.e0 70 79
drug
zidovudine
DrugDDI.d313.s32.e1 129 138
drug
zidovudine
DrugDDI.d313.s32.e2 187 198
drug
Itraconazole



Abstract Id: DrugDDI.d101
Sentence Id: DrugDDI.d101.s0
In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics ( penicillins or cephalosporins ) may result in a significant mutual inactivation.

DrugDDI.d101.s0.e0 17 30
drug
aminoglycoside
DrugDDI.d101.s0.e1 50 60
drug
antibiotics
DrugDDI.d101.s0.e2 62 72
drug
penicillins
DrugDDI.d101.s0.e3 75 88
drug
cephalosporins

interaction DrugDDI.d101.s0.e0 DrugDDI.d101.s0.e1
interaction DrugDDI.d101.s0.e0 DrugDDI.d101.s0.e3

Abstract Id: DrugDDI.d101
Sentence Id: DrugDDI.d101.s1
Even when an aminoglycoside and a penicillin -type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.

DrugDDI.d101.s1.e0 10 23
drug
aminoglycoside
DrugDDI.d101.s1.e1 28 37
drug
penicillin
DrugDDI.d101.s1.e2 102 115
drug
aminoglycoside

interaction DrugDDI.d101.s1.e0 DrugDDI.d101.s1.e1

Abstract Id: DrugDDI.d101
Sentence Id: DrugDDI.d101.s2
Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function..

DrugDDI.d101.s2.e0 29 42
drug
aminoglycoside



Abstract Id: DrugDDI.d386
Sentence Id: DrugDDI.d386.s0
Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine .

DrugDDI.d386.s0.e0 31 42
drug
barbiturates
DrugDDI.d386.s0.e1 49 57
drug
narcotics
DrugDDI.d386.s0.e2 81 88
drug
ketamine

interaction DrugDDI.d386.s0.e0 DrugDDI.d386.s0.e2

Abstract Id: DrugDDI.d386
Sentence Id: DrugDDI.d386.s1
Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.

DrugDDI.d386.s1.e0 0 7
drug
Ketamine
DrugDDI.d386.s1.e1 64 79
drug
anesthetic agents



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s0
Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system.

DrugDDI.d245.s0.e0 0 11
drug
Ketoconazole
DrugDDI.d245.s0.e1 35 51
drug
cytochrome P450 3A4



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s1
Coadministration of NIZORAL@ Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.

DrugDDI.d245.s1.e0 36 40
drug
drugs
DrugDDI.d245.s1.e1 66 82
drug
cytochrome P450 3A4
DrugDDI.d245.s1.e2 140 144
drug
drugs



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s3
The following drug interactions have been identified involving NIZORAL span class= c97 @ Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine , resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite .

DrugDDI.d245.s3.e0 91 95
drug
drugs
DrugDDI.d245.s3.e1 112 128
drug
cytochrome P450 3A4
DrugDDI.d245.s3.e2 142 153
drug
Ketoconazole
DrugDDI.d245.s3.e3 183 193
drug
terfenadine
DrugDDI.d245.s3.e4 238 248
drug
terfenadine
DrugDDI.d245.s3.e5 279 292
drug
acid metabolite

interaction DrugDDI.d245.s3.e2 DrugDDI.d245.s3.e3

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s4
The increased plasma concentration of terfenadine or its metabolite may result in prolonged QT intervals.

DrugDDI.d245.s4.e0 33 43
drug
terfenadine
DrugDDI.d245.s4.e1 49 58
drug
metabolite



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s5
Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole , resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.

DrugDDI.d245.s5.e0 35 46
drug
ketoconazole
DrugDDI.d245.s5.e1 70 79
drug
astemizole
DrugDDI.d245.s5.e2 114 123
drug
astemizole
DrugDDI.d245.s5.e3 130 145
drug
active metabolite

interaction DrugDDI.d245.s5.e0 DrugDDI.d245.s5.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s6
Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.

DrugDDI.d245.s6.e0 18 27
drug
astemizole
DrugDDI.d245.s6.e1 32 43
drug
ketoconazole

interaction DrugDDI.d245.s6.e0 DrugDDI.d245.s6.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s7
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride .

DrugDDI.d245.s7.e0 41 52
drug
ketoconazole
DrugDDI.d245.s7.e1 84 92
drug
cisapride
DrugDDI.d245.s7.e2 134 142
drug
cisapride

interaction DrugDDI.d245.s7.e0 DrugDDI.d245.s7.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s8
Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.

DrugDDI.d245.s8.e0 37 48
drug
ketoconazole
DrugDDI.d245.s8.e1 52 60
drug
cisapride

interaction DrugDDI.d245.s8.e0 DrugDDI.d245.s8.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s9
Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.

DrugDDI.d245.s9.e0 36 47
drug
ketoconazole
DrugDDI.d245.s9.e1 59 67
drug
cisapride

interaction DrugDDI.d245.s9.e0 DrugDDI.d245.s9.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s10
Ketoconazole tablets may alter the metabolism of cyclosporine , tacrolimus , and methylprednisolone , resulting in elevated plasma concentrations of the latter drugs .

DrugDDI.d245.s10.e0 0 11
drug
Ketoconazole
DrugDDI.d245.s10.e1 42 53
drug
cyclosporine
DrugDDI.d245.s10.e2 55 64
drug
tacrolimus
DrugDDI.d245.s10.e3 69 86
drug
methylprednisolone
DrugDDI.d245.s10.e4 138 142
drug
drugs

interaction DrugDDI.d245.s10.e0 DrugDDI.d245.s10.e1
interaction DrugDDI.d245.s10.e0 DrugDDI.d245.s10.e3

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s11
Dosage adjustment may be required if cyclosporine , tacrolimus , or methylprednisolone are given concomitantly with NIZORAL@ Tablets.

DrugDDI.d245.s11.e0 31 42
drug
cyclosporine
DrugDDI.d245.s11.e1 44 53
drug
tacrolimus
DrugDDI.d245.s11.e2 57 74
drug
methylprednisolone



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s12
Coadministration of NIZORAL@ Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs .

DrugDDI.d245.s12.e0 37 45
drug
midazolam
DrugDDI.d245.s12.e1 48 56
drug
triazolam
DrugDDI.d245.s12.e2 112 116
drug
drugs



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s13
This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents.

DrugDDI.d245.s13.e0 27 34
drug
hypnotic
DrugDDI.d245.s13.e1 38 45
drug
sedative



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s15
If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.

DrugDDI.d245.s15.e0 2 10
drug
midazolam
DrugDDI.d245.s15.e1 73 80
drug
sedative



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s16
Rare cases of elevated plasma concentrations of digoxin have been reported.

DrugDDI.d245.s16.e0 41 47
drug
digoxin



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s18
It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole .

DrugDDI.d245.s18.e0 33 39
drug
digoxin
DrugDDI.d245.s18.e1 73 84
drug
ketoconazole

interaction DrugDDI.d245.s18.e0 DrugDDI.d245.s18.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s19
When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin -like drugs .

DrugDDI.d245.s19.e0 16 24
drug
imidazole
DrugDDI.d245.s19.e1 38 49
drug
ketoconazole
DrugDDI.d245.s19.e2 84 91
drug
coumarin
DrugDDI.d245.s19.e3 97 101
drug
drugs

interaction DrugDDI.d245.s19.e0 DrugDDI.d245.s19.e2

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s20
In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.

DrugDDI.d245.s20.e0 27 35
drug
imidazole
DrugDDI.d245.s20.e1 44 51
drug
coumarin

interaction DrugDDI.d245.s20.e0 DrugDDI.d245.s20.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s21
Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out.

DrugDDI.d245.s21.e0 72 85
drug
oral miconazole
DrugDDI.d245.s21.e1 89 97
drug
imidazole
DrugDDI.d245.s21.e2 106 123
drug
hypoglycemic agents
DrugDDI.d245.s21.e3 199 210
drug
ketoconazole
DrugDDI.d245.s21.e4 221 229
drug
imidazole

interaction DrugDDI.d245.s21.e0 DrugDDI.d245.s21.e2

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s22
Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs .

DrugDDI.d245.s22.e0 27 38
drug
ketoconazole
DrugDDI.d245.s22.e1 50 58
drug
phenytoin
DrugDDI.d245.s22.e2 96 100
drug
drugs

interaction DrugDDI.d245.s22.e0 DrugDDI.d245.s22.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s23
It is suggested to monitor both ketoconazole and phenytoin .

DrugDDI.d245.s23.e0 26 37
drug
ketoconazole
DrugDDI.d245.s23.e1 41 49
drug
phenytoin



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s24
Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.

DrugDDI.d245.s24.e0 27 34
drug
rifampin
DrugDDI.d245.s24.e1 39 50
drug
ketoconazole

interaction DrugDDI.d245.s24.e0 DrugDDI.d245.s24.e1

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s25
INH ( Isoniazid ) is also reported to affect ketoconazole concentrations adversely.

DrugDDI.d245.s25.e0 0 2
drug
INH
DrugDDI.d245.s25.e1 4 12
drug
Isoniazid
DrugDDI.d245.s25.e2 36 47
drug
ketoconazole

interaction DrugDDI.d245.s25.e1 DrugDDI.d245.s25.e2

Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s26
These drugs should not be given concomitantly.

DrugDDI.d245.s26.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s27
After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (@ 142 S.D.) and 251% (@ 68 S.D.), respectively, of those obtained after co-treatment with placebo.

DrugDDI.d245.s27.e0 73 82
drug
loratadine
DrugDDI.d245.s27.e1 111 120
drug
loratadine



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s28
The AUC and Cmax of descarboethoxyloratadine, an active metabolite , averaged 155% (@ 27 S.D.) and 141% (@ 35 S.D.), respectively.

DrugDDI.d245.s28.e0 42 57
drug
active metabolite



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s30
Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole .

DrugDDI.d245.s30.e0 67 76
drug
loratadine
DrugDDI.d245.s30.e1 105 116
drug
ketoconazole



Abstract Id: DrugDDI.d245
Sentence Id: DrugDDI.d245.s31
Rare cases of a disulfiram -like reaction to alcohol have been reported.

DrugDDI.d245.s31.e0 12 21
drug
disulfiram
DrugDDI.d245.s31.e1 37 43
drug
alcohol

interaction DrugDDI.d245.s31.e0 DrugDDI.d245.s31.e1

Abstract Id: DrugDDI.d209
Sentence Id: DrugDDI.d209.s0
Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin .

DrugDDI.d209.s0.e0 0 11
drug
Cyclosporine
DrugDDI.d209.s0.e1 60 70
drug
cyclosporin

interaction DrugDDI.d209.s0.e0 DrugDDI.d209.s0.e1

Abstract Id: DrugDDI.d209
Sentence Id: DrugDDI.d209.s1
Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.

DrugDDI.d209.s1.e0 0 19
drug
Ibuprofen - L-arginine
DrugDDI.d209.s1.e1 46 54
drug
ibuprofen

interaction DrugDDI.d209.s1.e0 DrugDDI.d209.s1.e1

Abstract Id: DrugDDI.d209
Sentence Id: DrugDDI.d209.s2
Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.

DrugDDI.d209.s2.e0 7 14
drug
nitrates
DrugDDI.d209.s2.e1 82 89
drug
nitrates

interaction DrugDDI.d209.s2.e0 DrugDDI.d209.s2.e1

Abstract Id: DrugDDI.d209
Sentence Id: DrugDDI.d209.s3
Sildenafil citrate - Theoretically, L- arginine supplements taken concomitantly with sildenafil citrate , may potentiate the effects of the drug .

DrugDDI.d209.s3.e0 0 16
drug
Sildenafil citrate
DrugDDI.d209.s3.e1 34 41
drug
arginine
DrugDDI.d209.s3.e2 75 91
drug
sildenafil citrate
DrugDDI.d209.s3.e3 121 124
drug
drug

interaction DrugDDI.d209.s3.e1 DrugDDI.d209.s3.e2

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s0
No drug , nutritional supplement, food or herb interactions are known.

DrugDDI.d554.s0.e0 2 5
drug
drug



Abstract Id: DrugDDI.d45
Sentence Id: DrugDDI.d45.s0
Interacts with valproic acid .

DrugDDI.d45.s0.e0 13 24
drug
valproic acid



Abstract Id: DrugDDI.d204
Sentence Id: DrugDDI.d204.s0
No well-known drug interactions with glutamic acid .

DrugDDI.d204.s0.e0 32 43
drug
glutamic acid



Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s0
Human growth hormone - Concomitant use of L- glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.

DrugDDI.d415.s0.e0 0 17
drug
Human growth hormone
DrugDDI.d415.s0.e1 37 45
drug
glutamine
DrugDDI.d415.s0.e2 49 66
drug
human growth hormone

interaction DrugDDI.d415.s0.e1 DrugDDI.d415.s0.e2

Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s1
L-glutamine has orphan drug status for this indication.

DrugDDI.d415.s1.e0 0 10
drug
L-glutamine
DrugDDI.d415.s1.e1 14 23
drug
orphan drug



Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s2
Indomethacin - Concomitant use of L- glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin .

DrugDDI.d415.s2.e0 0 11
drug
Indomethacin
DrugDDI.d415.s2.e1 31 39
drug
glutamine
DrugDDI.d415.s2.e2 43 54
drug
indomethacin
DrugDDI.d415.s2.e3 107 118
drug
indomethacin

interaction DrugDDI.d415.s2.e1 DrugDDI.d415.s2.e2

Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s3
The reported dose used for L- glutamine was 21 grams daily taken in divided doses three times a day.

DrugDDI.d415.s3.e0 24 32
drug
glutamine



Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s4
Further, misoprostol is reported to have a synergistic effect with this combination in ameliorating intestinal permeability.

DrugDDI.d415.s4.e0 8 18
drug
misoprostol



Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s5
Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L- glutamine for chemotherapy-induced mucositis.

DrugDDI.d415.s5.e0 0 11
drug
Methotrexate
DrugDDI.d415.s5.e1 33 44
drug
methotrexate
DrugDDI.d415.s5.e2 96 104
drug
glutamine



Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s6
In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L- glutamine at a dose of 0.5 gram/kilogram/day.

DrugDDI.d415.s6.e0 132 140
drug
glutamine



Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s7
Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel , appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel .

DrugDDI.d415.s7.e0 0 9
drug
Paclitaxel
DrugDDI.d415.s7.e1 23 33
drug
L-glutamine
DrugDDI.d415.s7.e2 92 101
drug
paclitaxel
DrugDDI.d415.s7.e3 113 119
drug
prevent
DrugDDI.d415.s7.e4 175 184
drug
paclitaxel

interaction DrugDDI.d415.s7.e1 DrugDDI.d415.s7.e2

Abstract Id: DrugDDI.d100
Sentence Id: DrugDDI.d100.s0
Concomitant use of calcium supplements and L-lysine may increase calcium absorption .

DrugDDI.d100.s0.e0 16 22
drug
calcium
DrugDDI.d100.s0.e1 37 44
drug
L-lysine
DrugDDI.d100.s0.e2 56 62
drug
calcium

interaction DrugDDI.d100.s0.e0 DrugDDI.d100.s0.e1

Abstract Id: DrugDDI.d231
Sentence Id: DrugDDI.d231.s0
Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .

DrugDDI.d231.s0.e0 0 12
drug
Acetaminophen
DrugDDI.d231.s0.e1 16 27
drug
methotrexate
DrugDDI.d231.s0.e2 78 90
drug
acetaminophen
DrugDDI.d231.s0.e3 116 127
drug
methotrexate

interaction DrugDDI.d231.s0.e1 DrugDDI.d231.s0.e2

Abstract Id: DrugDDI.d231
Sentence Id: DrugDDI.d231.s1
Theoretically, it may decrease hepatic toxicity in the case of other potential hepatotoxic drugs , as well.

DrugDDI.d231.s1.e0 78 82
drug
drugs



Abstract Id: DrugDDI.d231
Sentence Id: DrugDDI.d231.s2
Gentamicin - Methionine may protect against the ototoxic effects of gentamicin .

DrugDDI.d231.s2.e0 0 9
drug
Gentamicin
DrugDDI.d231.s2.e1 58 67
drug
gentamicin

interaction DrugDDI.d231.s2.e0 DrugDDI.d231.s2.e1

Abstract Id: DrugDDI.d155
Sentence Id: DrugDDI.d155.s0
Non-selective monoamine oxidase (MAO) inhibitors - including phenelzine sulfate , tranylcypromine sulfate and pargyline HC1.

DrugDDI.d155.s0.e0 13 28
drug
monoamine oxidase
DrugDDI.d155.s0.e1 54 70
drug
phenelzine sulfate
DrugDDI.d155.s0.e2 72 93
drug
tranylcypromine sulfate
DrugDDI.d155.s0.e3 97 105
drug
pargyline



Abstract Id: DrugDDI.d155
Sentence Id: DrugDDI.d155.s1
Concomitant use of L- phenylalanine and non-selective MAO inhibitors may cause hypertension.

DrugDDI.d155.s1.e0 18 30
drug
phenylalanine
DrugDDI.d155.s1.e1 47 59
drug
MAO inhibitors

interaction DrugDDI.d155.s1.e0 DrugDDI.d155.s1.e1

Abstract Id: DrugDDI.d155
Sentence Id: DrugDDI.d155.s2
Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.

DrugDDI.d155.s2.e0 0 9
drug
Selegiline
DrugDDI.d155.s2.e1 41 52
drug
MAO inhibitor
DrugDDI.d155.s2.e2 81 94
drug
antidepressant

interaction DrugDDI.d155.s2.e0 DrugDDI.d155.s2.e1

Abstract Id: DrugDDI.d155
Sentence Id: DrugDDI.d155.s3
Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.

DrugDDI.d155.s3.e0 0 15
drug
Neuroleptic Drugs
DrugDDI.d155.s3.e1 80 95
drug
neuroleptic drugs

interaction DrugDDI.d155.s3.e0 DrugDDI.d155.s3.e1

Abstract Id: DrugDDI.d37
Sentence Id: DrugDDI.d37.s0
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan ), phenelzine (e.g., Nardil ), procarbazine (e.g., Matulane ), selegiline (e.g., Eldepryl ), and tranylcypromine (e.g., Parnate ): Using these medicines with L- tryptophan may increase the chance of side effects.

DrugDDI.d37.s0.e0 0 15
drug
Monoamine oxidase
DrugDDI.d37.s0.e1 37 49
drug
isocarboxazid
DrugDDI.d37.s0.e2 56 62
drug
Marplan
DrugDDI.d37.s0.e3 65 74
drug
phenelzine
DrugDDI.d37.s0.e4 81 86
drug
Nardil
DrugDDI.d37.s0.e5 89 100
drug
procarbazine
DrugDDI.d37.s0.e6 107 114
drug
Matulane
DrugDDI.d37.s0.e7 117 126
drug
selegiline
DrugDDI.d37.s0.e8 133 140
drug
Eldepryl
DrugDDI.d37.s0.e9 146 160
drug
tranylcypromine
DrugDDI.d37.s0.e10 167 173
drug
Parnate
DrugDDI.d37.s0.e11 186 194
drug
medicines
DrugDDI.d37.s0.e12 201 210
drug
tryptophan

interaction DrugDDI.d37.s0.e11 DrugDDI.d37.s0.e12

Abstract Id: DrugDDI.d511
Sentence Id: DrugDDI.d511.s0
Non-selective MAO inhibitors including tranylcypromine sulfate , phenelzine sulfate , and pargyline HC1: Concomitant use of L- tyrosine and non-selective MAO inhibitors may cause hypertension.

DrugDDI.d511.s0.e0 13 25
drug
MAO inhibitors
DrugDDI.d511.s0.e1 35 56
drug
tranylcypromine sulfate
DrugDDI.d511.s0.e2 58 74
drug
phenelzine sulfate
DrugDDI.d511.s0.e3 79 87
drug
pargyline
DrugDDI.d511.s0.e4 110 117
drug
tyrosine
DrugDDI.d511.s0.e5 134 146
drug
MAO inhibitors

interaction DrugDDI.d511.s0.e4 DrugDDI.d511.s0.e5

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s0
In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.

DrugDDI.d559.s0.e0 32 43
drug
labetalol HCl
DrugDDI.d559.s0.e1 61 84
drug
tricyclic antidepressants
DrugDDI.d559.s0.e2 138 149
drug
labetalol HCl

interaction DrugDDI.d559.s0.e0 DrugDDI.d559.s0.e1

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s2
Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drug s in patients with bronchospasm; .

DrugDDI.d559.s2.e0 0 4
drug
Drugs
DrugDDI.d559.s2.e1 49 62
drug
bronchodilator
DrugDDI.d559.s2.e2 84 94
drug
agonist drug

interaction DrugDDI.d559.s2.e0 DrugDDI.d559.s2.e2

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s3
therefore, doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required.

DrugDDI.d559.s3.e0 54 84
drug
beta-agonist bronchodilator drugs



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s4
Cimetidine has been shown to increase the bioavailability of labetalol HCl .

DrugDDI.d559.s4.e0 0 9
drug
Cimetidine
DrugDDI.d559.s4.e1 52 63
drug
labetalol HCl

interaction DrugDDI.d559.s4.e0 DrugDDI.d559.s4.e1

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s5
Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl , special care should be used in establishing the dose required for blood pressure control in such patients.

DrugDDI.d559.s5.e0 88 99
drug
labetalol HCl



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s6
Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl .

DrugDDI.d559.s6.e0 28 36
drug
halothane
DrugDDI.d559.s6.e1 75 86
drug
labetalol HCl

interaction DrugDDI.d559.s6.e0 DrugDDI.d559.s6.e1

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s7
During controlled hypotensive anesthesia using labetalol HCl in association with halothane , high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.

DrugDDI.d559.s7.e0 42 53
drug
labetalol HCl
DrugDDI.d559.s7.e1 71 79
drug
halothane
DrugDDI.d559.s7.e2 112 120
drug
halothane

interaction DrugDDI.d559.s7.e0 DrugDDI.d559.s7.e1

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s8
The anesthesiologist should be informed when a patient is receiving labetalol HCl .

DrugDDI.d559.s8.e0 58 69
drug
labetalol HCl



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s9
Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without prevent ing its hypotensive effect.

DrugDDI.d559.s9.e0 0 11
drug
Labetalol HCl
DrugDDI.d559.s9.e1 48 60
drug
nitroglycerin
DrugDDI.d559.s9.e2 68 74
drug
prevent

interaction DrugDDI.d559.s9.e0 DrugDDI.d559.s9.e1

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s10
If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.

DrugDDI.d559.s10.e0 2 13
drug
labetalol HCl
DrugDDI.d559.s10.e1 24 36
drug
nitroglycerin
DrugDDI.d559.s10.e2 76 91
drug
antihypertensive

interaction DrugDDI.d559.s10.e0 DrugDDI.d559.s10.e1

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s11
Care should be taken if labetalol is used concomitantly with calcium antagonist s of the verapamil type.

DrugDDI.d559.s11.e0 19 27
drug
labetalol
DrugDDI.d559.s11.e1 51 67
drug
calcium antagonist
DrugDDI.d559.s11.e2 74 82
drug
verapamil

interaction DrugDDI.d559.s11.e0 DrugDDI.d559.s11.e1

Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s12
Risk of Anaphylactic Reaction While taking beta-blockers , patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.

DrugDDI.d559.s12.e0 37 49
drug
beta-blockers



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s13
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

DrugDDI.d559.s13.e0 46 56
drug
epinephrine



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s14
Drug /Laboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine and vanillylmandelic acid when measured by fluorimetric or photometric methods.

DrugDDI.d559.s14.e0 0 3
drug
Drug
DrugDDI.d559.s14.e1 44 52
drug
labetalol
DrugDDI.d559.s14.e2 161 180
drug
vanillylmandelic acid



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s15
In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl , a specific method, such as a high performance liquid chromatographic assay with solid phase extraction (e.g., J Chromatogr 385:241,1987) should be employed in determining levels of catecholamines.

DrugDDI.d559.s15.e0 72 83
drug
labetalol HCl



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s16
Labetalol HCl has also been reported to produce a false positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A@ (thin-layer chromatographic assay) and Emit-d.a.u.@ (radioenzymatic assay).

DrugDDI.d559.s16.e0 0 11
drug
Labetalol HCl
DrugDDI.d559.s16.e1 61 71
drug
amphetamine
DrugDDI.d559.s16.e2 106 110
drug
drugs



Abstract Id: DrugDDI.d559
Sentence Id: DrugDDI.d559.s17
When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.

DrugDDI.d559.s17.e0 28 36
drug
labetalol
DrugDDI.d559.s17.e1 62 72
drug
amphetamine



Abstract Id: DrugDDI.d192
Sentence Id: DrugDDI.d192.s0
Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose -induced drop in colonic pH.

DrugDDI.d192.s0.e0 66 73
drug
antacids
DrugDDI.d192.s0.e1 95 103
drug
lactulose
DrugDDI.d192.s0.e2 124 132
drug
lactulose

interaction DrugDDI.d192.s0.e0 DrugDDI.d192.s0.e1

Abstract Id: DrugDDI.d192
Sentence Id: DrugDDI.d192.s1
Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose .

DrugDDI.d192.s1.e0 89 93
drug
drugs
DrugDDI.d192.s1.e1 119 127
drug
lactulose

interaction DrugDDI.d192.s1.e0 DrugDDI.d192.s1.e1

Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s0
Lamivudine is predominantly eliminated in the urine by active organic cation ic secretion.

DrugDDI.d562.s0.e0 0 9
drug
Lamivudine
DrugDDI.d562.s0.e1 60 65
drug
cation



Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s1
The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim ).

DrugDDI.d562.s1.e0 37 41
drug
drugs
DrugDDI.d562.s1.e1 192 203
drug
trimethoprim



Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s2
TMP 160 mg/SMX 800 mg once daily has been shown to increase lamivudine exposure (AUC) by 44%.

DrugDDI.d562.s2.e0 0 2
drug
TMP
DrugDDI.d562.s2.e1 48 57
drug
lamivudine

interaction DrugDDI.d562.s2.e0 DrugDDI.d562.s2.e1

Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s3
No change in dose of either drug is recommended.

DrugDDI.d562.s3.e0 22 25
drug
drug



Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s4
There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP /SMX such as those used to treat Pneumocystis carinii pneumonia.

DrugDDI.d562.s4.e0 40 49
drug
lamivudine
DrugDDI.d562.s4.e1 81 83
drug
TMP



Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s5
No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine .

DrugDDI.d562.s5.e0 48 52
drug
drugs
DrugDDI.d562.s5.e1 100 109
drug
lamivudine



Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s6
Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.

DrugDDI.d562.s6.e0 0 9
drug
Lamivudine
DrugDDI.d562.s6.e1 13 23
drug
zalcitabine

interaction DrugDDI.d562.s6.e0 DrugDDI.d562.s6.e1

Abstract Id: DrugDDI.d562
Sentence Id: DrugDDI.d562.s7
Therefore, use of lamivudine in combination with zalcitabine is not recommended .

DrugDDI.d562.s7.e0 15 24
drug
lamivudine
DrugDDI.d562.s7.e1 42 52
drug
zalcitabine

interaction DrugDDI.d562.s7.e0 DrugDDI.d562.s7.e1

Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s0
Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes .

DrugDDI.d384.s0.e0 0 11
drug
Lansoprazole
DrugDDI.d384.s0.e1 35 48
drug
cytochrome P450
DrugDDI.d384.s0.e2 78 82
drug
CYP3A
DrugDDI.d384.s0.e3 93 100
drug
isozymes

interaction DrugDDI.d384.s0.e0 DrugDDI.d384.s0.e1
interaction DrugDDI.d384.s0.e0 DrugDDI.d384.s0.e3

Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s1
Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects.

DrugDDI.d384.s1.e0 20 31
drug
lansoprazole
DrugDDI.d384.s1.e1 85 89
drug
drugs
DrugDDI.d384.s1.e2 106 119
drug
cytochrome P450
DrugDDI.d384.s1.e3 133 140
drug
warfarin
DrugDDI.d384.s1.e4 142 151
drug
antipyrine
DrugDDI.d384.s1.e5 153 164
drug
indomethacin
DrugDDI.d384.s1.e6 166 174
drug
ibuprofen
DrugDDI.d384.s1.e7 176 184
drug
phenytoin
DrugDDI.d384.s1.e8 186 196
drug
propranolol
DrugDDI.d384.s1.e9 198 207
drug
prednisone
DrugDDI.d384.s1.e10 209 216
drug
diazepam
DrugDDI.d384.s1.e11 218 231
drug
clarithromycin
DrugDDI.d384.s1.e12 235 245
drug
terfenadine



Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s2
These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2 , CYP2C9 , CYP2C19 , CYP2D6 , and CYP3A .

DrugDDI.d384.s2.e0 42 55
drug
cytochrome P450
DrugDDI.d384.s2.e1 73 78
drug
CYP1A2
DrugDDI.d384.s2.e2 80 85
drug
CYP2C9
DrugDDI.d384.s2.e3 87 93
drug
CYP2C19
DrugDDI.d384.s2.e4 95 100
drug
CYP2D6
DrugDDI.d384.s2.e5 105 109
drug
CYP3A



Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s3
When lansoprazole was administered concomitantly with theophylline ( CYP1A2 , CYP3A ), a minor increase (10%) in the clearance of theophylline was seen.

DrugDDI.d384.s3.e0 4 15
drug
lansoprazole
DrugDDI.d384.s3.e1 48 59
drug
theophylline
DrugDDI.d384.s3.e2 61 66
drug
CYP1A2
DrugDDI.d384.s3.e3 68 72
drug
CYP3A
DrugDDI.d384.s3.e4 110 121
drug
theophylline

interaction DrugDDI.d384.s3.e0 DrugDDI.d384.s3.e1
interaction DrugDDI.d384.s3.e0 DrugDDI.d384.s3.e3

Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s4
Because the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be clinical concern.

DrugDDI.d384.s4.e0 52 63
drug
theophylline



Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s5
Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.

DrugDDI.d384.s5.e0 66 77
drug
theophylline
DrugDDI.d384.s5.e1 88 99
drug
lansoprazole

interaction DrugDDI.d384.s5.e0 DrugDDI.d384.s5.e1

Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s6
Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin .

DrugDDI.d384.s6.e0 0 11
drug
Lansoprazole
DrugDDI.d384.s6.e1 72 82
drug
amoxicillin



Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s7
In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate .

DrugDDI.d384.s7.e0 37 52
drug
lansoprazole 30 mg
DrugDDI.d384.s7.e1 56 69
drug
omeprazole 20 mg
DrugDDI.d384.s7.e2 111 120
drug
sucralfate
DrugDDI.d384.s7.e3 142 161
drug
proton pump inhibitors
DrugDDI.d384.s7.e4 263 272
drug
sucralfate

interaction DrugDDI.d384.s7.e0 DrugDDI.d384.s7.e2

Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s8
Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate .

DrugDDI.d384.s8.e0 10 29
drug
proton pump inhibitors
DrugDDI.d384.s8.e1 66 75
drug
sucralfate

interaction DrugDDI.d384.s8.e0 DrugDDI.d384.s8.e1

Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s9
In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules; .

DrugDDI.d384.s9.e0 17 24
drug
antacids
DrugDDI.d384.s9.e1 58 69
drug
lansoprazole

interaction DrugDDI.d384.s9.e0 DrugDDI.d384.s9.e1

Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s11
Lansoprazole causes a profound and long lasting inhibition of gastric acid secretion; .

DrugDDI.d384.s11.e0 0 11
drug
Lansoprazole



Abstract Id: DrugDDI.d384
Sentence Id: DrugDDI.d384.s12
therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole , ampicillin esters, iron salts, digoxin ).

DrugDDI.d384.s12.e0 39 50
drug
lansoprazole
DrugDDI.d384.s12.e1 82 86
drug
drugs
DrugDDI.d384.s12.e2 147 158
drug
ketoconazole
DrugDDI.d384.s12.e3 160 169
drug
ampicillin
DrugDDI.d384.s12.e4 187 193
drug
digoxin

interaction DrugDDI.d384.s12.e0 DrugDDI.d384.s12.e1
interaction DrugDDI.d384.s12.e0 DrugDDI.d384.s12.e3

Abstract Id: DrugDDI.d270
Sentence Id: DrugDDI.d270.s0
In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost .

DrugDDI.d270.s0.e0 68 77
drug
thimerosal
DrugDDI.d270.s0.e1 90 100
drug
latanoprost

interaction DrugDDI.d270.s0.e0 DrugDDI.d270.s0.e1

Abstract Id: DrugDDI.d270
Sentence Id: DrugDDI.d270.s1
If such drugs are used they should be administered with an interval of at least 5 minutes between applications.

DrugDDI.d270.s1.e0 6 10
drug
drugs



Abstract Id: DrugDDI.d412
Sentence Id: DrugDDI.d412.s0
Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID@ ( lenalidomide ) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450 -based metabolic drug interactions in man.

DrugDDI.d412.s0.e0 79 90
drug
lenalidomide
DrugDDI.d412.s0.e1 137 150
drug
cytochrome P450
DrugDDI.d412.s0.e2 172 183
drug
lenalidomide
DrugDDI.d412.s0.e3 215 218
drug
P450



Abstract Id: DrugDDI.d412
Sentence Id: DrugDDI.d412.s1
Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin .

DrugDDI.d412.s1.e0 40 51
drug
lenalidomide
DrugDDI.d412.s1.e1 103 110
drug
warfarin



Abstract Id: DrugDDI.d412
Sentence Id: DrugDDI.d412.s2
Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide .

DrugDDI.d412.s2.e0 34 41
drug
warfarin
DrugDDI.d412.s2.e1 81 92
drug
lenalidomide



Abstract Id: DrugDDI.d412
Sentence Id: DrugDDI.d412.s3
Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.

DrugDDI.d412.s3.e0 65 72
drug
warfarin
DrugDDI.d412.s3.e1 131 142
drug
lenalidomide



Abstract Id: DrugDDI.d325
Sentence Id: DrugDDI.d325.s0
Concomitant treatment with thrombolytic s (eg, rt-PA or streptokinase ) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation .

DrugDDI.d325.s0.e0 24 35
drug
thrombolytic
DrugDDI.d325.s0.e1 41 45
drug
rt-PA
DrugDDI.d325.s0.e2 48 60
drug
streptokinase
DrugDDI.d325.s0.e3 136 143
drug
REFLUDAN



Abstract Id: DrugDDI.d325
Sentence Id: DrugDDI.d325.s1
Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.

DrugDDI.d325.s1.e0 24 31
drug
coumarin
DrugDDI.d325.s1.e1 67 71
drug
drugs

interaction DrugDDI.d325.s1.e0 DrugDDI.d325.s1.e1

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s0
ERGAMISOL@ ( levamisole hydrochloride ) has been reported to produce ANTABUSE -like side effects when given concomitantly with alcohol .

DrugDDI.d462.s0.e0 11 33
drug
levamisole hydrochloride
DrugDDI.d462.s0.e1 59 66
drug
ANTABUSE
DrugDDI.d462.s0.e2 109 115
drug
alcohol

interaction DrugDDI.d462.s0.e0 DrugDDI.d462.s0.e2

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s1
Concomitant administration of phenytoin and ERGAMISOL@ plus fluorouracil has lead to increased plasma levels of phenytoin .

DrugDDI.d462.s1.e0 27 35
drug
phenytoin
DrugDDI.d462.s1.e1 53 64
drug
fluorouracil
DrugDDI.d462.s1.e2 97 105
drug
phenytoin

interaction DrugDDI.d462.s1.e0 DrugDDI.d462.s1.e1

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s2
The physician is advised to monitor plasma levels of phenytoin and to decrease the dose if necessary.

DrugDDI.d462.s2.e0 44 52
drug
phenytoin



Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s3
Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium , it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin -like drugs should be adjusted accordingly, in patients taking both drugs .

DrugDDI.d462.s3.e0 101 110
drug
levamisole
DrugDDI.d462.s3.e1 114 127
drug
warfarin sodium
DrugDDI.d462.s3.e2 197 210
drug
warfarin sodium
DrugDDI.d462.s3.e3 218 225
drug
coumarin
DrugDDI.d462.s3.e4 231 235
drug
drugs
DrugDDI.d462.s3.e5 284 288
drug
drugs

interaction DrugDDI.d462.s3.e0 DrugDDI.d462.s3.e1

Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s1
Levetiracetam and its major metabolite , at concentrations well above cmax levels achieved within the therapeutic dose range, are neither inhibitors of nor high affinity substrates for human liver cytochrome P450 isoforms, epoxide hydrolase or UDP -glucuronidation enzymes.

DrugDDI.d316.s1.e0 0 12
drug
Levetiracetam
DrugDDI.d316.s1.e1 24 33
drug
metabolite
DrugDDI.d316.s1.e2 168 181
drug
cytochrome P450
DrugDDI.d316.s1.e3 191 206
drug
epoxide hydrolase
DrugDDI.d316.s1.e4 209 211
drug
UDP



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s2
In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid .

DrugDDI.d316.s2.e0 11 23
drug
levetiracetam
DrugDDI.d316.s2.e1 64 75
drug
valproic acid



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s3
Levetiracetam circulates largely unbound ( 10% bound) to plasma proteins ; .

DrugDDI.d316.s3.e0 0 12
drug
Levetiracetam
DrugDDI.d316.s3.e1 49 62
drug
plasma proteins



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s4
clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely.

DrugDDI.d316.s4.e0 42 46
drug
drugs
DrugDDI.d316.s4.e1 68 74
drug
protein



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s5
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , valproate , oral contraceptive , digoxin , warfarin , probenecid ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.

DrugDDI.d316.s5.e0 81 89
drug
phenytoin
DrugDDI.d316.s5.e1 91 99
drug
valproate
DrugDDI.d316.s5.e2 101 117
drug
oral contraceptive
DrugDDI.d316.s5.e3 119 125
drug
digoxin
DrugDDI.d316.s5.e4 127 134
drug
warfarin
DrugDDI.d316.s5.e5 136 145
drug
probenecid



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s6
Drug-Drug Interactions Between Keppra@ And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra@ (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.

DrugDDI.d316.s6.e0 43 60
drug
Antiepileptic Drugs
DrugDDI.d316.s6.e1 67 75
drug
Phenytoin
DrugDDI.d316.s6.e2 140 148
drug
phenytoin



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s7
Pharmacokinetics of levetiracetam were also not affected by phenytoin .

DrugDDI.d316.s7.e0 18 30
drug
levetiracetam
DrugDDI.d316.s7.e1 52 60
drug
phenytoin



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s8
Valproate Keppra@ (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.

DrugDDI.d316.s8.e0 0 8
drug
Valproate
DrugDDI.d316.s8.e1 66 74
drug
valproate



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s9
Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.

DrugDDI.d316.s9.e0 0 8
drug
Valproate
DrugDDI.d316.s9.e1 53 65
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s10
There also was no effect on exposure to and the excretion of the primary metabolite , ucb L057.

DrugDDI.d316.s10.e0 59 68
drug
metabolite



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s11
Potential drug interactions between Keppra@ and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.

DrugDDI.d316.s11.e0 52 64
drug
carbamazepine
DrugDDI.d316.s11.e1 66 75
drug
gabapentin
DrugDDI.d316.s11.e2 77 87
drug
lamotrigine
DrugDDI.d316.s11.e3 89 101
drug
phenobarbital
DrugDDI.d316.s11.e4 103 111
drug
phenytoin
DrugDDI.d316.s11.e5 113 121
drug
primidone
DrugDDI.d316.s11.e6 125 133
drug
valproate
DrugDDI.d316.s11.e7 187 199
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s12
These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam .

DrugDDI.d316.s12.e0 21 33
drug
levetiracetam
DrugDDI.d316.s12.e1 134 146
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s13
Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.

DrugDDI.d316.s13.e0 14 22
drug
Pediatric
DrugDDI.d316.s13.e1 86 98
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s14
Dose adjustment is not recommended. Levetiracetam had no effect on plasma concentrations of carbamazepine , valproate , topiramate , or lamotrigine .

DrugDDI.d316.s14.e0 31 43
drug
Levetiracetam
DrugDDI.d316.s14.e1 79 91
drug
carbamazepine
DrugDDI.d316.s14.e2 93 101
drug
valproate
DrugDDI.d316.s14.e3 103 112
drug
topiramate
DrugDDI.d316.s14.e4 116 126
drug
lamotrigine



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s15
Other Drug Interactions Oral Contraceptives Keppra@ (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.

DrugDDI.d316.s15.e0 5 8
drug
Drug
DrugDDI.d316.s15.e1 101 117
drug
oral contraceptive
DrugDDI.d316.s15.e2 134 149
drug
ethinyl estradiol
DrugDDI.d316.s15.e3 159 172
drug
levonorgestrel
DrugDDI.d316.s15.e4 181 191
drug
luteinizing
DrugDDI.d316.s15.e5 247 259
drug
contraceptive



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s16
Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam .

DrugDDI.d316.s16.e0 22 38
drug
oral contraceptive
DrugDDI.d316.s16.e1 75 87
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s17
Digoxin Keppra@ (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.

DrugDDI.d316.s17.e0 0 6
drug
Digoxin
DrugDDI.d316.s17.e1 92 98
drug
digoxin



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s18
Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam .

DrugDDI.d316.s18.e0 18 24
drug
digoxin
DrugDDI.d316.s18.e1 61 73
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s19
Warfarin Keppra@ (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin .

DrugDDI.d316.s19.e0 0 7
drug
Warfarin
DrugDDI.d316.s19.e1 74 81
drug
warfarin



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s20
Prothrombin time was not affected by levetiracetam .

DrugDDI.d316.s20.e0 31 43
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s21
Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam .

DrugDDI.d316.s21.e0 18 25
drug
warfarin
DrugDDI.d316.s21.e1 59 71
drug
levetiracetam



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s22
Probenecid Probenecid, a renal tubular secretion blocking agent , administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.

DrugDDI.d316.s22.e0 0 9
drug
Probenecid
DrugDDI.d316.s22.e1 27 55
drug
tubular secretion blocking agent
DrugDDI.d316.s22.e2 130 148
drug
levetiracetam 1000 mg



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s23
Cssmax of the metabolite , ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same.

DrugDDI.d316.s23.e0 11 20
drug
metabolite
DrugDDI.d316.s23.e1 68 77
drug
probenecid
DrugDDI.d316.s23.e2 96 99
drug
drug



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s24
Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057.

DrugDDI.d316.s24.e0 38 47
drug
probenecid



Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s25
The effect of Keppra@ on probenecid was not studied.

DrugDDI.d316.s25.e0 20 29
drug
probenecid



Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s0
Chirocaine @ should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.

DrugDDI.d438.s0.e0 0 9
drug
Chirocaine
DrugDDI.d438.s0.e1 58 73
drug
local anesthetics
DrugDDI.d438.s0.e2 103 128
drug
amide-type local anesthetics
DrugDDI.d438.s0.e3 156 160
drug
drugs

interaction DrugDDI.d438.s0.e0 DrugDDI.d438.s0.e1

Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s1
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine , respectively.

DrugDDI.d438.s1.e0 22 34
drug
CYP3A4 isoform
DrugDDI.d438.s1.e1 38 50
drug
CYP1A2 isoform
DrugDDI.d438.s1.e2 73 87
drug
levobupivacaine
DrugDDI.d438.s1.e3 98 112
drug
levobupivacaine
DrugDDI.d438.s1.e4 125 139
drug
levobupivacaine



Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s2
Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine .

DrugDDI.d438.s2.e0 10 15
drug
likely
DrugDDI.d438.s2.e1 49 58
drug
Chirocaine
DrugDDI.d438.s2.e2 83 97
drug
isoenzyme family
DrugDDI.d438.s2.e3 124 133
drug
Chirocaine

interaction DrugDDI.d438.s2.e0 DrugDDI.d438.s2.e1

Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s3
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole ; .

DrugDDI.d438.s3.e0 72 86
drug
levobupivacaine
DrugDDI.d438.s3.e1 110 115
drug
CYP3A4
DrugDDI.d438.s3.e2 131 139
drug
phenytoin
DrugDDI.d438.s3.e3 141 153
drug
phenobarbital
DrugDDI.d438.s3.e4 155 162
drug
rifampin
DrugDDI.d438.s3.e5 165 170
drug
CYP3A4
DrugDDI.d438.s3.e6 204 215
drug
ketoconazole

interaction DrugDDI.d438.s3.e0 DrugDDI.d438.s3.e1
interaction DrugDDI.d438.s3.e0 DrugDDI.d438.s3.e3
interaction DrugDDI.d438.s3.e0 DrugDDI.d438.s3.e5

Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s4
certain protease inhibitors e.g., ritanovir; .

DrugDDI.d438.s4.e0 7 24
drug
protease inhibitors



Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s5
macrolide antibiotics e.g., erythromycin ; .

DrugDDI.d438.s5.e0 0 19
drug
macrolide antibiotics
DrugDDI.d438.s5.e1 25 36
drug
erythromycin



Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s6
and calcium channel antagonists e.g., verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin ).

DrugDDI.d438.s6.e0 3 16
drug
calcium channel
DrugDDI.d438.s6.e1 33 41
drug
verapamil
DrugDDI.d438.s6.e2 44 49
drug
CYP1A2
DrugDDI.d438.s6.e3 59 68
drug
omeprazole
DrugDDI.d438.s6.e4 73 78
drug
CYP1A2
DrugDDI.d438.s6.e5 90 100
drug
furafylline
DrugDDI.d438.s6.e6 104 117
drug
clarithromycin



Abstract Id: DrugDDI.d438
Sentence Id: DrugDDI.d438.s7
Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.

DrugDDI.d438.s7.e0 34 48
drug
levobupivacaine
DrugDDI.d438.s7.e1 79 84
drug
CYP3A4
DrugDDI.d438.s7.e2 98 103
drug
CYP1A2
DrugDDI.d438.s7.e3 124 138
drug
levobupivacaine

interaction DrugDDI.d438.s7.e0 DrugDDI.d438.s7.e1

Abstract Id: DrugDDI.d541
Sentence Id: DrugDDI.d541.s0
Specific drug interaction studies have not been conducted with Levofloxacin .

DrugDDI.d541.s0.e0 54 65
drug
Levofloxacin



Abstract Id: DrugDDI.d541
Sentence Id: DrugDDI.d541.s1
However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant warfarin and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.

DrugDDI.d541.s1.e0 39 48
drug
quinolones
DrugDDI.d541.s1.e1 92 103
drug
theophylline
DrugDDI.d541.s1.e2 133 140
drug
caffeine
DrugDDI.d541.s1.e3 167 191
drug
oral anticoagulant warfarin
DrugDDI.d541.s1.e4 198 208
drug
derivatives
DrugDDI.d541.s1.e5 297 308
drug
cyclosporine

interaction DrugDDI.d541.s1.e0 DrugDDI.d541.s1.e1
interaction DrugDDI.d541.s1.e0 DrugDDI.d541.s1.e2
interaction DrugDDI.d541.s1.e0 DrugDDI.d541.s1.e3
interaction DrugDDI.d541.s1.e0 DrugDDI.d541.s1.e4
interaction DrugDDI.d541.s1.e0 DrugDDI.d541.s1.e5

Abstract Id: DrugDDI.d454
Sentence Id: DrugDDI.d454.s0
Interactions with Other CNS Agents : Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic antidepressants , phenothiazines , tranquilizers , skeletal muscle relaxants and antihistamines ) may result in additive central nervous system depressant effects.

DrugDDI.d454.s0.e0 21 29
drug
CNS Agents
DrugDDI.d454.s0.e1 46 58
drug
Levo-Dromoran
DrugDDI.d454.s0.e2 66 96
drug
central nervous system depressants
DrugDDI.d454.s0.e3 101 107
drug
alcohol
DrugDDI.d454.s0.e4 109 117
drug
sedatives
DrugDDI.d454.s0.e5 119 127
drug
hypnotics
DrugDDI.d454.s0.e6 134 140
drug
opioids
DrugDDI.d454.s0.e7 142 159
drug
general anesthetics
DrugDDI.d454.s0.e8 161 172
drug
barbiturates
DrugDDI.d454.s0.e9 174 197
drug
tricyclic antidepressants
DrugDDI.d454.s0.e10 199 212
drug
phenothiazines
DrugDDI.d454.s0.e11 214 226
drug
tranquilizers
DrugDDI.d454.s0.e12 228 250
drug
skeletal muscle relaxants
DrugDDI.d454.s0.e13 254 267
drug
antihistamines
DrugDDI.d454.s0.e14 288 317
drug
central nervous system depressant

interaction DrugDDI.d454.s0.e1 DrugDDI.d454.s0.e3
interaction DrugDDI.d454.s0.e1 DrugDDI.d454.s0.e5
interaction DrugDDI.d454.s0.e1 DrugDDI.d454.s0.e7
interaction DrugDDI.d454.s0.e1 DrugDDI.d454.s0.e9
interaction DrugDDI.d454.s0.e1 DrugDDI.d454.s0.e11
interaction DrugDDI.d454.s0.e1 DrugDDI.d454.s0.e13

Abstract Id: DrugDDI.d454
Sentence Id: DrugDDI.d454.s3
Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors .

DrugDDI.d454.s3.e0 28 40
drug
MAO inhibitors
DrugDDI.d454.s3.e1 44 56
drug
Levo-Dromoran
DrugDDI.d454.s3.e2 101 113
drug
MAO inhibitors



Abstract Id: DrugDDI.d454
Sentence Id: DrugDDI.d454.s4
Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration.

DrugDDI.d454.s4.e0 47 59
drug
Levo-Dromoran
DrugDDI.d454.s4.e1 170 173
drug
drug
DrugDDI.d454.s4.e2 176 184
drug
nonopioid
DrugDDI.d454.s4.e3 235 245
drug
levorphanol
DrugDDI.d454.s4.e4 255 259
drug
drugs

interaction DrugDDI.d454.s4.e0 DrugDDI.d454.s4.e4

Abstract Id: DrugDDI.d454
Sentence Id: DrugDDI.d454.s5
The initial dose of levorphanol should be reduced by approximately 50% or more when it is given to patients along with another drug affecting respiration.

DrugDDI.d454.s5.e0 16 26
drug
levorphanol
DrugDDI.d454.s5.e1 105 108
drug
drug



Abstract Id: DrugDDI.d454
Sentence Id: DrugDDI.d454.s6
Interactions with Mixed Agonist /Antagonist Opioid Analgesics : Agonist /antagonist analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .

DrugDDI.d454.s6.e0 21 27
drug
Agonist
DrugDDI.d454.s6.e1 28 54
drug
/Antagonist Opioid Analgesics
DrugDDI.d454.s6.e2 56 62
drug
Agonist
DrugDDI.d454.s6.e3 74 83
drug
analgesics
DrugDDI.d454.s6.e4 88 98
drug
pentazocine
DrugDDI.d454.s6.e5 100 109
drug
nalbuphine
DrugDDI.d454.s6.e6 111 121
drug
butorphanol
DrugDDI.d454.s6.e7 123 130
drug
dezocine
DrugDDI.d454.s6.e8 134 146
drug
buprenorphine
DrugDDI.d454.s6.e9 233 239
drug
agonist
DrugDDI.d454.s6.e10 261 273
drug
Levo-Dromoran

interaction DrugDDI.d454.s6.e2 DrugDDI.d454.s6.e9
interaction DrugDDI.d454.s6.e3 DrugDDI.d454.s6.e9
interaction DrugDDI.d454.s6.e4 DrugDDI.d454.s6.e10
interaction DrugDDI.d454.s6.e6 DrugDDI.d454.s6.e10
interaction DrugDDI.d454.s6.e8 DrugDDI.d454.s6.e10

Abstract Id: DrugDDI.d454
Sentence Id: DrugDDI.d454.s7
In opioid -dependent patients, mixed agonist /antagonist analgesics may precipitate withdrawal symptoms.

DrugDDI.d454.s7.e0 2 7
drug
opioid
DrugDDI.d454.s7.e1 32 38
drug
agonist
DrugDDI.d454.s7.e2 50 59
drug
analgesics

interaction DrugDDI.d454.s7.e1 DrugDDI.d454.s7.e2

Abstract Id: DrugDDI.d148
Sentence Id: DrugDDI.d148.s0
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide mononitrate , carvedilol , ethanol or itraconazole .

DrugDDI.d148.s0.e0 29 40
drug
Levosimendan
DrugDDI.d148.s0.e1 102 110
drug
captopril
DrugDDI.d148.s0.e2 112 124
drug
beta-blockers
DrugDDI.d148.s0.e3 126 135
drug
felodipine
DrugDDI.d148.s0.e4 137 143
drug
digoxin
DrugDDI.d148.s0.e5 145 152
drug
warfarin
DrugDDI.d148.s0.e6 154 174
drug
isosorbide mononitrate
DrugDDI.d148.s0.e7 176 185
drug
carvedilol
DrugDDI.d148.s0.e8 187 193
drug
ethanol
DrugDDI.d148.s0.e9 196 207
drug
itraconazole



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s0
The magnitude and relative importance of the effects noted below are likely to be patient specific and may vary by such factors as age, gender, race, intercurrent illnesses, dose of either agent, additional concomitant medications , and timing of drug administration.

DrugDDI.d528.s0.e0 185 195
drug
medications



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s1
Any agent that alters thyroid hormone synthesis, secretion, distribution, effect on target tissues, metabolism, or elimination may alter the optimal therapeutic dose of levothyroxine sodium.

DrugDDI.d528.s1.e0 18 31
drug
thyroid hormone
DrugDDI.d528.s1.e1 146 158
drug
levothyroxine

interaction DrugDDI.d528.s1.e0 DrugDDI.d528.s1.e1

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s2
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride , ferrous sulfate , sodium polystyrene sulfonate , soybean flour (e.g., infant formula), sucralfate .

DrugDDI.d528.s2.e0 0 12
drug
Levothyroxine
DrugDDI.d528.s2.e1 78 90
drug
levothyroxine
DrugDDI.d528.s2.e2 143 156
drug
cholestyramine
DrugDDI.d528.s2.e3 163 185
drug
colestipol hydrochloride
DrugDDI.d528.s2.e4 187 200
drug
ferrous sulfate
DrugDDI.d528.s2.e5 202 227
drug
sodium polystyrene sulfonate
DrugDDI.d528.s2.e6 229 235
drug
soybean
DrugDDI.d528.s2.e7 262 271
drug
sucralfate



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s3
Binding to Serum Proteins : The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic hormones, asparaginase , clofibrate , estrogens and estrogen-containing compounds , 5-fluorouracil , furosemide , glucocorticoids, meclofenamic acid , mefenamic acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .

DrugDDI.d528.s3.e0 9 21
drug
Serum Proteins
DrugDDI.d528.s3.e1 57 69
drug
levothyroxine
DrugDDI.d528.s3.e2 85 97
drug
serum proteins
DrugDDI.d528.s3.e3 129 143
drug
binding proteins
DrugDDI.d528.s3.e4 145 153
drug
androgens
DrugDDI.d528.s3.e5 181 192
drug
asparaginase
DrugDDI.d528.s3.e6 194 203
drug
clofibrate
DrugDDI.d528.s3.e7 205 213
drug
estrogens
DrugDDI.d528.s3.e8 217 244
drug
estrogen-containing compounds
DrugDDI.d528.s3.e9 246 259
drug
5-fluorouracil
DrugDDI.d528.s3.e10 261 270
drug
furosemide
DrugDDI.d528.s3.e11 288 303
drug
meclofenamic acid
DrugDDI.d528.s3.e12 305 317
drug
mefenamic acid
DrugDDI.d528.s3.e13 319 327
drug
methadone
DrugDDI.d528.s3.e14 329 340
drug
perphenazine
DrugDDI.d528.s3.e15 342 355
drug
phenylbutazone
DrugDDI.d528.s3.e16 357 365
drug
phenytoin
DrugDDI.d528.s3.e17 367 377
drug
salicylates
DrugDDI.d528.s3.e18 379 387
drug
tamoxifen



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s4
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide , p-aminosalicylic acid , amiodarone , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate ), antithyroid drugs , b-adrenergic blocking agents , carbamazepine , chloral hydrate , diazepam , dopamine and dopamine agonists , ethionamide , glucocorticoids, heparin , hepatic enzyme inducers, insulin , iodinated cholestographic agents, iodine- containing compounds, levodopa , lovastatin , lithium , 6-mercaptopurine , metoclopramide , mitotane , nitroprusside , phenobarbital , phenytoin , resorcinol , rifampin , somatostatin analogs , sulfonamides , sulfonylureas , thiazide diuretics .

DrugDDI.d528.s4.e0 0 6
drug
Thyroid
DrugDDI.d528.s4.e1 44 57
drug
thyroid hormone
DrugDDI.d528.s4.e2 90 103
drug
thyroid hormone
DrugDDI.d528.s4.e3 198 214
drug
aminoglutethimide
DrugDDI.d528.s4.e4 216 235
drug
p-aminosalicylic acid
DrugDDI.d528.s4.e5 237 246
drug
amiodarone
DrugDDI.d528.s4.e6 248 256
drug
androgens
DrugDDI.d528.s4.e7 322 334
drug
pertechnetate
DrugDDI.d528.s4.e8 337 352
drug
antithyroid drugs
DrugDDI.d528.s4.e9 354 379
drug
b-adrenergic blocking agents
DrugDDI.d528.s4.e10 381 393
drug
carbamazepine
DrugDDI.d528.s4.e11 395 408
drug
chloral hydrate
DrugDDI.d528.s4.e12 410 417
drug
diazepam
DrugDDI.d528.s4.e13 419 426
drug
dopamine
DrugDDI.d528.s4.e14 430 445
drug
dopamine agonists
DrugDDI.d528.s4.e15 447 457
drug
ethionamide
DrugDDI.d528.s4.e16 475 481
drug
heparin
DrugDDI.d528.s4.e17 505 511
drug
insulin
DrugDDI.d528.s4.e18 571 578
drug
levodopa
DrugDDI.d528.s4.e19 580 589
drug
lovastatin
DrugDDI.d528.s4.e20 591 597
drug
lithium
DrugDDI.d528.s4.e21 599 614
drug
6-mercaptopurine
DrugDDI.d528.s4.e22 616 629
drug
metoclopramide
DrugDDI.d528.s4.e23 631 638
drug
mitotane
DrugDDI.d528.s4.e24 640 652
drug
nitroprusside
DrugDDI.d528.s4.e25 654 666
drug
phenobarbital
DrugDDI.d528.s4.e26 668 676
drug
phenytoin
DrugDDI.d528.s4.e27 678 687
drug
resorcinol
DrugDDI.d528.s4.e28 689 696
drug
rifampin
DrugDDI.d528.s4.e29 698 716
drug
somatostatin analogs
DrugDDI.d528.s4.e30 718 729
drug
sulfonamides
DrugDDI.d528.s4.e31 731 743
drug
sulfonylureas
DrugDDI.d528.s4.e32 745 761
drug
thiazide diuretics



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s5
Adrenocorticoids: Metabolic clearance of adrenocorticoids is decreased in hypothyroid patients and increased in hyperthyroid patients, and may therefore change with changing thyroid status.

DrugDDI.d528.s5.e0 153 159
drug
thyroid



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s6
Amiodarone : Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.

DrugDDI.d528.s6.e0 0 9
drug
Amiodarone
DrugDDI.d528.s6.e1 11 20
drug
Amiodarone



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s7
Anticoagulants (Oral): The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently by increased catabloism of vitamin K -dependent clotting factors.

DrugDDI.d528.s7.e0 0 13
drug
Anticoagulants
DrugDDI.d528.s7.e1 51 64
drug
anticoagulants
DrugDDI.d528.s7.e2 115 122
drug
vitamin K

interaction DrugDDI.d528.s7.e1 DrugDDI.d528.s7.e2

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s8
Antidiabetic Agents ( Insulin , Sulfonylureas ): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.

DrugDDI.d528.s8.e0 0 17
drug
Antidiabetic Agents
DrugDDI.d528.s8.e1 19 25
drug
Insulin
DrugDDI.d528.s8.e2 27 39
drug
Sulfonylureas
DrugDDI.d528.s8.e3 57 63
drug
insulin
DrugDDI.d528.s8.e4 70 87
drug
antidiabetic agents
DrugDDI.d528.s8.e5 186 192
drug
thyroid



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s9
b-Adrenergic Blocking Agents : Actions of some of beta-blocking agent s may be impaired when hypothyroid patients become euthyroid.

DrugDDI.d528.s9.e0 0 25
drug
b-Adrenergic Blocking Agents
DrugDDI.d528.s9.e1 42 59
drug
beta-blocking agent



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s10
Cytokines ( interferon , interleukin ): Cytokines have been reported to induce both hyperthyroidism and hypothyroidism.

DrugDDI.d528.s10.e0 0 8
drug
Cytokines
DrugDDI.d528.s10.e1 10 19
drug
interferon
DrugDDI.d528.s10.e2 21 31
drug
interleukin
DrugDDI.d528.s10.e3 34 42
drug
Cytokines



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s11
Digitalis Glycosides : Therapeutic effects of digitalis glycosides may be reduced.

DrugDDI.d528.s11.e0 0 18
drug
Digitalis Glycosides
DrugDDI.d528.s11.e1 40 58
drug
digitalis glycosides



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s13
Ketamine : Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine .

DrugDDI.d528.s13.e0 0 7
drug
Ketamine
DrugDDI.d528.s13.e1 101 113
drug
levothyroxine
DrugDDI.d528.s13.e2 123 130
drug
ketamine

interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e2

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s14
Maprotiline : Risk of cardiac arrhythmias may increase.

DrugDDI.d528.s14.e0 0 10
drug
Maprotiline



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s15
Sodium Iodide (123I and 131I), Sodium Pertechnetate Tc99m: Uptake of radiolabeled ions may be decreased.

DrugDDI.d528.s15.e0 0 11
drug
Sodium Iodide



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s16
Somatrem / Somatropin : Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure.

DrugDDI.d528.s16.e0 0 7
drug
Somatrem
DrugDDI.d528.s16.e1 9 18
drug
Somatropin
DrugDDI.d528.s16.e2 44 57
drug
thyroid hormone



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s17
Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin .

DrugDDI.d528.s17.e0 58 65
drug
somatrem
DrugDDI.d528.s17.e1 68 77
drug
somatropin



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s18
Theophylline : Theophylline clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.

DrugDDI.d528.s18.e0 0 11
drug
Theophylline
DrugDDI.d528.s18.e1 13 24
drug
Theophylline



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s19
Tricyclic Antidepressants : Concurrent use may increase the therapeutic and toxic effects of both drugs , possibly due to increased catecholamine sensitivity.

DrugDDI.d528.s19.e0 0 23
drug
Tricyclic Antidepressants
DrugDDI.d528.s19.e1 84 88
drug
drugs



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s20
Onset of action of tricyclics may be accelerated.

DrugDDI.d528.s20.e0 15 24
drug
tricyclics



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s21
Sympathomimetic Agents : Possible increased risk of coronary insufficiency in patients with coronary artery disease.

DrugDDI.d528.s21.e0 0 20
drug
Sympathomimetic Agents



Abstract Id: DrugDDI.d141
Sentence Id: DrugDDI.d141.s0
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.

DrugDDI.d141.s0.e0 19 33
drug
local anesthetic
DrugDDI.d141.s0.e1 53 63
drug
epinephrine
DrugDDI.d141.s0.e2 66 79
drug
norepinephrine
DrugDDI.d141.s0.e3 99 124
drug
monoamine oxidase inhibitors
DrugDDI.d141.s0.e4 127 150
drug
tricyclic antidepressants

interaction DrugDDI.d141.s0.e0 DrugDDI.d141.s0.e3
interaction DrugDDI.d141.s0.e1 DrugDDI.d141.s0.e3
interaction DrugDDI.d141.s0.e2 DrugDDI.d141.s0.e3

Abstract Id: DrugDDI.d141
Sentence Id: DrugDDI.d141.s1
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .

DrugDDI.d141.s1.e0 0 13
drug
Phenothiazines
DrugDDI.d141.s1.e1 17 30
drug
butyrophenones
DrugDDI.d141.s1.e2 52 64
drug
pressor effect
DrugDDI.d141.s1.e3 67 77
drug
epinephrine

interaction DrugDDI.d141.s1.e0 DrugDDI.d141.s1.e3

Abstract Id: DrugDDI.d141
Sentence Id: DrugDDI.d141.s4
Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

DrugDDI.d141.s4.e0 26 41
drug
vasopressor drugs
DrugDDI.d141.s4.e1 109 121
drug
oxytocic drugs

interaction DrugDDI.d141.s4.e0 DrugDDI.d141.s4.e1

Abstract Id: DrugDDI.d86
Sentence Id: DrugDDI.d86.s0
Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents .

DrugDDI.d86.s0.e0 0 9
drug
Lincomycin
DrugDDI.d86.s0.e1 89 115
drug
neuromuscular blocking agents

interaction DrugDDI.d86.s0.e0 DrugDDI.d86.s0.e1

Abstract Id: DrugDDI.d86
Sentence Id: DrugDDI.d86.s2
Antagonism between lincomycin and erythromycin in vitro has been demonstrated.

DrugDDI.d86.s2.e0 17 26
drug
lincomycin
DrugDDI.d86.s2.e1 30 41
drug
erythromycin

interaction DrugDDI.d86.s2.e0 DrugDDI.d86.s2.e1

Abstract Id: DrugDDI.d86
Sentence Id: DrugDDI.d86.s3
Because of possible clinical significance, the two drugs should not be administered concurrently.

DrugDDI.d86.s3.e0 44 48
drug
drugs



Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s0
Monoamine Oxidase Inhibition: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase .

DrugDDI.d571.s0.e0 0 15
drug
Monoamine Oxidase
DrugDDI.d571.s0.e1 27 35
drug
Linezolid
DrugDDI.d571.s0.e2 73 88
drug
monoamine oxidase

interaction DrugDDI.d571.s0.e1 DrugDDI.d571.s0.e2

Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s1
Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents .

DrugDDI.d571.s1.e0 10 18
drug
linezolid
DrugDDI.d571.s1.e1 65 82
drug
serotonergic agents

interaction DrugDDI.d571.s1.e0 DrugDDI.d571.s1.e1

Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s2
Adrenergic Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents , vasopressor or dopaminergic agents .

DrugDDI.d571.s2.e0 0 15
drug
Adrenergic Agents
DrugDDI.d571.s2.e1 41 45
drug
ZYVOX
DrugDDI.d571.s2.e2 86 92
drug
pressor
DrugDDI.d571.s2.e3 118 138
drug
sympathomimetic agents
DrugDDI.d571.s2.e4 140 150
drug
vasopressor
DrugDDI.d571.s2.e5 153 170
drug
dopaminergic agents

interaction DrugDDI.d571.s2.e1 DrugDDI.d571.s2.e3
interaction DrugDDI.d571.s2.e1 DrugDDI.d571.s2.e5

Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s3
Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.

DrugDDI.d571.s3.e0 12 16
drug
drugs
DrugDDI.d571.s3.e1 23 41
drug
phenylpropanolamine
DrugDDI.d571.s3.e2 45 59
drug
pseudoephedrine



Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s4
Initial doses of adrenergic agents , such as dopamine or epinephrine , should be reduced and titrated to achieve the desired response.

DrugDDI.d571.s4.e0 14 29
drug
adrenergic agents
DrugDDI.d571.s4.e1 37 44
drug
dopamine
DrugDDI.d571.s4.e2 47 57
drug
epinephrine



Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s5
Serotonergic Agents : Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.

DrugDDI.d571.s5.e0 0 17
drug
Serotonergic Agents
DrugDDI.d571.s5.e1 38 46
drug
linezolid
DrugDDI.d571.s5.e2 50 67
drug
serotonergic agents



Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s6
Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents , including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.

DrugDDI.d571.s6.e0 70 74
drug
ZYVOX
DrugDDI.d571.s6.e1 78 95
drug
serotonergic agents
DrugDDI.d571.s6.e2 106 120
drug
antidepressants
DrugDDI.d571.s6.e3 136 162
drug
serotonin reuptake inhibitors



Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s7
Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).

DrugDDI.d571.s7.e0 25 29
drug
ZYVOX
DrugDDI.d571.s7.e1 44 61
drug
serotonergic agents

interaction DrugDDI.d571.s7.e0 DrugDDI.d571.s7.e1

Abstract Id: DrugDDI.d571
Sentence Id: DrugDDI.d571.s8
If any signs or symptoms occur physicians should consider discontinuation of either one or both agents ( ZYVOX or concomitant serotonergic agents ).

DrugDDI.d571.s8.e0 88 92
drug
ZYVOX
DrugDDI.d571.s8.e1 106 123
drug
serotonergic agents



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s0
Oral Anticoagulants : Thyroid hormones appear to increase catabolism of vitamin K -dependent clotting factors.

DrugDDI.d85.s0.e0 0 17
drug
Oral Anticoagulants
DrugDDI.d85.s0.e1 19 33
drug
Thyroid hormones
DrugDDI.d85.s0.e2 62 69
drug
vitamin K

interaction DrugDDI.d85.s0.e1 DrugDDI.d85.s0.e2

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s1
If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired.

DrugDDI.d85.s1.e0 2 19
drug
oral anticoagulants
DrugDDI.d85.s1.e1 61 74
drug
clotting factor



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s2
Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.

DrugDDI.d85.s2.e0 20 37
drug
oral anticoagulants
DrugDDI.d85.s2.e1 58 64
drug
thyroid
DrugDDI.d85.s2.e2 113 119
drug
thyroid



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s3
If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required.

DrugDDI.d85.s3.e0 55 67
drug
anticoagulant



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s4
No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy.

DrugDDI.d85.s4.e0 114 120
drug
thyroid



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s5
Insulin or Oral Hypoglycemics : Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.

DrugDDI.d85.s5.e0 0 6
drug
Insulin
DrugDDI.d85.s5.e1 9 25
drug
Oral Hypoglycemics
DrugDDI.d85.s5.e2 37 43
drug
thyroid
DrugDDI.d85.s5.e3 81 87
drug
insulin
DrugDDI.d85.s5.e4 90 93
drug
oral

interaction DrugDDI.d85.s5.e2 DrugDDI.d85.s5.e3

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s6
The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparation s and endocrine status of the patient.

DrugDDI.d85.s6.e0 82 99
drug
thyroid preparation



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s7
Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.

DrugDDI.d85.s7.e0 17 23
drug
insulin
DrugDDI.d85.s7.e1 26 42
drug
oral hypoglycemics
DrugDDI.d85.s7.e2 83 89
drug
thyroid

interaction DrugDDI.d85.s7.e0 DrugDDI.d85.s7.e2

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s8
Cholestyramine : Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones .

DrugDDI.d85.s8.e0 0 13
drug
Cholestyramine
DrugDDI.d85.s8.e1 15 28
drug
Cholestyramine
DrugDDI.d85.s8.e2 38 39
drug
T4
DrugDDI.d85.s8.e3 43 44
drug
T3
DrugDDI.d85.s8.e4 90 104
drug
thyroid hormones

interaction DrugDDI.d85.s8.e1 DrugDDI.d85.s8.e2

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s10
Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones .

DrugDDI.d85.s10.e0 54 67
drug
cholestyramine
DrugDDI.d85.s10.e1 71 85
drug
thyroid hormones

interaction DrugDDI.d85.s10.e0 DrugDDI.d85.s10.e1

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s11
Estrogen , Oral Contraceptives : Estrogens tend to increase serum thyroxine-binding globulin (TBg).

DrugDDI.d85.s11.e0 0 7
drug
Estrogen
DrugDDI.d85.s11.e1 9 26
drug
Oral Contraceptives
DrugDDI.d85.s11.e2 28 36
drug
Estrogens
DrugDDI.d85.s11.e3 56 80
drug
thyroxine-binding globulin

interaction DrugDDI.d85.s11.e2 DrugDDI.d85.s11.e3

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s12
In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.

DrugDDI.d85.s12.e0 55 61
drug
thyroid
DrugDDI.d85.s12.e1 85 97
drug
levothyroxine
DrugDDI.d85.s12.e2 116 124
drug
estrogens
DrugDDI.d85.s12.e3 149 155
drug
thyroid



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s13
However, if the patients thyroid gland has sufficient function, the decreased free thyroxin e will result in a compensatory increase in thyroxin e output by the thyroid .

DrugDDI.d85.s13.e0 67 78
drug
free thyroxin
DrugDDI.d85.s13.e1 115 122
drug
thyroxin
DrugDDI.d85.s13.e2 135 141
drug
thyroid



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s14
Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen -containing oral contraceptives are given.

DrugDDI.d85.s14.e0 57 63
drug
thyroid
DrugDDI.d85.s14.e1 104 110
drug
thyroid
DrugDDI.d85.s14.e2 117 125
drug
estrogens
DrugDDI.d85.s14.e3 128 135
drug
estrogen
DrugDDI.d85.s14.e4 147 164
drug
oral contraceptives



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s15
Tricyclic Antidepressants : Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.

DrugDDI.d85.s15.e0 0 23
drug
Tricyclic Antidepressants
DrugDDI.d85.s15.e1 30 36
drug
thyroid
DrugDDI.d85.s15.e2 49 58
drug
imipramine
DrugDDI.d85.s15.e3 67 90
drug
tricyclic antidepressants
DrugDDI.d85.s15.e4 131 144
drug
antidepressant

interaction DrugDDI.d85.s15.e1 DrugDDI.d85.s15.e2

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s16
Thyroid hormone activity may also be enhanced.

DrugDDI.d85.s16.e0 0 13
drug
Thyroid hormone



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s17
Digitalis : Thyroid preparation s may potentiate the toxic effects of digitalis .

DrugDDI.d85.s17.e0 0 8
drug
Digitalis
DrugDDI.d85.s17.e1 10 27
drug
Thyroid preparation
DrugDDI.d85.s17.e2 59 67
drug
digitalis

interaction DrugDDI.d85.s17.e1 DrugDDI.d85.s17.e2

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s18
Thyroid hormonal replacement increases metabolic rate, which requires an increase in digitalis dosage.

DrugDDI.d85.s18.e0 0 14
drug
Thyroid hormonal
DrugDDI.d85.s18.e1 74 82
drug
digitalis



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s19
Ketamine : When administered to patients on a thyroid preparation , this parenteral anesthetic may cause hypertension and tachycardia.

DrugDDI.d85.s19.e0 0 7
drug
Ketamine
DrugDDI.d85.s19.e1 38 55
drug
thyroid preparation
DrugDDI.d85.s19.e2 61 80
drug
parenteral anesthetic



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s21
Vasopressor s: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine .

DrugDDI.d85.s21.e0 0 10
drug
Vasopressor
DrugDDI.d85.s21.e1 13 21
drug
Thyroxine
DrugDDI.d85.s21.e2 72 82
drug
epinephrine
DrugDDI.d85.s21.e3 86 99
drug
norepinephrine

interaction DrugDDI.d85.s21.e1 DrugDDI.d85.s21.e2

Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s22
Therefore, injection of these agents into patients receiving thyroid preparation s increases the risk of precipitating coronary insufficiency especially in patients with coronary artery disease.

DrugDDI.d85.s22.e0 53 70
drug
thyroid preparation



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s24
Drug /Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine-containing preparations and the numerous preparations containing salicylates .

DrugDDI.d85.s24.e0 0 3
drug
Drug
DrugDDI.d85.s24.e1 43 47
drug
drugs
DrugDDI.d85.s24.e2 117 130
drug
thyroid hormone
DrugDDI.d85.s24.e3 139 147
drug
androgens
DrugDDI.d85.s24.e4 149 163
drug
corticosteroids
DrugDDI.d85.s24.e5 165 173
drug
estrogens
DrugDDI.d85.s24.e6 175 192
drug
oral contraceptives
DrugDDI.d85.s24.e7 203 211
drug
estrogens
DrugDDI.d85.s24.e8 213 241
drug
iodine-containing preparations
DrugDDI.d85.s24.e9 278 288
drug
salicylates



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s25
- Changes in TBg concentration should be taken into consideration in the interpretation of T4 and T3 values.

DrugDDI.d85.s25.e0 77 78
drug
T4
DrugDDI.d85.s25.e1 82 83
drug
T3



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s27
Pregnancy estrogens and estrogen -containing oral contraceptives increase TBg concentrations.

DrugDDI.d85.s27.e0 9 17
drug
estrogens
DrugDDI.d85.s27.e1 21 28
drug
estrogen
DrugDDI.d85.s27.e2 40 57
drug
oral contraceptives



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s29
Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy.

DrugDDI.d85.s29.e0 69 76
drug
androgen



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s30
Familial hyper- or hypo- thyroxin e-binding-globulinemias have been described.

DrugDDI.d85.s30.e0 21 28
drug
thyroxin



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s32
The binding of thyroxin e by thyroxine-binding prealbumin (TBPA) is inhibited by salicylates .

DrugDDI.d85.s32.e0 12 19
drug
thyroxin
DrugDDI.d85.s32.e1 23 49
drug
thyroxine-binding prealbumin
DrugDDI.d85.s32.e2 69 79
drug
salicylates



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s34
- Medicinal or dietary iodine interferes with all in vivo tests of radio-iodine uptake producing low uptakes which may not be reflective of a true decrease in hormone synthesis .

DrugDDI.d85.s34.e0 19 24
drug
iodine



Abstract Id: DrugDDI.d85
Sentence Id: DrugDDI.d85.s37
Intracellular resistance to thyroid hormone is quite rare.

DrugDDI.d85.s37.e0 25 38
drug
thyroid hormone



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s0
Urinary acidifying agents@These agents ( ammonium chloride , sodium acid phosphate , etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.

DrugDDI.d34.s0.e0 36 51
drug
ammonium chloride
DrugDDI.d34.s0.e1 53 71
drug
sodium acid phosphate
DrugDDI.d34.s0.e2 126 136
drug
amphetamine

interaction DrugDDI.d34.s0.e0 DrugDDI.d34.s0.e2

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s1
Both groups of agents lower blood levels and efficacy of amphetamines .

DrugDDI.d34.s1.e0 47 58
drug
amphetamines



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s2
Adrenergic blockers @Adrenergic blockers are inhibited by amphetamines .

DrugDDI.d34.s2.e0 0 17
drug
Adrenergic blockers
DrugDDI.d34.s2.e1 51 62
drug
amphetamines

interaction DrugDDI.d34.s2.e0 DrugDDI.d34.s2.e1

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s3
Antidepressants , tricyclic@Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents ; .

DrugDDI.d34.s3.e0 0 14
drug
Antidepressants
DrugDDI.d34.s3.e1 61 84
drug
tricyclic antidepressants
DrugDDI.d34.s3.e2 87 107
drug
sympathomimetic agents

interaction DrugDDI.d34.s3.e0 DrugDDI.d34.s3.e1

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s4
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; .

DrugDDI.d34.s4.e0 0 12
drug
d-amphetamine
DrugDDI.d34.s4.e1 17 27
drug
desipramine
DrugDDI.d34.s4.e2 30 42
drug
protriptyline
DrugDDI.d34.s4.e3 59 68
drug
tricyclics
DrugDDI.d34.s4.e4 123 135
drug
d-amphetamine

interaction DrugDDI.d34.s4.e0 DrugDDI.d34.s4.e1
interaction DrugDDI.d34.s4.e0 DrugDDI.d34.s4.e3

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s6
MAO inhibitors@MAOI antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism.

DrugDDI.d34.s6.e0 18 32
drug
antidepressants
DrugDDI.d34.s6.e1 43 52
drug
metabolite
DrugDDI.d34.s6.e2 55 66
drug
furazolidone
DrugDDI.d34.s6.e3 72 82
drug
amphetamine

interaction DrugDDI.d34.s6.e0 DrugDDI.d34.s6.e3

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s7
This slowing potentiates amphetamines , increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; .

DrugDDI.d34.s7.e0 22 33
drug
amphetamines
DrugDDI.d34.s7.e1 70 83
drug
norepinephrine

interaction DrugDDI.d34.s7.e0 DrugDDI.d34.s7.e1

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s10
Antihistamines@Amphetamines may counteract the sedative effect of antihistamines .

DrugDDI.d34.s10.e0 43 50
drug
sedative
DrugDDI.d34.s10.e1 59 72
drug
antihistamines



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s11
Antihypertensives@Amphetamines may antagonize the hypotensive effects of antihypertensives .

DrugDDI.d34.s11.e0 66 82
drug
antihypertensives



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s12
Chlorpromazine@Chlorpromazine blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.

DrugDDI.d34.s12.e0 35 42
drug
dopamine
DrugDDI.d34.s12.e1 46 68
drug
norepinephrine receptors
DrugDDI.d34.s12.e2 87 102
drug
central stimulant
DrugDDI.d34.s12.e3 112 123
drug
amphetamines

interaction DrugDDI.d34.s12.e0 DrugDDI.d34.s12.e3

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s13
Ethosuximide@Amphetamines may delay intestinal absorption of ethosuximide .

DrugDDI.d34.s13.e0 55 66
drug
ethosuximide



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s14
Haloperidol@Haloperidol blocks dopamine receptors , thus inhibiting the central stimulant effects of amphetamines .

DrugDDI.d34.s14.e0 29 45
drug
dopamine receptors
DrugDDI.d34.s14.e1 64 79
drug
central stimulant
DrugDDI.d34.s14.e2 89 100
drug
amphetamines

interaction DrugDDI.d34.s14.e0 DrugDDI.d34.s14.e2

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s15
Lithium carbonate@The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate .

DrugDDI.d34.s15.e0 0 6
drug
Lithium
DrugDDI.d34.s15.e1 52 63
drug
amphetamines
DrugDDI.d34.s15.e2 80 95
drug
lithium carbonate

interaction DrugDDI.d34.s15.e1 DrugDDI.d34.s15.e2

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s16
Meperidine@Amphetamines potentiate the analgesic effect of meperidine .

DrugDDI.d34.s16.e0 53 62
drug
meperidine



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s17
Methenamine therapy@Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.

DrugDDI.d34.s17.e0 0 10
drug
Methenamine
DrugDDI.d34.s17.e1 37 48
drug
amphetamines
DrugDDI.d34.s17.e2 105 115
drug
methenamine



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s18
Norepinephrine@Amphetamines enhance the adrenergic effect of norepinephrine .

DrugDDI.d34.s18.e0 55 68
drug
norepinephrine



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s19
Phenobarbital@Amphetamines may delay intestinal absorption of phenobarbital ; .

DrugDDI.d34.s19.e0 56 68
drug
phenobarbital



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s20
co-administration of phenobarbital may produce a synergistic anticonvulsant action.

DrugDDI.d34.s20.e0 19 31
drug
phenobarbital
DrugDDI.d34.s20.e1 54 67
drug
anticonvulsant



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s21
Phenytoin@Amphetamines may delay intestinal absorption of phenytoin ; .

DrugDDI.d34.s21.e0 52 60
drug
phenytoin



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s22
co-administration of phenytoin may produce a synergistic anticonvulsant action.

DrugDDI.d34.s22.e0 19 27
drug
phenytoin
DrugDDI.d34.s22.e1 50 63
drug
anticonvulsant



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s23
Propoxyphene@In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.

DrugDDI.d34.s23.e0 22 33
drug
propoxyphene
DrugDDI.d34.s23.e1 45 58
drug
amphetamine CNS



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s24
Veratrum alkaloids@Amphetamines inhibit the hypotensive effect of veratrum alkaloids .

DrugDDI.d34.s24.e0 59 75
drug
veratrum alkaloids



Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s25
Drug /Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.

DrugDDI.d34.s25.e0 0 3
drug
Drug
DrugDDI.d34.s25.e1 32 43
drug
Amphetamines
DrugDDI.d34.s25.e2 81 94
drug
corticosteroid

interaction DrugDDI.d34.s25.e1 DrugDDI.d34.s25.e2

Abstract Id: DrugDDI.d34
Sentence Id: DrugDDI.d34.s27
Amphetamines may interfere with urinary steroid determinations.

DrugDDI.d34.s27.e0 0 11
drug
Amphetamines



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s0
Hypotension - Patients on Diuretic Therapy: Patients on diuretics , and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL .

DrugDDI.d3.s0.e0 48 56
drug
diuretics
DrugDDI.d3.s0.e1 207 214
drug
PRINIVIL

interaction DrugDDI.d3.s0.e0 DrugDDI.d3.s0.e1

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s1
The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL .

DrugDDI.d3.s1.e0 38 45
drug
PRINIVIL
DrugDDI.d3.s1.e1 84 91
drug
diuretic
DrugDDI.d3.s1.e2 149 156
drug
PRINIVIL



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s2
If it is necessary to continue the diuretic , initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.

DrugDDI.d3.s2.e0 28 35
drug
diuretic
DrugDDI.d3.s2.e1 56 63
drug
PRINIVIL



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s3
When a diuretic is added to the therapy of a patient receiving PRINIVIL , an additional antihypertensive effect is usually observed.

DrugDDI.d3.s3.e0 5 12
drug
diuretic
DrugDDI.d3.s3.e1 51 58
drug
PRINIVIL
DrugDDI.d3.s3.e2 72 87
drug
antihypertensive

interaction DrugDDI.d3.s3.e0 DrugDDI.d3.s3.e1

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s4
Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic .

DrugDDI.d3.s4.e0 11 23
drug
ACE inhibitors
DrugDDI.d3.s4.e1 41 49
drug
diuretics
DrugDDI.d3.s4.e2 74 85
drug
ACE inhibitor
DrugDDI.d3.s4.e3 116 123
drug
diuretic



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s5
Non-steroidal Anti-inflammatory Agents : In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs , the co-administration of lisinopril may result in a further deterioration of renal function.

DrugDDI.d3.s5.e0 0 35
drug
Non-steroidal Anti-inflammatory Agents
DrugDDI.d3.s5.e1 101 135
drug
non-steroidal anti-inflammatory drugs
DrugDDI.d3.s5.e2 159 168
drug
lisinopril

interaction DrugDDI.d3.s5.e1 DrugDDI.d3.s5.e2

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s7
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors , including lisinopril .

DrugDDI.d3.s7.e0 18 23
drug
NSAIDs
DrugDDI.d3.s7.e1 38 53
drug
antihypertensive
DrugDDI.d3.s7.e2 62 74
drug
ACE inhibitors
DrugDDI.d3.s7.e3 85 94
drug
lisinopril

interaction DrugDDI.d3.s7.e0 DrugDDI.d3.s7.e2

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s8
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors .

DrugDDI.d3.s8.e0 57 62
drug
NSAIDs
DrugDDI.d3.s8.e1 80 92
drug
ACE inhibitors



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s9
In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin , the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.

DrugDDI.d3.s9.e0 58 73
drug
antihypertensive
DrugDDI.d3.s9.e1 83 90
drug
PRINIVIL
DrugDDI.d3.s9.e2 110 117
drug
PRINIVIL
DrugDDI.d3.s9.e3 140 151
drug
indomethacin
DrugDDI.d3.s9.e4 161 172
drug
indomethacin
DrugDDI.d3.s9.e5 198 213
drug
antihypertensive



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s10
Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.

DrugDDI.d3.s10.e0 12 19
drug
PRINIVIL
DrugDDI.d3.s10.e1 48 55
drug
nitrates
DrugDDI.d3.s10.e2 62 68
drug
digoxin



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s11
This included post myocardial infarction patients who were receiving intravenous or transdermal nitroglycerin .

DrugDDI.d3.s11.e0 73 96
drug
transdermal nitroglycerin



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s12
No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide .

DrugDDI.d3.s12.e0 60 67
drug
PRINIVIL
DrugDDI.d3.s12.e1 92 102
drug
propranolol
DrugDDI.d3.s12.e2 105 123
drug
hydrochlorothiazide



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s13
The presence of food in the stomach does not alter the bioavailability of PRINIVIL .

DrugDDI.d3.s13.e0 61 68
drug
PRINIVIL



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s14
Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics .

DrugDDI.d3.s14.e0 31 38
drug
PRINIVIL
DrugDDI.d3.s14.e1 49 57
drug
potassium
DrugDDI.d3.s14.e2 70 91
drug
thiazide-type diuretics

interaction DrugDDI.d3.s14.e0 DrugDDI.d3.s14.e2

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s15
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone , triamterene , or amiloride ), potassium supplement s, or potassium-containing salt substitutes may lead to significant increases in serum potassium.

DrugDDI.d3.s15.e0 5 12
drug
PRINIVIL
DrugDDI.d3.s15.e1 17 42
drug
potassium-sparing diuretics
DrugDDI.d3.s15.e2 49 62
drug
spironolactone
DrugDDI.d3.s15.e3 64 74
drug
triamterene
DrugDDI.d3.s15.e4 78 86
drug
amiloride
DrugDDI.d3.s15.e5 89 107
drug
potassium supplement
DrugDDI.d3.s15.e6 112 146
drug
potassium-containing salt substitutes

interaction DrugDDI.d3.s15.e0 DrugDDI.d3.s15.e1
interaction DrugDDI.d3.s15.e0 DrugDDI.d3.s15.e3
interaction DrugDDI.d3.s15.e0 DrugDDI.d3.s15.e5

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s17
Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL .

DrugDDI.d3.s17.e0 0 8
drug
Potassium
DrugDDI.d3.s17.e1 87 94
drug
PRINIVIL

interaction DrugDDI.d3.s17.e0 DrugDDI.d3.s17.e1

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s18
Lithium : Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium , including ACE inhibitors .

DrugDDI.d3.s18.e0 0 6
drug
Lithium
DrugDDI.d3.s18.e1 57 63
drug
lithium
DrugDDI.d3.s18.e2 81 85
drug
drugs
DrugDDI.d3.s18.e3 109 114
drug
sodium
DrugDDI.d3.s18.e4 125 137
drug
ACE inhibitors

interaction DrugDDI.d3.s18.e1 DrugDDI.d3.s18.e2

Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s19
Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor .

DrugDDI.d3.s19.e0 56 62
drug
lithium
DrugDDI.d3.s19.e1 69 80
drug
ACE inhibitor



Abstract Id: DrugDDI.d3
Sentence Id: DrugDDI.d3.s20
It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium .

DrugDDI.d3.s20.e0 60 67
drug
PRINIVIL
DrugDDI.d3.s20.e1 99 105
drug
lithium

interaction DrugDDI.d3.s20.e0 DrugDDI.d3.s20.e1

Abstract Id: DrugDDI.d380
Sentence Id: DrugDDI.d380.s0
- Lofexidine may enhance the CNS depressive effects of alcohol , barbiturates and other sedatives .

DrugDDI.d380.s0.e0 1 10
drug
Lofexidine
DrugDDI.d380.s0.e1 46 52
drug
alcohol
DrugDDI.d380.s0.e2 54 65
drug
barbiturates
DrugDDI.d380.s0.e3 74 82
drug
sedatives

interaction DrugDDI.d380.s0.e0 DrugDDI.d380.s0.e1
interaction DrugDDI.d380.s0.e0 DrugDDI.d380.s0.e3

Abstract Id: DrugDDI.d380
Sentence Id: DrugDDI.d380.s2
- Lofexidine may enhance the effects of anti-hypertensive drug therapy .

DrugDDI.d380.s2.e0 1 10
drug
Lofexidine
DrugDDI.d380.s2.e1 33 53
drug
anti-hypertensive drug

interaction DrugDDI.d380.s2.e0 DrugDDI.d380.s2.e1

Abstract Id: DrugDDI.d380
Sentence Id: DrugDDI.d380.s4
- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine .

DrugDDI.d380.s4.e0 17 40
drug
tricyclic antidepressants
DrugDDI.d380.s4.e1 63 72
drug
lofexidine

interaction DrugDDI.d380.s4.e0 DrugDDI.d380.s4.e1

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s0
Theophylline : In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin .

DrugDDI.d374.s0.e0 0 11
drug
Theophylline
DrugDDI.d374.s0.e1 76 87
drug
theophylline
DrugDDI.d374.s0.e2 155 166
drug
lomefloxacin



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s1
In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.

DrugDDI.d374.s1.e0 43 54
drug
theophylline
DrugDDI.d374.s1.e1 63 74
drug
lomefloxacin
DrugDDI.d374.s1.e2 119 130
drug
theophylline
DrugDDI.d374.s1.e3 165 176
drug
theophylline



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s3
Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx@ ( didanosine ), chewable/ buffer ed tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.

DrugDDI.d374.s3.e0 0 7
drug
Antacids
DrugDDI.d374.s3.e1 11 20
drug
sucralfate
DrugDDI.d374.s3.e2 22 31
drug
Sucralfate
DrugDDI.d374.s3.e3 35 42
drug
antacids
DrugDDI.d374.s3.e4 53 61
drug
magnesium
DrugDDI.d374.s3.e5 123 129
drug
cations
DrugDDI.d374.s3.e6 143 152
drug
didanosine
DrugDDI.d374.s3.e7 164 169
drug
buffer
DrugDDI.d374.s3.e8 184 192
drug
pediatric
DrugDDI.d374.s3.e9 243 254
drug
lomefloxacin

interaction DrugDDI.d374.s3.e2 DrugDDI.d374.s3.e9
interaction DrugDDI.d374.s3.e5 DrugDDI.d374.s3.e9
interaction DrugDDI.d374.s3.e8 DrugDDI.d374.s3.e9

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s4
Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).

DrugDDI.d374.s4.e0 0 9
drug
Sucralfate
DrugDDI.d374.s4.e1 34 45
drug
lomefloxacin
DrugDDI.d374.s4.e2 79 81
drug
max
DrugDDI.d374.s4.e3 104 106
drug
max

interaction DrugDDI.d374.s4.e0 DrugDDI.d374.s4.e1

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s5
Magnesium - and aluminum-containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin .

DrugDDI.d374.s5.e0 0 8
drug
Magnesium
DrugDDI.d374.s5.e1 13 39
drug
aluminum-containing antacids
DrugDDI.d374.s5.e2 70 81
drug
lomefloxacin
DrugDDI.d374.s5.e3 130 141
drug
lomefloxacin

interaction DrugDDI.d374.s5.e0 DrugDDI.d374.s5.e2

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s6
Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability; .

DrugDDI.d374.s6.e0 20 26
drug
antacid
DrugDDI.d374.s6.e1 30 41
drug
lomefloxacin



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s7
therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.

DrugDDI.d374.s7.e0 50 61
drug
lomefloxacin
DrugDDI.d374.s7.e1 84 95
drug
lomefloxacin



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s8
Caffeine : Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.

DrugDDI.d374.s8.e0 0 7
drug
Caffeine
DrugDDI.d374.s8.e1 23 30
drug
caffeine
DrugDDI.d374.s8.e2 159 170
drug
lomefloxacin



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s9
This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite , paraxanthine.

DrugDDI.d374.s9.e0 99 106
drug
caffeine
DrugDDI.d374.s9.e1 117 126
drug
metabolite



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s10
No data are available on potential interactions in individuals who consume greater than 200 mg of caffeine per day or in those, such as the geriatric population, who are generally believed to be more susceptible to the development of drug-induced CNS-related adverse effects.

DrugDDI.d374.s10.e0 82 89
drug
caffeine



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s11
Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine , resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine .

DrugDDI.d374.s11.e0 5 14
drug
quinolones
DrugDDI.d374.s11.e1 78 85
drug
caffeine
DrugDDI.d374.s11.e2 195 202
drug
caffeine

interaction DrugDDI.d374.s11.e0 DrugDDI.d374.s11.e1

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s12
Cimetidine : Cimetidine has been demonstrated to interfere with the elimination of other quinolones .

DrugDDI.d374.s12.e0 0 9
drug
Cimetidine
DrugDDI.d374.s12.e1 11 20
drug
Cimetidine
DrugDDI.d374.s12.e2 76 85
drug
quinolones

interaction DrugDDI.d374.s12.e1 DrugDDI.d374.s12.e2

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s14
The interaction between lomefloxacin and cimetidine has not been studied.

DrugDDI.d374.s14.e0 21 32
drug
lomefloxacin
DrugDDI.d374.s14.e1 36 45
drug
cimetidine



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s15
Cyclosporine : Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class .

DrugDDI.d374.s15.e0 0 11
drug
Cyclosporine
DrugDDI.d374.s15.e1 34 45
drug
cyclosporine
DrugDDI.d374.s15.e2 82 93
drug
cyclosporine
DrugDDI.d374.s15.e3 115 128
drug
quinolone class

interaction DrugDDI.d374.s15.e2 DrugDDI.d374.s15.e3

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s16
Interaction between lomefloxacin and cyclosporine has not been studied.

DrugDDI.d374.s16.e0 18 29
drug
lomefloxacin
DrugDDI.d374.s16.e1 33 44
drug
cyclosporine



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s17
Omeprazole : No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.

DrugDDI.d374.s17.e0 0 9
drug
Omeprazole
DrugDDI.d374.s17.e1 43 54
drug
lomefloxacin
DrugDDI.d374.s17.e2 77 79
drug
max
DrugDDI.d374.s17.e3 84 86
drug
max
DrugDDI.d374.s17.e4 117 133
drug
lomefloxacin 400 mg
DrugDDI.d374.s17.e5 162 171
drug
omeprazole



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s18
Changes in omeprazole pharmacokinetics were not studied.

DrugDDI.d374.s18.e0 9 18
drug
omeprazole



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s19
Phenytoin : No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.

DrugDDI.d374.s19.e0 0 8
drug
Phenytoin
DrugDDI.d374.s19.e1 52 60
drug
phenytoin
DrugDDI.d374.s19.e2 66 68
drug
max
DrugDDI.d374.s19.e3 77 79
drug
max
DrugDDI.d374.s19.e4 90 92
drug
max
DrugDDI.d374.s19.e5 112 128
drug
extended phenytoin
DrugDDI.d374.s19.e6 175 186
drug
lomefloxacin



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s20
Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.

DrugDDI.d374.s20.e0 0 11
drug
Lomefloxacin
DrugDDI.d374.s20.e1 48 56
drug
phenytoin



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s21
Probenecid : Probenecid slows the renal elimination of lome-floxacin.

DrugDDI.d374.s21.e0 0 9
drug
Probenecid
DrugDDI.d374.s21.e1 11 20
drug
Probenecid



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s22
An increase of 63% in the mean AUC and increases of 50% and 4%, respectively, in the mean T max and mean C max were noted in 1 study of 6 individuals.

DrugDDI.d374.s22.e0 73 75
drug
max
DrugDDI.d374.s22.e1 84 86
drug
max



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s23
Terfenadine : No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.

DrugDDI.d374.s23.e0 0 10
drug
Terfenadine
DrugDDI.d374.s23.e1 88 98
drug
terfenadine
DrugDDI.d374.s23.e2 111 122
drug
lomefloxacin
DrugDDI.d374.s23.e3 172 183
drug
lomefloxacin
DrugDDI.d374.s23.e4 187 197
drug
terfenadine



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s24
Warfarin : Quinolones may enhance the effects of the oral anticoagulant , warfarin , or its derivatives .

DrugDDI.d374.s24.e0 0 7
drug
Warfarin
DrugDDI.d374.s24.e1 9 18
drug
Quinolones
DrugDDI.d374.s24.e2 44 60
drug
oral anticoagulant
DrugDDI.d374.s24.e3 62 69
drug
warfarin
DrugDDI.d374.s24.e4 76 86
drug
derivatives

interaction DrugDDI.d374.s24.e1 DrugDDI.d374.s24.e3
interaction DrugDDI.d374.s24.e2 DrugDDI.d374.s24.e4

Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s25
When these products are administered concomitantly, prothrombin or other suitable coagulation tests should be monitored closely.

DrugDDI.d374.s25.e0 46 56
drug
prothrombin



Abstract Id: DrugDDI.d374
Sentence Id: DrugDDI.d374.s26
However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.

DrugDDI.d374.s26.e0 89 98
drug
enantiomer
DrugDDI.d374.s26.e1 170 177
drug
warfarin
DrugDDI.d374.s26.e2 181 192
drug
lomefloxacin



Abstract Id: DrugDDI.d475
Sentence Id: DrugDDI.d475.s0
There was no evidence in clinical trials of drug interactions with concurrent medications .

DrugDDI.d475.s0.e0 66 76
drug
medications



Abstract Id: DrugDDI.d289
Sentence Id: DrugDDI.d289.s0
Probenecid : As with other b-lactam antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef .

DrugDDI.d289.s0.e0 0 9
drug
Probenecid
DrugDDI.d289.s0.e1 22 40
drug
b-lactam antibiotics
DrugDDI.d289.s0.e2 58 67
drug
loracarbef
DrugDDI.d289.s0.e3 81 90
drug
probenecid
DrugDDI.d289.s0.e4 139 148
drug
loracarbef

interaction DrugDDI.d289.s0.e2 DrugDDI.d289.s0.e3

Abstract Id: DrugDDI.d357
Sentence Id: DrugDDI.d357.s0
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin , cimetidine , and ketoconazole in controlled clinical pharmacology studies in adult volunteers.

DrugDDI.d357.s0.e0 0 9
drug
Loratadine
DrugDDI.d357.s0.e1 68 79
drug
erythromycin
DrugDDI.d357.s0.e2 81 90
drug
cimetidine
DrugDDI.d357.s0.e3 95 106
drug
ketoconazole



Abstract Id: DrugDDI.d357
Sentence Id: DrugDDI.d357.s1
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine , as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.

DrugDDI.d357.s1.e0 51 60
drug
loratadine
DrugDDI.d357.s1.e1 130 139
drug
loratadine
DrugDDI.d357.s1.e2 155 159
drug
drugs
DrugDDI.d357.s1.e3 252 261
drug
loratadine

interaction DrugDDI.d357.s1.e1 DrugDDI.d357.s1.e2

Abstract Id: DrugDDI.d357
Sentence Id: DrugDDI.d357.s3
No effects on plasma concentrations of cimetidine or ketoconazole were observed.

DrugDDI.d357.s3.e0 33 42
drug
cimetidine
DrugDDI.d357.s3.e1 45 56
drug
ketoconazole



Abstract Id: DrugDDI.d357
Sentence Id: DrugDDI.d357.s4
Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.

DrugDDI.d357.s4.e0 34 45
drug
erythromycin
DrugDDI.d357.s4.e1 80 89
drug
loratadine
DrugDDI.d357.s4.e2 116 127
drug
erythromycin

interaction DrugDDI.d357.s4.e0 DrugDDI.d357.s4.e1

Abstract Id: DrugDDI.d357
Sentence Id: DrugDDI.d357.s7
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and Descarboethoxyloratadine After 10 Days of Coadministration ( Loratadine 10 mg ) in Normal Volunteers .

DrugDDI.d357.s7.e0 49 58
drug
Loratadine
DrugDDI.d357.s7.e1 116 129
drug
Loratadine 10 mg



Abstract Id: DrugDDI.d357
Sentence Id: DrugDDI.d357.s8
@ Loratadine Descarboethoxyloratadine .

DrugDDI.d357.s8.e0 1 10
drug
Loratadine



Abstract Id: DrugDDI.d357
Sentence Id: DrugDDI.d357.s12
There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine .

DrugDDI.d357.s12.e0 68 85
drug
oral contraceptives
DrugDDI.d357.s12.e1 89 98
drug
loratadine



Abstract Id: DrugDDI.d166
Sentence Id: DrugDDI.d166.s0
Tablets: The benzodiazepines , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol .

DrugDDI.d166.s0.e0 11 25
drug
benzodiazepines
DrugDDI.d166.s0.e1 36 44
drug
lorazepam
DrugDDI.d166.s0.e2 53 73
drug
CNS-depressant effects
DrugDDI.d166.s0.e3 98 108
drug
medications
DrugDDI.d166.s0.e4 111 122
drug
barbiturates
DrugDDI.d166.s0.e5 125 131
drug
alcohol

interaction DrugDDI.d166.s0.e0 DrugDDI.d166.s0.e3
interaction DrugDDI.d166.s0.e0 DrugDDI.d166.s0.e5
interaction DrugDDI.d166.s0.e1 DrugDDI.d166.s0.e4

Abstract Id: DrugDDI.d166
Sentence Id: DrugDDI.d166.s1
Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , MAO inhibitors , and other antidepressants .When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.

DrugDDI.d166.s1.e0 10 18
drug
Lorazepam
DrugDDI.d166.s1.e1 48 62
drug
benzodiazepines
DrugDDI.d166.s1.e2 127 138
drug
ethyl alcohol
DrugDDI.d166.s1.e3 140 153
drug
phenothiazines
DrugDDI.d166.s1.e4 155 166
drug
barbiturates
DrugDDI.d166.s1.e5 168 180
drug
MAO inhibitors
DrugDDI.d166.s1.e6 190 204
drug
antidepressants
DrugDDI.d166.s1.e7 210 220
drug
scopolamine
DrugDDI.d166.s1.e8 254 262
drug
lorazepam

interaction DrugDDI.d166.s1.e0 DrugDDI.d166.s1.e2
interaction DrugDDI.d166.s1.e0 DrugDDI.d166.s1.e4
interaction DrugDDI.d166.s1.e0 DrugDDI.d166.s1.e6
interaction DrugDDI.d166.s1.e1 DrugDDI.d166.s1.e3
interaction DrugDDI.d166.s1.e1 DrugDDI.d166.s1.e5
interaction DrugDDI.d166.s1.e7 DrugDDI.d166.s1.e8

Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s0
CYP3A4 Interactions .

DrugDDI.d556.s0.e0 0 5
drug
CYP3A4



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s1
Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; .

DrugDDI.d556.s1.e0 0 9
drug
Lovastatin
DrugDDI.d556.s1.e1 25 30
drug
CYP3A4
DrugDDI.d556.s1.e2 39 44
drug
CYP3A4

interaction DrugDDI.d556.s1.e0 DrugDDI.d556.s1.e1

Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s2
therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4 .

DrugDDI.d556.s2.e0 62 66
drug
drugs
DrugDDI.d556.s2.e1 80 85
drug
CYP3A4



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s3
Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of lovastatin .

DrugDDI.d556.s3.e0 18 23
drug
CYP3A4
DrugDDI.d556.s3.e1 82 91
drug
lovastatin

interaction DrugDDI.d556.s3.e0 DrugDDI.d556.s3.e1

Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s5
Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily) .

DrugDDI.d556.s5.e0 0 11
drug
Itraconazole



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s6
Interactions with lipid-lowering drugs that can cause myopathy when given alone.

DrugDDI.d556.s6.e0 16 34
drug
lipid-lowering drugs



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s7
The risk of myopathy is also increased by the following lipid-lowering drugs that are not potent CYP3A4 inhibitors, but which can cause myopathy when given alone.

DrugDDI.d556.s7.e0 46 64
drug
lipid-lowering drugs
DrugDDI.d556.s7.e1 81 86
drug
CYP3A4



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s9
Gemfibrozil Other fibrates Niacin ( nicotinic acid ) (=1 g/day) .

DrugDDI.d556.s9.e0 0 10
drug
Gemfibrozil
DrugDDI.d556.s9.e1 31 43
drug
nicotinic acid



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s11
Danazol : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).

DrugDDI.d556.s11.e0 0 6
drug
Danazol
DrugDDI.d556.s11.e1 80 86
drug
danazol
DrugDDI.d556.s11.e2 116 125
drug
lovastatin

interaction DrugDDI.d556.s11.e1 DrugDDI.d556.s11.e2

Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s12
Amiodarone or Verapamil : The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).

DrugDDI.d556.s12.e0 0 9
drug
Amiodarone
DrugDDI.d556.s12.e1 12 20
drug
Verapamil
DrugDDI.d556.s12.e2 75 84
drug
amiodarone
DrugDDI.d556.s12.e3 87 95
drug
verapamil
DrugDDI.d556.s12.e4 145 169
drug
HMG-CoA reductase inhibitor

interaction DrugDDI.d556.s12.e2 DrugDDI.d556.s12.e4

Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s13
Coumarin Anticoagulant s: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.

DrugDDI.d556.s13.e0 0 20
drug
Coumarin Anticoagulant
DrugDDI.d556.s13.e1 51 60
drug
lovastatin
DrugDDI.d556.s13.e2 78 85
drug
warfarin



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s14
However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin .

DrugDDI.d556.s14.e0 15 39
drug
HMG-CoA reductase inhibitor
DrugDDI.d556.s14.e1 143 150
drug
warfarin

interaction DrugDDI.d556.s14.e0 DrugDDI.d556.s14.e1

Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s15
Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulant s concomitantly with lovastatin .

DrugDDI.d556.s15.e0 79 99
drug
coumarin anticoagulant
DrugDDI.d556.s15.e1 118 127
drug
lovastatin

interaction DrugDDI.d556.s15.e0 DrugDDI.d556.s15.e1

Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s16
It is recommended that in patients taking anticoagulants , prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.

DrugDDI.d556.s16.e0 35 48
drug
anticoagulants
DrugDDI.d556.s16.e1 91 100
drug
lovastatin



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s17
Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulant s.

DrugDDI.d556.s17.e0 119 139
drug
coumarin anticoagulant



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s18
If the dose of lovastatin is changed, the same procedure should be repeated.

DrugDDI.d556.s18.e0 11 20
drug
lovastatin



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s19
Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants .

DrugDDI.d556.s19.e0 0 9
drug
Lovastatin
DrugDDI.d556.s19.e1 98 111
drug
anticoagulants



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s20
Propranolol : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol .

DrugDDI.d556.s20.e0 0 10
drug
Propranolol
DrugDDI.d556.s20.e1 149 158
drug
lovastatin
DrugDDI.d556.s20.e2 162 172
drug
propranolol



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s21
Digoxin : In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.

DrugDDI.d556.s21.e0 0 6
drug
Digoxin
DrugDDI.d556.s21.e1 70 79
drug
lovastatin
DrugDDI.d556.s21.e2 83 89
drug
digoxin
DrugDDI.d556.s21.e3 110 116
drug
digoxin



Abstract Id: DrugDDI.d556
Sentence Id: DrugDDI.d556.s22
Oral Hypoglycemic Agents : In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide .

DrugDDI.d556.s22.e0 4 21
drug
Hypoglycemic Agents
DrugDDI.d556.s22.e1 49 55
drug
MEVACOR
DrugDDI.d556.s22.e2 143 151
drug
glipizide
DrugDDI.d556.s22.e3 158 171
drug
chlorpropamide



Abstract Id: DrugDDI.d510
Sentence Id: DrugDDI.d510.s0
There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam .

DrugDDI.d510.s0.e0 105 112
drug
loxapine
DrugDDI.d510.s0.e1 116 124
drug
lorazepam

interaction DrugDDI.d510.s0.e0 DrugDDI.d510.s0.e1

Abstract Id: DrugDDI.d510
Sentence Id: DrugDDI.d510.s1
The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated.

DrugDDI.d510.s1.e0 14 21
drug
loxapine
DrugDDI.d510.s1.e1 39 53
drug
CNS-active drugs

interaction DrugDDI.d510.s1.e0 DrugDDI.d510.s1.e1

Abstract Id: DrugDDI.d510
Sentence Id: DrugDDI.d510.s2
Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.

DrugDDI.d510.s2.e0 58 65
drug
loxapine
DrugDDI.d510.s2.e1 69 83
drug
CNS-active drugs

interaction DrugDDI.d510.s2.e0 DrugDDI.d510.s2.e1

Abstract Id: DrugDDI.d276
Sentence Id: DrugDDI.d276.s0
The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies , iron or zinc supplement s.

DrugDDI.d276.s0.e0 15 25
drug
lymecycline
DrugDDI.d276.s0.e1 83 90
drug
remedies
DrugDDI.d276.s0.e2 92 95
drug
iron
DrugDDI.d276.s0.e3 98 111
drug
zinc supplement

interaction DrugDDI.d276.s0.e0 DrugDDI.d276.s0.e1
interaction DrugDDI.d276.s0.e0 DrugDDI.d276.s0.e3

Abstract Id: DrugDDI.d276
Sentence Id: DrugDDI.d276.s1
Oral contraceptives may be less effective while you are taking lymecycline .

DrugDDI.d276.s1.e0 0 17
drug
Oral contraceptives
DrugDDI.d276.s1.e1 53 63
drug
lymecycline

interaction DrugDDI.d276.s1.e0 DrugDDI.d276.s1.e1

Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s0
Warfarin Meclofenamate sodium enhances the effect of warfarin .

DrugDDI.d197.s0.e0 8 26
drug
Meclofenamate sodium
DrugDDI.d197.s0.e1 46 53
drug
warfarin

interaction DrugDDI.d197.s0.e0 DrugDDI.d197.s0.e1

Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s1
Therefore, when meclofenamate sodium is given to a patient receiving warfarin , the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.

DrugDDI.d197.s1.e0 14 32
drug
meclofenamate sodium
DrugDDI.d197.s1.e1 59 66
drug
warfarin
DrugDDI.d197.s1.e2 79 86
drug
warfarin
DrugDDI.d197.s1.e3 104 110
drug
prevent

interaction DrugDDI.d197.s1.e0 DrugDDI.d197.s1.e1

Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s2
Aspirin Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein -binding sites.

DrugDDI.d197.s2.e0 0 6
drug
Aspirin
DrugDDI.d197.s2.e1 33 39
drug
aspirin
DrugDDI.d197.s2.e2 48 66
drug
meclofenamate sodium
DrugDDI.d197.s2.e3 102 108
drug
protein

interaction DrugDDI.d197.s2.e0 DrugDDI.d197.s2.e2

Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s3
The urinary excretion of meclofenamate sodium is unaffected by aspirin , indicating no change in meclofenamate sodium absorption.

DrugDDI.d197.s3.e0 21 39
drug
meclofenamate sodium
DrugDDI.d197.s3.e1 54 60
drug
aspirin
DrugDDI.d197.s3.e2 82 100
drug
meclofenamate sodium



Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s4
Meclofenamate sodium does not affect serum salicylate levels.

DrugDDI.d197.s4.e0 0 18
drug
Meclofenamate sodium



Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s5
Greater fecal blood loss results from concomitant administration of both drugs than from either drug alone.

DrugDDI.d197.s5.e0 63 67
drug
drugs
DrugDDI.d197.s5.e1 82 85
drug
drug



Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s6
Propoxyphene The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of meclofenamate sodium .

DrugDDI.d197.s6.e0 0 11
drug
Propoxyphene
DrugDDI.d197.s6.e1 41 65
drug
propoxyphene hydrochloride
DrugDDI.d197.s6.e2 99 117
drug
meclofenamate sodium



Abstract Id: DrugDDI.d197
Sentence Id: DrugDDI.d197.s7
Antacids Concomitant administration of aluminum and magnesium hydroxide s does not interfere with absorption of meclofenamate sodium .

DrugDDI.d197.s7.e0 0 7
drug
Antacids
DrugDDI.d197.s7.e1 46 63
drug
magnesium hydroxide
DrugDDI.d197.s7.e2 97 115
drug
meclofenamate sodium



Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s0
Aspirin : As with other NSAIDs , concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.

DrugDDI.d359.s0.e0 0 6
drug
Aspirin
DrugDDI.d359.s0.e1 19 24
drug
NSAIDs
DrugDDI.d359.s0.e2 53 59
drug
Ponstel
DrugDDI.d359.s0.e3 63 69
drug
aspirin

interaction DrugDDI.d359.s0.e1 DrugDDI.d359.s0.e3
interaction DrugDDI.d359.s0.e2 DrugDDI.d359.s0.e3

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s1
Methotrexate : NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.

DrugDDI.d359.s1.e0 0 11
drug
Methotrexate
DrugDDI.d359.s1.e1 13 18
drug
NSAIDs
DrugDDI.d359.s1.e2 57 68
drug
methotrexate

interaction DrugDDI.d359.s1.e1 DrugDDI.d359.s1.e2

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s2
This may indicate that they could enhance the toxicity of methotrexate .

DrugDDI.d359.s2.e0 48 59
drug
methotrexate



Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s3
Caution should be used when NSAIDs are administered concomitantly with methotrexate .

DrugDDI.d359.s3.e0 23 28
drug
NSAIDs
DrugDDI.d359.s3.e1 61 72
drug
methotrexate

interaction DrugDDI.d359.s3.e0 DrugDDI.d359.s3.e1

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s4
ACE inhibitors : Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors .

DrugDDI.d359.s4.e0 0 12
drug
ACE inhibitors
DrugDDI.d359.s4.e1 32 37
drug
NSAIDs
DrugDDI.d359.s4.e2 52 67
drug
antihypertensive
DrugDDI.d359.s4.e3 76 88
drug
ACE inhibitors

interaction DrugDDI.d359.s4.e1 DrugDDI.d359.s4.e3

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s5
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors .

DrugDDI.d359.s5.e0 57 62
drug
NSAIDs
DrugDDI.d359.s5.e1 80 92
drug
ACE inhibitors

interaction DrugDDI.d359.s5.e0 DrugDDI.d359.s5.e1

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s6
Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.

DrugDDI.d359.s6.e0 0 9
drug
Furosemide
DrugDDI.d359.s6.e1 75 80
drug
NSAIDs
DrugDDI.d359.s6.e2 93 103
drug
natriuretic
DrugDDI.d359.s6.e3 112 121
drug
furosemide
DrugDDI.d359.s6.e4 125 133
drug
thiazides

interaction DrugDDI.d359.s6.e1 DrugDDI.d359.s6.e3
interaction DrugDDI.d359.s6.e1 DrugDDI.d359.s6.e4

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s7
This response has been attributed to inhibition of renal prostaglandin synthesis.

DrugDDI.d359.s7.e0 48 60
drug
prostaglandin



Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s8
During concomitant therapy of Ponstel with furosemide , the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.

DrugDDI.d359.s8.e0 26 32
drug
Ponstel
DrugDDI.d359.s8.e1 37 46
drug
furosemide
DrugDDI.d359.s8.e2 120 127
drug
diuretic

interaction DrugDDI.d359.s8.e0 DrugDDI.d359.s8.e1

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s9
Lithium : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.

DrugDDI.d359.s9.e0 0 6
drug
Lithium
DrugDDI.d359.s9.e1 8 13
drug
NSAIDs
DrugDDI.d359.s9.e2 78 84
drug
lithium

interaction DrugDDI.d359.s9.e1 DrugDDI.d359.s9.e2

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s10
The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.

DrugDDI.d359.s10.e0 14 20
drug
lithium



Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s11
These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID .

DrugDDI.d359.s11.e0 49 61
drug
prostaglandin
DrugDDI.d359.s11.e1 76 80
drug
NSAID

interaction DrugDDI.d359.s11.e0 DrugDDI.d359.s11.e1

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s12
Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

DrugDDI.d359.s12.e0 9 14
drug
NSAIDs
DrugDDI.d359.s12.e1 18 24
drug
lithium

interaction DrugDDI.d359.s12.e0 DrugDDI.d359.s12.e1

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s13
Warfarin : The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.

DrugDDI.d359.s13.e0 0 7
drug
Warfarin
DrugDDI.d359.s13.e1 21 28
drug
warfarin
DrugDDI.d359.s13.e2 32 37
drug
NSAIDs
DrugDDI.d359.s13.e3 84 88
drug
drugs
DrugDDI.d359.s13.e4 148 151
drug
drug

interaction DrugDDI.d359.s13.e1 DrugDDI.d359.s13.e2

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s14
Antacids : In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.@ A number of compounds are inhibitors of CYP2C9 including fluconazole , lovastatin and trimethoprim .

DrugDDI.d359.s14.e0 0 7
drug
Antacids
DrugDDI.d359.s14.e1 46 52
drug
antacid
DrugDDI.d359.s14.e2 73 90
drug
magnesium hydroxide
DrugDDI.d359.s14.e3 103 115
drug
mefenamic acid
DrugDDI.d359.s14.e4 140 152
drug
mefenamic acid
DrugDDI.d359.s14.e5 213 218
drug
CYP2C9
DrugDDI.d359.s14.e6 228 238
drug
fluconazole
DrugDDI.d359.s14.e7 240 249
drug
lovastatin
DrugDDI.d359.s14.e8 253 264
drug
trimethoprim

interaction DrugDDI.d359.s14.e1 DrugDDI.d359.s14.e3
interaction DrugDDI.d359.s14.e2 DrugDDI.d359.s14.e3

Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s15
Drug interaction studies of mefenamic acid and these compounds have not been conducted.

DrugDDI.d359.s15.e0 24 36
drug
mefenamic acid



Abstract Id: DrugDDI.d359
Sentence Id: DrugDDI.d359.s16
The possibility of altered safety and efficacy should be considered when Ponstel is used concomitantly with these drugs .

DrugDDI.d359.s16.e0 62 68
drug
Ponstel
DrugDDI.d359.s16.e1 97 101
drug
drugs

interaction DrugDDI.d359.s16.e0 DrugDDI.d359.s16.e1

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s0
Drug-drug interactions with Mefloquine have not been explored in detail.

DrugDDI.d520.s0.e0 25 34
drug
Mefloquine



Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s1
There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker ( propranolol ).

DrugDDI.d520.s1.e0 80 90
drug
beta blocker
DrugDDI.d520.s1.e1 92 102
drug
propranolol



Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s3
The benefits of Mefloquine therapy should be weighed against the possibility of adverse effects in patients with cardiac disease.

DrugDDI.d520.s3.e0 13 22
drug
Mefloquine



Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s4
Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine .

DrugDDI.d520.s4.e0 66 77
drug
halofantrine
DrugDDI.d520.s4.e1 124 133
drug
Mefloquine

interaction DrugDDI.d520.s4.e0 DrugDDI.d520.s4.e1

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s5
Concomitant administration of Mefloquine and other related compounds (eg, quinine , quinidine and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions.

DrugDDI.d520.s5.e0 27 36
drug
Mefloquine
DrugDDI.d520.s5.e1 45 60
drug
related compounds
DrugDDI.d520.s5.e2 65 71
drug
quinine
DrugDDI.d520.s5.e3 73 81
drug
quinidine
DrugDDI.d520.s5.e4 85 95
drug
chloroquine

interaction DrugDDI.d520.s5.e0 DrugDDI.d520.s5.e1
interaction DrugDDI.d520.s5.e0 DrugDDI.d520.s5.e2
interaction DrugDDI.d520.s5.e0 DrugDDI.d520.s5.e3
interaction DrugDDI.d520.s5.e0 DrugDDI.d520.s5.e4

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s6
If these drugs are to be used in the initial treatment of severe malaria , Mefloquine administration should be delayed at least 12 hours after the last dose.

DrugDDI.d520.s6.e0 7 11
drug
drugs
DrugDDI.d520.s6.e1 52 58
drug
malaria
DrugDDI.d520.s6.e2 60 69
drug
Mefloquine

interaction DrugDDI.d520.s6.e0 DrugDDI.d520.s6.e2

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s7
There is evidence that the use of halofantrine after Mefloquineuine causes a significant lengthening of the QTc interval.

DrugDDI.d520.s7.e0 27 38
drug
halofantrine



Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s9
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents , calcium channel blockers , antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval.

DrugDDI.d520.s9.e0 65 74
drug
Mefloquine
DrugDDI.d520.s9.e1 121 125
drug
drugs
DrugDDI.d520.s9.e2 159 173
drug
anti-arrhythmic
DrugDDI.d520.s9.e3 176 204
drug
beta-adrenergic blocking agents
DrugDDI.d520.s9.e4 206 227
drug
calcium channel blockers
DrugDDI.d520.s9.e5 229 242
drug
antihistamines
DrugDDI.d520.s9.e6 263 286
drug
tricyclic antidepressants
DrugDDI.d520.s9.e7 290 303
drug
phenothiazines

interaction DrugDDI.d520.s9.e0 DrugDDI.d520.s9.e1
interaction DrugDDI.d520.s9.e0 DrugDDI.d520.s9.e2
interaction DrugDDI.d520.s9.e0 DrugDDI.d520.s9.e3
interaction DrugDDI.d520.s9.e0 DrugDDI.d520.s9.e4
interaction DrugDDI.d520.s9.e0 DrugDDI.d520.s9.e5
interaction DrugDDI.d520.s9.e0 DrugDDI.d520.s9.e6
interaction DrugDDI.d520.s9.e0 DrugDDI.d520.s9.e7

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s11
In patients taking an anticonvulsant (eg, valproic acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant .

DrugDDI.d520.s11.e0 18 31
drug
anticonvulsant
DrugDDI.d520.s11.e1 36 47
drug
valproic acid
DrugDDI.d520.s11.e2 49 61
drug
carbamazepine
DrugDDI.d520.s11.e3 63 75
drug
phenobarbital
DrugDDI.d520.s11.e4 78 86
drug
phenytoin
DrugDDI.d520.s11.e5 108 117
drug
Mefloquine
DrugDDI.d520.s11.e6 171 184
drug
anticonvulsant

interaction DrugDDI.d520.s11.e0 DrugDDI.d520.s11.e5
interaction DrugDDI.d520.s11.e1 DrugDDI.d520.s11.e5
interaction DrugDDI.d520.s11.e2 DrugDDI.d520.s11.e5
interaction DrugDDI.d520.s11.e3 DrugDDI.d520.s11.e5
interaction DrugDDI.d520.s11.e4 DrugDDI.d520.s11.e5

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s12
Therefore, patients concurrently taking antiseizure medication and Mefloquine should have the blood level of their antiseizure medication monitored and the dosage adjusted appropriately.

DrugDDI.d520.s12.e0 36 56
drug
antiseizure medication
DrugDDI.d520.s12.e1 60 69
drug
Mefloquine
DrugDDI.d520.s12.e2 100 120
drug
antiseizure medication

interaction DrugDDI.d520.s12.e0 DrugDDI.d520.s12.e1

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s13
When Mefloquine is taken concurrently with oral live typhoid vaccines , attenuation of immunization cannot be excluded.

DrugDDI.d520.s13.e0 4 13
drug
Mefloquine
DrugDDI.d520.s13.e1 37 59
drug
oral live typhoid vaccines

interaction DrugDDI.d520.s13.e0 DrugDDI.d520.s13.e1

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s14
Vaccinations with attenuated live bacteria should therefore be completed at least 3 days before the first dose of Mefloquine .

DrugDDI.d520.s14.e0 96 105
drug
Mefloquine



Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s16
Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants , should be checked before departure.

DrugDDI.d520.s16.e0 25 34
drug
Mefloquine
DrugDDI.d520.s16.e1 104 117
drug
anticoagulants

interaction DrugDDI.d520.s16.e0 DrugDDI.d520.s16.e1

Abstract Id: DrugDDI.d520
Sentence Id: DrugDDI.d520.s17
In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile.

DrugDDI.d520.s17.e0 47 57
drug
sulfadoxine
DrugDDI.d520.s17.e1 61 73
drug
pyrimethamine



Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s0
Broad-Spectrum Antibiotics-Broad-spectrum antibiotics may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.

DrugDDI.d2.s0.e0 85 92
drug
vitamin K



Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s1
Cephalosporins -Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia.

DrugDDI.d2.s1.e0 0 13
drug
Cephalosporins
DrugDDI.d2.s1.e1 73 83
drug
cefmenoxime
DrugDDI.d2.s1.e2 85 96
drug
cefoperazone
DrugDDI.d2.s1.e3 98 106
drug
cefotetan
DrugDDI.d2.s1.e4 108 118
drug
cefamandole
DrugDDI.d2.s1.e5 120 128
drug
latamoxef
DrugDDI.d2.s1.e6 150 158
drug
cefazolin



Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s2
These cephalosporins are inhibitors of hepatic vitamin K epoxide reductase .

DrugDDI.d2.s2.e0 5 18
drug
cephalosporins
DrugDDI.d2.s2.e1 41 64
drug
vitamin K epoxide reductase

interaction DrugDDI.d2.s2.e0 DrugDDI.d2.s2.e1

Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s3
Cholestyramine -Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K .

DrugDDI.d2.s3.e0 0 13
drug
Cholestyramine
DrugDDI.d2.s3.e1 34 47
drug
cholestyramine
DrugDDI.d2.s3.e2 51 58
drug
vitamin K
DrugDDI.d2.s3.e3 83 90
drug
vitamin K

interaction DrugDDI.d2.s3.e1 DrugDDI.d2.s3.e2

Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s4
Colestipol -Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K .

DrugDDI.d2.s4.e0 0 9
drug
Colestipol
DrugDDI.d2.s4.e1 30 39
drug
colestipol
DrugDDI.d2.s4.e2 43 50
drug
vitamin K
DrugDDI.d2.s4.e3 75 82
drug
vitamin K

interaction DrugDDI.d2.s4.e1 DrugDDI.d2.s4.e2

Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s5
Mineral Oil -Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K .

DrugDDI.d2.s5.e0 0 9
drug
Mineral Oil
DrugDDI.d2.s5.e1 30 39
drug
mineral oil
DrugDDI.d2.s5.e2 43 50
drug
vitamin K
DrugDDI.d2.s5.e3 75 82
drug
vitamin K

interaction DrugDDI.d2.s5.e1 DrugDDI.d2.s5.e2

Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s6
Orlistat -Orlistat may decrease the absorption of vitamin K .

DrugDDI.d2.s6.e0 0 7
drug
Orlistat
DrugDDI.d2.s6.e1 43 50
drug
vitamin K

interaction DrugDDI.d2.s6.e0 DrugDDI.d2.s6.e1

Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s7
Salicylates -Salicylates in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.

DrugDDI.d2.s7.e0 0 10
drug
Salicylates
DrugDDI.d2.s7.e1 45 68
drug
vitamin K epoxide reductase

interaction DrugDDI.d2.s7.e0 DrugDDI.d2.s7.e1

Abstract Id: DrugDDI.d2
Sentence Id: DrugDDI.d2.s8
Warfarin- Vitamin K can antagonize the effect of warfarin .

DrugDDI.d2.s8.e0 9 16
drug
Vitamin K
DrugDDI.d2.s8.e1 41 48
drug
warfarin

interaction DrugDDI.d2.s8.e0 DrugDDI.d2.s8.e1

Abstract Id: DrugDDI.d267
Sentence Id: DrugDDI.d267.s0
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants , including alcohol , barbiturates and narcotic analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).

DrugDDI.d267.s0.e0 0 7
drug
Nabilone
DrugDDI.d267.s0.e1 66 82
drug
psychoactive drugs
DrugDDI.d267.s0.e2 85 98
drug
CNS depressants
DrugDDI.d267.s0.e3 109 115
drug
alcohol
DrugDDI.d267.s0.e4 117 128
drug
barbiturates
DrugDDI.d267.s0.e5 132 149
drug
narcotic analgesics

interaction DrugDDI.d267.s0.e0 DrugDDI.d267.s0.e1
interaction DrugDDI.d267.s0.e0 DrugDDI.d267.s0.e3
interaction DrugDDI.d267.s0.e0 DrugDDI.d267.s0.e5

Abstract Id: DrugDDI.d267
Sentence Id: DrugDDI.d267.s1
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam , secobarbitone sodium , alcohol or codeine .

DrugDDI.d267.s1.e0 0 7
drug
Nabilone
DrugDDI.d267.s1.e1 36 48
drug
CNS depressant
DrugDDI.d267.s1.e2 74 81
drug
diazepam
DrugDDI.d267.s1.e3 96 101
drug
sodium
DrugDDI.d267.s1.e4 103 109
drug
alcohol
DrugDDI.d267.s1.e5 112 118
drug
codeine

interaction DrugDDI.d267.s1.e0 DrugDDI.d267.s1.e2
interaction DrugDDI.d267.s1.e0 DrugDDI.d267.s1.e4

Abstract Id: DrugDDI.d329
Sentence Id: DrugDDI.d329.s0
In vitro studies have shown that, because of its affinity for protein , 6MNA may displace other protein -bound drugs from their binding site.

DrugDDI.d329.s0.e0 51 57
drug
protein
DrugDDI.d329.s0.e1 59 62
drug
6MNA
DrugDDI.d329.s0.e2 79 85
drug
protein

interaction DrugDDI.d329.s0.e1 DrugDDI.d329.s0.e2

Abstract Id: DrugDDI.d329
Sentence Id: DrugDDI.d329.s1
Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs .

DrugDDI.d329.s1.e0 41 50
drug
nabumetone
DrugDDI.d329.s1.e1 55 62
drug
warfarin
DrugDDI.d329.s1.e2 101 106
drug
NSAIDs

interaction DrugDDI.d329.s1.e0 DrugDDI.d329.s1.e1

Abstract Id: DrugDDI.d329
Sentence Id: DrugDDI.d329.s2
Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA .

DrugDDI.d329.s2.e0 29 54
drug
aluminum-containing antacid
DrugDDI.d329.s2.e1 99 102
drug
6MNA



Abstract Id: DrugDDI.d329
Sentence Id: DrugDDI.d329.s4
however, the total amount of 6MNA in the plasma is unchanged .

DrugDDI.d329.s4.e0 24 27
drug
6MNA



Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s0
No pharmacokinetic-based drug-drug interaction studies have been conducted with SYNAREL .

DrugDDI.d354.s0.e0 71 77
drug
SYNAREL



Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s1
However, because nafarelin acetate is a peptide that is primarily degraded by peptidase and not by cytochrome P-450 enzymes, and the drug is only about 80% bound to plasma proteins at 4@C, drug interactions would not be expected to occur.

DrugDDI.d354.s1.e0 15 30
drug
nafarelin acetate
DrugDDI.d354.s1.e1 34 40
drug
peptide
DrugDDI.d354.s1.e2 66 74
drug
peptidase
DrugDDI.d354.s1.e3 83 97
drug
cytochrome P-450
DrugDDI.d354.s1.e4 112 115
drug
drug
DrugDDI.d354.s1.e5 137 150
drug
plasma proteins



Abstract Id: DrugDDI.d179
Sentence Id: DrugDDI.d179.s0
Tetracycline , a bacteriostat ic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.

DrugDDI.d179.s0.e0 0 11
drug
Tetracycline
DrugDDI.d179.s0.e1 14 25
drug
bacteriostat
DrugDDI.d179.s0.e2 75 84
drug
penicillin
DrugDDI.d179.s0.e3 108 112
drug
drugs

interaction DrugDDI.d179.s0.e0 DrugDDI.d179.s0.e2

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s0
Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.

DrugDDI.d334.s0.e0 44 48
drug
REVIA
DrugDDI.d334.s0.e1 52 56
drug
drugs
DrugDDI.d334.s0.e2 66 72
drug
opiates



Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s1
Consequently, caution is advised if the concomitant administration of REVIA and other drugs is required.

DrugDDI.d334.s1.e0 61 65
drug
REVIA
DrugDDI.d334.s1.e1 74 78
drug
drugs



Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s2
The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.

DrugDDI.d334.s2.e0 38 42
drug
REVIA
DrugDDI.d334.s2.e1 46 55
drug
disulfiram
DrugDDI.d334.s2.e2 113 123
drug
medications

interaction DrugDDI.d334.s2.e0 DrugDDI.d334.s2.e1

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s3
Lethargy and somnolence have been reported following doses of REVIA and thioridazine .

DrugDDI.d334.s3.e0 53 57
drug
REVIA
DrugDDI.d334.s3.e1 61 72
drug
thioridazine

interaction DrugDDI.d334.s3.e0 DrugDDI.d334.s3.e1

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s4
Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics .

DrugDDI.d334.s4.e0 14 18
drug
REVIA
DrugDDI.d334.s4.e1 36 41
drug
opioid
DrugDDI.d334.s4.e2 122 137
drug
opioid analgesics



Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s5
In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA , the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.

DrugDDI.d334.s5.e0 26 31
drug
opioid
DrugDDI.d334.s5.e1 78 82
drug
REVIA
DrugDDI.d334.s5.e2 95 100
drug
opioid

interaction DrugDDI.d334.s5.e0 DrugDDI.d334.s5.e1

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s0
The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.

DrugDDI.d500.s0.e0 8 13
drug
NSAIDs
DrugDDI.d500.s0.e1 39 51
drug
ACE inhibitors

interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e1

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s1
In vitro studies have shown that naproxen anion, because of its affinity for protein , may displace from their binding sites other drugs which are also albumin -bound .

DrugDDI.d500.s1.e0 27 34
drug
naproxen
DrugDDI.d500.s1.e1 64 70
drug
protein
DrugDDI.d500.s1.e2 109 113
drug
drugs
DrugDDI.d500.s1.e3 126 132
drug
albumin



Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s2
Theoretically, the naproxen anion itself could likewise be displaced.

DrugDDI.d500.s2.e0 17 24
drug
naproxen



Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s3
Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants .

DrugDDI.d500.s3.e0 52 55
drug
drug
DrugDDI.d500.s3.e1 123 149
drug
coumarin-type anticoagulants



Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s5
Similarly, patients receiving the drug and a hydantoin , sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs .

DrugDDI.d500.s5.e0 30 33
drug
drug
DrugDDI.d500.s5.e1 38 46
drug
hydantoin
DrugDDI.d500.s5.e2 48 58
drug
sulfonamide
DrugDDI.d500.s5.e3 61 72
drug
sulfonylurea
DrugDDI.d500.s5.e4 114 118
drug
drugs

interaction DrugDDI.d500.s5.e0 DrugDDI.d500.s5.e1
interaction DrugDDI.d500.s5.e0 DrugDDI.d500.s5.e3

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s6
Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations and peak plasma levels.

DrugDDI.d500.s6.e0 27 34
drug
naproxen
DrugDDI.d500.s6.e1 38 44
drug
aspirin
DrugDDI.d500.s6.e2 68 75
drug
naproxen
DrugDDI.d500.s6.e3 142 148
drug
aspirin

interaction DrugDDI.d500.s6.e0 DrugDDI.d500.s6.e1

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s7
The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class.

DrugDDI.d500.s7.e0 3 13
drug
natriuretic
DrugDDI.d500.s7.e1 22 31
drug
furosemide
DrugDDI.d500.s7.e2 66 70
drug
drugs

interaction DrugDDI.d500.s7.e0 DrugDDI.d500.s7.e1

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s8
Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.

DrugDDI.d500.s8.e0 17 23
drug
lithium
DrugDDI.d500.s8.e1 59 65
drug
lithium

interaction DrugDDI.d500.s8.e0 DrugDDI.d500.s8.e1

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s9
Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers .

DrugDDI.d500.s9.e0 0 7
drug
Naproxen
DrugDDI.d500.s9.e1 16 21
drug
NSAIDs
DrugDDI.d500.s9.e2 34 49
drug
antihypertensive
DrugDDI.d500.s9.e3 58 68
drug
propranolol
DrugDDI.d500.s9.e4 77 89
drug
beta-blockers

interaction DrugDDI.d500.s9.e0 DrugDDI.d500.s9.e3
interaction DrugDDI.d500.s9.e1 DrugDDI.d500.s9.e3

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s10
Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.

DrugDDI.d500.s10.e0 0 9
drug
Probenecid
DrugDDI.d500.s10.e1 36 43
drug
naproxen

interaction DrugDDI.d500.s10.e0 DrugDDI.d500.s10.e1

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s11
Caution should be used if naproxen is administered concomitantly with methotrexate .

DrugDDI.d500.s11.e0 21 28
drug
naproxen
DrugDDI.d500.s11.e1 60 71
drug
methotrexate



Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s12
Naproxen , naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate .

DrugDDI.d500.s12.e0 0 7
drug
Naproxen
DrugDDI.d500.s12.e1 9 22
drug
naproxen sodium
DrugDDI.d500.s12.e2 31 36
drug
NSAIDs
DrugDDI.d500.s12.e3 82 93
drug
methotrexate
DrugDDI.d500.s12.e4 141 152
drug
methotrexate

interaction DrugDDI.d500.s12.e0 DrugDDI.d500.s12.e3
interaction DrugDDI.d500.s12.e2 DrugDDI.d500.s12.e3

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s13
Drug /Laboratory Test Interactions Naproxen may decrease platelet aggregation and prolong bleeding time.

DrugDDI.d500.s13.e0 0 3
drug
Drug
DrugDDI.d500.s13.e1 31 38
drug
Naproxen



Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s15
The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay.

DrugDDI.d500.s15.e0 19 26
drug
naproxen
DrugDDI.d500.s15.e1 115 118
drug
drug
DrugDDI.d500.s15.e2 128 138
drug
metabolites

interaction DrugDDI.d500.s15.e1 DrugDDI.d500.s15.e2

Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s16
Although 17-hydroxy- corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.

DrugDDI.d500.s16.e0 19 32
drug
corticosteroid
DrugDDI.d500.s16.e1 128 135
drug
naproxen
DrugDDI.d500.s16.e2 174 180
drug
adrenal



Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s17
Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).

DrugDDI.d500.s17.e0 0 7
drug
Naproxen



Abstract Id: DrugDDI.d573
Sentence Id: DrugDDI.d573.s0
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.

DrugDDI.d573.s0.e0 16 20
drug
drugs



Abstract Id: DrugDDI.d573
Sentence Id: DrugDDI.d573.s1
Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type medications (like dihydroergotamine or methysergide ) and naratriptan within 24 hours is contraindicated.

DrugDDI.d573.s1.e0 66 75
drug
ergotamine
DrugDDI.d573.s1.e1 99 109
drug
medications
DrugDDI.d573.s1.e2 115 131
drug
dihydroergotamine
DrugDDI.d573.s1.e3 134 145
drug
methysergide
DrugDDI.d573.s1.e4 150 160
drug
naratriptan

interaction DrugDDI.d573.s1.e0 DrugDDI.d573.s1.e4
interaction DrugDDI.d573.s1.e2 DrugDDI.d573.s1.e4

Abstract Id: DrugDDI.d573
Sentence Id: DrugDDI.d573.s2
The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.

DrugDDI.d573.s2.e0 19 29
drug
naratriptan
DrugDDI.d573.s2.e1 44 51
drug
agonists



Abstract Id: DrugDDI.d573
Sentence Id: DrugDDI.d573.s3
Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.

DrugDDI.d573.s3.e0 62 72
drug
naratriptan
DrugDDI.d573.s3.e1 86 93
drug
agonists

interaction DrugDDI.d573.s3.e0 DrugDDI.d573.s3.e1

Abstract Id: DrugDDI.d573
Sentence Id: DrugDDI.d573.s4
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists .

DrugDDI.d573.s4.e0 9 35
drug
serotonin reuptake inhibitors
DrugDDI.d573.s4.e1 49 58
drug
fluoxetine
DrugDDI.d573.s4.e2 60 70
drug
fluvoxamine
DrugDDI.d573.s4.e3 72 81
drug
paroxetine
DrugDDI.d573.s4.e4 83 92
drug
sertraline
DrugDDI.d573.s4.e5 192 199
drug
agonists

interaction DrugDDI.d573.s4.e0 DrugDDI.d573.s4.e5
interaction DrugDDI.d573.s4.e2 DrugDDI.d573.s4.e5
interaction DrugDDI.d573.s4.e4 DrugDDI.d573.s4.e5

Abstract Id: DrugDDI.d573
Sentence Id: DrugDDI.d573.s5
If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.

DrugDDI.d573.s5.e0 26 36
drug
naratriptan



Abstract Id: DrugDDI.d573
Sentence Id: DrugDDI.d573.s6
Drug / Laboratory Test Interactions AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests.

DrugDDI.d573.s6.e0 0 3
drug
Drug
DrugDDI.d573.s6.e1 31 36
drug
AMERGE



Abstract Id: DrugDDI.d274
Sentence Id: DrugDDI.d274.s0
After multiple dosing, interferon beta-1a (AVONEX@ 30 mcg IM once weekly) reduced TYSABRI@ clearance by approximately 30%.

DrugDDI.d274.s0.e0 20 36
drug
interferon beta-1a



Abstract Id: DrugDDI.d274
Sentence Id: DrugDDI.d274.s2
Results of studies in multiple sclerosis patients taking TYSABRI@ and concomitant interferon beta-1a (AVONEX@ 30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate .

DrugDDI.d274.s2.e0 71 87
drug
interferon beta-1a
DrugDDI.d274.s2.e1 116 132
drug
glatiramer acetate
DrugDDI.d274.s2.e2 190 204
drug
beta-interferon
DrugDDI.d274.s2.e3 207 223
drug
glatiramer acetate



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s0
Nelfinavir is an inhibitor of CYP3A ( cytochrome P450 3A ).

DrugDDI.d400.s0.e0 0 9
drug
Nelfinavir
DrugDDI.d400.s0.e1 25 29
drug
CYP3A
DrugDDI.d400.s0.e2 31 46
drug
cytochrome P450 3A



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s1
Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers ) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.

DrugDDI.d400.s1.e0 18 25
drug
VIRACEPT
DrugDDI.d400.s1.e1 29 33
drug
drugs
DrugDDI.d400.s1.e2 56 60
drug
CYP3A
DrugDDI.d400.s1.e3 82 103
drug
calcium channel blockers
DrugDDI.d400.s1.e4 155 158
drug
drug



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s2
Nelfinavir is metabolized in proof by C.P.A.

DrugDDI.d400.s2.e0 0 9
drug
Nelfinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s3
Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.

DrugDDI.d400.s3.e0 18 25
drug
VIRACEPT
DrugDDI.d400.s3.e1 29 33
drug
drugs
DrugDDI.d400.s3.e2 44 48
drug
CYP3A
DrugDDI.d400.s3.e3 60 69
drug
nelfinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s4
Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.

DrugDDI.d400.s4.e0 18 25
drug
VIRACEPT
DrugDDI.d400.s4.e1 29 33
drug
drugs
DrugDDI.d400.s4.e2 45 49
drug
CYP3A
DrugDDI.d400.s4.e3 61 70
drug
nelfinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s5
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone , trimethoprim / sulfamethoxazole , clarithromycin , erythromycin , itraconazole or fluconazole .

DrugDDI.d400.s5.e0 88 95
drug
VIRACEPT
DrugDDI.d400.s5.e1 99 105
drug
dapsone
DrugDDI.d400.s5.e2 107 118
drug
trimethoprim
DrugDDI.d400.s5.e3 120 135
drug
sulfamethoxazole
DrugDDI.d400.s5.e4 137 150
drug
clarithromycin
DrugDDI.d400.s5.e5 152 163
drug
erythromycin
DrugDDI.d400.s5.e6 165 176
drug
itraconazole
DrugDDI.d400.s5.e7 179 189
drug
fluconazole



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s6
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone , quinidine Antihistamines: astemizole , terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride .

DrugDDI.d400.s6.e0 0 4
drug
Drugs
DrugDDI.d400.s6.e1 38 45
drug
VIRACEPT
DrugDDI.d400.s6.e2 62 71
drug
amiodarone
DrugDDI.d400.s6.e3 73 81
drug
quinidine
DrugDDI.d400.s6.e4 97 106
drug
astemizole
DrugDDI.d400.s6.e5 108 118
drug
terfenadine
DrugDDI.d400.s6.e6 132 147
drug
ergot derivatives
DrugDDI.d400.s6.e7 172 179
drug
rifampin
DrugDDI.d400.s6.e8 205 213
drug
triazolam
DrugDDI.d400.s6.e9 231 239
drug
cisapride



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s7
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin .

DrugDDI.d400.s7.e0 0 4
drug
Drugs
DrugDDI.d400.s7.e1 52 59
drug
VIRACEPT
DrugDDI.d400.s7.e2 84 92
drug
rifabutin



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s8
Other Potentially Clinically Significant Drug Interactions With VIRACEPT * Anticonvulsants: carbamazepine , phenobarbital , phenytoin May decrease nelfinavir plasma concentrations** Anti-HIV protease inhibitors: indinavir , ritonavir May increase nelfinavir plasma concentrations Oral contraceptives: ethinyl estradiol , norethindrone Plasma concentrations may be decreased by VIRACEPT .

DrugDDI.d400.s8.e0 57 64
drug
VIRACEPT
DrugDDI.d400.s8.e1 82 94
drug
carbamazepine
DrugDDI.d400.s8.e2 96 108
drug
phenobarbital
DrugDDI.d400.s8.e3 110 118
drug
phenytoin
DrugDDI.d400.s8.e4 130 139
drug
nelfinavir
DrugDDI.d400.s8.e5 189 197
drug
indinavir
DrugDDI.d400.s8.e6 199 207
drug
ritonavir
DrugDDI.d400.s8.e7 219 228
drug
nelfinavir
DrugDDI.d400.s8.e8 268 283
drug
ethinyl estradiol
DrugDDI.d400.s8.e9 285 297
drug
norethindrone
DrugDDI.d400.s8.e10 334 341
drug
VIRACEPT



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s9
* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly .

DrugDDI.d400.s9.e0 29 36
drug
VIRACEPT
DrugDDI.d400.s9.e1 68 77
drug
nelfinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s10
Antihistamines .

DrugDDI.d400.s10.e0 0 13
drug
Antihistamines



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s11
Terfenadine : Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma; .

DrugDDI.d400.s11.e0 0 10
drug
Terfenadine
DrugDDI.d400.s11.e1 28 38
drug
terfenadine
DrugDDI.d400.s11.e2 43 50
drug
VIRACEPT
DrugDDI.d400.s11.e3 85 95
drug
terfenadine



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s12
therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.

DrugDDI.d400.s12.e0 10 17
drug
VIRACEPT
DrugDDI.d400.s12.e1 57 67
drug
terfenadine



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s13
Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole .

DrugDDI.d400.s13.e0 35 42
drug
VIRACEPT
DrugDDI.d400.s13.e1 86 95
drug
astemizole



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s14
Anti-HIV Protease Inhibitors .

DrugDDI.d400.s14.e0 0 25
drug
Anti-HIV Protease Inhibitors



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s15
Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.

DrugDDI.d400.s15.e0 0 8
drug
Indinavir
DrugDDI.d400.s15.e1 28 36
drug
indinavir
DrugDDI.d400.s15.e2 41 48
drug
VIRACEPT
DrugDDI.d400.s15.e3 74 83
drug
nelfinavir
DrugDDI.d400.s15.e4 110 118
drug
indinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s17
Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.

DrugDDI.d400.s17.e0 0 8
drug
Ritonavir
DrugDDI.d400.s17.e1 28 36
drug
ritonavir
DrugDDI.d400.s17.e2 41 48
drug
VIRACEPT
DrugDDI.d400.s17.e3 74 83
drug
nelfinavir
DrugDDI.d400.s17.e4 114 122
drug
ritonavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s19
Saquinavir : Coadministration of saquinavir (using an experimental soft- gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.

DrugDDI.d400.s19.e0 0 9
drug
Saquinavir
DrugDDI.d400.s19.e1 29 38
drug
saquinavir
DrugDDI.d400.s19.e2 64 70
drug
gelatin
DrugDDI.d400.s19.e3 91 100
drug
saquinavir
DrugDDI.d400.s19.e4 112 119
drug
VIRACEPT
DrugDDI.d400.s19.e5 145 154
drug
nelfinavir
DrugDDI.d400.s19.e6 184 193
drug
saquinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s20
If used in combination with saquinavir hard gelatin capsules at the recommended dose of 600 mg tid, no dose adjustments are needed.

DrugDDI.d400.s20.e0 23 32
drug
saquinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s22
Antifungal Agents .

DrugDDI.d400.s22.e0 0 15
drug
Antifungal Agents



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s23
Ketoconazole : Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.

DrugDDI.d400.s23.e0 0 11
drug
Ketoconazole
DrugDDI.d400.s23.e1 31 42
drug
ketoconazole
DrugDDI.d400.s23.e2 47 54
drug
VIRACEPT
DrugDDI.d400.s23.e3 79 88
drug
nelfinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s24
This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.

DrugDDI.d400.s24.e0 78 89
drug
ketoconazole
DrugDDI.d400.s24.e1 93 100
drug
VIRACEPT



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s25
Anti-HIV Reverse Transcriptase Inhibitors .

DrugDDI.d400.s25.e0 0 37
drug
Anti-HIV Reverse Transcriptase Inhibitors



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s26
Didanosine : It is recommended that didanosine be administered on an empty stomach; .

DrugDDI.d400.s26.e0 0 9
drug
Didanosine
DrugDDI.d400.s26.e1 30 39
drug
didanosine



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s27
therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine .

DrugDDI.d400.s27.e0 10 19
drug
nelfinavir
DrugDDI.d400.s27.e1 86 95
drug
didanosine



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s28
Zidovudine : Coadministration of zidovudine and lamivudine with VIRACEPT resulted in a 35% decrease in zidovudine plasma A.C.

DrugDDI.d400.s28.e0 0 9
drug
Zidovudine
DrugDDI.d400.s28.e1 29 38
drug
zidovudine
DrugDDI.d400.s28.e2 42 51
drug
lamivudine
DrugDDI.d400.s28.e3 56 63
drug
VIRACEPT
DrugDDI.d400.s28.e4 88 97
drug
zidovudine



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s29
A dose adjustment is not needed when zidovudine is administered with VIRACEPT .

DrugDDI.d400.s29.e0 30 39
drug
zidovudine
DrugDDI.d400.s29.e1 58 65
drug
VIRACEPT



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s30
Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine .

DrugDDI.d400.s30.e0 45 48
drug
drug
DrugDDI.d400.s30.e1 64 71
drug
VIRACEPT
DrugDDI.d400.s30.e2 93 102
drug
lamivudine
DrugDDI.d400.s30.e3 105 113
drug
stavudine



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s31
Antimycobacterial Agents .

DrugDDI.d400.s31.e0 0 22
drug
Antimycobacterial Agents



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s32
Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.

DrugDDI.d400.s32.e0 0 8
drug
Rifabutin
DrugDDI.d400.s32.e1 28 36
drug
rifabutin
DrugDDI.d400.s32.e2 40 47
drug
VIRACEPT
DrugDDI.d400.s32.e3 72 81
drug
nelfinavir
DrugDDI.d400.s32.e4 109 117
drug
rifabutin



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s33
It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT .

DrugDDI.d400.s33.e0 28 36
drug
rifabutin
DrugDDI.d400.s33.e1 88 95
drug
VIRACEPT



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s34
Rifampin : Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.

DrugDDI.d400.s34.e0 0 7
drug
Rifampin
DrugDDI.d400.s34.e1 27 34
drug
rifampin
DrugDDI.d400.s34.e2 38 45
drug
VIRACEPT
DrugDDI.d400.s34.e3 71 80
drug
nelfinavir



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s35
VIRACEPT and rifampin should not be coadministered.

DrugDDI.d400.s35.e0 0 7
drug
VIRACEPT
DrugDDI.d400.s35.e1 11 18
drug
rifampin



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s36
Oral Contraceptives .

DrugDDI.d400.s36.e0 0 17
drug
Oral Contraceptives



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s37
Ethinyl Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.

DrugDDI.d400.s37.e0 0 15
drug
Ethinyl Estradiol
DrugDDI.d400.s37.e1 19 31
drug
Norethindrone
DrugDDI.d400.s37.e2 51 58
drug
VIRACEPT
DrugDDI.d400.s37.e3 63 70
drug
OVCON-35
DrugDDI.d400.s37.e4 95 110
drug
ethinyl estradiol
DrugDDI.d400.s37.e5 129 141
drug
norethindrone



Abstract Id: DrugDDI.d400
Sentence Id: DrugDDI.d400.s38
Alternate or additional contraceptive measures should be used during therapy with VIRACEPT .

DrugDDI.d400.s38.e0 21 33
drug
contraceptive
DrugDDI.d400.s38.e1 71 78
drug
VIRACEPT



Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s0
Certain antibiotics , especially neomycin , streptomycin and kanamycin , have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.

DrugDDI.d349.s0.e0 7 17
drug
antibiotics
DrugDDI.d349.s0.e1 29 36
drug
neomycin
DrugDDI.d349.s0.e2 38 49
drug
streptomycin
DrugDDI.d349.s0.e3 53 61
drug
kanamycin



Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s1
These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.

DrugDDI.d349.s1.e0 5 15
drug
antibiotics
DrugDDI.d349.s1.e1 127 144
drug
anticholinesterase



Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s2
Local and some general anesthetics , antiarrhythmic agent s and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis; .

DrugDDI.d349.s2.e0 12 29
drug
general anesthetics
DrugDDI.d349.s2.e1 31 49
drug
antiarrhythmic agent
DrugDDI.d349.s2.e2 59 63
drug
drugs



Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s3
the dose of Prostigmin may have to be increased accordingly.

DrugDDI.d349.s3.e0 9 18
drug
Prostigmin



Abstract Id: DrugDDI.d111
Sentence Id: DrugDDI.d111.s0
No trials specifically examining potential drug interactions with Natrecor were conducted, although many concomitant drugs were used in clinical trials.

DrugDDI.d111.s0.e0 58 65
drug
Natrecor
DrugDDI.d111.s0.e1 103 107
drug
drugs



Abstract Id: DrugDDI.d111
Sentence Id: DrugDDI.d111.s1
No drug interactions were detected except for an increase in symptomatic hypotension in patients receiving oral ACE inhibitors .

DrugDDI.d111.s1.e0 96 108
drug
ACE inhibitors



Abstract Id: DrugDDI.d111
Sentence Id: DrugDDI.d111.s2
The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).

DrugDDI.d111.s2.e0 22 29
drug
Natrecor
DrugDDI.d111.s2.e1 36 47
drug
vasodilators
DrugDDI.d111.s2.e2 54 66
drug
nitroglycerin
DrugDDI.d111.s2.e3 68 80
drug
nitroprusside
DrugDDI.d111.s2.e4 82 90
drug
milrinone
DrugDDI.d111.s2.e5 96 108
drug
ACE inhibitors
DrugDDI.d111.s2.e6 134 138
drug
drugs
DrugDDI.d111.s2.e7 165 172
drug
Natrecor



Abstract Id: DrugDDI.d310
Sentence Id: DrugDDI.d310.s0
Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.

DrugDDI.d310.s0.e0 0 9
drug
Netilmicin
DrugDDI.d310.s0.e1 56 68
drug
loop diuretics
DrugDDI.d310.s0.e2 75 84
drug
furosemide
DrugDDI.d310.s0.e3 88 101
drug
ethacrynic acid

interaction DrugDDI.d310.s0.e0 DrugDDI.d310.s0.e1
interaction DrugDDI.d310.s0.e0 DrugDDI.d310.s0.e3

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s0
Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6.

DrugDDI.d312.s0.e0 0 9
drug
Nevirapine
DrugDDI.d312.s0.e1 39 43
drug
liver
DrugDDI.d312.s0.e2 50 63
drug
cytochrome P450

interaction DrugDDI.d312.s0.e0 DrugDDI.d312.s0.e2

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s1
Nevirapine is known to be an inducer of these enzymes.

DrugDDI.d312.s1.e0 0 9
drug
Nevirapine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s2
As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine .

DrugDDI.d312.s2.e0 10 14
drug
drugs
DrugDDI.d312.s2.e1 111 120
drug
nevirapine

interaction DrugDDI.d312.s2.e0 DrugDDI.d312.s2.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s3
The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in CLINICAL PHARMACOLOGY, Table 1.

DrugDDI.d312.s3.e0 65 74
drug
nevirapine
DrugDDI.d312.s3.e1 83 87
drug
drugs

interaction DrugDDI.d312.s3.e0 DrugDDI.d312.s3.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s6
In addition to established drug interactions, there may be potential pharmacokinetic interactions between nevirapine and other drug classes that are metabolized by the cytochrome P450 system.

DrugDDI.d312.s6.e0 93 102
drug
nevirapine
DrugDDI.d312.s6.e1 111 114
drug
drug
DrugDDI.d312.s6.e2 145 158
drug
cytochrome P450

interaction DrugDDI.d312.s6.e0 DrugDDI.d312.s6.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s8
Although specific drug interaction studies in HIV-1 seropositive subjects have not been conducted for the classes of drugs listed in Table 4, additional clinical monitoring may be warranted when co-administering these drugs .

DrugDDI.d312.s8.e0 100 104
drug
drugs
DrugDDI.d312.s8.e1 187 191
drug
drugs



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s9
The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.

DrugDDI.d312.s9.e0 28 37
drug
nevirapine
DrugDDI.d312.s9.e1 44 62
drug
antithrombotic agent

interaction DrugDDI.d312.s9.e0 DrugDDI.d312.s9.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s10
As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time.

DrugDDI.d312.s10.e0 25 29
drug
drugs
DrugDDI.d312.s10.e1 50 57
drug
warfarin

interaction DrugDDI.d312.s10.e0 DrugDDI.d312.s10.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s11
When warfarin is co-administered with nevirapine , anticoagulation levels should be monitored frequently.

DrugDDI.d312.s11.e0 4 11
drug
warfarin
DrugDDI.d312.s11.e1 33 42
drug
nevirapine

interaction DrugDDI.d312.s11.e0 DrugDDI.d312.s11.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s13
Drug Name .

DrugDDI.d312.s13.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s14
Effect on Concentration of Nevirapine or Concomitant Drug .

DrugDDI.d312.s14.e0 23 32
drug
Nevirapine
DrugDDI.d312.s14.e1 46 49
drug
Drug



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s16
Clarithromycin .

DrugDDI.d312.s16.e0 0 13
drug
Clarithromycin



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s17
@ Clarithromycin @14OH- clarithromycin .

DrugDDI.d312.s17.e0 1 14
drug
Clarithromycin



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s18
Clarithromycin exposure was significantly decreased by nevirapine ; .

DrugDDI.d312.s18.e0 0 13
drug
Clarithromycin
DrugDDI.d312.s18.e1 49 58
drug
nevirapine

interaction DrugDDI.d312.s18.e0 DrugDDI.d312.s18.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s19
however, 14-OH metabolite concentrations were increased.Because clarithromycin active metabolite has reduced activity against Mycobacteriumavium-intracellulare complex, overallactivity against this pathogen may bealtered.

DrugDDI.d312.s19.e0 58 71
drug
clarithromycin



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s20
Alternatives to clarithromycin ,such as azithromycin , should be considered.

DrugDDI.d312.s20.e0 14 27
drug
clarithromycin
DrugDDI.d312.s20.e1 35 46
drug
azithromycin



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s21
Efavirenz .

DrugDDI.d312.s21.e0 0 8
drug
Efavirenz



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s22
@ Efavirenz .

DrugDDI.d312.s22.e0 1 9
drug
Efavirenz



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s24
Ethinyl estradiol and Norethindrone .

DrugDDI.d312.s24.e0 0 15
drug
Ethinyl estradiol
DrugDDI.d312.s24.e1 19 31
drug
Norethindrone



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s25
@ Ethinyl estradiol  span class= c272 @Norethindrone .

DrugDDI.d312.s25.e0 1 16
drug
Ethinyl estradiol



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s26
Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine , since nevirapinemay lower the plasma levels of thesemedications.

DrugDDI.d312.s26.e0 0 17
drug
Oral contraceptives
DrugDDI.d312.s26.e1 43 54
drug
birth control
DrugDDI.d312.s26.e2 113 122
drug
nevirapine

interaction DrugDDI.d312.s26.e0 DrugDDI.d312.s26.e2

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s28
Fluconazole .

DrugDDI.d312.s28.e0 0 10
drug
Fluconazole



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s29
@ Nevirapine .

DrugDDI.d312.s29.e0 1 10
drug
Nevirapine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s30
Because of the risk of increased exposure tonevirapine, caution should be used inconcomitant administration, and patients should be monitored closely for nevirapine -associated adverse events.

DrugDDI.d312.s30.e0 133 142
drug
nevirapine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s31
Indinavir .

DrugDDI.d312.s31.e0 0 8
drug
Indinavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s32
@ Indinavir .

DrugDDI.d312.s32.e0 1 9
drug
Indinavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s33
Appropriate doses for this combination arenot established, but an increase in thedosage of indinavir may be required.

DrugDDI.d312.s33.e0 78 86
drug
indinavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s34
Ketoconazole .

DrugDDI.d312.s34.e0 0 11
drug
Ketoconazole



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s35
@ Ketoconazole .

DrugDDI.d312.s35.e0 1 12
drug
Ketoconazole



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s36
Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug .

DrugDDI.d312.s36.e0 0 9
drug
Nevirapine
DrugDDI.d312.s36.e1 13 24
drug
ketoconazole
DrugDDI.d312.s36.e2 79 90
drug
ketoconazole
DrugDDI.d312.s36.e3 136 139
drug
drug

interaction DrugDDI.d312.s36.e0 DrugDDI.d312.s36.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s37
Lopinavir / Ritonavir .

DrugDDI.d312.s37.e0 0 8
drug
Lopinavir
DrugDDI.d312.s37.e1 10 18
drug
Ritonavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s38
@ Lopinavir .

DrugDDI.d312.s38.e0 1 9
drug
Lopinavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s39
A dose increase of lopinavir / ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine .

DrugDDI.d312.s39.e0 15 23
drug
lopinavir
DrugDDI.d312.s39.e1 25 33
drug
ritonavir
DrugDDI.d312.s39.e2 93 102
drug
nevirapine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s40
Methadone .

DrugDDI.d312.s40.e0 0 8
drug
Methadone



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s42
Methadone levels may be decreased;increased dosages may be required toprevent symptoms of opiate withdrawal.Methadone maintained patients beginningnevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.

DrugDDI.d312.s42.e0 0 8
drug
Methadone
DrugDDI.d312.s42.e1 78 83
drug
opiate



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s43
Nelfinavir .

DrugDDI.d312.s43.e0 0 9
drug
Nelfinavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s44
@ Nelfinavir M8 Metabolite  span class= c272 @NelfinavirCmin ?

DrugDDI.d312.s44.e0 1 12
drug
Nelfinavir M8



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s45
The appropriate dose for nelfinavir incombination with nevirapine , with respectto safety and efficacy, has not been established.

DrugDDI.d312.s45.e0 21 30
drug
nelfinavir
DrugDDI.d312.s45.e1 48 57
drug
nevirapine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s46
Rifabutin .

DrugDDI.d312.s46.e0 0 8
drug
Rifabutin



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s48
Rifabutin and its metabolite concentrationswere moderately increased.

DrugDDI.d312.s48.e0 0 8
drug
Rifabutin
DrugDDI.d312.s48.e1 15 24
drug
metabolite



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s51
Rifampin .

DrugDDI.d312.s51.e0 0 7
drug
Rifampin



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s52
@ Nevirapine .

DrugDDI.d312.s52.e0 1 10
drug
Nevirapine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s53
Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug .

DrugDDI.d312.s53.e0 0 9
drug
Nevirapine
DrugDDI.d312.s53.e1 13 20
drug
rifampin
DrugDDI.d312.s53.e2 75 84
drug
nevirapine
DrugDDI.d312.s53.e3 130 133
drug
drug

interaction DrugDDI.d312.s53.e0 DrugDDI.d312.s53.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s54
Physicians needing to treatpatients co-infected with tuberculosis andusing a nevirapine containing regimen mayuse rifabutin instead.

DrugDDI.d312.s54.e0 68 77
drug
nevirapine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s55
Saquinavir .

DrugDDI.d312.s55.e0 0 9
drug
Saquinavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s57
Appropriate doses for this combination arenot established, but an increase in thedosage of saquinavir may be required.

DrugDDI.d312.s57.e0 78 87
drug
saquinavir



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s58
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone .

DrugDDI.d312.s58.e0 17 24
drug
narcotic
DrugDDI.d312.s58.e1 64 73
drug
nevirapine
DrugDDI.d312.s58.e2 77 85
drug
methadone
DrugDDI.d312.s58.e3 143 151
drug
methadone

interaction DrugDDI.d312.s58.e0 DrugDDI.d312.s58.e1
interaction DrugDDI.d312.s58.e1 DrugDDI.d312.s58.e2

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s59
Table 4 @@@@@@@Potential Drug Interactions:Use With Caution, Dose Adjustment of Co-administered Drug May Be Needed due to Possible Decrease in Clinical Effect .

DrugDDI.d312.s59.e0 22 25
drug
Drug



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s60
Examples of Drugs in Which Plasma Concentrations May Be Decreased By Co-administration With Nevirapine .

DrugDDI.d312.s60.e0 10 14
drug
Drugs
DrugDDI.d312.s60.e1 79 88
drug
Nevirapine

interaction DrugDDI.d312.s60.e0 DrugDDI.d312.s60.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s61
Drug Class Examples of Drugs .

DrugDDI.d312.s61.e0 0 3
drug
Drug
DrugDDI.d312.s61.e1 19 23
drug
Drugs



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s62
Antiarrhythmics .

DrugDDI.d312.s62.e0 0 14
drug
Antiarrhythmics



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s63
Amiodarone , disopyramide , lidocaine .

DrugDDI.d312.s63.e0 0 9
drug
Amiodarone
DrugDDI.d312.s63.e1 11 22
drug
disopyramide
DrugDDI.d312.s63.e2 24 32
drug
lidocaine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s64
Anticonvulsants .

DrugDDI.d312.s64.e0 0 14
drug
Anticonvulsants



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s65
Carbamazepine , clonazepam , ethosuximide .

DrugDDI.d312.s65.e0 0 12
drug
Carbamazepine
DrugDDI.d312.s65.e1 14 23
drug
clonazepam
DrugDDI.d312.s65.e2 25 36
drug
ethosuximide



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s66
Antifungals .

DrugDDI.d312.s66.e0 0 10
drug
Antifungals



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s67
Itraconazole .

DrugDDI.d312.s67.e0 0 11
drug
Itraconazole



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s68
Calcium channel blockers .

DrugDDI.d312.s68.e0 0 21
drug
Calcium channel blockers



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s69
Diltiazem , nifedipine , verapamil .

DrugDDI.d312.s69.e0 0 8
drug
Diltiazem
DrugDDI.d312.s69.e1 10 19
drug
nifedipine
DrugDDI.d312.s69.e2 21 29
drug
verapamil



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s71
Cyclophosphamide .

DrugDDI.d312.s71.e0 0 15
drug
Cyclophosphamide



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s72
Ergot alkaloids .

DrugDDI.d312.s72.e0 0 13
drug
Ergot alkaloids



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s73
Ergotamine .

DrugDDI.d312.s73.e0 0 9
drug
Ergotamine



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s74
Immunosuppressants .

DrugDDI.d312.s74.e0 0 17
drug
Immunosuppressants



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s75
Cyclosporin , tacrolimus , sirolimus .

DrugDDI.d312.s75.e0 0 10
drug
Cyclosporin
DrugDDI.d312.s75.e1 12 21
drug
tacrolimus
DrugDDI.d312.s75.e2 23 31
drug
sirolimus



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s77
Cisapride .

DrugDDI.d312.s77.e0 0 8
drug
Cisapride



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s78
Opiate agonists .

DrugDDI.d312.s78.e0 0 13
drug
Opiate agonists



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s79
Fentanyl .

DrugDDI.d312.s79.e0 0 7
drug
Fentanyl



Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s80
Examples of Drugs in Which Plasma Concentrations May Be Increased By Co-administration With Nevirapine .

DrugDDI.d312.s80.e0 10 14
drug
Drugs
DrugDDI.d312.s80.e1 79 88
drug
Nevirapine

interaction DrugDDI.d312.s80.e0 DrugDDI.d312.s80.e1

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s82
Warfarin .

DrugDDI.d312.s82.e0 0 7
drug
Warfarin



Abstract Id: DrugDDI.d563
Sentence Id: DrugDDI.d563.s0
Interactions for Vitamin B3 ( Niacin ): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.

DrugDDI.d563.s0.e0 15 23
drug
Vitamin B3
DrugDDI.d563.s0.e1 25 30
drug
Niacin
DrugDDI.d563.s0.e2 57 69
drug
Nicotinic acid
DrugDDI.d563.s0.e3 95 118
drug
ganglionic blocking agents
DrugDDI.d563.s0.e4 132 136
drug
drugs

interaction DrugDDI.d563.s0.e2 DrugDDI.d563.s0.e3

Abstract Id: DrugDDI.d563
Sentence Id: DrugDDI.d563.s1
Aspirin : Concomitant aspirin may decrease the metabolic clearance of nicotinic acid .

DrugDDI.d563.s1.e0 0 6
drug
Aspirin
DrugDDI.d563.s1.e1 19 25
drug
aspirin
DrugDDI.d563.s1.e2 60 72
drug
nicotinic acid

interaction DrugDDI.d563.s1.e1 DrugDDI.d563.s1.e2

Abstract Id: DrugDDI.d563
Sentence Id: DrugDDI.d563.s3
Other: Concomitant alcohol or hot drinks may increase the side effects of flushing and pruritus and should be avoided at the time of drug ingestion.

DrugDDI.d563.s3.e0 17 23
drug
alcohol



Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s0
Beta-Blockers In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with nicardipine HCl .

DrugDDI.d30.s0.e0 0 12
drug
Beta-Blockers
DrugDDI.d30.s0.e1 41 71
drug
adrenergic beta-receptor blockers
DrugDDI.d30.s0.e2 119 132
drug
nicardipine HCl



Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s2
Cimetidine Cimetidine increases nicardipine HCl plasma levels.

DrugDDI.d30.s2.e0 0 9
drug
Cimetidine
DrugDDI.d30.s2.e1 29 42
drug
nicardipine HCl

interaction DrugDDI.d30.s2.e0 DrugDDI.d30.s2.e1

Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s3
Patients receiving the two drugs concomitantly should be carefully monitored.

DrugDDI.d30.s3.e0 23 27
drug
drugs



Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s4
Digoxin Some calcium blockers may increase the concentration of digitalis preparation s in the blood.

DrugDDI.d30.s4.e0 0 6
drug
Digoxin
DrugDDI.d30.s4.e1 55 74
drug
digitalis preparation

interaction DrugDDI.d30.s4.e0 DrugDDI.d30.s4.e1

Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s5
Nicardipine HCl usually does not alter the plasma levels of digoxin , however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.

DrugDDI.d30.s5.e0 0 13
drug
Nicardipine HCl
DrugDDI.d30.s5.e1 50 56
drug
digoxin
DrugDDI.d30.s5.e2 128 141
drug
nicardipine HCl



Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s6
Maalox@* Coadministration of Maalox TC had no effect on nicardipine HCl absorption.

DrugDDI.d30.s6.e0 26 33
drug
Maalox TC
DrugDDI.d30.s6.e1 47 60
drug
nicardipine HCl



Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s7
Fentanyl Anesthesia Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta-blocker and a calcium channel blocker .

DrugDDI.d30.s7.e0 0 7
drug
Fentanyl
DrugDDI.d30.s7.e1 56 63
drug
fentanyl
DrugDDI.d30.s7.e2 95 106
drug
beta-blocker
DrugDDI.d30.s7.e3 111 131
drug
calcium channel blocker

interaction DrugDDI.d30.s7.e1 DrugDDI.d30.s7.e2

Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s8
Even though such interactions were not seen during clinical studies with nicardipine HCl , an increased volume of circulating fluids might be required if such an interaction were to occur.

DrugDDI.d30.s8.e0 62 75
drug
nicardipine HCl



Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s9
Cyclosporine Concomitant administration of nicardipine and cyclosporine levels.

DrugDDI.d30.s9.e0 0 11
drug
Cyclosporine
DrugDDI.d30.s9.e1 39 49
drug
nicardipine
DrugDDI.d30.s9.e2 53 64
drug
cyclosporine



Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s10
Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine .

DrugDDI.d30.s10.e0 22 33
drug
cyclosporine
DrugDDI.d30.s10.e1 120 130
drug
nicardipine

interaction DrugDDI.d30.s10.e0 DrugDDI.d30.s10.e1

Abstract Id: DrugDDI.d30
Sentence Id: DrugDDI.d30.s11
When therapeutic concentrations of furosemide , propranolol , dipyridamole , warfarin , quinidine , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.

DrugDDI.d30.s11.e0 31 40
drug
furosemide
DrugDDI.d30.s11.e1 42 52
drug
propranolol
DrugDDI.d30.s11.e2 54 65
drug
dipyridamole
DrugDDI.d30.s11.e3 67 74
drug
warfarin
DrugDDI.d30.s11.e4 76 84
drug
quinidine
DrugDDI.d30.s11.e5 88 95
drug
naproxen
DrugDDI.d30.s11.e6 107 117
drug
human plasma
DrugDDI.d30.s11.e7 131 143
drug
plasma protein
DrugDDI.d30.s11.e8 153 166
drug
nicardipine HCl



Abstract Id: DrugDDI.d533
Sentence Id: DrugDDI.d533.s0
Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications , such as tricyclic antidepressants and theophylline .

DrugDDI.d533.s0.e0 130 140
drug
medications
DrugDDI.d533.s0.e1 148 171
drug
tricyclic antidepressants
DrugDDI.d533.s0.e2 175 186
drug
theophylline



Abstract Id: DrugDDI.d533
Sentence Id: DrugDDI.d533.s1
Doses of these and perhaps other medications may need to be adjusted in patients who successfully quit smoking.

DrugDDI.d533.s1.e0 22 37
drug
other medications



Abstract Id: DrugDDI.d254
Sentence Id: DrugDDI.d254.s0
In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems.

DrugDDI.d254.s0.e0 8 17
drug
nilutamide
DrugDDI.d254.s0.e1 57 71
drug
cytochrome P-450

interaction DrugDDI.d254.s0.e0 DrugDDI.d254.s0.e1

Abstract Id: DrugDDI.d254
Sentence Id: DrugDDI.d254.s1
Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin , and theophylline , could have a delayed elimination and increases in their serum half-life leading to a toxic level.

DrugDDI.d254.s1.e0 13 17
drug
drugs
DrugDDI.d254.s1.e1 70 78
drug
phenytoin
DrugDDI.d254.s1.e2 83 94
drug
theophylline



Abstract Id: DrugDDI.d254
Sentence Id: DrugDDI.d254.s2
The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide .

DrugDDI.d254.s2.e0 16 20
drug
drugs
DrugDDI.d254.s2.e1 108 117
drug
nilutamide

interaction DrugDDI.d254.s2.e0 DrugDDI.d254.s2.e1

Abstract Id: DrugDDI.d254
Sentence Id: DrugDDI.d254.s3
For example, when vitamin K antagonists are administered concomitantly with nilutamide , prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.

DrugDDI.d254.s3.e0 66 75
drug
nilutamide



Abstract Id: DrugDDI.d13
Sentence Id: DrugDDI.d13.s0
It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop@.

DrugDDI.d13.s0.e0 46 67
drug
calcium channel blockers



Abstract Id: DrugDDI.d13
Sentence Id: DrugDDI.d13.s1
In Europe, Nimotop@ was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension; .

DrugDDI.d13.s1.e0 62 77
drug
antihypertensive



Abstract Id: DrugDDI.d13
Sentence Id: DrugDDI.d13.s3
A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.

DrugDDI.d13.s3.e0 60 69
drug
nimodipine
DrugDDI.d13.s3.e1 150 159
drug
cimetidine
DrugDDI.d13.s3.e2 176 185
drug
nimodipine

interaction DrugDDI.d13.s3.e1 DrugDDI.d13.s3.e2

Abstract Id: DrugDDI.d13
Sentence Id: DrugDDI.d13.s4
This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine , which could decrease first pass metabolism of nimodipine .

DrugDDI.d13.s4.e0 45 66
drug
hepatic cytochrome P- 450
DrugDDI.d13.s4.e1 69 78
drug
cimetidine
DrugDDI.d13.s4.e2 119 128
drug
nimodipine

interaction DrugDDI.d13.s4.e1 DrugDDI.d13.s4.e2

Abstract Id: DrugDDI.d181
Sentence Id: DrugDDI.d181.s0
No formal drug-interaction studies have been performed, and a clinically significant interaction with other medications used in the treatment of hypoxic respiratory failure cannot be excluded based on the available data.

DrugDDI.d181.s0.e0 89 104
drug
other medications



Abstract Id: DrugDDI.d181
Sentence Id: DrugDDI.d181.s1
INOmax has been administered with tolazoline , dopamine , dobutamine , steroids, surfactant , and high-frequency ventilation.

DrugDDI.d181.s1.e0 0 5
drug
INOmax
DrugDDI.d181.s1.e1 29 38
drug
tolazoline
DrugDDI.d181.s1.e2 40 47
drug
dopamine
DrugDDI.d181.s1.e3 49 58
drug
dobutamine
DrugDDI.d181.s1.e4 69 78
drug
surfactant



Abstract Id: DrugDDI.d181
Sentence Id: DrugDDI.d181.s2
Although there are no study data to evaluate the possibility, nitric oxide donor compounds , including sodium nitroprusside and nitroglycerin , may have an additive effect with INOmax on the risk of developing methemoglobinemia.

DrugDDI.d181.s2.e0 52 76
drug
nitric oxide donor compounds
DrugDDI.d181.s2.e1 87 105
drug
sodium nitroprusside
DrugDDI.d181.s2.e2 109 121
drug
nitroglycerin
DrugDDI.d181.s2.e3 150 155
drug
INOmax

interaction DrugDDI.d181.s2.e0 DrugDDI.d181.s2.e3
interaction DrugDDI.d181.s2.e2 DrugDDI.d181.s2.e3

Abstract Id: DrugDDI.d181
Sentence Id: DrugDDI.d181.s3
An association between prilocaine and an increased risk of methaemoglobinaemia, particularly in infants, has specifically been described in a literature case report.

DrugDDI.d181.s3.e0 20 29
drug
prilocaine



Abstract Id: DrugDDI.d181
Sentence Id: DrugDDI.d181.s4
This risk is present whether the drugs are administered as oral, parenteral, or topical formulations.

DrugDDI.d181.s4.e0 27 31
drug
drugs



Abstract Id: DrugDDI.d198
Sentence Id: DrugDDI.d198.s0
Antacids containing magnesium trisilicate , when administered concomitantly with nitrofurantoin , reduce both the rate and extent of absorption.

DrugDDI.d198.s0.e0 0 7
drug
Antacids
DrugDDI.d198.s0.e1 18 37
drug
magnesium trisilicate
DrugDDI.d198.s0.e2 72 85
drug
nitrofurantoin

interaction DrugDDI.d198.s0.e0 DrugDDI.d198.s0.e2

Abstract Id: DrugDDI.d198
Sentence Id: DrugDDI.d198.s1
The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate .

DrugDDI.d198.s1.e0 52 65
drug
nitrofurantoin
DrugDDI.d198.s1.e1 82 101
drug
magnesium trisilicate

interaction DrugDDI.d198.s1.e0 DrugDDI.d198.s1.e1

Abstract Id: DrugDDI.d198
Sentence Id: DrugDDI.d198.s2
Uricosuric drugs , such as probenecid and sulfinpyrazone , can inhibit renal tubular secretion of nitrofurantoin .

DrugDDI.d198.s2.e0 10 14
drug
drugs
DrugDDI.d198.s2.e1 22 31
drug
probenecid
DrugDDI.d198.s2.e2 35 48
drug
sulfinpyrazone
DrugDDI.d198.s2.e3 83 96
drug
nitrofurantoin

interaction DrugDDI.d198.s2.e0 DrugDDI.d198.s2.e3
interaction DrugDDI.d198.s2.e2 DrugDDI.d198.s2.e3

Abstract Id: DrugDDI.d198
Sentence Id: DrugDDI.d198.s3
The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial .

DrugDDI.d198.s3.e0 22 35
drug
nitrofurantoin
DrugDDI.d198.s3.e1 132 144
drug
antibacterial



Abstract Id: DrugDDI.d198
Sentence Id: DrugDDI.d198.s4
Drug /Laboratory Test Interactions As a result of the presence of nitrofurantoin , a false-positive reaction for glucose in the urine may occur.

DrugDDI.d198.s4.e0 0 3
drug
Drug
DrugDDI.d198.s4.e1 55 68
drug
nitrofurantoin
DrugDDI.d198.s4.e2 96 102
drug
glucose



Abstract Id: DrugDDI.d198
Sentence Id: DrugDDI.d198.s5
This has been observed with Benedict@s and Fehling@s solutions but not with the glucose enzymatic test.

DrugDDI.d198.s5.e0 67 73
drug
glucose



Abstract Id: DrugDDI.d56
Sentence Id: DrugDDI.d56.s0
The vasodilating effects of nitroglycerin may be additive with those of other vasodilators .

DrugDDI.d56.s0.e0 24 36
drug
nitroglycerin
DrugDDI.d56.s0.e1 66 77
drug
vasodilators

interaction DrugDDI.d56.s0.e0 DrugDDI.d56.s0.e1

Abstract Id: DrugDDI.d56
Sentence Id: DrugDDI.d56.s1
Alcohol , in particular, has been found to exhibit additive effects of this variety.

DrugDDI.d56.s1.e0 0 6
drug
Alcohol



Abstract Id: DrugDDI.d56
Sentence Id: DrugDDI.d56.s2
Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.

DrugDDI.d56.s2.e0 58 79
drug
calcium channel blockers
DrugDDI.d56.s2.e1 90 97
drug
nitrates

interaction DrugDDI.d56.s2.e0 DrugDDI.d56.s2.e1

Abstract Id: DrugDDI.d287
Sentence Id: DrugDDI.d287.s0
The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs , including ganglionic blocking agents , negative inotropic agent s, and inhaled anesthetics .

DrugDDI.d287.s0.e0 22 40
drug
sodium nitroprusside
DrugDDI.d287.s0.e1 69 84
drug
hypotensive drugs
DrugDDI.d287.s0.e2 95 118
drug
ganglionic blocking agents
DrugDDI.d287.s0.e3 128 141
drug
inotropic agent
DrugDDI.d287.s0.e4 147 164
drug
inhaled anesthetics

interaction DrugDDI.d287.s0.e0 DrugDDI.d287.s0.e1
interaction DrugDDI.d287.s0.e0 DrugDDI.d287.s0.e3

Abstract Id: DrugDDI.d416
Sentence Id: DrugDDI.d416.s0
No interactions have been observed between nizatidine and theophylline , chlordiazepoxide , lorazepam , lidocaine , phenytoin , and warfarin .

DrugDDI.d416.s0.e0 37 46
drug
nizatidine
DrugDDI.d416.s0.e1 50 61
drug
theophylline
DrugDDI.d416.s0.e2 63 78
drug
chlordiazepoxide
DrugDDI.d416.s0.e3 80 88
drug
lorazepam
DrugDDI.d416.s0.e4 90 98
drug
lidocaine
DrugDDI.d416.s0.e5 100 108
drug
phenytoin
DrugDDI.d416.s0.e6 113 120
drug
warfarin



Abstract Id: DrugDDI.d416
Sentence Id: DrugDDI.d416.s1
Nizatidine does not inhibit the cytochrome P-450-linked drug -metabolizing enzyme system; .

DrugDDI.d416.s1.e0 0 9
drug
Nizatidine
DrugDDI.d416.s1.e1 27 52
drug
cytochrome P-450-linked drug



Abstract Id: DrugDDI.d416
Sentence Id: DrugDDI.d416.s3
In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine , 150 mg b.i.d., was administered concurrently.

DrugDDI.d416.s3.e0 38 44
drug
aspirin
DrugDDI.d416.s3.e1 95 104
drug
nizatidine

interaction DrugDDI.d416.s3.e0 DrugDDI.d416.s3.e1

Abstract Id: DrugDDI.d186
Sentence Id: DrugDDI.d186.s0
The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine , and barbiturates , and the antituberculosis drug rifampin.

DrugDDI.d186.s0.e0 18 26
drug
progestin
DrugDDI.d186.s0.e1 70 74
drug
drugs
DrugDDI.d186.s0.e2 84 98
drug
anticonvulsants
DrugDDI.d186.s0.e3 109 121
drug
carbamazepine
DrugDDI.d186.s0.e4 126 137
drug
barbiturates
DrugDDI.d186.s0.e5 145 160
drug
antituberculosis

interaction DrugDDI.d186.s0.e0 DrugDDI.d186.s0.e1
interaction DrugDDI.d186.s0.e0 DrugDDI.d186.s0.e3
interaction DrugDDI.d186.s0.e0 DrugDDI.d186.s0.e5

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s0
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.

DrugDDI.d530.s0.e0 22 33
drug
theophylline
DrugDDI.d530.s0.e1 65 73
drug
quinolone

interaction DrugDDI.d530.s0.e0 DrugDDI.d530.s0.e1

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s1
There have been reports of theophylline -related side effects in patients on concomitant therapy with norfloxacin and theophylline .

DrugDDI.d530.s1.e0 22 33
drug
theophylline
DrugDDI.d530.s1.e1 87 97
drug
norfloxacin
DrugDDI.d530.s1.e2 101 112
drug
theophylline

interaction DrugDDI.d530.s1.e1 DrugDDI.d530.s1.e2

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s2
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.

DrugDDI.d530.s2.e0 22 33
drug
theophylline



Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s3
Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin .

DrugDDI.d530.s3.e0 21 32
drug
cyclosporine
DrugDDI.d530.s3.e1 69 80
drug
cyclosporine
DrugDDI.d530.s3.e2 85 95
drug
norfloxacin

interaction DrugDDI.d530.s3.e1 DrugDDI.d530.s3.e2

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s4
Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.

DrugDDI.d530.s4.e0 10 21
drug
cyclosporine
DrugDDI.d530.s4.e1 64 75
drug
cyclosporine
DrugDDI.d530.s4.e2 106 110
drug
drugs

interaction DrugDDI.d530.s4.e0 DrugDDI.d530.s4.e1

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s5
Quinolones , including norfloxacin , may enhance the effects of oral anticoagulants , including warfarin or its derivatives or similar agents.

DrugDDI.d530.s5.e0 0 9
drug
Quinolones
DrugDDI.d530.s5.e1 20 30
drug
norfloxacin
DrugDDI.d530.s5.e2 54 71
drug
oral anticoagulants
DrugDDI.d530.s5.e3 82 89
drug
warfarin
DrugDDI.d530.s5.e4 95 105
drug
derivatives

interaction DrugDDI.d530.s5.e0 DrugDDI.d530.s5.e2
interaction DrugDDI.d530.s5.e0 DrugDDI.d530.s5.e4
interaction DrugDDI.d530.s5.e1 DrugDDI.d530.s5.e3

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s7
The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.

DrugDDI.d530.s7.e0 30 39
drug
quinolones
DrugDDI.d530.s7.e1 49 59
drug
norfloxacin
DrugDDI.d530.s7.e2 64 72
drug
glyburide
DrugDDI.d530.s7.e3 75 86
drug
sulfonylurea



Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s9
Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin .

DrugDDI.d530.s9.e0 28 38
drug
norfloxacin
DrugDDI.d530.s9.e1 90 99
drug
probenecid
DrugDDI.d530.s9.e2 103 113
drug
norfloxacin

interaction DrugDDI.d530.s9.e1 DrugDDI.d530.s9.e2

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s10
The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.

DrugDDI.d530.s10.e0 19 32
drug
nitrofurantoin
DrugDDI.d530.s10.e1 54 67
drug
nitrofurantoin
DrugDDI.d530.s10.e2 84 96
drug
antibacterial
DrugDDI.d530.s10.e3 105 115
drug
Norfloxacin

interaction DrugDDI.d530.s10.e1 DrugDDI.d530.s10.e2

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s11
Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .

DrugDDI.d530.s11.e0 0 12
drug
Multivitamins
DrugDDI.d530.s11.e1 39 42
drug
iron
DrugDDI.d530.s11.e2 45 48
drug
zinc
DrugDDI.d530.s11.e3 50 57
drug
antacids
DrugDDI.d530.s11.e4 60 69
drug
sucralfate
DrugDDI.d530.s11.e5 147 157
drug
norfloxacin
DrugDDI.d530.s11.e6 233 243
drug
norfloxacin

interaction DrugDDI.d530.s11.e0 DrugDDI.d530.s11.e5
interaction DrugDDI.d530.s11.e3 DrugDDI.d530.s11.e5

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s12
Videx ( Didanosine ) chewable/ buffer ed tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin , because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin .

DrugDDI.d530.s12.e0 0 4
drug
Videx
DrugDDI.d530.s12.e1 6 15
drug
Didanosine
DrugDDI.d530.s12.e2 26 31
drug
buffer
DrugDDI.d530.s12.e3 46 54
drug
pediatric
DrugDDI.d530.s12.e4 153 163
drug
norfloxacin
DrugDDI.d530.s12.e5 248 258
drug
norfloxacin

interaction DrugDDI.d530.s12.e0 DrugDDI.d530.s12.e4

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s13
Some quinolones have also been shown to interfere with the metabolism of caffeine .

DrugDDI.d530.s13.e0 4 13
drug
quinolones
DrugDDI.d530.s13.e1 61 68
drug
caffeine

interaction DrugDDI.d530.s13.e0 DrugDDI.d530.s13.e1

Abstract Id: DrugDDI.d530
Sentence Id: DrugDDI.d530.s14
This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.

DrugDDI.d530.s14.e0 31 38
drug
caffeine



Abstract Id: DrugDDI.d182
Sentence Id: DrugDDI.d182.s0
Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin .

DrugDDI.d182.s0.e0 122 129
drug
rifampin



Abstract Id: DrugDDI.d182
Sentence Id: DrugDDI.d182.s1
A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72.

DrugDDI.d182.s1.e0 57 68
drug
barbiturates
DrugDDI.d182.s1.e1 70 83
drug
phenylbutazone
DrugDDI.d182.s1.e2 85 99
drug
phenytoin sodium
DrugDDI.d182.s1.e3 101 113
drug
carbamazepine
DrugDDI.d182.s1.e4 115 126
drug
griseofulvin
DrugDDI.d182.s1.e5 128 137
drug
topiramate
DrugDDI.d182.s1.e6 154 163
drug
ampicillin
DrugDDI.d182.s1.e7 167 179
drug
tetracyclines



Abstract Id: DrugDDI.d182
Sentence Id: DrugDDI.d182.s2
A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. Johns Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. Johns Wort .

DrugDDI.d182.s2.e0 48 61
drug
contraceptives
DrugDDI.d182.s2.e1 84 95
drug
St. Johns Wort
DrugDDI.d182.s2.e2 116 132
drug
oral contraceptive
DrugDDI.d182.s2.e3 190 201
drug
St. Johns Wort

interaction DrugDDI.d182.s2.e0 DrugDDI.d182.s2.e1

Abstract Id: DrugDDI.d182
Sentence Id: DrugDDI.d182.s3
Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort .

DrugDDI.d182.s3.e0 52 65
drug
contraceptives
DrugDDI.d182.s3.e1 87 98
drug
St. Johns Wort

interaction DrugDDI.d182.s3.e0 DrugDDI.d182.s3.e1

Abstract Id: DrugDDI.d182
Sentence Id: DrugDDI.d182.s4
Healthcare prescribers are advised to consult the package inserts of medication administered concomitantly with oral contraceptives .

DrugDDI.d182.s4.e0 59 68
drug
medication
DrugDDI.d182.s4.e1 98 115
drug
oral contraceptives



Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s0
Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.

DrugDDI.d439.s0.e0 33 56
drug
tricyclic antidepressants
DrugDDI.d439.s0.e1 96 105
drug
cimetidine
DrugDDI.d439.s0.e2 135 138
drug
drug

interaction DrugDDI.d439.s0.e0 DrugDDI.d439.s0.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s1
Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.

DrugDDI.d439.s1.e0 7 21
drug
anticholinergic
DrugDDI.d439.s1.e1 127 150
drug
tricyclic antidepressants
DrugDDI.d439.s1.e2 155 164
drug
cimetidine
DrugDDI.d439.s1.e3 177 180
drug
drug

interaction DrugDDI.d439.s1.e1 DrugDDI.d439.s1.e2

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s2
In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine .

DrugDDI.d439.s2.e0 63 86
drug
tricyclic antidepressants
DrugDDI.d439.s2.e1 148 157
drug
cimetidine

interaction DrugDDI.d439.s2.e0 DrugDDI.d439.s2.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s3
In well-controlled patients undergoing concurrent therapy with cimetidine , a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.

DrugDDI.d439.s3.e0 56 65
drug
cimetidine
DrugDDI.d439.s3.e1 114 137
drug
tricyclic antidepressants

interaction DrugDDI.d439.s3.e0 DrugDDI.d439.s3.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s4
The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.

DrugDDI.d439.s4.e0 24 47
drug
tricyclic antidepressants
DrugDDI.d439.s4.e1 83 92
drug
cimetidine

interaction DrugDDI.d439.s4.e0 DrugDDI.d439.s4.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s5
Several of the tricyclic antidepressants have been cited in these reports.

DrugDDI.d439.s5.e0 12 35
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s6
There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants , including nortriptyline , when fluoxetine hydrochloride has been administered in combination with these agents.

DrugDDI.d439.s6.e0 76 90
drug
antidepressants
DrugDDI.d439.s6.e1 101 113
drug
nortriptyline
DrugDDI.d439.s6.e2 119 141
drug
fluoxetine hydrochloride

interaction DrugDDI.d439.s6.e0 DrugDDI.d439.s6.e2

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s7
Fluoxetine and its active metabolite , norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine ), that may affect strategies during conversion from one drug to the other.

DrugDDI.d439.s7.e0 0 9
drug
Fluoxetine
DrugDDI.d439.s7.e1 16 31
drug
active metabolite
DrugDDI.d439.s7.e2 79 91
drug
norfluoxetine
DrugDDI.d439.s7.e3 140 143
drug
drug

interaction DrugDDI.d439.s7.e0 DrugDDI.d439.s7.e2

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s8
Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a @stimulating@ effect in some depressed patients.

DrugDDI.d439.s8.e0 16 24
drug
reserpine
DrugDDI.d439.s8.e1 43 65
drug
tricyclic antidepressant

interaction DrugDDI.d439.s8.e0 DrugDDI.d439.s8.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s9
Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs .

DrugDDI.d439.s9.e0 62 87
drug
nortriptyline hydrochloride
DrugDDI.d439.s9.e1 103 122
drug
anticholinergic drugs
DrugDDI.d439.s9.e2 125 144
drug
sympathomimetic drugs

interaction DrugDDI.d439.s9.e0 DrugDDI.d439.s9.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s10
The patient should be informed that the response to alcohol may be exaggerated.

DrugDDI.d439.s10.e0 43 49
drug
alcohol



Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s11
Drugs Metabolized by P450IID6 @A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6.

DrugDDI.d439.s11.e0 0 4
drug
Drugs
DrugDDI.d439.s11.e1 85 88
drug
drug
DrugDDI.d439.s11.e2 117 130
drug
cytochrome P450

interaction DrugDDI.d439.s11.e0 DrugDDI.d439.s11.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s12
Such individuals are referred to as @poor metabolizers@ of drugs such as debrisoquin , dextromethorphan , and the tricyclic antidepressants .

DrugDDI.d439.s12.e0 50 54
drug
drugs
DrugDDI.d439.s12.e1 61 71
drug
debrisoquin
DrugDDI.d439.s12.e2 73 88
drug
dextromethorphan
DrugDDI.d439.s12.e3 96 119
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s13
These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses.

DrugDDI.d439.s13.e0 63 86
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s14
In addition, certain drugs that are metabolized by this isoenzyme , including many antidepressants ( tricyclic antidepressants , selective serotonin reuptake inhibitors , and others), may inhibit the activity of this isoenzyme , and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.

DrugDDI.d439.s14.e0 18 22
drug
drugs
DrugDDI.d439.s14.e1 47 55
drug
isoenzyme
DrugDDI.d439.s14.e2 70 84
drug
antidepressants
DrugDDI.d439.s14.e3 86 109
drug
tricyclic antidepressants
DrugDDI.d439.s14.e4 120 146
drug
serotonin reuptake inhibitors
DrugDDI.d439.s14.e5 186 194
drug
isoenzyme
DrugDDI.d439.s14.e6 292 296
drug
drugs

interaction DrugDDI.d439.s14.e0 DrugDDI.d439.s14.e5
interaction DrugDDI.d439.s14.e3 DrugDDI.d439.s14.e5

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s15
Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

DrugDDI.d439.s15.e0 16 39
drug
tricyclic antidepressants
DrugDDI.d439.s15.e1 49 53
drug
drugs
DrugDDI.d439.s15.e2 67 76
drug
cytochrome
DrugDDI.d439.s15.e3 138 160
drug
tricyclic antidepressant
DrugDDI.d439.s15.e4 171 174
drug
drug

interaction DrugDDI.d439.s15.e0 DrugDDI.d439.s15.e1

Abstract Id: DrugDDI.d439
Sentence Id: DrugDDI.d439.s16
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme , including other antidepressants , phenothiazines , carbamazepine , and Type 1C antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution.

DrugDDI.d439.s16.e0 29 52
drug
tricyclic antidepressants
DrugDDI.d439.s16.e1 62 66
drug
drugs
DrugDDI.d439.s16.e2 91 99
drug
isoenzyme
DrugDDI.d439.s16.e3 115 129
drug
antidepressants
DrugDDI.d439.s16.e4 131 144
drug
phenothiazines
DrugDDI.d439.s16.e5 146 158
drug
carbamazepine
DrugDDI.d439.s16.e6 169 183
drug
antiarrhythmics
DrugDDI.d439.s16.e7 188 198
drug
propafenone
DrugDDI.d439.s16.e8 200 209
drug
flecainide
DrugDDI.d439.s16.e9 214 222
drug
encainide
DrugDDI.d439.s16.e10 252 260
drug
quinidine

interaction DrugDDI.d439.s16.e0 DrugDDI.d439.s16.e1
interaction DrugDDI.d439.s16.e0 DrugDDI.d439.s16.e4
interaction DrugDDI.d439.s16.e0 DrugDDI.d439.s16.e6
interaction DrugDDI.d439.s16.e0 DrugDDI.d439.s16.e8

Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s0
Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.

DrugDDI.d445.s0.e0 13 19
drug
PEGASYS
DrugDDI.d445.s0.e1 87 90
drug
P450
DrugDDI.d445.s0.e2 111 122
drug
theophylline

interaction DrugDDI.d445.s0.e0 DrugDDI.d445.s0.e2

Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s1
Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS .

DrugDDI.d445.s1.e0 99 110
drug
theophylline
DrugDDI.d445.s1.e1 114 120
drug
PEGASYS

interaction DrugDDI.d445.s1.e0 DrugDDI.d445.s1.e1

Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s2
There was no effect on the pharmacokinetics of representative drugs metabolized by CYP 2C9 , CYP 2C19 , CYP 2D6 or CYP 3A4.

DrugDDI.d445.s2.e0 53 57
drug
drugs
DrugDDI.d445.s2.e1 71 76
drug
CYP 2C9
DrugDDI.d445.s2.e2 78 84
drug
CYP 2C19
DrugDDI.d445.s2.e3 86 91
drug
CYP 2D6
DrugDDI.d445.s2.e4 94 96
drug
CYP



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s3
In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS , PEGASYS treatment did not affect ribavirin distribution or clearance.

DrugDDI.d445.s3.e0 42 48
drug
PEGASYS
DrugDDI.d445.s3.e1 66 72
drug
COPEGUS
DrugDDI.d445.s3.e2 74 80
drug
PEGASYS
DrugDDI.d445.s3.e3 102 110
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s4
Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.

DrugDDI.d445.s4.e0 0 28
drug
Nucleoside Analogues Didanosine
DrugDDI.d445.s4.e1 48 54
drug
COPEGUS
DrugDDI.d445.s4.e2 58 67
drug
didanosine

interaction DrugDDI.d445.s4.e1 DrugDDI.d445.s4.e2

Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s6
Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV .

DrugDDI.d445.s6.e0 0 8
drug
Stavudine
DrugDDI.d445.s6.e1 12 21
drug
Zidovudine
DrugDDI.d445.s6.e2 54 62
drug
antiviral
DrugDDI.d445.s6.e3 73 81
drug
stavudine
DrugDDI.d445.s6.e4 85 94
drug
zidovudine
DrugDDI.d445.s6.e5 102 104
drug
HIV

interaction DrugDDI.d445.s6.e1 DrugDDI.d445.s6.e3
interaction DrugDDI.d445.s6.e1 DrugDDI.d445.s6.e4

Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s7
Therefore, concomitant use of ribavirin with either of these drugs should be avoided.

DrugDDI.d445.s7.e0 26 34
drug
ribavirin
DrugDDI.d445.s7.e1 52 56
drug
drugs

interaction DrugDDI.d445.s7.e0 DrugDDI.d445.s7.e1

Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s8
Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis PEGASYS has not been tested for its carcinogenic potential.

DrugDDI.d445.s8.e0 62 68
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s9
Mutagenesis PEGASYS did not cause DNA damage when tested in the Ame s bacterial mutagenicity assay and in the in vitro chromosomal aberration assay in human lymphocytes, either in the presence or absence of metabolic activation.

DrugDDI.d445.s9.e0 11 17
drug
PEGASYS
DrugDDI.d445.s9.e1 53 55
drug
Ame



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s10
Use With Ribavirin Ribavirin is genotoxic and mutagenic.

DrugDDI.d445.s10.e0 7 15
drug
Ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s11
The carcinogenic potential of ribavirin has not been fully determined.

DrugDDI.d445.s11.e0 26 34
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s12
In a p53 (+/-) mouse carcinogenicity study at doses up to the maximum tolerated dose of 100 mg/kg/day ribavirin was not oncogenic.

DrugDDI.d445.s12.e0 3 5
drug
p53
DrugDDI.d445.s12.e1 84 92
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s13
However, on a body surface area basis, this dose was 0.5 times maximum recommended human 24-hour dose of ribavirin .

DrugDDI.d445.s13.e0 87 95
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s14
A study in rats to assess the carcinogenic potential of ribavirin is ongoing.

DrugDDI.d445.s14.e0 46 54
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s15
Mutagenesis Impairment of Fertility PEGASYS may impair fertility in women.

DrugDDI.d445.s15.e0 32 38
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s16
Prolonged menstrual cycles and/or amenorrhea were observed in female cynomolgus monkeys given sc injections of 600 m g/kg/dose (7200 m g/m2/dose) of PEGASYS every other day for one month, at approximately 180 times the recommended weekly human dose for a 60 kg person (based on body surface area).

DrugDDI.d445.s16.e0 127 133
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s17
Menstrual cycle irregularities were accompanied by both a decrease and delay in the peak 17b - estradiol and progesterone levels following administration of PEGASYS to female monkeys.

DrugDDI.d445.s17.e0 79 87
drug
estradiol
DrugDDI.d445.s17.e1 134 140
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s19
Every other day dosing with 100m g/kg (1200m g/m2) PEGASYS (equivalent to approximately 30 times the recommended human dose) had no effects on cycle duration or reproductive hormone status.

DrugDDI.d445.s19.e0 42 48
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s20
The effects of PEGASYS on male fertility have not been studied.

DrugDDI.d445.s20.e0 12 18
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s21
However, no adverse effects on fertility were observed in male Rhesus monkeys treated with non- pegylated interferon alfa-2a for 5 months at doses up to 25 x 106 IU/kg/day.

DrugDDI.d445.s21.e0 81 106
drug
pegylated interferon alfa-2a



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s22
Pregnancy Pregnancy: Category C PEGASYS has not been studied for its teratogenic effect.

DrugDDI.d445.s22.e0 28 34
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s23
Non- pegylated interferon alfa-2a treatment of pregnant Rhesus monkeys at approximately 20 to 500 times the human weekly dose resulted in a statistically significant increase in abortions.

DrugDDI.d445.s23.e0 4 29
drug
pegylated interferon alfa-2a



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s24
No teratogenic effects were seen in the offspring deliver ed at term.

DrugDDI.d445.s24.e0 42 48
drug
deliver



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s25
PEGASYS should be assumed to have abortifacient potential.

DrugDDI.d445.s25.e0 0 6
drug
PEGASYS
DrugDDI.d445.s25.e1 28 40
drug
abortifacient



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s26
There are no adequate and well-controlled studies of PEGASYS in pregnant women.

DrugDDI.d445.s26.e0 45 51
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s27
PEGASYS is to be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

DrugDDI.d445.s27.e0 0 6
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s28
PEGASYS is recommended for use in women of childbearing potential only when they are using effective contraception during therapy.

DrugDDI.d445.s28.e0 0 6
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s29
Pregnancy: Category X: Use With Ribavirin (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin .

DrugDDI.d445.s29.e0 27 35
drug
Ribavirin
DrugDDI.d445.s29.e1 151 159
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s30
COPEGUS therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant .

DrugDDI.d445.s30.e0 0 6
drug
COPEGUS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s31
If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment cessation, such cases should be reported to the COPEGUS Pregnancy Registry at 1-800-526-6367.

DrugDDI.d445.s31.e0 133 139
drug
COPEGUS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s32
Nursing Mothers It is not known whether peginterferon or ribavirin or its components are excreted in human milk.

DrugDDI.d445.s32.e0 33 45
drug
peginterferon
DrugDDI.d445.s32.e1 48 56
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s33
The effect of orally ingested peginterferon or ribavirin from breast milk on the nursing infant has not been evaluated.

DrugDDI.d445.s33.e0 25 37
drug
peginterferon
DrugDDI.d445.s33.e1 40 48
drug
ribavirin



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s34
Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue PEGASYS and COPEGUS treatment.

DrugDDI.d445.s34.e0 47 51
drug
drugs
DrugDDI.d445.s34.e1 128 134
drug
PEGASYS
DrugDDI.d445.s34.e2 138 144
drug
COPEGUS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s35
Pediatric Use The safety and effectiveness of PEGASYS , alone or in combination with COPEGUS in patients below the age of 18 years have not been established.

DrugDDI.d445.s35.e0 0 8
drug
Pediatric
DrugDDI.d445.s35.e1 39 45
drug
PEGASYS
DrugDDI.d445.s35.e2 71 77
drug
COPEGUS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s36
PEGASYS contains benzyl alcohol .

DrugDDI.d445.s36.e0 0 6
drug
PEGASYS
DrugDDI.d445.s36.e1 15 27
drug
benzyl alcohol



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s37
Benzyl alcohol has been reported to be associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal.

DrugDDI.d445.s37.e0 0 12
drug
Benzyl alcohol



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s39
Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.

DrugDDI.d445.s39.e0 17 23
drug
PEGASYS
DrugDDI.d445.s39.e1 48 54
drug
COPEGUS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s40
Adverse reactions related to alpha interferon s, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of PEGASYS in this population.

DrugDDI.d445.s40.e0 25 39
drug
alpha interferon
DrugDDI.d445.s40.e1 155 161
drug
PEGASYS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s41
PEGASYS and COPEGUS are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.

DrugDDI.d445.s41.e0 0 6
drug
PEGASYS
DrugDDI.d445.s41.e1 10 16
drug
COPEGUS



Abstract Id: DrugDDI.d445
Sentence Id: DrugDDI.d445.s43
PEGASYS should be used with caution in patients with creatinine clearance  50 mL/min and COPEGUS should not be administered to patients with creatinine clearance  50 mL/min .

DrugDDI.d445.s43.e0 0 6
drug
PEGASYS
DrugDDI.d445.s43.e1 74 80
drug
COPEGUS



Abstract Id: DrugDDI.d142
Sentence Id: DrugDDI.d142.s0
Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).

DrugDDI.d142.s0.e0 0 13
drug
Phenothiazines
DrugDDI.d142.s0.e1 35 47
drug
phenothiazine



Abstract Id: DrugDDI.d142
Sentence Id: DrugDDI.d142.s1
Pyrantel (e.g., Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine .

DrugDDI.d142.s1.e0 0 7
drug
Pyrantel
DrugDDI.d142.s1.e1 14 22
drug
Antiminth
DrugDDI.d142.s1.e2 31 40
drug
piperazine
DrugDDI.d142.s1.e3 44 51
drug
pyrantel
DrugDDI.d142.s1.e4 83 92
drug
piperazine



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s0
ACE inhibitors : Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.

DrugDDI.d286.s0.e0 0 12
drug
ACE inhibitors
DrugDDI.d286.s0.e1 32 37
drug
NSAIDs
DrugDDI.d286.s0.e2 52 67
drug
antihypertensive
DrugDDI.d286.s0.e3 76 102
drug
Angiotensin Converting Enzyme

interaction DrugDDI.d286.s0.e1 DrugDDI.d286.s0.e3

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s1
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril , 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.

DrugDDI.d286.s1.e0 68 72
drug
VIOXX
DrugDDI.d286.s1.e1 92 101
drug
benazepril
DrugDDI.d286.s1.e2 199 210
drug
ACE inhibitor

interaction DrugDDI.d286.s1.e0 DrugDDI.d286.s1.e1

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s2
This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors .

DrugDDI.d286.s2.e0 57 61
drug
VIOXX
DrugDDI.d286.s2.e1 79 91
drug
ACE inhibitors

interaction DrugDDI.d286.s2.e0 DrugDDI.d286.s2.e1

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s3
Aspirin Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.

DrugDDI.d286.s3.e0 0 6
drug
Aspirin
DrugDDI.d286.s3.e1 42 48
drug
aspirin
DrugDDI.d286.s3.e2 53 57
drug
VIOXX
DrugDDI.d286.s3.e3 134 138
drug
VIOXX

interaction DrugDDI.d286.s3.e1 DrugDDI.d286.s3.e2

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s4
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.

DrugDDI.d286.s4.e0 158 170
drug
coated aspirin
DrugDDI.d286.s4.e1 175 179
drug
VIOXX
DrugDDI.d286.s4.e2 213 221
drug
ibuprofen



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s5
Patients taking low-dose aspirin plus ibuprofen were not studied.

DrugDDI.d286.s5.e0 22 28
drug
aspirin
DrugDDI.d286.s5.e1 33 41
drug
ibuprofen



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s6
At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin , as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.

DrugDDI.d286.s6.e0 14 18
drug
VIOXX
DrugDDI.d286.s6.e1 94 100
drug
aspirin



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s7
Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.

DrugDDI.d286.s7.e0 34 38
drug
VIOXX
DrugDDI.d286.s7.e1 58 64
drug
aspirin



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s8
Therefore, in patients taking VIOXX , antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis.

DrugDDI.d286.s8.e0 26 30
drug
VIOXX



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s9
Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.

DrugDDI.d286.s9.e0 57 61
drug
VIOXX
DrugDDI.d286.s9.e1 65 71
drug
aspirin



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s10
Cimetidine Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1 /2 by 15%.

DrugDDI.d286.s10.e0 0 9
drug
Cimetidine
DrugDDI.d286.s10.e1 42 55
drug
cimetidine [800
DrugDDI.d286.s10.e2 87 95
drug
rofecoxib
DrugDDI.d286.s10.e3 126 127
drug
t1

interaction DrugDDI.d286.s10.e1 DrugDDI.d286.s10.e2

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s12
Digoxin Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.

DrugDDI.d286.s12.e0 0 6
drug
Digoxin
DrugDDI.d286.s12.e1 99 105
drug
digoxin



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s13
Furosemide Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.

DrugDDI.d286.s13.e0 0 9
drug
Furosemide
DrugDDI.d286.s13.e1 74 79
drug
NSAIDs
DrugDDI.d286.s13.e2 92 102
drug
natriuretic
DrugDDI.d286.s13.e3 111 120
drug
furosemide
DrugDDI.d286.s13.e4 124 132
drug
thiazides

interaction DrugDDI.d286.s13.e1 DrugDDI.d286.s13.e3
interaction DrugDDI.d286.s13.e1 DrugDDI.d286.s13.e4

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s14
This response has been attributed to inhibition of renal prostaglandin synthesis.

DrugDDI.d286.s14.e0 48 60
drug
prostaglandin



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s15
Ketoconazole Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib .

DrugDDI.d286.s15.e0 0 11
drug
Ketoconazole
DrugDDI.d286.s15.e1 95 103
drug
rofecoxib



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s16
Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.

DrugDDI.d286.s16.e0 0 6
drug
Lithium
DrugDDI.d286.s16.e1 77 83
drug
lithium

interaction DrugDDI.d286.s16.e0 DrugDDI.d286.s16.e1

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s18
Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

DrugDDI.d286.s18.e0 9 13
drug
VIOXX
DrugDDI.d286.s18.e1 17 23
drug
lithium

interaction DrugDDI.d286.s18.e0 DrugDDI.d286.s18.e1

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s19
Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.

DrugDDI.d286.s19.e0 0 11
drug
Methotrexate
DrugDDI.d286.s19.e1 108 119
drug
methotrexate
DrugDDI.d286.s19.e2 172 183
drug
methotrexate



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s20
At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.

DrugDDI.d286.s20.e0 29 33
drug
VIOXX
DrugDDI.d286.s20.e1 142 153
drug
methotrexate

interaction DrugDDI.d286.s20.e0 DrugDDI.d286.s20.e1

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s21
At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).

DrugDDI.d286.s21.e0 57 68
drug
methotrexate
DrugDDI.d286.s21.e1 105 116
drug
methotrexate
DrugDDI.d286.s21.e2 142 150
drug
rofecoxib
DrugDDI.d286.s21.e3 159 170
drug
methotrexate

interaction DrugDDI.d286.s21.e1 DrugDDI.d286.s21.e2

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s22
Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.

DrugDDI.d286.s22.e0 67 71
drug
VIOXX
DrugDDI.d286.s22.e1 75 86
drug
methotrexate

interaction DrugDDI.d286.s22.e0 DrugDDI.d286.s22.e1

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s23
Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone .

DrugDDI.d286.s23.e0 0 17
drug
Oral Contraceptives
DrugDDI.d286.s23.e1 88 103
drug
ethinyl estradiol
DrugDDI.d286.s23.e2 107 119
drug
norethindrone



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s24
Prednisone / prednisolone Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone .

DrugDDI.d286.s24.e0 0 9
drug
Prednisone
DrugDDI.d286.s24.e1 11 22
drug
prednisolone
DrugDDI.d286.s24.e2 93 104
drug
prednisolone
DrugDDI.d286.s24.e3 107 116
drug
prednisone



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s25
Rifampin Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.

DrugDDI.d286.s25.e0 0 7
drug
Rifampin
DrugDDI.d286.s25.e1 27 31
drug
VIOXX
DrugDDI.d286.s25.e2 36 48
drug
rifampin 600 mg
DrugDDI.d286.s25.e3 123 131
drug
rofecoxib

interaction DrugDDI.d286.s25.e1 DrugDDI.d286.s25.e2

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s26
Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.

DrugDDI.d286.s26.e0 36 40
drug
VIOXX
DrugDDI.d286.s26.e1 94 98
drug
VIOXX



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s27
Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0-@)) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline .

DrugDDI.d286.s27.e0 0 11
drug
Theophylline
DrugDDI.d286.s27.e1 76 87
drug
theophylline
DrugDDI.d286.s27.e2 169 180
drug
theophylline



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s28
Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline .

DrugDDI.d286.s28.e0 20 31
drug
theophylline
DrugDDI.d286.s28.e1 85 89
drug
VIOXX
DrugDDI.d286.s28.e2 129 140
drug
theophylline

interaction DrugDDI.d286.s28.e1 DrugDDI.d286.s28.e2

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s29
These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 ( CYP ) 1A2.

DrugDDI.d286.s29.e0 20 28
drug
rofecoxib
DrugDDI.d286.s29.e1 58 71
drug
cytochrome P450
DrugDDI.d286.s29.e2 73 75
drug
CYP

interaction DrugDDI.d286.s29.e0 DrugDDI.d286.s29.e1
interaction DrugDDI.d286.s29.e0 DrugDDI.d286.s29.e2

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s30
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline , tacrine , and zileuton ).

DrugDDI.d286.s30.e0 52 56
drug
drugs
DrugDDI.d286.s30.e1 77 82
drug
CYP 1A2
DrugDDI.d286.s30.e2 89 101
drug
amitriptyline
DrugDDI.d286.s30.e3 103 109
drug
tacrine
DrugDDI.d286.s30.e4 114 121
drug
zileuton



Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s31
Warfarin Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.

DrugDDI.d286.s31.e0 0 7
drug
Warfarin
DrugDDI.d286.s31.e1 101 105
drug
VIOXX
DrugDDI.d286.s31.e2 132 139
drug
warfarin

interaction DrugDDI.d286.s31.e1 DrugDDI.d286.s31.e2

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s32
In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib , prothrombin time (measured as INR) was increased by approximately 8% to 11%.

DrugDDI.d286.s32.e0 60 67
drug
warfarin
DrugDDI.d286.s32.e1 71 79
drug
rofecoxib

interaction DrugDDI.d286.s32.e0 DrugDDI.d286.s32.e1

Abstract Id: DrugDDI.d286
Sentence Id: DrugDDI.d286.s33
In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin .

DrugDDI.d286.s33.e0 146 150
drug
VIOXX
DrugDDI.d286.s33.e1 167 174
drug
warfarin

interaction DrugDDI.d286.s33.e0 DrugDDI.d286.s33.e1

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s1
Several drug interaction studies have been completed with both INVIRASE and FORTOVASE .

DrugDDI.d332.s1.e0 54 61
drug
INVIRASE
DrugDDI.d332.s1.e1 65 73
drug
FORTOVASE



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s2
Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE .

DrugDDI.d332.s2.e0 42 50
drug
FORTOVASE
DrugDDI.d332.s2.e1 72 79
drug
INVIRASE



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s3
Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.

DrugDDI.d332.s3.e0 7 15
drug
ritonavir
DrugDDI.d332.s3.e1 89 97
drug
ritonavir



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s4
The metabolism of saquinavir is mediated by cytochrome P450 , with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism.

DrugDDI.d332.s4.e0 15 24
drug
saquinavir
DrugDDI.d332.s4.e1 37 50
drug
cytochrome P450
DrugDDI.d332.s4.e2 67 81
drug
isoenzyme CYP3A4



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s5
Additionally, saquinavir is a substrate for P- Glycoprotein (Pgp).

DrugDDI.d332.s5.e0 13 22
drug
saquinavir
DrugDDI.d332.s5.e1 40 51
drug
Glycoprotein



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s6
Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir .

DrugDDI.d332.s6.e0 10 14
drug
drugs
DrugDDI.d332.s6.e1 25 30
drug
CYP3A4
DrugDDI.d332.s6.e2 71 80
drug
saquinavir

interaction DrugDDI.d332.s6.e0 DrugDDI.d332.s6.e2

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s7
Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp.

DrugDDI.d332.s7.e0 10 19
drug
saquinavir
DrugDDI.d332.s7.e1 61 65
drug
drugs
DrugDDI.d332.s7.e2 86 91
drug
CYP3A4

interaction DrugDDI.d332.s7.e0 DrugDDI.d332.s7.e1

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s8
Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS.

DrugDDI.d332.s8.e0 0 4
drug
Drugs



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s9
Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.

DrugDDI.d332.s9.e0 10 14
drug
drugs
DrugDDI.d332.s9.e1 59 66
drug
INVIRASE
DrugDDI.d332.s9.e2 70 78
drug
ritonavir

interaction DrugDDI.d332.s9.e0 DrugDDI.d332.s9.e1
interaction DrugDDI.d332.s9.e0 DrugDDI.d332.s9.e2

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s11
When coadministering INVIRASE / ritonavir with any agent having a narrow therapeutic margin, such as anticoagulants , anticonvulsants , and antiarrhythmics , special attention is warranted.

DrugDDI.d332.s11.e0 19 26
drug
INVIRASE
DrugDDI.d332.s11.e1 28 36
drug
ritonavir
DrugDDI.d332.s11.e2 86 99
drug
anticoagulants
DrugDDI.d332.s11.e3 101 115
drug
anticonvulsants
DrugDDI.d332.s11.e4 120 134
drug
antiarrhythmics

interaction DrugDDI.d332.s11.e0 DrugDDI.d332.s11.e2
interaction DrugDDI.d332.s11.e0 DrugDDI.d332.s11.e3
interaction DrugDDI.d332.s11.e0 DrugDDI.d332.s11.e4
interaction DrugDDI.d332.s11.e1 DrugDDI.d332.s11.e2
interaction DrugDDI.d332.s11.e1 DrugDDI.d332.s11.e3
interaction DrugDDI.d332.s11.e1 DrugDDI.d332.s11.e4

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s13
Drugs That Should Not Be Coadministered With INVIRASE / Ritonavir .

DrugDDI.d332.s13.e0 0 4
drug
Drugs
DrugDDI.d332.s13.e1 38 45
drug
INVIRASE
DrugDDI.d332.s13.e2 47 55
drug
Ritonavir

interaction DrugDDI.d332.s13.e0 DrugDDI.d332.s13.e1
interaction DrugDDI.d332.s13.e0 DrugDDI.d332.s13.e2

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s14
Drug Class: Drug Name Clinical Comment .

DrugDDI.d332.s14.e0 0 3
drug
Drug
DrugDDI.d332.s14.e1 10 13
drug
Drug



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s15
Antiarrhythmics : Amiodarone , bepridil , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.

DrugDDI.d332.s15.e0 0 14
drug
Antiarrhythmics
DrugDDI.d332.s15.e1 16 25
drug
Amiodarone
DrugDDI.d332.s15.e2 27 34
drug
bepridil
DrugDDI.d332.s15.e3 36 45
drug
flecainide
DrugDDI.d332.s15.e4 47 57
drug
propafenone
DrugDDI.d332.s15.e5 59 67
drug
quinidine



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s16
Antihistamines : astemizole *, terfenadine * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.

DrugDDI.d332.s16.e0 0 13
drug
Antihistamines
DrugDDI.d332.s16.e1 15 24
drug
astemizole
DrugDDI.d332.s16.e2 27 37
drug
terfenadine



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s17
Ergot Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.

DrugDDI.d332.s17.e0 0 15
drug
Ergot Derivatives
DrugDDI.d332.s17.e1 17 33
drug
Dihydroergotamine
DrugDDI.d332.s17.e2 35 44
drug
ergonovine
DrugDDI.d332.s17.e3 46 55
drug
ergotamine
DrugDDI.d332.s17.e4 57 72
drug
methylergonovine
DrugDDI.d332.s17.e5 151 155
drug
ergot



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s18
Antimycobacterial Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .

DrugDDI.d332.s18.e0 0 22
drug
Antimycobacterial Agents
DrugDDI.d332.s18.e1 24 31
drug
rifampin
DrugDDI.d332.s18.e2 88 97
drug
saquinavir
DrugDDI.d332.s18.e3 155 164
drug
saquinavir

interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e2

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s19
Garlic Cap sules Garlic capsules should not be used while taking saquinavir ( FORTOVASE ) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.

DrugDDI.d332.s19.e0 0 8
drug
Garlic Cap
DrugDDI.d332.s19.e1 54 63
drug
saquinavir
DrugDDI.d332.s19.e2 65 73
drug
FORTOVASE
DrugDDI.d332.s19.e3 84 100
drug
protease inhibitor
DrugDDI.d332.s19.e4 124 133
drug
saquinavir

interaction DrugDDI.d332.s19.e0 DrugDDI.d332.s19.e1
interaction DrugDDI.d332.s19.e0 DrugDDI.d332.s19.e2

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s20
No data are available for the coadministration of INVIRASE / ritonavir or FORTOVASE / ritonavir and garlic capsules.

DrugDDI.d332.s20.e0 42 49
drug
INVIRASE
DrugDDI.d332.s20.e1 51 59
drug
ritonavir
DrugDDI.d332.s20.e2 62 70
drug
FORTOVASE
DrugDDI.d332.s20.e3 72 80
drug
ritonavir
DrugDDI.d332.s20.e4 84 89
drug
garlic



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s21
GI Motility Agent: cisapride * CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.

DrugDDI.d332.s21.e0 16 24
drug
cisapride



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s22
Herbal Products: St. John@s wort ( hypericum perforatum ) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors .

DrugDDI.d332.s22.e0 29 47
drug
hypericum perforatum
DrugDDI.d332.s22.e1 127 134
drug
INVIRASE
DrugDDI.d332.s22.e2 149 166
drug
protease inhibitors



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s23
HMG-CoA Reductase Inhibitors : lovastatin , simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.

DrugDDI.d332.s23.e0 0 25
drug
HMG-CoA Reductase Inhibitors
DrugDDI.d332.s23.e1 27 36
drug
lovastatin
DrugDDI.d332.s23.e2 38 48
drug
simvastatin



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s24
Sedatives / Hypnotics : triazolam , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.

DrugDDI.d332.s24.e0 0 8
drug
Sedatives
DrugDDI.d332.s24.e1 10 18
drug
Hypnotics
DrugDDI.d332.s24.e2 20 28
drug
triazolam
DrugDDI.d332.s24.e3 30 38
drug
midazolam



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s26
Drugs That Are Mainly Metabolized by CYP3A4 .

DrugDDI.d332.s26.e0 0 4
drug
Drugs
DrugDDI.d332.s26.e1 31 36
drug
CYP3A4



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s27
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ; .

DrugDDI.d332.s27.e0 64 68
drug
drugs
DrugDDI.d332.s27.e1 95 100
drug
CYP3A4
DrugDDI.d332.s27.e2 105 126
drug
calcium channel blockers
DrugDDI.d332.s27.e3 128 134
drug
dapsone
DrugDDI.d332.s27.e4 136 147
drug
disopyramide
DrugDDI.d332.s27.e5 149 155
drug
quinine
DrugDDI.d332.s27.e6 157 166
drug
amiodarone
DrugDDI.d332.s27.e7 168 176
drug
quinidine
DrugDDI.d332.s27.e8 178 185
drug
warfarin
DrugDDI.d332.s27.e9 187 196
drug
tacrolimus
DrugDDI.d332.s27.e10 198 209
drug
cyclosporine
DrugDDI.d332.s27.e11 211 226
drug
ergot derivatives
DrugDDI.d332.s27.e12 228 235
drug
pimozide
DrugDDI.d332.s27.e13 237 249
drug
carbamazepine
DrugDDI.d332.s27.e14 251 258
drug
fentanyl
DrugDDI.d332.s27.e15 260 269
drug
alfentanyl
DrugDDI.d332.s27.e16 271 280
drug
alprazolam
DrugDDI.d332.s27.e17 285 293
drug
triazolam
DrugDDI.d332.s27.e18 352 361
drug
saquinavir

interaction DrugDDI.d332.s27.e0 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e1 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e2 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e3 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e4 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e5 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e6 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e7 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e8 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e9 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e10 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e11 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e12 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e13 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e14 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e15 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e16 DrugDDI.d332.s27.e18
interaction DrugDDI.d332.s27.e17 DrugDDI.d332.s27.e18

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s29
Since INVIRASE is coadministered with ritonavir , the ritonavir label should be reviewed for additional drugs that should not be coadministered.

DrugDDI.d332.s29.e0 5 12
drug
INVIRASE
DrugDDI.d332.s29.e1 33 41
drug
ritonavir
DrugDDI.d332.s29.e2 46 54
drug
ritonavir
DrugDDI.d332.s29.e3 89 93
drug
drugs

interaction DrugDDI.d332.s29.e0 DrugDDI.d332.s29.e1

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s30
Inducers of CYP3A4 .

DrugDDI.d332.s30.e0 10 15
drug
CYP3A4



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s31
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital , phenytoin , dexamethasone , carbamazepine ) may result in decreased plasma levels of saquinavir .

DrugDDI.d332.s31.e0 52 57
drug
CYP3A4
DrugDDI.d332.s31.e1 62 74
drug
phenobarbital
DrugDDI.d332.s31.e2 76 84
drug
phenytoin
DrugDDI.d332.s31.e3 86 98
drug
dexamethasone
DrugDDI.d332.s31.e4 100 112
drug
carbamazepine
DrugDDI.d332.s31.e5 148 157
drug
saquinavir

interaction DrugDDI.d332.s31.e0 DrugDDI.d332.s31.e5
interaction DrugDDI.d332.s31.e1 DrugDDI.d332.s31.e5
interaction DrugDDI.d332.s31.e2 DrugDDI.d332.s31.e5
interaction DrugDDI.d332.s31.e3 DrugDDI.d332.s31.e5
interaction DrugDDI.d332.s31.e4 DrugDDI.d332.s31.e5

Abstract Id: DrugDDI.d48
Sentence Id: DrugDDI.d48.s0
Sulfacetamide preparation s are incompatible with silver preparation s.

DrugDDI.d48.s0.e0 0 23
drug
Sulfacetamide preparation
DrugDDI.d48.s0.e1 44 60
drug
silver preparation



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s1
Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol ) (with long-term, high-dose use) or .

DrugDDI.d116.s1.e0 0 12
drug
Sulfapyridine
DrugDDI.d116.s1.e1 47 59
drug
Acetaminophen
DrugDDI.d116.s1.e2 66 72
drug
Tylenol



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s2
- Amiodarone (e.g., Cordarone ) or .

DrugDDI.d116.s2.e0 1 10
drug
Amiodarone
DrugDDI.d116.s2.e1 17 25
drug
Cordarone



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s3
- Anabolic steroids ( nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar ], oxymetholone [e.g., Anadrol ], stanozolol [e.g., Winstrol ]) or .

DrugDDI.d116.s3.e0 1 16
drug
Anabolic steroids
DrugDDI.d116.s3.e1 18 27
drug
nandrolone
DrugDDI.d116.s3.e2 44 54
drug
oxandrolone
DrugDDI.d116.s3.e3 61 66
drug
Anavar
DrugDDI.d116.s3.e4 69 80
drug
oxymetholone
DrugDDI.d116.s3.e5 87 93
drug
Anadrol
DrugDDI.d116.s3.e6 96 105
drug
stanozolol
DrugDDI.d116.s3.e7 112 119
drug
Winstrol



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s4
- Androgens (male hormones) or .

DrugDDI.d116.s4.e0 1 9
drug
Androgens



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s5
- Antithyroid agents ( medicine for overactive thyroid) or .

DrugDDI.d116.s5.e0 1 17
drug
Antithyroid agents
DrugDDI.d116.s5.e1 19 26
drug
medicine



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s6
- Carbamazepine (e.g., Tegretol ) or .

DrugDDI.d116.s6.e0 1 13
drug
Carbamazepine
DrugDDI.d116.s6.e1 20 27
drug
Tegretol



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s7
- Carmustine (e.g., BiCNU ) or .

DrugDDI.d116.s7.e0 1 10
drug
Carmustine
DrugDDI.d116.s7.e1 17 21
drug
BiCNU



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s8
- Chloroquine (e.g., Aralen ) or .

DrugDDI.d116.s8.e0 1 11
drug
Chloroquine
DrugDDI.d116.s8.e1 18 23
drug
Aralen



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s9
- Dantrolene (e.g., Dantrium ) or .

DrugDDI.d116.s9.e0 1 10
drug
Dantrolene
DrugDDI.d116.s9.e1 17 24
drug
Dantrium



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s10
- Daunorubicin (e.g., Cerubidine ) or .

DrugDDI.d116.s10.e0 1 12
drug
Daunorubicin
DrugDDI.d116.s10.e1 19 28
drug
Cerubidine



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s11
- Disulfiram (e.g., Antabuse ) or .

DrugDDI.d116.s11.e0 1 10
drug
Disulfiram
DrugDDI.d116.s11.e1 17 24
drug
Antabuse



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s12
- Divalproex (e.g., Depakote ) or .

DrugDDI.d116.s12.e0 1 10
drug
Divalproex
DrugDDI.d116.s12.e1 17 24
drug
Depakote



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s13
- Estrogens (female hormones) or .

DrugDDI.d116.s13.e0 1 9
drug
Estrogens



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s14
- Etretinate (e.g., Tegison ) or .

DrugDDI.d116.s14.e0 1 10
drug
Etretinate
DrugDDI.d116.s14.e1 17 23
drug
Tegison



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s15
- Gold salt s ( medicine for arthritis) or .

DrugDDI.d116.s15.e0 1 8
drug
Gold salt
DrugDDI.d116.s15.e1 11 18
drug
medicine



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s16
- Hydroxychloroquine (e.g., Plaquenil ) or .

DrugDDI.d116.s16.e0 1 18
drug
Hydroxychloroquine
DrugDDI.d116.s16.e1 25 33
drug
Plaquenil



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s17
- Mercaptopurine (e.g., Purinethol ) or .

DrugDDI.d116.s17.e0 1 14
drug
Mercaptopurine
DrugDDI.d116.s17.e1 21 30
drug
Purinethol



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s18
- Naltrexone (e.g., Trexan ) (with long-term, high-dose use) or .

DrugDDI.d116.s18.e0 1 10
drug
Naltrexone
DrugDDI.d116.s18.e1 17 22
drug
Trexan



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s19
- Oral contraceptives ( birth control pills ) containing estrogen or .

DrugDDI.d116.s19.e0 1 18
drug
Oral contraceptives
DrugDDI.d116.s19.e1 20 36
drug
birth control pills
DrugDDI.d116.s19.e2 48 55
drug
estrogen



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s20
- Other anti-infectives by mouth or by injection ( medicine for infection) or .

DrugDDI.d116.s20.e0 6 20
drug
anti-infectives
DrugDDI.d116.s20.e1 42 49
drug
medicine



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s21
- Phenothiazines ( acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine ], fluphenazine [e.g., Prolixin ], mesoridazine [e.g., Serentil ], perphenazine [e.g., Trilafon ], prochlorperazine [e.g., Compazine ], promazine [e.g., Sparine ], promethazine [e.g., Phenergan ], thioridazine [e.g., Mellaril ], trifluoperazine [e.g., Stelazine ], triflupromazine [e.g., Vesprin ], trimeprazine [e.g., Temaril ]) or .

DrugDDI.d116.s21.e0 1 14
drug
Phenothiazines
DrugDDI.d116.s21.e1 16 29
drug
acetophenazine
DrugDDI.d116.s21.e2 44 57
drug
chlorpromazine
DrugDDI.d116.s21.e3 64 72
drug
Thorazine
DrugDDI.d116.s21.e4 75 86
drug
fluphenazine
DrugDDI.d116.s21.e5 93 100
drug
Prolixin
DrugDDI.d116.s21.e6 103 114
drug
mesoridazine
DrugDDI.d116.s21.e7 121 128
drug
Serentil
DrugDDI.d116.s21.e8 131 142
drug
perphenazine
DrugDDI.d116.s21.e9 149 156
drug
Trilafon
DrugDDI.d116.s21.e10 159 174
drug
prochlorperazine
DrugDDI.d116.s21.e11 181 189
drug
Compazine
DrugDDI.d116.s21.e12 192 200
drug
promazine
DrugDDI.d116.s21.e13 207 213
drug
Sparine
DrugDDI.d116.s21.e14 216 227
drug
promethazine
DrugDDI.d116.s21.e15 234 242
drug
Phenergan
DrugDDI.d116.s21.e16 245 256
drug
thioridazine
DrugDDI.d116.s21.e17 263 270
drug
Mellaril
DrugDDI.d116.s21.e18 273 287
drug
trifluoperazine
DrugDDI.d116.s21.e19 294 302
drug
Stelazine
DrugDDI.d116.s21.e20 305 319
drug
triflupromazine
DrugDDI.d116.s21.e21 326 332
drug
Vesprin
DrugDDI.d116.s21.e22 335 346
drug
trimeprazine
DrugDDI.d116.s21.e23 353 359
drug
Temaril



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s22
- Plicamycin (e.g., Mithracin ) or .

DrugDDI.d116.s22.e0 1 10
drug
Plicamycin
DrugDDI.d116.s22.e1 17 25
drug
Mithracin



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s23
- Valproic acid (e.g., Depakene )@Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver .

DrugDDI.d116.s23.e0 1 12
drug
Valproic acid
DrugDDI.d116.s23.e1 19 26
drug
Depakene
DrugDDI.d116.s23.e2 34 46
drug
sulfapyridine
DrugDDI.d116.s23.e3 56 64
drug
medicines
DrugDDI.d116.s23.e4 110 114
drug
liver

interaction DrugDDI.d116.s23.e2 DrugDDI.d116.s23.e3

Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s24
- Acetohydroxamic acid (e.g., Lithostat ) or .

DrugDDI.d116.s24.e0 1 19
drug
Acetohydroxamic acid
DrugDDI.d116.s24.e1 26 34
drug
Lithostat



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s25
- Dapsone or .

DrugDDI.d116.s25.e0 1 7
drug
Dapsone



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s26
- Furazolidone (e.g., Furoxone ) or .

DrugDDI.d116.s26.e0 1 12
drug
Furazolidone
DrugDDI.d116.s26.e1 19 26
drug
Furoxone



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s27
- Nitrofurantoin (e.g., Furadantin ) or .

DrugDDI.d116.s27.e0 1 14
drug
Nitrofurantoin
DrugDDI.d116.s27.e1 21 30
drug
Furadantin



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s28
- Primaquine or .

DrugDDI.d116.s28.e0 1 10
drug
Primaquine



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s29
- Procainamide (e.g., Pronestyl ) or .

DrugDDI.d116.s29.e0 1 12
drug
Procainamide
DrugDDI.d116.s29.e1 19 27
drug
Pronestyl



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s30
- Quinidine (e.g., Quinidex ) or .

DrugDDI.d116.s30.e0 1 9
drug
Quinidine
DrugDDI.d116.s30.e1 16 23
drug
Quinidex



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s31
- Quinine (e.g., Quinamm ) or .

DrugDDI.d116.s31.e0 1 7
drug
Quinine
DrugDDI.d116.s31.e1 14 20
drug
Quinamm



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s32
- Sulfoxone (e.g., Diasone ) or .

DrugDDI.d116.s32.e0 1 9
drug
Sulfoxone
DrugDDI.d116.s32.e1 16 22
drug
Diasone



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s33
- Vitamin K (e.g., AquaMEPHYTON , Synkayvite)@Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood .

DrugDDI.d116.s33.e0 1 8
drug
Vitamin K
DrugDDI.d116.s33.e1 15 26
drug
AquaMEPHYTON
DrugDDI.d116.s33.e2 45 57
drug
sulfapyridine
DrugDDI.d116.s33.e3 67 75
drug
medicines

interaction DrugDDI.d116.s33.e2 DrugDDI.d116.s33.e3

Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s34
- Anticoagulants ( blood thinner s) or .

DrugDDI.d116.s34.e0 1 14
drug
Anticoagulants
DrugDDI.d116.s34.e1 16 27
drug
blood thinner



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s35
- Ethotoin (e.g., Peganone ) or .

DrugDDI.d116.s35.e0 1 8
drug
Ethotoin
DrugDDI.d116.s35.e1 15 22
drug
Peganone



Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s36
- Mephenytoin (e.g., Mesantoin )@Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines .

DrugDDI.d116.s36.e0 1 11
drug
Mephenytoin
DrugDDI.d116.s36.e1 18 26
drug
Mesantoin
DrugDDI.d116.s36.e2 34 46
drug
sulfapyridine
DrugDDI.d116.s36.e3 56 64
drug
medicines
DrugDDI.d116.s36.e4 105 113
drug
medicines

interaction DrugDDI.d116.s36.e2 DrugDDI.d116.s36.e4

Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s37
- Antidiabetics , oral (diabetes medicine you take by mouth)@Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics .

DrugDDI.d116.s37.e0 1 13
drug
Antidiabetics
DrugDDI.d116.s37.e1 61 73
drug
antidiabetics
DrugDDI.d116.s37.e2 78 90
drug
sulfapyridine
DrugDDI.d116.s37.e3 167 179
drug
antidiabetics

interaction DrugDDI.d116.s37.e1 DrugDDI.d116.s37.e2

Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s38
- Methotrexate (e.g., Mexate )@Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate .

DrugDDI.d116.s38.e0 1 12
drug
Methotrexate
DrugDDI.d116.s38.e1 19 24
drug
Mexate
DrugDDI.d116.s38.e2 32 43
drug
methotrexate
DrugDDI.d116.s38.e3 48 60
drug
sulfapyridine
DrugDDI.d116.s38.e4 106 110
drug
liver
DrugDDI.d116.s38.e5 133 144
drug
methotrexate

interaction DrugDDI.d116.s38.e2 DrugDDI.d116.s38.e3

Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s39
- Methyldopa (e.g., Aldomet )@Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood .

DrugDDI.d116.s39.e0 1 10
drug
Methyldopa
DrugDDI.d116.s39.e1 17 23
drug
Aldomet
DrugDDI.d116.s39.e2 31 40
drug
methyldopa
DrugDDI.d116.s39.e3 45 57
drug
sulfapyridine
DrugDDI.d116.s39.e4 103 107
drug
liver

interaction DrugDDI.d116.s39.e2 DrugDDI.d116.s39.e3

Abstract Id: DrugDDI.d116
Sentence Id: DrugDDI.d116.s40
- Phenytoin (e.g., Dilantin )@Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin .

DrugDDI.d116.s40.e0 1 9
drug
Phenytoin
DrugDDI.d116.s40.e1 16 23
drug
Dilantin
DrugDDI.d116.s40.e2 31 39
drug
phenytoin
DrugDDI.d116.s40.e3 44 56
drug
sulfapyridine
DrugDDI.d116.s40.e4 102 106
drug
liver
DrugDDI.d116.s40.e5 129 137
drug
phenytoin

interaction DrugDDI.d116.s40.e2 DrugDDI.d116.s40.e3

Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s0
In evaluating the potential for interactions among co-administered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration.

DrugDDI.d130.s0.e0 71 75
drug
drugs



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s1
Phenytoin , phenobarbital and carbamazepine are ge nerally classified as enzyme inducers; .

DrugDDI.d130.s1.e0 0 8
drug
Phenytoin
DrugDDI.d130.s1.e1 10 22
drug
phenobarbital
DrugDDI.d130.s1.e2 26 38
drug
carbamazepine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s2
valproate and gabapentin are not.

DrugDDI.d130.s2.e0 0 8
drug
valproate
DrugDDI.d130.s2.e1 12 21
drug
gabapentin



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s3
GABITRIL is considered to be a non-enzyme inducing AED.

DrugDDI.d130.s3.e0 0 7
drug
GABITRIL



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s5
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.

DrugDDI.d130.s5.e0 9 16
drug
GABITRIL
DrugDDI.d130.s5.e1 36 40
drug
Drugs
DrugDDI.d130.s5.e2 48 56
drug
Phenytoin
DrugDDI.d130.s5.e3 58 66
drug
Tiagabine
DrugDDI.d130.s5.e4 117 125
drug
phenytoin



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s6
Carbamazepine : Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.

DrugDDI.d130.s6.e0 0 12
drug
Carbamazepine
DrugDDI.d130.s6.e1 14 22
drug
Tiagabine
DrugDDI.d130.s6.e2 73 85
drug
carbamazepine
DrugDDI.d130.s6.e3 91 107
drug
epoxide metabolite



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s7
Valproate : Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.

DrugDDI.d130.s7.e0 0 8
drug
Valproate
DrugDDI.d130.s7.e1 10 18
drug
Tiagabine
DrugDDI.d130.s7.e2 64 72
drug
valproate

interaction DrugDDI.d130.s7.e1 DrugDDI.d130.s7.e2

Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s8
Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone .

DrugDDI.d130.s8.e0 0 12
drug
Phenobarbital
DrugDDI.d130.s8.e1 15 23
drug
Primidone
DrugDDI.d130.s8.e2 94 102
drug
tiagabine
DrugDDI.d130.s8.e3 123 135
drug
phenobarbital
DrugDDI.d130.s8.e4 138 146
drug
primidone



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s9
The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.

DrugDDI.d130.s9.e0 13 21
drug
tiagabine
DrugDDI.d130.s9.e1 104 116
drug
phenobarbital
DrugDDI.d130.s9.e2 119 127
drug
primidone



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s10
Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.

DrugDDI.d130.s10.e0 26 30
drug
Drugs
DrugDDI.d130.s10.e1 39 46
drug
GABITRIL
DrugDDI.d130.s10.e2 48 60
drug
Carbamazepine
DrugDDI.d130.s10.e3 107 115
drug
tiagabine
DrugDDI.d130.s10.e4 153 165
drug
carbamazepine

interaction DrugDDI.d130.s10.e3 DrugDDI.d130.s10.e4

Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s11
Phenytoin : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.

DrugDDI.d130.s11.e0 0 8
drug
Phenytoin
DrugDDI.d130.s11.e1 55 63
drug
tiagabine
DrugDDI.d130.s11.e2 101 109
drug
phenytoin

interaction DrugDDI.d130.s11.e1 DrugDDI.d130.s11.e2

Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s12
Phenobarbital ( Primidone ): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( primidone ) with or without other enzyme-inducing AEDs.

DrugDDI.d130.s12.e0 0 12
drug
Phenobarbital
DrugDDI.d130.s12.e1 14 22
drug
Primidone
DrugDDI.d130.s12.e2 70 78
drug
tiagabine
DrugDDI.d130.s12.e3 116 128
drug
phenobarbital
DrugDDI.d130.s12.e4 130 138
drug
primidone

interaction DrugDDI.d130.s12.e2 DrugDDI.d130.s12.e3
interaction DrugDDI.d130.s12.e2 DrugDDI.d130.s12.e4

Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s13
Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.

DrugDDI.d130.s13.e0 0 8
drug
Valproate
DrugDDI.d130.s13.e1 23 31
drug
tiagabine
DrugDDI.d130.s13.e2 48 56
drug
valproate
DrugDDI.d130.s13.e3 81 89
drug
tiagabine
DrugDDI.d130.s13.e4 110 118
drug
valproate
DrugDDI.d130.s13.e5 232 240
drug
tiagabine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s15
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.

DrugDDI.d130.s15.e0 13 20
drug
GABITRIL
DrugDDI.d130.s15.e1 30 34
drug
Drugs
DrugDDI.d130.s15.e2 36 45
drug
Cimetidine
DrugDDI.d130.s15.e3 66 75
drug
cimetidine
DrugDDI.d130.s15.e4 103 111
drug
tiagabine
DrugDDI.d130.s15.e5 136 144
drug
tiagabine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s16
Theophylline : A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.

DrugDDI.d130.s16.e0 0 11
drug
Theophylline
DrugDDI.d130.s16.e1 30 38
drug
tiagabine
DrugDDI.d130.s16.e2 72 83
drug
theophylline



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s17
Warfarin : No significant differences were observed in the steady-state pharmacokinetics of R- warfarin or S- warfarin with the addition of tiagabine given as a single dose.

DrugDDI.d130.s17.e0 0 7
drug
Warfarin
DrugDDI.d130.s17.e1 82 89
drug
warfarin
DrugDDI.d130.s17.e2 94 101
drug
warfarin
DrugDDI.d130.s17.e3 119 127
drug
tiagabine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s18
Prothrombin times were not affected by tiagabine .

DrugDDI.d130.s18.e0 33 41
drug
tiagabine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s19
Digoxin : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin .

DrugDDI.d130.s19.e0 0 6
drug
Digoxin
DrugDDI.d130.s19.e1 35 43
drug
tiagabine
DrugDDI.d130.s19.e2 89 95
drug
digoxin
DrugDDI.d130.s19.e3 128 134
drug
digoxin



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s20
Ethanol or Triazolam : No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.

DrugDDI.d130.s20.e0 0 6
drug
Ethanol
DrugDDI.d130.s20.e1 9 17
drug
Triazolam
DrugDDI.d130.s20.e2 78 86
drug
triazolam
DrugDDI.d130.s20.e3 99 107
drug
tiagabine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s21
The pharmacokinetics of ethanol were not affected by multiple-dose administration of tiagabine .

DrugDDI.d130.s21.e0 21 27
drug
ethanol
DrugDDI.d130.s21.e1 74 82
drug
tiagabine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s22
Tiagabine has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or alcohol .

DrugDDI.d130.s22.e0 0 8
drug
Tiagabine
DrugDDI.d130.s22.e1 90 96
drug
alcohol



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s23
Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine .

DrugDDI.d130.s23.e0 37 41
drug
drugs
DrugDDI.d130.s23.e1 73 79
drug
ethanol
DrugDDI.d130.s23.e2 82 90
drug
triazolam
DrugDDI.d130.s23.e3 130 138
drug
tiagabine

interaction DrugDDI.d130.s23.e0 DrugDDI.d130.s23.e2
interaction DrugDDI.d130.s23.e1 DrugDDI.d130.s23.e2

Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s24
Oral Contraceptives : Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.

DrugDDI.d130.s24.e0 0 17
drug
Oral Contraceptives
DrugDDI.d130.s24.e1 47 55
drug
tiagabine
DrugDDI.d130.s24.e2 108 125
drug
oral contraceptives



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s25
Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.

DrugDDI.d130.s25.e0 0 9
drug
Antipyrine
DrugDDI.d130.s25.e1 11 20
drug
Antipyrine
DrugDDI.d130.s25.e2 80 88
drug
tiagabine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s26
This indicates that tiagabine does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of antipyrine .

DrugDDI.d130.s26.e0 17 25
drug
tiagabine
DrugDDI.d130.s26.e1 71 86
drug
microsomal enzyme
DrugDDI.d130.s26.e2 123 132
drug
antipyrine



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s27
Interaction of GABITRIL with Highly Protein Bound Drugs: In vitro data showed that tiagabine is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.

DrugDDI.d130.s27.e0 13 20
drug
GABITRIL
DrugDDI.d130.s27.e1 31 37
drug
Protein
DrugDDI.d130.s27.e2 70 78
drug
tiagabine
DrugDDI.d130.s27.e3 96 108
drug
plasma protein



Abstract Id: DrugDDI.d130
Sentence Id: DrugDDI.d130.s28
Such an interaction can potentially lead to higher free fractions of either tiagabine or the competing drug .

DrugDDI.d130.s28.e0 64 72
drug
tiagabine
DrugDDI.d130.s28.e1 87 90
drug
drug



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s0
The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form.

DrugDDI.d265.s0.e0 29 38
drug
valdecoxib
DrugDDI.d265.s0.e1 60 69
drug
valdecoxib



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s1
The results from trials using the intravenous prodrug are reported in this section as they relate to the role of valdecoxib in drug interactions.

DrugDDI.d265.s1.e0 93 102
drug
valdecoxib



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s2
General: In humans, valdecoxib metabolism is predominantly mediated via CYP 3A4 and 2C9 with glucuronidation being a further (20%) route of metabolism.

DrugDDI.d265.s2.e0 17 26
drug
valdecoxib
DrugDDI.d265.s2.e1 63 65
drug
CYP
DrugDDI.d265.s2.e2 72 74
drug
2C9



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s3
In vitro studies indicate that valdecoxib is a moderate inhibitor of CYP 2C19 (IC50 = 6 @g/mL or 19 @M) and 2C9 (IC50 = 13 @g/mL or 41 @M), and a weak inhibitor of CYP 2D6 (IC50 = 31 @g/mL or 100 @M) and 3A4 (IC50 = 44 @g/mL or 141 @M )..

DrugDDI.d265.s3.e0 26 35
drug
valdecoxib
DrugDDI.d265.s3.e1 58 64
drug
CYP 2C19
DrugDDI.d265.s3.e2 130 135
drug
CYP 2D6



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s4
Aspirin : Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.

DrugDDI.d265.s4.e0 0 6
drug
Aspirin
DrugDDI.d265.s4.e1 35 41
drug
aspirin
DrugDDI.d265.s4.e2 46 55
drug
valdecoxib
DrugDDI.d265.s4.e3 122 131
drug
valdecoxib

interaction DrugDDI.d265.s4.e1 DrugDDI.d265.s4.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s5
Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.

DrugDDI.d265.s5.e0 37 46
drug
valdecoxib
DrugDDI.d265.s5.e1 66 72
drug
aspirin



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s6
In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin -mediated inhibition of arachidonate - or collagen -stimulated platelet aggregation.

DrugDDI.d265.s6.e0 72 81
drug
valdecoxib
DrugDDI.d265.s6.e1 112 121
drug
valdecoxib
DrugDDI.d265.s6.e2 142 148
drug
aspirin
DrugDDI.d265.s6.e3 170 181
drug
arachidonate
DrugDDI.d265.s6.e4 185 192
drug
collagen



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s7
Methotrexate : Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate .

DrugDDI.d265.s7.e0 0 11
drug
Methotrexate
DrugDDI.d265.s7.e1 13 26
drug
Valdecoxib 10 mg
DrugDDI.d265.s7.e2 95 106
drug
methotrexate



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s8
ACE-inhibitors :Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors .

DrugDDI.d265.s8.e0 0 13
drug
ACE-inhibitors
DrugDDI.d265.s8.e1 33 38
drug
NSAIDs
DrugDDI.d265.s8.e2 53 68
drug
antihypertensive
DrugDDI.d265.s8.e3 77 90
drug
ACE-inhibitors

interaction DrugDDI.d265.s8.e1 DrugDDI.d265.s8.e3

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s9
This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors .

DrugDDI.d265.s9.e0 57 62
drug
BEXTRA
DrugDDI.d265.s9.e1 80 93
drug
ACE-inhibitors

interaction DrugDDI.d265.s9.e0 DrugDDI.d265.s9.e1

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s10
Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.

DrugDDI.d265.s10.e0 0 9
drug
Furosemide
DrugDDI.d265.s10.e1 75 80
drug
NSAIDs
DrugDDI.d265.s10.e2 93 103
drug
natriuretic
DrugDDI.d265.s10.e3 112 121
drug
furosemide
DrugDDI.d265.s10.e4 125 133
drug
thiazides

interaction DrugDDI.d265.s10.e1 DrugDDI.d265.s10.e3
interaction DrugDDI.d265.s10.e1 DrugDDI.d265.s10.e4

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s11
This response has been attributed to inhibition of renal prostaglandin synthesis.

DrugDDI.d265.s11.e0 48 60
drug
prostaglandin



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s12
Anticonvulsants ( Phenytoin ): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).

DrugDDI.d265.s12.e0 0 14
drug
Anticonvulsants
DrugDDI.d265.s12.e1 16 24
drug
Phenytoin
DrugDDI.d265.s12.e2 59 68
drug
valdecoxib
DrugDDI.d265.s12.e3 74 76
drug
BID
DrugDDI.d265.s12.e4 160 168
drug
phenytoin
DrugDDI.d265.s12.e5 171 173
drug
CYP

interaction DrugDDI.d265.s12.e2 DrugDDI.d265.s12.e4

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s13
Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.

DrugDDI.d265.s13.e0 27 36
drug
valdecoxib
DrugDDI.d265.s13.e1 88 96
drug
phenytoin

interaction DrugDDI.d265.s13.e0 DrugDDI.d265.s13.e1

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s14
Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).

DrugDDI.d265.s14.e0 0 9
drug
Valdecoxib
DrugDDI.d265.s14.e1 74 82
drug
phenytoin
DrugDDI.d265.s14.e2 85 90
drug
CYP 2C9
DrugDDI.d265.s14.e3 94 100
drug
CYP 2C19



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s15
Drug interaction studies with other anticonvulsants have not been conducted.

DrugDDI.d265.s15.e0 31 45
drug
anticonvulsants



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s16
Routine monitoring should be performed when therapy with BEXTRA is either initiated or discontinued in patients on anticonvulsant therapy.

DrugDDI.d265.s16.e0 49 54
drug
BEXTRA



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s17
Dextromethorphan : Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.

DrugDDI.d265.s17.e0 0 15
drug
Dextromethorphan
DrugDDI.d265.s17.e1 17 32
drug
Dextromethorphan
DrugDDI.d265.s17.e2 57 62
drug
CYP 2D6



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s18
Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.

DrugDDI.d265.s18.e0 20 29
drug
valdecoxib
DrugDDI.d265.s18.e1 35 37
drug
BID
DrugDDI.d265.s18.e2 79 94
drug
dextromethorphan
DrugDDI.d265.s18.e3 135 144
drug
valdecoxib

interaction DrugDDI.d265.s18.e0 DrugDDI.d265.s18.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s19
Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.

DrugDDI.d265.s19.e0 6 21
drug
dextromethorphan
DrugDDI.d265.s19.e1 68 77
drug
valdecoxib
DrugDDI.d265.s19.e2 114 119
drug
CYP 2D6



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s20
Lithium : Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.

DrugDDI.d265.s20.e0 0 6
drug
Lithium
DrugDDI.d265.s20.e1 8 21
drug
Valdecoxib 40 mg
DrugDDI.d265.s20.e2 63 69
drug
lithium
DrugDDI.d265.s20.e3 148 154
drug
lithium

interaction DrugDDI.d265.s20.e1 DrugDDI.d265.s20.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s21
Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium .

DrugDDI.d265.s21.e0 0 6
drug
Lithium
DrugDDI.d265.s21.e1 85 90
drug
BEXTRA
DrugDDI.d265.s21.e2 110 116
drug
lithium

interaction DrugDDI.d265.s21.e1 DrugDDI.d265.s21.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s22
Lithium carbonate (450 mg BID for 7 days) had no effect on valdecoxib pharmacokinetics.

DrugDDI.d265.s22.e0 0 15
drug
Lithium carbonate
DrugDDI.d265.s22.e1 22 24
drug
BID
DrugDDI.d265.s22.e2 47 56
drug
valdecoxib



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s23
Warfarin : The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.

DrugDDI.d265.s23.e0 0 7
drug
Warfarin
DrugDDI.d265.s23.e1 20 29
drug
valdecoxib
DrugDDI.d265.s23.e2 56 63
drug
warfarin
DrugDDI.d265.s23.e3 122 127
drug
BEXTRA



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s24
Valdecoxib caused a statistically significant increase in plasma exposures of R- warfarin and S- warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin .

DrugDDI.d265.s24.e0 0 9
drug
Valdecoxib
DrugDDI.d265.s24.e1 70 77
drug
warfarin
DrugDDI.d265.s24.e2 83 90
drug
warfarin
DrugDDI.d265.s24.e3 179 186
drug
warfarin

interaction DrugDDI.d265.s24.e0 DrugDDI.d265.s24.e1
interaction DrugDDI.d265.s24.e0 DrugDDI.d265.s24.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s25
While mean INR values were only slightly increased with coadministration of valdecoxib , the day-to-day variability in individual INR values was increased.

DrugDDI.d265.s25.e0 65 74
drug
valdecoxib



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s26
Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.

DrugDDI.d265.s26.e0 99 104
drug
BEXTRA
DrugDDI.d265.s26.e1 124 131
drug
warfarin

interaction DrugDDI.d265.s26.e0 DrugDDI.d265.s26.e1

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s27
Fluconazole and Ketoconazole : Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.

DrugDDI.d265.s27.e0 0 10
drug
Fluconazole
DrugDDI.d265.s27.e1 14 25
drug
Ketoconazole
DrugDDI.d265.s27.e2 27 38
drug
Ketoconazole
DrugDDI.d265.s27.e3 42 52
drug
fluconazole
DrugDDI.d265.s27.e4 69 71
drug
CYP



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s28
Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib .

DrugDDI.d265.s28.e0 37 50
drug
valdecoxib 20 mg
DrugDDI.d265.s28.e1 70 81
drug
ketoconazole
DrugDDI.d265.s28.e2 85 95
drug
fluconazole
DrugDDI.d265.s28.e3 136 145
drug
valdecoxib

interaction DrugDDI.d265.s28.e0 DrugDDI.d265.s28.e1
interaction DrugDDI.d265.s28.e0 DrugDDI.d265.s28.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s29
Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole .

DrugDDI.d265.s29.e0 21 30
drug
valdecoxib
DrugDDI.d265.s29.e1 68 78
drug
fluconazole
DrugDDI.d265.s29.e2 107 118
drug
ketoconazole

interaction DrugDDI.d265.s29.e0 DrugDDI.d265.s29.e1
interaction DrugDDI.d265.s29.e0 DrugDDI.d265.s29.e2
interaction DrugDDI.d265.s29.e1 DrugDDI.d265.s29.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s30
Glyburide : Glyburide is a CYP 2C9 substrate.

DrugDDI.d265.s30.e0 0 8
drug
Glyburide
DrugDDI.d265.s30.e1 10 18
drug
Glyburide
DrugDDI.d265.s30.e2 22 27
drug
CYP 2C9



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s31
Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID ) did not affect the pharmacokinetics (exposure) of glyburide .

DrugDDI.d265.s31.e0 18 27
drug
valdecoxib
DrugDDI.d265.s31.e1 33 35
drug
BID
DrugDDI.d265.s31.e2 49 57
drug
glyburide
DrugDDI.d265.s31.e3 70 72
drug
BID
DrugDDI.d265.s31.e4 117 125
drug
glyburide



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s32
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide .

DrugDDI.d265.s32.e0 18 27
drug
valdecoxib
DrugDDI.d265.s32.e1 33 35
drug
BID
DrugDDI.d265.s32.e2 65 73
drug
glyburide
DrugDDI.d265.s32.e3 181 189
drug
glyburide



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s33
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.

DrugDDI.d265.s33.e0 18 27
drug
valdecoxib
DrugDDI.d265.s33.e1 33 35
drug
BID
DrugDDI.d265.s33.e2 65 73
drug
glyburide
DrugDDI.d265.s33.e3 79 87
drug
glyburide
DrugDDI.d265.s33.e4 115 123
drug
glyburide
DrugDDI.d265.s33.e5 148 156
drug
glyburide
DrugDDI.d265.s33.e6 184 190
drug
glucose

interaction DrugDDI.d265.s33.e0 DrugDDI.d265.s33.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s34
Insulin parameters were not affected.

DrugDDI.d265.s34.e0 0 6
drug
Insulin



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s35
Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID ) with valdecoxib coadministration (up to 40 mg QD) is not indicated.

DrugDDI.d265.s35.e0 41 50
drug
valdecoxib
DrugDDI.d265.s35.e1 171 179
drug
glyburide
DrugDDI.d265.s35.e2 193 195
drug
BID
DrugDDI.d265.s35.e3 201 210
drug
valdecoxib



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s36
Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID ) have not been studied.

DrugDDI.d265.s36.e0 18 26
drug
glyburide
DrugDDI.d265.s36.e1 50 59
drug
valdecoxib
DrugDDI.d265.s36.e2 70 72
drug
BID



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s37
Omeprazole : Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.

DrugDDI.d265.s37.e0 0 9
drug
Omeprazole
DrugDDI.d265.s37.e1 11 20
drug
Omeprazole
DrugDDI.d265.s37.e2 24 26
drug
CYP
DrugDDI.d265.s37.e3 42 48
drug
CYP 2C19



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s38
Valdecoxib steady state plasma concentrations (40 mg BID ) were not affected significantly with multiple doses of omeprazole (40 mg QD).

DrugDDI.d265.s38.e0 0 9
drug
Valdecoxib
DrugDDI.d265.s38.e1 46 48
drug
BID
DrugDDI.d265.s38.e2 97 106
drug
omeprazole



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s39
Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.

DrugDDI.d265.s39.e0 20 29
drug
valdecoxib
DrugDDI.d265.s39.e1 49 58
drug
omeprazole

interaction DrugDDI.d265.s39.e0 DrugDDI.d265.s39.e1

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s40
Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib .

DrugDDI.d265.s40.e0 0 4
drug
Drugs
DrugDDI.d265.s40.e1 87 96
drug
omeprazole
DrugDDI.d265.s40.e2 100 109
drug
valdecoxib

interaction DrugDDI.d265.s40.e1 DrugDDI.d265.s40.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s41
However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.

DrugDDI.d265.s41.e0 41 50
drug
omeprazole
DrugDDI.d265.s41.e1 114 123
drug
omeprazole



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s42
Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.

DrugDDI.d265.s42.e0 18 27
drug
valdecoxib
DrugDDI.d265.s42.e1 53 62
drug
omeprazole



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s43
Oral Contraceptives : Valdecoxib (40 mg BID ) did not induce the metabolism of the combination oral contraceptive norethindrone/ ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35@ ).

DrugDDI.d265.s43.e0 0 17
drug
Oral Contraceptives
DrugDDI.d265.s43.e1 19 28
drug
Valdecoxib
DrugDDI.d265.s43.e2 34 36
drug
BID
DrugDDI.d265.s43.e3 79 95
drug
oral contraceptive
DrugDDI.d265.s43.e4 110 125
drug
ethinyl estradiol
DrugDDI.d265.s43.e5 148 163
drug
Ortho-Novum 1/35@



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s44
Coadministration of valdecoxib and Ortho-Novum 1/35@ increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.

DrugDDI.d265.s44.e0 18 27
drug
valdecoxib
DrugDDI.d265.s44.e1 31 46
drug
Ortho-Novum 1/35@
DrugDDI.d265.s44.e2 69 81
drug
norethindrone
DrugDDI.d265.s44.e3 85 100
drug
ethinyl estradiol

interaction DrugDDI.d265.s44.e0 DrugDDI.d265.s44.e1

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s45
Although there is little risk for loss of contraceptive efficacy, the clinical significance of these increased exposures in terms of safety is not known.

DrugDDI.d265.s45.e0 34 46
drug
contraceptive



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s46
These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib .

DrugDDI.d265.s46.e0 25 37
drug
norethindrone
DrugDDI.d265.s46.e1 41 56
drug
ethinyl estradiol
DrugDDI.d265.s46.e2 102 118
drug
oral contraceptive
DrugDDI.d265.s46.e3 133 142
drug
valdecoxib



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s47
Diazepam : Diazepam ( Valium ) is a CYP 3A4 and CYP 2C19 substrate.

DrugDDI.d265.s47.e0 0 7
drug
Diazepam
DrugDDI.d265.s47.e1 9 16
drug
Diazepam
DrugDDI.d265.s47.e2 18 23
drug
Valium
DrugDDI.d265.s47.e3 28 30
drug
CYP
DrugDDI.d265.s47.e4 37 43
drug
CYP 2C19



Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s48
Plasma exposure of diazepam (10 mg BID ) was increased by 28% following administration of valdecoxib (40 mg BID ) for 12 days, while plasma exposure of valdecoxib (40 mg BID ) was not substantially increased following administration of diazepam (10 mg BID ) for 12 days.

DrugDDI.d265.s48.e0 16 23
drug
diazepam
DrugDDI.d265.s48.e1 29 31
drug
BID
DrugDDI.d265.s48.e2 75 84
drug
valdecoxib
DrugDDI.d265.s48.e3 90 92
drug
BID
DrugDDI.d265.s48.e4 125 134
drug
valdecoxib
DrugDDI.d265.s48.e5 140 142
drug
BID
DrugDDI.d265.s48.e6 197 204
drug
diazepam
DrugDDI.d265.s48.e7 210 212
drug
BID

interaction DrugDDI.d265.s48.e0 DrugDDI.d265.s48.e2

Abstract Id: DrugDDI.d265
Sentence Id: DrugDDI.d265.s49
Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.

DrugDDI.d265.s49.e0 31 38
drug
diazepam
DrugDDI.d265.s49.e1 75 84
drug
valdecoxib
DrugDDI.d265.s49.e2 158 165
drug
sedative
DrugDDI.d265.s49.e3 204 211
drug
diazepam



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s0
As with all drugs , the potential exists for interaction with other drugs by a variety of mechanisms.

DrugDDI.d81.s0.e0 9 13
drug
drugs
DrugDDI.d81.s0.e1 56 60
drug
drugs



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s1
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.

DrugDDI.d81.s1.e0 0 14
drug
CNS-Active Drugs
DrugDDI.d81.s1.e1 23 28
drug
Sonata
DrugDDI.d81.s1.e2 69 75
drug
ethanol
DrugDDI.d81.s1.e3 128 134
drug
ethanol
DrugDDI.d81.s1.e4 276 282
drug
ethanol

interaction DrugDDI.d81.s1.e1 DrugDDI.d81.s1.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s3
zaleplon did not affect the pharmacokinetics of ethanol .

DrugDDI.d81.s3.e0 0 7
drug
zaleplon
DrugDDI.d81.s3.e1 41 47
drug
ethanol



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s4
Imipramine : Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.

DrugDDI.d81.s4.e0 0 9
drug
Imipramine
DrugDDI.d81.s4.e1 42 47
drug
Sonata
DrugDDI.d81.s4.e2 55 68
drug
imipramine 75 mg

interaction DrugDDI.d81.s4.e1 DrugDDI.d81.s4.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s5
The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug .

DrugDDI.d81.s5.e0 77 80
drug
drug



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s6
Paroxetine : Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.

DrugDDI.d81.s6.e0 0 9
drug
Paroxetine
DrugDDI.d81.s6.e1 42 47
drug
Sonata
DrugDDI.d81.s6.e2 55 68
drug
paroxetine 20 mg



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s7
Additionally, paroxetine did not alter the pharmacokinetics of Sonata , reflecting the absence of a role of CYP2D6 in zaleplon@s metabolism.

DrugDDI.d81.s7.e0 13 22
drug
paroxetine
DrugDDI.d81.s7.e1 55 60
drug
Sonata
DrugDDI.d81.s7.e2 91 96
drug
CYP2D6



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s8
Thioridazine : Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.

DrugDDI.d81.s8.e0 0 11
drug
Thioridazine
DrugDDI.d81.s8.e1 44 49
drug
Sonata
DrugDDI.d81.s8.e2 57 72
drug
thioridazine 50 mg

interaction DrugDDI.d81.s8.e1 DrugDDI.d81.s8.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s9
The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug .

DrugDDI.d81.s9.e0 77 80
drug
drug



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s10
Venlafaxine : Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine .

DrugDDI.d81.s10.e0 0 10
drug
Venlafaxine
DrugDDI.d81.s10.e1 43 54
drug
zaleplon 10 mg
DrugDDI.d81.s10.e2 73 83
drug
venlafaxine
DrugDDI.d81.s10.e3 172 179
drug
zaleplon
DrugDDI.d81.s10.e4 182 192
drug
venlafaxine

interaction DrugDDI.d81.s10.e1 DrugDDI.d81.s10.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s11
In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.

DrugDDI.d81.s11.e0 76 83
drug
zaleplon
DrugDDI.d81.s11.e1 87 97
drug
venlafaxine



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s12
Promethazine : Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon , but no change in the area under the plasma concentration-time curve.

DrugDDI.d81.s12.e0 0 11
drug
Promethazine
DrugDDI.d81.s12.e1 44 51
drug
zaleplon
DrugDDI.d81.s12.e2 55 66
drug
promethazine
DrugDDI.d81.s12.e3 144 151
drug
zaleplon

interaction DrugDDI.d81.s12.e1 DrugDDI.d81.s12.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s13
However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.

DrugDDI.d81.s13.e0 47 54
drug
zaleplon
DrugDDI.d81.s13.e1 58 69
drug
promethazine



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s15
Drugs That Induce CYP3A4 Rifampin : CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon .

DrugDDI.d81.s15.e0 0 4
drug
Drugs
DrugDDI.d81.s15.e1 21 28
drug
Rifampin
DrugDDI.d81.s15.e2 30 35
drug
CYP3A4
DrugDDI.d81.s15.e3 74 81
drug
zaleplon



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s16
Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.

DrugDDI.d81.s16.e0 51 58
drug
rifampin
DrugDDI.d81.s16.e1 109 116
drug
zaleplon



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s17
The coadministration of a potent CYP3A4 enzyme inducer, although not posing a safety concern, thus could lead to ineffectiveness of zaleplon .

DrugDDI.d81.s17.e0 28 33
drug
CYP3A4
DrugDDI.d81.s17.e1 112 119
drug
zaleplon



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s18
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin , phenytoin , carbamazepine , and phenobarbital .

DrugDDI.d81.s18.e0 32 44
drug
hypnotic agent
DrugDDI.d81.s18.e1 76 81
drug
CYP3A4
DrugDDI.d81.s18.e2 96 103
drug
rifampin
DrugDDI.d81.s18.e3 105 113
drug
phenytoin
DrugDDI.d81.s18.e4 115 127
drug
carbamazepine
DrugDDI.d81.s18.e5 132 144
drug
phenobarbital



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s19
Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites , 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.

DrugDDI.d81.s19.e0 0 4
drug
Drugs
DrugDDI.d81.s19.e1 16 21
drug
CYP3A4
DrugDDI.d81.s19.e2 71 78
drug
zaleplon
DrugDDI.d81.s19.e3 120 125
drug
CYP3A4
DrugDDI.d81.s19.e4 140 150
drug
metabolites
DrugDDI.d81.s19.e5 250 257
drug
zaleplon

interaction DrugDDI.d81.s19.e0 DrugDDI.d81.s19.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s20
Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplon s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.

DrugDDI.d81.s20.e0 36 43
drug
zaleplon
DrugDDI.d81.s20.e1 48 59
drug
erythromycin
DrugDDI.d81.s20.e2 142 149
drug
zaleplon

interaction DrugDDI.d81.s20.e0 DrugDDI.d81.s20.e1

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s21
The magnitude of interaction with multiple doses of erythromycin is unknown.

DrugDDI.d81.s21.e0 44 55
drug
erythromycin



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s22
Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon .

DrugDDI.d81.s22.e0 42 53
drug
ketoconazole
DrugDDI.d81.s22.e1 94 101
drug
zaleplon

interaction DrugDDI.d81.s22.e0 DrugDDI.d81.s22.e1

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s23
A routine dosage adjustment of zaleplon is not considered necessary.

DrugDDI.d81.s23.e0 26 33
drug
zaleplon



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s24
Drugs That Inhibit Aldehyde Oxidase The aldehyde oxidase enzyme system is less well studied than the cytochrome P450 enzyme system.

DrugDDI.d81.s24.e0 0 4
drug
Drugs
DrugDDI.d81.s24.e1 16 30
drug
Aldehyde Oxidase
DrugDDI.d81.s24.e2 85 98
drug
cytochrome P450



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s25
Diphenhydramine : Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver , but its inhibitory effects in human liver are not known.

DrugDDI.d81.s25.e0 0 14
drug
Diphenhydramine
DrugDDI.d81.s25.e1 16 30
drug
Diphenhydramine
DrugDDI.d81.s25.e2 61 75
drug
aldehyde oxidase
DrugDDI.d81.s25.e3 81 85
drug
liver
DrugDDI.d81.s25.e4 117 121
drug
liver

interaction DrugDDI.d81.s25.e1 DrugDDI.d81.s25.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s26
There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug .

DrugDDI.d81.s26.e0 42 49
drug
zaleplon
DrugDDI.d81.s26.e1 53 67
drug
diphenhydramine
DrugDDI.d81.s26.e2 139 142
drug
drug



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s28
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine : Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.

DrugDDI.d81.s28.e0 0 4
drug
Drugs
DrugDDI.d81.s28.e1 20 34
drug
Aldehyde Oxidase
DrugDDI.d81.s28.e2 44 53
drug
Cimetidine
DrugDDI.d81.s28.e3 55 64
drug
Cimetidine
DrugDDI.d81.s28.e4 77 91
drug
aldehyde oxidase
DrugDDI.d81.s28.e5 104 109
drug
CYP3A4
DrugDDI.d81.s28.e6 186 193
drug
zaleplon

interaction DrugDDI.d81.s28.e3 DrugDDI.d81.s28.e4

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s29
Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon .

DrugDDI.d81.s29.e0 27 32
drug
Sonata
DrugDDI.d81.s29.e1 42 51
drug
cimetidine
DrugDDI.d81.s29.e2 101 108
drug
zaleplon

interaction DrugDDI.d81.s29.e0 DrugDDI.d81.s29.e1
interaction DrugDDI.d81.s29.e0 DrugDDI.d81.s29.e2

Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s30
An initial dose of 5 mg should be given to patients who are concomitantly being treated with cimetidine .

DrugDDI.d81.s30.e0 76 85
drug
cimetidine



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s31
Drugs Highly Bound to Plasma Protein Zaleplon is not highly bound to plasma proteins (fraction bound 60% span class= c104 @15%); .

DrugDDI.d81.s31.e0 0 4
drug
Drugs
DrugDDI.d81.s31.e1 18 30
drug
Plasma Protein
DrugDDI.d81.s31.e2 57 70
drug
plasma proteins



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s32
therefore, the disposition of zaleplon is not expected to be sensitive to alterations in protein binding.

DrugDDI.d81.s32.e0 26 33
drug
zaleplon



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s33
In addition, administration of Sonata to a patient taking another drug that is highly protein bound should not cause transient increase in free concentrations of the other drug .

DrugDDI.d81.s33.e0 27 32
drug
Sonata
DrugDDI.d81.s33.e1 56 59
drug
drug
DrugDDI.d81.s33.e2 72 78
drug
protein
DrugDDI.d81.s33.e3 145 148
drug
drug



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s34
Drugs with a Narrow Therapeutic Index Digoxin : Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).

DrugDDI.d81.s34.e0 0 4
drug
Drugs
DrugDDI.d81.s34.e1 32 38
drug
Digoxin
DrugDDI.d81.s34.e2 40 45
drug
Sonata
DrugDDI.d81.s34.e3 108 114
drug
digoxin



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s35
Warfarin : Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)- enantiomer s or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin .

DrugDDI.d81.s35.e0 0 7
drug
Warfarin
DrugDDI.d81.s35.e1 28 33
drug
Sonata
DrugDDI.d81.s35.e2 86 93
drug
warfarin
DrugDDI.d81.s35.e3 106 115
drug
enantiomer
DrugDDI.d81.s35.e4 186 193
drug
warfarin



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s36
Drugs That Alter Renal Excretion Ibuprofen : Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs .

DrugDDI.d81.s36.e0 0 4
drug
Drugs
DrugDDI.d81.s36.e1 28 36
drug
Ibuprofen
DrugDDI.d81.s36.e2 38 46
drug
Ibuprofen
DrugDDI.d81.s36.e3 121 125
drug
drugs



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s37
There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug .

DrugDDI.d81.s37.e0 51 58
drug
zaleplon
DrugDDI.d81.s37.e1 62 70
drug
ibuprofen
DrugDDI.d81.s37.e2 137 140
drug
drug



Abstract Id: DrugDDI.d81
Sentence Id: DrugDDI.d81.s38
This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.

DrugDDI.d81.s38.e0 22 29
drug
zaleplon
DrugDDI.d81.s38.e1 80 87
drug
zaleplon


